{
    "0": {
        "text": "npj | precision oncology\nReview\nPublished in partnership with The Hormel Institute, University of Minnesota\nhttps://doi.org/10.1038/s41698-025-00876-y\nCirculating tumor DNA to monitor\ntreatment response in solid tumors and\nadvance precision oncology\nCheck for updates\nAlexandra Bartolomucci1,2, Monyse Nobrega1,2, Tadhg Ferrier1,2, Kyle Dickinson1, Nivedita Kaorey1,2,\nAmélie Nadeau1,2, Alberto Castillo1,2 & Julia V. Burnier1,2,3",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 0
        }
    },
    "1": {
        "text": "Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, as evidenced by its\nincreasing integration into clinical practice. Carrying tumor speciﬁc characteristics, ctDNA can be\nused to inform treatment selection, monitor response, and identify drug resistance. In this review, we\nprovide a comprehensive, up-to-date summary of ctDNA in monitoring treatment response with a\nfocus on lung, colorectal, and breast cancers, and discuss current challenges and future directions.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 1
        }
    },
    "2": {
        "text": "Background\nThe therapeutic landscape for cancer has transformed signiﬁcantly over the\npast two decades with the advent of precision oncology. This paradigm shift\nunderscoresthecriticalimportanceofaligningpatientswiththeappropriate\nmolecular therapies at the right time, aiming to improve clinical outcomes\nwhile minimizing the use of ineffective and potentially toxic treatments.\nHowever, the methodologies for monitoring treatment response have not",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 2
        }
    },
    "3": {
        "text": "evolved at the same pace, still relying heavily on imaging and biomarkers\nthat often lack speciﬁcity. These approaches, while useful, have signiﬁcant\nlimitations,includinga lackofsensitivityand an inabilitytoprovide detailed\nmolecular insights that are crucial for clinical decision-making in the era of\ntargeted therapies.\nOne of the critical challenges in oncology is the dynamic stratiﬁcation\nof patients for appropriate treatments. Real-time stratiﬁcation is essential to",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 3
        }
    },
    "4": {
        "text": "ensure that therapeutic interventions are timely and effective. Traditional\ntissue biopsies, although informative, are often not feasible for repeated use\ndue to their invasive nature. They also fail to capture the full extent of tumor\nheterogeneity and dissemination, particularly in metastatic settings1.\nImagingtechniques,suchasthoseadheringtotheResponseEvaluation\nCriteria in Solid Tumors (RECIST), remain the gold standard for mon-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 4
        }
    },
    "5": {
        "text": "itoring treatment response2. The RECIST are a set of standardized criteria\ndeveloped to provide a consistent method for assessing tumor response to\ntreatment. These criteria are commonly used in clinical practice and in\nclinical trials to evaluate the efﬁcacy of chemotherapy and targeted therapy\nand are recognized by regulatory bodies like the Food and Drug Adminis-\ntration (FDA) and European Medicines Agency (EMA). An updated ver-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 5
        }
    },
    "6": {
        "text": "sion was recently introduced for evaluating responses in patients treated\nwithimmunotherapy,callediRECIST3.RECISTandiRECISTprimarilyrely\non imaging techniques, such as computed tomography (CT) and magnetic\nresonance imaging (MRI), to measure changes in tumor size. However, the\nfocus on macroscopic anatomical changes in tumor size do not always\ncorrelate with molecular or cellular changes that are critical for under-\nstanding the effectiveness of targeted therapies and immunotherapies, and",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 6
        }
    },
    "7": {
        "text": "in particular, does not detect microscopic disease such as in minimal resi-\ndual disease (MRD), which may lead to relapse. There is also a lack in\nsensitivity in detectingearlytreatment responses, particularly in caseswhere\ntumors do not shrink signiﬁcantly but undergo necrosis or other changes.\nLiquid biopsyhasemergedas a pivotalmodalityforcancer surveillance\nthrough the analysis of circulating biomarkers in bioﬂuids such as blood,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 7
        }
    },
    "8": {
        "text": "urine or saliva4. Unlike conventional tissue biopsies that require surgical\nprocedures, liquid biopsy is a minimally invasive approach for real-time\nanalysis of cancer burden, disease progression, and response to treatment5.\nThe procedural ease, low cost, and diminished invasiveness of liquid biopsy\nconfer substantial promise for integration into routine clinical practice,\nproviding a dynamic platform for personalized therapeutic interventions",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 8
        }
    },
    "9": {
        "text": "and quick adaptations to evolving disease states4,5.\nSeveral analytes can be studied through liquid biopsy, including\ncirculating tumor cells (CTCs), extracellular vesicles (EVs), and circu-\nlating tumor DNA (ctDNA). CTCs are tumor cells that have shed from\nthe primary tumor and circulate in the bloodstream6,7, while EVs include\na diverse group of nano-sized particles encased in a lipid bilayer mem-\nbrane released by various cell types8,9. Both EVs and CTCs have been",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 9
        }
    },
    "10": {
        "text": "shown to play central roles in tumor invasion and metastasis8,10. On the\nother hand, circulating tumor DNA (ctDNA) refers to small fragments of\nDNA that are released by tumor cells into the bloodstream. Nowadays,\nstudies are exploring a multi-omic approach to liquid biopsy research, in\nwhich multiple analytes are analyzed within the same liquid biopsy\nsample11.\n1Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 10
        }
    },
    "11": {
        "text": "2Department of Pathology, McGill University, Montreal, QC, Canada. 3Gerald Bronfman Department of Oncology,\nMcGill University, Montreal, QC, Canada.\ne-mail: julia.burnier@mcgill.ca\nnpj Precision Oncology |  (2025) 9:84 \n1\n1234567890():,;\n1234567890():,;\nctDNA arguably holds the most clinical potential as a biomarker, as\ndemonstratedbyitsclinicaladoptioninseveralapplications,andassuchwill\nbe the focus of the present review. Since blood, irrespective of health state,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 11
        }
    },
    "12": {
        "text": "contains cell-free DNA (cfDNA) derived mainly from the physiologic\napoptosis of hematopoietic and other normal cells12,13, evaluating ctDNA\ninvolves detecting a tumor-speciﬁc characteristic (e.g., somatic mutation,\nmethylation proﬁle or viral sequence) that distinguishes it from cfDNA of\nnon-tumor origin. The quantity of ctDNA found in the blood has been\ncorrelated to tumor burden and cell turnover14, ranging from below 1% of",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 12
        }
    },
    "13": {
        "text": "total cfDNA in early-stage cancer to upwards of 90% in late-stage disease15.\nThe half-life of cfDNA in circulation, estimated between 16 min and several\nhours16,17, enables real-time monitoring of tumor heterogeneity and sub-\nclonal changes18–20. Because cfDNA is thought to be released largely as a\nresult of cell death21, it can provide information on treatment response, with\nrecent data suggesting that early ctDNArelease may reﬂect outcomes across",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 13
        }
    },
    "14": {
        "text": "varioustumortypes22–26.Moreover,mutationsfoundincfDNAfrompatient\nplasmalikelyencompassbothprimarytumorandmetastaticsites,makingit\nrepresentativeofsystemicdisease27.Finally,recentstudieshaverevealedthat\nfragmentationpatternscanalsobeusedtodifferentiatectDNAfromnormal\ncfDNA28.Indeed,cfDNAfragmentationandend motifshavebeenshownto\ninform on pathological states29–31. Furthermore, cfDNA fragment size may\nreﬂect the emission process32,33, adding another layer of insight into the\ndynamics of ctDNA.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 14
        }
    },
    "15": {
        "text": "dynamics of ctDNA.\nWhile ctDNA has been investigated for cancer diagnostics and prog-\nnostication, arguably its most immediate clinical application is for the\nassessment of treatment response and MRD, as emphasized by the nature of\nthe several ctDNA assays already integrated into clinical practice34–36.\nctDNA offers advantages in providing a simple approach to detect minimal\nlevels of disease speciﬁcally and non-invasively, allowing assessment of",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 15
        }
    },
    "16": {
        "text": "response to treatment, presence of residual disease, and emergence of\nresistance37,38 (Fig. 1).\nDespite its promise, the clinical adoption of ctDNA faces several\nchallenges.LowctDNAabundanceandthelackoftechnicalstandardization\nare signiﬁcant hurdles. Addressing these challenges requires reﬁning\ndetection methods, establishing standardized protocols, and conducting\nlarge-scale clinical trials to validate the clinical utility of ctDNA across",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 16
        }
    },
    "17": {
        "text": "diverse cancer populations. While ctDNA is presently being explored for\nmultiple purposes, including early cancer diagnostics and prognostication,\nwe believe that the most immediate clinical application of ctDNA is in the\nmonitoring of treatment response39,40. This review aims to provide a com-\nprehensive overview of the current state of ctDNA research, including the\nnovel methodologies and bioﬂuids used for analysis, focusing speciﬁcally on",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 17
        }
    },
    "18": {
        "text": "the application of ctDNA in assessing treatment response in the most\ncommon solid tumors. We highlight clinical applications, ongoing trials,\nand emerging research. Additionally, we describe the analytical challenges\nand hurdles to its clinical adoption and discuss future directions.\nApproaches to ctDNA monitoring: advances and\nchallenges\nGiven the low abundance of ctDNA compared to non-cancer (normal)\ncfDNA, highly sensitive techniques are essential for effectively detecting",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 18
        }
    },
    "19": {
        "text": "tumor-speciﬁc DNA in the circulation. Numerous methods have been\napplied and developed for ctDNA detection and analysis, predominantly\nfocusing on identifying tumor-speciﬁc somatic mutations or other genomic\nalterations (previously reviewed in Siravegna et al.41 and Pessoa et al.42).\nDriver mutations detected in ctDNA are frequently utilized as an indicator\nof disease burden, under the assumption that these somatic events will be",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 19
        }
    },
    "20": {
        "text": "represented in a large proportion of the cancer cells43. Levels of ctDNA\nthrough the detection of such mutations can be tracked longitudinally to\nassess disease burden44,45, MRD46–48, and treatment response49,50. Assessing\nmolecular responseusingctDNAinvolves evaluatingctDNAclearanceafter\ntreatment, percent change from baseline, and other quantitative measures.\nAdditionally, emerging alterations such as acquired resistance mutations to",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 20
        }
    },
    "21": {
        "text": "targeted therapies or chemotherapy are invaluable as biomarkers to gauge\ntreatment response and to select/modify treatment approaches51,52.\nTargeted approaches, such as polymerase chain reaction (PCR)\nmethods, can detect mutations with high sensitivity and rapid turnaround\ntimes. Techniques like quantitative PCR (qPCR), digital (d)PCR and\nBEAMing (beads, emulsion, ampliﬁcation, and magnetics) are often\nemployed, and have been thoroughly reviewed in Wang et al.53 and Kim",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 21
        }
    },
    "22": {
        "text": "et al.54. These methods are particularly useful for tumor-informed analyses,\nwhere sequencing conducted on primary tumor tissue is used to identify\nmutations or somatic alterations of interest, which can then be targeted\nusing these assays.In contrast, commonly mutated genesin speciﬁc cancers,\nsuchasBRAFinmelanoma55,KRASinlungandcolorectalcancer(CRC)56,57,\nESR1 and PIK3CA in breast cancer58,59, androgen receptor (AR) in prostate",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 22
        }
    },
    "23": {
        "text": "cancer60, IDH in gliomas61, and GNAQ/11 in uveal melanoma62, can serve as\ntargets even without tumor tissue analysis. These targeted approaches\nfacilitate rapid and cost-effective analyses but are limited to a small number\nof mutations or alterations that can be monitored per assay.\nIn recent years, next-generation sequencing (NGS) methodologies\nhave advanced signiﬁcantly, offering broader ranges of genomic alterations\nwithin\npatient\nsamples\nwithout\nnecessitating\na\ntumor-informed",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 23
        }
    },
    "24": {
        "text": "samples\nwithout\nnecessitating\na\ntumor-informed\napproach63–65. NGS technologies, including whole-exome sequencing\n(WES) and whole-genome sequencing (WGS), as well as targeted approa-\nches such as tagged-amplicon deep sequencing (TAm-Seq)66, Safe-\nSequencing System (Safe-SeqS)67, CAncer Personalized Proﬁling by deep\nSequencing (CAPP-Seq)63, and targeted error correction sequencing (TEC-\nSeq)68 allow for comprehensive assessments of numerous patient-speciﬁc",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 24
        }
    },
    "25": {
        "text": "genomic changes, providing a more detailed understanding of the disease.\nThesemethodsareparticularlyrelevantforheterogeneouscancerswithhigh\ngenomic instability. However, a concern with NGS is that the PCR step\npresent in most NGS workﬂows introduces low-frequency errors which can\nFig. 1 | ctDNA levels to monitor treatment\nresponse. ctDNA can offer a more sensitive and\npersonalized approach to monitoring disease com-\npared to imaging or other conventional methods.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 25
        }
    },
    "26": {
        "text": "pared to imaging or other conventional methods.\nThis sensitivity can be explored in several ways: to\nassess response, MRD, and emergence of resistance.\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n2\nbe misidentiﬁed as low-frequency variants present in the ctDNA. As such,\nmany methods rely on unique molecular identiﬁers (UMIs), which are\nmolecular barcodes tagged onto DNA fragments before PCR ampliﬁcation,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 26
        }
    },
    "27": {
        "text": "which can help to ﬁlter out true mutations from sequencing artefacts69. In\n2012, Schmitt et al. introduced Duplex Sequencing, which became the gold-\nstandard of high-accuracy sequencing69. This method tags and sequences\neach of the two strands of a DNA duplex, relying on the fact that true\nmutationswouldbefoundinthesamepositiononbothstrands,thusfurther\nimproving error correction by UMIs69. However, generating a duplex\nconsensus is highly inefﬁcient, and thus several methods have been devel-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 27
        }
    },
    "28": {
        "text": "oped to address this shortcoming, including SaferSeqS70, NanoSeq71, and\nSingleton Correction72. Notably, most recently in 2023, Bae et al. developed\nConcatenating Original Duplex for Error Correction (CODEC), which\nallows for 1000-fold higher accuracy than NGS and uses up to 100-fold\nfewer reads than duplex sequencing, by reading both strands of each DNA\nduplex with single NGS read pairs73. NGS methodologies used for ctDNA",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 28
        }
    },
    "29": {
        "text": "analysis have also been thoroughly reviewed in Ferreira da Silva, et al.74.\nHowever, despite the continuing development of more sensitive NGS\nmethodologies, the limitation of low input ctDNA amounts in early-stage\ncancers and low-shedding tumors still exists63,75–77. Interestingly, in 2024\nMartin-Alonso et al. proposed the use of priming agents to transiently\nreduce cfDNA clearance in vivo to address the low levels of ctDNA in",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 29
        }
    },
    "30": {
        "text": "circulation, presenting a fascinating future direction for the ctDNA ﬁeld78.\nNevertheless, the presence of clonal hematopoiesis of indeterminate\npotential(CHIP) variantsinthecfDNApoolcanleadtofalsepositiveswhen\nsequencing79,80. Moreover, sequencing methods face challenges related to\ncost and longer analysis times, constraining their use in real-time decision-\nmaking51,81. Finally, the low input volumes of cfDNA require careful trade-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 30
        }
    },
    "31": {
        "text": "offsbetweenthebreadthanddepthofanalysistodetectlowcopyalterations.\nBeyond mutational analysis, non-mutation-based approaches have\nbeen explored for ctDNA monitoring. For example, viral cfDNA has been\ninvestigated for cancer types with viral etiologies, such as those associated\nwith human papillomaviruses (HPV) (oropharyngeal and cervical\ncancers)82,83, hepatitis B virus (hepatocellular carcinoma)84, and herpes-\nviruses (certain lymphomas, nasopharyngeal cancer, Kaposi sarcoma)85–87.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 31
        }
    },
    "32": {
        "text": "Otherwise, DNA methylation or fragmentome analysis have also been used\nfor ctDNA analyses32,33,88. Such approaches can help overcome traditional\nchallenges associated with genomic ctDNA studies, such as confounding\ndata from CHIP variants80.\nDNA methylation analysis can, in many ways, provide information\nthat is similar to other genetic analyses. As with mutational analysis, pro-\nmoter hypermethylation can be used for longitudinal disease monitoring at",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 32
        }
    },
    "33": {
        "text": "speciﬁc sites89–91. This generally requires information obtained from tumor\ntissue, often done using arrays92. Traditionally, DNA methylation analysis\nhas relied on bisulﬁte conversion, with analytical methods such as whole\ngenome bisulﬁte sequencing (WGBS) and targeted bisulﬁte sequencing.\nThese methods have shown to be effective in longitudinal monitoring of\ncancer patients in both plasma93 and urine92,94. Single gene hypermethyla-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 33
        }
    },
    "34": {
        "text": "tion, particularly of tumor suppressor genes such as p16 in hepatocellular\ncarcinoma, septin 9 in CRC, and MGMT in gliomas89–91, has also been an\neffective tool to detect cancer in liquid biopsies. More recently, bisulﬁte-free\nmethods have been incorporated to reduce the challenges associated with\nDNA degradation caused by bisulﬁte conversion95. Importantly, methods\nsuch as chromatin immunoprecipitation sequencing (ChIP-Seq) and other",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 34
        }
    },
    "35": {
        "text": "immunoprecipitation-based methods such as methylated DNA immuno-\nprecipitation sequencing (MeDIP-Seq) are gaining popularity in cfDNA\nanalysis, with especially useful applications in determining the cells of origin\nof cfDNA96–98.\ncfDNA fragmentomics is an emerging ﬁeld in liquid biopsy, referring\nto the study of cfDNA fragmentation patterns, fragment sizes, and end\ncharacteristics99–101. Studies have demonstrated that cancer patients often",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 35
        }
    },
    "36": {
        "text": "exhibit more diverse fragmentation patterns, leading to an overall smaller\naverage fragment size102, which can be used to distinguish cancer from non-\ncancer derived cfDNA. In fact, qPCR was used by Diehl et al. to ﬁrst suggest\nthat cfDNA fragments containing mutant sequences are generally shorter\nthan non-mutant cfDNA fragments103. Moreover, using an automated\nelectrophoresis system, our group has shown signiﬁcant increases in cfDNA",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 36
        }
    },
    "37": {
        "text": "fragment sizes in the plasma of HPV-positive head and neck cancerpatients\nafter treatment, suggesting a potential additional biomarker for monitoring\ntreatment response104. Recently, the development of novel bioinformatics\nmethodologies has allowed for the acquisition of larger, higher-throughput,\nand more detailed fragmentomic data28,105–109. For instance, in 2019, Cris-\ntiano et al. developed their method for the genome-wide analysis of cfDNA",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 37
        }
    },
    "38": {
        "text": "fragmentation patterns using low-coverage WGS called DELFI (DNA\nevaluation of fragments for early interception)28. Combining this machine\nlearning model that incorporates genome-wide fragmentation proﬁles with\nmutation-based cfDNA analyses, the sensitivity of cancer detection was\n91%. Other novel methods for fragmentomic analysis that have been\ndeveloped in recent years include orientation-aware cfDNA fragmentation\n(OCF)110, epigenetic expression inference from cfDNA-sequencing (EPIC-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 38
        }
    },
    "39": {
        "text": "seq)111,motifdiversityscore(MDS)112,windowedprotectionscore(WPS)105,\nassessing\ntranscription\nfactor-binding\nsite\naccessibility\n(TFBS)113,\nLIQUORICE114, and Grifﬁn115 which have all been thoroughly reviewed in\nLiu100 and Thierry et al.101.\nRecently, multimodal approaches combining various types of analyses\nhave become more common in the liquid biopsy ﬁeld. Studies now often\nincorporate combinations of multiple types of analyses, such as copy",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 39
        }
    },
    "40": {
        "text": "number alterations (CNA), genomic, epigenetic, and fragmentomic ana-\nlyses on cfDNA samples77,98,116,117. For example, Parikh et al. showed that\nintegrating epigenomic signatures increased sensitivity for recurrence by\n25–36% vs. genomic alterations alone118. Moreover, the spectrum of bio-\nﬂuids used for ctDNA analysis has also expanded beyond plasma to include\nurine26,119–122, saliva104,123–125, and cerebrospinal ﬂuid (CSF)126–129, among",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 40
        }
    },
    "41": {
        "text": "others, for monitoring treatment response and disease progression. Figure 2\npresents an overview of the current and emerging range of bioﬂuids and\nmethodologies that can be used for ctDNA analysis.\nAlthough most ctDNA studies to date have been observational in\nnature, the potential role of ctDNA monitoring to help guide clinical\ndecision-making cannot be overlooked. In fact, in recent years, several\nclinical trials have been initiated to evaluate the use of ctDNA monitoring in",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 41
        }
    },
    "42": {
        "text": "the clinical setting. Speciﬁcally, the potential for ctDNA use in helping\nclinicians with initial treatment selection or treatment modiﬁcation based\non ctDNA response have been explored. In the following sections, we will\nfocus on the use of ctDNA to monitor treatment response, MRD, and\nresistance in common solid cancers, and we will highlight current clinical\ntrials using ctDNA.\nLung cancer\nAs the leading cause of cancer-related deaths worldwide, lung cancer has",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 42
        }
    },
    "43": {
        "text": "beenextensivelystudied inthe liquid biopsy ﬁeld130.The approvalof theﬁrst\ndiagnostic liquid biopsy assay by the FDA in 2016 for use in non-small cell\nlung cancer (NSCLC)34 marked a signiﬁcant milestone in the use of liquid\nbiopsies. The Cobas EGFR Mutation Test v2 (Roche Molecular Systems,\nInc) is a real-time PCR assay that can detect 42 mutations in exons 18, 19, 20\nand 21 of the EGFR gene, and which can be used in the clinic for the",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 43
        }
    },
    "44": {
        "text": "prescription of EGFR inhibitors in NSCLC patients when biopsied tumor\ntissue is not available34. Since then, two other liquid biopsy-based tests were\napproved by the FDA for use in treatment selection in NSCLC patients, the\nGuardant 360 CDx and the FoundationOne Liquid CDx tests, which are\nboth NGS panel-based assays35,36. Currently, there exists a growing body of\nresearch focusing on the dynamic monitoring of ctDNA in lung cancer",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 44
        }
    },
    "45": {
        "text": "patients in order to assess treatment response,whichwill be reviewedbelow.\nAlthough the majority of these studies have centered on NSCLC, which\nmakes up 85% of lung cancer cases130, there has also been exploration into\nctDNAmonitoringinsmallcelllungcancer(SCLC) patientsinrecentyears.\nEarly studies evaluating ctDNA in NSCLC predominately used PCR-\nbased methods to detect speciﬁc point mutations in cfDNA, targeting genes\nsuch as KRAS or EGFR56,131. With the advent of NGS, sequencing-based",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 45
        }
    },
    "46": {
        "text": "methods for ctDNA analysis in NSCLC gained traction. Notably, in 2014,\nNewman et al. introduced CAPP-Seq and demonstrated its utility in\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n3\ndetecting ctDNA in NSCLC patients63. In their study, ctDNA was detectable\nin 100% of stage II-IV (n = 9) and 50% of stage I (n = 4) NSCLC patients,\nand ctDNA levels signiﬁcantly correlated with tumor volume63. This",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 46
        }
    },
    "47": {
        "text": "method was later was used by Chaudhuri et al. for longitudinal monitoring\nof ctDNA in lung cancer patients with localized disease (stages I-III)\nundergoing treatment with curative intent and was found to be useful in\ndetecting post-treatment MRD132. Further, in 2020, Moding et al. used\nCAPP-Seq to analyze ctDNA in 218 samples from 65 NSCLC patients with\nlocally advanced disease and found that ctDNA dynamics early during\nconsolidation immune checkpoint inhibition could be used to identify",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 47
        }
    },
    "48": {
        "text": "patients responding to the treatment50. In a cohort of 100 NSCLC stage I-III\npatients from the TRACERx (TRAcking non-small-cell lung Cancer Evo-\nlutionThroughTherapy(Rx))study,phylogeneticctDNAanalysiswasused\nto track the development of subclonal mutations and metastases133. Addi-\ntionally, many studies have highlighted the prognostic value and clinical\nutility of evaluating ctDNA dynamics in NSCLC through changes observed",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 48
        }
    },
    "49": {
        "text": "in pre- and post-surgery samples119,134,135. Moreover, other studies have\nhighlighted the usefulness of using ctDNA to detect MRD in the post-\noperative period in NSCLC46,136,137.\nWith the advent of immunotherapy and targeted therapies, there has\nbeen a paradigm shift in the treatment landscape of NSCLC, particularly for\npatients with late-stage and metastatic disease. Longitudinal monitoring of\nctDNA during personalized NSCLC treatments has become increasingly",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 49
        }
    },
    "50": {
        "text": "relevant, aiding in the detection of acquired resistance mutations and pre-\ndicting patient response to therapies138–144. For instance, studies have used\nNGS and/or dPCR to monitor ctDNA during treatment with EGFR-\ntyrosine kinase inhibitors (TKIs) such as afatinib138 or osimertinib140. In the\nlatter study, it was found that plasma ctDNA response to treatment occurs\nearly after treatment, suggesting that optimal ctDNA assessment may be",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 50
        }
    },
    "51": {
        "text": "within the ﬁrst cycle of therapy (before standard imaging timepoints).\nFurthermore, longitudinal ctDNA monitoring has been especially useful in\ndetecting mutations that confer acquired resistance to targeted therapies,\nsuch\nas\nEGFR\nT790M\nresistance\nmutations\nduring\nEGFR-TKI\ntreatment145,146 as well as response to ALK TKIs143 and BRAF inhibitors144.\nThis presents a potential means to monitor ctDNA for resistance mutations\neven before the development of disease progression. Moreover, recent",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 51
        }
    },
    "52": {
        "text": "studies have explored longitudinal disease monitoring with ctDNA to\npredict patient response totreatments and allow for earlier clinical decision-\nmaking and therapy intervention147–151. For instance, the European Orga-\nnisation for Research and Treatment of Cancer (EORTC) Lung Cancer\nGroup 1613 APPLE phase II clinical trial was designed to evaluate the\nfeasibility of using longitudinal plasma EGFR T790M monitoring by Cobas",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 52
        }
    },
    "53": {
        "text": "EGFR test v2 in determining the best treatment administration of geﬁtinib\nand osimertinib150. Overall, they found that serial monitoring of ctDNA\nallowed for identiﬁcation of molecular progression before RECIST pro-\ngressionandthus,allowingforanearlierswitchfromgeﬁtinibtoosimertinib\nin 17% of patients, resulting in satisfactory progression-free-survival (PFS)\nand overall survival (OS). A summary of the completed clinical trials",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 53
        }
    },
    "54": {
        "text": "assessing the use of ctDNA for clinical interventional purposes with pub-\nlished results in lung cancer can be found in Table 1. Also, there are many\nclinical trials that are ongoing to assess the use of ctDNA for interventional\npurposes. For instance, stage 1 of the BR.36 study was recently published,\nwhich is a phase 2 clinical trial of ctDNA molecular response-adaptive\nimmuno-chemotherapy\nfor\ntreatment-naïve\nNSCLC151.\nThis\nﬁrst",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 54
        }
    },
    "55": {
        "text": "for\ntreatment-naïve\nNSCLC151.\nThis\nﬁrst\nFig. 2 | Types of bioﬂuids, analyses, genomic regions, and methodologies that can\nbe used for ctDNA monitoring in cancer patients. A vast range of bioﬂuids can be\ncollected from cancer patients for cfDNA isolation. Following this, tumor-informed\nor uninformed, as well as mutation or non-mutation based analytical approaches\ncan be used for ctDNA analysis, with multimodal studies becoming more common\nin the ﬁeld.\nhttps://doi.org/10.1038/s41698-025-00876-y",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 55
        }
    },
    "56": {
        "text": "https://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n4\nTable 1 | Completed clinical trials with published results that used ctDNA for clinical decision making and treatment intervention in lung, colorectal, and breast cancersa\nCancer\nType\nStudy Name/ Clinical Trial Identiﬁer/\nPublications\nNumber of\nPatients\nStudy Goal\nctDNA Methodology\nKey Findings\nNSCLC\nLiquidLung-O\nNCT02769286290,291\n119\nTo determine treatment efﬁcacy of osimertinib in",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 56
        }
    },
    "57": {
        "text": "To determine treatment efﬁcacy of osimertinib in\npatients with NSCLC with activating EGFR mutations\n(cohort 1) or T790M EGFR mutations (cohort 2) which\nwere detected from ctDNA.\nPCR (PANA Mutyper R EGFR\nassay and Cobas EGFR Mutation\nTest v2)\nCohort 1: Osimertinib had favorable outcomes in the\nﬁrst-line treatment of metastatic NSCLC with activating\nEGFR mutations in ctDNA as well as tumor DNA.\nCohort 2: Osimertinib had favorable outcomes in\npatients with NSCLC with T790M detected from ctDNA,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 57
        }
    },
    "58": {
        "text": "with unknown tumor mutation status.\nNSCLC\nLiquid-Lung-A\nNCT02629523292\n331\nTo determine the efﬁciency of afatinib in treatment‐naïve\npatients with lung cancer harboring EGFR exon 19\ndeletions or exon 21 point mutations detected in ctDNA.\nPCR (PANA Mutyper R\nEGFR assay)\nAfatinib showed similar objective response rate and PFS\nin patients with lung cancer harboring EGFR mutations\nin their ctDNA regardless of tumor EGFR mutation\nresults. Thus, the survival beneﬁt of afatinib treatment",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 58
        }
    },
    "59": {
        "text": "can be achieved by using noninvasive (ctDNA) assays.\nNSCLC\nBFAST\nNCT03178552293–295\n2219\nTo evaluate the relationship between blood-based NGS\ndetection of actionable genetic alterations and activity of\ntargeted therapies or immunotherapy in treatment-naive\nadvanced or metastatic NSCLC.\nNGS (FoundationACT and a\nblood-based tumor mutational\nburden assay)\nResults from cohorts A, B, C published. Overall, the trial\nresults reveal the clinical application of blood-based",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 59
        }
    },
    "60": {
        "text": "NGS as a method to inform clinical decision-making.\nNSCLC\nAPPLE\nNCT02856893150\n103\nTo evaluate the feasibility of using longitudinal plasma\nEGFR T790M monitoring in determining the best\ntreatment administration of geﬁtinib and osimertinib.\nPCR (Cobas EGFR mutation\ntest v2)\nResults from arms B and C published. The serial\nmonitoring of ctDNA T790M status was not only feasible\nbut lead to the identiﬁcation of molecular progression\nbefore RECIST progression and an earlier switch to",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 60
        }
    },
    "61": {
        "text": "osimertinib in 17% of patients with satisfactory PFS and\nOS outcomes.\nNSCLC\nACCELERATE\nNCT04863924296\n150\nTo determine the association between ctDNA\ngenotyping before tissue diagnosis and time to\ntreatment.\nNGS (InVisionFirst-Lung)\nThe median time to treatment was 39 days for the\nACCELERATE cohort vs 62 days for the reference\ncohort. Thus, the use of plasma ctDNA genotyping\nbefore tissue diagnosis was associated with\naccelerated time to treatment.\nNSCLC\nLOCAL\nNCT03046316297\n60",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 61
        }
    },
    "62": {
        "text": "NSCLC\nLOCAL\nNCT03046316297\n60\nTo assess the feasibility of de-escalation of TKI\ntreatment guided by ctDNA for achieving complete\nremission after local consolidative therapy.\nNGS (oncoMRD-B panel of 338\ngenes (GenePlus))\nOverall, a ctDNA-guided adaptive de-escalation TKI\ntreatment strategy is feasible for patients with\nadvanced NSCLC.\nCRC\nTRIUMPH\nUMIN000027887200\n30\nTo evaluate the efﬁcacy of pertuzumab plus\ntrastuzumab for mCRC with HER2 ampliﬁcation\nconﬁrmed by tumor tissue or ctDNA analysis.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 62
        }
    },
    "63": {
        "text": "conﬁrmed by tumor tissue or ctDNA analysis.\nNGS (Guardant360)\nctDNA genotyping can identify patients who beneﬁt\nfrom dual-HER2 blockade and monitor treatment\nresponse.\nCRC\nCHRONOS\nNCT03227926196\n52\nTo identify RAS/BRAF/EGFR mutations in ctDNA to\ntailor a chemotherapy-free anti-EGFR rechallenge with\npanitumumab.\nNGS and ddPCR\nctDNA analysis is an effective, safe, and timely method\nto guide anti-EGFR rechallenge therapy with\npanitumumab in patients with mCRC.\nCRC\nDYNAMIC\nACTRN1261500038158349\n455",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 63
        }
    },
    "64": {
        "text": "CRC\nDYNAMIC\nACTRN1261500038158349\n455\nTo assess whether a ctDNA-guided approach could\nreduce the use of ACT without compromising\nrecurrence risk.\nNGS (Safe-SeqS)\nA ctDNA-guided approach reduced ACT use without\ncompromising recurrence-free survival.\nCRC\nCOBRA\nNCT04068103298\n635\nTo evaluate if positive ctDNA after resection can identify\npatients who will beneﬁt from ACT.\nNGS (Guardant LUNAR assay)\nPreliminary results in 635 patients showed no\nimprovement in ctDNA clearance after 6 months of",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 64
        }
    },
    "65": {
        "text": "improvement in ctDNA clearance after 6 months of\nchemotherapy for patients with ctDNA detected\nfollowing resection of stage IIA colon cancer. The phase\nII endpoint was not met and further enrollment has been\nstopped.\nBreast\nPlasmaMATCH\nNCT03182634299\n1034\nTo determine the ability of ctDNA testing to select\npatients for mutation-directed therapy.\nddPCR and NGS (Guardant360)\nThe analysis of ctDNA allows for accurate genotyping,\nfacilitating the identiﬁcation of mutation-speciﬁc",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 65
        }
    },
    "66": {
        "text": "treatments for breast cancer. Results highlighted the\neffectiveness of targeted therapies for uncommon\nHER2 and AKT1 mutations, conﬁrming their potential as\nactionable targets for treatment.\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n5\nobservational stage of the clinical trial showed that ctDNA molecular\nresponsecouldidentifypatientswithmetastaticNSCLClesslikelytoachieve\nfavorable clinical outcomes with single-agent PD-1 therapy. In stage 2 of the",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 66
        }
    },
    "67": {
        "text": "BR.36 trial, which is ongoing, patients at risk of progression as determined\nby ctDNA analysis, will be randomized into either treatment intensiﬁcation\nor continuation of therapy study arms. Additionally, there are several\nongoing clinical trials to determine if it is beneﬁcial to provide additional\ntreatmenttoNSCLCpatientswhohavedetectablectDNA(MRD)aftertheir\ninitial treatments or surgeries, including the ADAPT-E152, ADAPT-C153,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 67
        }
    },
    "68": {
        "text": "and ctDNA Lung RCT trials154. Figure 3 below exempliﬁes the current\napplications of ctDNA in precision oncology for NSCLC.\nDespite the extensive studies on ctDNA kinetics during cancer treat-\nment in NSCLC, there is limited research focused on ctDNA monitoring in\npatients with SCLC, an aggressive disease comprising 15% of lung cancer\ncases130. As SCLC is characterized by nearly consistent inactivation of TP53,\nearly ctDNA studies used PCR-based methods for the detection of TP53",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 68
        }
    },
    "69": {
        "text": "mutations in cfDNA of SCLC patients155,156. Subsequent studies have\nemployed NGS for longitudinal ctDNAanalysis in SCLC and demonstrated\nits ability to monitor disease157–163. Notably, Lovly’s group, using a targeted\nsequencing panel of 14 frequently mutated genes in SCLC, demonstrated\nthe potential of ctDNA analysis in providing evidence of disease relapse\nbefore conventional imaging157, as well as serving as a prognostic indicator",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 69
        }
    },
    "70": {
        "text": "post-treatment160. Likewise, Nong et al. used targeted deep sequencing of\n430 genes on pre and post-treatment plasma samples in 22 SCLC patients,\nand found that mutations in DNA repair and NOTCH signaling pathways\nwere enriched post-treatment, exemplifying that NGS can allow for the\nanalysis of the genomic evolution of SCLC158. More recently, WGS was used\nfor the detection of CNA in parallel with targeted sequencing of 110 SCLC-\nassociated genes to analyze cfDNA from 69 SCLC patients, of which",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 70
        }
    },
    "71": {
        "text": "longitudinal samples were obtained from 6 patients161. Moreover, a recent\nstudy from Sivapalan et al. used targeted error-correction sequencing and\nchromosomal arm-level structural alterations analysis on serial plasma\nctDNA and matched white blood cell DNA from 33 metastatic SCLC\npatients receiving chemotherapy or immunotherapy regimens162. Overall,\nboth these studies highlight the potential of using novel methodologies\ncombined with dynamic monitoring of ctDNA in order to assess molecular",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 71
        }
    },
    "72": {
        "text": "response to treatment in SCLC patients.\nColorectal cancer\nCRC is one of the most common cancers worldwide and has demonstrated\nhighsheddingofctDNAintothebloodstream,makingliquidbiopsyauseful\ntool in assessing treatment response and progression in this disease164,165. An\nearly and pivotal study by Diehl et al. demonstrated that ctDNA measure-\nments could be used to reliably monitor tumor dynamics in CRC patients\nundergoing surgery16. Speciﬁcally, they showed that median ctDNA",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 72
        }
    },
    "73": {
        "text": "decreased by 96.7% in less than a day and by 99% within 10 days, with\ndetectable ctDNA after surgery associated with relapse. Since then,\nnumerous other studies have demonstrated that the presence of ctDNA\npost-treatment (MRD) was associated with a higher likelihood of\nrelapse47,118,166–170. Notably, Henriksen et al. conducted a nationwide Danish\ncohort study in 851 stage II-III CRC patients treated with curative intent171.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 73
        }
    },
    "74": {
        "text": "They found that ctDNA detection, both post-operatively and serially, was\nassociated with recurrence.\nMRD detection is particularly important in high-risk stage II CRC\npatients. While the management of patients with stage I, III, and IV CRC is\nquite standardized, therapeutic strategies for stage II CRC are not\nstraightforward, as a one-size-ﬁts-all treatment is not suitable in this\nsetting172,173. Current adjuvant management in resected stage II colon can-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 74
        }
    },
    "75": {
        "text": "cers is based on risk stratiﬁcation using clinical and pathologic prognostic\nfactors. ctDNA is thus being investigated for its ability to assess the need for\nadjuvant chemotherapy in stage II patients174. Large and prospective studies\nhave shown that ctDNA is predictive of recurrence in patients with resected\nstage II colon cancer47,175–177. Notably, in a pioneering study by Tie et al. in\n230 patients with stage II colon cancer, post-operative ctDNA levels were",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 75
        }
    },
    "76": {
        "text": "Table 1 (continued) | Completed clinical trials with published results that used ctDNA for clinical decision making and treatment intervention in lung, colorectal, and breast\ncancersa\nCancer\nType\nStudy Name/ Clinical Trial Identiﬁer/\nPublications\nNumber of\nPatients\nStudy Goal\nctDNA Methodology\nKey Findings\nBreast\nPADA-1\nNCT03079011223\n1017\nTo demonstrate the effectiveness of early therapy\nchange based on increasing ESR1 mutation in blood,\nwhile evaluating the overall safety of combining",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 76
        }
    },
    "77": {
        "text": "while evaluating the overall safety of combining\nfulvestrant and palbociclib.\nmultiplex ddPCR\nThe early therapeutic targeting of blood ESR1 mutation\nin ER+/HER2- advanced breast cancer resulted in\nsigniﬁcant clinical beneﬁt.\nBreast\nACTDNA\nNCT05079074300,301\n223\nTo evaluate the efﬁcacy of re-subtyping and determining\ntreatment strategy based on ctDNA alterations.\nNGS\nPatients with druggable ctDNA alterations showed\nsigniﬁcant improvements in PFS and disease control",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 77
        }
    },
    "78": {
        "text": "rate when receiving guided therapy, compared to those\nreceiving standard treatment.\nBreast\nc-TRAK-TN\nNCT03145961232\n208\nTo assess the utility of ctDNA in detecting residual\ndisease following patients’ standard primary treatment\nfor TNBC.\nddPCR\nPatients had a high rate of metastatic disease on ctDNA\ndetection. Implementation of MRD detection with\npersonalized ctDNA assays was clinically achievable.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 78
        }
    },
    "79": {
        "text": "ACT adjuvant chemotherapy, ctDNA Circulating tumor DNA, ddPCR droplet digital PCR, ER Estrogen receptor, MBC Metastatic breast cancer, mCRC metastatic colorectal cancer, MRD Minimal residual disease, NGS Next-generation sequencing, NSCLC Non-small cell\nlung cancer, OS Overall survival, PCR Polymerase chain reaction, PFS Progression-free survival, Safe-SeqS: Safe-Sequencing System, TNBC Triple negative breast cancer, TKI Tyrosine kinase inhibitor, VAF variant allele frequency.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 79
        }
    },
    "80": {
        "text": "aTable 1 includes interventional, ctDNA lead, completed or terminated clinical trials with published results.\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n6\nprognostic, with a negative result associated with a signiﬁcantly increased\nrecurrence-free survival47.\nIn contrast to stage II disease, adjuvant chemotherapy has been the\nstandardofcareforstageIIICRCpatientssincethe90s178.However,inmore",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 80
        }
    },
    "81": {
        "text": "recent years, studies have demonstrated that many stage III CRC patients\ncan\nachieve\n5-year\ndisease-free\nsurvival\neven\nwithout\nadjuvant\nchemotherapy179. Thus, ctDNA monitoring has emerged as a powerful tool\nto potentially select stage III CRC patients for adjuvant therapy. Two pro-\nspective studies involving only stage III patients aimed to determine the\nclinical utility of using ctDNA to guide treatment166,180. The ﬁrst study of 96",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 81
        }
    },
    "82": {
        "text": "colon cancer patients treated with surgery and adjuvant chemotherapy\nshowed signiﬁcantly lower 3-year recurrence-free interval in patients with\ndetectable vs. undetectable ctDNA both after surgery and after che-\nmotherapy treatments166. In the second study, 168 CRC patients with stage\nIII disease were treated with curative intent180. Of these, 80% of post-\noperative ctDNA-positive patients treated with adjuvant chemotherapy\nrelapsed, while only patients who cleared ctDNA permanently during",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 82
        }
    },
    "83": {
        "text": "adjuvant chemotherapy remained relapse-free. Interestingly, the research-\ners also observed that the rate at which ctDNA increased following treat-\nment was signiﬁcantly related to patient survival. Additionally, a post-hoc\nanalysis of the PRODIGE-GERCOR IDEA-France trial analyzed ctDNA in\n1017 patients collected at both post-surgery and pre-chemotherapy time-\npoints, who were randomly assigned to receive either 3-month or 6-month",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 83
        }
    },
    "84": {
        "text": "oxaliplatin-based adjuvant chemotherapy. Only 13.8% of the patients were\nctDNA-positive after surgery, and these patients had a lower 3-year disease-\nfree survival rate compared to those who were ctDNA-negative181. Overall,\nthese studies emphasize the potential of using ctDNA monitoring for\ntherapy selection in stage III CRC patients, which could potentially reduce\nthe number of patients exposed to toxic anti-cancer treatments.\nctDNA has been most extensively studied in the context of stage IV",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 84
        }
    },
    "85": {
        "text": "metastatic (m)CRC, because of the high systemic cancer burden and cor-\nresponding elevated levels of ctDNA shed, providing a rich source for\nanalysis. Given the numerous studies in mCRC, meta-analyses have been\nconducted to analyze the collective data and have shown that the presence\nand levels of ctDNA are strongly associated with OS and risk of\nrecurrence182,183. Joneset al. identiﬁed28 studies, reporting on 2823 patients,\nwhere the measurement of ctDNA in stage IV CRC was correlated with",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 85
        }
    },
    "86": {
        "text": "clinical outcome182. They determined that ctDNAwas positive in 80–90% of\npatients prior to treatment with a strong correlation between detectable\nctDNAaftertreatment(surgeryorchemotherapy) and OS aswellasPFS.Of\nnote, the meta-analysis revealed that ctDNA consistently serves as an early\nindicator of long-term prognosis in irresectable disease, with changes after\njust one cycle of systemic therapy proving to have prognostic value. Simi-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 86
        }
    },
    "87": {
        "text": "larly, Wullaert et al. conducted a meta-analysis investigating the association\nbetween ctDNA in patients undergoing curative-intent local therapy for\nCRC liver metastasis183. Their ﬁndings revealed that following surgery,\nctDNA-positive patients had a signiﬁcantly higher risk of recurrence and\nshorter OS compared to those who were ctDNA-negative. A similar asso-\nciation was observed in patients who remained ctDNA-positive after\ncompleting adjuvant therapy.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 87
        }
    },
    "88": {
        "text": "completing adjuvant therapy.\nOverall,thestudiesinvestigatingctDNAasabiomarkertomonitorand\npredict response to treatment in CRC can be summarized by a large meta-\nanalysis by Reece et al. on 92 studies184. The studies collectively showed that\nctDNA is a reliable measure of tumor burden and useful in assessing the\nadequacy of surgical tumor clearance, with changes in ctDNA levels\nreﬂecting the response to systemic treatments as well as emergence of new",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 88
        }
    },
    "89": {
        "text": "mutations, allowing more sensitive monitoring than currently used clinical\ntools. As such, numerous clinical trials are currently underway to evaluate\nthe effectiveness of ctDNA-based treatment interventions in CRC. Notably,\nCIRCULATE-US185, TRACC Part C186, IMPROVE-IT2187, PEGASUS188,\nBESPOKE189, and AGITG DYNAMIC-Rectal190 are all large ongoing clin-\nical trials evaluating the use of ctDNA (MRD) detection to guide adjuvant",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 89
        }
    },
    "90": {
        "text": "treatment decisions. Additionally, recent reviews by Conca et al.,191 and\nRoazzi et al.,192 address the current state of ongoing clinical trials of ctDNA-\nguided treatment in CRC. Below we present a summary of the completed\nclinical trials designed to assess the use of ctDNA for interventional pur-\nposes in CRC (Table 1).\nctDNA also holds promise in elucidating the intricate landscape of\nresistance mechanisms that emerge during treatment in CRC, which can",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 90
        }
    },
    "91": {
        "text": "help guide clinical decision-making and therapeutic strategies. Initially, the\napplication of ctDNA in mCRC predominantly focused on detecting the\nmutational status of key genes such as RAS and BRAF, pivotal for guiding\npatient selection for anti-EGFR treatment alongside chemotherapy in the\nﬁrst-line setting. For example, studies have shown that mCRC patients with\nRAS mutations on ctDNA have signiﬁcantly worse response rates and",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 91
        }
    },
    "92": {
        "text": "survival after rechallenge withanti-EGFR agents comparedto RAS wildtype\npatients52,193,194. In a two phase-trial composed of REMARRY (monitoring\nphase) and PURSUIT (trial phase), the authors reported that patients with\nRAS-negative ctDNA beneﬁted from anti-EGFR rechallenge therapy195.\nThis was conﬁrmed by the landmark CHRONOS trial that used ctDNA to\nselect patients for chemotherapy-free anti-EGFR rechallenge with\npanitumumab196. Similarly, in the VELO randomized clinical trial, mCRC",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 92
        }
    },
    "93": {
        "text": "patients with pretreatment RAS/BRAF wildtype ctDNA experienced pro-\nlonged clinical beneﬁt when treated with panitumumab plus triﬂuridine-\ntipiracil, compared to those treated with triﬂuridine-tipiracil alone197. This\nsuggests that ctDNA could be useful to select patients who may beneﬁt from\nof anti-EGFR rechallenge. Expanding beyond EGFR-directed therapies,\nctDNAanalysis presentsan avenueforidentifyingcandidates for alternative\nFig. 3 | Current ctDNA precision oncology appli-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 93
        }
    },
    "94": {
        "text": "Fig. 3 | Current ctDNA precision oncology appli-\ncations in NSCLC. ctDNA can be used for ﬁrst- and\nsecond-line therapy selection, acquired resistance\ndetection, and MRD detection in NSCLC.\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n7\ntreatment modalities, including anti-HER2 regimens, in mCRC198–200.\nMoreover, comprehensive ctDNA proﬁling has unveiled a spectrum of\nadditional genetic alterations implicated in acquired resistance196,201–205.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 94
        }
    },
    "95": {
        "text": "Figure 4 outlines the current applications of ctDNA for personalized\ntreatment monitoring in CRC.\nBreast cancer\nBreast cancer is a highly diverse disease with various tumor subtypes, each\ndemanding distinct treatment strategies based on molecular and genomic\nproﬁling of the tumor tissue. For these reasons, molecular biomarkers to\nmonitortreatmentresponseandeffectivenessarevitaltoprecisiononcology\nstrategies in this disease context. ctDNA has been extensively linked to",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 95
        }
    },
    "96": {
        "text": "outcomeinbreastcancer(reviewedinXuetal.206).Notably,ourrecentmeta-\nanalysis reporting data from 4264 patients in 37 studies on metastatic breast\ncancer demonstrated that detection of ctDNA was associated with worse\nOS, PFS, and disease-free survival207.\nSeveral studies have shown the potential of ctDNA in guiding treat-\nment and improving patient outcomes in breast cancer. Riva F et al.208\nreported that tailored ctDNA detection using droplet (d)dPCR yielded a",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 96
        }
    },
    "97": {
        "text": "75% detection rate at baseline during neoadjuvant chemotherapy in triple\nnegative\nbreast\ncancer\n(TNBC)208.\nThey\nfound\nthat\nneoadjuvant\nchemotherapy led to a rapid reduction in ctDNA levels and the absence of\nMRD post-surgery. A gradual decline in ctDNA during neoadjuvant che-\nmotherapy was signiﬁcantly associated with a shorter survival period in\nTNBC. Aguilar-Mahecha et al.209 demonstrated that early on-treatment\nlevels of genomic instability in ctDNA can predict treatment response and",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 97
        }
    },
    "98": {
        "text": "outcomes in MBC209. They found that patients classiﬁed as ‘responders’,\nshowed decreased levels of genomic instability 3 months post-treatment\ncompared to the ‘non-responder’ group. Lin et al.210 have also demonstrated\nitsutilityasarobustpredictorforrelapseinpatientswithstageIItoIIIbreast\ncancer undergoing neoadjuvant therapy, with ctDNA-positive patients\npost-neoadjuvant therapy having worse recurrence-free survival than",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 98
        }
    },
    "99": {
        "text": "ctDNA-negative patients210. Interestingly, of the 13 study participants who\nachieveda pathologic completeresponse, only 2 had detectable ctDNA after\nneoadjuvant therapy, and both of these individuals went on to develop\nmetastasis. In contrast, the remaining 11 subjects did not experience\nrecurrence or metastasis. Ortolan et al.211 demonstrated that ctDNA can\neffectively predict the prognosis of TNBC patients undergoing neoadjuvant",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 99
        }
    },
    "100": {
        "text": "chemotherapy211. They found that ctDNA was detected in 77% of evaluable\ncases before the start of neoadjuvant chemotherapy, whereas it was present\ninonly43%ofcasesafterthetreatment.Inthemetastaticsetting,ctDNAhas\nbeen used for treatment tailoring, tracking mechanisms of drug resistance,\nFig. 4 | Current ctDNA precision oncology appli-\ncations in CRC. A ctDNA is being explored for the\ndetection of MRD and treatment escalation/de-\nescalation in the adjuvant setting in CRC. The",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 100
        }
    },
    "101": {
        "text": "escalation in the adjuvant setting in CRC. The\ndetection of speciﬁc alterations in ctDNA such as\nHER2 ampliﬁcations or B KRAS, NRAS, BRAF, or\nEGFR mutations can be used to guide personalized\ntreatment decisions.\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n8\nand for predicting disease response before imaging (reviewed in Amato\net al.212). These ﬁndings highlight the value of ctDNA in evaluating and\nguiding treatment strategies in breast cancer.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 101
        }
    },
    "102": {
        "text": "guiding treatment strategies in breast cancer.\nThe incorporation of ctDNA analysis into breast cancer clinical trials\nhas increasingly become a crucial component in personalizing treatment\napproaches. The SOLAR-1 trial, a phase 3 study, assessed the safety and\neffectiveness of the PIK3CA inhibitor alpelisib when combined with\nfulvestrant in patients with PIK3CA-mutated, hormone receptor-positive\n(HR+) / HER2- breast cancer213,214. Plasma ctDNA analysis revealed worse",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 102
        }
    },
    "103": {
        "text": "OS for PIK3CA-mutated patients treated with fulvestrant alone vs. in\ncombination with alpelisib. Consequently, the American Society of Clinical\nOncology (ASCO) updated its guidelines in 2022 to recommend ctDNA\ntesting for HR+/HER2- MBC to identify patients eligible for alpelisib plus\nfulvestranttreatment215.Also,CAPTUREisanongoingphaseIImulticentre\nclinical trial in Australia studying the use of alpelisib plus fulvestrant in\nER+/HER2- advanced breast cancer patients with detectable PIK3CA",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 103
        }
    },
    "104": {
        "text": "mutations in ctDNA who had progressed during or after treatments with\nCDK4/6 inhibitors and aromatase inhibitors216. ctDNA analysis of patients\nenrolled in the phase Ib MONALEESASIA trials identiﬁed several genomic\nalterations associated with treatment response to the CDK4/6 inhibitor\nribociclib217. Subsequently, in phase III of the MONALEESA trial, Andre\net al.218 found that patients with ERBB2, FAT3, FRS2, MDM2, SFRP1, and\nZNF217 mutations had better PFS with ribociclib compared to placebo,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 104
        }
    },
    "105": {
        "text": "while mutations in ANO1, CDKN2A/2B/2C, and RB1 reduced ribociclib\nsensitivity218. Table 1 offers a summary of various published clinical trials\nthat evaluated the application of ctDNA monitoring for clinical interven-\ntions in breast cancer.\nThe identiﬁcation of treatment resistance in breast cancer can also be\ngreatly aided by the use of ctDNA. ESR1 mutations are well established to\ndrive resistance to endocrine therapy in HR+ breast cancer. In 2016,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 105
        }
    },
    "106": {
        "text": "Fribbens et al. assessed the impact of ESR1 mutations on the sensitivity to\nstandard therapies from two phase III randomized trials: the SoFEA Trial219\nand the PALOMA3 trial220 indicating that plasma ESR1 mutations after\naromatase inhibitor therapy progression could guide subsequent endocrine\ntherapy221. The ALERT study further supported this by linking dynamic\nctDNA ﬂuctuations during treatment cycles with clinical beneﬁts and\nresistance in ER+MBC patients222. In the PADA-1 trial, ER+/HER2-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 106
        }
    },
    "107": {
        "text": "patients with rising plasma ESR1 ctDNA levels during ﬁrst-line aromatase\ninhibitor and palbociclib therapy were randomized to either continue their\ncurrent treatment or switch to fulvestrant and palbociclib223. Patients in the\nfulvestrant group had improved PFS compared to the aromatase inhibitor\ngroup. Similarly, in the EMERALD trial, patients with ESR1 mutations\ntreated with elacestrant showed improved survival compared to those",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 107
        }
    },
    "108": {
        "text": "receiving standard care224. As a result, ASCO now recommends ctDNA\ntesting to detect ESR1 mutations in advanced ER+/HER2- breast cancer\npatients who have progressed after endocrine therapy, to identify those who\nFig. 5 | Current ctDNA precision oncology appli-\ncations in breast cancer. A In HR+ breast cancer,\nctDNA can be used to detect the emergence of ESR1\nresistance mutations and second-line therapy\nselection. ctDNA can also be used for PIK3CA\nmutation detection and personalized treatment",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 108
        }
    },
    "109": {
        "text": "mutation detection and personalized treatment\nrecommendation of PI3K inhibitors. B ctDNA can\nbeused for MRD detection and treatment escalation.\nIn HER2+ breast cancer, ctDNA can be used for\ndetection of HER2 ampliﬁcations and therapy\nselection.\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n9\nmight beneﬁt from treatment with elacestrant225. This recommendation\nhighlights the importance of ctDNA biomarker studies and demonstrates",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 109
        }
    },
    "110": {
        "text": "the rapid integration of ctDNA biomarker studies into clinical practice.\nThe utility of ctDNA extends to the detection of MRD through post-\ntreatment monitoring, which is pivotal in predicting relapse in breast cancer\npatients226. A landmark study conducted by Garcia-Murillas et al. in 2015227\nshowed that ctDNA positivity after curative-intent surgery was a strong\npredictor of relapse, with a median lead time of 7.9 months before clinical",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 110
        }
    },
    "111": {
        "text": "recurrence227. They demonstrated that ctDNA analysis could detect MRD\nwith a sensitivity of 93% and speciﬁcity of 100%. Similarly, Olsson et al.\ndemonstrated that ctDNA could detect metastasis an average of 11 months\nbefore clinical detection, showing high accuracy in distinguishing patients\nwith and without clinically detected recurrence after surgery228. Further\nsupporting these ﬁndings, Magbanua et al.229 isolated cfDNA from 84 high-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 111
        }
    },
    "112": {
        "text": "risk early breast cancer patients in the neoadjuvant I-SPY 2 trial229. They\nfound that the absence of ctDNA clearance was a strong predictor of poor\nresponse and metastatic recurrence, whereas clearance was linked to\nimproved survival, even in patients who did not achieve a pathologic\ncomplete response. Zhou et al.230 also showed that detection of ctDNA in\npost-treatment samples was linked to a substantial likelihood of future\nrecurrence and an unfavorable response to neoadjuvant treatment230.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 112
        }
    },
    "113": {
        "text": "Coombes et al.220 also found that ctDNA detected pre-clinically or radi-\nologically in 16 of 18 patients (89% sensitivity) predicted metastatic relapse\nup to 2 years in advance, with a median lead time of 8.9 months and 100%\nspeciﬁcity220. However, Coakley et al.231 noted that different detection\nmethodologies, (NGS vs. dPCR) affect lead times from ctDNA detection to\nclinical relapse231. In a cohort of 22 early-stage breast cancer patients, NGS",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 113
        }
    },
    "114": {
        "text": "provided a lead time of 6.1 months compared to 3.9 months with dPCR.\nDespite the small sample size, these ﬁndings highlight the potential con-\nsiderations when using ctDNA for MRD detection. The c-TRAK TN trial, a\nphase II clinical trial, prospectively evaluated the effectiveness of ctDNA in\ndetecting MRD and guiding therapy in early-stage TNBC232. In the trial,\nctDNA-positive patients were assigned to either receive pembrolizumab or",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 114
        }
    },
    "115": {
        "text": "to be placed in an observation group. Interestingly, none of the participants\nin the intervention arm achieved ctDNA clearance. However, the assess-\nment was limited by the small sample size of patients receiving therapy,\nwhich resulted from a higher-than-anticipated rate of metastasis among\nstudy participants. Overall, these studies support the potential of ctDNA for\nuse as a valuable tool in early detection of MRD and metastasis. As such, a",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 115
        }
    },
    "116": {
        "text": "large scale multicenter ongoing clinical trial, MiRaDoR, is using ctDNA\nsurveillance on HR-positive/HER2-negative early-stage BC patients to\ndetect MRD and provide treatment at the event of ctDNA positivity233.\nThe FDA has approved certain ctDNA tests as companion diagnostics\nfor guiding targeted therapies in breast cancer. For instance, the Guar-\ndant360 CDx NGS panel detects ESR1 mutations in estrogen receptor-\npositive (ER+)/HER2- metastatic breast cancer (MBC), identifying candi-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 116
        }
    },
    "117": {
        "text": "datesforelacestrant234.Similarly,theQiagentherascreenPIK3CARGQPCR\nKit can identify PIK3CA mutations in ctDNA from plasma samples for\nbreast cancer patients who may be eligible for treatment with alpelisib235.\nFoundationOne CDx identiﬁes patients eligible for targeted therapies by\ndetecting ERBB2 (HER2) ampliﬁcations for treatment with trastuzumab,\nado-trastuzumab emtansine, and pertuzumab. It also detects AKT1 and\nPTEN alterations that can beneﬁt from AKT inhibitors like capivasertib and",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 117
        }
    },
    "118": {
        "text": "ipatasertib35,236,237. These FDA-approved ctDNAtests and genomic proﬁling\nassays are crucial in guiding the selection of targeted therapies for breast\ncancer patients, potentially improving outcomes.\nThe landscape of ctDNA research in breast cancer is evolving, with\nseveralnoveltrialsunderway.Also,recentlydevelopedpredictivemodelsfor\nneoadjuvant chemotherapy response in breast cancer patients, incorpor-\nating genomic features and clinical factors, demonstrate effective dis-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 118
        }
    },
    "119": {
        "text": "crimination between pathologic complete response and non-complete\nresponse with ctDNA status-enhancing predictive accuracy238. The MAG-\nNETIC 1 trial evaluates ctDNA’s diagnostic potential in monitoring\nHR + MBC during ﬁrst-line endocrine therapy239. The CIPHER study\nexplores ctDNA’s role in triple-negative and HER2+ early-stage breast\ncancer, enabling tailored interventions for these aggressive subtypes240.\nThese studies, among others, are paving the way for the integration of",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 119
        }
    },
    "120": {
        "text": "ctDNA into clinical practice, allowing earlier detection of MRD and treat-\nment resistance, and ultimately improving long-term survival rates and\nquality of life for breast cancer patients. Figure 5 summarizes the current\napplications of ctDNA monitoring in the various breast cancer subtypes.\nOther cancers\nIn the following section we will outline other notable advances and appli-\ncations of ctDNA monitoring in other solid tumor types. To begin, ctDNA",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 120
        }
    },
    "121": {
        "text": "has emerged as a promising marker for monitoring disease progression and\npost-treatment relapses in melanoma241,242. In recent years, the treatment\nlandscape for melanoma has shifted tremendously with the emergence of\nnew targeted therapies as well as the remarkable promise of immu-\nnotherapies. For instance, BRAF and MEK inhibitors243 as well as immu-\nnotherapies such as anti-PD1 treatment244,245 have been shown to increase",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 121
        }
    },
    "122": {
        "text": "patient survival246,247. However, selection of patients is essential and the\nresponse to such treatments is not always long-lasting, with secondary\nresistances often occurring. A study by Haselmann et al. in 634 stage I to IV\nmelanoma patients showed that detection of BRAF mutant ctDNA pre-\ncededrelapseasassessedbyRECISTandwasmorespeciﬁcthanserumS100\nand lactate dehydrogenase248. Additionally, Varaljai et al. assessed the pre-\nsence of BRAF, NRAS, and TERT mutations in ctDNA in 96 patients with",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 122
        }
    },
    "123": {
        "text": "advanced-stage melanoma, observing that changes in ctDNA correlated\nwith treatment response and that increasing ctDNA levels predicted disease\nprogression signiﬁcantly earlier than did routine radiologic scans, with a\nmean lead time of 3.5 months249. Moreover, ctDNA has been utilized to\nassess response to immunotherapies in melanoma. One study found that\nlongitudinal assessment of ctDNA in patients receiving PD1 inhibitors was",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 123
        }
    },
    "124": {
        "text": "an accurate predictor of tumor response as well as survival250. Another study\ndemonstrated that positive ctDNA during treatment (week 2 or 4) was an\nearly predictor of a complete lack of clinical beneﬁt under anti-PD1251.\nImportantly given the common resistance to immunotherapies, a previous\nstudy demonstrated emergence of dynamic complexity in mutational pro-\nﬁle of ctDNA during treatment with pembrolizumab or nivolumab treat-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 124
        }
    },
    "125": {
        "text": "ment, including multiple BRAF mutations in the same patient, clinically\nrelevant BRAF mutations emerging through therapy and co-occurring sub-\nclonal BRAF and NRAS mutations246.\nInterestingly, ctDNA has also been investigated in uveal melanoma, a\nrare form of melanoma that develops in melanocytes of the uveal track.\nWhile uveal melanoma represents only 5% of melanomas, it is the most\ncommon intraocular tumor in adults and is associated with high mortality",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 125
        }
    },
    "126": {
        "text": "rates252. Liquid biopsy is particularly useful in this context, where the\ndiagnosis of uveal melanoma is made through imaging, withhighly invasive\nintraocular biopsies usuallyperformed only for prognostication253. Blood, as\nwell as aqueous humor and vitreous humor, have been investigated as\nsources of ctDNA, and data has shown correlations between ctDNA and\ndisease severity, progression, metastasis and outcome62,254–257. The clinical",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 126
        }
    },
    "127": {
        "text": "utility of ctDNA in monitoring treatment response has also been tested,\nincluding\nin\nthe\ncontext\nof\nnovel\ntargeted\ntherapies\nsuch\nas\nimmunotherapy65,258,259 and protein kinase C inhibition260. In a phase II trial\nof tebentafusp, a soluble T cell receptor bispeciﬁc, in 127 patients with\ntreatment-refractorymetastaticuvealmelanoma(NCT02570308),earlyon-\ntreatment reduction in ctDNA was strongly associated with OS, even in\npatients with radiographic progression261.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 127
        }
    },
    "128": {
        "text": "patients with radiographic progression261.\nIn the realm of prostate cancer, several studies have highlighted the\npotential use of ctDNAas a biomarkerfor various clinical applications, such\nas predictingpostoperative recurrence262, monitoring drugresistance262,and\nassessing treatment response81. In particular, many studies have explored\nthe feasibility of detecting AR mutations and splice variants in ctDNA263–267.\nFor instance, in a studyusing a 3,334 patient cohort of metastatic castration-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 128
        }
    },
    "129": {
        "text": "resistant prostate cancer, it was demonstrated that ctDNA contained\nadditionalalterationsnotfoundintumortissue,includingabroad spectrum\nof AR resistance alterations and somatic BRCA1/2 mutations and\nreversions268. Also, a study by Romanel et al. investigated 274 plasma\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n10\nsamples from 97 castration-resistant prostate cancer treated with abirater-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 129
        }
    },
    "130": {
        "text": "one and found that ctDNA was useful in studying the dynamic evolution of\nAR alterations throughout treatment265. Speciﬁcally, this study provided\nevidence that resistant AR subclones can be detected in ctDNA even before\nclinical evidence of disease progression. In a more recent study, a shift in the\nctDNA population towards AR augmentation after treatment with AR\nsignaling inhibitors was observed81. Recent research also suggests that",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 130
        }
    },
    "131": {
        "text": "metastatic castration resistant prostate cancer patients with AR alterations\nonctDNAhadinferiorOSafterdiseaseprogressionontheﬁrstARsignaling\ninhibitor compared to those without AR ctDNA mutants269.\nThe dire prognosis of central nervous system tumors has prompted\nnew avenues for biomarker discovery to monitor patient response to\ntreatment. However, blood-based liquid biopsy analysis is challenged by the\nhighly selective nature of the blood brain barrier270. As such, many studies",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 131
        }
    },
    "132": {
        "text": "have turned towards the use of CSF as a source of ctDNA127,271. Indeed,\nseveral studies have reported ctDNA concentrations in several orders of\nmagnitude higher in CSF than plasma127,272 or urine273, where typical plasma\nvariant allele frequencies are <1%271,274. Notably, serial monitoring of CSF\nhas been used to detect MRD and treatment response in brain\ncancers48,271,275. In fact, a recent clinical trial showed that analyzing H3",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 132
        }
    },
    "133": {
        "text": "K27M-mutant diffuse midline gliomas from CSF ctDNA was a reliable\napproach to conﬁrm treatment response and identify subsequent tumor\nprogression275. Similar studies have also been explored in the context of\nbrain metastases. For instance, using CSF cfDNA, Pentsova et al.129 detected\nhigh-conﬁdence somatic alterations in 63% of patients with central nervous\nsystem metastases of solid tumors, 50% of patients with primary brain",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 133
        }
    },
    "134": {
        "text": "tumors, and 0% of patients without central nervous system involvement129.\nWhile these studiesadvocate for the use of CSF inprimarybraintumorsand\nbrain metastases, lumbar punctures remain signiﬁcantly more invasive than\nblood or urine collection276.\nIn recent years, viral ctDNA in virus-driven malignancies, which\naccount for ~10% of the worldwide cancer burden277, has also been inves-\ntigated as a tool to track disease progression and recurrence. This is espe-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 134
        }
    },
    "135": {
        "text": "cially prominent in cancers driven by HPV such as oropharyngeal and\ncervical cancers278. However, examiningviral DNA asopposedto mutations\nposesdifferentchallenges,sinceviralsequencesdivergeovertimeandacross\npopulations279. This has led to a wide array of experimental techniques for\ndetecting different portions of the viral genome. Generally, HPV-ctDNA\nhas been examined using ddPCR or HPV-speciﬁc sequencing techniques,\nandhasbeenshowntobeatoolformonitoringtreatmentresponseinbodily",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 135
        }
    },
    "136": {
        "text": "ﬂuids, including plasma and saliva83,104. While multiple studies have shown\nsigniﬁcant relationships between viral ctDNA levels and treatment\nresponse83,280–282, certain challenges still exist in these analyses, especially the\nvariable copy number caused by differences in the degree of integration of\nviral DNA into the host genome280,281,283. Globally, there has been a high\ndegree of sensitivity in studies monitoring plasma ctDNA in HPV-related",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 136
        }
    },
    "137": {
        "text": "head and neck cancers and in more advanced cervical cancers, though\ncertain studies have demonstrated lower sensitivity for lower-grade cervical\ncancer281,284.\nLimitations and future directions\nWhile ctDNA is emerging as a powerful tool for monitoring treatment\nresponse, certain limitations still exist that hinder its widespread imple-\nmentation into clinics. Particularly, there is a lack of guidelines for optimal\nliquid biopsy sampling timepoints, such as the ideal time after treatment to",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 137
        }
    },
    "138": {
        "text": "detect MRD and predict patient relapse. Furthermore, there is also a lack of\nstandardization of pre-analytical steps, including the type of collection tube\nor the speed and number of centrifugation steps needed for processing\nsamples285,286. There is also a lack of standardization of downstream analy-\ntical assays used, such as the use of tumor-informed or uninformed\napproaches, which ultimately leads to variability in clinical trial results287. In",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 138
        }
    },
    "139": {
        "text": "addition, ctDNA analysis can be limited by constraints such as low levels of\ninput DNA, rapid degradation of DNA fragments, and potential con-\nfounding\ndata\nfrom\nother\ndiseases\ncancer\npatients\nmight\nhave\nsimultaneously288. Future research should focus on reﬁning detection\nmethods and establishing standardized protocols across diverse cancer\npopulations285,288,289. Overall, liquid biopsy holds tremendous potential, both\nas a source of non-invasive biomarkers and as a methodology for studying",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 139
        }
    },
    "140": {
        "text": "cancer.However,welackasolidunderstandingof thefundamentaloriginof\ntumor-derived molecules. Addressing these gaps is the ﬁrst step to stan-\ndardizing ctDNA analysis and interpretation and determining its clinical\nutility in different cancer contexts. By tracking disseminated molecules and\nthe evolving dynamics of cancer, we will identify molecular alterations that\ncould be used for non-invasive diagnosis, prognosis, and detection of",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 140
        }
    },
    "141": {
        "text": "treatment resistance, ﬁnding new opportunities for personalized strategies\nto prevent and manage disease.\nData availability\nNo datasets were generated or analysed during the current study.\nReceived: 2 October 2024; Accepted: 11 March 2025;\nReferences\n1.\nClinton, T. N. et al. Genomic heterogeneity as a barrier to precision\noncology in urothelial cancer. Cell Rep. 41, 111859 (2022).\n2.\nEisenhauer, E. A. et al. New response evaluation criteria in solid",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 141
        }
    },
    "142": {
        "text": "tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45,\n228–247 (2009).\n3.\nSeymour, L. et al. iRECIST: guidelines for response criteria for use in\ntrials testing immunotherapeutics. Lancet Oncol. 18, e143–e152 (2017).\n4.\nAlix-Panabieres, C. & Pantel, K. Liquid biopsy: from discovery to\nclinical application. Cancer Discov. 11, 858–873 (2021).\n5.\nBoukovala, M., Westphalen, C. B. & Probst, V. Liquid biopsy into the\nclinics: Current evidence and future perspectives. J. Liq. Biopsy 4,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 142
        }
    },
    "143": {
        "text": "100146 (2024).\n6.\nAndrikou, K. et al. Circulating tumour cells: detection and application\nin advanced non-small cell lung cancer. Int J. Mol. Sci. 24, 16085\n(2023).\n7.\nMarkou, A., Tzanikou, E. & Lianidou, E. The potential of liquid biopsy\nin the management of cancer patients. Semin Cancer Biol. 84, 69–79\n(2022).\n8.\nBecker, A. et al. Extracellular vesicles in cancer: cell-to-cell\nmediators of metastasis. Cancer Cell 30, 836–848 (2016).\n9.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 143
        }
    },
    "144": {
        "text": "9.\nTsering, T., Nadeau, A., Wu, T., Dickinson, K. & Burnier, J. V.\nExtracellular vesicle-associated DNA: ten years since its discovery\nin human blood. Cell Death Dis. 15, 668 (2024).\n10.\nAlix-Panabières, C., Schwarzenbach, H. & Pantel, K. Circulating\ntumor cells and circulating tumor DNA. Annu Rev. Med 63, 199–215\n(2012).\n11.\nChen, G., Zhang, J., Fu, Q., Taly, V. & Tan, F. Correction: Integrative\nanalysis of multi-omics data for liquid biopsy. Br. J. Cancer 128, 702\n(2023).\n12.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 144
        }
    },
    "145": {
        "text": "(2023).\n12.\nMoss, J. et al. Comprehensive human cell-type methylation atlas\nrevealsorigins of circulating cell-free DNA in health and disease.Nat.\nCommun. 9, 5068 (2018).\n13.\nMattox, A. K. et al. The origin of highly elevated cell-free DNA in\nhealthy individuals and patients with pancreatic, colorectal, lung, or\novarian cancer. Cancer Discov. 13, 2166–2179 (2023).\n14.\nStroun, M., Lyautey, J., Lederrey, C., Mulcahy, H. E. & Anker, P. Alu",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 145
        }
    },
    "146": {
        "text": "repeat sequences are present in increased proportions compared to\na unique gene in plasma/serum DNA: evidence for a preferential\nrelease from viable cells? Ann. N. Y Acad. Sci. 945, 258–264 (2001).\n15.\nMyint, K. Z. Y. et al. Identiﬁcation of circulating tumour DNA (ctDNA)\nfrom the liquid biopsy results: Findings from an observational cohort\nstudy. Cancer Treat. Res Commun. 35, 100701 (2023).\n16.\nDiehl, F. et al. Circulating mutant DNA to assess tumor dynamics.\nNat. Med 14, 985–990 (2008).\n17.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 146
        }
    },
    "147": {
        "text": "Nat. Med 14, 985–990 (2008).\n17.\nLo, Y. M. et al. Rapid clearance of fetal DNA from maternal plasma.\nAm. J. Hum. Genet 64, 218–224 (1999).\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n11\n18.\nMurtaza, M. et al. Multifocal clonal evolution characterized using\ncirculating tumour DNA in a case of metastatic breast cancer. Nat.\nCommun. 6, 8760 (2015).\n19.\nDe Mattos-Arruda, L. et al. Capturing intra-tumor genetic",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 147
        }
    },
    "148": {
        "text": "heterogeneity by de novo mutation proﬁling of circulating cell-free\ntumor DNA: a proof-of-principle. Ann. Oncol. 25, 1729–1735 (2014).\n20.\nSun, K. et al. Plasma DNA tissue mapping by genome-wide\nmethylation sequencing for noninvasive prenatal, cancer, and\ntransplantation assessments. Proc. Natl Acad. Sci. USA 112,\nE5503–E5512 (2015).\n21.\nJahr, S. et al. DNA fragments in the blood plasma of cancer patients:\nquantitations and evidence for their origin from apoptotic and",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 148
        }
    },
    "149": {
        "text": "necrotic cells. Cancer Res 61, 1659–1665 (2001).\n22.\nKamat, A. A. et al. Circulating cell-free DNA: a novel biomarker for\nresponse to therapy in ovarian carcinoma. Cancer Biol. Ther. 5,\n1369–1374 (2006).\n23.\nRago, C. et al. Serial assessment of human tumor burdens in mice by\nthe analysis of circulating DNA. Cancer Res 67, 9364–9370 (2007).\n24.\nCao, H. et al. Quantitation of humanpapillomavirus DNA in plasma of\noropharyngeal carcinoma patients. Int J. Radiat. Oncol. Biol. Phys.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 149
        }
    },
    "150": {
        "text": "82, e351–e358 (2012).\n25.\nXi, L. et al. Circulating tumor DNA as an early indicator of response to\nT-cell transfer immunotherapy in metastatic melanoma. Clin. Cancer\nRes 22, 5480–5486 (2016).\n26.\nHusain, H. et al. Monitoring daily dynamics of early tumor response\nto targeted therapy by detecting circulating tumor DNA in urine. Clin.\nCancer Res 23, 4716–4723 (2017).\n27.\nPereira, B. et al. Cell-free DNA captures tumor heterogeneity and",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 150
        }
    },
    "151": {
        "text": "driver alterations in rapid autopsies with pre-treated metastatic\ncancer. Nat. Commun. 12, 3199 (2021).\n28.\nCristiano, S. et al. Genome-wide cell-free DNA fragmentation in\npatients with cancer. Nature 570, 385–389 (2019).\n29.\nZhou, Q. et al. Epigenetic analysis of cell-free DNA by fragmentomic\nproﬁling. Proc. Natl Acad. Sci. 119, e2209852119 (2022).\n30.\nZhou, Z. et al. Fragmentation landscape of cell-free DNA revealed by\ndeconvolutional analysis of end motifs. Proc. Natl Acad. Sci. USA",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 151
        }
    },
    "152": {
        "text": "120, e2220982120 (2023).\n31.\nBai, J. et al. Histone modiﬁcations of circulating nucleosomes are\nassociated with changes in cell-free DNA fragmentation patterns.\nProc. Natl Acad. Sci. 121, e2404058121 (2024).\n32.\nUnderhill, H. R. et al. Fragment length of circulating tumor DNA.\nPLoS Genet 12, e1006162 (2016).\n33.\nJiang, P. et al. Lengthening and shortening of plasma DNA in\nhepatocellular carcinoma patients. Proc. Natl Acad. Sci. USA 112,\nE1317–E1325 (2015).\n34.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 152
        }
    },
    "153": {
        "text": "E1317–E1325 (2015).\n34.\nBarr, M. P. et al. Liquid biopsy: a multi-parametric analysis of\nmutation status, circulating tumor cells and inﬂammatory markers in\nEGFR-mutated NSCLC. Diagnostics 12, 2360 (2022).\n35.\nWoodhouse, R. et al. Clinical and analytical validation of\nFoundationOne Liquid CDx, a novel 324-Gene cfDNA-based\ncomprehensive genomic proﬁling assay for cancers of solid tumor\norigin. PLOS ONE 15, e0237802 (2020).\n36.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 153
        }
    },
    "154": {
        "text": "origin. PLOS ONE 15, e0237802 (2020).\n36.\nBauml, J. M. et al. Clinical validation of Guardant360 CDx as a blood-\nbased companion diagnostic for sotorasib. Lung Cancer 166,\n270–278 (2022).\n37.\nDuffy, M. J. & Crown, J. Circulating tumor DNA as a biomarker for\nmonitoring patients with solid cancers: comparison with standard\nprotein biomarkers. Clin. Chem. 68, 1381–1390 (2022).\n38.\nZheng, J., Qin, C., Wang, Q., Tian, D. & Chen, Z. Circulating tumour",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 154
        }
    },
    "155": {
        "text": "DNA-Based molecular residual disease detection in resectable\ncancers: a systematic review and meta-analysis. EBioMedicine 103,\n105109 (2024).\n39.\nFiala, C. & Diamandis, E. P. Utility of circulating tumor DNA in cancer\ndiagnostics with emphasis on early detection. BMC Med 16, 166\n(2018).\n40.\nBittla, P. et al. Exploring Circulating Tumor DNA (CtDNA) and its role\nin early detection of cancer: a systematic review. Cureus 15, e45784\n(2023).\n41.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 155
        }
    },
    "156": {
        "text": "(2023).\n41.\nSiravegna, G. et al. How liquid biopsies can change clinical practice\nin oncology. Ann. Oncol. 30, 1580–1590 (2019).\n42.\nPessoa, L. S., Heringer, M. & Ferrer, V. P. ctDNA as a cancer\nbiomarker: A broad overview. Crit. Rev. Oncol. Hematol. 155,\n103109 (2020).\n43.\nHusain, H. et al. Tumor fraction correlates with detection of\nactionable variants across >23,000 circulating tumor DNA samples.\nJCO Precis Oncol. 6, e2200261 (2022).\n44.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 156
        }
    },
    "157": {
        "text": "JCO Precis Oncol. 6, e2200261 (2022).\n44.\nZhang, E. W. et al. Association between circulating tumor DNA\nburden and disease burden in patients with ALK-positive lung\ncancer. Cancer 126, 4473–4484 (2020).\n45.\nKirchweger, P. et al. Circulating tumor DNA correlates with tumor\nburden and predicts outcome in pancreatic cancer irrespective of\ntumor stage. Eur. J. Surg. Oncol. 48, 1046–1053 (2022).\n46.\nWang, S. et al. Circulating tumor DNA integrating tissue clonality",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 157
        }
    },
    "158": {
        "text": "detects minimal residual disease in resectable non-small-cell lung\ncancer. J. Hematol. Oncol. 15, 137 (2022).\n47.\nTie, J. et al. Circulating tumor DNA analysis detects minimal residual\ndisease and predicts recurrence in patients with stage II colon\ncancer. Sci. Transl. Med 8, 346ra92 (2016).\n48.\nLiu, A. P. Y. et al. Serial assessment of measurable residual disease in\nmedulloblastoma liquid biopsies. Cancer Cell 39, 1519–30 e4 (2021).\n49.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 158
        }
    },
    "159": {
        "text": "49.\nTie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy\nin Stage II Colon cancer. N. Engl. J. Med 386, 2261–2272 (2022).\n50.\nModing, E. J. et al. Circulating tumor DNA dynamics predict beneﬁt\nfrom consolidation immunotherapy in locally advanced non-small\ncell lung cancer. Nat. Cancer 1, 176–183 (2020).\n51.\nMurtaza, M. et al. Non-invasive analysis of acquired resistance to\ncancer therapy by sequencing of plasma DNA. Nature 497, 108–112\n(2013).\n52.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 159
        }
    },
    "160": {
        "text": "(2013).\n52.\nCremolini, C. et al. Rechallenge for patients with RAS and BRAF\nwild-type metastatic colorectal cancer with acquired resistance to\nﬁrst-line Cetuximab and Irinotecan: A Phase 2 single-arm clinical\ntrial. JAMA Oncol. 5, 343–350 (2019).\n53.\nWang, Y. H., Song, Z., Hu, X. Y. & Wang, H. S. Circulating tumor DNA\nanalysis for tumor diagnosis. Talanta 228, 122220 (2021).\n54.\nKim, H. & Park, K. U. Clinical circulating tumor DNA testing for",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 160
        }
    },
    "161": {
        "text": "precision oncology. Cancer Res Treat. 55, 351–366 (2023).\n55.\nSyeda,M. M. etal. CirculatingtumourDNA in patientswithadvanced\nmelanoma treated with dabrafenib or dabrafenib plus trametinib: a\nclinical validation study. Lancet Oncol. 22, 370–380 (2021).\n56.\nGautschi, O. et al. Origin and prognostic value of circulating KRAS\nmutations in lung cancer patients. Cancer Lett. 254, 265–273 (2007).\n57.\nHolm, M. et al. Detection of KRAS mutations in liquid biopsies from",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 161
        }
    },
    "162": {
        "text": "metastatic colorectal cancer patients using droplet digital PCR,\nIdylla, and next generation sequencing. PLoS One 15, e0239819\n(2020).\n58.\nSchiavon, G. et al. Analysis of ESR1 mutation in circulating tumor\nDNA demonstrates evolution during therapy for metastatic breast\ncancer. Sci. Transl. Med 7, 313ra182 (2015).\n59.\nDumbrava, E. E. et al. PIK3CA mutations in plasma circulating tumor\nDNA predict survival and treatment outcomes in patients with\nadvanced cancers. ESMO Open 6, 100230 (2021).\n60.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 162
        }
    },
    "163": {
        "text": "advanced cancers. ESMO Open 6, 100230 (2021).\n60.\nSumiyoshi, T. et al. Clinical utility of androgen receptor gene\naberrations in circulating cell-free DNA as a biomarker for treatment\nof castration-resistant prostate cancer. Sci. Rep. 9, 4030 (2019).\n61.\nCrucitta, S. etal. IDH1 mutation isdetectablein plasmacell-freeDNA\nand is associated with survival outcome in glioma patients. BMC\nCancer 24, 31 (2024).\n62.\nBustamante, P. et al. Circulating tumor DNA tracking through driver",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 163
        }
    },
    "164": {
        "text": "mutations as a liquid biopsy-based biomarker for uveal melanoma.\nJ. Exp. Clin. Cancer Res 40, 196 (2021).\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n12\n63.\nNewman, A. M. et al. An ultrasensitive method for quantitating\ncirculating tumor DNA with broad patient coverage. Nat. Med 20,\n548–554 (2014).\n64.\nNewman, A. M. et al. Integrated digital error suppression for\nimproved detection of circulating tumor DNA. Nat. Biotechnol. 34,\n547–555 (2016).\n65.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 164
        }
    },
    "165": {
        "text": "547–555 (2016).\n65.\nCabel, L. et al. Circulatingtumor DNA changesfor earlymonitoring of\nanti-PD1 immunotherapy: a proof-of-concept study.Ann. Oncol. 28,\n1996–2001 (2017).\n66.\nForshew, T. et al. Noninvasive identiﬁcation and monitoring of\ncancer mutations by targeted deep sequencing of plasma DNA. Sci.\nTransl. Med 4, 136ra68 (2012).\n67.\nKinde, I., Wu, J., Papadopoulos, N., Kinzler, K. W. & Vogelstein, B.\nDetection and quantiﬁcation of rare mutations with massively",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 165
        }
    },
    "166": {
        "text": "parallel sequencing. Proc. Natl Acad. Sci. USA 108, 9530–9535\n(2011).\n68.\nPhallen, J. et al. Direct detection of early-stage cancers using\ncirculating tumor DNA. Sci. Transl. Med 9, eaan2415 (2017).\n69.\nSchmitt, M. W. et al. Detection of ultra-rare mutations by next-\ngeneration sequencing. Proc. Natl Acad. Sci. USA 109,\n14508–14513 (2012).\n70.\nCohen, J. D. et al. Detection of low-frequency DNA variants by\ntargeted sequencing of the Watson and Crick strands. Nat.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 166
        }
    },
    "167": {
        "text": "Biotechnol. 39, 1220–1227 (2021).\n71.\nAbascal, F. et al. Somatic mutation landscapes at single-molecule\nresolution. Nature 593, 405–410 (2021).\n72.\nWang, T. T. et al. High efﬁciency error suppression for accurate\ndetection of low-frequency variants. Nucleic Acids Res. 47, e87-e\n(2019).\n73.\nBae, J. H. et al. Single duplex DNA sequencing with CODEC detects\nmutations with high sensitivity. Nat. Genet. 55, 871–879 (2023).\n74.\nSilva, T. F. et al. From haystack to high precision: advanced",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 167
        }
    },
    "168": {
        "text": "sequencing methods to unraveling circulating tumor DNA\nmutations. Front Mol. Biosci. 11, 1423470 (2024).\n75.\nBettegowda, C. et al. Detection of circulating tumor DNA in early-\nand late-stage human malignancies. Sci. Transl. Med 6, 224ra24\n(2014).\n76.\nCohen, J. D. et al. Detection and localization of surgically resectable\ncancers with a multi-analyte blood test. Science 359, 926–930\n(2018).\n77.\nWong, D. et al. Integrated, longitudinal analysis of cell-free DNA in",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 168
        }
    },
    "169": {
        "text": "Uveal Melanoma. Cancer Res Commun. 3, 267–280 (2023).\n78.\nMartin-Alonso, C. et al. Priming agents transiently reduce the\nclearance of cell-free DNA to improve liquid biopsies. Science 383,\neadf2341 (2024).\n79.\nShao, Y. et al. Colorectal cancer-derived small extracellular vesicles\nestablish an inﬂammatory premetastatic niche in liver metastasis.\nCarcinogenesis 39, 1368–1379 (2018).\n80.\nRazavi, P. et al. High-intensity sequencing reveals the sources of",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 169
        }
    },
    "170": {
        "text": "plasma circulating cell-free DNA variants. Nat. Med 25, 1928–1937\n(2019).\n81.\nHerberts, C. et al. Deep whole-genome ctDNA chronology of\ntreatment-resistant prostate cancer. Nature 608, 199–208 (2022).\n82.\nChera, B. S. et al. Plasma circulating tumor HPV DNA for the\nsurveillance of cancer recurrence in HPV-associated oropharyngeal\ncancer. J. Clin. Oncol. 38, 1050–1058 (2020).\n83.\nLeung, E. et al. HPV sequencingfacilitates ultrasensitive detection of",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 170
        }
    },
    "171": {
        "text": "HPV circulating tumor DNA. Clin. Cancer Res 27, 5857–5868 (2021).\n84.\nLi,C. L. et al.Cell-free virus-hostchimeraDNA From Hepatitis Bvirus\nintegration sites as a circulating biomarker of hepatocellular cancer.\nHepatology 72, 2063–2076 (2020).\n85.\nChan, A. T. et al. Plasma Epstein-Barr virus DNA and residual\ndisease after radiotherapy for undifferentiated nasopharyngeal\ncarcinoma. J. Natl Cancer Inst. 94, 1614–1619 (2002).\n86.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 171
        }
    },
    "172": {
        "text": "86.\nYalcin, B., Kutluk, T., Agbaba, S. K., Demir, C. & Talim, B. Circulating\nEpstein-Barr virus DNA and cell-free DNA in pediatric lymphomas.\nTurk. J. Pediatr. 62, 541–550 (2020).\n87.\nWang, W. Y. et al. Plasma EBV DNA clearance rate as a novel\nprognostic marker for metastatic/recurrent nasopharyngeal\ncarcinoma. Clin. Cancer Res 16, 1016–1024 (2010).\n88.\nStutheit-Zhao, E. Y. et al. Early changes in tumor-naive cell-free\nmethylomes and fragmentomes predict outcomes in",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 172
        }
    },
    "173": {
        "text": "methylomes and fragmentomes predict outcomes in\npembrolizumab-treated solid tumors. Cancer Discov. 14,\n1048–1063 (2024).\n89.\nGrützmann, R. et al. Sensitive detection of colorectal cancer in\nperipheral blood by septin 9 DNA methylation assay. PLoS One 3,\ne3759 (2008).\n90.\nFiano, V. et al. MGMT promoter methylation in plasma of glioma\npatients receiving temozolomide. J. Neurooncol. 117, 347–357\n(2014).\n91.\nWong, I. H., Zhang, J., Lai, P. B., Lau, W. Y. & Lo, Y. M. Quantitative",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 173
        }
    },
    "174": {
        "text": "analysis of tumor-derived methylated p16INK4a sequences in\nplasma, serum, and blood cells of hepatocellular carcinoma\npatients. Clin. Cancer Res 9, 1047–1052 (2003).\n92.\nChan, K. C. et al. Noninvasive detection of cancer-associated\ngenome-wide hypomethylation and copy number aberrations by\nplasma DNA bisulﬁte sequencing. Proc. Natl Acad. Sci. USA 110,\n18761–18768 (2013).\n93.\nMo, S. et al. Early Detection of Molecular Residual Disease and Risk",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 174
        }
    },
    "175": {
        "text": "Stratiﬁcationfor StageIto IIIColorectalCancerviaCirculatingTumor\nDNA Methylation. JAMA Oncol. 9, 770–778 (2023).\n94.\nCheng, T. H. T. et al. Noninvasive Detection of Bladder Cancer by\nShallow-Depth Genome-Wide Bisulﬁte Sequencing of Urinary Cell-\nFree DNA for Methylation and Copy Number Proﬁling. Clin. Chem.\n65, 927–936 (2019).\n95.\nKresse, S. H. et al. Evaluation of commercial kits for isolation and\nbisulﬁte conversion of circulating cell-free tumor DNA from blood.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 175
        }
    },
    "176": {
        "text": "Clin. Epigenet. 15, 151 (2023).\n96.\nSadeh, R. et al. ChIP-seq of plasma cell-free nucleosomes identiﬁes\ngene expression programs of the cells of origin. Nat. Biotechnol. 39,\n586–598 (2021).\n97.\nShen, S. Y. et al. Sensitive tumour detection and classiﬁcation using\nplasma cell-free DNA methylomes. Nature 563, 579–583 (2018).\n98.\nBie, F. et al. Multimodal analysis of cell-free DNA whole-methylome\nsequencing for cancer detection and localization. Nat. Commun. 14,\n6042 (2023).\n99.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 176
        }
    },
    "177": {
        "text": "6042 (2023).\n99.\nIvanov, M., Baranova, A., Butler, T., Spellman, P. & Mileyko, V. Non-\nrandom fragmentation patterns in circulating cell-free DNA reﬂect\nepigenetic regulation. BMC Genomics 16, S1 (2015). Suppl 13.\n100.\nLiu, Y. At the dawn: cell-free DNA fragmentomics and gene\nregulation. Br. J. Cancer 126, 379–390 (2022).\n101.\nThierry, A. R. Circulating DNA fragmentomics and cancer screening.\nCell Genom. 3, 100242 (2023).\n102.\nMouliere, F. et al. Enhanced detection of circulating tumor DNA by",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 177
        }
    },
    "178": {
        "text": "fragment size analysis. Sci. Transl. Med 10, eaat4921 (2018).\n103.\nDiehl, F. et al. Detection and quantiﬁcation of mutations in the\nplasma of patients with colorectal tumors. Proc. Natl Acad. Sci. USA\n102, 16368–16373 (2005).\n104.\nFerrier, S. T., Tsering, T., Sadeghi, N., Zeitouni, A. & Burnier, J. V.\nBlood and saliva-derived ctDNA is a marker of residual disease after\ntreatment and correlates with recurrence in human papillomavirus-\nassociated head and neck cancer. Cancer Med 12, 15777–15787",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 178
        }
    },
    "179": {
        "text": "(2023).\n105.\nSnyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. & Shendure, J. Cell-\nfree DNA comprises an in vivo nucleosome footprint that informs its\ntissues-of-origin. Cell 164, 57–68 (2016).\n106.\nUlz, P. et al. Inferring expressed genes by whole-genome\nsequencing of plasma DNA. Nat. Genet 48, 1273–1278 (2016).\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n13\n107.\nFoda, Z. H. et al. Detecting liver cancer using cell-free DNA",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 179
        }
    },
    "180": {
        "text": "Fragmentomes. Cancer Discov. 13, 616–631 (2023).\n108.\nWang, S. et al. Multidimensional Cell-Free DNA Fragmentomic\nAssay for Detection of Early-Stage Lung Cancer. Am. J. Respir. Crit.\nCare Med. 207, 1203–1213 (2023).\n109.\nHelzer, K. T. et al. Fragmentomic analysis of circulating tumor DNA-\ntargeted cancer panels. Ann. Oncol. 34, 813–825 (2023).\n110.\nSun, K. et al. Orientation-aware plasma cell-free DNA fragmentation\nanalysis in open chromatin regions informs tissue of origin. Genome",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 180
        }
    },
    "181": {
        "text": "Res. 29, 418–427 (2019).\n111.\nEsfahani, M. S. et al. Inferring gene expression from cell-free DNA\nfragmentation proﬁles. Nat. Biotechnol. 40, 585–597 (2022).\n112.\nJiang, P. et al. Plasma DNA End-Motif proﬁling as a fragmentomic\nmarker in cancer, pregnancy, and transplantation. Cancer Discov.\n10, 664–673 (2020).\n113.\nUlz, P. et al. Inference of transcription factor binding from cell-free\nDNA enables tumor subtype prediction and early detection. Nat.\nCommun. 10, 4666 (2019).\n114.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 181
        }
    },
    "182": {
        "text": "Commun. 10, 4666 (2019).\n114.\nPeneder, P. et al. Multimodal analysis of cell-free DNA whole-\ngenome sequencing for pediatric cancers with low mutational\nburden. Nat. Commun. 12, 3230 (2021).\n115.\nDoebley, A.-L. et al. A framework for clinical cancer subtyping from\nnucleosome proﬁling of cell-free DNA. Nat. Commun. 13, 7475\n(2022).\n116.\nBessa, X. et al. High accuracy of a blood ctDNA-based multimodal\ntest to detect colorectal cancer. Ann. Oncol. 34, 1187–1193 (2023).\n117.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 182
        }
    },
    "183": {
        "text": "117.\nMoldovan, N. et al. Multi-modal cell-free DNA genomic and\nfragmentomic patterns enhance cancer survival and recurrence\nanalysis. Cell Rep. Med. 5, 101349 (2024).\n118.\nParikh, A. R. et al. Minimal residual disease detection using a\nplasma-only circulating tumor DNA assay in patients with colorectal\ncancer. Clin. Cancer Res. 27, 5586–5594 (2021).\n119.\nChen, S., Zhao, J., Cui, L. & Liu, Y. Urinary circulating DNA detection\nfor dynamic tracking of EGFR mutations for NSCLC patients treated",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 183
        }
    },
    "184": {
        "text": "with EGFR-TKIs. Clin. Transl. Oncol. 19, 332–340 (2017).\n120.\nHentschel, A. E. et al. The origin of tumor DNA in urine of urogenital\ncancer patients: local shedding and transrenal excretion. Cancers\n13, 535 (2021).\n121.\nSu, Y. H. et al. Human urine contains small, 150 to 250 nucleotide-\nsized, soluble DNA derived from the circulation and may be useful in\nthe detection of colorectal cancer. J. Mol. Diagn. 6, 101–107 (2004).\n122.\nDudley, J. C. et al. Detection and surveillance of bladder cancer",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 184
        }
    },
    "185": {
        "text": "using urine tumor DNA. Cancer Discov. 9, 500–509 (2019).\n123.\nKim, C. et al. Longitudinal circulating tumor DNA analysis in blood\nand saliva for prediction of response to Osimertinib and Disease\nProgression in EGFR-Mutant Lung Adenocarcinoma. Cancers\n(Basel) 13, 3342 (2021).\n124.\nSethi, S., Benninger, M. S., Lu, M., Havard, S. & Worsham, M. J.\nNoninvasive molecular detection of head and neck squamous cell\ncarcinoma: an exploratory analysis. Diagn. Mol. Pathol. 18, 81–87\n(2009).\n125.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 185
        }
    },
    "186": {
        "text": "(2009).\n125.\nAhn, S. M. et al. Saliva and plasma quantitative polymerase chain\nreaction-based detection and surveillanceof humanpapillomavirus-\nrelated head and neck cancer. JAMA Otolaryngol. Head. Neck Surg.\n140, 846–854 (2014).\n126.\nPanditharatna, E. et al. Clinically relevant and minimally invasive\ntumor surveillance of pediatric diffuse midline gliomas using patient-\nderived liquid biopsy. Clin. Cancer Res. 24, 5850–5859 (2018).\n127.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 186
        }
    },
    "187": {
        "text": "127.\nDe Mattos-Arruda, L. et al. Cerebrospinal ﬂuid-derived circulating\ntumour DNA better represents the genomic alterations of brain\ntumours than plasma. Nat. Commun. 6, 8839 (2015).\n128.\nPan, W., Gu, W., Nagpal, S., Gephart, M. H. & Quake, S. R. Brain\ntumor mutations detected in cerebral spinal ﬂuid. Clin. Chem. 61,\n514–522 (2015).\n129.\nPentsova, E. I. et al. Evaluating cancer of the central nervous system\nthrough next-generation sequencing of cerebrospinal ﬂuid. J. Clin.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 187
        }
    },
    "188": {
        "text": "Oncol. 34, 2404–2415 (2016).\n130.\nThai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F. & Heist, R. S.\nLung cancer. Lancet 398, 535–554 (2021).\n131.\nRosell, R. et al. Screening for epidermal growth factor receptor\nmutations in lung cancer. N. Engl. J. Med 361, 958–967 (2009).\n132.\nChaudhuri, A. A.et al.Earlydetectionof molecular residualdiseasein\nlocalized lung cancer by circulating tumor DNA proﬁling. Cancer\nDiscov. 7, 1394–1403 (2017).\n133.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 188
        }
    },
    "189": {
        "text": "Discov. 7, 1394–1403 (2017).\n133.\nAbbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage\nlung cancer evolution. Nature 545, 446–451 (2017).\n134.\nGuo, N. et al. Circulating tumor DNA detection in lung cancer\npatients before and after surgery. Sci. Rep. 6, 33519 (2016).\n135.\nKuang, P. P. et al. Circulating tumor DNA analyses as a potential\nmarker of recurrence and effectiveness of adjuvant chemotherapy\nfor resected non-small-cell lung cancer. Front Oncol. 10, 595650\n(2020).\n136.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 189
        }
    },
    "190": {
        "text": "(2020).\n136.\nGale, D. et al. Residual ctDNA after treatment predicts early relapse\nin patients with early-stage non-small cell lung cancer. Ann. Oncol.\n33, 500–510 (2022).\n137.\nXia, L. et al. Perioperative ctDNA-based molecular residual disease\ndetection for non-small cell lung cancer: a prospective multicenter\ncohort study (LUNGCA-1). Clin. Cancer Res. 28, 3308–3317 (2022).\n138.\nIwama, E. et al. Monitoring of somatic mutations in circulating cell-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 190
        }
    },
    "191": {
        "text": "free DNA by digital PCR and next-generation sequencing during\nafatinib treatment in patients with lung adenocarcinoma positive for\nEGFR activating mutations. Ann. Oncol. 28, 136–141 (2017).\n139.\nGiroux Leprieur, E. et al. Circulating tumor DNA evaluated by Next-\nGeneration Sequencing is predictive of tumor response and\nprolonged clinical beneﬁt with nivolumab in advanced non-small cell\nlung cancer. Oncoimmunology 7, e1424675 (2018).\n140.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 191
        }
    },
    "192": {
        "text": "140.\nCheng, M. L. et al. Plasma ctDNA response is an early marker of\ntreatment effect in advanced NSCLC. JCO Precis Oncol. 5,\nPO.20.00419 (2021).\n141.\nZhou, C. et al. Early clearance of plasma EGFR mutations as a\npredictor of response to osimertinib and comparator EGFR-TKIs in\nthe FLAURA trial. J. Clin. Oncol. 37, 9020- (2019).\n142.\nMack, P. C. et al. Residual circulating tumor DNA (ctDNA) after two\nmonths of therapy to predict progression-free and overall survival in",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 192
        }
    },
    "193": {
        "text": "patientstreated on S1403 with afatinib +/- cetuximab. J. Clin. Oncol.\n38, 9532- (2020).\n143.\nDagogo-Jack, I. et al. Tracking the evolution of resistance to ALK\nTyrosine Kinase inhibitors through longitudinal analysis of\ncirculating tumor DNA. JCO Precis Oncol. 2018, PO.17.00160\n(2018).\n144.\nOrtiz-Cuaran, S. et al. Circulating tumor DNA genomics reveal\npotential mechanisms of resistance to BRAF-targeted therapies in\npatients with BRAF-mutant metastatic non-small cell lung cancer.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 193
        }
    },
    "194": {
        "text": "Clin. Cancer Res 26, 6242–6253 (2020).\n145.\nZheng, D. et al. Plasma EGFR T790M ctDNA status is associated\nwith clinical outcome in advanced NSCLC patients with acquired\nEGFR-TKI resistance. Sci. Rep. 6, 20913 (2016).\n146.\nUchida, J. et al. Dynamics of circulating tumor DNA represented by\nthe activating and resistant mutations in epidermal growth factor\nreceptor tyrosine kinase inhibitor treatment. Cancer Sci. 107,\n353–358 (2016).\n147.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 194
        }
    },
    "195": {
        "text": "353–358 (2016).\n147.\nHartmaier, R. J. et al. Osimertinib + Savolitinib to overcome acquired\nMET-mediated resistance in epidermal growth factor\nreceptor–mutated, MET-ampliﬁed non–small cell lung cancer:\nTATTON. Cancer Discov. 13, 98–113 (2023).\n148.\nAssaf, Z. J. F. et al. A longitudinal circulating tumor DNA-based\nmodel associated with survival in metastatic non-small-cell lung\ncancer. Nat. Med. 29, 859–868 (2023).\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 195
        }
    },
    "196": {
        "text": "https://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n14\n149.\nAbbosh,C.etal.Trackingearlylungcancermetastaticdisseminationin\nTRACERx using ctDNA. Nature 616, 553–562 (2023).\n150.\nRemon, J. et al. Osimertinib treatment based on plasma T790M\nmonitoring in patients with EGFR-mutant non-small-cell lung cancer\n(NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II\nrandomized clinical trial. Ann. Oncol. 34, 468–476 (2023).\n151.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 196
        }
    },
    "197": {
        "text": "151.\nAnagnostou, V. et al. ctDNA response after pembrolizumab in non-\nsmall cell lung cancer: phase 2 adaptive trial results. Nat. Med 29,\n2559–2569 (2023).\n152.\nAdjuvant ctDNA-Adapted Personalized Treatment in Early Stage\nNSCLC (ADAPT-E) [Internet] https://clinicaltrials.gov/study/\nNCT04585477 (2020).\n153.\nPersonalized Escalation of Consolidation Treatment Following\nChemoradiotherapy and Immunotherapy in Stage III NSCLC\n[Internet]. Available from: https://clinicaltrials.gov/study/",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 197
        }
    },
    "198": {
        "text": "NCT04585490 (2020).\n154.\nFrom Liquid Biopsy to Cure: Using ctDNA Detection of Minimal\nResidual Disease to Identify Patients for Curative Therapy After Lung\nCancerResection[Internet].Available from:https://clinicaltrials.gov/\nstudy/NCT04966663 (2021).\n155.\nGonzalez, R. et al. Microsatellite alterations and TP53 mutations in\nplasma DNA of small-cell lung cancer patients: follow-up study and\nprognostic signiﬁcance. Ann. Oncol. 11, 1097–1104 (2000).\n156.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 198
        }
    },
    "199": {
        "text": "156.\nFernandez-Cuesta, L. et al. Identiﬁcation of circulating tumor DNA for the\nearlydetectionofsmall-celllungcancer.EBioMedicine10,117–123(2016).\n157.\nAlmodovar, K. et al. Longitudinal cell-free DNA analysis in patients\nwith small cell lung cancer reveals dynamic insights into treatment\nefﬁcacy and disease relapse. J. Thorac. Oncol. 13, 112–123 (2018).\n158.\nNong, J. et al. Circulating tumor DNA analysis depicts subclonal\narchitecture and genomic evolution of small cell lung cancer. Nat.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 199
        }
    },
    "200": {
        "text": "Commun. 9, 3114 (2018).\n159.\nDevarakonda, S. et al. Circulating Tumor DNA proﬁling in small-cell\nlung cancer identiﬁes potentially targetable alterations. Clin. Cancer\nRes 25, 6119–6126 (2019).\n160.\nIams, W. T. et al. Blood-based surveillance monitoring of circulating\ntumor DNA from patients with SCLC detects disease relapse and\npredicts death in patients with limited-stage disease. JTO Clin. Res\nRep. 1, 100024 (2020).\n161.\nMohan, S. et al. Proﬁling of circulating free DNA using targeted and",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 200
        }
    },
    "201": {
        "text": "genome-wide sequencing in patients with SCLC. J. Thorac. Oncol.\n15, 216–230 (2020).\n162.\nSivapalan, L. et al. Dynamics of sequence and structural cell-free\nDNA landscapes in small-cell lung cancer. Clin. Cancer Res 29,\n2310–2323 (2023).\n163.\nPark, S. et al. Predicting disease recurrence in limited disease small cell\nlung cancer using cell-free DNA-based mutation and fragmentome\nanalyses. Transl. Lung Cancer Res. 13, 280–291 (2024).\n164.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 201
        }
    },
    "202": {
        "text": "164.\nNakamura, Y. et al. Clinical utility of circulating tumor DNA\nsequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-\nSCREEN and GOZILA studies. Nat. Med. 26, 1859–1864 (2020).\n165.\nAndersen, L. et al. Exploring the biology of ctDNA release in\ncolorectal cancer. Eur. J. Cancer 207, 114186 (2024).\n166.\nTie, J. et al. Circulating Tumor DNA Analyses as markers of\nrecurrence risk and beneﬁt of adjuvant therapy for Stage III colon\ncancer. JAMA Oncol. 5, 1710–1717 (2019).\n167.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 202
        }
    },
    "203": {
        "text": "cancer. JAMA Oncol. 5, 1710–1717 (2019).\n167.\nReinert, T. et al. Analysis of plasma cell-free DNA by ultradeep\nsequencing in patients with Stages I to III Colorectal Cancer. JAMA\nOncol. 5, 1124–1131 (2019).\n168.\nScholer, L. V. et al. Clinical implications of monitoring circulating\ntumor DNA in patients with colorectal cancer. Clin. Cancer Res 23,\n5437–5445 (2017).\n169.\nParikh, A. R. et al. Minimal residual disease using a plasma-only",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 203
        }
    },
    "204": {
        "text": "circulating tumor DNA assay to predict recurrence of metastatic\ncolorectal cancer following curative intent treatment. Clin. Cancer\nRes 30, 2964–2973 (2024).\n170.\nSlater, S. et al. Tissue-free liquid biopsies combining genomic and\nmethylation signals for minimal residual disease detection in\npatients with early colorectal cancer from the UK TRACC Part B\nstudy. Clin. Cancer Res 30, 3459–3469 (2024).\n171.\nHenriksen, T. V. et al. Unraveling the potential clinical utility of",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 204
        }
    },
    "205": {
        "text": "circulating tumor DNA detection in colorectal cancer-evaluation in a\nnationwide Danish cohort. Ann. Oncol. 35, 229–239 (2024).\n172.\nEdwards, R. L., Menteer, J., Lestz, R. M. & Baxter-Lowe, L. A. Cell-\nfree DNA as a solid-organ transplant biomarker: technologies and\napproaches. Biomark. Med 16, 401–415 (2022).\n173.\nAmri, R., England, J., Bordeianou, L. G. & Berger, D. L. Risk\nstratiﬁcation in patients with Stage II Colon Cancer. Ann. Surg.\nOncol. 23, 3907–3914 (2016).\n174.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 205
        }
    },
    "206": {
        "text": "Oncol. 23, 3907–3914 (2016).\n174.\nParent, P. et al. A comprehensive overview of promising\nbiomarkers in stage II colorectal cancer. Cancer Treat. Rev. 88,\n102059 (2020).\n175.\nFaulkner, L. G., Howells, L. M., Pepper, C., Shaw, J. A. & Thomas, A.\nL. The utility of ctDNAin detectingminimal residual disease following\ncurative surgery in colorectal cancer: a systematic review and meta-\nanalysis. Br. J. Cancer 128, 297–309 (2023).\n176.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 206
        }
    },
    "207": {
        "text": "analysis. Br. J. Cancer 128, 297–309 (2023).\n176.\nGrancher, A. et al. Postoperative circulating tumor DNA detection is\nassociated with the risk of recurrence in patients resected for a stage\nII colorectal cancer. Front. Oncol. 12, 973167 (2022).\n177.\nFan, W. et al. Circulating tumor DNA analysis predicts recurrence\nand avoids unnecessary adjuvant chemotherapy in I-IV colorectal\ncancer. Ther. Adv. Med. Oncol. 16, 17588359231220607 (2024).\n178.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 207
        }
    },
    "208": {
        "text": "178.\nMoertel, C. G. et al. Levamisole and ﬂuorouracil for adjuvant therapy\nof resected colon carcinoma. N. Engl. J. Med. 322, 352–358 (1990).\n179.\nBöckelman, C., Engelmann, B. E., Kaprio, T., Hansen, T. F. &\nGlimelius, B. Risk of recurrence in patients with colon cancer stage II\nand III: a systematic review and meta-analysis of recent literature.\nActa Oncol. 54, 5–16 (2015).\n180.\nHenriksen, T. V. et al. Circulating Tumor DNA in Stage III colorectal",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 208
        }
    },
    "209": {
        "text": "cancer, beyond minimal residual disease detection, toward\nassessment of adjuvant therapy efﬁcacy and clinical behavior of\nrecurrences. Clin. Cancer Res. 28, 507–517 (2022).\n181.\nTaieb, J. et al. Prognostic value and relation with adjuvant treatment\nduration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of\nthe PRODIGE-GERCOR IDEA-France Trial. Clin. Cancer Res. 27,\n5638–5646 (2021).\n182.\nJones, R. P., Pugh, S. A., Graham, J., Primrose, J. N. & Barriuso, J.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 209
        }
    },
    "210": {
        "text": "Circulating tumour DNA as a biomarker in resectable and\nirresectable stage IV colorectal cancer; a systematic review and\nmeta-analysis. Eur. J. Cancer 144, 368–381 (2021).\n183.\nWullaert, L. et al. Circulating tumour DNA as biomarker for colorectal\nliver metastases: a systematic review and meta-analysis. Cells 12,\n2520 (2023).\n184.\nReece, M. et al. The use of circulating tumor DNA to monitor and\npredict response to treatment in colorectal cancer. Front Genet 10,\n1118 (2019).\n185.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 210
        }
    },
    "211": {
        "text": "1118 (2019).\n185.\nSahin, I. H. et al. Minimal residual disease-directed adjuvant therapy\nfor patients with early-stage colon cancer: CIRCULATE-US.\nOncology 36, 604–608 (2022).\n186.\nSlater, S. et al. ctDNA guided adjuvant chemotherapy versus\nstandard of care adjuvant chemotherapy after curative surgery in\npatients with high risk stage II or stage III colorectal cancer: a multi-\ncentre, prospective, randomised control trial (TRACC Part C). BMC\nCancer 23, 257 (2023).\n187.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 211
        }
    },
    "212": {
        "text": "Cancer 23, 257 (2023).\n187.\nNors, J. et al. IMPROVE-IT2: implementing noninvasive circulating\ntumor DNA analysis to optimize the operative and postoperative\ntreatment for patients with colorectal cancer - intervention trial 2.\nStudy protocol. Acta Oncol. 59, 336–341 (2020).\n188.\nLonardi, S. et al. LBA28 The PEGASUS trial: Post-surgical liquid\nbiopsy-guided treatment of stage III and high-risk stage II colon\ncancer patients. Ann. Oncol. 34, S1268–S1269 (2023).",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 212
        }
    },
    "213": {
        "text": "https://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n15\n189.\nKasi, P. M. et al. Circulating tumor DNA (ctDNA) for informing\nadjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC):\nInterim analysis of BESPOKE CRC study. J. Clin. Oncol. 42, 9 (2024).\n190.\nTie, J. et al. Circulating tumor DNA analysis informing adjuvant\nchemotherapy in locally advanced rectal cancer: The randomized\nAGITG DYNAMIC-Rectal study. J. Clin. Oncol. 42, 12 (2024).\n191.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 213
        }
    },
    "214": {
        "text": "191.\nConca, V. et al. Waiting for the “liquid revolution” in the adjuvant\ntreatment of colon cancer patients:a reviewof ongoingtrials. Cancer\nTreat. Rev. 126, 102735 (2024).\n192.\nRoazzi, L. et al. Ongoing clinical trials and future research scenarios\nof circulating tumor DNA for the treatment of metastatic colorectal\ncancer. Clin. Colorectal Cancer 23, 295–308 (2024).\n193.\nCiardiello, D. et al. Anti-EGFR rechallenge in patients with refractory\nctDNA RAS/BRAF wt metastatic colorectal cancer: a",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 214
        }
    },
    "215": {
        "text": "ctDNA RAS/BRAF wt metastatic colorectal cancer: a\nnonrandomized controlled trial. JAMA Netw. Open 7, e245635\n(2024).\n194.\nMartinelli, E. et al. Cetuximab Rechallenge Plus Avelumab in\npretreated patients With RAS wild-type metastatic colorectal\ncancer: The Phase 2 Single-Arm Clinical CAVE Trial. JAMA Oncol. 7,\n1529–1535 (2021).\n195.\nNakajima, H. et al. REMARRY and PURSUIT trials: liquid biopsy-\nguided rechallenge with anti-epidermal growth factor receptor",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 215
        }
    },
    "216": {
        "text": "(EGFR) therapy with panitumumab plus irinotecan for patients with\nplasma RAS wild-type metastatic colorectal cancer. BMC Cancer\n21, 674 (2021).\n196.\nSartore-Bianchi, A. et al. Circulating tumor DNA to guide rechallenge\nwith panitumumab in metastatic colorectal cancer: the phase 2\nCHRONOS trial. Nat. Med 28, 1612–1618 (2022).\n197.\nNapolitano, S. et al. Panitumumab Plus Triﬂuridine-Tipiracil as Anti-\nEpidermal Growth Factor Receptor Rechallenge Therapy for",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 216
        }
    },
    "217": {
        "text": "Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2\nRandomized Clinical Trial. JAMA Oncol. 9, 966–970 (2023).\n198.\nSiravegna, G. et al. Plasma HER2 (ERBB2) Copy Number Predicts\nResponse to HER2-targeted Therapy in Metastatic Colorectal\nCancer. Clin. Cancer Res. 25, 3046–3053 (2019).\n199.\nYoshino, T. et al. Final results of DESTINY-CRC01 investigating\ntrastuzumab deruxtecan in patients with HER2-expressing\nmetastatic colorectal cancer. Nat. Commun. 14, 3332 (2023).\n200.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 217
        }
    },
    "218": {
        "text": "200.\nNakamura, Y. et al. Circulating tumor DNA-guided treatment with\npertuzumab plus trastuzumab for HER2-ampliﬁed metastatic\ncolorectal cancer: a phase 2 trial. Nat. Med. 27, 1899–1903 (2021).\n201.\nSiravegna, G. et al. Clonal evolution and resistance to EGFR\nblockade in the blood of colorectal cancer patients. Nat. Med. 21,\n827 (2015).\n202.\nStrickler, J. H. et al. Genomic Landscape of Cell-Free DNA in\nPatients with Colorectal Cancer. Cancer Discov. 8, 164–173 (2018).\n203.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 218
        }
    },
    "219": {
        "text": "203.\nPietrantonio, F. et al. Heterogeneity of Acquired Resistance to Anti-\nEGFR Monoclonal Antibodies in Patients with Metastatic Colorectal\nCancer. Clin. Cancer Res. 23, 2414–2422 (2017).\n204.\nMontagut, C. et al. Identiﬁcation of a mutation in the extracellular\ndomain of the Epidermal Growth Factor Receptor conferring\ncetuximab resistance in colorectal cancer. Nat. Med. 18, 221–223\n(2012).\n205.\nPeeters, M. et al. Evaluation of emergent mutations in circulating",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 219
        }
    },
    "220": {
        "text": "cell-free DNA and clinical outcomes in patients with metastatic\ncolorectal cancer treated with Panitumumab in the ASPECCT Study.\nClin. Cancer Res. 25, 1216–1225 (2019).\n206.\nXu, J. et al. Circulating tumor DNA: from discovery to clinical\napplication in breast cancer. Front Immunol. 15, 1355887 (2024).\n207.\nDickinson, K. et al. Circulating Tumor DNA and survival in metastatic\nbreast cancer: a systematic review and meta-analysis. JAMA Netw.\nOpen 7, e2431722 (2024).\n208.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 220
        }
    },
    "221": {
        "text": "Open 7, e2431722 (2024).\n208.\nRiva,F.et al.Patient-speciﬁccirculatingtumorDNA detectionduring\nneoadjuvant chemotherapy in triple-negative breast cancer. Clin.\nChem. 63, 691–699 (2017).\n209.\nAguilar-Mahecha, A. et al. Early, on-treatment levels and dynamic\nchanges of genomic instability in circulating tumor DNA predict\nresponse to treatment and outcome in metastatic breast cancer\npatients. Cancers 13, 1331 (2021).\n210.\nLin, P. H. et al. Circulating Tumor DNA as a predictive marker of",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 221
        }
    },
    "222": {
        "text": "recurrence for patients with Stage II-III Breast cancer treated with\nneoadjuvant therapy. Front Oncol. 11, 736769 (2021).\n211.\nOrtolan, E. et al. Blood-based genomics of triple-negative breast\ncancer progression in patients treated with neoadjuvant\nchemotherapy. ESMO Open 6, 100086 (2021).\n212.\nAmato, O., Giannopoulou, N. & Ignatiadis, M. Circulating tumor DNA\nvalidity and potential uses in metastatic breast cancer. NPJ Breast\nCancer 10, 21 (2024).\n213.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 222
        }
    },
    "223": {
        "text": "Cancer 10, 21 (2024).\n213.\nAndré,F.etal.AlpelisibforPIK3CA-mutated,hormonereceptor-positive\nadvanced breast cancer. N. Engl. J. Med 380, 1929–1940 (2019).\n214.\nAndré, F. et al. Alpelisib plus fulvestrant for PIK3CA-mutated,\nhormone receptor-positive, human epidermal growth factor\nreceptor-2-negative advanced breast cancer: ﬁnal overall survival\nresults from SOLAR-1. Ann. Oncol. 32, 208–217 (2021).\n215.\nHenry, N. L. et al. Biomarkers for systemic therapy in metastatic",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 223
        }
    },
    "224": {
        "text": "breast cancer: ASCO Guideline Update. J. Clin. Oncol. 40,\n3205–3221 (2022).\n216.\nDawson, S.-J. BCT 1901 (CAPTURE): A phase II randomised study\nto evaluate alpelisib plus fulvestrant versus capecitabine in\noestrogen receptor positive, HER2-negative advanced breast\ncancer patients with PIK3CA mutant circulating DNA. https://anzctr.\norg.au/Trial/Registration/TrialReview.aspx?id=377949&isReview=\ntrue: Australian New Zealand Clinical Trial Registry (2019).\n217.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 224
        }
    },
    "225": {
        "text": "217.\nChiu, J. et al. Potential value of ctDNA monitoring in metastatic HR\n+/HER2−breast cancer: longitudinal ctDNA analysis in the phase Ib\nMONALEESASIA trial. BMC Med. 21, 306 (2023).\n218.\nAndré, F. et al. Pooled ctDNA analysis of MONALEESA phase III\nadvanced breast cancer trials. Ann. Oncol. 34, 1003–1014 (2023).\n219.\nDodwell, D., Coombes, G., Bliss, J. M., Kilburn, L. S. & Johnston, S.\nCombining fulvestrant (Faslodex) with continued oestrogen",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 225
        }
    },
    "226": {
        "text": "suppression in endocrine-sensitive advanced breast cancer: the\nSoFEA trial. Clin. Oncol. (R. Coll. Radiol.) 20, 321–324 (2008).\n220.\nCoombes, R. C. et al. Personalized detection of circulating tumor\nDNA antedates breast cancer metastatic recurrence. Clin. Cancer\nRes. 25, 4255–4263 (2019).\n221.\nFribbens, C. et al. Plasma ESR1 mutations and the treatment of\nestrogen receptor–positive advanced breast cancer. J. Clin. Oncol.\n34, 2961–2968 (2016).\n222.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 226
        }
    },
    "227": {
        "text": "34, 2961–2968 (2016).\n222.\nAllsopp, R. C. et al. Circulating tumour DNA dynamics during\nalternating chemotherapy and hormonal therapy in metastatic\nbreast cancer: the ALERT study. Breast Cancer Res. Treat. 206,\n377–385 (2024).\n223.\nBidard, F. C. et al. Switch to fulvestrant and palbociclib versus no\nswitch in advanced breast cancer with rising ESR1 mutation during\naromatase inhibitor and palbociclib therapy (PADA-1): a\nrandomised, open-label, multicentre, phase 3 trial. LancetOncol. 23,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 227
        }
    },
    "228": {
        "text": "1367–1377 (2022).\n224.\nBidard, F. C. et al. Elacestrant (oral selective estrogen receptor\ndegrader) Versus Standard Endocrine Therapy for Estrogen\nReceptor-Positive, Human Epidermal Growth Factor Receptor\n2-Negative Advanced Breast Cancer: Results From the Randomized\nPhase III EMERALD Trial. J. Clin. Oncol. 40, 3246–3256 (2022).\n225.\nBurstein, H. J., DeMichele, A., Somerﬁeld, M. R. & Henry, N. L.\nTesting for ESR1 Mutations to Guide Therapy for Hormone",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 228
        }
    },
    "229": {
        "text": "Receptor-Positive, Human Epidermal Growth Factor Receptor\n2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid\nRecommendation Update. J. Clin. Oncol. 41, 3423–3425 (2023).\n226.\nCailleux, F. et al. Circulating Tumor DNA after neoadjuvant\nchemotherapy in breast cancer is associated with disease relapse.\nJCO Precis Oncol. 6, e2200148 (2022).\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n16\n227.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 229
        }
    },
    "230": {
        "text": "npj Precision Oncology |  (2025) 9:84 \n16\n227.\nGarcia-Murillas,I.etal.MutationtrackingincirculatingtumorDNApredicts\nrelapse in early breast cancer. Sci. Transl. Med 7, 302ra133 (2015).\n228.\nOlsson, E. et al. Serial monitoring of circulating tumor DNA in\npatients with primary breast cancer for detection of occult\nmetastatic disease. EMBO Mol. Med. 7, 1034–1047 (2015).\n229.\nMagbanua, M. J. M. et al. Circulating tumor DNA in neoadjuvant-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 230
        }
    },
    "231": {
        "text": "treated breast cancer reﬂects response and survival. Ann. Oncol. 32,\n229–239 (2021).\n230.\nZhou, Q. et al. Persistence of ctDNA in Patients with Breast Cancer\nDuring Neoadjuvant Treatment Is a Signiﬁcant Predictor of Poor\nTumor Response. Clin. Cancer Res. 28, 697–707 (2022).\n231.\nCoakley, M. et al. Comparison of Circulating Tumor DNA Assays for\nMolecular Residual Disease Detection in Early-Stage Triple-\nNegative Breast Cancer. Clin. Cancer Res. 30, 895–903 (2024).\n232.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 231
        }
    },
    "232": {
        "text": "232.\nTurner, N. C. et al. Results of the c-TRAK TN trial: a clinical trial\nutilising ctDNA mutation tracking to detect molecular residual\ndisease and trigger intervention in patients with moderate- and high-\nrisk early-stage triple-negative breast cancer. Ann. Oncol. 34,\n200–211 (2023).\n233.\nA Proof of Concept Study to Evaluate Treatments’ Efﬁcacy by\nMonitoring Minimal Residual Disease Using ctDNA in HR-positive/\nHER2-negative Early Breast Cancer Population. Available from:",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 232
        }
    },
    "233": {
        "text": "https://clinicaltrials.gov/study/NCT05708235 (2023).\n234.\nTalasaz, A. et al. Use of the GUARDANT360 noninvasive tumor\nsequencing assay on 300 patients across colorectal, melanoma,\nlung, breast, and prostate cancers and its clinical utility. J. Clin.\nOncol. 32, e22041-e (2014).\n235.\nMartínez-Sáez, O. et al. Frequencyand spectrumof PIK3CA somatic\nmutations in breast cancer. Breast Cancer Res. 22, 45 (2020).\n236.\nJacob,S.etal.TheuseofserialcirculatingtumorDNA(ctDNA)todetect",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 233
        }
    },
    "234": {
        "text": "resistance alterations in progressive metastatic breast cancer. Clin.\nCancer Res. J. Am. Assoc. Cancer Res. 27, 1361–1370 (2020).\n237.\nTurner, N. C. et al. Capivasertib IN HORMONE RECEPTOR-\nPOSITIVE ADVANCED BREAST CANCer. N. Engl. J. Med. 388,\n2058–2070 (2023).\n238.\nLiu, Z. et al. Construction of a risk stratiﬁcation model integrating\nctDNA to predict response and survival in neoadjuvant-treated\nbreast cancer. BMC Med 21, 493 (2023).\n239.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 234
        }
    },
    "235": {
        "text": "breast cancer. BMC Med 21, 493 (2023).\n239.\nMonitoring luminAl Breast Cancer Through the Evaluation of\nMutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA.\n2023. Available from: https://clinicaltrials.gov/study/NCT05814224\n240.\nCIPHER Study: Pilot Study to Study the Role of ctDNA in Triple\nNegative and HER2 Positive Early Stage Breast Cancer. Available\nfrom: https://clinicaltrials.gov/study/NCT05333874 (2022).\n241.\nTivey, A. et al. Circulating Tumour DNA in Melanoma-Clinic Ready?",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 235
        }
    },
    "236": {
        "text": "Curr. Oncol. Rep. 24, 363–373 (2022).\n242.\nKaminska,P.etal.Liquidbiopsyinmelanoma:signiﬁcanceindiagnostics,\nprediction and treatment monitoring. Int J. Mol. Sci. 22, 9714 (2021).\n243.\nMunoz-Couselo, E., Garcia, J. S., Perez-Garcia, J. M., Cebrian, V. O.\n& Castan, J. C. Recent advances in the treatment of melanoma with\nBRAF and MEK inhibitors. Ann. Transl. Med. 3, 207 (2015).\n244.\nHuang, A. C. & Zappasodi, R. A decade of checkpoint blockade",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 236
        }
    },
    "237": {
        "text": "immunotherapy in melanoma: understanding the molecular basis for\nimmune sensitivity and resistance. Nat. Immunol. 23, 660–670 (2022).\n245.\nKiniwa, Y. & Okuyama, R. Recent advances in molecular targeted\ntherapy for unresectable and metastatic BRAF-mutated melanoma.\nJpn J. Clin. Oncol. 51, 315–320 (2021).\n246.\nFitzgerald, S. et al. Dynamic ctDNAmutationalcomplexityin patients\nwith melanoma receiving immunotherapy. Mol. Diagn. Ther. 27,\n537–550 (2023).\n247.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 237
        }
    },
    "238": {
        "text": "537–550 (2023).\n247.\nJohnson, D. B. & Puzanov, I. Treatment of NRAS-mutant melanoma.\nCurr. Treat. Options Oncol. 16, 15 (2015).\n248.\nHaselmann, V. et al. Liquid proﬁling of circulating tumor DNA in plasma\nof melanoma patients for companion diagnostics and monitoring of\nBRAF inhibitor therapy. Clin. Chem. 64, 830–842 (2018).\n249.\nVaraljai, R. et al. Application of circulating cell-free tumor DNA\nproﬁles for therapeutic monitoring and outcome prediction in",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 238
        }
    },
    "239": {
        "text": "genetically heterogeneous metastatic melanoma. JCO Precis.\nOncol. 3, PO.18.00229 (2020).\n250.\nLee, J. H. et al. Circulating tumour DNA predicts response to anti-PD1\nantibodies in metastatic melanoma. Ann. Oncol. 28, 1130–1136 (2017).\n251.\nHerbreteau, G. et al. Circulating Tumor DNA Early Kinetics Predict\nResponse of Metastatic Melanoma to Anti-PD1 Immunotherapy:\nValidation Study. Cancers 13, 1826 (2021).\n252.\nBustamante P., Piquet L., Landreville S., Burnier J. V. Uveal melanoma",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 239
        }
    },
    "240": {
        "text": "pathobiology: Metastasis to the liver. Semin Cancer Biol. (2020)\n253.\nJin, E. & Burnier, J. V. Liquid Biopsy in Uveal Melanoma: Are We\nThere Yet? Ocul. Oncol. Pathol. 7, 1–16 (2021).\n254.\nBidard, F.-C. et al. Detection rate and prognostic value of circulating\ntumor cells and circulating tumor DNA in metastatic uveal\nmelanoma. Int. J. Cancer 134, 1207–1213 (2014).\n255.\nBeasley,A. B.et al.Detectionofmetastasesusing circulatingtumour\nDNA in uveal melanoma. J. Cancer Res. Clin. Oncol. 149,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 240
        }
    },
    "241": {
        "text": "14953–14963 (2023).\n256.\nMariani, P. et al. Circulating Tumor DNA as a Prognostic Factor in\nPatients With Resectable Hepatic Metastases of Uveal Melanoma.\nAnn. Surg. 278, e827–e834 (2023).\n257.\nLe Guin, C. H. D. et al. Early detection of metastatic uveal melanoma\nby the analysis of tumor-speciﬁc mutations in cell-free plasma DNA.\nCancer Med. 10, 5974–5982 (2021).\n258.\nNy, L. et al. The PEMDAC phase 2 study of pembrolizumab and\nentinostat in patients with metastatic uveal melanoma. Nat.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 241
        }
    },
    "242": {
        "text": "Commun. 12, 5155 (2021).\n259.\nFrancis, J. H., Barker, C. A., Canestraro, J., Abramson, D. H. &\nShoushtari, A. N. Clearance of plasma cell free DNA in metastatic\nuveal melanoma with radiographic response to immune checkpoint\ninhibitors. Am. J. Ophthalmol. Case Rep. 34, 102021 (2024).\n260.\nPark, J. J. et al. Circulating Tumor DNA Reﬂects Uveal Melanoma\nResponses To Protein Kinase C Inhibition. Cancers 13, 1740 (2021).\n261.\nCarvajal, R. D. et al. Clinical and molecular response to tebentafusp",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 242
        }
    },
    "243": {
        "text": "in previously treated patients with metastatic uveal melanoma: a\nphase 2 trial. Nat. Med. 28, 2364–2373 (2022).\n262.\nFonseca, N. M. et al. Prediction of plasma ctDNA fraction and\nprognostic implications of liquid biopsy in advanced prostate\ncancer. Nat. Commun. 15, 1828 (2024).\n263.\nAzad, A. A. et al. Androgen Receptor Gene Aberrations in Circulating\nCell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-\nResistant Prostate Cancer. Clin. Cancer Res. 21, 2315–2324 (2015).\n264.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 243
        }
    },
    "244": {
        "text": "264.\nFettke, H. et al. Combined Cell-free DNA and RNA Proﬁling of the\nAndrogenReceptor:ClinicalUtilityofaNovelMultianalyteLiquidBiopsy\nAssay for Metastatic Prostate Cancer. Eur. Urol. 78, 173–180 (2020).\n265.\nRomanel, A. et al. Plasma AR and abiraterone-resistant prostate\ncancer. Sci. Transl. Med 7, 312re10 (2015).\n266.\nWyatt, A. W. et al. Concordance of Circulating Tumor DNA and\nMatched Metastatic Tissue Biopsy in Prostate Cancer. JNCI: J. Natl\nCancer Inst. 109, djx118 (2017).\n267.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 244
        }
    },
    "245": {
        "text": "Cancer Inst. 109, djx118 (2017).\n267.\nKubota, Y. et al. Prognostic signiﬁcance of total plasma cell-free\nDNA level and androgen receptor ampliﬁcation in castration-\nresistant prostate cancer. World J. Urol. 39, 3265–3271 (2021).\n268.\nTukachinsky, H. et al. Genomic Analysis of Circulating Tumor DNA in\n3,334 Patients with Advanced Prostate Cancer Identiﬁes Targetable\nBRCAAlterations and AR Resistance Mechanisms.Clin. Cancer Res\n27, 3094–3105 (2021).\n269.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 245
        }
    },
    "246": {
        "text": "27, 3094–3105 (2021).\n269.\nTripathi, N. et al. Impact of androgen receptor alterations on cell-free\nDNA genomic proﬁling on survival outcomes in metastatic castration-\nresistant prostate cancer. Prostate 83, 1602–1609 (2023).\n270.\nSofﬁetti, R. et al. Liquid biopsy in gliomas: A RANO review and\nproposals for clinical applications. Neuro Oncol. 24, 855–871 (2022).\n271.\nMiller, A. M. et al. Tracking tumour evolution in glioma through liquid",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 246
        }
    },
    "247": {
        "text": "biopsies of cerebrospinal ﬂuid. Nature 565, 654–658 (2019).\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n17\n272.\nEscudero, L. et al. Circulating tumour DNA from the cerebrospinal\nﬂuidallowsthecharacterisation andmonitoringof medulloblastoma.\nNat. Commun. 11, 5376 (2020).\n273.\nMouliere, F. et al. Fragmentation patterns and personalized\nsequencing of cell-free DNA in urine and plasma of glioma patients.\nEMBO Mol. Med. 13, e12881 (2021).\n274.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 247
        }
    },
    "248": {
        "text": "EMBO Mol. Med. 13, e12881 (2021).\n274.\nPiccioni, D. E. et al. Analysis of cell-free circulating tumor DNA in 419\npatients with glioblastoma and other primary brain tumors. CNS\nOncol. 8, CNS34 (2019).\n275.\nCantor, E. et al. Serial H3K27M cell-free tumor DNA (cf-tDNA)\ntracking predicts ONC201 treatment response and progression in\ndiffuse midline glioma. Neuro Oncol. 24, 1366–1374 (2022).\n276.\nWadden, J., Ravi, K., John, V., Babila, C. M. & Koschmann, C. Cell-",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 248
        }
    },
    "249": {
        "text": "Free Tumor DNA (cf-tDNA) Liquid Biopsy: Current methods and use\nin brain tumor immunotherapy. Front. Immunol. 13, 882452 (2022).\n277.\nSchiller, J. T. & Lowy, D. R. An introduction to virus infections and\nhuman cancer. Recent Results Cancer Res. 217, 1–11 (2021).\n278.\nMittelstadt, S. et al. Detection of circulating cell-free HPV DNA of 13\nHPV types for patients with cervical cancer as potential biomarker to\nmonitor therapy response and to detect relapse. Br. J. Cancer 128,\n2097–2103 (2023).\n279.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 249
        }
    },
    "250": {
        "text": "2097–2103 (2023).\n279.\nMolet, L. et al. Identiﬁcation by high-throughput sequencing of HPV\nvariants and quasispecies that are untypeable by linear reverse blotting\nassay in cervical specimens. Papillomavirus Res. 8, 100169 (2019).\n280.\nChera, B. S. et al. Rapid clearance proﬁle of plasma circulating tumor\nHPV Type 16 DNA during chemoradiotherapy correlates with\ndisease control in HPV-Associated Oropharyngeal Cancer. Clin.\nCancer Res. 25, 4682–4690 (2019).\n281.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 250
        }
    },
    "251": {
        "text": "Cancer Res. 25, 4682–4690 (2019).\n281.\nJeannot,E. et al. CirculatingHPV DNA as a markerfor early detection\nof relapse in patients with cervical cancer. Clin. Cancer Res. 27,\n5869–5877 (2021).\n282.\nHan, K. et al. Clinical Validation of Human Papilloma Virus Circulating\nTumor DNA for early detection of residual disease after chemoradiation\nin cervical cancer. J. Clin. Oncol. 42, 431–440 (2024).\n283.\nSymer, D. E. et al. Diverse tumorigenic consequences of human",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 251
        }
    },
    "252": {
        "text": "papillomavirus integration in primary oropharyngeal cancers.\nGenome Res. 32, 55–70 (2022).\n284.\nHanna, G. J. et al. Negative Predictive Value of Circulating Tumor\nTissue Modiﬁed Viral (TTMV)-HPV DNA for HPV-driven\nOropharyngeal Cancer Surveillance. Clin. Cancer Res. 29,\n4306–4313 (2023).\n285.\nParpart-Li, S. et al. The effect of preservative and temperature on the\nanalysisofcirculatingtumorDNA.Clin.CancerRes.23,2471–2477(2017).\n286.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 252
        }
    },
    "253": {
        "text": "286.\nRisberg, B. et al. Effects of collection and processing procedures on\nplasma circulating cell-free DNA from cancer patients. J. Mol. Diagn.\n20, 883–892 (2018).\n287.\nCrisafulli, G. Liquid biopsy and challenge of assay heterogeneity for\nminimal residual disease assessment in colon cancer treatment.\nGenes 16, 71 (2025).\n288.\nWan, J. C. M. et al. Liquid biopsies come of age: towards\nimplementation of circulating tumour DNA. Nat. Rev. Cancer 17,\n223–238 (2017).\n289.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 253
        }
    },
    "254": {
        "text": "223–238 (2017).\n289.\nFridlich, O. et al. Elevated cfDNA after exercise is derived primarily\nfrom mature polymorphonuclear neutrophils, with a minor\ncontribution of cardiomyocytes. Cell Rep. Med. 4, 101074 (2023).\n290.\nPark, C. K., Cho, H. J., Choi, Y. D., Oh, I. J. & Kim, Y. C. A Phase II Trial\nof Osimertinib asthe ﬁrst-line treatmentof non-small cell lungcancer\nharboring activating EGFR mutations in circulating tumor DNA:\nLiquidLung-O-Cohort 1. Cancer Res. Treat. 53, 93–103 (2021).\n291.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 254
        }
    },
    "255": {
        "text": "291.\nPark, C. K., Cho, H. J., Choi, Y. D., Oh, I. J. & Kim, Y. C. A Phase II Trial\nof Osimertinib in the Second-Line Treatment of Non-small Cell Lung\nCancer with the EGFR T790M Mutation, Detected from Circulating\nTumor DNA: LiquidLung-O-Cohort 2. Cancer Res. Treat. 51,\n777–787 (2019).\n292.\nPark, C. K. et al. Phase II open-label multicenter study to assess the\nantitumor activity of afatinib in lung cancer patients with activating\nepidermal growth factor receptor mutation from circulating tumor",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 255
        }
    },
    "256": {
        "text": "DNA: Liquid-Lung-A. Thorac. Cancer 12, 444–452 (2021).\n293.\nDziadziuszko, R. et al. Blood First Assay Screening Trial (BFAST) in\ntreatment-naive advanced or metastatic NSCLC: Initial Results of\nthe Phase 2 ALK-Positive Cohort. J. Thorac. Oncol. 16, 2040–2050\n(2021).\n294.\nPeters, S. et al. Atezolizumab versus chemotherapy in advanced or\nmetastatic NSCLC with high blood-based tumor mutational burden:\nprimary analysis of BFAST cohort C randomized phase 3 trial. Nat.\nMed. 28, 1831–1839 (2022).\n295.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 256
        }
    },
    "257": {
        "text": "Med. 28, 1831–1839 (2022).\n295.\nDziadziuszko, R. et al. High-dose alectinib for RET fusion-positive\nnon-small cell lung cancer in the Blood First Assay Screening Trial.\nContemp. Oncol. 27, 217–223 (2023).\n296.\nGarcia-Pardo, M. et al. Associationof Circulating Tumor DNA testing\nbefore tissue diagnosis with time to treatment among patients with\nsuspected advanced lung cancer: The ACCELERATE\nNonrandomized Clinical Trial. JAMA Netw. Open 6, e2325332\n(2023).\n297.",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 257
        }
    },
    "258": {
        "text": "(2023).\n297.\nDong, S. et al. Circulating Tumor DNA-Guided de-escalation\ntargeted therapy for advanced non-small cell lung cancer: a\nnonrandomized controlled trial. JAMA Oncol. 10, 932–940 (2024).\n298.\nMorris, V. K. et al. Phase II results of circulating tumor DNA as a\npredictive biomarker in adjuvant chemotherapy in patients with\nstage II colon cancer: NRG-GI005 (COBRA) phase II/III study. J. Clin.\nOncol. 42, 5 (2024).\n299.\nTurner, N. C. et al. Circulating tumour DNA analysis to direct therapy",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 258
        }
    },
    "259": {
        "text": "in advanced breast cancer (plasmaMATCH): a multicentre,\nmulticohort, phase 2a, platform trial. Lancet Oncol. 21, 1296–1308\n(2020).\n300.\nTang, Y. et al. Circulating tumor DNA proﬁle and its clinical\nsigniﬁcance in patients with hormone receptor-positive and HER2-\nnegative mBC. Front. Endocrinol. 13, 1075830 (2022).\n301.\nHu, Z. Y. et al. Subtyping of metastatic breast cancer based on\nplasma circulating tumor DNA alterations: An observational,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 259
        }
    },
    "260": {
        "text": "multicentre platform study. EClinicalMedicine 51, 101567 (2022).\nAcknowledgements\nFigures created with BioRender.com. This work was funded by the McGill\nUniversity Health Centre Foundation (to JVB), Fonds de Recherche du\nQuébec en Santé (to JVB [#312831] and AB [#330312]), Canadian Graduate\nScholarship (to TF [#476766]) and Canadian Cancer Society (to MN\n[#708387]).\nAuthor contributions\nJ.V.B. was responsible for conceptualization. A.B., M.N., T.F., K.D., A.N.,",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 260
        }
    },
    "261": {
        "text": "N.K., A.C., and J.V.B. were responsible for writing the ﬁrst draft of the\nmanuscript. All authors contributed in editing and approving the ﬁnal\nmanuscript.\nCompeting interests\nThe authors declare no competing interests.\nAdditional information\nCorrespondence and requests for materials should be addressed to\nJulia V. Burnier.\nReprints and permissions information is available at\nhttp://www.nature.com/reprints\nPublisher’s note Springer Nature remains neutral withregardtojurisdictional",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 261
        }
    },
    "262": {
        "text": "claims in published maps and institutional afﬁliations.\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n18\nOpen Access This article is licensed under a Creative Commons\nAttribution-NonCommercial-NoDerivatives 4.0 International License,\nwhich permits any non-commercial use, sharing, distribution and\nreproduction in any medium or format, as long as you give appropriate\ncredit to the original author(s) and the source, provide a link to the Creative",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 262
        }
    },
    "263": {
        "text": "Commons licence, and indicate if you modiﬁed the licensed material. You\ndo not have permission under this licence to share adapted material\nderived from this article or parts of it. The images or other third party\nmaterial in this article are included in the article’s Creative Commons\nlicence, unless indicated otherwise in a credit line to the material. If material\nisnot includedin thearticle’s CreativeCommons licenceandyour intended",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 263
        }
    },
    "264": {
        "text": "use is not permitted by statutory regulation or exceeds the permitted use,\nyou will need to obtain permission directly from the copyright holder. To\nview a copy of this licence, visit http://creativecommons.org/licenses/by-\nnc-nd/4.0/.\n© The Author(s) 2025\nhttps://doi.org/10.1038/s41698-025-00876-y\nReview\nnpj Precision Oncology |  (2025) 9:84 \n19",
        "metadata": {
            "source": "41698_2025_Article_876.pdf",
            "chunk_id": 264
        }
    },
    "265": {
        "text": "Page 1 of 7\n© Annals of Translational Medicine. All rights reserved.\n  Ann Transl Med 2019;7(20):595 | http://dx.doi.org/10.21037/atm.2019.05.58\nImmunotherapy and targeted therapy—the new roadmap in \ncancer treatment\nKamran Shahid, Mustafa Khalife, Raetasha Dabney, Alexandria T. Phan\nDivision of Hematology & Oncology, University of Texas Health Science Center at Tyler, UT Health North Campus Tyler, Tyler, TX, USA",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 0
        }
    },
    "266": {
        "text": "Contributions: (I) Conception and design: K Shahid, AT Phan; (II) Administrative support: All authors; (III) Provision of study materials or patients: K \nShahid, AT Phan; (IV) Collection and assembly of data: K Shahid; (V) Data analysis and interpretation: K Shahid, AT Phan; (VI) Manuscript writing: \nAll authors; (VII) Final approval of manuscript: All authors.",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 1
        }
    },
    "267": {
        "text": "Correspondence to: Alexandria T. Phan, MD. UT Health North Campus Tyler, University of Texas Health Science Center at Tyler, 11937 U.S. Hwy. \n271, Tyler, TX 75708, USA. Email: Alexandria.phan@uthct.edu. \nAbstract: Immunotherapy is the new frontier in cancer medicine. This manuscript summarizes historical \naspect of immunotherapy, particularly its pathway to drug approval as the main therapeutic modality used in",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 2
        }
    },
    "268": {
        "text": "clinical medicine. We will discuss the role of immunotherapy in treating various types of cancers and how the \ntreatment landscape once dominated by chemotherapy is rapidly changing.\nKeywords: Immunotherapy; chimeric antigen receptor T-cells (CAR T-cells); check point inhibitors; cancer \ntreatment\nSubmitted May 07, 2019. Accepted for publication May 20, 2019.\ndoi: 10.21037/atm.2019.05.58\nView this article at: http://dx.doi.org/10.21037/atm.2019.05.58\nIntroduction",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 3
        }
    },
    "269": {
        "text": "Introduction\nMedicine has witnessed many discoveries in the last century. \nFrom the discovery of diphtheria anti-toxin leading to the \nfirst Nobel Prize in medicine awarded to Emil von Behring \nin 1901, to discovery of penicillin by Alexander Fleming, \nto treatment of HIV, there have been many breakthroughs \nover the years. This has been amply represented in the \ndistribution of Nobel prizes in medicine and physiology \nover the years. Every era and every year depicting a",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 4
        }
    },
    "270": {
        "text": "breakthrough which has helped humanity in fighting \nailments. If twentieth century was the antibiotics era, \nthis century should be dubbed—the immunotherapy era, \nconsidering the difference it has already made in improving \nsurvival in cancer patients. In this context it would not be \nwrong to call the year 2018—the year of immunotherapy. \nIn 2018, the noble prize in medicine was awarded to basic \nscience researcher, James Allison, who is rightfully dubbed",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 5
        }
    },
    "271": {
        "text": "as the father of check point inhibitors. Dr. Allison described \nthe checkpoint molecule cytotoxic T lymphocyte associated \nprotein 4 (CTLA-4) and its inhibitory function in the \nactivation of T-cells. In mid 1990s, he showed anti-tumor \neffect in a series of mouse models by antibody blockade \nof CTLA-4 (1). This is the critical juncture in history of \nmedicine which shifted the paradigm from attempting to \nactivate the immune system that is vaccinating, to releasing",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 6
        }
    },
    "272": {
        "text": "the checkpoints that keep it in negative regulatory mode. \nThis ultimately led to the development of check-point \ninhibitors and it was in 2011 when the U. S. Food and Drug \nAdministration (FDA) approved ipilimumab. This was the \nfirst drug in this class which was noted to improve overall \nsurvival in metastatic melanoma (2).\nImmunotherapy versus chemotherapy\nSystemic therapy for cancer consists of anti-cancer agents \nadministered into the system to damage or destroy cancer",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 7
        }
    },
    "273": {
        "text": "cells and hence cancer growth, which can be either \nmolecularly targeted therapy, biological therapy such as \nimmunotherapy or cytotoxic therapy. Cytotoxic therapy, \nalso known as chemotherapy, has been traditionally \nthought of as the preferred weaponry for all cancers; it \nis now not a necessary therapeutic foundation for several \nmalignancies. Many people compare giving cytotoxic \nsystemic chemotherapy to “carpet bombing” in modern \nReview Article on Health and Medicine: a new era",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 8
        }
    },
    "274": {
        "text": "Review Article on Health and Medicine: a new era\nShahid et al. Immunotherapy—the new road map in cancer treatment\n© Annals of Translational Medicine. All rights reserved.\n  Ann Transl Med 2019;7(20):595 | http://dx.doi.org/10.21037/atm.2019.05.58\nPage 2 of 7\nwarfare where the idea is simple, the goal being to blast \noff foreign invasion called cancer, regardless of collateral \ndamage. Compare this with check point inhibitors, a type of",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 9
        }
    },
    "275": {
        "text": "immunotherapy, very little of cytotoxic side-effects occur. \nHowever, check point blockade is associated with a unique \nspectrum of side effects called immune related adverse \nevents (irAEs) (3). These usually occur due to hyperactivity \nof the immune system. Grade 1 and 2 irAEs are usually \nmanageable by temporary interruption of treatment and \nthe use of corticosteroids to suppress this hyperdrive of \nthe immune system. Grade 3 and 4 irAEs rarely occurred",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 10
        }
    },
    "276": {
        "text": "with immunotherapy, but they are nevertheless managed by \nhigh dose of intravenous corticosteroids and other potent \nimmunosuppressive agents like infliximab (4).\nSince the first check point inhibitor ipilimumab, newer \ncheck point inhibitors are being developed and FDA \napproved, with much less severity and frequency of irAEs. \nThe field of immunotherapy in cancer care has significantly \nexpanded, with additional monoclonal antibodies differently",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 11
        }
    },
    "277": {
        "text": "directed against CTLA-4, programmed cell death protein \n1 (PD-1) and programmed death-ligand 1 (PD-L1). \nNivolumab is a human immunoglobulin G4 (IgG4) \nmonoclonal antibody that binds to the PD-1 receptor \nand blocks its interaction with PD-L1, releasing PD-1 \npathway-mediated inhibition of the immune response, \nincluding the anti-cancer immune response. Results from \nthe CheckMate 026 (5) and CheckMate 370 (6) clinical \ntrials, comparing nivolumab with chemotherapy in patients",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 12
        }
    },
    "278": {
        "text": "with metastatic non-small cell lung cancer, showed \nrevolutionary results of improved survival benefit. In \n2015, nivolumab was initially FDA-approved for patients \nwith advanced/metastatic non-small cell lung cancer and \nexpanded to many other cancers since.\nExpanding impact of immunotherapy on current cancer care\nSince the first FDA-approval of ipilimumab treatment \nin solid malignancies had been significantly impacted \nby the introduction of immunotherapy particularly with",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 13
        }
    },
    "279": {
        "text": "immune checkpoint inhibitors. Immunotherapy was \nmost transformative in the management and treatment \nof melanoma. Advanced or metastatic melanoma has \nalways been considered the most virulent and resistant \nof all cancers, with dismal survival rates. The incidence \nof melanoma is currently on the rise with one-fifth of \nthe diagnosed patients expected to develop metastatic \ndisease (7). Treatment options were limited and included \ntoxic chemotherapy and interferon treatments which had",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 14
        }
    },
    "280": {
        "text": "deleterious side-effects, including hypertriglyceridemia, \nhyperuricemia, hepatotoxicity, flu like symptoms, depressive \nmood disorder, suicidal thoughts among many others (8). \nOne-year survival rate 25.5% and a 6.2-month median \nsurvival duration (9). Ten-year survival rates improved \nto 22% with the monoclonal antibody directed against \nCTLA-4, compared to historical control of 10% (10,11). \nKEYNOTE-001 trial of pembrolizumab in patients with",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 15
        }
    },
    "281": {
        "text": "advanced/metastatic melanoma, demonstrated an improved \n5-year overall survival rate (OS) to 34% in all patients and \n41% in treatment-naive patients (12). The study was one \nof the first to depict how much we have evolved in treating \nmetastatic melanoma and with more tolerable irAEs. Table 1 \nsummarizes for various immunotherapies used in clinical \npractice and the year they were approved for clinical use.\nFor advanced stage head and neck cancers, cytotoxic",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 16
        }
    },
    "282": {
        "text": "chemotherapy is still the first line treatment and prognosis \nare bad for patients who progress during treatment. \nSecond line therapeutic options were limited, until the \nadvent of introduction of immune checkpoint inhibitors. \nNivolumab was the first immunotherapy FDA-approved \nin head and neck cancers because of the results from \nCheckMate-141 (13), followed by pembrolizumab FDA-\napproval for second-line therapy because of the results from \nKEYNOTE-40 (14).",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 17
        }
    },
    "283": {
        "text": "KEYNOTE-40 (14).\nIn most cases, esophageal cancer is a treatable disease, \nbut it is rarely curable in advanced or metastatic disease. \nEsophageal cancer is not as common in the U.S., but \nit has limited treatment options and prognosis is poor. \nSurvival rates at 5 years for advanced stages esophageal \ncancer, is typically 5–20%. Breakthrough in the search \nfor effective second line treatment of patients with \nadvanced esophageal cancers, came from findings",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 18
        }
    },
    "284": {
        "text": "advanced esophageal cancers, came from findings \nof the KEYNOTE-181 trial. Results demonstrated \npembrolizumab improve OS in patients with PD-\nL1 combined positive score (CPS) >10 (15). CPS was \ndeveloped to evaluate the number of PD-L1 staining \ncells relative to all viable tumor cells, and it has become \na surrogate marker for patients who may benefit from \ntreatment with pembrolizumab. The role of combination \npembrolizumab and cytotoxic chemotherapy in esophageal",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 19
        }
    },
    "285": {
        "text": "cancers, is currently being studied in the frontline setting \nin an ongoing phase III trial, KEYNOTE-811 trial (16). \nIn a phase II trial of patients with untreated metastatic \ngastric, gastroesophageal junctional and esophageal cancers \noverexpressing HER2NEU, the role of immune checkpoint \ninhibitor in combination with trastuzumab (monoclonal \nantibody against HER2NEU) has demonstrated preliminary \nAnnals of Translational Medicine, Vol 7, No 20 October 2019\nPage 3 of 7",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 20
        }
    },
    "286": {
        "text": "Page 3 of 7\n© Annals of Translational Medicine. All rights reserved.\n  Ann Transl Med 2019;7(20):595 | http://dx.doi.org/10.21037/atm.2019.05.58\nTable 1 Selected Immunotherapy drugs in clinical practice\nDrug name\nMechanism of action\nClinical uses\nApproval \nyear\nIpilimumab\nCTLA-4 Antibody\nMelanoma metastatic\n2011\nNivolumab\nCheck-point inhibitor\nNon-small cell lung cancer metastatic progressive\n2015\nMelanoma unresectable or metastatic\n2015\nRenal cell cancer advanced previously treated\n2015",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 21
        }
    },
    "287": {
        "text": "2015\nSmall cell lung cancer, metastatic\n2016\nSmall cell lung cancer, metastatic in combination with ipilimumab\n2016\nHead and neck cancer, squamous cell, recurrent or metastatic\n2016\nUrothelial carcinoma, locally advanced or metastatic\n2017\nMelanoma unresectable previously untreated, with ipilimumab \ncombination\n2017\nMelanoma metastatic with brain metastasis\n2018\nRenal cell cancer advanced previously untreated with ipilimumab \ncombination\n2018\nPembrolizumab\nAnti PD1 monoclonal antibody",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 22
        }
    },
    "288": {
        "text": "2018\nPembrolizumab\nAnti PD1 monoclonal antibody\nMelanoma unresectable or metastatic\n2015\nMerkel cell carcinoma, recurrent or metastatic\n2016\nNon-small cell lung cancer, metastatic, single agent\n2016\nPrimary mediastinal large B cell, relapsed or refractory\n2017\nUrothelial carcinoma, locally advanced or metastatic\n2017\nNon-small cell lung cancer, non-squamous, metastatic in \ncombination\n2018\nNon-small cell lung cancer, squamous, metastatic in combinations\n2018\nMelanoma Stage III adjuvant \n2018",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 23
        }
    },
    "289": {
        "text": "2018\nMelanoma Stage III adjuvant \n2018\nCervical cancer recurrent or metastatic\n2018\nGastric cancer recurrent locally advanced or metastatic\n2018\nHepatocellular carcinoma advanced\n2018\nHead and neck cancer, squamous cell, recurrent or metastatic\n2018\nIbrutinib\nBruton tyrosine kinase inhibitor\nMantle cell lymphoma\n2013\nCLL/SLL monotherapy or in combination BR or obinutuzumab\n2014\nCLL/SLL with 17p deletion\n2014\nWaldenstrom macroglobulinemia, monotherapy or rituximab \ncombination\n2015",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 24
        }
    },
    "290": {
        "text": "combination\n2015\nMarginal zone lymphoma\n2017\nAxicabtagene \nciloleucel\nCAR T-cell immunotherapy\nLarge B cell lymphoma\n2017\nTisagenlecleucel\nCAR T-cell immunotherapy\nAcute lymphoblastic lymphoma-relapsed or refractory\n2017\nDiffuse large B cell relapsed or refractory\n2017\nShahid et al. Immunotherapy—the new road map in cancer treatment\n© Annals of Translational Medicine. All rights reserved.\n  Ann Transl Med 2019;7(20):595 | http://dx.doi.org/10.21037/atm.2019.05.58\nPage 4 of 7",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 25
        }
    },
    "291": {
        "text": "Page 4 of 7\npromising results, with median progression free survival \nreaching 11 months (17).\nDramatic improvement in survival benefits with \nimmunotherapy compared to cytotoxic chemotherapy \nin lung cancers and melanoma, has led to the expanded \ndevelopment of immunotherapy in hematologic \nmalignancies. In recent years, the paradigm for treatment \nof hematologic malignancies had dramatically changed. \nGone are the days when fludarabine based combination",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 26
        }
    },
    "292": {
        "text": "chemotherapy was used to treat chronic lymphocytic \nleukemia (CLL) (18). Imagine the toxicity of chemotherapy \ncompared to the newer treatment options in the form \nof immunotherapy. Ibrutinib is a small molecular drug \nthat irreversibly binds to an important B cell enzyme, \nBruton’s tyrosine kinase (BTK). It is essentially the \nwonder drug being currently used to treat B-cell \ncancers like CLL, mantle cell lymphoma, and Wald \nEnstrom’s macroglobulinemia, giving patients an",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 27
        }
    },
    "293": {
        "text": "Enstrom’s macroglobulinemia, giving patients an \neffective chemotherapy-free option. Improved survival \noutcomes in both RESONATE 2 (19) comparing \nibrutinib with chlorambucil and iLLUMINATE (20) \ncomparing combination ibrutinib with obinutuzumab \n(fully humanized CD20 targeted monoclonal antibody) \nwith standard chemoimmunotherapy regimen, validated \ncurrent use of ibrutinib in front-line setting for patients \nwith CLL. Additionally, the results of the iLLUMINATE",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 28
        }
    },
    "294": {
        "text": "trial continued to show progression free survival benefit \neven in high risk sub-groups (del17p or TP53 mutation, \ndel11q or unmutated IGHV) compared with standard \nchemoimmunotherapy arm. \nIn classic Hodgkin lymphoma (cHL), investigators \nhave evaluated the role of check point inhibitors to \nimprove response rates (21-23). Pembrolizumab is another \nhumanized IgG4 isotype antibody that binds to PD-1 \nlocated on lymphocytes and blocks the interaction of",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 29
        }
    },
    "295": {
        "text": "PD-L1 and PD-1. Results from KEYNOTE-087 (24) \ndemonstrated that treating patients with relapsed refractory \nclassic Hodgkin lymphoma with pembrolizumab, improved \noverall response rate. Similarly, treatment with combination \nof nivolumab and brentuximab vedotin, resulted in \nimproved response rates for cHL patients in first relapse (25) \nand relapsing post-transplant (22). Based on these results \nand advances anti-PD-1 antibodies have now been FDA-",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 30
        }
    },
    "296": {
        "text": "approved for cHL patients with relapse and/or refractory \ndiseases. \nImmune checkpoint inhibitors are but one-way \nmodulation of immune system infiltrate and revolutionize \ncancer care. Another success in immunotherapy is with \nCAR (chimeric antigen receptor) T-cell therapy. CAR \nT-cell therapy is considered the most innovative example in \npersonalized cancer medicine. This is a type of treatment in \nwhich a patient’s own T-cells are changed in the laboratory",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 31
        }
    },
    "297": {
        "text": "so they will specifically attack that patient’s cancer cells. \nThese T-cells are taken from a patient’s blood. Then the \ngene for a special receptor that binds to a certain protein \non the patient’s cancer cells is added in the laboratory, to \ngenetically programmed and trained the T-cells to attack \ncancer cells. The special receptor is called a chimeric \nantigen receptor. Large numbers of the CAR T-cells are \ngrown in the laboratory and infuse back into the patient.",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 32
        }
    },
    "298": {
        "text": "CAR T-cell therapy has been FDA-approved for certain \ntypes of lymphoma and leukemia since 2017. Results from \nZUMA-1 (26) endorsed the FDA approval of axicabtagene \nciloleucel (CD 19 directed CAR T-cell therapy) for patients \nwith relapsed, refractory diffuse large B-cell lymphoma, \nfollicular lymphoma with transformation and high-grade \nB-cell lymphoma with failure of two prior systemic lines of \ntherapy. Tisagenlecleucel is another CD19-directed CAR",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 33
        }
    },
    "299": {
        "text": "T-cell therapy which was FDA-approved and currently \nbeing used for treatment of patients with B-cell precursor \nacute lymphoblastic leukemia that is refractory or in second \nor later relapse (27,28). Complete response rates were \n80–90% in this sub-group however the relapse free survival \ndeclined to 60 per cent in the 12 months and these are \nthought to be due to early CAR T-cell loss, also called T-cell \nexhaustion. Investigators are currently studying the use of",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 34
        }
    },
    "300": {
        "text": "immune checkpoint inhibitors in combination with CAR \nT-cell therapy to determine if the persistence of T-cell can \nbe sustained, hence improving relapsed free survival.\nFuture directions of immunotherapy and resistance \nmechanisms\nImmunotherapy with immune checkpoint inhibitors has \nreplaced the foundation for many solid malignancies, \nnotably melanoma and lung cancers. The impact is more \ndramatic in hematologic malignancies. Results from",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 35
        }
    },
    "301": {
        "text": "different clinical trials, have demonstrated the shift in \ntreatment paradigm, where immunotherapy (both immune \ncheckpoint inhibitors and CAR T-cell therapy) is completely \nchanging the landscape which was previously occupied \nby cytotoxic chemotherapy or chemoimmunotherapy in \nhematologic malignancies. Are we looking at chemotherapy \nfree future in all hematologic cancers? Not likely, as \ninduction chemotherapy is still the standard of care in acute",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 36
        }
    },
    "302": {
        "text": "myeloid leukemia and aggressive non-Hodgkin lymphomas \nAnnals of Translational Medicine, Vol 7, No 20 October 2019\nPage 5 of 7\n© Annals of Translational Medicine. All rights reserved.\n  Ann Transl Med 2019;7(20):595 | http://dx.doi.org/10.21037/atm.2019.05.58\nand clinical trials are ongoing to further evaluate the role of \nimmunotherapy-based combination for these patients with \naggressive and harder to treat hematologic malignancies. \nThe search goes on for potential immunotherapy targets,",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 37
        }
    },
    "303": {
        "text": "resistance mechanisms and how to further enhance their \nresponses. More and more cancer types which were \npreviously considered non-immunogenic with limited role \nof immunotherapy are now showing signs of change. A \nvery good example being triple negative, her 2 neu positive \nmetastatic breast cancer where ongoing clinical trials show \npromising results (29).\nPancreatic cancer is another example which has been \ntraditionally known to be resistant to immunotherapy. A",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 38
        }
    },
    "304": {
        "text": "detailed understanding of the cancer micro-environment \nnow shows potential for VISTA pathway which can \ndeactivate T-cells and hence suppress immune response \nleading to theoretical failure of PD-1/PDL1 inhibition. \nVISTA is expressed on macrophages which play a key role in \ninnate immune response. Studying the milieu in pancreatic \ncancer shows increased macrophages in the stroma and \nmuch higher expression of VISTA pointing towards \nresistance mechanism for immunotherapy (30,31). Other",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 39
        }
    },
    "305": {
        "text": "immune resistance pathway recently discovered is in K-ras \nmutant lung cancer. The MAPK signaling where expression \nof a protein called ZEB1 (presence of KRAS mutation is \nessential), targets the IL17RD protein suppression shutting \ndown the pathway. This protein expression directs epithelial \ncells to transition to mesenchymal cell lines. This transition \nis important and noted in development and progression of \nvarious tumors (32). This also explains the reason why many",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 40
        }
    },
    "306": {
        "text": "tumors become resistant to treatment with the passage of \ntime. This phenomenon called Epithelial to mesenchymal \ntransition has been studied previously in dissemination of \ncancer cells (33).\nCurrently there are lot of molecular studies looking into \nimmune resistant pathways and time will tell if we will be \nable to decipher them effectively to be clinically relevant. \nA more detailed understanding of the tumor micro-\nenvironment, role of small molecule Immuno-oncology,",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 41
        }
    },
    "307": {
        "text": "understanding resistance to NK cell immunotherapy against \nsolid tumors, finding molecular markers of resistance, \ntumor evasion mechanisms and role of combining cytotoxic \nchemotherapy and its proper sequencing in treatment holds \nthe key to the future. \nConclusions\nImmunotherapy is currently becoming the new foundation \nstone in treatment of various malignancies and more \nrecent clinical guidelines are constantly being updated \nto incorporate immunotherapy in the mix. This is a field",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 42
        }
    },
    "308": {
        "text": "which previously only included cytotoxic chemotherapy. \nEvery researcher irrespective of the organ system is either \nstudying it or trying to incorporate it into clinical trials. The \nnext goal would be to determine sequencing of treatment \noptions and which type of immunotherapy to choose from. \nCAR T-cells have shown promising results and a leap \ntowards personalized medicine which without any doubts \nseem to be the future of oncology. Having achieved this",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 43
        }
    },
    "309": {
        "text": "status in cancer treatment starting from melanoma then \nlung cancer and now other cancers, we can only hope \nfor better and better results in all cancer types including \nhematologic malignancies. New clinical trials are looking \nto enhance the excellent current clinical response rates \nachieved by immunotherapy and finding ways to overcome \nthe known and unknown immune resistance pathways. \nWith immunotherapy we are in the right direction and are",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 44
        }
    },
    "310": {
        "text": "looking forward to the day when cancer will just be called a \nchronic disease.\nAcknowledgments\nNone.\nFootnote\nConflicts of Interest: The authors have no conflicts of interest \nto declare.\nReferences\n1.\t\nLeach DR, Krummel MF, Allison JP. Enhancement \nof antitumor immunity by CTLA-4 blockade. Science \n1996;271:1734-6.\n2.\t\nHersh EM, O'Day SJ, Powderly J, et al. A phase II \nmulticenter study of ipilimumab with or without \ndacarbazine in chemotherapy-naive patients with advanced",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 45
        }
    },
    "311": {
        "text": "melanoma. Invest New Drugs;29:489-98.\n3.\t\nYERVOY. Insert package of Ipilimumab 2016, August 10. \nAvailable online:  http://packageinserts.bms.com/pi/pi_\nyervoy.pdf\n4.\t\nHowell M, Lee R, Bowyer S, et al. Optimal management \nof immune-related toxicities associated with checkpoint \ninhibitors in lung cancer. Lung Cancer 2015;88:117-23.\n5.\t\nAn open-label, randomized, phase 3 trial of nivolumab \nversus investigator’s choice chemotherapy as first-line",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 46
        }
    },
    "312": {
        "text": "Shahid et al. Immunotherapy—the new road map in cancer treatment\n© Annals of Translational Medicine. All rights reserved.\n  Ann Transl Med 2019;7(20):595 | http://dx.doi.org/10.21037/atm.2019.05.58\nPage 6 of 7\ntherapy for stage IV or recurrent PD-L1+ non-small \ncell lung cancer (CheckMate 026). National Library of \nMedicine (US), 2018. \n6.\t\nA master protocol study of nivolumab in advanced non-\nsmall cell lung cancer (NSCLC) (CheckMate 370). \nNational Library of Medicine (US), 2018.\n7.",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 47
        }
    },
    "313": {
        "text": "National Library of Medicine (US), 2018.\n7.\t\nCorrie P, Hategan M, Fife K, et al. Management of \nmelanoma. Br Med Bull 2014;111:149-62.\n8.\t\nSleijfer S, Bannink M, Van Gool AR, et al. Side \neffects of interferon-alpha therapy. Pharm World Sci \n2005;27:423-31.\n9.\t\nFava P, Astrua C, Sanlorenzo M, et al. Treatment of \nmetastatic melanoma: a multidisciplinary approach. G Ital \nDermatol Venereol;152:241-61.\n10.\t Hodi FS, O'Day SJ, McDermott DF, et al. Improved",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 48
        }
    },
    "314": {
        "text": "survival with ipilimumab in patients with metastatic \nmelanoma. N Engl J Med;363:711-23.\n11.\t Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis \nof Long-Term Survival Data From Phase II and Phase \nIII Trials of Ipilimumab in Unresectable or Metastatic \nMelanoma. J Clin Oncol 2015;33:1889-94.\n12.\t Hamid O, Robert C, Daud A, et al. Five-year survival \noutcomes for patients with advanced melanoma treated \nwith pembrolizumab in KEYNOTE-001. Ann Oncol. \n2019;30:582-88.",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 49
        }
    },
    "315": {
        "text": "2019;30:582-88.\n13.\t Karabajakian A, Reverdy T, Gau M, et al. Nivolumab in \nrecurrent/metastatic head and neck cancers. Future Oncol \n2018;14:603-9.\n14.\t Cohen EEW, Soulieres D, Le Tourneau C, et al. \nPembrolizumab versus methotrexate, docetaxel, or \ncetuximab for recurrent or metastatic head-and-neck \nsquamous cell carcinoma (KEYNOTE-040): a randomised, \nopen-label, phase 3 study. Lancet 2019;393:156-67.\n15.\t Shah MA, Kojima T, Hochhauser D, et al. Efficacy",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 50
        }
    },
    "316": {
        "text": "and Safety of Pembrolizumab for Heavily Pretreated \nPatients With Advanced, Metastatic Adenocarcinoma or \nSquamous Cell Carcinoma of the Esophagus: The Phase 2 \nKEYNOTE-180 Study. JAMA Oncol 2019;5:546-50.\n16.\t Pembrolizumab/Placebo Plus Trastuzumab Plus \nChemotherapy in Human Epidermal Growth Factor \nReceptor 2 Positive (HER2+) Advanced Gastric or \nGastroesophageal Junction (GEJ) Adenocarcinoma \n(MK-3475-811/KEYNOTE-811). National Library of \nMedicine, 2019.",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 51
        }
    },
    "317": {
        "text": "Medicine, 2019.\n17.\t Tabernero J, Hoff PM, Shen L, et al. Pertuzumab plus \ntrastuzumab and chemotherapy for HER2-positive \nmetastatic gastric or gastro-oesophageal junction cancer \n(JACOB): final analysis of a double-blind, randomised, \nplacebo-controlled phase 3 study. Lancet Oncol \n2018;19:1372-84.\n18.\t Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition \nof rituximab to fludarabine and cyclophosphamide \nin patients with chronic lymphocytic leukaemia:",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 52
        }
    },
    "318": {
        "text": "in patients with chronic lymphocytic leukaemia: \na randomised, open-label, phase 3 trial. Lancet \n2010;376:1164-74.\n19.\t Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as \nInitial Therapy for Patients with Chronic Lymphocytic \nLeukemia. N Engl J Med 2015;373:2425-37.\n20.\t Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus \nobinutuzumab versus chlorambucil plus obinutuzumab \nin first-line treatment of chronic lymphocytic leukaemia \n(iLLUMINATE): a multicentre, randomised, open-label,",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 53
        }
    },
    "319": {
        "text": "phase 3 trial. Lancet Oncol 2019;20:43-56.\n21.\t Ansell SM. Immunotherapy of Hodgkin Lymphoma: \nMobilizing the Patient's Immune Response. Cancer J \n2018;24:249-53.\n22.\t Armand P, Engert A, Younes A, et al. Nivolumab for \nRelapsed/Refractory Classic Hodgkin Lymphoma After \nFailure of Autologous Hematopoietic Cell Transplantation: \nExtended Follow-Up of the Multicohort Single-Arm Phase \nII CheckMate 205 Trial. J Clin Oncol 2018;36:1428-39.\n23.\t Foran AE, Nadel HR, Lee AF, et al. Nivolumab in the",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 54
        }
    },
    "320": {
        "text": "Treatment of Refractory Pediatric Hodgkin Lymphoma. J \nPediatr Hematol Oncol 2017;39:e263-e6.\n24.\t Chen R, Zinzani PL, Fanale MA, et al. Phase II Study of \nthe Efficacy and Safety of Pembrolizumab for Relapsed/\nRefractory Classic Hodgkin Lymphoma. J Clin Oncol \n2017;35:2125-32.\n25.\t Wang Y, Nowakowski GS, Wang ML, et al. Advances in \nCD30- and PD-1-targeted therapies for classical Hodgkin \nlymphoma. J Hematol Oncol 2018;11:57.\n26.\t Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 55
        }
    },
    "321": {
        "text": "Ciloleucel CAR T-Cell Therapy in Refractory Large \nB-Cell Lymphoma. N Engl J Med 2017;377:2531-44.\n27.\t KYMRIAH™ (tisagenlecleucel). FDA. 2018, May. \nAvailable online: https://www.fda.gov/downloads/\nBiologicsBloodVaccines/CellularGeneTherapyProducts/\nApprovedProducts/UCM573941.pdf\n28.\t Park JH, Riviere I, Gonen M, et al. Long-Term Follow-\nup of CD19 CAR Therapy in Acute Lymphoblastic \nLeukemia. N Engl J Med 2018;378:449-59.\n29.\t Tolba MF, Omar HA. Immunotherapy, an evolving",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 56
        }
    },
    "322": {
        "text": "approach for the management of triple negative breast \ncancer: Converting non-responders to responders. Crit \nRev Oncol Hematol 2018;122:202-7.\n30.\t Blando J, Sharma A, Higa MG, et al. Comparison of \nAnnals of Translational Medicine, Vol 7, No 20 October 2019\nPage 7 of 7\n© Annals of Translational Medicine. All rights reserved.\n  Ann Transl Med 2019;7(20):595 | http://dx.doi.org/10.21037/atm.2019.05.58\nCite this article as: Shahid K, Khalife M, Dabney R, Phan AT.",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 57
        }
    },
    "323": {
        "text": "Immunotherapy and targeted therapy—the new roadmap in \ncancer treatment. Ann Transl Med 2019;7(20):595. doi: 10.21037/\natm.2019.05.58\nimmune infiltrates in melanoma and pancreatic cancer \nhighlights VISTA as a potential target in pancreatic cancer. \nProc Natl Acad Sci U S A 2019;116:1692-7.\n31.\t Nowak EC, Lines JL, Varn FS, et al. Immunoregulatory \nfunctions of VISTA. Immunol Rev 2017;276:66-79.\n32.\t Peng DH, Kundu ST, Fradette JJ, et al. ZEB1 suppression",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 58
        }
    },
    "324": {
        "text": "sensitizes KRAS mutant cancers to MEK inhibition by an \nIL17RD-dependent mechanism. Sci Transl Med 2019. doi: \n10.1126/scitranslmed.aaq1238\n33.\t Wu Y, Yang X, Chen Z, et al. m6A-induced lncRNA RP11 \ntriggers the dissemination of colorectal cancer cells via \nupregulation of Zeb1. Mol Cancer 2019;18:87.",
        "metadata": {
            "source": "atm-07-20-595.pdf",
            "chunk_id": 59
        }
    },
    "325": {
        "text": "The Warburg effect: 80 years on\nMichelle Potter, Emma Newport and Karl J. Morten\nNuffield Department of Obstetrics and Gynaecology, The Women Centre, University of Oxford, John Radcliffe Hospital, Oxford, U.K.\nCorrespondence: Karl J. Morten (karl.morten@obs-gyn.ox.ac.uk)\nInﬂuential research by Warburg and Cori in the 1920s ignited interest in how cancer cells’\nenergy generation is different from that of normal cells. They observed high glucose con-",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 0
        }
    },
    "326": {
        "text": "sumption and large amounts of lactate excretion from cancer cells compared with normal\ncells, which oxidised glucose using mitochondria. It was therefore assumed that cancer\ncells were generating energy using glycolysis rather than mitochondrial oxidative\nphosphorylation, and that the mitochondria were dysfunctional. Advances in research\ntechniques since then have shown the mitochondria in cancer cells to be functional",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 1
        }
    },
    "327": {
        "text": "across a range of tumour types. However, different tumour populations have different\nbioenergetic alterations in order to meet their high energy requirement; the Warburg\neffect is not consistent across all cancer types. This review will discuss the metabolic\nreprogramming of cancer, possible explanations for the high glucose consumption in\ncancer cells observed by Warburg, and suggest key experimental practices we should\nconsider when studying the metabolism of cancer.\nThe Warburg effect",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 2
        }
    },
    "328": {
        "text": "The Warburg effect\nDespite decades of research and countless ﬁnancial investments, cancer continues to elude our\ncomplete understanding and more importantly our therapies. Pivotal research in the 1920s by\nWarburg and Cori demonstrated that cancer avidly consumes glucose and excretes lactate [1,2]. When\noxygen is present, normal cells use mitochondria to oxidise glucose, but in the absence of oxygen,",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 3
        }
    },
    "329": {
        "text": "glucose is converted into lactate. Otto Warburg ﬁrst described in the 1920s that cancer cells utilised\nhigher levels of glucose in the presence of oxygen with an associated increase in lactate production.\nThe phenomenon of aerobic glycolysis, termed the Warburg effect, has been observed in a variety of\nother tumour types, including colorectal cancer [3], breast [4], lung [5] and glioblastoma [6,7]. From",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 4
        }
    },
    "330": {
        "text": "his observations, Warburg concluded that the mitochondria were dysfunctional [8,9]. The Warburg\neffect has been conﬁrmed in previous studies including those of DeBerardinis et al. [10], where cells\nwere incubated under oxygenated conditions in 10 mM C-13-labelled glucose. Cells were then per-\nfused using 4 mM glucose prior to metabolomics analysis and even in the presence of oxygen, high\nlevels of glycolytic metabolites were observed supporting Warburg’s hypothesis. In addition, Fantin",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 5
        }
    },
    "331": {
        "text": "et al. [11] made the observation that inhibiting lactate dehydrogenase preventing the conversion of\npyruvate to lactate reduced tumourigenicity. These data were interpreted as tumourigenicity being\ndependent on high levels of energy derived from glycolysis. Another study by Schulz et al. [12]\nshowed that when mitochondrial oxidative phosphorylation is up-regulated by overexpression of fra-\ntaxin, malignant growth and tumourigenic capacity are decreased. The authors suggest that rather",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 6
        }
    },
    "332": {
        "text": "than an increase in glycolysis being the main cause of malignant tumour growth, it is the efﬁciency of\nmitochondrial energy conversion that is the key metabolic factor.\nOver the past couple of decades, advances in technology have allowed mitochondrial function to be\nstudied in a far greater detail, and it is now realised that cancer cells have active and functional mito-\nchondria, contrary to Warburg’s theory [13,14]. In the last decade, research has shown that different",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 7
        }
    },
    "333": {
        "text": "tumour types (and indeed subpopulations within a tumour) have different bioenergetic alterations.\nThis was shown as early as 1967, when Weinhouse reported that slow-growing rat hepatoma cells\nwere oxidative, whereas the more proliferative hepatomas were glycolytic [15]. The Warburg effect is\nnot consistent across all tumours, and the phenomenon of aerobic glycolysis has now been challenged\nby several groups with many cell lines reported as having mitochondrial function [16–18]. In a",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 8
        }
    },
    "334": {
        "text": "Version of Record published:\n19 October 2016\nReceived: 1 April 2016\nRevised: 29 June 2016\nAccepted: 25 July 2016\n© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).1499\nBiochemical Society Transactions (2016) 44 1499–1505\nDOI: 10.1042/BST20160094",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 9
        }
    },
    "335": {
        "text": "DOI: 10.1042/BST20160094\ntumour, it is likely that a dynamic interplay exists between oxidative metabolism and glycolysis. Metabolic ﬂexi-\nbility has now been observed in a range of cancers, including cervical, breast and pancreatic cancer (see ref.\n[16] and reviewed in ref. [19]). In 2004, Zu and Guppy reported that adenosine triphosphate (ATP) derived\nthrough glycolysis in various cancers and cell lines accounts for only 17% of the total ATP. In fact, the ATP",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 10
        }
    },
    "336": {
        "text": "generated through glycolysis was highly dependent on the cell type and could be as low as 0.31% (ﬁbrosar-\ncoma) or as high as 64% (hepatoma), with the remaining ATP being derived from mitochondrial oxidative\nphosphorylation [20]. In addition to metabolic ﬂexibility linked to environmental conditions, there is also the\ninﬂuence of various cancer-associated mutations, many of which have an impact on metabolism. Mutations in",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 11
        }
    },
    "337": {
        "text": "the mitochondrial tricarboxylic acid cycle and respiratory chain component succinate dehydrogenase, for\nexample, can cause phenochromocytoma and paraganglioma, where neuroendocrine tumours arise in the\nadrenal medulla and paraganglia in the autonomic nervous system [21,22]. Mutations in isocitrate dehydrogen-\nase 1 are associated with adult cases of glioblastoma and appear to have a major role in the development of the",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 12
        }
    },
    "338": {
        "text": "tumour by a gain-of-function effect [23,24]. Understanding how cancer cell environment and mutations affect\nmetabolism will be of fundamental importance in selecting appropriate metabolic drug combinations to impact\non patients’ cancer cell growth.\nCancer hallmarks and metabolic reprogramming\nCancer cells show complex, dynamic behaviour allowing survival even in the most unfavourable conditions of",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 13
        }
    },
    "339": {
        "text": "substrate and oxygen stress. Advances in technology have helped in furthering our knowledge of the underlying\nmolecular processes underpinning cancer, but there are still many unanswered questions. In 2000, Hanahan\nand Weinberg published a highly cited review article identifying six cancer hallmarks [25]. These included\nuncontrolled proliferative signalling, resistance to apoptosis, initiating angiogenesis, acquiring replicative",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 14
        }
    },
    "340": {
        "text": "immortality, activating invasion and metastasis and evading growth suppressors. Over the last decade, research\nhas increased our knowledge of cancer, and in 2011, Hanahan and Weinberg extended the list of cancer hall-\nmarks to include metabolic reprogramming/deregulated cellular energetics as an emerging hallmark and potential\ncancer target [26]. Uncontrolled proliferation is one of the essential characteristics of cancer. It has been",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 15
        }
    },
    "341": {
        "text": "proposed that reprogramming energy metabolism is essential to fuel and maintain such behaviour [26]. The\nexact reasons behind the metabolic switch are not known, but likely reasons include: (i) sustaining high prolif-\nerative rates in hypoxia [27] and (ii) evading apoptosis as a result of reduced mitochondrial function [28].\nIncreases in glycolysis have been linked to invasiveness, with changes in glycolysis identiﬁed in several studies",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 16
        }
    },
    "342": {
        "text": "[29,30]. However, in all studies listed above, cancer cells were grown on cell culture media containing high\nlevels of glucose between 10 and 25 mM. This is considerably higher than plasma glucose, which lies between 4\nand 6 mM. Levels in a rapidly dividing tumour with poor vasculature are considerably lower. The same is true\nof studies investigating the role of hypoxia in down-regulating mitochondrial respiration and increasing glycoly-",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 17
        }
    },
    "343": {
        "text": "sis, where 25 mM glucose is used in the culture media of key publications [31–34]. The impact of high levels of\nglucose on the above ﬁndings is a key consideration for future studies, where it is crucial to test new drugs tar-\ngeting cancer cell metabolism under physiologically relevant conditions. Metformin, for example, a drug cur-\nrently being investigated as an anticancer agent in a wide range of cancers [35], has recently been shown to be",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 18
        }
    },
    "344": {
        "text": "more effective in enhancing chemotherapy sensitivity of oesophageal squamous cancer cells under reduced\nglucose conditions [36]. Although its mode of action on cancer cells in vivo is not entirely clear, mitochondrial\nstudies suggest that metformin can directly impair complex I of the respiratory chain [37,38]. The effect\nobserved by Yu et al. is probably due to a greater reliance of the cancer cells on mitochondrial respiration for",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 19
        }
    },
    "345": {
        "text": "energy production when cultured on reduced glucose conditions. Previous studies have shown that high levels\nof glucose in the culture media can signiﬁcantly reduce levels of mitochondrial respiration, with reduced\nglucose conditions showing much higher rates of mitochondrial respiration, as cells use other substrates for\ncellular ATP production [39,40]. Similar results are shown in Figure 1, where the oxygen consumption rates",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 20
        }
    },
    "346": {
        "text": "(OCRs; mitochondrial respiration) and extracellular acidiﬁcation rates (ECAR; glycolysis) of a range of cancer\ncell lines are compared under high (25 mM) and low (1 mM) glucose conditions. Under high glucose (25 mM)\nconditions, cancer cell lines either show the Warburg effect (low OCR and high ECAR), high rates of OCR and\nlow ECAR or something in between high/moderate OCR with high/moderate ECAR. A ﬁnding highly relevant",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 21
        }
    },
    "347": {
        "text": "to the situation in vivo is that when cultured under low glucose (1 mM) conditions, all cancer lines tested show\nhigh–moderate OCR with very little ECAR (glycolysis).\n1500 © 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).\nBiochemical Society Transactions (2016) 44 1499–1505\nDOI: 10.1042/BST20160094",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 22
        }
    },
    "348": {
        "text": "DOI: 10.1042/BST20160094\nPositron emission tomography imaging and the reverse\nWarburg effect\nPositron\nemission\ntomography\n(PET)\nimaging\nuses\na\nradioisotope-labelled\nglucose\ntracer,\n18F-ﬂuorodeoxyglucose (18F-FDG), to identify areas of high glucose uptake/metabolism in the body. 18F-FDG is\ntransported into cells by glucose transporters (GLUTs) and phosphorylated by hexokinase (HK) to\n18F-FDG-6-phosphate (18F-FDG-6-P). Once inside the cell,\n18F-FDG-6-P cannot be further metabolised",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 23
        }
    },
    "349": {
        "text": "18F-FDG-6-P cannot be further metabolised\nthrough the glycolytic pathway and due to its high polar nature becomes trapped. Tumours above a certain size\nlabel strongly with this approach, and it is used to identify the presence of solid tumours and the effectiveness\nof treatments. Other highly metabolically active tissues, such as the brain and heart, also label strongly. It is\nbelieved that PET scans show an increased uptake of glucose in tumours due to overexpression of GLUTs",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 24
        }
    },
    "350": {
        "text": "[41–43]. Historically, increased glucose uptake has been associated with supporting the Warburg effect [20].\nHowever, high glucose uptake does not automatically equate to increased glycolysis and reduced mitochondrial\nmetabolism. An increased PET signal could be due to a general increase in glucose oxidation with increased\nglycolysis and mitochondrial respiration or a high demand for lipids derived from glucose. In addition, over-",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 25
        }
    },
    "351": {
        "text": "expression of GLUTs cannot be assumed to correlate with increased metabolic ﬂux. A high PET signal would\nbe obtained if glucose entered the cancer cell and was not metabolised. Many tumours are characterised by\nFigure 1. Bioenergetic proﬁles of cancer cell lines RD, RH30, U87MG, M059K, SF188, KNS42, UW479 and Res259.\nOCR and ECAR are plotted to quantify mitochondrial respiration and to give an indication of glycolysis rates. OCR and ECAR",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 26
        }
    },
    "352": {
        "text": "are expressed as changes in ﬂuorescence life time/h/75 000 cells (n = 3). Assays were set up in black 96-well plates with\npre-incubation in 1 mM and 25 mM glucose media carried out for 16 h. Oxygen and glycolysis sensing probes: MitoXpress xtra\nand pH xtra from Luxcel Biosciences were used to determine OCR and ECAR (http://luxcel.com/).",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 27
        }
    },
    "353": {
        "text": "© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).1501\nBiochemical Society Transactions (2016) 44 1499–1505\nDOI: 10.1042/BST20160094\nincreased levels of GLUTs (particularly GLUT 1 and GLUT 3) and high expression of HK (I and II), which is",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 28
        }
    },
    "354": {
        "text": "associated with the increases in 18F-FDG signal compared with surrounding tissues as reviewed in ref. [44].\nHowever, not all cancers are easily detected by PET imaging, including renal clear cell carcinoma, which is a\nprototypical Warburg cancer [45]. Conversely, not all 18F-FDG avid tissue is malignant; inﬂammation can also\nlead to a positive PET signal. Interestingly, Hodgkin’s lymphoma responds well to PET imaging [46]. This",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 29
        }
    },
    "355": {
        "text": "tumour is less than 10% cancer cells, and the remaining cells are stromal/inﬂammation cells [47].\nAlthough PET imaging is undeniably an extremely useful and an important clinical technique, there can be\nissues with the interpretation of the image. It is a common problem that the PET images can often overestimate\nthe actual size of the tumour. A possible reason for this is that the microenvironment of the tumour is glyco-",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 30
        }
    },
    "356": {
        "text": "lytic in a phenomenon that has been called the reverse Warburg effect. First postulated by Pavlides et al. in\n2009 [48], the reverse Warburg effect describes how oxidative stress in the cancer-associated ﬁbroblasts (CAF)\ninduces mitophagy and autophagy. The hypothesis is that hydrogen peroxide secreted from the cancer cells\nleads to oxidative stress in the CAF. The ﬁbroblasts then undergo cellular catabolism, which results in a loss of",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 31
        }
    },
    "357": {
        "text": "mitochondrial function and ultimately a switch from aerobic metabolism to glycolysis [49]. This glycolytic\nswitch results in increased lactate production by CAF, which is then exported into the extracellular space by\nmonocarboxylate transporter 4 (MCT4). The lactate is ultimately taken up by the cancer cells via MCT1 and\nused to fuel oxidative metabolism [50,51]. In ref. [50], the authors demonstrate support for the reverse",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 32
        }
    },
    "358": {
        "text": "Warburg effect by culturing human breast cancer cell lines with human ﬁbroblasts. Both MCF-7 and\nMDA-MB-231, when co-cultured with ﬁbroblasts, show reduced mitochondrial function in ﬁbroblasts with\nincreased activity in the cancer cell lines. As in the studies of the Warburg effect and the impact of hypoxia\ndescribed earlier, studies to date on the reverse Warburg effect use high concentrations of glucose 25 mM. If",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 33
        }
    },
    "359": {
        "text": "glucose is rapidly removed from the media by the cancer cells, this would tend to drive the cancer cells to use\nmitochondrial respiration (see Figure 1). Under high glucose conditions, this property of cancer cell lines will\nbe held back by glucose inhibition of mitochondrial respiration.\nLactate was discovered in the late 1700s and was traditionally thought of as a waste product of glycolysis. In",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 34
        }
    },
    "360": {
        "text": "reality, lactate is an extremely efﬁcient fuel and also an important signalling molecule [52,53]. It is constantly\nturned around in our cells, regardless of oxygenation state. Lactate is a key metabolite in the body, capable\nof replacing glucose as an energy source. Lactate is also capable of stabilising hypoxia-inducing factor and\nincreasing vascular endothelial growth factor expression [53]. The ﬁbroblast–tumour metabolic coupling",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 35
        }
    },
    "361": {
        "text": "proposed to exist in the reverse Warburg effect is analogous to the metabolic symbiosis seen in the brain\n(Figure 2). The brain is a metabolically demanding organ that gives high PET signals. Its avidity for glucose\nwas historically attributed to the neurons; however, it is the astrocytes that are glucose hungry and glycolytic.\nThe lactate secreted by the astrocytes then fuels the neurons, which use oxidative phosphorylation to generate",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 36
        }
    },
    "362": {
        "text": "ATP [54]. The Warburg effect is not a universal feature of cancer, and similarly the reverse Warburg is not\nuniversal in all tumours. Yoshida, in 2015, showed that tumours expressing high levels of MCT4 do no exhibit\nthe reverse Warburg effect [55]. The microenvironment of cancer is ever changing, and cancer cells can and\ndo vary in their metabolic phenotype even within the same tumour mass [56]. Although hard to generalise in",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 37
        }
    },
    "363": {
        "text": "solid tumours with a hypoxic core, perhaps the Warburg effect most probably predominates with reduced\noxygen levels driving the cells to make the most of all available glucose. The more actively proliferating cells in\nthe periphery may perhaps use the lactate excreted in the hypoxic region and oxidise it [57], leading to a\nsymbiotic relationship between the hypoxic and aerobic cell populations. In vitro metabolism studies are",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 38
        }
    },
    "364": {
        "text": "useful tools, but it only serves to hinder therapeutic translation when non-physiological glucose concentrations\nup to and including 25 mM glucose are used instead of a physiological concentration of 5 mM (plasma) or\n<5 mM (tissue).\nIn summary, we have sought here to revisit the Warburg effect and review its signiﬁcance in cancer based on\nrecent advances in our knowledge and understanding of the complex biology underlying this disease. It is",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 39
        }
    },
    "365": {
        "text": "indisputable that certain features of cancer are indeed hallmarks that are essential for most types of cancer.\nHowever, looking to the future, the role of aerobic glycolysis needs further elucidation, as it is not a consistent\nfeature in all cancers. Recent research has shown there to be a broad spectrum of bioenergetic phenotypes dis-\nplayed by cancer both in vivo and in vitro, with many cancer types displaying a surprising degree of mitochondrial",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 40
        }
    },
    "366": {
        "text": "activity. When investigating the role of aerobic glycolysis in vitro, it is pertinent to use physiologically relevant\nconcentrations of nutrients, in particular glucose. The excessive glucose often found in cell culture media can\ndecrease mitochondrial respiration, allowing aerobic glycolysis to predominate. Reducing the glucose in the\nmedia to physiological levels will give a truer picture of the complex metabolic processes at work.",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 41
        }
    },
    "367": {
        "text": "1502 © 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).\nBiochemical Society Transactions (2016) 44 1499–1505\nDOI: 10.1042/BST20160094\nAbbreviations\n18F-FDG, 18F-ﬂuorodeoxyglucose; 18F-FDG-6-P, 18F-FDG-6-phosphate; ATP, adenosine triphosphate; CAF,",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 42
        }
    },
    "368": {
        "text": "cancer-associated ﬁbroblasts; ECAR, extracellular acidiﬁcation rate; GLUT, glucose transporter; HK, hexokinase;\nMCT4, monocarboxylate transporter 4; OCR, oxygen consumption rate; PET, positron emission tomography.\nFigure 2. The astrocyte–neuron shuttle (A) and the reverse Warburg effect (B).\n(A) Glutamate is released from activated synapses and taken up by astrocytes triggering an increase in glycolysis and lactate",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 43
        }
    },
    "369": {
        "text": "production. The lactate can be oxidised by the neurons in response to their increased energy requirement to produce ATP.\n(B) nIn the proposed reverse Warburg effect, hydrogen peroxide is secreted by cancer cells leading to oxidative stress in the\nassociated ﬁbroblasts. The resulting loss of mitochondrial function acts as a switch from aerobic metabolism to glycolysis.",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 44
        }
    },
    "370": {
        "text": "© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).1503\nBiochemical Society Transactions (2016) 44 1499–1505\nDOI: 10.1042/BST20160094\nFunding\nMichelle Potter and Emma Newport were supported by Williams fund (http://www.williamsfund.co.uk/).\nCompeting Interests",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 45
        }
    },
    "371": {
        "text": "Competing Interests\nThe Authors declare that there are no competing interests associated with the manuscript.\nReferences\n1\nWarburg, O., Wind, F. and Negelein, E. (1927) The metabolism of tumors in the body. J. Gen. Physiol. 8, 519–530 doi:10.1085/jgp.8.6.519\n2\nCori, C.A. and Cori, G.T. (1925) The carbohydrate metabolism of tumours. J. Biol. Chem. 65, 397–405\n3",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 46
        }
    },
    "372": {
        "text": "3\nSakashita, M., Aoyama, N., Minami, R., Maekawa, S., Kuroda, K., Shirasaka, D. et al. (2001) Glut1 expression in T1 and T2 stage colorectal\ncarcinomas: its relationship to clinicopathological features. Eur. J. Cancer 37, 204–209 doi:10.1016/S0959-8049(00)00371-3\n4\nGrover-McKay, M., Walsh, S.A., Seftor, E.A., Thomas, P.A. and Hendrix, M.J.C. (1998) Role for glucose transporter 1 protein in human breast cancer.\nPathol. Oncol. Res. 4, 115–120 doi:10.1007/BF02904704\n5",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 47
        }
    },
    "373": {
        "text": "5\nWu, M., Neilson, A., Swift, A.L., Moran, R., Tamagnine, J., Parslow, D. et al. (2007) Multiparameter metabolic analysis reveals a close link between\nattenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am. J. Physiol. Cell Physiol. 292,\nC125–C136 doi:10.1152/ajpcell.00247.2006\n6\nLai, J.-H., Jan, H.-J., Liu, L.-W., Lee, C.-C., Wang, S.-G., Hueng, D.-Y. et al. (2013) Nodal regulates energy metabolism in glioma cells by inducing",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 48
        }
    },
    "374": {
        "text": "expression of hypoxia-inducible factor 1α. Neuro-Oncology 15, 1330–1341 doi:10.1093/neuonc/not086\n7\nMichelakis, E.D., Sutendra, G., Dromparis, P., Webster, L., Haromy, A., Niven, E. et al. (2010) Metabolic modulation of glioblastoma with dichloroacetate.\nSci. Transl. Med. 2, 31ra34 doi:10.1126/scitranslmed.3000677\n8\nWarburg, O. (1956) On the origin of cancer cells. Science 123, 309–314 doi:10.1126/science.123.3191.309\n9",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 49
        }
    },
    "375": {
        "text": "9\nWarburg, O. (1956) On respiratory impairment in cancer cells. Science 124, 269–270 PMID: 13351639\n10\nDeBerardinis, R.J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S. et al. (2007) Beyond aerobic glycolysis: transformed cells can\nengage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Natl Acad. Sci. USA 104, 19345–19350\ndoi:10.1073/pnas.0709747104\n11",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 50
        }
    },
    "376": {
        "text": "doi:10.1073/pnas.0709747104\n11\nFantin, V.R., St-Pierre, J. and Leder, P. (2006) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor\nmaintenance. Cancer Cell 9, 425–434 doi:10.1016/j.ccr.2006.04.023\n12\nSchulz, T.J., Thierbach, R., Voigt, A., Drewes, G., Mietzner, B., Steinberg, P. et al. (2006) Induction of oxidative metabolism by mitochondrial frataxin",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 51
        }
    },
    "377": {
        "text": "inhibits cancer growth: OTTO WARBURG REVISITED. J. Biol. Chem. 281, 977–981 doi:10.1074/jbc.M511064200\n13\nJu, Y.S., Alexandrov, L.B., Gerstung, M., Martincorena, I., Nik-Zainal, S., Ramakrishna, M. et al. (2014) Origins and functional consequences of somatic\nmitochondrial DNA mutations in human cancer. eLife 3, e02935 doi:10.7554/eLife.02935\n14\nXu, X.D., Shao, S.X., Jiang, H.P., Cao, Y.W., Wang, Y.H., Yang, X.C. et al. (2015) Warburg effect or reverse Warburg effect? A review of cancer",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 52
        }
    },
    "378": {
        "text": "metabolism. Oncol. Res. Treat. 38, 117–122 doi:10.1159/000375435\n15\nWeinhouse, S. (1967) Hepatomas. Science 158, 542–545 doi:10.1126/science.158.3800.542\n16\nJose, C., Bellance, N. and Rossignol, R. (2011) Choosing between glycolysis and oxidative phosphorylation: a tumor’s dilemma? Biochim. Biophys. Acta,\nBioenerg. 1807, 552–561 doi:10.1016/j.bbabio.2010.10.012\n17",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 53
        }
    },
    "379": {
        "text": "17\nMoreno-Sánchez, R., Rodríguez-Enríquez, S., Marín-Hernández, A. and Saavedra, E. (2007) Energy metabolism in tumor cells. FEBS J. 274,\n1393–1418 doi:10.1111/j.1742-4658.2007.05686.x\n18\nMartin, M., Beauvoit, B., Voisin, P.J., Canioni, P., Guérin, B. and Rigoulet, M. (1998) Energetic and morphological plasticity of C6 glioma cells grown on\n3-D support; effect of transient glutamine deprivation. J. Bioenerg. Biomembr. 30, 565–578 doi:10.1023/A:1020584517588\n19",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 54
        }
    },
    "380": {
        "text": "19\nObre, E. and Rossignol, R. (2015) Emerging concepts in bioenergetics and cancer research: metabolic ﬂexibility, coupling, symbiosis, switch, oxidative\ntumors, metabolic remodeling, signaling and bioenergetic therapy. Int. J. Biochem. Cell Biol. 59, 167–181 doi:10.1016/j.biocel.2014.12.008\n20\nZu, X.L. and Guppy, M. (2004) Cancer metabolism: facts, fantasy, and ﬁction. Biochem. Biophys. Res. Commun. 313, 459–465 doi:10.1016/j.bbrc.\n2003.11.136\n21",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 55
        }
    },
    "381": {
        "text": "2003.11.136\n21\nAstuti, D., Latif, F., Dallol, A., Dahia, P.L.M., Douglas, F., George, E. et al. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause\nsusceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet. 69, 49–54 doi:10.1086/321282\n22\nBaysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A. et al. (2000) Mutations in SDHD, a mitochondrial complex II",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 56
        }
    },
    "382": {
        "text": "gene, in hereditary paraganglioma. Science 287, 848–851 doi:10.1126/science.287.5454.848\n23\nDang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M. et al. (2009) Cancer-associated IDH1 mutations produce\n2-hydroxyglutarate. Nature 462, 739–744 doi:10.1038/nature08617\n24\nYan, H., Bigner, D.D., Velculescu, V. and Parsons, D.W. (2009) Mutant metabolic enzymes are at the origin of gliomas. Cancer Res. 69, 9157–9159\ndoi:10.1158/0008-5472.CAN-09-2650\n25",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 57
        }
    },
    "383": {
        "text": "doi:10.1158/0008-5472.CAN-09-2650\n25\nHanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100, 57–70 doi:10.1016/S0092-8674(00)81683-9\n26\nHanahan, D. and Weinberg, R.A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646–674 doi:10.1016/j.cell.2011.02.013\n27\nGatenby, R.A. and Gillies, R.J. (2004) Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4, 891–899 doi:10.1038/nrc1478\n28",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 58
        }
    },
    "384": {
        "text": "28\nGogvadze, V., Orrenius, S. and Zhivotovsky, B. (2008) Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 18,\n165–173 doi:10.1016/j.tcb.2008.01.006\n29\nWeinhouse, S., Shatton, J.B., Criss, W.E. and Morris, H.P. (1972) Molecular forms of enzymes in cancer. Biochimie 54, 685–693 doi:10.1016/\nS0300-9084(72)80167-6\n30\nBettum, I.J., Gorad, S.S., Barkovskaya, A., Pettersen, S., Moestue, S.A., Vasiliauskaite, K. et al. (2015) Metabolic reprogramming supports the invasive",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 59
        }
    },
    "385": {
        "text": "phenotype in malignant melanoma. Cancer Lett. 366, 71–83 doi:10.1016/j.canlet.2015.06.006\n31\nIyer, N.V., Kotch, L.E., Agani, F., Leung, S.W., Laughner, E., Wenger, R.H. et al. (1998) Cellular and developmental control of O2 homeostasis by\nhypoxia-inducible factor 1α. Genes Dev. 12, 149–162 doi:10.1101/gad.12.2.149",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 60
        }
    },
    "386": {
        "text": "1504 © 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).\nBiochemical Society Transactions (2016) 44 1499–1505\nDOI: 10.1042/BST20160094\n32\nKim, J.-w., Tchernyshyov, I., Semenza, G.L. and Dang, C.V. (2006) HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 61
        }
    },
    "387": {
        "text": "required for cellular adaptation to hypoxia. Cell Metab. 3, 177–185 doi:10.1016/j.cmet.2006.02.002\n33\nPapandreou, I., Cairns, R.A., Fontana, L., Lim, A.L. and Denko, N.C. (2006) HIF-1 mediates adaptation to hypoxia by actively downregulating\nmitochondrial oxygen consumption. Cell Metab. 3, 187–197 doi:10.1016/j.cmet.2006.01.012\n34\nSeagroves, T.N., Ryan, H.E., Lu, H., Wouters, B.G., Knapp, M., Thibault, P. et al. (2001) Transcription factor HIF-1 is a necessary mediator of the",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 62
        }
    },
    "388": {
        "text": "Pasteur effect in mammalian cells. Mol. Cell. Biol. 21, 3436–3444 doi:10.1128/MCB.21.10.3436-3444.2001\n35\nQuinn, B.J., Kitagawa, H., Memmott, R.M., Gills, J.J. and Dennis, P.A. (2013) Repositioning metformin for cancer prevention and treatment. Trends\nEndocrinol. Metab. 24, 469–480 doi:10.1016/j.tem.2013.05.004\n36\nYu, H., Bian, X., Gu, D. and He, X. (2016) Metformin synergistically enhances cisplatin-induced cytotoxicity in esophageal squamous cancer cells under",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 63
        }
    },
    "389": {
        "text": "glucose-deprivation conditions. Biomed. Res. Int. 2016, 8 doi:10.1155/2016/8678634\n37\nEl-Mir, M.-Y., Nogueira, V., Fontaine, E., Averet, N., Rigoulet, M. and Leverve, X. (2000) Dimethylbiguanide inhibits cell respiration via an indirect effect\ntargeted on the respiratory chain complex I. J. Biol. Chem. 275, 223–228 doi:10.1074/jbc.275.1.223\n38\nOwen, M.R., Doran, E. and Halestrap, A.P. (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 64
        }
    },
    "390": {
        "text": "mitochondrial respiratory chain. Biochem. J. 348, 607–614 doi:10.1042/bj3480607\n39\nGohil, V.M., Sheth, S.A., Nilsson, R., Wojtovich, A.P., Lee, J.H., Perocchi, F. et al. (2010) Nutrient-sensitized screening for drugs that shift energy\nmetabolism from mitochondrial respiration to glycolysis. Nat. Biotechnol. 28, 249–255 doi:10.1038/nbt.1606\n40\nMarroquin, L.D., Hynes, J., Dykens, J.A., Jamieson, J.D. and Will, Y. (2007) Circumventing the Crabtree effect: replacing media glucose with galactose",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 65
        }
    },
    "391": {
        "text": "increases susceptibility of HepG2 cells to mitochondrial toxicants. Toxicol. Sci. 97, 539–547 doi:10.1093/toxsci/kfm052\n41\nPark, S.G., Lee, J.H., Lee, W.A. and Han, K.M. (2012) Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in\nmalignant melanoma. Nucl. Med. Biol. 39, 1167–1172 doi:10.1016/j.nucmedbio.2012.07.003\n42",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 66
        }
    },
    "392": {
        "text": "42\nRiedl, C.C., Brader, P., Zanzonico, P., Reid, V., Woo, Y., Wen, B. et al. (2008) Tumor hypoxia imaging in orthotopic liver tumors and peritoneal\nmetastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort. Eur. J. Nucl. Med. Mol. Imaging 35, 39–46\ndoi:10.1007/s00259-007-0522-2\n43\nYen, T.C., See, L.C., Lai, C.H., Yah-Huei, C.W., Ng, K.K., Ma, S.Y., et al. (2004) 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 67
        }
    },
    "393": {
        "text": "with glucose transporter 1 expression. J. Nucl. Med. 45, 22–29 PMID: 14734665\n44\nBarron, C.C., Bilan, P.J., Tsakiridis, T. and Tsiani, E. (2016) Facilitative glucose transporters: implications for cancer detection, prognosis and treatment.\nMetabolism 65, 124–139 doi:10.1016/j.metabol.2015.10.007\n45\nSotgia, F., Martinez-Outschoorn, U.E., Pavlides, S., Howell, A., Pestell, R.G. and Lisanti, M.P. (2011) Understanding the Warburg effect and the",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 68
        }
    },
    "394": {
        "text": "prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res. 13, 213 doi:10.1186/bcr2892\n46\nWeiler-Sagie, M., Bushelev, O., Epelbaum, R., Dann, E.J., Haim, N., Avivi, I. et al. (2010) 18F-FDG avidity in lymphoma readdressed: a study of 766\npatients. J. Nucl. Med. 51, 25–30 doi:10.2967/jnumed.109.067892\n47\nAldinucci, D., Gloghini, A., Pinto, A., De Filippi, R. and Carbone, A. (2010) The classical Hodgkin’s lymphoma microenvironment and its role in",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 69
        }
    },
    "395": {
        "text": "promoting tumour growth and immune escape. J. Pathol. 221, 248–263 doi:10.1002/path.2711\n48\nPavlides, S., Whitaker-Menezes, D., Castello-Cros, R., Flomenberg, N., Witkiewicz, A.K., Frank, P.G. et al. (2009) The reverse Warburg effect: aerobic\nglycolysis in cancer associated ﬁbroblasts and the tumor stroma. Cell Cycle 8, 3984–4001 doi:10.4161/cc.8.23.10238\n49\nWallace, D.C. (2012) Mitochondria and cancer. Nat. Rev. Cancer 12, 685–698 doi:10.1038/nrc3365\n50",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 70
        }
    },
    "396": {
        "text": "50\nMartinez-Outschoorn, U.E., Lin, Z., Trimmer, C., Flomenberg, N., Wang, C., Pavlides, S. et al. (2011) Cancer cells metabolically ‘fertilize’ the tumor\nmicroenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle 10, 2504–2520 doi:10.\n4161/cc.10.15.16585\n51\nWhitaker-Menezes, D., Martinez-Outschoorn, U.E., Lin, Z., Ertel, A., Flomenberg, N., Witkiewicz, A.K. et al. (2011) Evidence for a stromal-epithelial",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 71
        }
    },
    "397": {
        "text": "‘lactate shuttle’ in human tumors. Cell Cycle 10, 1772–1783 doi:10.4161/cc.10.11.15659\n52\nGladden, L.B. (2004) Lactate metabolism: a new paradigm for the third millennium. J. Physiol. 558, 5–30 doi:10.1113/jphysiol.2003.058701\n53\nGoodwin, M.L., Gladden, L.B., Nijsten, M.W.N. and Jones, K.B. (2015) Lactate and cancer: revisiting the Warburg effect in an era of lactate shuttling.\nFront. Nutr. 1, 27 doi:10.3389/fnut.2014.00027\n54",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 72
        }
    },
    "398": {
        "text": "Front. Nutr. 1, 27 doi:10.3389/fnut.2014.00027\n54\nItoh, Y., Esaki, T., Shimoji, K., Cook, M., Law, M. J., Kaufman, E. et al. (2003) Dichloroacetate effects on glucose and lactate oxidation by neurons and\nastroglia in vitro and on glucose utilization by brain in vivo. Proc. Natl Acad. Sci. USA 100, 4879–4884 doi:10.1073/pnas.0831078100\n55\nYoshida, G.J. (2015) Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J. Exp. Clin. Cancer Res. 34, 111 doi:10.",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 73
        }
    },
    "399": {
        "text": "1186/s13046-015-0221-y\n56\nLee, M. and Yoon, J.-H. (2015) Metabolic interplay between glycolysis and mitochondrial oxidation: the reverse Warburg effect and its therapeutic\nimplication. World J. Biol. Chem. 6, 148–161 doi:10.4331/wjbc.v6.i3.148\n57\nSonveaux, P., Végran, F., Schroeder, T., Wergin, M.C., Verrax, J., Rabbani, Z.N. et al. (2008) Targeting lactate-fueled respiration selectively kills hypoxic\ntumor cells in mice. J. Clin. Invest. 118, 3930–3942 doi:10.1172/JCI36843",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 74
        }
    },
    "400": {
        "text": "© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND).1505\nBiochemical Society Transactions (2016) 44 1499–1505\nDOI: 10.1042/BST20160094",
        "metadata": {
            "source": "BST-2016-0094.pdf",
            "chunk_id": 75
        }
    },
    "401": {
        "text": "441\n© 2017 Indian Journal of Cancer | Pulished by Wolters Kluwer - Medknow\nCancer and cure: A critical analysis\nRoy PS, Saikia BJ\nDepartment of Medical Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India\nCorrespondence to: Dr. Roy PS, E‑mail: drpsr.roy@rediffmail.com\nAbstract\nCancer is one of the most dreaded diseases of the 20th century and spreading further with continuance and increasing incidence in the 21st century.",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 0
        }
    },
    "402": {
        "text": "The situation is so alarming that every fourth person is having a lifetime risk of cancer. India registers more than 11 lakh new cases of cancer \nevery year, whereas, this figure is above 14 million worldwide. Is cancer curable? The short answer to this question is “Yes.” In fact, all cancers \nare curable if they are caught early enough. Cancer cells continue to grow unless one of four things occur: (1) The cancerous mass is removed",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 1
        }
    },
    "403": {
        "text": "surgically; (2) using chemotherapy or another type of cancer‑specific medication, such as hormonal therapy; (3) using radiation therapy; or (4) the \ncancer cells shrink and disappear on their own.\nKey Words: Cancer, carcinogenesis, targeted therapy\nIntroduction\nA hundred years ago, cancer was not so common; however, \nsince the last couple of decades, its incidence has been rising \nalarmingly, probably due to our changing lifestyle, habits,",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 2
        }
    },
    "404": {
        "text": "and increased life expectancy. Cancer is one of the most \ndreaded diseases of the 20th  century and spreading further \nwith continuance and increasing incidence in the 21st century. \nThe situation is so alarming that every fourth person is \nhaving a lifetime risk of cancer.[1] India registers more than \n11 lakh new cases of cancer every year, whereas, this figure \nis above 14 million worldwide. We are constantly exposed \nto a variety of cancer causing agents, known as carcinogens.",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 3
        }
    },
    "405": {
        "text": "What is cancer? Put simply; cancer is the abnormal growth \nof cells. Cancers arise from any organ or body structure and \nare composed of tiny cells that have lost the ability to stop \ngrowing. Occasionally, cancer may be detected “incidentally” by \na laboratory test or radiological routine test or for an entirely \ndifferent reason. In general, cancer must reach a size of 1 \ncm, or be comprised of 1 million cells, before it is detected.",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 4
        }
    },
    "406": {
        "text": "At this point, it may be referred to as a “‘mass,” a “growth,” \na “tumor,” a “nodule,” a “lump,” or a “lesion.” Exceptions \nto this general rule include cancers of the blood and bone \nmarrow (leukemia’s and lymphomas) – which frequently do \nnot produce a “mass,” but will be evident on laboratory tests.\nTransformation of a normal cell into a cancerous cell is \nprobably not such a critical event in the genesis of cancer; \nrather it is the inability of immune cells of the body to",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 5
        }
    },
    "407": {
        "text": "identify and destroy the newly formed cancer cells when \nthey are a few in numbers.[2] The risk of cancer is multiplied \nin those persons, whose immune system is suppressed due \nto any factor including chronic stress, old age, chronic \ndebilitating disease, previous use of chemotherapy, and abuse \nof drugs such as analgesics, antibiotics, and corticosteroids.\nMultidisciplinary Aspects\nCancer cells continue to grow unless one of four things \noccur:  (1) The cancerous mass is removed surgically;",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 6
        }
    },
    "408": {
        "text": "(2) using chemotherapy or another type of cancer‑specific \nmedication, such as hormonal therapy; (3) using radiation \ntherapy; or (4) the cancer cells shrink and disappear on their \nown. This last event, while extremely rare, can occur with \nsome melanomas or some kidney cancers.\nSurgery, radiotherapy, and chemotherapy from the \nconventional approaches are used to treat cancer. Surgery \nwas the first modality used successfully in the treatment of",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 7
        }
    },
    "409": {
        "text": "cancer. It is the only curative therapy for many common \nsolid tumors. The most important determinant of a successful \nsurgical therapy is the absence of distant metastases and \nno local infiltration. Chemotherapy is the administration \nof cytotoxic agents  (orally or intravenously, usually in \ncombinations) resulting in cytotoxicity to both resting and \ndividing cells. The objective of cancer chemotherapy is to \nprevent cancer cells from multiplying, invading, metastasizing,",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 8
        }
    },
    "410": {
        "text": "and killing the patient. Systemic chemotherapy is the main \ntreatment available for disseminated malignant diseases. \nRadiation therapy is a local modality used in the treatment of \ncancer. Other conventional techniques used in the treatment \nof cancer including bone marrow transplantation, peripheral \nstem cell transplantation, hormone therapy, photodynamic \ntherapy, cryosurgery, immunotherapy, and gene therapy.\nIs cancer curable? The short answer to this question is “Yes.” In",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 9
        }
    },
    "411": {
        "text": "fact, all cancers are curable if they are caught early enough. That \nis the justification for screening tests (such as mammograms, \ncolonoscopies, and Pap smear examination). When cancers are \ncaught early, they tend to be smaller; they are thus either easier \nto remove surgically or more likely to shrink in response to \nchemotherapy or radiation therapy. When cancer is localized, it \ncan be totally removed by surgery but in most of the cases, it",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 10
        }
    },
    "412": {
        "text": "is practically impossible to detect cancer at such an early stage. \nEarly detection is often the key to surviving any form of cancer.\nThe diagnosis and treatment of cancer have come a long way \nin the last 50 years. In the past, cancer, the “C‑word,” was a \ndeath sentence. Today, we can treat and cure several types of \ncancer; however, it is evident that these cancers need to be \nfound at an early stage. More than 7 out of 10 children are",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 11
        }
    },
    "413": {
        "text": "cured of cancer. Testicular cancer, Hodgkin’s lymphoma and \nHow to cite this article: Roy P, Saikia B. Cancer and cure: A \ncritical analysis. Indian J Cancer 2016;53:441-2.\nThis is an open access article distributed under the terms of the Creative Commons \nAttribution‑NonCommercial‑ShareAlike 3.0 License, which allows others to remix, \ntweak, and build upon the work non‑commercially, as long as the author is credited \nand the new creations are licensed under the identical terms.",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 12
        }
    },
    "414": {
        "text": "For reprints contact: reprints@medknow.com\nReview \nArticle\nAccess this article online\nQuick Response Code:\nWebsite: \nwww.indianjcancer.com\nDOI: \n10.4103/0019-509X.200658 \nPMID: \n***\nRoy and Saikia: Cancer and cure\nIndian Journal of Cancer | July-September 2016 | Volume 53 | Issue 3\n442\nmany cases of leukemia can all be cured in adults with current \ntreatments. Most skin cancers are cured with surgery. Moreover, \nmany cases of thyroid cancer and cancer of the larynx are cured",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 13
        }
    },
    "415": {
        "text": "with radiotherapy. Many other types of cancer are also cured \nif they are found early enough – for example, 75% of breast \ncancers found at an early stage. Of course, there is still a long \nway to go before we can cure most cancers. The difficulty is \nthat different cancers are caused by different things, so there \nis not one strategy that can prevent them. They also respond \nto different treatments, so not one kind of treatment can cure",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 14
        }
    },
    "416": {
        "text": "them all. Even though we can cure several types of cancers, it \nis important to maintain vigilance about screening for cancer.\nSome forms of cancer are curable no matter when they \nare detected, and some are only curable if they are caught \nat any early stage. For example, acute leukemia and some \ntypes of lymphoma can be curable with chemotherapy. \nCertain lymphomas such as Hodgkin’s disease require \nradiation therapy for a cure. Other common cancers such",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 15
        }
    },
    "417": {
        "text": "as colon cancer, breast cancer, prostate cancer, lung cancer, \nand pancreatic cancer are all curable, but only if they are \ndetected in early stages (Stage I or II).\nSome cancers have high survival rates with early detection. \nSix highly treatable cancers among others are – cancers of \nbreast, skin  (nonmelanomas), colon, prostate, testes, and \ncervix. Most of the childhood malignancies (both solid and \nhematolymphoid) are curable.\nBreast cancer is the most common nonskin cancer among",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 16
        }
    },
    "418": {
        "text": "women, as one out of every eight women will be diagnosed \nin her lifetime. In patients whose breast cancer is detected \nwhile still in localized form have a 5‑year survival rate of \n98%, compared with a survival rate of 72% by Stage III \nand just 22% by Stage IV.[3,4]\nSkin cancers  (basal cell carcinoma and squamous cell \ncarcinoma) are the most common form of all human cancers, \nand if found early, skin cancer is nearly 100% treatable.",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 17
        }
    },
    "419": {
        "text": "Likewise, diagnosing cervical cancer while the lesions are \nprecancerous leads to a near 100% survival rate, but the \nrate drops to just 32% if diagnosed in Stage III and 16% if \ndiagnosed at Stage IV. Testicular cancer is treatable in 99% \nof the time when detected early, but only 73% are cancer‑free \nafter 5 years if diagnosed in advanced stages. Similarly, 5‑year \nsurvival rate when colon cancer is detected early is 90%, yet \nonly 39% of cases are diagnosed before cancer has begun to",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 18
        }
    },
    "420": {
        "text": "spread. According to the Surveillance, Epidemiology, and End \nResults Program, it is 98% survivable for 5 or more years \nif prostate cancer diagnosed at stages when the disease is \nconfined to the prostate gland (Stage I and II).[1] The survival \nrate drops to about 28% if diagnosed at Stage IV.\nCancers cells not only have mutations that result in \ndysregulated expression of oncogenes and tumor suppressor \ngenes, but these changes result in the alteration of expression",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 19
        }
    },
    "421": {
        "text": "of hundreds of genes. Looking at this, we have various forms \nof “targeted” therapy directed at specific single molecular \ntargets or a class of molecular targets in cancer cells. With \ntargeted therapy, the specific mechanism of action of the drug \nresults in an increase in its therapeutic index. Currently, the \ntwo major classes of targeted therapy are the small molecule \ntyrosine kinase inhibitors and monoclonal antibodies (MABs). \nImatinib, for instance, has been amazingly successful as a",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 20
        }
    },
    "422": {
        "text": "targeted agent directed against several members of a class of \nenzyme known as tyrosine kinases, and by that mechanism, \nit has been phenomenally successful as a treatment of chronic \nmyeloid leukemia and gastrointestinal stromal tumors. \nTamoxifen is a targeted therapy directed at the estrogen \nreceptor (ER), and it still remains a mainstay of treatment for \nER‑positive breast cancers, along with a newer class of drugs \nknown as aromatase inhibitors.",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 21
        }
    },
    "423": {
        "text": "known as aromatase inhibitors.\nCancer researchers work on developing new and more \neffective surgery techniques, radiotherapy and chemotherapy \ndrugs all the time. Biological therapies such as MABs, \ncancer vaccines, and gene therapies are all active areas of \nresearch. There are various anti‑angiogenic drugs that can \nstop cancers from growing the blood vessels that they need. \nResearch is also looking into developing cost‑effective ways",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 22
        }
    },
    "424": {
        "text": "of screening for the different common cancers so they can \nbe diagnosed early enough to be cured.\nAvoiding immune destruction is now considered a hallmark \nof cancer, and the immunotherapy arena has exploded \nwith the recent advances demonstrating an improvement \nin survival and a durability of response in patients with \ndifferent cancer types, like in melanoma, which translates \ninto an improved overall survival benefit.[5] To name those \nimmunotherapeutic strategies that include the adoptive",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 23
        }
    },
    "425": {
        "text": "transfer of ex vivo activated T cells, immunomodulatory \nMABs, and cancer vaccines. Advances in molecular \npathology will provide the means to identify the targets \nand will be used to subtype tumors and will provide predict \nresponse to therapy and provide prognostic information.[6]\nConclusion\nUnfortunately, although we do fairly well (and in some cases \nvery well) against early stage cancer, we do not do so well \nagainst Stage IV metastatic disease, particularly solid tumors.",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 24
        }
    },
    "426": {
        "text": "There is still a long way to go before we can cure most cancers.\nFinancial support and sponsorship\nNil.\nConflicts of interest\nThere are no conflicts of interest.\nReferences\n1.\t\nMackay J, Jemal A, Lee NC, Parkin DM. The Cancer Atlas. Atlanta: \nAmerican Cancer Society; 2006.\n2.\t\nHanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell \n2011;144:646‑74.\n3.\t\nReeves GK, Beral V, Green J, Gathani T, Bull D; Million Women Study",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 25
        }
    },
    "427": {
        "text": "Collaborators. Hormonal therapy for menopause and breast‑cancer risk \nby histological type: A cohort study and meta‑analysis. Lancet Oncol \n2006;7:910‑8.\n4.\t\nCuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. \nPreventive therapy for breast cancer: A consensus statement. Lancet \nOncol 2011;12:496‑503.\n5.\t\nCouzin‑Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. \nScience 2013;342:1432‑3.\n6.\t\nBennett WP, Hussain SP, Vahakangas KH, Khan MA, Shields PG,",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 26
        }
    },
    "428": {
        "text": "Harris CC. Molecular epidemiology of human cancer risk: Gene‑environment \ninteractions and p53 mutation spectrum in human lung cancer. J Pathol \n1999;187:8‑18.",
        "metadata": {
            "source": "cancer_and_cure__a_critical_analysis.27.pdf",
            "chunk_id": 27
        }
    },
    "429": {
        "text": "The Warburg Effect: How Does it Benefit Cancer Cells?\nMaria V. Liberti1,2 and Jason W. Locasale2\n1 Department of Molecular Biology and Genetics, Graduate Field of Biochemistry, Molecular and \nCell Biology, Cornell University, Ithaca, NY, USA\n2 Department of Pharmacology and Cancer Biology, Duke University Medical Center, Duke \nMolecular Physiology Institute, Duke Cancer Institute, Durham, NC, USA\nAbstract",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 0
        }
    },
    "430": {
        "text": "Abstract\nCancer cells rewire their metabolism to promote growth, survival, proliferation, and long-term \nmaintenance. The common feature of this altered metabolism is increased glucose uptake and \nfermentation of glucose to lactate. This phenomenon is observed even in the presence of \ncompletely functioning mitochondria and together is known as the Warburg Effect. The Warburg \nEffect has been documented for over 90 years and extensively studied over the past 10 years with",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 1
        }
    },
    "431": {
        "text": "thousands of papers reporting to have established either its causes or its functions. Despite this \nintense interest, the function of the Warburg Effect remains unclear. Here, we analyze several \nproposed biological explanations for the Warburg Effect, emphasize their rationale, and discuss \ntheir controversies.\nKeywords\nWarburg Effect; ATP synthesis; microenvironment acidification; ROS; chromatin remodeling\nGlucose Metabolism and the Warburg Effect",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 2
        }
    },
    "432": {
        "text": "Glucose Metabolism and the Warburg Effect\nThe metabolism of glucose, the central macronutrient, allows for energy to be harnessed in \nthe form of ATP through the oxidation of its carbon bonds. This process is essential for \nsustaining all mammalian life. In mammals, the end product can be lactate or, upon full \noxidation of glucose via respiration in the mitochondria, CO2. In tumors and other \nproliferating or developing cells, the rate of glucose uptake dramatically increases and",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 3
        }
    },
    "433": {
        "text": "lactate is produced, even in the presence of oxygen and fully functioning mitochondria. This \nprocess, known as the Warburg Effect, has been studied extensively (Figure 1). However, \nafter careful inspection, it becomes apparent that its benefits for cell growth and survival are \nnot yet resolved. This analysis will focus on several proposals for its function, and in each \ncase we discuss their appeal as well as their drawbacks. Before our discussion of each",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 4
        }
    },
    "434": {
        "text": "proposal, we first introduce the Warburg Effect in a historical context with an emphasis on \nCorrespondence: jason.locasale@duke.edu. \nPublisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our \ncustomers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 5
        }
    },
    "435": {
        "text": "the resulting proof before it is published in its final citable form. Please note that during the production process errors may be \ndiscovered which could affect the content, and all legal disclaimers that apply to the journal pertain.\nHHS Public Access\nAuthor manuscript\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nPublished in final edited form as:\nTrends Biochem Sci. 2016 March ; 41(3): 211–218. doi:10.1016/j.tibs.2015.12.001.\nAuthor Manuscript\nAuthor Manuscript",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 6
        }
    },
    "436": {
        "text": "Author Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nlesser-appreciated aspects of its conceptual development. It is our hope that this \nretrospective brings additional context to current ideas in cancer metabolism.\nHistorical perspectives of the Warburg Effect\nIn the 1920s, Otto Warburg and colleagues made the observation that tumors were taking up \nenormous amounts of glucose compared to what was seen in the surrounding tissue.",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 7
        }
    },
    "437": {
        "text": "Additionally, glucose was fermented to produce lactate even in the presence of oxygen, thus \nthe term aerobic glycolysis [1, 2]. However, it was also noted that respiration alone could \nmaintain tumor viability. Therefore, it was concluded that in order to kill tumor cells by \ndepriving them of energy, both glucose and oxygen had to be eliminated [3]. Subsequently, \nin 1929, an English biochemist, Herbert Crabtree, extended Warburg’s work and studied the",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 8
        }
    },
    "438": {
        "text": "heterogeneity of glycolysis in tumor types. He confirmed Warburg’s findings, but further \ndiscovered that the magnitude of respiration in tumors was variable with many tumors \nexhibiting a substantial amount of respiration [4]. Therefore, Crabtree concluded that not \nonly do tumor cells exhibit aerobic glycolysis, but that there is also variability in \nfermentation presumably due to environmental or genetic influences.",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 9
        }
    },
    "439": {
        "text": "Contrary to the findings of these previous works and for reasons unclear to these authors, \nWarburg later proposed that dysfunctional mitochondria is the root of aerobic glycolysis [5]. \nWarburg further hypothesized that this event is the primary cause of cancer. This \nphenomenon was then termed the Warburg Effect in the early 1970s by Efraim Racker, who \nalso pointed out that previous data show respiratory capability of tumors. Racker developed",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 10
        }
    },
    "440": {
        "text": "his own theories about the origins of the Warburg Effect ranging from imbalances in \nintracellular pH to defects in ATPase activity [6]. It was later observed by Racker, Jeffrey \nFlier and Morris Birnbaum that aerobic glycolysis was a controllable process that can be \ndirectly regulated by growth factor signaling. By that time, the discovery of oncogenes led \nto the conclusion that aberrant regulation of growth factor signaling is an initiating event in",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 11
        }
    },
    "441": {
        "text": "oncogenesis. Thus, their observations brought newfound significance to Warburg’s \nhypothesis in cancer biology [7-10]. Nevertheless, it remained unclear whether the Warburg \nEffect was a bystander in cancer pathogenesis until more recently, when genetic and \npharmacological studies conclusively showed that the Warburg Effect was required for \ntumor growth [11, 12]. Coming back to the original findings on tumor metabolism, it is now",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 12
        }
    },
    "442": {
        "text": "apparent that targeting both aerobic glycolysis and mitochondrial metabolism may be \nrequired [13-16]. Throughout this history, its functions have remained controversial. Here, \nwe discuss several of the major proposals and argue that the functions of the Warburg Effect \nfor tumor growth even today remain unknown.\nWarburg Effect and rapid ATP synthesis\nPer unit of glucose, aerobic glycolysis is an inefficient means of generating ATP compared",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 13
        }
    },
    "443": {
        "text": "to the amount obtained by mitochondrial respiration [17, 18]. However, the rate of glucose \nmetabolism through aerobic glycolysis is higher such that the production of lactate from \nglucose occurs 10-100 times faster than the complete oxidation of glucose in the \nmitochondria. In fact, the amount of ATP synthesized over any given period of time is \ncomparable when either form of glucose metabolism is utilized [19]. Thus, a reasonable \nLiberti and Locasale\nPage 2",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 14
        }
    },
    "444": {
        "text": "Liberti and Locasale\nPage 2\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nhypothesis on the reason that cancer employs aerobic glycolysis should account for this \ninherent difference in kinetics.\nTheoretical calculations using evolutionary game theory support that cells with a higher rate, \nbut lower yield, of ATP production may gain a selective advantage when competing for",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 15
        }
    },
    "445": {
        "text": "shared and limited energy resources (Figure 2, Key Figure) [20, 21]. In fact, tumor \nmicroenvironments have limited availability of glucose and undergo competition for \nnutrients with stromal cells and the immune compartment [22, 23]. Additional support is \nfound in a recent study that showed when changes to the cellular environment were induced \nto greatly increase ATP demand by altering the demand of ATP-dependent membrane",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 16
        }
    },
    "446": {
        "text": "pumps, aerobic glycolysis increased rapidly and oxidative phosphorylation remained \nconstant [24]. This finding provides additional rationale for the function of the Warburg \nEffect to be supporting the rapid production of ATP that can be rapidly tuned to support the \ndemand for ATP synthesis.\nDespite this attractive proposal, there are difficulties. Simple empirical calculations indicate \nthat the amount of ATP required for cell growth and division may be much less than that",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 17
        }
    },
    "447": {
        "text": "required for normal cellular maintenance [18, 25]. Thus, ATP demand may never reach \nlimiting values during tumor cell growth. Furthermore, the mechanisms that are available to \nother cell types in cases of rapid ATP demand are present in tumor cells as well. For \nexample, rapid ATP synthesis from creatine kinases in exercised muscle or adenylate kinase \nunder hormonal changes are present in most tumor cells and should be able to meet ATP",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 18
        }
    },
    "448": {
        "text": "demand. Thus further studies are needed to show whether this mechanism can account for \nthe role of aerobic glycolysis.\nWarburg Effect and biosynthesis\nThe Warburg Effect has been proposed to be an adaptation mechanism to support the \nbiosynthetic requirements of uncontrolled proliferation (Figure 2, Key Figure). In this \nscenario, the increased glucose consumption is used as a carbon source for anabolic",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 19
        }
    },
    "449": {
        "text": "processes needed to support cell proliferation [17, 26-32]. This excess carbon is used for the \nde novo generation of nucleotides, lipids, and proteins and can be diverted into multiple \nbranching pathways that emanate from glycolysis. One example is the diversion of \nglycolytic flux into de novo serine biosynthesis through the enzyme phosphoglycerate \ndehydrogenase (PHGDH) [18]. In addition to the usage of additional carbon from enhanced",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 20
        }
    },
    "450": {
        "text": "glucose metabolism for cellular building blocks, a now famous argument is that rather than \nhaving a rate-limiting demand for ATP, proliferating cells are in greater need of reducing \nequivalents in the form of NADPH. Increased glucose uptake allows for greater synthesis of \nthese reducing equivalents in the oxidative branch of the pentose phosphate pathway, which \nare then used in reductive biosynthesis, most notably in de novo lipid synthesis [17, 33].",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 21
        }
    },
    "451": {
        "text": "Another proposed mechanism to account for the biosynthetic function of the Warburg Effect \nis the regeneration of NAD+ from NADH in the pyruvate to lactate step that completes \naerobic glycolysis. In this scenario, NADH that is produced by glyceraldehyde phosphate \ndehydrogenase (GAPDH) must be consumed to regenerate NAD+ to keep glycolysis active. \nThis high rate of glycolysis allows for supply lines to remain open that can, for example, \nLiberti and Locasale\nPage 3",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 22
        }
    },
    "452": {
        "text": "Liberti and Locasale\nPage 3\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nsiphon 3-phosphoglycerate (3PG) to serine for one-carbon metabolism-mediated production \nof NADPH and nucleotides [17, 25]. These proposals together conclude that the Warburg \nEffect supports a metabolic environment that allows for the rapid biosynthesis to support \ngrowth and proliferation.",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 23
        }
    },
    "453": {
        "text": "growth and proliferation.\nFurthermore, others have proposed that aerobic glycolysis is a tradeoff to support \nbiosynthesis [34, 35]. In these scenarios, the inefficient way of making ATP occurs as a cost \nof maintaining high fluxes through anabolic pathways. These pathways require increased \nexpression of biosynthesis genes such as those involved in nucleotide and lipid metabolism \nand the tradeoff occurs by limiting the use of mitochondria in order to preserve high",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 24
        }
    },
    "454": {
        "text": "expression of biosynthetic enzymes in the face of limited protein number that can be made. \nAnother scenario of such a tradeoff comes from the idea that the physical volume available \nper cell may limit mitochondria number and thus any energy and biomass that exceed the \nlimited mitochondrial capacity needs to be produced from aerobic glycolysis [36-38]. This \nconcept has been termed the solvent capacity constraint. In both of these cases, the Warburg",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 25
        }
    },
    "455": {
        "text": "Effect is an adaptation to support biomass production in the face of limited options for ATP \ngeneration.\nThe attractiveness of this proposal in part comes from its ability to provide a simple \nexplanation for the apparent correlation between aerobic glycolysis and cell growth and \nproliferation. Furthermore, it appears intuitive to some that the branching pathways from \nglycolysis would be used to a greater extent during the Warburg Effect since rate of",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 26
        }
    },
    "456": {
        "text": "glycolysis is larger and lactate production in this case would serve to regenerate NAD+ to \nallow for glycolysis to continue. Also, the requirements of NADPH for lipid generation can \nbe summarized in a very simple chemical equation showing that the demand for NADPH is \nhigher than that of ATP for biosynthesis [17].\nHowever, there are major limitations for this proposed function of the Warburg Effect. First,",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 27
        }
    },
    "457": {
        "text": "during aerobic glycolysis, most of the carbon is not retained and is instead excreted as \nlactate [25]. In fact, the overall equation of 1 glucose molecule being converted into 2 lactate \nmolecules with no overall gain or loss of NAD+ and NADH leaves no room for biomass. \nThat is, due to the stoichiometry of glycolysis, biomass production is mutually exclusive \nwith lactate generation and it is not possible for the regeneration of NAD+ by lactate alone",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 28
        }
    },
    "458": {
        "text": "to account for biosynthesis. Thus, the avenues that lead to the biosynthesis from glucose \noccur in the complete absence of making lactate which is the hallmark of the Warburg \nEffect. Also, it is now widely accepted that mitochondria are key components of the \nbiosynthetic program whose substrates in the TCA cycle are used for nucleotide, amino acid, \nand lipid biosynthesis [39, 40]. In light of this evidence, it remains difficult to fathom how",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 29
        }
    },
    "459": {
        "text": "the Warburg Effect can directly promote biosynthesis.\nRegarding proposals that define the Warburg Effect as a tradeoff to promote biosynthesis, \nrecent estimates from quantitative proteomics show that the cost of protein production for \nconducting aerobic glycolysis is enormous. In fact, cells devote as much as 10% of their \nentire proteome and half of all of their metabolic genes to produce proteins involved in",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 30
        }
    },
    "460": {
        "text": "glycolysis [41]. In contrast, biosynthetic programs in cells require much lower amounts of \nprotein. Thus, the cost of producing proteins for aerobic glycolysis is as large, if not larger, \nLiberti and Locasale\nPage 4\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nthan the cost of producing proteins for biosynthesis. These proposals are further challenged",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 31
        }
    },
    "461": {
        "text": "by the evidence showing that mitochondrial functions occur concomitantly with the \nWarburg Effect and thus limiting mitochondrial activity appears not to occur during the \nWarburg Effect. Ultimately, further research is needed to elucidate whether the Warburg \nEffect functions to support biosynthetic programs.\nWarburg Effect and the tumor microenvironment\nIn contrast to the cell-intrinsic functions described in the previous sections, the Warburg",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 32
        }
    },
    "462": {
        "text": "Effect may present an advantage for cell growth in a multicellular environment. \nAcidification of the microenvironment and other metabolic crosstalk are intriguing \npossibilities. Elevated glucose metabolism decreases the pH in the microenvironment due to \nlactate secretion (Figure 2, Key Figure) [42]. The potential benefits of acidosis to cancer \ncells are multifold. An acid-mediated invasion hypothesis suggests that H+ ions secreted",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 33
        }
    },
    "463": {
        "text": "from cancer cells diffuse into the surrounding environment and alter the tumorstroma \ninterface allowing for enhanced invasiveness [42, 43]. A recent study showed that tumor-\nderived lactate is a contributor to M2 tissue-associated macrophage (TAM) polarization \n[44]. Also as briefly mentioned previously, the availability of glucose appears to be a result \nof direct competition between tumor and tumor infiltrating lymphocytes (TIL) [22, 23]. The",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 34
        }
    },
    "464": {
        "text": "high rates of glycolysis limit the availability of glucose for TILs that require sufficient \nglucose for their effector functions. Supporting this proposal is direct evidence indicating \nthat targeting aerobic glycolysis in the tumor has the added benefit of increasing the supply \nof glucose to TILs and thus boosting their main function, which is to eradicate the tumor \ncells. Together, this body of evidence indicates that tumor cells can communicate with cells",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 35
        }
    },
    "465": {
        "text": "in the immune system to support pro-tumor immunity.\nIt is likely that the Warburg Effect provides an overall benefit that supports a tumor \nmicroenvironment conducive to cancer cell proliferation. However, the Warburg Effect is \nthought to be an early event in oncogenesis that is an immediate consequence of an initial \noncogenic mutation, such as that of KRAS in pancreatic cancer or BRAF in melanoma thus",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 36
        }
    },
    "466": {
        "text": "occurring before cell invasion and in benign and early stage lesions as well [45, 46]. Another \nissue is that in conditions completely isolated from the environment such as in the growth \nphase of unicellular yeast, the Warburg Effect remains the choice of energy metabolism \nfrom glucose [38]. Altogether, these data suggest that non cell-intrinsic functions of the \nWarburg Effect are insufficient to entirely explain its functions.\nThe Warburg Effect and cell signaling",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 37
        }
    },
    "467": {
        "text": "The Warburg Effect and cell signaling\nWe and others have proposed that the Warburg Effect confers direct signaling functions to \ntumor cells [18, 39, 47-49]. This proposal is particularly attractive since it identifies a direct \ncausal role of altered glucose metabolism in promoting tumorigenesis through this signal \ntransduction affecting other cellular processes. Two areas of signaling function are the \ngeneration and modulation of reactive oxygen species (ROS) and the modulation of",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 38
        }
    },
    "468": {
        "text": "chromatin state. Other studies have identified additional possible signaling mechanisms [23, \n50].\nLiberti and Locasale\nPage 5\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nMaintaining the appropriate balance of ROS is essential [51]. Excessive ROS damages cell \nmembranes, nucleic acids, and has other deleterious effects. Insufficient ROS disturbs",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 39
        }
    },
    "469": {
        "text": "signaling processes that are beneficial for cell proliferation, such as by inactivating \nphosphatase and tensin homolog (PTEN) and tyrosine phosphatases. The Warburg Effect \ncauses alterations in mitochondrial redox potential, ultimately changing ROS generation \n[18].\nAn important determinant of redox potential in cells is the NADH that is available in the \nmitochondria for electron transport. Cellular mechanisms to maintain redox homeostasis are",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 40
        }
    },
    "470": {
        "text": "in place when glycolysis rates fluctuate. Up to a certain extent of glycolysis, the malate-\naspartate shuttle through the mitochondria is able to restore the NADH imbalance [18]. \nHowever, when glycolysis rates are faster than what can be accommodated by the malate-\naspartate shuttle, the conversion of pyruvate into lactate via lactate dehydrogenase (LDH) is \nable to regenerate NAD+. This process may also affect the homeostasis of ROS generation",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 41
        }
    },
    "471": {
        "text": "by affecting the concentration of reducing equivalents in the mitochondria (Figure 2, Key \nFigure) [18, 52]. This consequence of the Warburg Effect may be directly involved in \noncogene-induced senescence (OIS) [53]. OIS has a tumor-suppressive cellular function and \na recent study has reported that increased glucose oxidation through pyruvate dehydrogenase \n(PDH) can regulate OIS. This finding shows that the redox balance of NADH may",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 42
        }
    },
    "472": {
        "text": "contribute to direct signaling roles for the Warburg Effect.\nIn addition, metabolic pathways that stimulate redox homeostasis are upregulated alongside \nthe Warburg Effect. For example, the pentose phosphate pathway coming from glycolysis \ngenerates NADPH. De novo serine metabolism, which feeds into the one-carbon \nmetabolism, produces NADPH and glutathione, which modulate ROS levels [54, 55]. \nTogether these findings provide direct biochemical links between aerobic glycolysis and",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 43
        }
    },
    "473": {
        "text": "ROS availability that could in turn affect myriad signaling processes.\nIn addition to cell signaling through ROS, a signaling link between glucose metabolism and \nhistone acetylation has been well documented [56-59]. The status of chromatin structure is \nresponsible for regulating different cellular functions including DNA repair and gene \ntranscription. It has been established that acetyl-CoA, the substrate for histone acetylation",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 44
        }
    },
    "474": {
        "text": "can be regulated by glucose flux [59]. Studies have shown that there is a direct link between \ncellular metabolism and regulation of growth genes and that intracellular acetyl-CoA levels \nmay represent a widely conserved mechanism that promotes this important link [60]. The \nactivity of ATP-citrate lyase, the enzyme responsible for converting citrate into acetyl-coA \ncan influence histone acetylation levels [47]. Elevated levels of acetyl-CoA may be enough",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 45
        }
    },
    "475": {
        "text": "to drive cells into growth phase via histone acetylation [56]. Removal of glucose or \nreduction of ATP-citrate lyase results in loss of acetylation on several histones and causes \ndecreased transcription of genes involved in glucose metabolism. This indicates that there is \nsome interplay between glucose metabolism and histone acetylation. Supporting this idea, \nglycolytic metabolism has been found to impact chromatin structure [58].",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 46
        }
    },
    "476": {
        "text": "In addition to histone acetylation responding to glucose availability in cells, deacetylation \ncan be influenced by nutrient availability as well [39]. Deacetylation plays an important role \nin nutrient sensing and signaling since the activity of multiple deacetylases are modulated by \nLiberti and Locasale\nPage 6\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 47
        }
    },
    "477": {
        "text": "Author Manuscript\nAuthor Manuscript\nNAD+ levels. More specifically, the ratio of NAD+/NADH increases in nutrient deprived \nconditions [39, 56, 57]. Therefore, both acetylation and deacetylation can be influenced by \nnutrient availability, indicating that their statuses may be consequences of the Warburg \nEffect. These multiple lines of evidence point to glycolysis having cell signaling functions.\nHowever, difficulties also limit this proposal from being the general mechanism that benefits",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 48
        }
    },
    "478": {
        "text": "cancer cells by undergoing aerobic glycolysis. One such limitation is that it is hard to \nimagine how molecular specificity arises through such a gross global signaling mechanism. \nIn contrast to, for example, growth factor signaling in which ligand-binding to a substrate \ninduces conformational and enzymatic activity changes that affect specific cellular \nprocesses, a mechanism whereby the state of glycolysis signals to other cellular processes",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 49
        }
    },
    "479": {
        "text": "lacks obvious sources of specificity. Another limitation is that such proposals typically lack \nfalsifiability. This means it is extremely difficult to design experiments to conclusively show \nthat a specific signaling mechanism, such as chromatin structure modulation, directly comes \nfrom the status of glucose metabolism as the key benefit for aerobic glycolysis. One reason \nfor this is that the biochemical interaction occurs rapidly but the cellular phenotypic",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 50
        }
    },
    "480": {
        "text": "alterations evolve over much longer times resulting in many confounding factors that occur \nalong the way. Genetic models that could test these hypotheses are difficult to conceive, and \nother experiments lack the ability to test whether specific cellular outcomes occur through \nsuch signaling mechanisms and not through indirect means. The extent to which these \ngeneral features, such as ROS signaling homeostasis and chromatin structure organization,",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 51
        }
    },
    "481": {
        "text": "are key events in tumorigenesis also remains unclear [61]. In the future, such specificity and \nability to experimentally test these hypotheses may come from observing quantitative \naspects of the mechanism as has been shown in other studies of signal transduction. \nExperiments that can precisely control the levels of acetyl-CoA and ROS could allow for \none to decouple many of the downstream effects of the Warburg Effect.\nConcluding remarks",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 52
        }
    },
    "482": {
        "text": "Concluding remarks\nExtensive research on the Warburg Effect and its functions in cancer cells have advanced \nour understanding of its causes and requirements for tumor cell proliferation [29, 52]. \nHowever, we argue that it has left us with a surprising lack of clarity regarding its ontology. \nThese uncertainties should challenge us to better understand its function in promoting tumor \ngrowth. It is likely we will require a better understanding of the biology of Warburg Effect if",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 53
        }
    },
    "483": {
        "text": "therapeutic advances are to be made in treating and preventing cancer using dietary and \npharmacological intervention in metabolism, and in using glucose metabolism to manipulate \nthe immune system, which are currently subjects of intense interest.\nAcknowledgements\nThis work was supported by awards from the National Institute of Health (R00CA168997, R01CA193256 and \nT32GM007273), the National Science Foundation, and the Sloan Foundation. JWL acknowledges Donald",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 54
        }
    },
    "484": {
        "text": "McDonnell and numerous other colleagues, notably Lew Cantley, for helpful discussions on the history of the \nWarburg Effect.\nLiberti and Locasale\nPage 7\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nGlossary\nAerobic \nglycolysis\nenhanced rate of glycolysis and fermentation to lactate that occurs in the \npresence of functioning mitochondria.\nATP\nadenosine triphosphate. The source of energy in cells.",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 55
        }
    },
    "485": {
        "text": "Flux\nthe rate of flow in a metabolic pathway from one metabolite to another.\nNADH\nreduced nicotinamide adenine dinucleotide. A reducing agent involved in \nredox reactions that is responsible for the transfer of electrons. NADH is \na key reducing equivalent in glycolysis and the mitochondria.\nNADPH\nreduced nicotinamide adenine dinucleotide phosphate. NADPH is most \nwell-known for its use in reductive biosynthesis and regenerating \nreduced glutathione.\nROS",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 56
        }
    },
    "486": {
        "text": "reduced glutathione.\nROS\nreactive oxygen species. Chemically reactive molecules that contain \noxygen radicals.\nWarburg \nEffect\nanother name for aerobic glycolysis. Coined by Efraim Racker in the \nearly 1970s.\nReferences\n1. Warburg O. The metabolism of carcinoma cells. The Journal of Cancer Research. 1925; 9(1):148–\n163.\n2. Warburg O, Posener K, Negelein E. Ueber den stoffwechsel der tumoren. Biochemische Zeitschrift. \n1924; 152(1):319–344.",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 57
        }
    },
    "487": {
        "text": "1924; 152(1):319–344.\n3. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. The Journal of general \nphysiology. 1927; 8(6):519–530. [PubMed: 19872213] \n4. Crabtree HG. Observations on the carbohydrate metabolism of tumours. Biochemical journal. 1929; \n23(3):536. [PubMed: 16744238] \n5. Warburg O. On the origin of cancer cells. Science. 1956; 123(3191):309–314. [PubMed: 13298683] \n6. Racker E. Bioenergetics and the Problem of Tumor Growth: An understanding of the mechanism of",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 58
        }
    },
    "488": {
        "text": "the generation and control of biological energy may shed light on the problem of tumor growth. \nAmerican scientist. 1972:56–63. [PubMed: 4332766] \n7. Boerner P, Resnick RJ, Racker E. Stimulation of glycolysis and amino acid uptake in NRK-49F \ncells by transforming growth factor beta and epidermal growth factor. Proc Natl Acad Sci U S A. \n1985; 82(5):1350–3. [PubMed: 3871948] \n8. Flier JS, et al. Elevated levels of glucose transport and transporter messenger RNA are induced by",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 59
        }
    },
    "489": {
        "text": "ras or src oncogenes. Science. 1987; 235(4795):1492–5. [PubMed: 3103217] \n9. Birnbaum MJ, Haspel HC, Rosen OM. Transformation of rat fibroblasts by FSV rapidly increases \nglucose transporter gene transcription. Science. 1987; 235(4795):1495–8. [PubMed: 3029870] \n10. Hiraki Y, Rosen OM, Birnbaum MJ. Growth factors rapidly induce expression of the glucose \ntransporter gene. J Biol Chem. 1988; 263(27):13655–62. [PubMed: 3262104]",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 60
        }
    },
    "490": {
        "text": "11. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between \nglycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006; 9(6):425–34. \n[PubMed: 16766262] \n12. Shim H, et al. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proceedings of \nthe National Academy of Sciences. 1998; 95(4):1511–1516.\n13. Birsoy K, et al. An Essential Role of the Mitochondrial Electron Transport Chain in Cell",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 61
        }
    },
    "491": {
        "text": "Proliferation Is to Enable Aspartate Synthesis. Cell. 2015; 162(3):540–51. [PubMed: 26232224] \nLiberti and Locasale\nPage 8\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\n14. Flaveny CA, et al. Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the \nWarburg Effect and Lipogenesis. Cancer Cell. 2015; 28(1):42–56. [PubMed: 26120082]",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 62
        }
    },
    "492": {
        "text": "15. Sullivan LB, et al. Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in \nProliferating Cells. Cell. 2015; 162(3):552–63. [PubMed: 26232225] \n16. Viale A, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial \nfunction. Nature. 2014; 514(7524):628–32. [PubMed: 25119024] \n17. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 63
        }
    },
    "493": {
        "text": "requirements of cell proliferation. science. 2009; 324(5930):1029–1033. [PubMed: 19460998] \n18. Locasale JW, Cantley LC. Metabolic flux and the regulation of mammalian cell growth. Cell \nmetabolism. 2011; 14(4):443–451. [PubMed: 21982705] \n19. Shestov AA, et al. Quantitative determinants of aerobic glycolysis identify flux through the \nenzyme GAPDH as a limiting step. Elife. 2014; 3:e03342.\n20. Pfeiffer T, Schuster S, Bonhoeffer S. Cooperation and competition in the evolution of ATP-",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 64
        }
    },
    "494": {
        "text": "producing pathways. Science. 2001; 292(5516):504–507. [PubMed: 11283355] \n21. Slavov N, et al. Constant growth rate can be supported by decreasing energy flux and increasing \naerobic glycolysis. Cell reports. 2014; 7(3):705–714. [PubMed: 24767987] \n22. Chang C-H, et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer \nProgression. Cell. 2015\n23. Ho P-C, et al. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. \nCell. 2015",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 65
        }
    },
    "495": {
        "text": "Cell. 2015\n24. Epstein T, et al. Separation of metabolic supply and demand: aerobic glycolysis as a normal \nphysiological response to fluctuating energetic demands in the membrane. Cancer Metab. 2014; \n2(7)\n25. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell \nproliferation. Annual review of cell and developmental biology. 2011; 27:441–464.\n26. Levine AJ, Puzio-Kuter AM. The control of the metabolic switch in cancers by oncogenes and",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 66
        }
    },
    "496": {
        "text": "tumor suppressor genes. Science. 2010; 330(6009):1340–1344. [PubMed: 21127244] \n27. DeBerardinis RJ, et al. The biology of cancer: metabolic reprogramming fuels cell growth and \nproliferation. Cell metabolism. 2008; 7(1):11–20. [PubMed: 18177721] \n28. Dang CV. Links between metabolism and cancer. Genes & development. 2012; 26(9):877–890. \n[PubMed: 22549953] \n29. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 67
        }
    },
    "497": {
        "text": "metabolism. Nature Reviews Cancer. 2011; 11(5):325–337. [PubMed: 21508971] \n30. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature Reviews Cancer. \n2011; 11(2):85–95. [PubMed: 21258394] \n31. Patra KC, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic \ndeletion is therapeutic in mouse models of cancer. Cancer Cell. 2013; 24(2):213–28. [PubMed: \n23911236]",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 68
        }
    },
    "498": {
        "text": "23911236] \n32. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. \nNature cell biology. 2015; 17(4):351–359. [PubMed: 25774832] \n33. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not \nanticipate. Cancer cell. 2012; 21(3):297–308. [PubMed: 22439925] \n34. Hermsen R, et al. A growth-rate composition formula for the growth of E.coli on co-utilized \ncarbon substrates. Mol Syst Biol. 2015; 11(4):801. [PubMed: 25862745]",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 69
        }
    },
    "499": {
        "text": "35. Hui S, et al. Quantitative proteomic analysis reveals a simple strategy of global resource allocation \nin bacteria. Mol Syst Biol. 2015; 11(1):784. [PubMed: 25678603] \n36. Shlomi T, et al. Genome-scale metabolic modeling elucidates the role of proliferative adaptation in \ncausing the Warburg effect. PLoS Comput Biol. 2011; 7(3):e1002018. [PubMed: 21423717] \n37. Vazquez A, et al. Catabolic efficiency of aerobic glycolysis: the Warburg effect revisited. BMC",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 70
        }
    },
    "500": {
        "text": "Syst Biol. 2010; 4:58. [PubMed: 20459610] \n38. Molenaar D, et al. Shifts in growth strategies reflect tradeoffs in cellular economics. Mol Syst Biol. \n2009; 5:323. [PubMed: 19888218] \nLiberti and Locasale\nPage 9\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\n39. Wellen KE, Thompson CB. A two-way street: reciprocal regulation of metabolism and signalling.",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 71
        }
    },
    "501": {
        "text": "Nature reviews Molecular cell biology. 2012; 13(4):270–276. [PubMed: 22395772] \n40. Carracedo A, Cantley LC, Pandolfi PP. Cancer metabolism: fatty acid oxidation in the limelight. \nNature reviews Cancer. 2013; 13(4):227–232.\n41. Madhukar NS, Warmoes MO, Locasale JW. Organization of enzyme concentration across the \nmetabolic network in cancer cells. PLoS One. 2015; 10(1):e0117131. [PubMed: 25621879]",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 72
        }
    },
    "502": {
        "text": "42. Estrella V, et al. Acidity generated by the tumor microenvironment drives local invasion. Cancer \nresearch. 2013; 73(5):1524–1535. [PubMed: 23288510] \n43. Gatenby RA, Gawlinski ET. A reaction-diffusion model of cancer invasion. Cancer research. 1996; \n56(24):5745–5753. [PubMed: 8971186] \n44. Colegio OR, et al. Functional polarization of tumour-associated macrophages by tumour-derived \nlactic acid. Nature. 2014",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 73
        }
    },
    "503": {
        "text": "lactic acid. Nature. 2014\n45. Ying H, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose \nmetabolism. Cell. 2012; 149(3):656–670. [PubMed: 22541435] \n46. Shain AH, et al. The Genetic Evolution of Melanoma from Precursor Lesions. New England \nJournal of Medicine. 2015; 373(20):1926–1936. [PubMed: 26559571] \n47. Wellen KE, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009; \n324(5930):1076–1080. [PubMed: 19461003]",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 74
        }
    },
    "504": {
        "text": "324(5930):1076–1080. [PubMed: 19461003] \n48. Wellen KE, Thompson CB. Cellular metabolic stress: considering how cells respond to nutrient \nexcess. Molecular cell. 2010; 40(2):323–332. [PubMed: 20965425] \n49. Hamanaka RB, Chandel NS. Warburg effect and redox balance. Science. 2011; 334(6060):1219–\n1220. [PubMed: 22144609] \n50. Chang C-H, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. \n2013; 153(6):1239–1251. [PubMed: 23746840]",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 75
        }
    },
    "505": {
        "text": "2013; 153(6):1239–1251. [PubMed: 23746840] \n51. Sena LA, Chandel NS. Physiological roles of mitochondrial reactive oxygen species. Mol Cell. \n2012; 48(2):158–67. [PubMed: 23102266] \n52. Locasale JW. The consequences of enhanced cell-autonomous glucose metabolism. Trends in \nEndocrinology & Metabolism. 2012; 23(11):545–551. [PubMed: 22920571] \n53. Kaplon J, et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 76
        }
    },
    "506": {
        "text": "induced senescence. Nature. 2013; 498(7452):109–112. [PubMed: 23685455] \n54. Mehrmohamadi M, et al. Characterization of the usage of the serine metabolic network in human \ncancer. Cell reports. 2014; 9(4):1507–1519. [PubMed: 25456139] \n55. Fan J, et al. Human Phosphoglycerate Dehydrogenase Produces the Oncometabolite d-2-\nHydroxyglutarate. ACS chemical biology. 2014\n56. Lu C, Thompson CB. Metabolic regulation of epigenetics. Cell metabolism. 2012; 16(1):9–17. \n[PubMed: 22768835]",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 77
        }
    },
    "507": {
        "text": "[PubMed: 22768835] \n57. Cluntun AA, et al. The rate of glycolysis quantitatively mediates specific histone acetylation sites. \nCancer & metabolism. 2015; 3(1):1–12. [PubMed: 25621173] \n58. Liu X-S, Little JB, Yuan Z-M. Glycolytic metabolism influences global chromatin structure. \nOncotarget. 2015; 6(6):4214. [PubMed: 25784656] \n59. Evertts AG, et al. Quantitative dynamics of the link between cellular metabolism and histone",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 78
        }
    },
    "508": {
        "text": "acetylation. Journal of Biological Chemistry. 2013; 288(17):12142–12151. [PubMed: 23482559] \n60. Cai L, et al. Acetyl-CoA induces cell growth and proliferation by promoting the acetylation of \nhistones at growth genes. Molecular cell. 2011; 42(4):426–437. [PubMed: 21596309] \n61. DeNicola GM, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and \ntumorigenesis. Nature. 2011; 475(7354):106–109. [PubMed: 21734707] \nLiberti and Locasale\nPage 10",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 79
        }
    },
    "509": {
        "text": "Liberti and Locasale\nPage 10\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nOutstanding Questions[NN1]\n•\nDoes the Warburg Effect promote the development of cancer or is it a \ndependency imposed by other cancer-promoting processes?\n•\nHow can experimental systems be devised that can conclusively test the \nproposals for the function of the Warburg Effect?\n•",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 80
        }
    },
    "510": {
        "text": "•\nDoes resolution of any given function of the Warburg Effect have immediate \ntherapeutic consequences?\n•\nDoes the function of the Warburg Effect provide insights into its role in tumor \nevolution?\n•\nDo the requirements of the Warburg Effect provide clues for its function?\nLiberti and Locasale\nPage 11\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nTrends\n•",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 81
        }
    },
    "511": {
        "text": "Author Manuscript\nAuthor Manuscript\nTrends\n•\nBoth glycolytic and mitochondrial metabolism are essential for cell proliferation \nin both past and present conceptions of the Warburg Effect.\n•\nNumerous proposals of the Warburg Effect functions have emerged over the \nyears.\n•\nEach of the proposed functions of the Warburg Effect are attractive, but also \nraise unanswered questions.\n•\nSignal transduction functions for the Warburg Effect appear likely, but are \ndifficult to test experimentally.",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 82
        }
    },
    "512": {
        "text": "difficult to test experimentally.\nLiberti and Locasale\nPage 12\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nFigure 1. The frequency of publications on the Warburg Effect from the 1920s-2010s\nThe Warburg Effect has been studied extensively since the 1920s with a surge in the number \nof publications from the 2000s to today. Many of the proposed functions of the Warburg",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 83
        }
    },
    "513": {
        "text": "Effect have also gained vastly renewed interest. Although energy (ATP), biosynthesis, and \nROS have been intricately studied in the context of the Warburg Effect, acidification and \nacetylation have only recently gained attention.\nLiberti and Locasale\nPage 13\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nFigure 2. Summary of the proposed functions of the Warburg Effect",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 84
        }
    },
    "514": {
        "text": "The Warburg Effect is defined as an increase in the rate of glucose uptake and preferential \nproduction of lactate, even in the presence of oxygen. Each of these functions have been \nhypothesized to be the function of the Warburg Effect.\nLiberti and Locasale\nPage 14\nTrends Biochem Sci. Author manuscript; available in PMC 2017 March 01.\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript\nAuthor Manuscript",
        "metadata": {
            "source": "nihms-744404.pdf",
            "chunk_id": 85
        }
    },
    "515": {
        "text": "Mapping cancer origins\nRichard J. Gilbertson\nDepartments of Developmental Neurobiology and Oncology, St Jude Children’s Research\nHospital, 262 Danny Thomas Place, Memphis, TN, 38105, USA. Richard.Gilbertson@stjude.org\nSummary\nCancer comprises a bewildering assortment of diseases that kill 7.5 million people each year. Poor\nunderstanding of cancer’s diversity currently thwarts our goal of a cure for every patient, but",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 0
        }
    },
    "516": {
        "text": "recent integration of genomic and stem cell technologies promises a route through this impasse.\nWhy haven’t we cured cancer?\nSeventy years since the first reported use of cancer chemotherapy, malignancies are the\nsecond most common cause of death among children and adults. Why are the headlines\nrarely punctuated with cancer success stories? One explanation is that while classifying\ncancers is relatively straightforward, understanding the basis of cancer heterogeneity is",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 1
        }
    },
    "517": {
        "text": "complex. Over the years we have become quite proficient at cataloging cancer according to\npatterns of epidemiology and pathology. Each cancer is recognized to occur at a particular\nage, more frequently in one sex than another, and have a particular morphology—usually\nresembling the originating tissue. Advances in imaging and histology have enabled us to\nfurther segregate cancer diagnoses into distinct stages and grades that predict different\ntreatment responses and prognoses.",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 2
        }
    },
    "518": {
        "text": "treatment responses and prognoses.\nDespite this exhaustive work, our attempts to understand the processes that generate the\ndifferent forms of cancer have proved far less fruitful, hamstringing efforts to advance\ntherapy in the clinic. Failure to determine the biological basis of histologically similar but\nclinically and molecularly distinct cancers (inter-tumoral heterogeneity) has proved\nespecially limiting: preventing the development of preclinical models of the full spectrum of",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 3
        }
    },
    "519": {
        "text": "human cancers, and fostering a clinical trials culture that accepts ‘all comers’ with only the\nbroadest categories of histological criteria to filter eligibility.\nOur failure to define the origins of cancer subtypes is not for want of trying. However, our\nrelatively crude understanding what drives cancers, coupled with uncertainty about initiating\ncell types has prevented investigators from making the jump from correlative observation to",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 4
        }
    },
    "520": {
        "text": "functional understanding. Recently, a string of publications suggest that the genomic\nrevolution may provide a route through this impasse. Microarray technologies have\ntransformed the depth with which we can interrogate cancers like leukemias (Ross et al.,\n2004), breast cancers (Sotiriou et al., 2003) and brain tumors (Gibson et al., 2010; Johnson\net al., 2010; Northcott et al., 2010; TCGA, 2008), partitioning these diseases into robust",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 5
        }
    },
    "521": {
        "text": "subgroups according to genome wide patterns of gene expression, copy number alteration\nand mutation. These genomic profiles correlate with long recognized epidemiological,\n© 2011 Elsevier Inc. All rights reserved.\nPublisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our\ncustomers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 6
        }
    },
    "522": {
        "text": "the resulting proof before it is published in its final citable form. Please note that during the production process errors may be\ndiscovered which could affect the content, and all legal disclaimers that apply to the journal pertain.\nNIH Public Access\nAuthor Manuscript\nCell. Author manuscript; available in PMC 2012 April 1.\nPublished in final edited form as:\nCell. 2011 April 1; 145(1): 25–29. doi:10.1016/j.cell.2011.03.019.\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 7
        }
    },
    "523": {
        "text": "NIH-PA Author Manuscript\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\npathological and clinical characteristics, provide fundamental biological insights, and detect\nmolecular echoes of tumor origins.\nLessons from leukemia\nDifferent types of chromosomal translocations—the principal oncogenic mutations in the\nblood—have long been associated with specific subtypes of leukemia. Genomic, stem cell\nand cancer assays have taught us important lessons about the basis of this ‘matching’. First,",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 8
        }
    },
    "524": {
        "text": "the different forms of leukemia appear to arise from distinct points in the hematopoietic\nlineage that are susceptible to specific translocations. For example the BCR-ABL\ntranslocation seen in human chronic myeloid leukemia (CML) only initiates CML in\nuncommitted hematopoietic stem cells (HSCs) (Huntly et al., 2004), while translocations\ninvolving the mixed-lineage leukemia (MLL) gene can initiate acute leukemias in both HSCs",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 9
        }
    },
    "525": {
        "text": "and committed progenitor cells (Barabé et al., 2007; Chen et al., 2008; Krivtsov et al.,\n2006).\nWhat is the biology behind this translocation-lineage stage matching? Comparative gene\nexpression profiling suggests the answer might lie in the capacity of translocations to\nactivate key leukemogenic programs. Extensive self-renewal is considered a requisite\nfeature of leukemic stem cells. When committed, non-self-renewing granulocyte",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 10
        }
    },
    "526": {
        "text": "macrophage progenitors (GMP) are transduced with MLL–AF9 they generate AML. The\nleukemic stem cells in this model retain a GMP-like gene expression profile, but they also\nacquire an aberrant self-renewal signature and self-renewal capacity, normally seen only in\nHSCs (Krivtsov et al., 2006). Since BCR-ABL does not appear to activate self-renewal, but\nrather enhanced cell proliferation and survival, its leukemogenic potential might be",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 11
        }
    },
    "527": {
        "text": "restricted to HSCs that already possess the capacity to self-renew (Huntly et al., 2004;\nSchemionek et al., 2010). Further probing of gene expression profile differences between\nnormal and transformed hematopoietic cells has also highlighted new therapeutic\nopportunities. The transcriptome of MLL-AF9 transformed GMPs encodes a reactivated\nBeta-catenin (Ctnnb1) signal that drives leukemogenic self-renewal, and that might be\nblocked for therapeutic gain (Wang et al., 2010).",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 12
        }
    },
    "528": {
        "text": "blocked for therapeutic gain (Wang et al., 2010).\nAlthough it is intuitive that cancers arise from specific combinations of mutations and\nsusceptible cell types, these landmark studies of leukemia demonstrate the power of\ngenomic technologies to decipher this process. Importantly, these data demonstrate that\nmutations can activate oncogenic signals without globally reprogramming the initiating cell.\nAs we shall see, the legacy of the initiating cell transcriptome within cancer cells can",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 13
        }
    },
    "529": {
        "text": "provide crucial clues to tumor origins as well as unmask novel therapeutic targets.\nCharting cancer origins in solid tissues\nThe availability of assays for each stage in the hematopoietic lineage as well as the liquidity\nof blood has accelerated understanding of leukemogenesis beyond that of solid\ntumorigenesis. But studies of solid cancers are catching up. The rigid anatomical\norganization of solid tissues has allowed investigators to map cells that express",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 14
        }
    },
    "530": {
        "text": "transcriptomes similar to those seen in cancers, and improved techniques to isolate and\nculture cells in solid tissue hierarchies have advanced the study of these populations. These\nstudies have identified cells in solid tissues that share the transcriptomes of solid tumors and\nmight therefore initiate cancer (Figure 1).\nLike most solid tissues, those of the central nervous system (CNS) give rise to a variety of",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 15
        }
    },
    "531": {
        "text": "cancers classified according to patterns of histology. Intracranial ependymomas are the third\nmost common brain tumor of children, and carry a much worse prognosis than spinal forms\nof the disease that predominate in adults. Ependymomas contain transcriptomes and DNA\nGilbertson\nPage 2\nCell. Author manuscript; available in PMC 2012 April 1.\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 16
        }
    },
    "532": {
        "text": "NIH-PA Author Manuscript\nNIH-PA Author Manuscript\ncopy number alterations that correlate with tumor location (Johnson et al., 2010; Taylor et\nal., 2005). Similarly, gene expression profiles of medulloblastomas—the most common\nmalignant pediatric brain tumor—carve these cancers into clinically and molecularly distinct\nsubgroups, including the Sonic Hedgehog (SHH)-subtype driven by aberrant SHH signaling,\nand the highly curable WNT-subtype containing mutations in CTNNB1 (Northcott et al.,\n2010).",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 17
        }
    },
    "533": {
        "text": "2010).\nTo uncover the cellular origins of these diverse brain tumors, investigators tested the\nhypothesis that brain tumor subtypes inherit significant portions of their transcriptome from\ninitiating CNS cells. Initial in situ hybridization analyses showed that the subventricular\nzone of the embryonic lateral ventricle and peri-canal region of the adult spine express the\ntranscriptomes of human cerebral and spinal ependymoma, respectively (Taylor et al.,",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 18
        }
    },
    "534": {
        "text": "2005). Since these regions house neural stem cells (NSCs) the investigators looked for\ntranscriptomic similarities between regionally and developmentally discrete mouse NSCs\nand human ependymomas (Johnson et al., 2010). Using a powerful new cross-species\ngenomics algorithm, the investigators pinpointed embryonic cerebral and adult spinal NSCs\nas candidate cells-of-origin of cerebral and spinal ependymomas, respectively.",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 19
        }
    },
    "535": {
        "text": "This approach has also provided clues to the origins of medulloblastomas, yielding the\nsurprising insight that some of these tumors might arise outside of the cerebellum (Gibson et\nal., 2010). SHH-subtype medulloblastomas have been shown to arise from committed\ncerebellar granule neuron precursor cells (GNPCs) (Schuller et al., 2008; Yang et al., 2008).\nNot surprisingly therefore, in situ hybridization and cross-species genomics revealed a close",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 20
        }
    },
    "536": {
        "text": "match between SHH-subtype medulloblastomas and GNPC transcriptomes (Gibson et al.,\n2010). In stark contrast, the transcriptome of WNT-subtype medulloblastoma matched that\nof neural precursor cells of the lower rhombic lip and embryonic dorsal brainstem (Gibson\net al., 2010). Remarkably, magnetic resonance imaging demonstrated that while human\nSHH-subtype medulloblastomas are confined to the cerebellum, WNT-subtype tumors",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 21
        }
    },
    "537": {
        "text": "invariably involve the dorsal brainstem, supporting further the notion that these different\ntumor types have distinct cellular origins (Gibson et al., 2010).\nClues to cancer origins are not just present in the transcriptomes of leukemias and brain\ntumors, but have also been uncovered through comparative profiling of breast cancers and\nthe normal mammary gland. The ducts and lobules of the human breast are lined by two cell",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 22
        }
    },
    "538": {
        "text": "layers: an inner luminal cell population and a heterogeneous outer cell layer that includes\nbasal progenitor cells. Basal-like breast cancers, so called for their basal-cell\nimmunophenotype (cytokeratins 5/6, 14, and 17), are aggressive tumors, particularly\nprevalent among women with germline mutations in BRCA1. It seemed intuitive that basal-\nlike tumors would arise from basal progenitor cells; however, recent data suggest these",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 23
        }
    },
    "539": {
        "text": "cancers actually arise from luminal progenitors. The pre-neoplastic breasts of BRCA1\nmutant woman contain an expanded population of aberrant luminal progenitor cells, and the\ntranscriptomes of BRCA1-mutant breast tissue and basal-type breast cancers are more like\nthat of luminal progenitors than other normal breast cell types (Lim et al., 2009).\nTranscriptome mapping indentifies solid tumor initiating cells",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 24
        }
    },
    "540": {
        "text": "Although the transcriptomes of certain normal and malignant solid tissue cells correlate,\ndoes this pinpoint cancer origins? Studies of mammary tissue have delineated a cellular\nhierarchy on which to frame this question in the breast. Cell transplant studies have\nidentified a Lin− CD29hiCD24+ mammary stem cell (MaSC) capable of reconstituting the\nentire breast via lineage-committed progenitors (e.g., Lin−CD29loCD24+ luminal",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 25
        }
    },
    "541": {
        "text": "progenitors) (Shackleton et al., 2006; Stingl et al., 2006). Initial studies indicate that\ndifferent cells in the mammary hierarchy are susceptible to different mutations. For\nGilbertson\nPage 3\nCell. Author manuscript; available in PMC 2012 April 1.\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nexample, transgenic expression of Wnt1 via the MMTV promoter generates heterogeneous\nbreast cancers in mice that are preceded by the accumulation of aberrantly self-renewing",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 26
        }
    },
    "542": {
        "text": "MaSCs (Shackleton et al., 2006). In contrast, the mammary glands of MMTV-neu mice\ncontain normal numbers of MaSCs and develop luminal breast cancers, while forced\nexpression of Notch1 in MaSCs expands the luminal progenitor population, leading to basal-\nlike breast cancers (Bouras et al., 2008).\nTargeting tumor type-specific mutations to transcriptome-matched normal cells has provided\ndirect evidence that comparative gene expression profiling can identify cancer origins",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 27
        }
    },
    "543": {
        "text": "(Figure 2). In the breast, conditional deletion of Brca1 from mouse luminal progenitors, but\nnot basal progenitors, produced tumors that mimic the histology and transcriptome of human\nBRCA1- mutant and sporadic basal-type breast cancers, thus confirming comparative gene\nexpression profile predictions (Lim et al., 2009;Molyneux et al., 2010). Similarly embryonic\ncerebral NSCs that were predicted by transcriptome mapping to initiate cerebral",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 28
        }
    },
    "544": {
        "text": "ependymomas, generated these tumors when challenged with mutations found exclusively in\nthis form of the human disease (Johnson et al., 2010). Further, mouse models have validated\nthe surprising prediction that WNT-subtype medulloblastomas likely arise from progenitor\ncells in the dorsal brainstem (Gibson et al., 2010). Mutation of Ctnnb1—an invariable\nfeature of WNT-subtype medulloblastoma—had little impact on progenitor cell populations",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 29
        }
    },
    "545": {
        "text": "in the cerebellum, but caused the abnormal accumulation of neuron precursor cells in the\ndorsal brainstem that progressed to form medulloblastomas that recapitulate the anatomy\nand gene expression profiles of human WNT-subtype medulloblastoma.\nFurther study will doubtless reveal significant exceptions and nuances in the relationship\nbetween the transcriptomes of normal cells and their malignant offspring. Nevertheless,",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 30
        }
    },
    "546": {
        "text": "integrated genomic and stem cell studies have provided a useful framework for investigating\nthe origin of cancer subtypes.\nIn the right place at the wrong time\nTissues have been viewed largely as passive players in cancer pathogenesis; their risk of\nmalignant transformation being dictated by heritable mutations and environmental\nexposures. But if cancers arise from preordained combinations of specific cell types and",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 31
        }
    },
    "547": {
        "text": "matched mutations, then the availability of either of these factors could dictate the\nepidemiology of cancer. In its broadest terms this concept is not new. The very different\ncancer types observed in children and adults have long been suspected to have their roots in\ndevelopment (Figure 1). However, evidence is emerging that more subtle shifts in the\nmakeup of cell hierarchies might account for changes in cancer incidence. For example, it is",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 32
        }
    },
    "548": {
        "text": "tempting to speculate that the expanded population of aberrant luminal progenitors seen in\nthe breasts of cancer-free patients carrying the BRCA1 mutation provides a source of cells\nsusceptible to additional transforming mutations, and thereby an increased risk of\ndeveloping basal-type cancers (Lim et al., 2009;Molyneux et al., 2010).\nShifts in cell hierarchies might also explain the association between certain physiological",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 33
        }
    },
    "549": {
        "text": "states and cancer. For example, if the massive progesterone-induced increases in mouse\nMaSCs prove to occur in humans, then this may explain why breast cancer is associated\nwith early menarche, late menopause and the inclusion of progestin in hormone replacement\ntherapy (Joshi et al., 2010).\nAs genomic and stem cell technologies allow further dissection of cancer subgroups and\ntheir origins, it will be interesting to see if these studies provide answers to other key",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 34
        }
    },
    "550": {
        "text": "questions about cancer epidemiology. For example, do temporal changes in the GNPC\nlineage explain why SHH-subtype medulloblastoma incidence peaks in both early childhood\nand later life (Northcott et al., 2010)? And might the close matching of adult spinal NSC and\nGilbertson\nPage 4\nCell. Author manuscript; available in PMC 2012 April 1.\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nspinal ependymoma transcriptomes explain why these tumors occur almost exclusively in",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 35
        }
    },
    "551": {
        "text": "adults (Johnson et al., 2010)?\nToward cancer cures\nMost biomedical discoveries rarely translate rapidly into improved patient care. However,\nrecent discoveries that genomic tools can identify robust cancer subgroups, and point to the\norigins of these cancers, have immediate clinical relevance. This promise lies in the\nprofound implications this information holds for the full spectrum of cancer research.\nNon-specific cytotoxic treatments remain the mainstay of cancer therapy. Efforts to",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 36
        }
    },
    "552": {
        "text": "introduce more directed treatments that target mutant proteins in cancers have met with\nmixed results. The inefficiency of this process results in part from prior failures to\nadequately capture the heterogeneity of cancers in preclinical models. The integration of\nstem cell biology and genomics outlined in this review is producing multiple, highly\naccurate models of human cancer subgroups (Gibson et al., 2010; Johnson et al., 2010;",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 37
        }
    },
    "553": {
        "text": "Molyneux et al., 2010; Yang et al., 2008). Preclinical drug development using these models\nshould allow investigators to better predict which forms of leukemias and solid cancers are\nmost likely to respond to certain treatments (Figure 2). Such preclinical data could then be\nused to design genomic metrics that would direct treatments to the most appropriate patients\nin early clinical trials.\nCancer models built from specific cells-of-origin offer an additional advantage to drug",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 38
        }
    },
    "554": {
        "text": "developers. Therapies that cripple critical processes in cancer cells carry significant risks of\ndamaging normal cell hierarchies. Understanding the origin of cancers might therefore allow\nthe development of effective drugs with fewer side effects. For example, evidence that\nCtnnb1 mediated self-renewal driven by MLL-AF9 in AML is not required by adult HSCs,\nsuggests CTNNB1 might be targeted therapeutically in this disease without incurring",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 39
        }
    },
    "555": {
        "text": "significant hematological toxicity (Wang et al., 2010).\nFinally, the approaches outlined here promise to shed light on one of the greatest\ncontemporary controversies in cancer research—the cancer stem cell hypothesis. Evidence\nthat cancers are propagated and maintained by sub-populations of stem-like cancer cells has\ncome largely from studies of human cancer xenografts in mice. But these systems do not\nallow lineage tracing of cancer development, and their interpretation is complicated by",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 40
        }
    },
    "556": {
        "text": "species differences. New mouse models of human tumors initiated from predefined and\nselected cells are enabling investigators to track tumorigenesis with much greater precision.\nComparative genomic studies of initiating and daughter cancer cells should provide a more\ncomprehensive view of the processes that cause and propagate cancer.\nAcknowledgments\nI apologize to those investigators whose work could not be referenced because of space limitations.\nReferences",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 41
        }
    },
    "557": {
        "text": "References\nBarabé F, Kennedy JA, Hope KJ, Dick JE. Science. 2007; 316:600–604. [PubMed: 17463288]\nBouras T, Pal B, Vaillant F, Harburg G, Asselin-Labat ML, Oakes SR, Lindeman GJ, Visvader JE.\nCell Stem Cell. 2008; 3:429–441. [PubMed: 18940734]\nChen W, Kumar AR, Hudson WA, Li Q, Wu B, Staggs RA, Lund EA, Sam TN, Kersey JH. Cancer\nCell. 2008; 13:432–440. [PubMed: 18455126]\nGibson P, Tong Y, Robinson G, Thompson MC, Currle DS, Eden C, Kranenburg TA, Hogg T,",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 42
        }
    },
    "558": {
        "text": "Poppleton H, Martin J, et al. Nature. 2010; 468:1095–1099. [PubMed: 21150899]\nGilbertson\nPage 5\nCell. Author manuscript; available in PMC 2012 April 1.\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nHuntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, Duclos N, Rowan R, Amaral S, Curley D,\nWilliams IR, et al. Cancer Cell. 2004; 6:587–596. [PubMed: 15607963]\nJohnson RA, Wright KD, Poppleton H, Mohankumar KM, Finkelstein D, Pounds SB, Rand V, Leary",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 43
        }
    },
    "559": {
        "text": "SE, White E, Eden C, et al. Nature. 2010; 466:632–636. [PubMed: 20639864]\nJoshi PA, Jackson HW, Beristain AG, Di Grappa MA, Mote PA, Clarke CL, Stingl J, Waterhouse PD,\nKhokha R. Nature. 2010; 465:803–807. [PubMed: 20445538]\nKrivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC,\nGilliland DG, et al. Nature. 2006; 442:818–822. [PubMed: 16862118]\nLim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T,",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 44
        }
    },
    "560": {
        "text": "Partanen A, et al. Nat Med. 2009; 15:907–913. Epub 2009 Aug 2002. [PubMed: 19648928]\nMolyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis\nA, Tutt A, Ashworth A, et al. Cell Stem Cell. 2010; 7:403–417. [PubMed: 20804975]\nNorthcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC,\nHawkins CE, French P, et al. J Clin Oncol. 2010 Epub ahead of print.",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 45
        }
    },
    "561": {
        "text": "Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, Song G, Shurtleff SA, Pounds S, Cheng C, Ma J, et\nal. Blood. 2004; 104:3679–3687. Epub 2004 Jun 3629. [PubMed: 15226186]\nSchemionek M, Elling C, Steidl U, Baumer N, Hamilton A, Spieker T, Gothert JR, Stehling M,\nWagers A, Huettner CS, et al. Blood. 2010; 115:3185–3195. [PubMed: 20053753]\nSchuller U, Heine VM, Mao J, Kho AT, Dillon AK, Han YG, Huillard E, Sun T, Ligon AH, Qian Y, et\nal. Cancer Cell. 2008; 14:123–134. [PubMed: 18691547]",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 46
        }
    },
    "562": {
        "text": "Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat ML, Wu L, Lindeman GJ,\nVisvader JE. Nature. 2006; 439:84–88. [PubMed: 16397499]\nSotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu\nET. Proc Natl Acad Sci U S A. 2003; 100:10393–10398. Epub 12003 Aug 10313. [PubMed:\n12917485]\nStingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, Eaves CJ. Nature. 2006;\n439:993–997. Epub 2006 Jan 2004. [PubMed: 16395311]",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 47
        }
    },
    "563": {
        "text": "Taylor MD, Poppleton H, Fuller C, Su X, Liu Y, Jensen P, Magdaleno S, Dalton J, Calabrese C, Board\nJ, et al. Cancer Cell. 2005; 8:323–335. [PubMed: 16226707]\nTCGA. Nature. 2009; 455:1061–1068.\nWang Y, Krivtsov AV, Sinha AU, North TE, Goessling W, Feng Z, Zon LI, Armstrong SA. Science.\n2010; 327:1650–1653. [PubMed: 20339075]\nYang ZJ, Ellis T, Markant SL, Read TA, Kessler JD, Bourboulas M, Schuller U, Machold R, Fishell\nG, Rowitch DH, et al. Cancer Cell. 2008; 14:135–145. [PubMed: 18691548]",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 48
        }
    },
    "564": {
        "text": "Gilbertson\nPage 6\nCell. Author manuscript; available in PMC 2012 April 1.\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nFigure 1. Cross-species genomics matches cells in developing and adult mouse tissues with\nhuman tumor subgroups\nMatching of developing mouse tissues with childhood cancers (left). Different cell stages in\nan embryonic mouse tissue hierarchy are colored according to differentiation stage.",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 49
        }
    },
    "565": {
        "text": "Expression profiling segregates these cells according to transcriptome (top-left).\nHistologically similar but clinically distinct tumors from the corresponding childhood tissue\nexpress different transcriptomes driven by different mutations (mut1–3) (bottom-left). Cross-\nspecies genomics matches human tumors with their candidate cells-of-origin in the\ncorresponding developing mouse tissue. As development proceeds (right), the spectrum of",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 50
        }
    },
    "566": {
        "text": "normal cell types (top right) and cancers (bottom right) changes. The same approach shown\nfor childhood cancers can match tumors with candidate cells-of-origin in adult tissues.\nGilbertson\nPage 7\nCell. Author manuscript; available in PMC 2012 April 1.\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nFigure 2. Modeling cancer heterogeneity\nSubgroups of the childhood cancer shown in Figure 1 can be modeled accurately when",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 51
        }
    },
    "567": {
        "text": "transcriptome matched normal cell types are challenged with mutations found in the\ncorresponding cancer. These models should prove extremely useful for developing new\ntherapies for specific cancer subgroups.\nGilbertson\nPage 8\nCell. Author manuscript; available in PMC 2012 April 1.\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript\nNIH-PA Author Manuscript",
        "metadata": {
            "source": "nihms284090.pdf",
            "chunk_id": 52
        }
    },
    "568": {
        "text": "ONCOLOGY REPORTS  49:  106,  2023\nAbstract. Circulating tumor DNA (ctDNA) has emerged as a \npromising biomarker of minimal residual disease (MRD) in solid \ntumors. There is increasing evidence to suggest that the detection \nof ctDNA following curative‑intent treatments has high potential \nin anticipating future relapse in various solid tumors. Multiple \nliquid biopsy technical approaches and commercial platforms, \nincluding tumor‑informed and tumor‑agnostic ctDNA assays,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 0
        }
    },
    "569": {
        "text": "have been developed for ctDNA‑based MRD detection in solid \ntumors. Accurate ctDNA‑based MRD analysis remains a critical \ntechnical challenge due to the very low concentration of ctDNA \nin peripheral blood samples, particularly in cancer patients \nfollowing a curative‑intent surgery or treatment. The present \nreview summarizes the current key technical approaches that \ncan be used to analyze ctDNA in the surveillance of MRD in \nsolid tumors and provides a brief update on current commercial",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 1
        }
    },
    "570": {
        "text": "assays or platforms available for ctDNA‑based MRD detection. \nThe available evidence to date supporting ctDNA as a biomarker \nfor detection of MRD in various types of solid tumors is also \nreviewed. In addition, technical and biological variables and \nconsiderations in pre‑analytical and analytical steps associated \nwith ctDNA‑based MRD detection are discussed.\nContents\n1.\t Introduction\n2.\t Biology of cfDNA and ctDNA\n3.\t \u0007Current technologies/approaches and commercial plat‑",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 2
        }
    },
    "571": {
        "text": "forms for ctDNA‑based MRD analysis in solid tumors\n4.\t Evidence supporting ctDNA MRD in solid tumors \n5.\t Technical considerations and challenges of ctDNA analysis \n6.\t Conclusions and future perspectives \n1. Introduction\nWith rapidly growing morbidity and mortality, cancer remains \nthe leading cause of mortality globally. Worldwide, there are \n~19.3 million new cancer cases and 10 million cancer‑related \ndeaths annually (1). In recent decades, continuous efforts have",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 3
        }
    },
    "572": {
        "text": "been made to improve the outcomes and prognosis of cancer \npatients. However, following curative treatments, patients \nstill face a high risk of disease recurrence, progression and \ntherapeutic resistance, owing to relapse and the development of \nmetastases. The ability to monitor disease recurrence or progres‑\nsion following primary curative treatment is key to providing \nimmediate effective interventions to eliminate or control",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 4
        }
    },
    "573": {
        "text": "residual tumor cells in patients with a high risk of relapse. The \ncurrent standard‑of‑care mainly relies on traditional diagnostic \nmethods, such as regular clinical examination, and radiological \nimaging to detect disease recurrence or metastasis. However, \na large proportion of patients with successful curative treat‑\nment may harbor clinical micrometastases or minimal residual \ndisease (MRD) (2,3), a potential source of subsequent early",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 5
        }
    },
    "574": {
        "text": "relapse locally and/or metastatic relapse at distant sites, which \ncannot be reliably assessed and monitored by standard radio‑\nlogical imaging or regular clinical examination due to the lack \nof sensitivity. In various types of tumors, there is ample evidence \nto support the clinical validity of MRD detection in anticipating \nfuture recurrence in patients treated for early‑stage cancer (4‑8). \nMRD detection is well‑established and widely employed in",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 6
        }
    },
    "575": {
        "text": "hematological cancers; however, it remains challenging in solid \ntumors, although MRD detection has been mentioned in the \nNational Comprehensive Cancer Network (NCCN) guidelines \nfor solid tumors. Performing serial biopsies of solid tumors for \nMRD detection is not practical, as it is invasive, and there is \nintratumor heterogeneity and difficultly in sampling once the \ntumor has metastasized to a distant site.\nDetecting liquid remnants of solid tumors treated",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 7
        }
    },
    "576": {
        "text": "with curative intent: Circulating tumor DNA as a \nbiomarker of minimal residual disease (Review)\nHUIJUAN CHEN1‑3  and  QIMING ZHOU2,4\n1Computer Network Information Center, Chinese Academy of Sciences, Beijing 100190; 2ChosenMed Clinical  \nLaboratory (Beijing) Co., Ltd.; 3WillingMed Technology Beijing Co., Ltd., Beijing 100176;  \n4ChosenMed Technology (Zhejiang) Co., Ltd., Hangzhou, Zhejiang 311103, P.R. China\nReceived February 1, 2023;  Accepted March 13, 2023\nDOI: 10.3892/or.2023.8543",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 8
        }
    },
    "577": {
        "text": "DOI: 10.3892/or.2023.8543\nCorrespondence to: Dr Qiming Zhou, ChosenMed Clinical \nLaboratory (Beijing) Co., Ltd., Jinghai Industrial Park, 156 Jinghai \n4th Road, Economic and Technological Development Area, \nBeijing 100176, P.R. China\nE‑mail: qimingzhou@chosenmedtech.com\nKey words: circulating tumor DNA, biomarker, minimal residual \ndisease, liquid biopsy, solid tumors\nCHEN  and  ZHOU:  ctDNA AS A PROMISING BIOMARKER OF MRD IN SOLID TUMORS\n2",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 9
        }
    },
    "578": {
        "text": "2\nLiquid biopsy, which detects blood‑based tumor‑specific \nbiomarkers, has exhibited good potential in identifying MRD in \ncancer patients. Analytes of liquid biopsies include circulating \ntumor cells, proteins, extracellular vesicles, cell‑free DNA \n(cfDNA), circulating tumor DNA (ctDNA), exosomes, circu‑\nlating tumor RNA, metabolites, or other biological components \nthat are shed into the bloodstream by tumor cells (9,10). Among \nthese, ctDNA is a widely used biomarker as it carries the",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 10
        }
    },
    "579": {
        "text": "comprehensive genetic and epigenetic aberrations of cancers, \nincluding point mutation, deletion, amplification, gene fusion, \nhypermethylation and hypomethylation (10), which are repre‑\nsentative of the entire tumor profile, including the intratumor \nheterogeneity of a patient. Therefore, it can be utilized as a \nsubstitution of tumor DNA to detect and characterize MRD in \na number of cancer types. There are several potential benefits \nof detecting MRD using ctDNA as a biomarker compared",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 11
        }
    },
    "580": {
        "text": "with traditional diagnostic methods. First, ctDNA‑based MRD \ndetection can predict disease relapse several months or even \nyears before current radiological imaging procedures (11,12). \nSecond, ctDNA may depict a more comprehensive genetic and \nepigenetic landscape of tumor heterogeneity, possibly allowing \nfor the quantitative and qualitative real‑time evaluation of the \ncharacteristics of multiple cancer types in a particular patient.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 12
        }
    },
    "581": {
        "text": "Third, ctDNA‑based MRD detection is safer, easier to obtain, \nless invasive, and less dangerous and painful than a tumor \nbiopsy. Finally, ctDNA‑based MRD detection may monitor the \nmolecular evolution of residual tumor cells in real time during \ntumor progression, thereby aiding in precision treatment to \ndelay or eliminate metastatic recurrence.\nHerein, the current approaches and commercial plat‑\nforms of plasma‑based ctDNA MRD assays are discussed,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 13
        }
    },
    "582": {
        "text": "and the evidence of using ctDNA as a promising biomarker \nfor the detection and characterization of MRD in solid \ntumors is summarized. The present review also discusses the \nexperimental workflow considerations and the technical and \nbiological challenges of ctDNA‑based MRD analysis using \nplasma and its future horizon.\n2. Biology of cfDNA and ctDNA\ncfDNA was first discovered by Mandel and Métais (13) in \nhuman blood plasma in 1948. cfDNA are fragments of extra‑",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 14
        }
    },
    "583": {
        "text": "cellular nucleic acids, which are released into biological fluids \nthrough multiple mechanisms, such as cellular apoptosis, \nnecrosis, phagocytosis and possibly active secretion (14,15) \n(Fig. 1). cfDNA exists in various bodily fluids, including blood \nplasma (16), saliva (17), urine (18), cerebrospinal fluid (19) and \npleural fluid (20), but mostly in blood plasma. cfDNA is typi‑\ncally double‑stranded, highly fragmented and ~150‑200 base",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 15
        }
    },
    "584": {
        "text": "pairs (bp) in length. The prominent length of cfDNA frag‑\nments is 166 bp, corresponding to the length of DNA wrapped \nin a chromatosome (21). The half‑life of cfDNA is relatively \nshort, from 16 min to 2.5 h (22). This may be prolonged up to \n10‑fold by binding to protein complexes, cell membranes, or \nextracellular vesicles (22,23). In healthy individuals, cfDNA \nmainly originates from cells of hematopoietic lineage, such \nas erythrocytes, leukocytes and endothelial cells (24‑26).",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 16
        }
    },
    "585": {
        "text": "The concentration of cfDNA is usually low, ranging from \na negligible amount to 10 ng/ml of plasma, and is rarely \n>30 ng/ml (27). Under certain physiological and pathological \nconditions, including intense exercise, trauma, pregnancy, \ninflammation, infection and cancer, the concentration of \ncfDNA significantly increases (28,29). In a malignant state, \nthe levels of cfDNA may increase 50‑fold over the normal \nlevels to 50‑1,000 ng/ml plasma (14), presumably due to a",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 17
        }
    },
    "586": {
        "text": "higher cellular turnover rate.\nctDNA, released by tumor cells, is a fraction of cfDNA. \nA higher concentration cfDNA was found in cancer patients \nby Leon et al (30) in 1977, and Stroun et al (31) first identi‑\nfied tumor‑derived cfDNA, referring to it as ctDNA in 1989. \nThe fraction of ctDNA is highly variable, ranging from \n<0.05% (32) to 90% (14). It is influenced by a number of \nfactors, including the type of tumor, tumor size and staging,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 18
        }
    },
    "587": {
        "text": "localization and vascularization, tumor microenvironment, \nantitumor treatments, and hepatic, splenic and renal clear‑\nance (33). ctDNA is more fragmented than healthy cfDNA, \nwith a shorter fragment length distribution of 132‑145 bp, and \nthe mean length is ~143 bp (34). ctDNA analysis is consid‑\nered as a ‘real‑time’ reflection of tumor burden for the short \nhalf‑life. ctDNA can be enriched through some DNA extrac‑\ntion and fragment enrichment procedures, considering the size",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 19
        }
    },
    "588": {
        "text": "difference between ctDNA and healthy cfDNA. To prevent the \ndegradation, purified ctDNA should be stored at ‑20˚C, with \nno more than one freeze‑thaw cycle.\n3. Current technologies/approaches and commercial \nplatforms for ctDNA‑based MRD analysis in solid tumors\nStrategies for ctDNA‑based MRD assays are based on the \ndetection and/or tracking of tumor‑specific genomic altera‑\ntions in the ctDNA of patients with definitive therapy. The \ndetection of ctDNA of MRD requires a significantly higher",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 20
        }
    },
    "589": {
        "text": "sensitivity to increase the likelihood of detecting low‑variant \nallele frequency (VAF). The relatively lower concentration of \nctDNA in plasma following curative‑intent treatments, even \n<0.01% of total cfDNA (9), poses a key challenge to MRD \ndetection. With immense efforts being made over the past \ndecades, multiple approaches based on different technologies \nhave been developed and utilized for ctDNA‑based MRD \ndetection (Fig. 1, bottom panel). These include PCR‑based",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 21
        }
    },
    "590": {
        "text": "methods, such as allele‑specific PCR, droplet digital PCR \n(ddPCR), and beads, emulsions, amplification and magnetics \n(BEAM)ing‑PCR (35); PCR amplicon‑based next‑generation \nsequencing (NGS) approaches, such as Safe‑Sequencing \n(Safe‑SeqS) (36), Signatera (Natera Inc), ArcherDX's person‑\nalized cancer monitoring assay and RaDaR assay (Inivata); \nhybridization capture‑based NGS approaches, such as Cancer \nPersonalized Profiling by Deep Sequencing (CAPP‑Seq),",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 22
        }
    },
    "591": {
        "text": "AVENIO assay (Roche Diagnostics), and Phased variant \nEnrichment and detection Sequencing (PhasED‑Seq) (37); and \nwhole‑genome sequencing (WGS), whole‑exome sequencing \n(WES), and other approaches based on epigenetic features, \nsuch as the Guardant Reveal assay. PCR‑based methods, \nparticularly ddPCR, have a high possibility to reliably detect \nknown genomic alterations with high sensitivity, down to a \nVAF of 0.01% (38). PCR‑based methods to assess MRD have",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 23
        }
    },
    "592": {
        "text": "been broadly used in hematological malignancies with a or \nseveral specific mutations, such as BRAF V600E in hairy cell \nleukemia (39). In addition, promising results were observed \nin one study on solid tumors with well‑established hotspot \nONCOLOGY REPORTS  49:  106,  2023\n3\ndriver mutations  (40). The NGS‑based approaches with \nhigh‑throughput ability and hypersensitivity are currently the \nmost broadly used ctDNA detection techniques (16,41). All",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 24
        }
    },
    "593": {
        "text": "those approaches can be classified into two broad categories: \ntumor‑informed and tumor‑agnostic approaches.\nTumor‑informed ctDNA‑based MRD approaches. \nTumor‑informed approaches are based on prior knowledge \nof the tumor‑specific mutational profile. Thus, the sensitivity \nand specificity can be enhanced by tracking patient‑specific \ngenomic alterations expected to be present in plasma vs. \nde novo potential false‑positive alterations originated from",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 25
        }
    },
    "594": {
        "text": "non‑tumor, such as clonal hematopoiesis of indeterminate \npotential (CHIP) (42,43). Typically, tumor biopsy or surgical \ntissue is sequenced by WGS, WES, or a large NGS panel to \nidentify the genomic alterations that were not found in the \ncorresponding germline sample, and the identified alterations \nare monitored by tumor‑informed fixed or bespoke panels, or \ncustom‑based PCR assays in post‑treatment plasma. The use of \nWGS, WES, or a large NGS panel to identify somatic mutations",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 26
        }
    },
    "595": {
        "text": "detected as ctDNA in plasma by custom‑based panel broad \nWGS, WES, or large NGS panel and/or custom‑based panel \nintegrated as a combinatorial approach has demonstrated the \nfeasibility to detect MRD in previous clinical studies (44‑46). \nThe outstanding advantage of this design is the comprehensive \nexploration of genomic alterations of the corresponding tumor \nto provide multiple follow‑up targets in the subsequent plasma, \nthereby improving the sensitivity and reliability of detection.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 27
        }
    },
    "596": {
        "text": "Moreover, using a small target‑sized patient‑specific panel \nallows for a lower limit of detection (LOD) by deep sequencing \nat a lower cost. Some approaches, such as Safe‑SeqS (36) and \ntargeted digital sequencing (TARDIS) (46), which combine \nultra‑deep sequencing with unique molecular identifier (UMI) \nbarcoding, or MRDetect (47) and the Integration of Variant \nReads (INVAR) pipeline (48), which increase the number of \ninformative targets in an assay, can detect tumor VAF as low",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 28
        }
    },
    "597": {
        "text": "Figure 1. Origins of ctDNA and technologies for ctDNA MRD detection. Top panel: ctDNA, released from tumor cells via apoptosis, necrosis, and active \nsecretion, can be extracted from the plasma of patients with cancer. Tumor‑associated genetic aberrations can be analyzed in the isolated ctDNA. Bottom \npanel: Several different technologies for ctDNA MRD analysis in solid tumor patients with definitive therapy.cfDNA, cell‑free DNA; ctDNA, circulating",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 29
        }
    },
    "598": {
        "text": "tumor DNA; MRD, minimal residual disease; NGS, next‑generation sequencing; AS‑PCR, allele‑specific PCR; ddPCR, droplet digital PCR; BEAMing‑PCR, \nBeads, Emulsions, Amplification, and Magnetics‑ing PCR; Safe‑SeqS, Safe‑Sequencing; CAPP‑Seq, Cancer Personalized Profiling by Deep Sequencing; \nPhasED‑Seq, Phased variant Enrichment and detection Sequencing; WGS, whole‑genome sequencing; WES, whole‑exome sequencing.\nCHEN  and  ZHOU:  ctDNA AS A PROMISING BIOMARKER OF MRD IN SOLID TUMORS\n4",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 30
        }
    },
    "599": {
        "text": "4\nas 0.002%. However, the selection of follow‑up tumor variants \n(tumor variants that should be included in the patient‑specific \npanel) and the threshold of ctDNA positivity (the limit number \nof variants per sample to follow) are subjective or arbitrary, \nmostly based on investigator's personal criterion and/or \ndisease‑pertinence bioinformatic algorithms. The number of \ntracking variants ranges from 1 to 115 in the currently used \ntumor‑informed approaches (36,49,50). A previous study",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 31
        }
    },
    "600": {
        "text": "found that tracking at least two variants in plasma increased \nthe ability to identify MRD by 87.5% (6). The sensitivity of \nMRD detection by tracking multiple somatic variants (both \ndriver and passenger) has been found to be significantly higher \nthan that of MRD detection by tracking a single mutation \n(94 vs. 58%, respectively) (51).\nThe tumor‑informed approach offers a cost‑effective \nsolution to examine only tumor‑specific genomic alterations",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 32
        }
    },
    "601": {
        "text": "present in the primary tumor in ctDNA, which lowers the risk \nof false‑positive findings, decreases demands for blood volume, \nand increases sensitivity compared with the tumor‑agnostic \napproach. However, the tumor‑informed approach requires \ntumor biopsy or surgical tissue for genotyping and may pose \nseveral limitations. First, the turnaround time (TAT) is longer, \nand more resources are required for custom personalized assay \ndevelopment compared with the tumor‑agnostic approach,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 33
        }
    },
    "602": {
        "text": "where generally only plasma is required. Second, in numerous \ncases, biopsy or surgical tumor specimens with limited tumor \ncellularity, particularly in tumors with neoadjuvant therapy, \nare insufficient for molecular analysis, which hinders the \napplication of the tumor‑informed approach. In a previous \nstudy, up to 9% of the specimens were reported as inadequate \nfor tissue sequencing, given their insufficient tumor content, \nDNA yield, or DNA quality (52). Third, NGS panels based on",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 34
        }
    },
    "603": {
        "text": "a particular part of the tested tissue cannot capture the whole \ngenomic alteration view due to tumor heterogeneity (subclones \nin different parts of the same tumor or distant metastases). A \npatient‑specific panel developed according to the genomic \nprofile of primary tumor may miss new potentially informative \ntargets in the plasma that occur during the evolution of tumor \nmetastases or the natural selection of tumor clones during \ntreatment. Despite these drawbacks, the tumor‑informed",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 35
        }
    },
    "604": {
        "text": "approach still has immense potential to become the gold stan‑\ndard of ctDNA MRD detection for its ability to reliably detect \nvery low quantities of tumor variants (53).\nTumor‑agnostic ctDNA‑based MRD approaches. \nTumor‑agnostic or tumor‑uninformed (tumor‑naïve) approaches \ndetect plasma only and are conducted without a prior tumor \ngenomic profiling in the tumor of a particular patient. Currently \navailable liquid biopsy assays designed for identifying action‑",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 36
        }
    },
    "605": {
        "text": "able tumor mutations in advanced tumors are not suitable for \nctDNA‑based MRD detection due to a low reliability (<0.5% \nVAF) (54). Tumor‑agnostic approaches need to be developed \nfor the primary purpose of ctDNA‑based MRD detection, with \nhigh specificity and low LOD. NGS combined with specific \nenrichment strategies and/or other supplementary methods, \ne.g., using UMI allows tumor‑agnostic assays to maintain high \nspecificity and accuracy, while detecting the lower ctDNA",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 37
        }
    },
    "606": {
        "text": "allele fraction. Targeted sequencing approaches examining \na larger number of loci of interest with deep sequencing are \noptimal for tumor‑agnostic ctDNA MRD detection. Typically, \nmultiple PCR amplicons [e.g., simple, multiplexed, PCR‑based \nbarcoding of DNA for sensitive mutation detection using \nsequencing or SiM Sen‑seq (55)] and hybrid capture with \nmolecular barcoding [e.g., CAPP‑Seq (56)] are the two main \nenrichment strategies.\nMultiplexed PCR‑based assays generally demand multiple",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 38
        }
    },
    "607": {
        "text": "separate reaction pools running simultaneously to cover the \nlarge genomic space of designed gene panels, considering the \nlimited multiplex‑ability of PCR in a single reaction pool up to \n2,000 bp of genomic breadth (57,58), which may be challenging \nwhen the total cfDNA quantity is limited. In comparison, \nhybrid capture‑based assays have the ability to enrich and \nsequence tens of thousands to millions of bp in a single reac‑\ntion. However, these assays may have a higher false‑positive",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 39
        }
    },
    "608": {
        "text": "rate (due to the increased opportunity for artifactual mutations \nto arise across a large genomic space), and a longer TAT for \ntarget enrichment compared with PCR‑based assays (58). \nIncorporation with single‑strand and/or double‑strand UMI \nor other molecular barcodes and bioinformatics pipelines, can \nreduce the artifactual mutations and technical noise derived \nfrom enrichment and sequencing errors, allowing for the \ndetection of molecular alterations present at very low allele",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 40
        }
    },
    "609": {
        "text": "frequency in high sequencing depth. The CAPP‑seq approach \nenables the detection of a ctDNA mutant allele fraction from \n0.1% to as low as ~0.0001% and yields very promising results \nin specific cancer‑type MRD detection (56). Tumor‑agnostic \nassays integrating both standard genomic alterations and \nDNA methylation status, such as the Guardant Health Reveal \ntest (59), exhibit an increased sensitivity compared with those \naddressing genomic alterations alone.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 41
        }
    },
    "610": {
        "text": "addressing genomic alterations alone.\nCommercial platforms of ctDNA‑based MRD detection. With \nthe advancement and distinct advantages of each strategy, \nmultiple companies have adopted these technologies to \ndevelop their own ctDNA‑based MRD assays. To date, several \ncommercial platforms are available, including tumor‑informed \nassays Signatera™ (Natera), PCM™ (ArcherDX), RaDaR™ \n(Inivata), MRDetect™ (C2i Genomics) and PhasED‑Seq™ \n(Foresight Diagnostic), and tumor‑agnostic assays predi‑",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 42
        }
    },
    "611": {
        "text": "cineALERT™ (predicine), AVENIO™ (Roche), Guardant \nreveal™ (Guardant Health) and NavDX™ (Naveris) (Table SI).\nTumor‑informed commercial platforms. Signatera™, \nwhich has received three US Food and Drug Administration \n(FDA) breakthrough device designations for MRD testing (one \nin May, 2019 and two in March, 2021), utilizes a patient's top \n16 somatic variants from the primary tumor detected by WES \nto personalize a 16‑plex multiplex PCR‑based NGS approach",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 43
        }
    },
    "612": {
        "text": "for the detection of MRD in plasma. Each target can achieve \nan average depth of 100,000x with ultra‑deep sequencing, and \nthis approach has exhibited a sensitivity >98% at 0.01‑0.02% \nctDNA concentrations (60). The total TAT of the Signatera™ \nassay is between 4‑5 weeks, including ~2 weeks for tumor \nsequencing results, 1 week for designing the patient‑specific \nPCR primers and assay, and 1‑2 weeks for post‑treatment \nblood sample testing. Promising results and evidence of",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 44
        }
    },
    "613": {
        "text": "clinical validity were observed using the Signatera™ assay \nin several studies for multiple solid tumor types, including \ncolorectal cancer (CRC), non‑small cell lung cancer (NSCLC), \nbreast cancer and bladder cancer. Moreover, recurrence was \ndetected by the Signatera™ assay prior to clinical evidence \nONCOLOGY REPORTS  49:  106,  2023\n5\nby a median lead time of 2.3‑10.1 months, depending on the \ntumor type (11,61‑63).\nArcherDX received a breakthrough device designation",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 45
        }
    },
    "614": {
        "text": "by the FDA in January, 2019 for its Personalized Cancer \nMonitoring (PCM™) assay that uses the company's proprietary \nanchored‑multiplex PCR technology for ctDNA MRD detec‑\ntion. PCM™ uses patient‑specific anchored‑multiplex PCR \nenrichment panels developed based on somatic variants via \nWES of the resected tumor to identify MRD in plasma, which \nhas served as companion diagnostics in the MERMAID‑1 \nstudy (NCT04385368). Inivata's RaDaR™ assay, a multiplex",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 46
        }
    },
    "615": {
        "text": "PCR‑based assay based on InVision® platform, was granted \nbreakthrough device designation by the FDA in March, 2021 \nas an assay for ctDNA MRD detection. RaDaR™ tracks a set \nof up to 48 patient‑specific variants for assessing ctDNA MRD \nin various types of solid tumor, with a LOD of 0.0011% VAF \nreported by Inivata. Similar to Signatera™, the total TAT of \nRaDaR™ is 5 weeks, including 4 weeks for initial bespoke \npersonalized assay design and development and 7 calendar",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 47
        }
    },
    "616": {
        "text": "days for plasma cfDNA analysis (64). \nMRDetectTM is a WGS‑based cfDNA assay for MRD \ndetection, and all somatic single‑nucleotide alterations \nand copy number alterations (CNAs) of the tumor tissue \nvia WGS are used to inform each personalized ctDNA \nassay. For integrating genome‑wide genomic signature with \nmachine‑learning artificial intelligence‑based error suppres‑\nsion models, this assay requires only 2‑3  ml peripheral \nblood and exhibits a great LOD of 0.001% tumor fraction at",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 48
        }
    },
    "617": {
        "text": "a genome‑wide sequencing depth of 35x (47). PhasED‑Seq, \na hybrid capture‑based sequencing assay, detects the phased \nvariants [two or more SNVs that occur with 150 bp regions \non the same individual DNA molecule (in cis)] to improve the \nsensitivity, allowing a 100‑fold improvement over traditional \nSNV‑based ctDNA MRD assays, with a LOD of below 1 \npart‑per‑million (<0.0001%) (ppm) tumor fraction (37). With \nhigh sensitivity, PhasED‑Seq offers the potential for detecting",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 49
        }
    },
    "618": {
        "text": "ctDNA during and immediately after curative intent treatment.\nTumor‑agnostic commercial platforms. Predicine \nALERT™ is an integrated MRD assay, including a targeted \npanel covering hotspot mutations and important genes, \nPredicineCNB™ (a companion LP‑WGS assay for copy \nnumber burden), and PredicineEPIC™ (a whole‑genome \nmethylation assay). It detects the genomic variants, aberrant \nmethylation and chromosomal abnormalities simultaneously \nfor ctDNA MRD detection. With a LOD of 0.005% VAF,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 50
        }
    },
    "619": {
        "text": "Predicine ALERT™ can be a personalized assay based on the \nmolecular profile of the patient's plasma, urine, or tissue or a \nbaseline‑agnostic assay with a simple blood draw to predict \nresidual disease (65). The AVENIO ctDNA Surveillance kit, \none of three assays in the AVENIO ctDNA assay portfolio, is \na hybrid capture‑based NGS assay designed and optimized for \nthe longitudinal monitoring of tumor burden in lung cancer \nand CRC. The surveillance kit, containing 197 genes with a",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 51
        }
    },
    "620": {
        "text": "panel size of 198 kb, exhibits >99% specificity and >99% posi‑\ntive predictive value (PPV) for all four classes of alterations \n(SNVs, indels, fusions, and CNAs) with a LOD of 0.1% VAF. \nThe clinical utility and validity of the platform are currently \nbeing investigated. In a previous study on 24 patients with \noligometastatic CRC, the use the tumor‑agnostic approach \nbased on the AVENIO assay to detect plasma and urine \nsamples yielded a sensitivity and specificity of 95 and 100%",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 52
        }
    },
    "621": {
        "text": "for plasma‑based ctDNA analysis, respectively, and a sensi‑\ntivity and specificity of 64 and 100% for urine‑based ctDNA \nanalysis, respectively, due to the lower ctDNA levels in urine \n(~11‑fold lower than in plasma) (66). Guardant Reveal™, \na 500 kb hybrid capture‑based gene panel, is a blood‑only \nMRD assay for MRD assessment in early‑stage CRC, breast \ncancer and lung cancer. Utilizing Guardant Health proprietary \nbioinformatics software, Guardant Reveal™ can query the",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 53
        }
    },
    "622": {
        "text": "genomic and epigenomic signatures simultaneously and filter \nout biological noise derived from CHIP without the paired \nblood mononuclear cell sequencing data. In early‑stage CRC, \nGuardant Reveal™ exhibits 91% sensitivity at a LOD of 0.01%. \nIn addition, favorable sensitivity and specificity for recur‑\nrence were observed in a prospective observational study that \nenrolled 103 patients with stage I‑IV CRC with curative‑intent \ntherapies (59).\n4. Evidence supporting ctDNA MRD in solid tumors",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 54
        }
    },
    "623": {
        "text": "4. Evidence supporting ctDNA MRD in solid tumors\nThe significant development of cfDNA‑sequencing methods \nexpands the potential clinical use of ctDNA profiling for the \ndetection of MRD and molecular relapse. Multiple studies \nusing a variety of ctDNA‑based MRD approaches in various \ntypes of solid tumors have indicated that ctDNA has the poten‑\ntial as a predictor of cancer recurrence with high specificity \nand sensitivity, and the detailed performances are shown in \nTable SII and Fig. 2.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 55
        }
    },
    "624": {
        "text": "Table SII and Fig. 2.\nLung cancer. The TRACERx study (NCT01888601), a multi‑\ncenter prospective trial that aimed to enroll >800 patients with \nprimary stage I‑III NSCLC treated with surgery for tracking \ntumor evolutionary dynamics in ctDNA through cancer \nrelapse and metastases, was one of the first studies demon‑\nstrating the clinical utility of ctDNA MRD in patients with \nearly‑stage NSCLC following curative‑intent treatment. In",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 56
        }
    },
    "625": {
        "text": "2017, based on the analysis of a subgroup of 24 patients using \na tumor‑informed multiplex‑PCR NGS approach (Signatera™ \nassay), Abbosh et al (50) reported that 13/14 (93% sensitivity) \npatients with confirmed NSCLC relapse had positive ctDNA \ndetection prior to or at clinical relapse. The median lead time \nof ctDNA detection prior to NSCLC relapse confirmed by \nradiographic evidence was 70 days (range, 10‑346 days); one \npatient was ctDNA‑positive among 10 patients without clinical",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 57
        }
    },
    "626": {
        "text": "evidence of relapse (90% specificity) (50). The updated data \nof that study using Archer DX technology revealed that 37/45 \n(82.2%) patients who suffered relapse of their primary NSCLC \nwere ctDNA‑positive before or at the clinical relapse, with a \nmedian ctDNA lead time of 151 days (range, 0‑984 days). \nFor 23 relapse‑free patients at a median of 1,184 days of \nstudy follow‑up, ctDNA was detected in 1 of 199 time points \nanalyzed, reflecting the specificity of the ctDNA MRD \nassay (67).",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 58
        }
    },
    "627": {
        "text": "assay (67).\nIn a surveillance study on 40 patients treated with cura‑\ntive intent for stage I‑III localized lung cancer, ctDNA MRD \ndetection using CAPP‑seq ctDNA analysis with a LOD of \n~0.002% VAF revealed that 94% sensitivity and 100% speci‑\nficity were achieved by tracking multiple somatic variants \neach patient at the MRD landmark (defined as first ctDNA \ndetected within 4 months of treatment completion). Compared \nCHEN  and  ZHOU:  ctDNA AS A PROMISING BIOMARKER OF MRD IN SOLID TUMORS\n6",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 59
        }
    },
    "628": {
        "text": "6\nwith patients with detectable ctDNA at the MRD landmark, \nctDNA‑negative patients had an improved disease‑specific \nsurvival and overall survival (OS). The serial ctDNA analysis \nof 37 patients with detectable pretreatment ctDNA revealed \nthat 20 patients (54%) were ctDNA‑positive at least at one \npost‑treatment time point during follow‑up, and all of these \n20  patients ultimately recurred. Recurrence detected by \nctDNA was earlier than that detected by radiographic imaging",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 60
        }
    },
    "629": {
        "text": "in 72% of the recurred patients by a median of 5.2 months (4). \nPeng et al (68) found that among 19 patients with recurrent \nNSCLC, 17 were ctDNA‑positive within 2 weeks after surgery, \nand post‑operative ctDNA detection preceded the radiographic \nfindings by a median of 12.6 months. A significantly improved \nprogression‑free survival (PFS) and OS were observed in \npatients with undetectable postoperative ctDNA  (68). In \na recent surveillance study on 88 patients with localized",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 61
        }
    },
    "630": {
        "text": "early‑stage (IA‑IIIB) NSCLC, serial ctDNA in post‑operative \nplasma samples was analyzed using personalized RaDaR™ \nassay to detect residual disease and recurrence. ctDNA MRD \ndetection yielded 95% PPV and 98.7% specificity for relapse \nprediction of primary tumor, with a median lead time of \n212.5 days relative to clinical recurrence (69).\nCRC. Although the majority of CRC cases are diagnosed at \nearly stages (I‑III), a higher recurrence rate (30‑40%) remains",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 62
        }
    },
    "631": {
        "text": "for patients with stage IIB and higher CRC following surgical \nresection plus adjuvant chemotherapy, and in the majority \nof cases (80%), recurrence occurs within the first 2 years of \nsurgery (70). Several studies have demonstrated that ctDNA \nMRD detection can predict the risk of relapse in patients \nwith resected, localized CRC with 82‑100% sensitivity and \n89‑100% specificity (Table SII). In a cohort of 230 patients \nwith stage II CRC treated with surgical resection, ctDNA in",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 63
        }
    },
    "632": {
        "text": "plasma was detected by designed personalized Safe‑SeqS \nassay. ctDNA was detected in 14/178 (7.9%) patients without \nchemotherapy treatment, and 11/14 (78.6%) had clinical recur‑\nrence. In 164 of 178 (92.1%) post‑operative ctDNA‑negative \npatients, disease recurrence occurred in 16 (9.8%) patients. The \npost‑operative ctDNA status was an independent predictor of \ninferior recurrence‑free survival (RFS). ctDNA‑based MRD \nanalysis yielded a 48% sensitivity and 100% specificity in",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 64
        }
    },
    "633": {
        "text": "predicting recurrence at 36 months after surgery. The median \nlead time of ctDNA over radiological recurrence was 167 days \n(81‑279 days), longer than that of carcinoembryonic antigen \nelevation (61 days; 0‑207 days) (71). In another prospective \nstudy on 130 patients with stage I‑III CRC following defini‑\ntive therapy, longitudinal ctDNA analysis using Signatera™ \ntechnology identified 14 of 16 (87.5%) patients with clinical \nrecurrence, and ctDNA‑positive patients exhibited 40‑fold",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 65
        }
    },
    "634": {
        "text": "increased risk of recurrence. Serial ctDNA analyses with 88% \nsensitivity and 98% specificity for relapse provided a median \nlead time of 8.7 months (0.8‑16.5 months) relative to the radio‑\ngraphic recurrence (11).\nRecently, Parikh et al (59) provided a plasma‑only MRD \nassay (Guardant Reveal™) in patients with stage I‑IV CRC \npost‑definitive therapy. At the landmark time point (blood \ndrawn 1 month after definitive therapy; median, 31.5 days),",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 66
        }
    },
    "635": {
        "text": "15 patients were ctDNA‑positive, and all of them recurred at \nFigure 2. Performances of ctDNA‑based MRD approaches in various types of solid tumors. ctDNA, circulating tumor DNA; MRD, minimal residual disease; \nHNSCC, head and neck squamous cell carcinoma; PDAC, pancreatic ductal adenocarcinoma; CAPP‑Seq, Cancer Personalized Profiling by deep Sequencing;",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 67
        }
    },
    "636": {
        "text": "TARDIS, targeted digital sequencing; Safe‑SeqS, Safe‑Sequencing System; cSMART, circulating single‑molecule amplification and resequencing technology.\nONCOLOGY REPORTS  49:  106,  2023\n7\na median of 162 days following definitive therapy. The assay \ndemonstrated 55.6% sensitivity and 100% specificity for land‑\nmark recurrence. Integrating serial longitudinal (blood drawn \nsubsequently after the ‘landmark’ time point) and surveillance",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 68
        }
    },
    "637": {
        "text": "(blood drawn within 4 months of clinical recurrence) analyses \nimproved the sensitivity from 55.6 to 69.0 and 91%, respec‑\ntively, with the specificity remaining at 100%. Incorporating \nepigenomic signatures improved MRD detection sensitivity \nby 25‑36% compared with the assessment of genomic variants \nalone. The results revealed that the sensitivity of ctDNA‑based \nMRD for recurrence prediction could be improved by \ncombining the genomic and epigenomic signatures and by",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 69
        }
    },
    "638": {
        "text": "integrating serial longitudinal and surveillance samples. This \nassay with acceptable assay performance characteristics is \ncurrently commercially available for clinical use to identify \nCRC patients at high risk of recurrence after curative‑intent \nresection and is used in multiple ongoing prospective studies \nto collect additional datasets for further validation of the assay \nperformances and clinical utility. ctDNA‑MRD analysis is",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 70
        }
    },
    "639": {
        "text": "also a powerful prognostic factor in patients with resectable \ncolorectal liver metastasis (CRLM), as well as in patients \nwith non‑metastatic CRC. The serial analysis of ctDNA using \nSafe‑Sequencing (Safe‑SeqS) assay in 54 patients with resect‑\nable CRLM revealed that post‑operative ctDNA clearance was \nsignificantly associated with an improved PFS. All 8 patients \nwith persistently detectable ctDNA of serial analysis during \nadjuvant chemotherapy recurred (72).",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 71
        }
    },
    "640": {
        "text": "adjuvant chemotherapy recurred (72).\nBreast cancer. An initial study on ctDNA MRD \ndetection in breast cancer was performed in 2015 by \nGarcia‑Murillas  et  al  (73). In this prospective cohort \nof 55  patients with high‑risk early‑stage breast cancer \nwith neoadjuvant chemotherapy (NAC), personalized \ntumor‑specific dPCR assays were designed for each somatic \nmutation identified in the corresponding primary tumor. \nTracking these mutations in the single or serial blood samples",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 72
        }
    },
    "641": {
        "text": "obtained at different post‑curative therapy time points \nyielded a high early relapse prediction accuracy (hazard ratio, \n25.1). Mutation tracking in serial blood samples improved \nthe sensitivity of relapse prediction compared with a single \npostoperative sample (from 50 to 80%), with a median lead \ntime of 7.9 months (range, 0.03‑13.6 months) relative to \nclinical relapse (73). In the same year, a retrospective study \non 20 patients with primary breast cancer revealed that serial",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 73
        }
    },
    "642": {
        "text": "ctDNA analysis using a quantitative ddPCR‑based personal‑\nized rearrangement analysis had a 93% sensitivity and 100% \nspecificity for recurrence prediction, with a median lead time \nof 11 months (range, 0‑37 months) relative to the clinical recur‑\nrence in 86% (12/14) of patients (51). In another pilot study on \n38 patients with early‑stage triple‑negative breast cancer who \nreceived multiple‑agent NAC, the Oncomine Research Panel \nconsisting of 134 cancer genes was used to detect the muta‑",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 74
        }
    },
    "643": {
        "text": "tions in the primary tumor and track the mutations in the \nfollowing plasma. A total of 4 of the 33 patients with muta‑\ntions identified in their primary tumors were ctDNA‑positive \nin their plasma, and all four patients had disease recurrence \n(100% specificity) within 9 months. However, sensitivity was \nlimited to detect only 4 of 13 patients who clinically relapsed \n(31% sensitivity) (74). Another study revealed that the detec‑\ntion of ctDNA during follow‑up was associated with the risk",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 75
        }
    },
    "644": {
        "text": "of relapse in all early‑stage breast cancer subtypes, with a \nmedian lead time of 10.7 months (8.1‑19.1 months) prior \nto clinical relapse. A total of 22 of 23 patients (96%) with \ndistant extracranial metastatic relapse were ctDNA‑positive \ncompared with 1 of 6 (17%) patients with brain‑only metas‑\ntasis, suggesting that relapse sites may affect the sensitivity \nof ctDNA MRD detection (75).\nIn a study on 49 patients with high‑risk with stage I‑III",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 76
        }
    },
    "645": {
        "text": "breast cancer, serial plasma ctDNA analysis by Signatera™ \nyielded 88.9% sensitivity and 100% specificity for predicting \nrelapse, with a lead time of up to 2 years (median, 8.9 months; \nrange, 0.5‑24.0  months) ahead of clinical or radiologic \nrelapse (63). A personalized ctDNA analysis using TARDIS, \ndeveloped by McDonald et al (45), demonstrated excellent \naccuracy for identifying molecular response and residual \ndisease in patients with stage I‑III breast cancer treated with",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 77
        }
    },
    "646": {
        "text": "curative intent. In addition, a novel, ultrasensitive assay for \ntracking hundreds of patient‑specific mutations to detect \nMRD in patients with early‑stage breast cancer revealed that \ntracking a larger number of individualized tumor mutations \nin cfDNA could increase the reliability and improve the \nsensitivity of ctDNA MRD detection (76). This approach \ndemonstrated a 100‑fold higher sensitivity than ddPCR when \ntracking 488 mutations. The presence of ctDNA MRD soon",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 78
        }
    },
    "647": {
        "text": "after curative surgery and at a post‑operative landmark (1 year \nafter surgery) was highly predictive of distant relapse. The \nmedian lead time of ctDNA detection over clinical relapse was \n18.9 months (3.4‑39.2 months) (76). In the multicenter I‑SPY 2 \ntrial (NCT01042379), serial ctDNA testing was able to predict \npathological complete response (pCR) and metastatic recur‑\nrence risk in high‑risk early breast cancer patients treated with",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 79
        }
    },
    "648": {
        "text": "NAC. Patients who were ctDNA‑positive at 3 weeks following \nthe initiation of paclitaxel treatment were significantly \nmore likely to have residual disease after NAC compared \nwith patients with cleared ctDNA (83% non‑pCR vs. 52% \nnon‑pCR). Among the 43 patients who failed to achieve pCR, \n14% patients who were ctDNA MRD‑positive experienced a \nsignificantly higher risk of metastatic recurrence. Notably, the \nremaining 86% patients with cleared ctDNA had a favorable",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 80
        }
    },
    "649": {
        "text": "prognosis, similar to those who achieved pCR. The lack of \nctDNA clearance was a strong predictor of poor treatment \nresponse and higher metastatic recurrence (46).\nOther solid tumors. ctDNA‑based MRD detection has also \nshown the ability of reliably predicting recurrence in a number \nof other solid tumors, such as pancreatic, bladder, head and \nneck, and esophageal cancer. In a study on 68 patients with \nlocalized advanced bladder cancer treated with NAC and",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 81
        }
    },
    "650": {
        "text": "surgery, serial ctDNA analysis by Signatera™ during surveil‑\nlance following cystectomy demonstrated 100% sensitivity \n(13/13  patients) and 98% specificity (48/49  patients) in \nidentifying metastatic relapse, with a median lead time of \n96 days relative to radiographic imaging (61). Positive ctDNA \nat diagnosis before chemotherapy, after chemotherapy and \nbefore cystectomy, and during disease surveillance after \ncystectomy was significantly associated with a poor DFS and",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 82
        }
    },
    "651": {
        "text": "inferior OS, and in a multivariate analysis, positive ctDNA \nwas the strongest predictor of RFS after cystectomy [hazard \nratio (HR), 129.6; P<0.001] (61). In a prospective study that \nenrolled 45 patients with localized esophageal cancer (ESCA) \nCHEN  and  ZHOU:  ctDNA AS A PROMISING BIOMARKER OF MRD IN SOLID TUMORS\n8\ntreated with esophagectomy or chemo‑radio therapy (CRT), \nctDNA analysis used a designed CAPP‑Seq ESCA panel \ntargeted 802 regions of 607 genes (77). The detected ctDNA",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 83
        }
    },
    "652": {
        "text": "post‑CRT was significantly associated with an increased risk \nof disease progression (HR, 18.7), distant metastasis (HR, \n32.1) and disease‑specific mortality (HR, 23.1). The detection \nof ctDNA post‑CRT was able to detect relapse on an average \nof 2.8 months before radiographic evidence, with 71.4% sensi‑\ntivity and 100% specificity for recurrence prediction (77).\nThe value of ctDNA in predicting relapse was investigated \nusing panel‑captured sequencing in patients with pancreatic",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 84
        }
    },
    "653": {
        "text": "ductal adenocarcinoma following surgical treatment  (78). \nSpecifically, 8/9 (88%) patients with detected post‑operative \nctDNA ultimately recurred, and post‑operative positive ctDNA \nwas an independent prognostic factor for DFS (HR, 3.60) and \nwas significantly associated with disease relapse in univariate \nanalysis and multivariate analyses (78). For gastric cancer, \nctDNA MRD detection could identify early‑stage patients with \na high risk of recurrence and facilitate new adjuvant therapy",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 85
        }
    },
    "654": {
        "text": "studies to improve survival in the adjuvant treatment setting (12). \nIn a prospective cohort study on 46 patients with stage I‑III, \nresectable gastric cancer, positive ctDNA after surgery was \nsignificantly associated with a higher risk of relapse. All patients \nwith ctDNA positivity in the immediate postoperative period \neventually recurred, with a median time of 179 days prior to \nradiographic recurrence. Positive ctDNA at any post‑operative",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 86
        }
    },
    "655": {
        "text": "subsequent longitudinal time point was associated with a \npoor DFS and OS. Post‑operative ctDNA positivity yielded \ntime‑dependent sensitivity and specificity in predicting recur‑\nrence, with 30% sensitivity and 100% specificity at 30 months \nafter surgery (12). In the chemotherapy vs. chemoradiotherapy \nafter surgery and preoperative chemotherapy for resectable \ngastric cancer (CRITICS) study (NCT00407186), all 11 patients \nwith operable gastric cancer with ctDNA clearance at the median",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 87
        }
    },
    "656": {
        "text": "post‑operative 42‑month follow‑up were alive and free of recur‑\nrence, and 6/9 patients with detected ctDNA at the post‑operative \ntime point experienced disease recurrence and succumbed \ndue to metastatic disease. Moreover, patients with detectable \ntumor‑specific mutations after surgery exhibited a significantly \nshorter median OS and event‑free survival (28.7 months and \n18.7 months vs. median not reached, respectively), as well as",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 88
        }
    },
    "657": {
        "text": "a 21.8‑fold higher risk of relapse. ctDNA analysis determined \ndisease recurrence at 1.3 months, with a median lead time of \n8.9 months relative to clinical recurrence (79).\nIn another study, serial ctDNA analyses were conducted \nin 20 patients with locally advanced head and neck squamous \ncell carcinoma (HNSCC) treated with definitive radio‑chemo‑\ntherapy (80). Furthermore, 2/8 (25%) patients suffering from \na relapse were ctDNA‑positive, and both had a significant",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 89
        }
    },
    "658": {
        "text": "number of tumor fragments with ctDNA MRD scores of 12.16 \n(recurrence within 101 days) and 2.44 (distant relapse after \n833 days). All 8 patients (100%) who were relapse‑free were \nctDNA‑negative. The same dynamic properties were observed \nin circulating HPV DNA (cvDNA) and ctDNA levels during \ntreatment in that study (80). In another single‑center prospec‑\ntive cohort study of 17 patients with stage III‑IVb HNSCC, \nplasma ctDNA was detected in all 5 patients with clinical",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 90
        }
    },
    "659": {
        "text": "recurrence prior to disease progression, with the lead time \nranging from 108 to 253 days (44). In a study on 133 patients \nwith resected melanoma, positive ctDNA at the post‑operative \ntime point was a stronger predictor of recurrence than that at \nthe baseline time point and was significantly associated with \ndistant metastasis‑free survival. All patients with post‑oper‑\natively detected ctDNA eventually experienced recurrence. \nThe time‑dependent accuracy of post‑operative ctDNA in",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 91
        }
    },
    "660": {
        "text": "predicting clinical relapse was observed during 6‑30 months \nof follow‑up after resection, and, 55% sensitivity and 94% \nspecificity at 12 months after resection were observed (81).\n5. Technical considerations and challenges of ctDNA \nanalysis\nExtensive research has demonstrated the high potential \nof ctDNA in determining MRD in solid tumors; however, \nctDNA‑based MRD detection is still complex as there are \na number of technical and biological challenges to its wide‑",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 92
        }
    },
    "661": {
        "text": "spread clinical application. An accurate ctDNA analysis \nremains a critical technical challenge, particularly in patients \nwith curative treatments, due to the ultra‑low ctDNA level in \nbody fluids. Pre‑analytical workflows are crucial for reliable \nctDNA MRD analysis and analytical approaches. All param‑\neters of the entire experimental workflow that may impact \nthe accuracy and reproducibility of the final result, including \npre‑analytical factors, should be considered (Fig. 3).",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 93
        }
    },
    "662": {
        "text": "Pre‑analytical variables and considerations. The timing \nof sample collection, sample collection tubes, storage and \ntransportation conditions, centrifuge processing and extrac‑\ntion protocols are the main pre‑analytical variables of plasma \nctDNA MRD detection (Fig. 3). The ctDNA level and fraction \nmay be affected by various factors, such as the physiological \ncondition of a patient and concurrent inflammatory processes. \nThe timing of post‑treatment sampling is significantly asso‑",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 94
        }
    },
    "663": {
        "text": "ciated with the clinical sensitivity and specificity of ctDNA \nMRD assay, particularly in studies employing an MRD \nlandmark analysis (82). The blood draw timing after the \ncompletion of curative therapy was heterogenous across the \nreported ctDNA MRD studies, and there is still no standard \nfor the first and serial longitudinal blood draw timing. The \nEuropean Society for Medical Oncology (EMSO) recom‑\nmends that for ctDNA MRD detection after surgery, the ideal",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 95
        }
    },
    "664": {
        "text": "timing of blood sampling is at least 1 week after surgery and at \nleast 2 weeks for major surgeries for longer healing time (83). \nPlasma is the preferred source for cfDNA analysis in blood, \ngiven that cfDNA in serum is usually contaminated with \nlarger DNA fragments originating from the ex vivo rupture of \nleukocytes and other cells during coagulation. Storage condi‑\ntions, extraction options, sample integrity, and the quality and \nquantity of cfDNA are highly dependent on the blood collec‑",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 96
        }
    },
    "665": {
        "text": "tion tube type. There are various blood plasma collection \ntubes available, and the choice of collection tubes should be \ncompatible with the ctDNA assays to be deployed. Ethylene \ndiaminetetraacetic acid (EDTA, K2EDTA and K3EDTA) tubes \nare widely used non‑preservative collection tubes for blood, \nwhich require plasma isolation within 6 h, as recommended in \nthe majority of studies if stored at room temperature following \nvenipuncture (84). If stored at 4˚C, the time can be extended",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 97
        }
    },
    "666": {
        "text": "to 24 or 48 h, as previously reported (85). Cell‑preservative \nblood collection tubes, such as Cell‑Free DNA BCT (Streck) \nand PAXgene Blood ccfDNA tubes (PreAnalytix), allow the \nONCOLOGY REPORTS  49:  106,  2023\n9\nextension of the time required for plasma isolation to several \ndays or weeks (7‑30 days) (86).\nAn initial slow centrifuge speed (3,000 x g), followed by \na high‑speed centrifuge (>10,000 x g), is a recommended \nand broadly used protocol to isolate plasma from blood.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 98
        }
    },
    "667": {
        "text": "There is also a report demonstrating that a second low‑speed \ncentrifuge at 3,000 x g provides similar cfDNA yields as \nsecond high‑speed centrifuge (87). Temperature variations or \nexposure to high temperatures may lead to damage and the \ndegradation of cfDNA; thus, plasma should be stored at ‑80˚C \nand freeze‑thawing should be avoided. The DNA integrity \nindex is significantly decreased after three freeze–thaw cycles \ncompared with only one cycle (88). Numerous commercial",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 99
        }
    },
    "668": {
        "text": "cfDNA extraction methods are available, including the \nmanual and automated methods. The majority of these use \nsilicon membrane‑based spin columns or magnetic beads. \nSize discrimination, reproducibility and recovery efficiency \nare highly variable among these methods. Generally, magnetic \nbead‑based methods appear to have a higher recovery effi‑\nciency for small cfDNA fragments (50‑250 bp) than silicon \nmembrane‑based spin columns (86). Selecting the cfDNA",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 100
        }
    },
    "669": {
        "text": "extraction methods or kits needs to be based on the consid‑\neration of their compatibility with the blood collection tubes \nused and the analytical approach to be used. The optimiza‑\ntion and standardization of pre‑analytical procedures are as \ncritical as the analytical approach. More importantly, the \nwhole pre‑analytical sample handling and processing should \nalways follow validated standard operation procedures and be \nperformed in dedicated areas of laboratories to reduce the risk",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 101
        }
    },
    "670": {
        "text": "of contamination.\nAnalytical variables and considerations. There are multiple \ntechnical and biological factors that may generate false‑nega‑\ntive or false‑positive results in ctDNA MRD analysis. A low \nlevel of ctDNA in the limited volume of plasma is one of the \nmost common causes of false‑negative results and a great \ntechnical challenge of ctDNA MRD analysis. NGS panels with \nhigh‑depth sequencing, monitoring numerous patient‑specific",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 102
        }
    },
    "671": {
        "text": "mutations, and serial testing may improve the assay sensitivity \nand enhance the reliability of plasma ctDNA MRD detection. \nSeveral ctDNA analysis methods with ultra‑deep sequencing \nare being developed, which can detect ctDNA as low as \n~0.0001% (37,56). The emergence of new clonal or subclonal \nvariants is another cause of false‑negative results, particularly \nin tumor‑informed ctDNA‑based MRD approaches. In addi‑\ntion, some biological factors, such as variable ctDNA levels",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 103
        }
    },
    "672": {
        "text": "between tumors or even between patients with the same \ntumor, hidden micrometastasis and the location of metastasis \nitself, can cause unavoidable false‑negative results. Higher \nctDNA levels have been found in patients with CRC with liver \nmetastases than in those with nodal or lung metastases (89). \nMoreover, ctDNA MRD analysis has revealed a higher sensi‑\ntivity for distant metastasis than for local recurrence in some \nstudies (77,90). The biological mechanism remains unclear,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 104
        }
    },
    "673": {
        "text": "although it is hypothesized that a higher tumor burden may \nexist in metastases than in residual local disease.\nThe introduction of artifactual mutations during sample \nprocessing, such as unrepaired DNA polymerase errors \narising during PCR amplification and/or oxidative DNA \ndamage in library preparation and sequencing, is still the \nmain cause of false‑positive results. Several error‑suppres‑\nsion strategies, such as using unique molecular identifier,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 105
        }
    },
    "674": {
        "text": "duplex sequencing, or the in silico elimination of stereo‑\ntypical background artifacts (91,92), have been developed \nand utilized to decrease the artifactual alterations arising \nex vivo during the various cfDNA profiling steps. Somatic \nalterations derived from CHIP are one of the most common \nbiological sources of false‑positive mutations. The number \nof variants, allele fractions and genes involved in CHIP is \nprone to change over time, and is associated with smoking,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 106
        }
    },
    "675": {
        "text": "previous cancer therapy and an increasing age  (93,94). \nThese false‑positive mutations can be reduced by the paired \nFigure 3. Overview of variables and considerations of preanalytical and analytical steps in ctDNA MRD measurements. RT, room temperature; IQC, internal \nquality control; EQA, external quality assessment.\nCHEN  and  ZHOU:  ctDNA AS A PROMISING BIOMARKER OF MRD IN SOLID TUMORS\n10\nsequencing of white blood cell (WBC) DNA or matched",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 107
        }
    },
    "676": {
        "text": "tumor tissues or by utilizing advanced bioinformatics \nanalysis. The synchronous profiling of plasma ctDNA and \npaired WBC DNA to exclude CHIP‑associated variants is \nhighly recommended in ctDNA MRD analysis, particularly \nin plasma‑only approaches. Nevertheless, accurately sepa‑\nrating all non‑tumor variants from tumor variants remains \ndifficult. Somatic mutations from diverse non‑malignant cell \ntypes, such as epithelial, endothelial and stromal cells, can",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 108
        }
    },
    "677": {
        "text": "be detected in cfDNA. A previous study found that ~10% \nof variants detected in cfDNA were not present in matched \nWBCs (95). Tumor‑informed approaches that track specific \nmutations identified in tumor tissues can effectively guard \nagainst these sources of biological background.\n6. Conclusions and future perspectives\nThere is rapidly increasing evidence demonstrating the capa‑\nbility of ctDNA‑based MRD to predict future relapse several",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 109
        }
    },
    "678": {
        "text": "months or even years prior to clinical or radiologic recurrence \nin various types of solid tumors, with high sensitivity and \nspecificity. However, there are still several hurdles to be over‑\ncome before this approach can be integrated into the current \nclinical practice workflow. First, although the clinical validity \nof ctDNA‑based MRD testing has clearly been demonstrated \nthrough a number of studies (11,51,63,68,69,71,72,74,78,81),",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 110
        }
    },
    "679": {
        "text": "the clinical utility remains to be fully established. Although \npreliminary data on the clinical benefit of ctDNA‑based MRD \ntesting for personalizing consolidation systemic therapies \nor adjuvant in ctDNA‑positive patients are promising, the \navailable studies involved mostly a small proportion of partici‑\npants, restricted to limited applications and lacked validation \ncohorts. In addition, there is less evidence of the use of ctDNA \nto guide the de‑escalation or discontinuation of adjuvant,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 111
        }
    },
    "680": {
        "text": "consolidation systemic therapies in ctDNA‑negative patients. \nHence, multiple carefully designed large‑scale prospective \nrandomized clinical trials are critical to firmly establish and \nvalidate the clinical utility of ctDNA‑based MRD analysis for \ntreatment personalization in various types of solid tumors. \nSecond, the lack of standardization is another major issue \nfor ctDNA‑based MRD detection in clinical practice. As \naforementioned, multiple pre‑analytical and analytical factors",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 112
        }
    },
    "681": {
        "text": "have an effect on the sensitivity and specificity of ctDNA \nMRD. Optimizations of the standardization of pre‑analytical \nvariables, NGS standards and post‑analytical ctDNA interpre‑\ntation are the key improvement areas to use ctDNA MRD as \nrobust standalone blood‑based biopsy in solid tumor manage‑\nment. The basic standardization of pre‑analytical conditions \nhas been established in ctDNA MRD commercial assays (e.g., \nplasma is the required source and Streck tubes are the required",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 113
        }
    },
    "682": {
        "text": "blood collection tubes) (96). However, multiple aspects, such \nas assay timing, number of collection time points, variable \nctDNA shedding between cancer types and patients, and \nLODs of the detection approaches, still have to be optimized \nand considered by commercial and academic partners before \nctDNA MRD is incorporated into clinical practice workflow.\nMultiple studies (12,46,50,59,61,67,73,77,80) suggest that \nctDNA is a stronger predictor of relapse, and ctDNA MRD",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 114
        }
    },
    "683": {
        "text": "following curative‑intent treatments has high PPV for the risk \nof recurrence in multiple types of solid tumors. With immense \nefforts being made over the past decade, several academic and \ncommercial ctDNA MRD assays/platforms have been developed \nand implemented in clinical trials/practice. Although ctDNA \nMRD assays are still facing multiple technical difficulties due to \nthe very low ctDNA concentration at post‑treatment time points,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 115
        }
    },
    "684": {
        "text": "no standardized methods, the lack of validated large‑scale \nclinical trials and other obstacles, there is no doubt that ctDNA \nMRD assays will play an increasing role in the personalized \nmanagement of consolidation systemic therapies and/or adjuvant \nfor various types of solid tumors in the coming years.\nAcknowledgements \nNot applicable.\nFunding\nThis work was support by Cancer  Genome Atlas of China \n(CGAC) project (YCZYPT [2018]06) from the  National Human",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 116
        }
    },
    "685": {
        "text": "Genetic  Resources Sharing Service Platform (2005DKA21300).\nAvailability of data and materials\nNot applicable.\nAuthors' contributions \nBoth authors (HC and QZ) were involved in the collection and \ninterpretation of data to be included in the review, in reviewing \nthe literature, as well as in drafting and revising the manu‑\nscript. Both authors agree to be accountable for all aspects of \nthe work. Data authentication is not applicable.\nEthics approval and consent to participate",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 117
        }
    },
    "686": {
        "text": "Ethics approval and consent to participate \nNot applicable. \nPatient consent for publication\nNot applicable.\nCompeting interests \nThe authors declare that they have no competing interests. \nReferences\n  1.\tSung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, \nJemal A and Bray F: Global Cancer Statistics 2020: GLOBOCAN \nestimates of incidence and mortality worldwide for 36 cancers in \n185 countries. CA Cancer J Clin 71: 209‑249, 2021.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 118
        }
    },
    "687": {
        "text": "2.\tQiu B, Guo W, Zhang F, Lv F, Ji Y, Peng Y, Chen X, Bao H, \nXu Y, Shao Y, et al: Dynamic recurrence risk and adjuvant \nchemotherapy benefit prediction by ctDNA in resected NSCLC. \nNat Commun 12: 6770‑6780, 2021. \n  3.\tLi H, Ma ZL, Li B, Pan YJ, Xiang JQ, Zhang YW, Sun YH, \nHou T, Lizaso A, Chen Y, et al: Potential utility of longitudinal \nsomatic mutation and methylation profiling for predicting \nmolecular residual disease in postoperative non‑small cell lung",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 119
        }
    },
    "688": {
        "text": "cancer patients. Cancer Med 10: 8377‑8386, 2021.\n  4.\tChaudhuri AA, Chabon JJ, Lovejoy AF, Newman AM, Stehr H, \nAzad TD, Khodadoust MS, Esfahani MS, Liu CL, Zhou L, et al: \nEarly detection of molecular residual disease in localized lung \ncancer by circulating tumor DNA profiling. Cancer Discov 7: \n1394‑1403, 2017.\nONCOLOGY REPORTS  49:  106,  2023\n11\n  5.\tGale D, Heider K, Ruiz‑Valdepenas A, Hackinger S, Perry M, \nMarsico G, Rundell V, Wulff J, Sharma G, Knock H, et al:",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 120
        }
    },
    "689": {
        "text": "Residual ctDNA after treatment predicts early relapse in patients \nwith early‑stage non‑small cell lung cancer. Ann Oncol 33: \n500‑510, 2022. \n  6.\t Tarazona  N, Gimeno‑Valiente  F, Gambardella  V, Zuñiga  S, \nRentero‑Garrido P, Huerta M, Roselló S, Martinez‑Ciarpaglini C, \nCarbonell‑Asins JA, Carrasco F, et al: Targeted next‑generation \nsequencing of circulating‑tumor DNA for tracking minimal residual \ndisease in localized colon cancer. Ann Oncol 30: 1804‑1812, 2019.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 121
        }
    },
    "690": {
        "text": "7.\t Gögenur M, Hadi NA, Qvortrup C, Andersen CL and Gögenur I: \nctDNA for risk of recurrence assessment in patients treated with \nneoadjuvant treatment: A systematic review and meta‑analysis. \nAnn Surg Oncol 29: 8666‑8674, 2022.\n  8.\tCullinane  C, Fleming  C, O'Leary  DP, Hassan  F, Kelly  L, \nO'Sullivan MJ, Corrigan MA and Redmond HP: Association \nof circulating tumor DNA with disease‑free survival in breast \ncancer: A systematic review and meta‑analysis. JAMA Netw \nOpen 3: e2026921, 2020.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 122
        }
    },
    "691": {
        "text": "Open 3: e2026921, 2020.\n  9.\tPantel K and Alix‑Panabières C: Liquid biopsy and minimal \nresidual disease‑latest advances and implications for cure. Nat \nRev Clin Oncol 16: 409‑424, 2019. \n10.\tHeitzer E, Haque IS, Roberts CES and Speicher MR: Current \nand future perspectives of liquid biopsies in genomics‑driven \noncology. Nat Rev Genet 20: 71‑88, 2019.\n11.\t Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, \nSethi H, Knudsen M, Nordentoft I, Wu HT, Tin AS, et al:",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 123
        }
    },
    "692": {
        "text": "Analysis of plasma cell‑free DNA by ultradeep sequencing in \npatients with stages I to III colorectal cancer. JAMA Oncol 5: \n1124‑1131, 2019.\n12.\tYang J, Gong Y, Lam VK, Shi Y, Guan Y, Zhang Y, Ji L, Chen Y, \nZhao Y, Qian F, et al: Deep sequencing of circulating tumor \nDNA detects molecular residual disease and predicts recurrence \nin gastric cancer. Cell Death Dis 11: 346‑354, 2020.\n13.\tMandeL P and Metais P: Les acides nucléiques du plasma",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 124
        }
    },
    "693": {
        "text": "sanguin chez l'homme (Nuclear Acids in Human Blood Plasma). \nC R Seances Soc Biol Fil 142: 241‑243, 1948 (In French).\n14.\t Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD \nand Knippers R: DNA fragments in the blood plasma of cancer \npatients: Quantitations and evidence for their origin from apop‑\ntotic and necrotic cells. Cancer Res 61: 1659‑1665, 2001.\n15.\tThakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa‑Silva B,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 125
        }
    },
    "694": {
        "text": "Zheng Y, Hoshino A, Brazier H, Xiang J, et al: Double‑stranded \nDNA in exosomes: A novel biomarker in cancer detection. Cell \nRes 24: 766‑779, 2014. \n16.\tChin RI, Chen K, Usmani A, Chua C, Harris PK, Binkley MS, \nAzad TD, Dudley JC and Chaudhuri AA: Detection of solid \ntumor molecular residual disease (MRD) using circulating tumor \nDNA (ctDNA). Mol Diagn Ther 23: 311‑331, 2019.\n17.\t Wei F, Lin CC, Joon A, Feng Z, Troche G, Lira ME, Chia D,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 126
        }
    },
    "695": {
        "text": "Mao M, Ho CL, Su WC, et al: Noninvasive saliva‑based EGFR \ngene mutation detection in patients with lung cancer. Am J Respir \nCrit Care Med 190: 1117‑1126, 2014.\n18.\tDudley  JC, Schroers‑Martin  J, Lazzareschi  DV, Shi  WY, \nChen SB, Esfahani MS, Trivedi D, Chabon JJ, Chaudhuri AA, \nStehr H, et al: Detection and surveillance of bladder cancer using \nurine tumor DNA. Cancer Discov 9: 500‑509, 2019. \n19.\t De  Mattos‑Arruda  L, Mayor  R, Ng  CKY, Weigelt  B,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 127
        }
    },
    "696": {
        "text": "Martínez‑Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, \nTang J, et al: Cerebrospinal fluid‑derived circulating tumour \nDNA better represents the genomic alterations of brain tumours \nthan plasma. Nat Commun 6: 8839, 2015.\n20.\tHusain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, \nVenkatapathy S, Duttagupta R, Fung E, Lippman SM, et al: \nCell‑free DNA from ascites and pleural effusions: Molecular \ninsights into genomic aberrations and disease biology. Mol",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 128
        }
    },
    "697": {
        "text": "Cancer Ther 16: 948‑955, 2017.\n21.\t Jiang P and Lo Y MD: The long and short of circulating cell‑free \nDNA and the ins and outs of molecular diagnostics. Trends \nGenet 32: 360‑371, 2016.\n22.\tYao W, Mei C, Nan X and Hui L: Evaluation and comparison of \nin vitro degradation kinetics of DNA in serum, urine and saliva: \nA qualitative study. Gene 590: 142‑148, 2016.\n23.\tLo YM, Zhang J, Leung TN, Lau TK, Chang AM and Hjelm NM: \nRapid clearance of fetal DNA from maternal plasma. Am J Hum",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 129
        }
    },
    "698": {
        "text": "Genet 64: 218‑224, 1999.\n24.\tWong FC, Sun K, Jiang P, Cheng YK, Chan KC, Leung TY, \nChiu RW and Lo YM: Cell‑free DNA in maternal plasma and \nserum: A comparison of quantity, quality and tissue origin \nusing genomic and epigenomic approaches. Clin Biochem 49: \n1379‑1386, 2016.\n25.\tLam WKJ, Gai W, Sun K, Wong RSM, Chan RWY, Jiang P, \nChan NPH, Hui WWI, Chan AWH, Szeto CC, et al: DNA of \nerythroid origin is present in human plasma and informs the \ntypes of anemia. Clin Chem 63: 1614‑1623, 2017.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 130
        }
    },
    "699": {
        "text": "types of anemia. Clin Chem 63: 1614‑1623, 2017. \n26.\tRazavi P, Li BT, Brown DN, Jung B, Hubbell E, Shen R, Abida W, \nJuluru K, De Bruijn I, Hou C, et al: High‑intensity sequencing \nreveals the sources of plasma circulating cell‑free DNA variants. \nNat Med 25: 1928‑1937, 2019. \n27.\t Breitbach S, Tug S, Helmig S, Zahn D, Kubiak T, Michal M, \nGori T, Ehlert T, Beiter T and Simon P: Direct quantification of \ncell‑free, circulating DNA from unpurified plasma. PLoS One 9: \ne87838, 2014.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 131
        }
    },
    "700": {
        "text": "e87838, 2014.\n28.\tTug  S, Helmig  S, Deichmann  ER, Schmeier‑Jürchott  A, \nWagner E, Zimmermann T, Radsak M, Giacca M and Simon P: \nExercise‑induced increases in cell free DNA in human plasma \noriginate predominantly from cells of the haematopoietic \nlineage. Exerc Immunol Rev 21: 164‑173, 2015.\n29.\tLo  YM, Corbetta  N, Chamberlain  PF, Rai  V, Sargent  IL, \nRedman CW, Redman CW and Wainscoat JS: Presence of fetal \nDNA in maternal plasma and serum. Lancet 350: 485‑487, 1997.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 132
        }
    },
    "701": {
        "text": "30.\tLeon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in \nthe serum of cancer patients and the effect of therapy. Cancer \nRes 37: 646‑450, 1977.\n31.\t Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C and \nBeljanski M: Neoplastic characteristics of the DNA found in the \nplasma of cancer patients. Oncology 46: 318‑322, 1989.\n32.\t Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, \nThornton K, Agrawal N, Sokoll L, Szabo SA, et al: Circulating",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 133
        }
    },
    "702": {
        "text": "mutant DNA to assess tumor dynamics. Nat Med 14: 985‑990, 2008. \n33.\tLuo H, Wei W, Ye Z, Zheng J and Xu RH: Liquid biopsy of \nmethylation biomarkers in cell‑free DNA. Trends Mol Med 27: \n482‑500, 2021.\n34.\tUnderhill HR, Kitzman JO, Hellwig S, Welker NC, Daza R, \nBaker DN, Gligorich KM, Rostomily RC, Bronner MP and \nShendure J: Fragment length of circulating tumor DNA. PLoS \nGenet 12: e1006162, 2016.\n35.\t Dressman D, Yan H, Traverso G, Kinzler KW and Vogelstein B:",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 134
        }
    },
    "703": {
        "text": "Transforming single DNA molecules into fluorescent magnetic \nparticles for detection and enumeration of genetic variations. \nProc Natl Acad Sci USA 100: 8817‑8822, 2003. \n36.\tTie  J, Cohen  JD, Wang  Y, Christie  M, Simons  K, Lee  M, \nWong R, Kosmider S, Ananda S, McKendrick J, et al: Circulating \ntumor DNA analyses as markers of recurrence risk and benefit \nof adjuvant therapy for stage III colon cancer. JAMA Oncol 5: \n1710‑1717, 2019.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 135
        }
    },
    "704": {
        "text": "1710‑1717, 2019.\n37.\t Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, \nSchultz A, Jin MC, Scherer F, Garofalo A, et al: Enhanced detection \nof minimal residual disease by targeted sequencing of phased vari‑\nants in circulating tumor DNA. Nat Biotechnol 39: 1537‑1547, 2021.\n38.\tMcDuff SGR, Hardiman KM, Ulintz PJ, Parikh AR, Zheng H, \nKim DW, Lennerz JK, Hazar‑Rethinam M, Van Seventer EE, \nFetter IJ, et al: Circulating tumor DNA predicts pathologic and",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 136
        }
    },
    "705": {
        "text": "clinical outcomes following neoadjuvant chemoradiation and \nsurgery for patients with locally advanced rectal cancer. JCO \nPrecis Oncol 5: PO.20.00220, 2021.\n39.\t Guerrini  F, Paolicchi  M, Ghio  F, Ciabatti  E, Grassi  S, \nSalehzadeh S, Ercolano G, Metelli MR, Del Re M, Iovino L, et al: \nThe droplet digital PCR: A new valid molecular approach for the \nassessment of B‑RAF V600E mutation in hairy cell leukemia. \nFront Pharmacol 7: 363, 2016.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 137
        }
    },
    "706": {
        "text": "Front Pharmacol 7: 363, 2016.\n40.\tHuerta M, Roselló S, Sabater L, Ferrer A, Tarazona N, Roda D, \nGambardella V, Alfaro‑Cervelló C, Garcés‑Albir M, Cervantes A \nand Ibarrola‑Villava M: Circulating tumor DNA detection by \ndigital‑droplet PCR in pancreatic ductal adenocarcinoma: A \nsystematic review. Cancers (Basel) 13: 994, 2021.\n41.\t Elazezy M and Joosse SA: Techniques of using circulating tumor \nDNA as a liquid biopsy component in cancer management.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 138
        }
    },
    "707": {
        "text": "Comput Struct Biotechnol J 16: 370‑378, 2018.\n42.\tHu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, \nGuibert NM, Awad MM, Wong KK, Jänne PA, et al: False‑positive \nplasma genotyping due to clonal hematopoiesis. Clin Cancer \nRes 24: 4437‑4443, 2018.\n43.\tAbbosh C, Swanton C and Birkbak NJ: Clonal haematopoiesis: \nA source of biological noise in cell‑free DNA analyses. Ann \nOncol 30: 358‑359, 2019. \n44.\tFlach S, Howarth K, Hackinger S, Pipinikas C, Ellis P, McLay K,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 139
        }
    },
    "708": {
        "text": "Marsico G, Forshew T, Walz C, Reichel CA, et al: Liquid BIOpsy \nfor MiNimal RESidual DiSease Detection in head and neck \nsquamous cell carcinoma (LIONESS)‑a personalised circulating \ntumour DNA analysis in head and neck squamous cell carci‑\nnoma. Br J Cancer 126: 1186‑1195, 2022. \nCHEN  and  ZHOU:  ctDNA AS A PROMISING BIOMARKER OF MRD IN SOLID TUMORS\n12\n45.\tMcDonald  BR, Contente‑Cuomo  T, Sammut  SJ, \nOdenheimer‑Bergman  A, Ernst  B, Perdigones  N, Chin  SF,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 140
        }
    },
    "709": {
        "text": "Farooq M, Mejia R, Cronin PA, et al: Personalized circulating \ntumor DNA analysis to detect residual disease after neoadjuvant \ntherapy in breast cancer. Sci Transl Med 11: eaax7392, 2019.\n46.\tMagbanua MJM, Swigart LB, Wu HT, Hirst GL, Yau C, Wolf DM, \nTin A, Salari R, Shchegrova S, Pawar H, et al: Circulating tumor \nDNA in neoadjuvant‑treated breast cancer reflects response and \nsurvival. Ann Oncol 32: 229‑239, 2021.\n47.\t Loomis B, Ishii J, Wolchok JD, Boland G, Robine N, Altorki NK",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 141
        }
    },
    "710": {
        "text": "and Landau DA: Genome‑wide cell‑free DNA mutational inte‑\ngration enables ultra‑sensitive cancer monitoring. Nat Med 26: \n1114‑1124, 2020.\n48.\tWan JCM, Heider K, Gale D, Murphy S, Fisher E, Mouliere F, \nRuiz‑Valdepenas A, Santonja A, Morris J, Chandrananda D, et al: \nctDNA monitoring using patient‑specific sequencing and inte‑\ngration of variant reads. Sci Transl Med 12: eaaz8084, 2020.\n49.\t Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 142
        }
    },
    "711": {
        "text": "Kotani D, Powles T, Li BT, Pusztai L, Aushev VN, et al: Impact \nof circulating tumor DNA‑Based detection of molecular residual \ndisease on the conduct and design of clinical trials for solid \ntumors. JCO Precis Oncol 6: e2100181, 2022.\n50.\tAbbosh  C, Birkbak  NJ, Wilson  GA, Jamal‑Hanjani  M, \nConstantin T, Salari R, Le Quesne J, Moore DA, Veeriah S, \nRosenthal  R,  et  al: Phylo genetic ctDNA analysis depicts \nearly‑stage lung cancer evolution. Nature 545: 446‑451, 2017.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 143
        }
    },
    "712": {
        "text": "51.\t Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MH, \nDahlgren M, Schulz R, Grabau D, van Westen D, et al: Serial \nmonitoring of circulating tumor DNA in patients with primary \nbreast cancer for detection of occult metastatic disease. EMBO \nMol Med 7: 1034‑1047, 2015. \n52.\tZehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, \nSrinivasan  P, Gao  J, Chakravarty  D, Devlin  SM,  et  al: \nMutational landscape of metastatic cancer revealed from",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 144
        }
    },
    "713": {
        "text": "prospective clinical sequencing of 10,000 patients. Nat Med 23: \n703‑713, 2017.\n53.\t Honoré N, Galot R, van Marcke C, Limaye N and Machiels JP: \nLiquid biopsy to detect minimal residual disease: Methodology \nand impact. Cancers (Basel) 13: 5364, 2021.\n54.\tDeveson  IW, Gong  B, Lai  K, LoCoco  JS, Richmond  TA, \nSchageman  J, Zhang  Z, Novoradovskaya  N, Willey  JC, \nJones W, et al: Evaluating the analytical validity of circulating \ntumor DNA sequencing assays for precision oncology. Nat",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 145
        }
    },
    "714": {
        "text": "Biotechnol 39: 1115‑1128, 2021.\n55.\t Stahlberg A, Krzyzanowski PM, Egyud M, Filges S, Stein L \nand Godfrey TE: Simple multiplexed PCR‑based barcoding of \nDNA for ultrasensitive mutation detection by next‑generation \nsequencing. Nat Protoc 12: 664‑682, 2017.\n56.\tNewman  AM, Bratman  SV, To  J, Wynne  JF, Eclov  NC, \nModlin LA, Liu CL, Neal JW, Wakelee HA, Merritt RE, et al: \nAn ultrasensitive method for quantitating circulating tumor DNA \nwith broad patient coverage. Nat Med 20: 548‑554, 2014.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 146
        }
    },
    "715": {
        "text": "57.\t Tewhey  R, Warner  JB, Nakano  M, Libby  B, Medkova  M, \nDavid  PH, Kotsopoulos  SK, Samuels  ML, Hutchison  JB, \nLarson  JW,  et  al: Microdroplet‑based PCR enrichment for \nlarge‑scale targeted sequencing. Nat Biotechnol 27: 1025‑1031, \n2009.\n58.\tDudley JC and Diehn M: Detection and diagnostic utilization of \ncellular and cell‑free tumor DNA. Annu Rev Pathol 16: 199‑222, \n2021.\n59.\t Parikh  AR, Van  Seventer  EE, Siravegna  G, Hartwig  AV,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 147
        }
    },
    "716": {
        "text": "Jaimovich  A, He  Y, Kanter  K, Fish  MG, Fosbenner  KD, \nMiao  B,  et  al: Minimal residual disease detection using a \nplasma‑only circulating tumor DNA assay in patients with \ncolorectal cancer. Clin Cancer Res 27: 5586‑5594, 2021.\n60.\tSethi H, Salari R, Navarro S, Natarajan P, Srinivasan R, Dashner S, \nTin T, Balcioglu M, Swenerton R and Zimmermann B: Abstract \n4542: Analytical validation of the SignateraTM RUO assay, \na highly sensitive patient‑specific multiplex PCR NGS‑based",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 148
        }
    },
    "717": {
        "text": "noninvasive cancer recurrence detection and therapy monitoring \nassay. Cancer Res 78: 4542, 2018.\n61.\t Christensen  E, Birkenkamp‑Demtröder  K, Sethi  H, \nShchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, \nLamy P, Lindskrog SV, et al: Early detection of metastatic \nrelapse and monitoring of therapeutic efficacy by Ultra‑Deep \nsequencing of plasma cell‑Free DNA in patients with urothelial \nbladder carcinoma. J Clin Oncol 37: 1547‑1557, 2019.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 149
        }
    },
    "718": {
        "text": "62.\tJamal‑Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, \nWatkins  TBK, Veeriah  S, Shafi  S, Johnson  DH, Mitter  R, \nRosenthal R, et al: Tracking the evolution of non‑small‑cell lung \ncancer. N Engl J Med 376: 2109‑2121, 2017.\n63.\tCoombes RC, Page K, Salari R, Hastings RK, Armstrong A, \nAhmed S, Ali S, Cleator S, Kenny L, Stebbing J, et al: Personalized \ndetection of circulating tumor DNA antedates breast cancer \nmetastatic recurrence. Clin Cancer Res 25: 4255‑4263, 2019.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 150
        }
    },
    "719": {
        "text": "64.\tLipsyc‑Sharf M, de Bruin EC, Santos K, McEwen R, Stetson D, \nPatel A, Kirkner GJ, Hughes ME, Tolaney SM, Partridge AH, et al: \nCirculating Tumor DNA and Late Recurrence in High‑Risk Hormone \nReceptor‑Positive, Human Epidermal Growth Factor Receptor \n2‑Negative Breast Cancer. J Clin Oncol 40: 2408‑2419, 2022. \n65.\tLi R, Bonora G, Dai C, Xiang B, Zheng T, Mo W, Wang X, \nZhou K, Jia S, Luo S, et al: 911P the development and applica‑",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 151
        }
    },
    "720": {
        "text": "tion of a baseline‑agnostic minimal residual disease assay. Ann \nOncol 33: S964, 2022.\n66.\tPellini B, Pejovic N, Feng W, Earland N, Harris PK, Usmani A, \nSzymanski JJ, Qaium F, Mudd J, Petty M, et al: ctDNA MRD \ndetection and personalized oncogenomic analysis in oligo‑\nmetastatic colorectal cancer from plasma and urine. JCO Precis \nOncol 5: PO.20.00276, 2021.\n67.\t Abbosh C, Frankell A, Garnett A, Harrison T, Weichert M, \nLicon  A, Veeriah  S, Daber  B, Moreau  M, Chesh  A,  et  al:",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 152
        }
    },
    "721": {
        "text": "Abstract CT023: Phylogenetic tracking and minimal residual \ndisease detection using ctDNA in early‑stage NSCLC: A lung \nTRACERx study. Cancer Res 80: CT023, 2020. \n68.\tPeng M, Huang Q, Yin W, Tan S, Chen C, Liu W, Tang J, \nWang X, Zhang B, Zou M, et al: Circulating tumor DNA as a \nprognostic biomarker in localized Non‑small Cell lung cancer. \nFront Oncol 10: 561598, 2020.\n69.\tGroot VP, Mosier S, Javed AA, Teinor JA, Gemenetzis G, Ding D,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 153
        }
    },
    "722": {
        "text": "Haley LM, Yu J, Burkhart RA, Hasanain A, et al: Circulating \ntumor DNA as a clinical test in resected pancreatic cancer. Clin \nCancer Res 25: 4973‑4984, 2019.\n70.\tDuineveld LA, van Asselt KM, Bemelman WA, Smits AB, \nTanis PJ, van Weert HC and Wind J: Symptomatic and asymp‑\ntomatic colon cancer recurrence: A multicenter cohort study. \nAnn Fam Med 14: 215‑220, 2016.\n71.\t Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, Silliman N, \nTacey M, Wong HL, Christie M, et al: Circulating tumor DNA",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 154
        }
    },
    "723": {
        "text": "analysis detects minimal residual disease and predicts recur‑\nrence in patients with stage II colon cancer. Sci Transl Med 8: \n346ra92, 2016.\n72.\tTie J, Wang Y, Cohen J, Li L, Hong W, Christie M, Wong HL, \nKosmider S, Wong R, Thomson B, et al: Circulating tumor DNA \ndynamics and recurrence risk in patients undergoing curative \nintent resection of colorectal cancer liver metastases: A prospec‑\ntive cohort study. PLoS Med 18: e1003620, 2021.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 155
        }
    },
    "724": {
        "text": "tive cohort study. PLoS Med 18: e1003620, 2021.\n73.\tGarcia‑Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, \nCutts RJ, Cheang M, Osin P, Nerurkar A, Kozarewa I, et al: \nMutation tracking in circulating tumor DNA predicts relapse in \nearly breast cancer. Sci Transl Med 7: 302ra1332, 2015. \n74.\tChen YH, Hancock BA, Solzak JP, Brinza D, Scafe C, Miller KD \nand Radovich M: Next‑generation sequencing of circulating \ntumor DNA to predict recurrence in triple‑negative breast cancer",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 156
        }
    },
    "725": {
        "text": "patients with residual disease after neoadjuvant chemotherapy. \nNPJ Breast Cancer 3: 24, 2017.\n75.\t Garcia‑Murillas I, Chopra N, Comino‑Méndez I, Beaney M, \nTovey  H, Cutts  RJ, Swift  C, Kriplani  D, Afentakis  M, \nHrebien S, et al: Assessment of molecular relapse detection in \nearly‑stage breast cancer. JAMA Oncol 5: 1473‑1478, 2019. \n76.\tParsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, \nXiong K, Lo CC, Li T, Fleharty M, et al: Sensitive detection of",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 157
        }
    },
    "726": {
        "text": "minimal residual disease in patients treated for early‑stage breast \ncancer. Clin Cancer Res 26: 2556‑2564, 2020.\n77.\t Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, \nHamilton  EG, Yang  YD, Lovejoy  A, Newman  AM,  et  al: \nCirculating tumor DNA analysis for detection of minimal \nresidual disease after chemoradiotherapy for localized esopha‑\ngeal cancer. Gastroenterology 158: 494‑505, 2020.\n78.\tJiang J, Ye S, Xu Y, Chang L, Hu X, Ru G, Guo Y, Yi X, Yang L",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 158
        }
    },
    "727": {
        "text": "and Huang D: Circulating tumor DNA as a potential marker \nto detect minimal residual disease and predict recurrence in \npancreatic cancer. Front Oncol 10: 1220, 2020.\n79.\t Leal A, van Grieken NCT, Palsgrove DN, Phallen J, Medina JE, \nHruban  C, Broeckaert  MAM, Anagnostou  V, Adleff  V, \nBruhm DC, et al: White blood cell and cell‑free DNA analyses for \ndetection of residual disease in gastric cancer. Nat Commun 11: \n525, 2020.\n80.\tHilke FJ, Muyas F, Admard J, Kootz B, Nann D, Welz S, Rieß O,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 159
        }
    },
    "728": {
        "text": "Zips D, Ossowski S, Schroeder C and Clasen K: Dynamics of \ncell‑free tumour DNA correlate with treatment response of \nhead and neck cancer patients receiving radiochemo therapy. \nRadiother Oncol 151: 182‑189, 2020.\nONCOLOGY REPORTS  49:  106,  2023\n13\n81.\t Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, \nMiddlehurst P, Wallace A, Raleigh J, et al: Prediction and moni‑\ntoring of relapse in stage III melanoma using circulating tumor \nDNA. Ann Oncol 30: 804‑814, 2019.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 160
        }
    },
    "729": {
        "text": "DNA. Ann Oncol 30: 804‑814, 2019.\n82.\tModing EJ, Nabet BY, Alizadeh AA and Diehn M: Detecting \nliquid remnants of solid tumors: circulating tumor DNA minimal \nresidual disease. Cancer Discov 11: 2968‑2986, 2021.\n83.\t Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos‑Arruda L, \nDiehn M, Italiano A, Lindberg J, Merker JD, Montagut C, et al: \nESMO recommendations on the use of circulating tumour DNA \nassays for patients with cancer: A report from the ESMO Precision",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 161
        }
    },
    "730": {
        "text": "Medicine Working Group. Ann Oncol 33: 750‑768, 2022.\n84.\tAndersson D, Kristiansson H, Kubista M and Stahlberg A: \nUltrasensitive circulating tumor DNA analysis enables precision \nmedicine: Experimental workflow considerations. Expert Rev \nMol Diagn 21: 299‑310, 2021.\n85.\t Nikolaev S, Lemmens L, Koessler T, Blouin JL and Nouspikel T: \nCirculating tumoral DNA: Preanalytical validation and quality \ncontrol in a diagnostic laboratory. Anal Biochem 542: 34‑39, 2018.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 162
        }
    },
    "731": {
        "text": "86.\tUngerer V, Bronkhorst AJ and Holdenrieder S: Preanalytical \nvariables that affect the outcome of cell‑free DNA measure‑\nments. Crit Rev Clin Lab Sci 57: 484‑507, 2020.\n87.\t Risberg B, Tsui DWY, Biggs H, Ruiz‑Valdepenas Martin de Alm\nagro A, Dawson SJ, Hodgkin C, Jones L, Parkinson C, Piskorz A, \nMarass F, et al: Effects of collection and processing procedures \non plasma circulating cell‑free DNA from cancer patients. J Mol \nDiagn 20: 883‑892, 2018.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 163
        }
    },
    "732": {
        "text": "Diagn 20: 883‑892, 2018.\n88.\tChiu  RW, Lui  WB, El‑Sheikhah  A, Chan  AT, Lau  TK, \nNicolaides  KH and Lo  YM: Comparison of protocols for \nextracting circulating DNA and RNA from maternal plasma. \nClin Chem 51: 2209‑2210, 2005.\n89.\tVidal J, Muinelo L, Dalmases A, Jones F, Edelstein D, Iglesias M, \nOrrillo M, Abalo A, Rodríguez C, Brozos E, et al: Plasma ctDNA \nRAS mutation analysis for the diagnosis and treatment moni‑\ntoring of metastatic colorectal cancer patients. Ann Oncol 28:",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 164
        }
    },
    "733": {
        "text": "1325‑1332, 2017.\n90.\tTie J, Cohen JD, Lo SN, Wang Y, Li L, Christie M, Lee M, \nWong R, Kosmider S, Skinner I, et al: Prognostic significance of \npostsurgery circulating tumor DNA in nonmetastatic colorectal \ncancer: Individual patient pooled analysis of three cohort studies. \nInt J Cancer 148: 1014‑1026, 2021. \n91.\t Abbosh  C, Birkbak  NJ and Swanton  C: Early stage \nNSCLC‑challenges to implementing ctDNA‑based screening \nand MRD detection. Nat Rev Clin Oncol 15: 577‑586, 2018.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 165
        }
    },
    "734": {
        "text": "92.\tMansukhani S, Barber LJ, Kleftogiannis D, Moorcraft SY, \nDavidson  M, Woolston  A, Proszek  PZ, Griffiths  B, \nFenwick K, Herman B, et al: Ultra‑sensitive mutation detec‑\ntion and genome‑wide DNA copy number reconstruction \nby error‑corrected circulating tumor DNA sequencing. Clin \nChem 64: 1626‑1635, 2018.\n93.\tBolton KL, Ptashkin RN, Gao T, Braunstein L, Devlin SM, \nKelly D, Patel M, Berthon A, Syed A, Yabe M, et al: Cancer",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 166
        }
    },
    "735": {
        "text": "therapy shapes the fitness landscape of clonal hematopoiesis. Nat \nGenet 52: 1219‑1226, 2020.\n94.\tCoombs  CC, Zehir  A, Devlin  SM, Kishtagari  A, Syed  A, \nJonsson P, Hyman DM, Solit DB, Robson ME, Baselga J, et al: \nTherapy‑related clonal hematopoiesis in patients with \nnon‑hematologic cancers is common and associated \nwith adverse clinical outcomes. Cell Stem Cell 21: 374‑382, 2017.\n95.\tChabon  JJ, Hamilton  EG, Kurtz  DM, Esfahani  MS,",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 167
        }
    },
    "736": {
        "text": "Moding EJ, Stehr H, Schroers‑Martin J, Nabet BY, Chen B, \nChaudhuri AA, et al: Integrating genomic features for non‑inva‑\nsive early lung cancer detection. Nature 580: 245‑251, 2020.\n96.\tChen K, Shields MD, Chauhan PS, Ramirez RJ, Harris PK, \nReimers MA, Zevallos JP, Davis AA, Pellini B and Chaudhuri AA: \nCommercial ctDNA assays for minimal residual disease detection \nof solid tumors. Mol Diagn Ther 25: 757‑774, 2021. \nThis work is licensed under a Creative Commons",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 168
        }
    },
    "737": {
        "text": "This work is licensed under a Creative Commons \nAttribution-NonCommercial-NoDerivatives 4.0 \nInternational (CC BY-NC-ND 4.0) License.",
        "metadata": {
            "source": "or-49-05-08543.pdf",
            "chunk_id": 169
        }
    },
    "738": {
        "text": "Field cancerization in breast cancer\nEmanuela Gadaleta1 , Graeme J Thorn1 , Helen Ross-Adams1 , Louise J Jones2* and Claude Chelala1*\n1 Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK\n2 Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, UK\n*Correspondence to: C Chelala, Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London,",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 0
        }
    },
    "739": {
        "text": "Charterhouse Square, London, EC1M 6BQ, UK or LJ Jones, Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London,\nCharterhouse Square, London, EC1M 6BQ, UK. E-mail: c.chelala@qmul.ac.uk or l.j.jones@qmul.ac.uk\nAbstract\nBreast cancer affects one in seven women worldwide during their lifetime. Widespread mammographic screening\nprograms and education campaigns allow for early detection of the disease, often during its asymptomatic phase.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 1
        }
    },
    "740": {
        "text": "Current practice in treatment and recurrence monitoring is based primarily on pathological evaluations but can\nalso encompass genomic evaluations, both of which focus on the primary tumor. Although breast cancer is one\nof the most studied cancers, patients still recur at a rate of up to 15% within the ﬁrst 10 years post-surgery.\nLocal recurrence was originally attributed to tumor cells contaminating histologically normal (HN) tissues beyond",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 2
        }
    },
    "741": {
        "text": "the surgical margin, but advances in technology have allowed for the identiﬁcation of distinct aberrations that\nexist in the peri-tumoral tissues themselves. One leading theory to explain this phenomenon is the ﬁeld cancer-\nization theory. Under this hypothesis, tumors arise from a ﬁeld of molecularly altered cells that create a permissive\nenvironment for malignant evolution, which can occur with or without morphological changes. The traditional",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 3
        }
    },
    "742": {
        "text": "histopathology paradigm dictates that molecular alterations are reﬂected in the tissue phenotype. However,\nthe spectrum of inter-patient variability of normal breast tissue may obfuscate recognition of a cancerized ﬁeld\nduring routine diagnostics. In this review, we explore the concept of ﬁeld cancerization focusing on HN peri-\ntumoral tissues: we present the pathological and molecular features of ﬁeld cancerization within these tissues",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 4
        }
    },
    "743": {
        "text": "and discuss how the use of peri-tumoral tissues can affect research. Our observations suggest that pathological\nand molecular evaluations could be used synergistically to assess risk and guide the therapeutic management of\npatients.\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great\nBritain and Ireland.\nKeywords: breast cancer; ﬁeld cancerization; cancer-adjacent tissues; histologically normal",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 5
        }
    },
    "744": {
        "text": "Received 14 February 2022; Revised 23 March 2022; Accepted 29 March 2022\nNo conﬂicts of interest were declared.\nIntroduction\nBreast cancer is the most common invasive cancer in\nwomen worldwide, affecting one in seven women during\ntheir lifetime [1]. Widespread mammographic screening\nprograms, enhanced education campaigns, and advances\nin detection methods and therapeutic regimes allow for\nthe detection of asymptomatic disease, resulting in signif-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 6
        }
    },
    "745": {
        "text": "icant improvements in overall survival [2]. This early\ndetection has led to the increased implementation of\nbreast conservation therapy, which has signiﬁcantly\nimproved the management of early breast cancer.\nCurrently, pathological evaluations and genomic tests\nthat focus on the primary tumor are employed to deter-\nmine therapeutic management and risk of recurrence.\nAlthough breast cancer has been studied extensively,\npatients who undergo breast conservation surgery with",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 7
        }
    },
    "746": {
        "text": "post-operative radiotherapy still have a recurrence rate\nof between 3% and 15% within 10 years [3].\nOriginally, it was presumed that local recurrence fol-\nlowing surgery was attributable to tumor cells contami-\nnating histologically normal (HN) tissues beyond the\nsurgical margin [4]. However, advances in technology\nhave allowed researchers to better characterize tumors\nand their associated HN tissues, with several studies\nreporting aberrations in peri-tumoral tissues and deter-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 8
        }
    },
    "747": {
        "text": "mining that these tissues provide distinct information\nbeyond that available from tumor. Two main theories\nhave been proposed to explain these observations: the\nﬁeld cancerization theory and the tumor microenviron-\nment theory [5,6].\nThe ﬁeld cancerization theory proposes the creation of\na ﬁeld of molecularly altered cells or an environment\nwith an inherent predisposition to malignant evolution\nthat can occur with or without morphological change",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 9
        }
    },
    "748": {
        "text": "[7]; the tumor microenvironment theory suggests that\nmicroenvironmental factors are key drivers of tumor ini-\ntiation and progression. These theories are unlikely to be\nJournal of Pathology\nJ Pathol July 2022; 257: 561–574\nPublished online 3 May 2022 in Wiley Online Library\n(wileyonlinelibrary.com) DOI: 10.1002/path.5902\nINVITED REVIEW\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 10
        }
    },
    "749": {
        "text": "This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any\nmedium, provided the original work is properly cited.\nmutually exclusive but instead co-exist in an intricate\nrelationship that potentially inﬂuences manifested phe-\nnotypes [8].\nIn this review, we explore the concepts of ﬁeld cancer-\nization in HN tissues. We present the pathologic and\nmolecular characteristics of ﬁeld cancerization and dis-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 11
        }
    },
    "750": {
        "text": "cuss the implications of using peri-tumoral tissues in\nresearch (Figure 1).\nDevelopment and evolution of ﬁeld cancerization\ntheories\n‘Field cancerization’ was ﬁrst deﬁned by Slaughter et al\nto describe hyperplastic and atypical epithelia surround-\ning multifocal oral squamous carcinoma [7]. They attrib-\nuted the high rate of local recurrence to a progressive\nchange in peri-tumoral cells rather than the inﬂuence of\npre-existing cancer cells. The authors concluded that a",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 12
        }
    },
    "751": {
        "text": "preconditioned microenvironmental milieu was created,\nin which cells underwent irreversible changes to confer\ntumor growth.\nSince this original deﬁnition, the concept of ﬁeld can-\ncerization has been continually adapted to remain\nabreast of knowledge attained from advances in molecu-\nlar technologies [9–11]. In light of evidence from genetic\nprogression models, current deﬁnitions support the pre-\nsupposition that cells within the preneoplastic ﬁeld accu-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 13
        }
    },
    "752": {
        "text": "mulate pro-tumorigenic molecular alterations. However,\nthe tissue itself may not exhibit obvious morphological\nchange as determined by histopathology, meaning that\nthese aberrant cells remain clinically hidden. The criteria\nthat deﬁne morphologically normal tissues are being\nchallenged as we begin to understand how ‘normal var-\niation’ may impact cancer risk.\nThe mechanisms by which the molecularly altered\ncells develop are not fully understood, but clonal expan-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 14
        }
    },
    "753": {
        "text": "sion and intra-epithelial migration of these cells within\ncontiguous epithelial structures have been proposed\n[11]. It has been suggested that cancerization can be\nattributed to the divergence, selection, and expansion\nof one or more clones that ultimately confer a survival\nadvantage over the resident cell population [9].\nThe ‘etiological ﬁeld effect’ reassesses the concept of\nﬁeld cancerization by taking a more holistic approach\n[11]. Here, it is suggested that endogenous and exoge-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 15
        }
    },
    "754": {
        "text": "nous factors, such as ageing, diet, smoking, and expo-\nsure to ultraviolet light, individually and together affect\nbody tissues and contribute to a ﬁeld of cancer\npredisposition.\nMore recently, it has been proposed that ﬁeld cancer-\nization could be considered in terms of phenotypic traits,\nrather than underlying speciﬁc molecular aberrations.\nHere, the cancerized ﬁeld is deﬁned as a collection of\ncells that have acquired a subset of phenotypic alter-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 16
        }
    },
    "755": {
        "text": "ations required for malignancy even in the absence of\nhistological alterations [9].\nThe theories of ﬁeld cancerization will continue to\nevolve as studies discern the cellular mechanisms\nunderpinning its aetiology, thus allowing for the demar-\ncation of cancerized ﬁelds and elucidation of the proper-\nties that deﬁne patient outcome and response to therapy.\nDeterminants of ﬁeld cancerization in breast cancer\nTechnological advances offer the opportunity to gain a",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 17
        }
    },
    "756": {
        "text": "deeper understanding of cancer biology and its underly-\ning mechanisms from both a pathological and a molecu-\nlar aspect. Numerous studies have shown that patches of\nmolecularly altered, cancer-primed, cells are present in\nHN tissues surrounding breast tumors and that these\ncells create an environment with a predisposition to pro-\ngress to cancer [7,12–20]. These studies offer unparal-\nleled insights into the hidden depths of these peri-\ntumoral tissues.\nPathological",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 18
        }
    },
    "757": {
        "text": "tumoral tissues.\nPathological\nThe central tenet of histopathology is that molecular\nalterations are reﬂected in tissue phenotype, and decades\nof research have related speciﬁc phenotypic changes to\ndisease behaviour. In the breast, there is a well-deﬁned\nseries of proliferative changes that confer a variable risk\nfor development of breast cancer [21], with the risk\nbeing highest for atypical ductal hyperplasia [22].\nMolecular studies on atypical ductal hyperplasia have",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 19
        }
    },
    "758": {
        "text": "demonstrated some shared genomic alterations with\nestablished malignancy [17,23], which supports its pre-\ncursor nature and representation of cancerized ﬁeld. Rec-\nognition of these entities and subsequent management of\npatients based on predicted levels of associated risk are\nthe mainstay of protocol-driven patient management.\nHowever, beyond these well-recognized benign and atyp-\nical lesions, there is almost inﬁnite variation in the histo-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 20
        }
    },
    "759": {
        "text": "logical appearance of ‘normal’ breast tissue as well as\nmore subtle changes not captured in routine diagnostics\nthat may reﬂect a ﬁeld cancerization effect. This morpho-\nlogical variation represents the phenotypic manifestation\nof an individual’s genetic and hormonal environment\nand is increasingly recognized to inﬂuence cancer risk.\nOne such histological variation is manifested by the\nphysiological process of lobular involution [24,25],\nwhereby there is a reduction in the number of acini in a",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 21
        }
    },
    "760": {
        "text": "terminal ductal lobular unit (TDLU) and a reduction in\nthe number of lobules per unit area. The occurrence of\nlobular involution is most prominent around the peri-\nmenopausal years but is highly variable between indi-\nviduals, in terms of both stage of development and extent\nof development.\nThe status of lobular involution has been assessed\nsemi-quantitatively across large patient cohorts and\ndemonstrated that more advanced lobular involution in\nwomen who have had a biopsy showing benign breast",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 22
        }
    },
    "761": {
        "text": "women who have had a biopsy showing benign breast\ndisease is associated with signiﬁcantly reduced breast\ncancer risk [25,26]. Furthermore, longitudinal assess-\nment of lobular involution in women undergoing multi-\nple biopsies indicates that delayed lobular involution is\nassociated with breast cancer risk. This normal variation\n562\nE Gadaleta et al\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 23
        }
    },
    "762": {
        "text": "on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\nin breast histology also appears to modify the risk gener-\nated by recognized proliferative lesions. For example, in\nwomen with atypical epithelial hyperplasia, patients\nwith no lobular involution in surrounding breast tissue\nshow a signiﬁcantly higher risk of developing breast\ncancer compared with those with complete lobular invo-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 24
        }
    },
    "763": {
        "text": "lution, with a relative risk of 7.79 versus 1.49, respec-\ntively [27].\nFigure 1. Overview of how healthcare records and individual molecular data could be used to guide stratiﬁed care. (A) Patients would be\nreferred to hospital, where a subset would be presented with a breast cancer diagnosis. For each patient, the molecular characteristics of\nthe excised tumor and their associated peri-tumoral tissues would be recorded in their medical records. (B) Information from both electronic",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 25
        }
    },
    "764": {
        "text": "health records (e.g. demographics, pathology, imaging, etc.) and molecular assessments of tumor and surrounding histologically normal tis-\nsues (e.g. genomics, transcriptomics, etc.) would be available to clinicians. (C) This information would then be used to stratify patients into\nclinically signiﬁcant groups, such as risk of recurrence, or used to help guide the clinical management of patients based on pharmacogenomic\nvulnerabilities within the residing tissues.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 26
        }
    },
    "765": {
        "text": "vulnerabilities within the residing tissues.\nField cancerization in breast cancer\n563\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\nAnother normal variation in breast tissue composition\nis reﬂected in mammographic density. It is well estab-\nlished that high mammographic density, reﬂecting an",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 27
        }
    },
    "766": {
        "text": "increased ratio of ﬁbroglandular elements to adipose tis-\nsue, is a major risk factor for breast cancer [28]. Studies\nsuggest increased collagen deposition to be a major con-\ntributor to mammographic density [29], with enhanced\nperi-ductal collagen alignment, resulting in increased tis-\nsue stiffening, potentially mediating the pro-tumorigenic\neffects of mammographic density [30].\nWhile mammographic density represents a global\nreﬂection of breast cancer risk, the direct impact of",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 28
        }
    },
    "767": {
        "text": "collagen density and organization on tumor initiation\nand progression had been shown in several model sys-\ntems [31,32], and roles for stromal activation and\nepithelial–mesenchymal transition (EMT) have been\nwidely implicated in tumorigenesis [33,34]. As with lob-\nular involution, subtle features of stromal structure are\nnot captured in routine diagnostic pathology yet may sig-\nniﬁcantly inﬂuence subsequent cancer risk.\nLinking both mammographic density and lobular",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 29
        }
    },
    "768": {
        "text": "Linking both mammographic density and lobular\ninvolution is the effect of estrogen. Mammographic den-\nsity is inﬂuenced by reproductive and menstrual factors,\nwith pregnancy and the menopause associated with a\ndecrease in density [35]. Similarly, exogenous hormone\nuse also inﬂuences breast density [36]. Studies correlat-\ning endogenous hormone levels and breast density are\ninconsistent [37,38], probably due to multiple confound-\ning factors, though a relationship is supported by the",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 30
        }
    },
    "769": {
        "text": "association between some SNPs in the ESR1 gene and\npercent mammographic density [39]. Similarly, in both\npre- and post-menopausal women, higher circulating\nlevels of estrogen metabolites are associated with signif-\nicantly higher TDLU counts and reduced lobular involu-\ntion [40]. These ﬁndings support the well-recognized\nassociation between high estrogen levels and breast can-\ncer risk and suggest that at least part of this risk is medi-\nated through modulation of breast phenotype.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 31
        }
    },
    "770": {
        "text": "ated through modulation of breast phenotype.\nThe growing digitization of histopathology and\nadvancements in machine learning approaches offer the\nopportunity to capture and quantitate a greater wealth\nof information from histological sections, as was shown\nrecently with the application of a convolutional neural\nnetwork for automated quantitation of lobular involution\nin breast biopsies [41]. This opens the potential to better\nassess ﬁeld cancerization features in apparently normal",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 32
        }
    },
    "771": {
        "text": "tissue and improve patient care.\nMolecular\nThe risk of breast cancer recurrence is determined pri-\nmarily by histopathological evaluations of the tumor,\nthe results of which are used to guide the therapeutic\nmanagement of patients. However, genetic, epigenetic,\nand transcriptomic alterations have been identiﬁed in\ncancer-adjacent tissues of many epithelial cancers,\nincluding head and neck [7,12], colorectal [13,42–44],\nskin [45,46], bladder [13,47–49], lung [14,50], prostate",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 33
        }
    },
    "772": {
        "text": "[8,13,51,52], ovarian [53,54], and breast\n[10,13–\n15,18–20,55–68]. Moreover, persistent exposure to\nenvironmental risk factors (e.g. tobacco carcinogens\nand diet) and infectious agents (e.g. human papilloma\nvirus and Helicobacter pylori infections), and the pres-\nence of physiological conditions (e.g. diabetes), can fur-\nther induce molecular insults in cancer-adjacent tissues,\nresulting in an environment primed for tumor develop-\nment [42,69–71].",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 34
        }
    },
    "773": {
        "text": "ment [42,69–71].\nEvidence suggests that HN tissue resected adjacent to\nprimary tumors can be prognostic [13,72,73]. Further-\nmore, characterization of the spatial landscape of the\ncancerized ﬁeld has shown that molecular aberrations\nexist in morphologically normal tissues excised up to\n24 cm from the primary tumor, and that the ﬁeld itself\nis composed of distinct proﬁles of plasticity [55]. These\nobservations suggest that assessing tumors in combina-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 35
        }
    },
    "774": {
        "text": "tion with their surrounding tissues could improve prog-\nnostic and therapeutic determinations.\nPan-cancer studies provide a comprehensive over-\nview of the mechanistic proﬁles and aberrant pathways\nshared in peri-tumoral tissues across cancer cohorts,\nsuch as enrichment in immune response/inﬂammation,\nmetabolism, and cell growth [13,14,48]. These large-\nscale studies use sequencing and SNP data available\nfrom The Cancer Genome Atlas (TCGA). While being",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 36
        }
    },
    "775": {
        "text": "from The Cancer Genome Atlas (TCGA). While being\nan invaluable source of large-scale sample data gener-\nated from an array of platforms (e.g. RNA-seq, DNA-\nseq, methylation arrays, CGH, and SNP arrays, etc.)\nand sample types (e.g. tissues from tumor, metastasis,\nand cancer-adjacent tissues as well as blood-derived\nnormal), TCGA does not provide information pertain-\ning to the margins of excision, thereby limiting extrap-\nolations of the spatial implications of the cancerized",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 37
        }
    },
    "776": {
        "text": "ﬁeld. Pan-cancer studies are a robust method to high-\nlight alterations shared across cancer types, but they\ncan lack the granularity offered by cancer-speciﬁc\nresearch.\nGenomic instability is a major characteristic of most\ncancers that has also been observed in peri-tumoral tis-\nsues in breast cancer [61,64,66]. Deﬁning events of\ngenomic instability include telomere attrition, allelic\nimbalance (including loss of heterozygosity), promoter\nhypermethylation, copy number alterations (CNAs),",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 38
        }
    },
    "777": {
        "text": "hypermethylation, copy number alterations (CNAs),\nand somatic mutations.\nTable 1 presents an overview of key molecular\nmarkers reported to be associated with ﬁeld canceriza-\ntion in breast cancer.\nGenetic and epigenetic aberrations in breast cancer\nTelomere attrition and allelic imbalance\nThese have been identiﬁed in both tumor and matched\ncancer-adjacent tissues [10,55,59,61,67,74]. Telomeres\nin paired HN tissue resected within 1 cm from the tumor",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 39
        }
    },
    "778": {
        "text": "margin have been reported to be signiﬁcantly shorter\nthan in paired peri-tumoral tissues resected at 5 cm\n[10]. Similarly, the frequency of allelic imbalance and\nloss of heterozygosity is reported to decrease with\nincreased distance from tumor [68]. The cancer-adjacent\nallelic\nimbalance\nproﬁles\nrevealed\nsubstantial\n564\nE Gadaleta et al\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 40
        }
    },
    "779": {
        "text": "on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\nTable 1. Molecular alterations reported to be associated with ﬁeld cancerization in breast cancer.\nMolecular alteration\nSummary of observations\nSpecimens studied\nReference\nGenomics: telomere\nattrition\nTelomere attrition was observed in both cancer cells\nand luminal epithelial cells in HN TDLUs adjacent\nto cancer\nTumor\nMatched cancer-adjacent tissue",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 41
        }
    },
    "780": {
        "text": "to cancer\nTumor\nMatched cancer-adjacent tissue\nKurabayashi\net al [74]\nGenomics: telomere\nattrition and\nunbalanced loci\nTelomere attrition and unbalanced loci were\nobserved in HN cancer-adjacent tissues, with this\ngenomic instability being a function of distance\nfrom tumor\nMatched HN tissue excised 1 cm from tumor\nmargin (TAHN-1)\nMatched HN tissue excised 5 cm from tumor\nmargin (TAHN-5)\nHealthy breast tissue from reduction mammoplasty\nHeaphy et al\n[10]\nGenomics: allelic\nimbalance",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 42
        }
    },
    "781": {
        "text": "Heaphy et al\n[10]\nGenomics: allelic\nimbalance\nAllelic imbalance in matched HN microdissected\nbreast TDLUs from breast cancer patients and\nBRCA1 mutation carriers was three-fold greater\nthan in the reduction mammoplasty control group\nHN microdissected breast TDLUs from sporadic\nbreast cancer patients (precise distance from\ntumor is indeterminate)\nHN microdissected breast TDLUs from BRCA1 gene\nmutation carriers\nHN microdissected breast TDLUs from reduction\nmammoplasty\nLarson et al\n[59]",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 43
        }
    },
    "782": {
        "text": "mammoplasty\nLarson et al\n[59]\nGenomics: allelic\nimbalance\nThe mean frequency of allelic imbalance was higher\nin HN tissue adjacent to the primary cancer\n(15.4%) relative to distant tissue from the same\nbreast (3.7%)\nTumor (laser-assisted microdissection)\nDCIS (laser-assisted microdissection)\nMatched disease-free tissue adjacent to the\nprimary tumor (laser-assisted microdissection)\nMatched HN distant tissue (laser-assisted\nmicrodissection)\nEllsworth\net al [68]\nGenomics: loss of\nheterozygosity",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 44
        }
    },
    "783": {
        "text": "et al [68]\nGenomics: loss of\nheterozygosity\nNormal breast epithelial cells obtained from women\nwhose risk of breast cancer had been calculated\nusing the Gail model identiﬁed associations\nbetween frequency of loss of heterozygosity and\npatient risk, with a lower risk score of 16.7%\nreported in patients without loss of heterozygosity,\ncompared with 22.9% if loss of heterozygosity is\npresent\nFine needle aspirations from asymptomatic women\nwith known Gail risk score\nEuhus et al\n[63]",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 45
        }
    },
    "784": {
        "text": "with known Gail risk score\nEuhus et al\n[63]\nGenomics: differential\nmethylation at CpG loci\nSigniﬁcantly more CpG loci were identiﬁed as\ndifferentially methylated between contralateral-\nnormal and tumor (63 271 CpG loci q < 0.01) than\nbetween ipsilateral-normal and tumor (38 346\nCpG loci q < 0.01). Furthermore, differential\nmethylation in ipsilateral-normal relative to\ncontralateral-normal tissue (9562 CpG loci\np < 0.01) was also observed\nTumor\nMatched ipsilateral HN tissue excised ≥3 cm from",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 46
        }
    },
    "785": {
        "text": "Matched ipsilateral HN tissue excised ≥3 cm from\ntumor margin\nMatched contralateral HN tissue from contralateral\nbreast\nMuse et al\n[65]\nGenomics: genome-wide\nDNA methylation and\ncopy number calls\nIdentiﬁed hypervariable levels of DNA methylation\nand copy number alterations (CNAs) in normal-\nadjacent tissue (relative to tissue from healthy\nbreast samples), which then became further\nenriched in the matched tumors. Furthermore,\nchanges in DNA methylation in normal cells were",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 47
        }
    },
    "786": {
        "text": "changes in DNA methylation in normal cells were\nmore predictive of breast cancer status than their\nCNV counterparts\nTumor\nUnmatched cancer-adjacent tissue excised ≥3 cm\nfrom tumor margin\nHealthy breast from reduction mammoplasty\nTumor (TCGA)\nMatched cancer-adjacent tissue excised ≥2 cm\nfrom tumor margin (TCGA)\nGao et al\n[64]\nGenomics:\nhypermethylation of\nRUNX3\nNormal tissue in close proximity to the primary tumor\nexhibited hypermethylation of RUNX3\nTumor",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 48
        }
    },
    "787": {
        "text": "exhibited hypermethylation of RUNX3\nTumor\nMatched HN tissue excised 1 cm from visible tumor\nboundary (N1)\nMatched HN tissue excised 2 cm from visible tumor\nboundary (N2)\nMatched HN tissue excised 3 cm from visible tumor\nboundary (N3)\nMatched HN tissue excised 4 cm from visible tumor\nboundary (N4)\nHealthy breast tissue from reduction mammoplasty\nCheng et al\n[75]\nGenomics:\nhypermethylation and\nallelic imbalance of\nRASSF1A promoter\nregion\nFour locations (1, 2, 3, and 4 cm) in HN breast tissue",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 49
        }
    },
    "788": {
        "text": "from the affected and contralateral breast of\nbreast cancer patients identiﬁed hypermethylation\nin the ipsilateral samples relative to the\ncontralateral with the effect being more\npronounced in the vicinity of tumor\nTumor\nMatched HN tissue excised 1 cm from tumor\nmargin (TAHN-1)\nMatched HN tissue excised 2 cm from tumor\nmargin (TAHN-2)\nMatched HN tissue excised 3 cm from tumor\nmargin (TAHN-3)\nMatched HN tissue excised 4 cm from tumor\nmargin (TAHN-4)",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 50
        }
    },
    "789": {
        "text": "margin (TAHN-4)\nHealthy breast tissue from reduction mammoplasty\nYan et al\n[61]\n(Continues)\nField cancerization in breast cancer\n565\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\nTable 1. Continued\nMolecular alteration\nSummary of observations\nSpecimens studied\nReference\nGenomics: promoter\nmethylation",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 51
        }
    },
    "790": {
        "text": "Reference\nGenomics: promoter\nmethylation\nRARβ2 was observed hypermethylated with cancer-\nadjacent tissues (32%) relative to unaffected\nbreast (9%). Promoter methylation of RASSF1A\nand APC occurred more frequently in breast tissues\nfrom unaffected women at high risk for breast\ncancer than in tissues from women at\nlow/intermediate risk of breast cancer\nTumor (ﬁne needle aspiration)\nMatched benign tissue (ﬁne needle aspiration).\nSamples taken from ipsilateral breast in",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 52
        }
    },
    "791": {
        "text": "Samples taken from ipsilateral breast in\nquadrant opposite to cancer, with precise\ndistance from tumor indeterminate\nUnaffected patients (ﬁne needle aspiration)\nLewis et al\n[19]\nGenomics: copy number\nalterations and loss of\nheterozygosity\nIdentiﬁcation of tissue-speciﬁc CNAs in cancer-\nadjacent tissues from solid tumors, including\nbreast invasive carcinoma\nTumor (TCGA)\nMatched cancer-adjacent tissue excised ≥2 cm\nfrom tumor margin (TCGA)\nJakubek et al\n[48]\nGenomics: copy number\nalterations",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 53
        }
    },
    "792": {
        "text": "[48]\nGenomics: copy number\nalterations\nStudy of 282 females with sporadic breast cancer\nidentiﬁes 108 patients (38.3%) with cancer-\nassociated CNAs in at least one aberrant cancer-\nfree breast tissue\nTumor\nMatched HN tissue (Polish cohort, Bydgoszcz)\nexcised 4–8 cm from tumor margin\nMatched HN tissue (Swedish cohort, Falun) excised\nat variable distances from tumor margin\nMatched HN tissue (Polish cohort, Krakow) excised\nat variable distances from tumor margin\n(maximum 15 cm)",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 54
        }
    },
    "793": {
        "text": "(maximum 15 cm)\nMatched HN (tissue Polish cohort, Gdansk) excised\nat variable distances from tumor margin\nHealthy breast tissue from reduction mammoplasty\nForsberg\net al [55]\nGenomics and\ntranscriptomics:\nproﬁling\nBreast epithelial samples obtained from ducts\nleading to breast carcinomas and matched\nsamples from ducts on the opposite side of the\nnipple. Determined increased mRNA perturbation\nin proximity to the primary tumor, with these\naberrations not being explained by CNAs\nTumor",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 55
        }
    },
    "794": {
        "text": "aberrations not being explained by CNAs\nTumor\nMatched HN tissue taken from duct between tumor\nand nipple (D1)\nMatched epithelial sample closest to tumor with\nsome samples exhibiting atypical hyperplasia\ntaken from duct between tumor and nipple (D2)\nMatched HN control taken from the duct on the\nother side of the nipple within the same breast\n(O1)\nAbdalla et al\n[66]\nGenomics and\ntranscriptomics:\nproﬁling\nAbout 40% of HN cancer-adjacent tissues harbored\ngenomic defects in DNA copy number (10%),",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 56
        }
    },
    "795": {
        "text": "genomic defects in DNA copy number (10%),\nsequence, methylation, or in RNA sequence\n(>40%). These molecular alterations were not\nassociated with signiﬁcant differences in overall\nsurvival\nTumor (TCGA)\nMatched cancer-adjacent tissue excised ≥2 cm\nfrom tumor margin (TCGA)\nTroester et al\n[72]\nTranscriptomics and\nproteomics: proﬁling\nTranscriptomic and proteomic analysis of breast\ntumors and matched HN tissues resected proximal\nto (<2 cm) and distant from (5–10 cm) the primary",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 57
        }
    },
    "796": {
        "text": "to (<2 cm) and distant from (5–10 cm) the primary\ntumor, using tissues from reduction\nmammoplasties as baseline. Four distinct\ntranscriptomic subtypes are identiﬁed within\nmatched normal tissues: immune; matrisome/EMT,\nnon-coding enriched and metabolic, with the\nlatter associated with poor prognosis (p < 0.001,\nHR 6.1)\nTumor\nMatched HN tissue resected <2 cm from primary\ntumor (proximal)\nMatched HN tissue resected 5–10 cm from primary\ntumor (distal)\nProphylactic mastectomy",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 58
        }
    },
    "797": {
        "text": "tumor (distal)\nProphylactic mastectomy\nHealthy breast tissue from reduction mammoplasty\nTumor (TCGA)\nMatched cancer-adjacent tissue excised ≥2 cm\nfrom tumor margin (TCGA)\nGadaleta\net al [57]\nTranscriptomics: proﬁling\nPan-cancer study in which proﬁles from cancer-\nadjacent tissues were deemed to represent an\nintermediate state between tumor and healthy,\nwith both tumor-associated and unique features\nobserved in cancer-adjacent tissues.\nTumor (TCGA)\nMatched cancer-adjacent excised ≥2 cm from",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 59
        }
    },
    "798": {
        "text": "Matched cancer-adjacent excised ≥2 cm from\ntumor margin (TCGA)\nHealthy breast from autopsy (GTEx)\nAran et al\n[13]\nTranscriptomics: proﬁling\nPan-cancer study in which proﬁles from cancer-\nadjacent tissues were found to provide more\ninformation about patient survival than tumors\nTumor (TCGA)\nMatched HN excised ≥2 cm from tumor margin\n(TCGA)\nHuang et al\n[14]\nTranscriptomics:\nmolecular subtypes\nTranscriptomic analysis of two breast cancer datasets\nobserved intrinsic tumor subtypes to be reﬂected",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 60
        }
    },
    "799": {
        "text": "observed intrinsic tumor subtypes to be reﬂected\nin HN cancer-adjacent tissues, with this\nobservation not dependent on distance from\nprimary tumor\nTumor (PWBCS cohort)\nMatched HN tissue excised <2 cm from tumor\nmargin (PWBCS cohort)\nTumor (TCGA)\nMatched cancer-adjacent tissue excised ≥2 cm\nfrom tumor margin (TCGA)\nMatched HN tissue excised <2 cm from tumor\nmargin (peri-tumoral, NBS cohort)\nMatched HN tissue excised >2 cm from tumor\nmargin (remote, NBS cohort)\nCasbas-\nHernan\ndez et al\n[62]",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 61
        }
    },
    "800": {
        "text": "Casbas-\nHernan\ndez et al\n[62]\nTranscriptomics: proﬁling\nTumor\n(Continues)\n566\nE Gadaleta et al\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\nconcordance with those of tumor, implying clonal evolu-\ntion [10,56].\nThe Gail model is a predictive breast cancer risk\nassessment algorithm that uses demographic and clinical",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 62
        }
    },
    "801": {
        "text": "data to estimate a woman’s absolute risk of developing\nbreast cancer within speciﬁc time frames (up to the age\nof 90 years), with a score exceeding 1.67% being\ndeﬁned as high risk [77–79]. Euhus et al conducted a\nstudy in which 30 asymptomatic women, whose risk of\nbreast cancer had been calculated using the Gail model\n(11 with normal cytology and 19 with proliferative\ncytology), underwent breast epithelial cell sampling via\nﬁne-needle aspirate. Associations between the frequency",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 63
        }
    },
    "802": {
        "text": "of loss of heterozygosity and cancer risk were reported,\nwith the patient’s lifetime risk score increasing from\n16.7% to 22.9% if loss of heterozygosity was pre-\nsent [63].\nPromoter hypermethylation\nAberrant DNA methylation has been observed in tissues\nfrom tumor and matched HN tissues, with the methylo-\nmic\nlandscape\nof\ncancer-adjacent\ntissue\nbeing\nepigenetically distinct from that of tissue extracted from\nthe contralateral breast [65]. This observation is sup-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 64
        }
    },
    "803": {
        "text": "ported by inter-individual studies in which the cancer-\nadjacent tissues are found to be more highly methylated\ncompared with healthy control reduction mammoplasty\nsamples [64].\nPromoter region hypermethylation has been observed in\nboth cancer-adjacent tissues and in situ breast carcinomas\n[18,19,61,64,75]. Hypermethylation of the RASSF1A pro-\nmoter was observed in both tumor and cancer-adjacent tis-\nsues. Separately, hypermethylation of promoters, including",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 65
        }
    },
    "804": {
        "text": "RASSF1A, was found to be indicative of increased risk of\nbreast cancer: present in 70% of benign breast tissues from\nwomen at high risk (Gail risk index ≥2) compared with\n29% of women at low/intermediate risk [63].\nCopy number aberrations (CNAs)\nWhile CNAs have been identiﬁed in HN tissues\nadjacent to cancer, the prevalence and degree of these\nperturbations in peri-tumoral tissues are not as extensive\nas other genomic and transcriptomic events and they do\nnot\nappear\nto\nconfer\npredictive",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 66
        }
    },
    "805": {
        "text": "not\nappear\nto\nconfer\npredictive\ncapabilities\nTable 1. Continued\nMolecular alteration\nSummary of observations\nSpecimens studied\nReference\nTranscriptomic analyses stratiﬁed proﬁles from HN\ntissues adjacent to breast cancer or ductal\ncarcinoma in situ (DCIS) data into two\nextratumoral subtypes: active and inactive, with\nthe active subtype signiﬁcantly associated with\noverall survival in estrogen receptor (ER)-positive\npatients (HR 2.5, p = 0.062) and hormone-treated\npatients (HR 2.6, p = 0.045)",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 67
        }
    },
    "806": {
        "text": "patients (HR 2.6, p = 0.045)\nDCIS\nMatched HN tissue excised <2 cm from tumor/DCIS\nmargin (peri-tumoral)\nMatched HN tissue excised >2 cm from tumor/DCIS\nmargin (remote)\nRom\u0002an-\nPérez\net al [60]\nTranscriptomics: TERT\ngene expression\nNormal tissue proximal to breast tumors were found\nto contain a population of human mammary\nepithelial cells (HMECs) that expressed human\ntelomerase reverse transcriptase (hTERT)\nexpression levels similar to HMECs within the",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 68
        }
    },
    "807": {
        "text": "expression levels similar to HMECs within the\ntumor. hTERT expression decreased in HMECs from\nHN tissues at increased distance from tumor\nTumor\nMatched HN tissue excised 1 cm from tumor\nmargin (TAHN-1)\nMatched HN tissue excised 3 cm from tumor\nmargin (TAHN-3)\nMatched HN tissue excised 5 cm from tumor\nmargin (TAHN-5)\nHealthy breast tissue from reduction mammoplasty\nTrujillo et al\n[15]\nTranscriptomics: proﬁling\nComparison of the gene expression proﬁles of",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 69
        }
    },
    "808": {
        "text": "Comparison of the gene expression proﬁles of\nmicrodissected HN epithelium from tissues of\npatients with breast cancer, at high risk of breast\ncancer, and from reduction mammoplasty\nidentiﬁed deﬁning features within the HN tissues\nof patients with breast cancer relative to reduction\nmammoplasty\nHN epithelium from breast cancer patients\nHN epithelium from prophylactic mastectomy\nHN epithelium from reduction mammoplasty\nGraham et al\n[58]\nTranscriptomics: proﬁling",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 70
        }
    },
    "809": {
        "text": "Graham et al\n[58]\nTranscriptomics: proﬁling\nTranscriptomic proﬁling and immunohistochemistry\ndiscerned a signature of differential gene\nexpression that discriminated between paired\nbreast tissues excised at resection margins of 1\nand 5 cm from the primary tumor\nTumor\nMatched HN tissue excised 1 cm from tumor\nmargin (TAHN-1)\nMatched HN tissue excised 5 cm from tumor\nmargin (TAHN-5)\nHealthy breast tissue from reduction mammoplasty\nTrujillo et al\n[73]\nTranscriptomics: proﬁling",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 71
        }
    },
    "810": {
        "text": "Trujillo et al\n[73]\nTranscriptomics: proﬁling\nGene expression proﬁling of normal-appearing TDLUs\nof ER-positive breast cancer patients (n = 14) and\nof reduction mammoplasty (n = 15) identiﬁed\n105 differentially expressed genes. Investigations\nidentiﬁed cancer-associated alterations in the\nnormal-appearing TDLUs relative to TDLUs from\nreduction mammoplasty\nHN microdissected HN breast TDLUs adjacent to\nuntreated ER-positive breast cancer\nHN microdissected HN breast TDLUs from reduction",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 72
        }
    },
    "811": {
        "text": "HN microdissected HN breast TDLUs from reduction\nmammoplasty\nTripathi et al\n[76]\nField cancerization in breast cancer\n567\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\n[55,61,64,66,72]. Furthermore, cancer-adjacent tissues\nprimarily exhibit tumor-associated CNA proﬁles, with",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 73
        }
    },
    "812": {
        "text": "gains in established oncogenes and growth factor recep-\ntors, such as ERBB2, EGFR, and FGFR1 [48,55].\nMutations\nCancer-associated somatic mutation proﬁles appear\nmore frequent relative to CNAs in cancer-adjacent tis-\nsues. Troester et al reported 25% of cancer-adjacent\nsamples in TCGA to have moderate-to-high levels of\ntumor-like somatic mutations relative to CNAs in 10%\nin the triplet samples analysed, although the variant\nallele fraction was low (typically less than 5%), which",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 74
        }
    },
    "813": {
        "text": "was consistent with matched tumor cellularity [72]. Sim-\nilarly, mutation hotspots in speciﬁc genes, including\nZNF143, ALDOA, and LEPROTL1, have also been\nshown to reﬂecte proximity to the primary tumor [66].\nThe occurrences of genomic instability presented sug-\ngest that local peri-tumoral tissues provide a permissive\nenvironment for tumorigenesis and progression, with\nattenuation of this effect with increased distance from\nthe primary tumor.\nTranscriptomic aberrations in breast cancer",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 75
        }
    },
    "814": {
        "text": "Transcriptomic aberrations in breast cancer\nCancer-adjacent tissues are often considered to represent\nan intermediate state between tumor and healthy breast tis-\nsue, with their transcriptomic proﬁles sharing features of\nboth. However, distinct gene expression characteristics\ndeﬁning HN tissues and their associated subtypes suggest\nthat they represent a distinct entity [13,15,57,58,60,62,72].\nGlobal transcriptomic analyses have linked genes",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 76
        }
    },
    "815": {
        "text": "Global transcriptomic analyses have linked genes\ndifferentially expressed in HN peri-tumoral tissues to a\nrange of deregulated cancer-associated pathways, includ-\ning wound healing, extracellular matrix remodelling,\naltered metabolism, and EMT [13,15,57,58,60,72]. Spe-\nciﬁc prognostic signatures have consequently been devel-\noped [5,57,60,72]. Rom\u0002an-Pérez et al identiﬁed distinct\nactive and inactive transcriptomic subtypes in cancer-adja-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 77
        }
    },
    "816": {
        "text": "cent tissues from estrogen receptor-positive patients, with\nthe former correlating with poor outcome [60]. This active\nmRNA/miRNA signature was also identiﬁed in 40% of\nmatched cancer-adjacent breast tissues (n = 142) from\nthe TCGA breast cohort, with this subtype associated with\nworse poor 10-year survival in estrogen receptor-positive\npatients [72]. Moreover, analysis of TCGA data revealed\nthat gene expression proﬁles of peri-tumoral tissues corre-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 78
        }
    },
    "817": {
        "text": "late more closely with clinical outcome measures than their\ncorresponding tumors [14].\nSeveral transcriptomic studies also report that the\nnumber and degree of aberrations are dependent on dis-\ntance from the primary tumor [13,15,66], in concordance\nwith ﬁndings on genomic instability. However, we iden-\ntiﬁed four distinct transcriptomic subtypes within\nmatched\nperi-tumoral\ntissues\nexcised\nadjacent\nto\n(<2 cm) and distal from (5–10 cm) the primary breast",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 79
        }
    },
    "818": {
        "text": "tumor, which were found to be independent of distance\nfrom tumor. Most importantly, we found the metabolic\nsubtype, characterized by deregulation of mediators\ninvolved in metabolic processes, lipid and cholesterol\nmetabolism, and hypoxia-related events, to be signiﬁ-\ncantly associated with poor prognosis [hazard ratio\n(HR) 6.1]. We also observed a matrisome/EMT subtype\nthat was enriched in matrisomal elements; however, the\nsmall sample size and differing sampling design of the",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 80
        }
    },
    "819": {
        "text": "TCGA validation cohort prevented meaningful conclu-\nsions as to the clinical implications of this group.\nThat stromal alterations may contribute to a ﬁeld can-\ncerization effect is supported by Trujillo et al, who ana-\nlysed HN breast tissue taken 1 and 5 cm from invasive\nbreast cancer and compared the gene expression proﬁle\nwith reduction mammoplasty tissue [73]. They identiﬁed\na gene expression signature reﬂecting extracellular\nmatrix remodelling, ﬁbrosis, and EMT, which was more",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 81
        }
    },
    "820": {
        "text": "prevalent in tissues closest to the tumor and absent in\nreduction mammoplasty tissue. Similarly, the active\nmiRNA/RNA subtype identiﬁed in HN tissues repre-\nsented processes associated with activated stroma or\nEMT [60,72].\nTaken together, these studies suggest that the molecu-\nlar proﬁles of cancer-adjacent tissues both reﬂect those\nof the tumor and possess distinct intrinsic features. Sig-\nniﬁcant heterogeneity in the cancerized ﬁeld is observed,",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 82
        }
    },
    "821": {
        "text": "with clear clinically relevant molecular events linked\ndirectly to prognosis occurring even distal from the pri-\nmary tumor.\nFurther study is required to determine the extent to\nwhich molecular aberrations contribute to the precondi-\ntioned milieu for tumorigenesis. With genomic and tran-\nscriptomic\nevents\nbeing\ninherently\nintertwined,\na\nprognostic tool incorporating a combination of these\nevents will likely provide the greatest predictive value.\nChallenges for research",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 83
        }
    },
    "822": {
        "text": "Challenges for research\nAccess to well-annotated specimens from biobanks\nWell-annotated tumor and peri-tumoral samples with\ncomprehensive clinical data are key to fully understand-\ning the landscape of ﬁeld cancerization. Here, the role of\nbiobanks is crucial. Historically, these were localized\nspecimen repositories set up for the requirements of spe-\nciﬁc research projects. As the infrastructures developed,\nbiobanks soon\nbecame national\nand international",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 84
        }
    },
    "823": {
        "text": "biobanks soon\nbecame national\nand international\nresources designed to accelerate translational research\nefforts. Specimens supplied by biobanks are the corner-\nstone to generating molecular data and in allowing bio-\nbanks to evolve away from a narrow specimen-focused\napproach towards a data-driven future. However, for\nbiobanks to reach their full potential, they must provide\naccess to high-quality clinical samples linked to compre-\nhensive clinical, spatial, and molecular information.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 85
        }
    },
    "824": {
        "text": "One biobank that has recognized and anticipated the\nimportance of complete annotation and data legacy is\nthe Breast Cancer Now Tissue Bank (BCNTB) [80].\nThe BCNTB ensures that pathologists and researchers\nwork side-by-side to provide well-annotated specimens\nfrom an extensive range of tissues and body ﬂuids. These\ninclude tumors and tissues taken at speciﬁed distances\n568\nE Gadaleta et al\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 86
        }
    },
    "825": {
        "text": "on behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\nfrom margins of resection (adjacent <2 cm and surround-\ning 5–10 cm), which allow researchers to map the spatial\ncharacteristics of the cancerized ﬁeld. Furthermore, the\nBCNTB has implemented a data return policy in which\nresearchers are required to return research data generated\nfrom projects using BCNTB samples, meaning that each",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 87
        }
    },
    "826": {
        "text": "set of specimens gains additional layers of molecular and\npathological data. This then becomes available to subse-\nquent researchers, allowing the knowledge to build up\nincrementally, and is available to query from a dedicated\nBCNTB Analytics Hub [81].\nBiobanks need to provide an active response to the\nchanging needs of researchers and anticipate specimen\nand data requirements, thus ensuring that these are\nexploited to their full clinical potential.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 88
        }
    },
    "827": {
        "text": "exploited to their full clinical potential.\nCoding of ﬁeld cancerization concepts in electronic\nhealth records (EHRs)\nThe ability to access and interpret all information within\nEHRs is a prerequisite to understand disease processes,\nand to tailor treatments and health services effectively\nand safely for patient beneﬁt. NHS England has\nannounced that it will fund an initiative to audit metastatic\nbreast cancer to provide accurate information about",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 89
        }
    },
    "828": {
        "text": "patients living with this disease and reform how meta-\nstatic breast cancer is currently coded in EHRs [82],\nwhich will increase the understanding of recurrence and\nthe patient’s clinical journey. While EHRs currently\ninclude information pertaining to the status of the re-\nsection margins, there are few molecular data available\nrelating to this margin and its surrounding tissues.\nGenomics initiatives, such as the 100,000 Genomes\nProject, allow for a new branch of genomic medicine to",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 90
        }
    },
    "829": {
        "text": "serve the NHS, helping to realize the promise of personal-\nized medicine and driving cutting-edge research. If ﬁeld\ncancerization is responsible for recurrence, then limiting\nsequencing to tumors alone could prove a missed oppor-\ntunity to elucidate whether the cancerized ﬁeld arises from\ntumor inﬂuence, or whether it is, itself, an independent\nentity that drives tumorigenesis and recurrence. Introduc-\ning coding concepts, both histological and molecular, for",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 91
        }
    },
    "830": {
        "text": "ﬁeld cancerization into EHRs to complement histological\nassessments could drive new opportunities for patient-\ncentered research and information.\nBalancing the beneﬁts and harm of deﬁning a high-\nrisk cancerized ﬁeld\nBreast cancer screening programs enable the detection of\nasymptomatic breast cancer, allowing for early interven-\ntion and resulting in reductions of up to 20% in absolute\nmortality in the women screened [83]. However, screen-\ning programs exacerbate overdiagnosis, detecting indo-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 92
        }
    },
    "831": {
        "text": "lent cancers that would not have given rise to clinically\nrelevant disease [83–85].\nEstimates of overdiagnosis vary from near zero to\n50%, with these patients subject to unnecessary treat-\nment, increased psychological stress, and potential\nadverse reactions and complications associated with\ntreatment. Variations in these estimates are dependent\non the deﬁnition of overdiagnosis applied. While the\nnumerator represents the number of patients overdiag-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 93
        }
    },
    "832": {
        "text": "nosed, the denominator varies between studies depend-\ning how this value is deﬁned: by screening alone;\nduring the whole screening period; during both the\nscreening and the interval period; or during the screening\nperiod and for the remainder of the individual’s life-\ntime [83,84].\nLongitudinal studies, integrating molecular, patholog-\nical, and epidemiological data with corresponding\npatient clinical records, offer researchers the opportunity",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 94
        }
    },
    "833": {
        "text": "to characterize molecularly aberrant ﬁelds that generate a\npro-tumorigenic environment. They could also help\nidentify patients, in whom these ﬁelds are present, who\nwill progress to cancer, which will be essential to mini-\nmize overdiagnosis. Furthermore, these investigations\nalso have the potential to provide insights into whether\nthe deﬁning molecular and phenotypic characteristics\nof a cancerized ﬁeld categorized as high risk can be mod-\nulated by modiﬁcations to environmental factors.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 95
        }
    },
    "834": {
        "text": "ulated by modiﬁcations to environmental factors.\nThe added value of molecular pathological\nepidemiology\nTo better understand the cancerized ﬁeld and its implica-\ntion for breast cancer, researchers need to explore\nbeyond the boundaries of traditional methods. Novel\nlines of evidence point towards the beneﬁts of integrat-\ning molecular pathology and epidemiology – termed\nmolecular pathological epidemiology – to enable\nresearchers to link factors such as environmental expo-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 96
        }
    },
    "835": {
        "text": "sures and host genetics to pathologic features [86–91].\nEndogenous and exogenous factors (exposures) can\ncontribute to speciﬁc disease processes and heterogene-\nity of neoplastic disease: for instance, antibiotic-induced\nmicrobial dysbiosis in the gut is associated with tumor\nprogression [92–96]. Emerging evidence of the relation-\nship between dysbiosis and breast cancer has uncovered\nmicrobial signatures providing type-speciﬁc communi-\nties of organisms distinct to each breast cancer type",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 97
        }
    },
    "836": {
        "text": "[97,98]. Differences in breast microbiota DNA proﬁles\nfrom tumors relative to paired cancer-adjacent tissues\nand healthy controls have also been reported, with the\nmicrobial proﬁle of cancer-adjacent tissues exhibiting\ngreater similarities with their corresponding tumor than\nwith healthy controls [93,97,98].\nWhile it is possible that these studies indicate that dys-\nbiosis inﬂuences the environment surrounding a tumor,\npotentially modulating the risk of breast cancer, the",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 98
        }
    },
    "837": {
        "text": "reverse may also be true, in that the cancerized ﬁeld itself\ncreates a niche favoring differential microbiome compo-\nsition, which in turn may inﬂuence progression of the\ndisease.\nThe ﬁeld of molecular pathological epidemiology\nallows for the examination of complex relationships\nbetween a compendium of exposures. For instance, pos-\nitive associations have been reported between increased\nbody mass index, hip-to-waist ratio and reduced physi-\ncal activity, and increased risk of breast cancer",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 99
        }
    },
    "838": {
        "text": "cal activity, and increased risk of breast cancer\nField cancerization in breast cancer\n569\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\n[99–101]. Similarly, epigenetic modiﬁcations have been\nfound to be inﬂuenced by environmental exposures in\nwomen at high risk of breast cancer relative to healthy\ncontrols [12,90,102].",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 100
        }
    },
    "839": {
        "text": "controls [12,90,102].\nWhile genetic and environmental exposures are\nknown to contribute to breast cancer risk, the magnitude\nof interaction between these remains undeﬁned for many\ngenes [103–107]. However, there is evidence that host\nand environmental factors can modify the penetrance\nin germline BRCA1/2 mutation carriers. Increased fat\nmass and dysmetabolism are recognized to promote\nbreast cancer risk in the general population but there is",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 101
        }
    },
    "840": {
        "text": "evidence to indicate a greater impact in BRCA2 carriers\n[108], and diet has also been shown to inﬂuence BRCA\npenetrance [109]. It has also been shown that smoking\nfor at least 5 years prior to a ﬁrst pregnancy increases\nthe risk of developing breast cancer in BRCA1/2 muta-\ntion carriers [110]. A recent review outlines the com-\nplexity of gene–environment interactions in BRCA1/2\nmutation carriers [111].\nMolecular pathological epidemiology studies that inte-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 102
        }
    },
    "841": {
        "text": "grate data from the clinical records of patients will help to\nclarify the causal relationships between environmental\nexposures, pathologic interpretations, molecular aberra-\ntions, and disease evolution within the cancerized ﬁeld.\nBiobanks can facilitate such research by implement-\ning protocols to gather information pertaining to lifestyle\nand environmental exposures, as well as procedures for\nthe collection, management, storage, and distribution\nof longitudinal microbiota specimens.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 103
        }
    },
    "842": {
        "text": "of longitudinal microbiota specimens.\nDesignating appropriate control cohorts\nCollecting a germline genetic proﬁle from buffy coat\nsamples is common practice in DNA sequencing studies.\nHowever, it is less common to have matched tissue con-\ntrol samples for comparative transcriptomics, where spa-\ntial and temporal effects are signiﬁcant confounders.\nThat the ﬁeld of HN peri-tumoral tissues may have\nundergone a molecular insult is an inherent problem in",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 104
        }
    },
    "843": {
        "text": "study design. Using cancer-adjacent tissues to represent\na ‘healthy’ control could provide a false representation\nof baseline gene expression, leading to inaccurate tumor\nproﬁles, as well as limiting the opportunity to order\ntumor-associated molecular alterations chronologically.\nDesignation of an appropriate control cohort is depen-\ndent on the objective of a study. While cancer-adjacent\nsamples may have acquired molecular alterations, use\nof contralateral tissues could prove invaluable when",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 105
        }
    },
    "844": {
        "text": "conducting intra-individual and site-speciﬁc compari-\nsons. Furthermore, pan-cancer studies have reported that\nchanges in gene expression between paired tumor and\nadjacent tissues improve the forecast of disease aetiol-\nogy and patient outcome more than tumor alone [14].\nThe use of a control cohort of breast tissue from\nwomen without breast cancer (nor at known increased\nrisk of breast cancer), such as tissue from reduction\nmammoplasties, is often preferred. However, their use",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 106
        }
    },
    "845": {
        "text": "introduces inherent variability into analyses, particularly\nwhen attempting to determine subtle patient-speciﬁc\nvariations. This heterogeneity can be minimized by\nadopting stringent pre-deﬁned inclusion criteria, such\nas demographic (age, ethnicity, gender) or clinical (age\nof menarche, menopausal status, parity, BMI) and life-\nstyle features (smoking, contraceptive use), matching\nthose of the breast cancer cohort.\nIt is important to elucidate alterations within the can-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 107
        }
    },
    "846": {
        "text": "cerized ﬁeld as well as their clinical implications because\nit is these cancer-adjacent tissues that will remain unre-\nsected in commonly accepted guidelines and in breast\nconservation therapy. Researchers need to assess the\nstrengths and weaknesses of each candidate set of con-\ntrols, to make an informed decision and delineate appro-\npriate baseline cohorts. In addition, they also need to\nhave access to specimens or data with complete clinical",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 108
        }
    },
    "847": {
        "text": "and surgical information from independent cohorts for\nvalidation.\nExploiting the peri-tumoral ﬁeld for patient beneﬁt\nNatural processes associated with ageing, such as meth-\nylation and a lifetime exposure to endogenous and exog-\nenous factors, cause genomic changes that resemble\nthose of early cancer [9,71,112,113]. However, treating\nthe whole body as a cancerized ﬁeld has limited clinical\nutility. Similarly, germline breast cancer susceptibility",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 109
        }
    },
    "848": {
        "text": "gene variants, such as BRCA1 and BRCA2, are not con-\nsidered to contribute towards the traditional deﬁnition\nof a cancerized ﬁeld [11].\nWhile the cancerized ﬁeld represents a promising\ntherapeutic target, it is important to acknowledge that\npresence of the ﬁeld alone will not determine progres-\nsion to cancer or propensity to metastasize. To avoid\nthe pitfalls of overdiagnosis and overtreatment, we need\nto understand the underlying mechanism and molecular",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 110
        }
    },
    "849": {
        "text": "events and be able to differentiate between changes that\ndrive predisposed lineages further down the tumorigenic\nevolutionary pathway and those changes that have min-\nimal cancerization effect.\nCurrently, invasive procedures, such as colonoscopy\nand cervical cytology, tend to be employed for the early\ndetection of cancer. Non-invasive detection strategies\nusually rely on detecting cancer-speciﬁc biomarkers,\nwhich are developed for their ability to differentiate",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 111
        }
    },
    "850": {
        "text": "between tumor and normal tissues. Many of these strate-\ngies detect the presence of late-stage cancer or metastasis,\nwith few able to detect early-stage disease [114–116].\nTwo major liquid biopsy studies, CancerSEEK and\nGRAIL, support the premise that circulating tumor\nDNA is a promising biomarker for diagnostic screening\nfor sporadic cancer. CancerSEEK analysed mutated\nDNA and eight standard protein biomarkers in 1005\npatients previously diagnosed with stage I–III colorectal,",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 112
        }
    },
    "851": {
        "text": "breast, gastric, liver, oesophageal, ovarian, and pancre-\natic cancers [114]. GRAIL applied targeted whole-\ngenome bisulphite sequencing of plasma DNA to iden-\ntify distinct methylation patterns associated with speciﬁc\ncancers to detect a number of those cancers early and\n570\nE Gadaleta et al\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 113
        }
    },
    "852": {
        "text": "J Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\nsimultaneously provide information about the organ of\norigin [116]. This prospective multi-center case–control\nstudy comprised 6689 individuals, split one third with\ncancer and two thirds without cancer, representing more\nthan 50 primary cancer types across all clinical stages.\nWhile both studies exhibit speciﬁcities of more than\n99%, sensitivity was proven to be dependent on stage\n(CancerSEEK, \u000140% in stage I disease to approxi-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 114
        }
    },
    "853": {
        "text": "(CancerSEEK, \u000140% in stage I disease to approxi-\nmately 80% in stage III disease; GRAIL, \u000118% in stage\nI disease to \u000191% in stage IV disease).\nCirculating tumor DNA has been shown to recapitu-\nlate a subset of mutational signatures identiﬁed in the\nprimary tumor and to have good correlation with tumor\nburden in solid tumors [117–122]. Breast cancer studies\nhave reported elevated circulating tumor DNA burden to\nbe a strong predictive marker of disease progression,",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 115
        }
    },
    "854": {
        "text": "decreased progression-free and overall survival, and\npoor response to treatment [118,123–126]. However,\nalmost no studies into solid tumors have attempted to\ndetect distinct cancer-adjacent proﬁles in liquid biopsies.\nWu et al conducted a study on 27 patients with head\nand neck squamous carcinoma [12]. The authors\nobserved mutations unique to cancer-adjacent tissues in\npost-operative liquid biopsies from blood and saliva\nsamples from a subset of patients. Moreover, the study",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 116
        }
    },
    "855": {
        "text": "reported that integrating data on both cancer-adjacent-\nspeciﬁc\nmutations\nand\ntumor-speciﬁc\nmutations\nincreased the sensitivity of post-operative monitoring\nto predict relapse. These observations raise the question\nof whether treatment and predictive models could bene-\nﬁt from insights gained from distinct signatures originat-\ning from the cancerized ﬁeld.\nStudies indicating the importance of HN cancer-\nadjacent tissues in the context of their ability to prognos-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 117
        }
    },
    "856": {
        "text": "ticate outcome and response to treatment highlight the\nrequirement\nfor\nfurther\ninvestigations\n[12,57,63].\nUnderstanding the intricacies of ﬁeld cancerization and\ndeveloping predictive biomarkers that exploit the char-\nacteristics of this cancerized ﬁeld could help to improve\nprognostic and therapeutic determinations and inform\nclinical decision-making.\nIt is important to appreciate that ﬁeld cancerization is\ndynamic and inﬂuenced by a range of genetic and envi-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 118
        }
    },
    "857": {
        "text": "ronmental factors over time. As such, longitudinal clini-\ncal observation of breast cancer patients would enable\nclinicians to monitor trends in blood biomarker proﬁles\nand determine when the patient’s risk of recurrence\nchanges. Clinical management of the patient is thus\nenhanced by introducing more information to guide the\nlevel of surveillance.\nDiagnostic tissue biopsies serve to provide a snapshot\nof the tumor and surrounding tissues at a given point in",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 119
        }
    },
    "858": {
        "text": "time. Repeated invasive biopsies are not a feasible solu-\ntion to monitoring patient disease trajectory, whereas liq-\nuid biopsies have potential as clinical modalities able to\nyield important diagnostic, prognostic, and therapeutic\ninformation and to reduce the dependency on invasive\nprocedures and radiological tests.\nThe demarcation of surgical margins is not consistent\nbetween patients. Molecular signatures developed to\ndetect high-risk peri-tumoral tissues could be used in",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 120
        }
    },
    "859": {
        "text": "conjunction with morphological examinations to deﬁne\nexcision margins and determine the completeness of\nexcision in breast conservation therapy. Evidence of\nclear pathological and molecular margins could indicate\ndecreased risk of recurrence, thereby sparing patients\nadditional radiation therapy. Similarly, evidence of a\nﬁeld biomarker proﬁle associated with increased risk of\ncancer recurrence could distinguish patients requiring\nincreased surveillance or more aggressive treatment at",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 121
        }
    },
    "860": {
        "text": "the time of surgical intervention. As such, it is important\nfor cancerized ﬁeld-related concepts to be recorded as a\npart of medical health records.\nConclusion\nContinued technological advances will undoubtedly\nhave signiﬁcant repercussions in elucidating the cancer-\nized ﬁeld. This may result in a paradigmatic shift from\nhistopathological-driven therapeutics to a holistic evalu-\nation of clinical and molecular characteristics to comple-\nment current diagnostic techniques and help inform",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 122
        }
    },
    "861": {
        "text": "clinical decision-making.\nAcknowledgements\nWe would like to thank all the patients who donated their\ntissues, without whom advances in research would not\nbe possible. EG is funded by Breast Cancer Now\n(BCNTB Award to LJJ and CC). GJT and HR-A are\nfunded by Barts Cancer Institute (Incentivisation Award\nto CC).\nAuthor contributions statement\nEG and CC conceptualized the manuscript. EG, GJT and\nLJJ wrote the manuscript. EG, GJT, CC, HR-A and LJ\nreviewed and edited the manuscript. EG, HR-A, GJT",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 123
        }
    },
    "862": {
        "text": "reviewed and edited the manuscript. EG, HR-A, GJT\nand CC made revisions.\nReferences\n1. Cancer Research UK (CRUK). Breast cancer statistics. [Accessed\n14 February 2022]. Available from: https://www.cancerresearchuk.\norg/health-professional/cancer-statistics/statistics-by-cancer-type/\nbreast-cancer.\n2. Duffy SW, Tab\u0002ar L, Yen AMF, et al. Mammography screening\nreduces rates of advanced and fatal breast cancers: results in\n549,091 women. Cancer 2020; 126: 2971–2979.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 124
        }
    },
    "863": {
        "text": "549,091 women. Cancer 2020; 126: 2971–2979.\n3. Cleveland Clinic. Breast cancer recurrence: symptoms & treatment.\n[Accessed\n14\nFebruary\n2022].\nAvailable\nfrom:\nhttps://my.\nclevelandclinic.org/health/diseases/8328-breast-cancer-recurrence.\n4. Sadanandam A, Lal A, Benz SC, et al. Genomic aberrations in nor-\nmal tissue adjacent to HER2-ampliﬁed breast cancers: ﬁeld canceri-\nzation or contaminating tumor cells? Breast Cancer Res Treat 2012;\n136: 693–703.\nField cancerization in breast cancer\n571",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 125
        }
    },
    "864": {
        "text": "Field cancerization in breast cancer\n571\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\n5. Lebya K, Garcia-Smith R, Swaminathan R, et al. Towards a person-\nalized surgical margin for breast conserving surgery – implications\nof ﬁeld cancerization in local recurrence. J Surg Oncol 2017; 115:\n109–115.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 126
        }
    },
    "865": {
        "text": "109–115.\n6. Troester MA, Lee MH, Carter M, et al. Activation of host wound\nresponses in breast cancer microenvironment. Clin Cancer Res\n2009; 15: 7020–7028.\n7. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in\noral stratiﬁed squamous epithelium; clinical implications of multi-\ncentric origin. Cancer 1953; 6: 963–968.\n8. Trujillo KA, Jones AC, Grifﬁth JK, et al. Markers of ﬁeld canceriza-\ntion: proposed clinical applications in prostate biopsies. Prostate\nCancer 2012; 2012: 302894.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 127
        }
    },
    "866": {
        "text": "Cancer 2012; 2012: 302894.\n9. Curtius K, Wright NA, Graham TA. An evolutionary perspective on\nﬁeld cancerization. Nat Rev Cancer 2018; 18: 19–32.\n10. Heaphy CM, BisofﬁM, Fordyce CA, et al. Telomere DNA content\nand allelic imbalance demonstrate ﬁeld cancerization in histologi-\ncally normal tissue adjacent to breast tumors. Int J Cancer 2006;\n119: 108–116.\n11. Lochhead P, Chan AT, Nishihara R, et al. Etiologic ﬁeld effect: reap-\npraisal of the ﬁeld effect concept in cancer predisposition and pro-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 128
        }
    },
    "867": {
        "text": "gression. Mod Pathol 2015; 28: 14–29.\n12. Wu P, Xie C, Yang L, et al. The genomic architectures of tumour-\nadjacent tissues, plasma and saliva reveal evolutionary underpin-\nnings of relapse in head and neck squamous cell carcinoma. Br J\nCancer 2021; 125: 854–864.\n13. Aran D, Camarda R, Odegaard J, et al. Comprehensive analysis of nor-\nmal adjacent to tumor transcriptomes. Nat Commun 2017; 8: 1077.\n14. Huang X, Stern DF, Zhao H. Transcriptional proﬁles from paired",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 129
        }
    },
    "868": {
        "text": "normal samples offer complementary information on cancer patient\nsurvival – evidence from TCGA pan-cancer data. Sci Rep 2016; 6:\n20567.\n15. Trujillo KA, Hines WC, Vargas KM, et al. Breast ﬁeld canceriza-\ntion: isolation and comparison of telomerase-expressing cells in\ntumor and tumor adjacent, histologically normal breast tissue. Mol\nCancer Res 2011; 9: 1209–1221.\n16. Heaphy CM, Grifﬁth JK, BisofﬁM. Mammary ﬁeld cancerization:\nmolecular evidence and clinical importance. Breast Cancer Res",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 130
        }
    },
    "869": {
        "text": "Treat 2009; 118: 229–239.\n17. Gao Y, Niu Y, Wang X, et al. Genetic changes at speciﬁc stages of\nbreast cancer progression detected by comparative genomic hybrid-\nization. J Mol Med (Berl) 2009; 87: 145–152.\n18. Lehmann U, Länger F, Feist H, et al. Quantitative assessment of pro-\nmoter\nhypermethylation\nduring\nbreast\ncancer\ndevelopment.\nAm J Pathol 2002; 160: 605–612.\n19. Lewis CM, Cler LR, Bu D-W, et al. Promoter hypermethylation in",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 131
        }
    },
    "870": {
        "text": "benign breast epithelium in relation to predicted breast cancer risk.\nClin Cancer Res 2005; 11: 166–172.\n20. Rheinbay E, Parasuraman P, Grimsby J, et al. Recurrent and func-\ntional regulatory mutations in breast cancer. Nature 2017; 547:\n55–60.\n21. Elston CW, Ellis IO (eds). Epithelial hyperplasia. In Systemic\nPathology, The Breast, Symmers WStC (Emeritus Editor), Volume\n13. Churchill Livingstone: Edinburgh, 1998; 65–89.\n22. Kader T, Hill P, Rakha EA, et al. Atypical ductal hyperplasia: update",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 132
        }
    },
    "871": {
        "text": "on diagnosis, management, and molecular landscape. Breast Cancer\nRes 2018; 20: 39.\n23. O’Connell P, Pekkel V, Fuqua SA, et al. Analysis of loss of hetero-\nzygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl\nCancer Inst 1998; 90: 697–703.\n24. Henson DE, Tarone RE. Involution and the etiology of breast cancer.\nCancer 1994; 74: 424–429.\n25. Milanese TR, Hartmann LC, Sellers TA, et al. Age-related lobular\ninvolution and risk of breast cancer. J Natl Cancer Inst 2006; 98:",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 133
        }
    },
    "872": {
        "text": "1600–1607.\n26. Baer HJ, Collins LC, Connolly JL, et al. Lobule type and subsequent\nbreast cancer risk: results from the Nurses’ Health Studies. Cancer\n2009; 115: 1404–1411.\n27. Radisky DC, Visscher DW, Frank RD, et al. Natural history of age-\nrelated lobular involution and impact on breast cancer risk. Breast\nCancer Res Treat 2016; 155: 423–430.\n28. Martin LJ, Boyd NF. Mammographic density. Potential mechanisms\nof breast cancer risk associated with mammographic density:",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 134
        }
    },
    "873": {
        "text": "hypotheses based on epidemiological evidence. Breast Cancer Res\n2008; 10: 201.\n29. Li T, Sun L, Miller N, et al. The association of measured breast tissue\ncharacteristics with mammographic density and other risk factors for\nbreast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 343–349.\n30. McConnell JC, O’Connell OV, Brennan K, et al. Increased peri-\nductal collagen micro-organization may contribute to raised mam-\nmographic density. Breast Cancer Res 2016; 18: 5.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 135
        }
    },
    "874": {
        "text": "mographic density. Breast Cancer Res 2016; 18: 5.\n31. Levental KR, Yu H, Kass L, et al. Matrix crosslinking forces tumor pro-\ngression by enhancing integrin signaling. Cell 2009; 139: 891–906.\n32. Provenzano PP, Eliceiri KW, Campbell JM, et al. Collagen reorgani-\nzation at the tumor–stromal interface facilitates local invasion. BMC\nMed 2006; 4: 38.\n33. Schäfer M, Werner S. Cancer as an overhealing wound: an old\nhypothesis revisited. Nat Rev Mol Cell Biol 2008; 9: 628–638.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 136
        }
    },
    "875": {
        "text": "34. Kaushik S, Pickup MW, Weaver VM. From transformation to\nmetastasis: deconstructing the extracellular matrix in breast cancer.\nCancer Metastasis Rev 2016; 35: 655–667.\n35. Vachon CM, Kuni CC, Anderson K, et al. Association of mammo-\ngraphically deﬁned percent breast density with epidemiologic risk\nfactors for breast cancer (United States). Cancer Causes Control\n2000; 11: 653–662.\n36. Greendale GA, Reboussin BA, Slone S, et al. Postmenopausal hor-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 137
        }
    },
    "876": {
        "text": "mone therapy and change in mammographic density. J Natl\nCancer Inst 2003; 95: 30–37.\n37. Boyd N, Martin L, Chavez S, et al. Breast-tissue composition and\nother risk factors for breast cancer in young women: a cross-sectional\nstudy. Lancet Oncol 2009; 10: 569–580.\n38. Jung S, Stanczyk FZ, Egleston BL, et al. Endogenous sex hormones\nand breast density in young women. Cancer Epidemiol Biomarkers\nPrev 2015; 24: 369–378.\n39. Fjeldheim FN, Frydenberg H, Flote VG, et al. Polymorphisms in",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 138
        }
    },
    "877": {
        "text": "the estrogen receptor alpha gene (ESR1), daily cycling estrogen\nand mammographic density phenotypes. BMC Cancer 2016;\n16: 776.\n40. Oh H, Khodr ZG, Sherman ME, et al. Relation of serum estrogen\nmetabolites with terminal duct lobular unit involution among women\nundergoing diagnostic image-guided breast biopsy. Horm Cancer\n2016; 7: 305–315.\n41. de Bel T, Litjens G, Ogony J, et al. Automated quantiﬁcation of\nlevels of breast terminal duct lobular (TDLU) involution using deep",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 139
        }
    },
    "878": {
        "text": "learning. NPJ Breast Cancer 2022; 8: 13.\n42. Del Puerto-Nevado L, Minguez P, Corton M, et al. Molecular evi-\ndence of ﬁeld cancerization initiated by diabetes in colon cancer\npatients. Mol Oncol 2019; 13: 857–872.\n43. Guo H, Zeng W, Feng L, et al. Integrated transcriptomic analysis of\ndistance-related ﬁeld cancerization in rectal cancer patients.\nOncotarget 2017; 8: 61107–61117.\n44. Hawthorn L, Lan L, Mojica W. Evidence for ﬁeld effect canceriza-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 140
        }
    },
    "879": {
        "text": "tion in colorectal cancer. Genomics 2014; 103: 211–221.\n45. Cornejo CM, Jambusaria-Pahlajani A, Willenbrink TJ, et al. Field\ncancerization: treatment. J Am Acad Dermatol 2020; 83: 719–730.\n46. Hu B, Castillo E, Harewood L, et al. Multifocal epithelial tumors and\nﬁeld cancerization from loss of mesenchymal CSL signaling. Cell\n2012; 149: 1207–1220.\n47. Czerniak B, Dinney C, McConkey D. Origins of bladder cancer.\nAnnu Rev Pathol 2016; 11: 149–174.\n572\nE Gadaleta et al",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 141
        }
    },
    "880": {
        "text": "572\nE Gadaleta et al\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\n48. Jakubek YA, Chang K, Sivakumar S, et al. Large-scale analysis of\nacquired chromosomal alterations in non-tumor samples from\npatients with cancer. Nat Biotechnol 2020; 38: 90–96.\n49. Thomsen MBH, Nordentoft I, Lamy P, et al. Comprehensive multi-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 142
        }
    },
    "881": {
        "text": "regional analysis of molecular heterogeneity in bladder cancer. Sci\nRep 2017; 7: 11702.\n50. Kadara H, Fujimoto J, Yoo SY, et al. Transcriptomic architecture of\nthe adjacent airway ﬁeld cancerization in non-small cell lung cancer.\nJ Natl Cancer Inst 2014; 106: dju004.\n51. Amirrad F, Pytak PA, Sadeghiani-Pelar N, et al. Prostate ﬁeld can-\ncerization and exosomes: association between CD9, early growth\nresponse 1 and fatty acid synthase. Int J Oncol 2020; 56: 957–968.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 143
        }
    },
    "882": {
        "text": "52. Mehrotra J, Varde S, Wang H, et al. Quantitative, spatial resolution\nof the epigenetic ﬁeld effect in prostate cancer. Prostate 2008; 68:\n152–160.\n53. Buller RE, Skilling JS, Sood AK, et al. Field cancerization: why late\n“recurrent” ovarian cancer is not recurrent. Am J Obstet Gynecol\n1998; 178: 641–649.\n54. Giannopoulou L, Chebouti I, Pavlakis K, et al. RASSF1A promoter\nmethylation in high-grade serous ovarian cancer: a direct compari-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 144
        }
    },
    "883": {
        "text": "son study in primary tumors, adjacent morphologically tumor cell-\nfree tissues and paired circulating tumor DNA. Oncotarget 2017;\n8: 21429–21443.\n55. Forsberg LA, Rasi C, Pekar G, et al. Signatures of post-zygotic\nstructural genetic aberrations in the cells of histologically normal\nbreast tissue that can predispose to sporadic breast cancer. Genome\nRes 2015; 25: 1521–1535.\n56. Försti A, Louhelainen J, Söderberg M, et al. Loss of heterozygosity",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 145
        }
    },
    "884": {
        "text": "in tumour-adjacent normal tissue of breast and bladder cancer. Eur J\nCancer 2001; 37: 1372–1380.\n57. Gadaleta E, Fourgoux P, Pirr\u0002o S, et al. Characterization of four sub-\ntypes in morphologically normal tissue excised proximal and distal\nto breast cancer. NPJ Breast Cancer 2020; 6: 38.\n58. Graham K, de las Morenas A, Tripathi A, et al. Gene expression in\nhistologically normal epithelium from breast cancer patients and\nfrom cancer-free prophylactic mastectomy patients shares a similar",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 146
        }
    },
    "885": {
        "text": "proﬁle. Br J Cancer 2010; 102: 1284–1293.\n59. Larson PS, de las Morenas A, Cerda SR, et al. Quantitative analysis\nof allele imbalance supports atypical ductal hyperplasia lesions as\ndirect breast cancer precursors. J Pathol 2006; 209: 307–316.\n60. Rom\u0002an-Pérez E, Casbas-Hern\u0002andez P, Pirone JR, et al. Gene expres-\nsion in extratumoral microenvironment predicts clinical outcome in\nbreast cancer patients. Breast Cancer Res 2012; 14: R51.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 147
        }
    },
    "886": {
        "text": "61. Yan PS, Venkataramu C, Ibrahim A, et al. Mapping geographic\nzones of cancer risk with epigenetic biomarkers in normal breast tis-\nsue. Clin Cancer Res 2006; 12: 6626–6636.\n62. Casbas-Hernandez P, Sun X, Roman-Perez E, et al. Tumor intrinsic\nsubtype is reﬂected in cancer-adjacent tissue. Cancer Epidemiol\nBiomarkers Prev 2015; 24: 406–414.\n63. Euhus DM, Cler L, Shivapurkar N, et al. Loss of heterozygosity in\nbenign breast epithelium in relation to breast cancer risk. J Natl",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 148
        }
    },
    "887": {
        "text": "Cancer Inst 2002; 94: 858–860.\n64. Gao Y, Widschwendter M, Teschendorff AE. DNA methylation pat-\nterns in normal tissue correlate more strongly with breast cancer sta-\ntus than copy-number variants. EBioMedicine 2018; 31: 243–252.\n65. Muse ME, Titus AJ, Salas LA, et al. Enrichment of CpG island shore\nregion hypermethylation in epigenetic breast ﬁeld cancerization.\nEpigenetics 2020; 15: 1093–1106.\n66. Abdalla M, Tran-Thanh D, Moreno J, et al. Mapping genomic and",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 149
        }
    },
    "888": {
        "text": "transcriptomic alterations spatially in epithelial cells adjacent to\nhuman breast carcinoma. Nat Commun 2017; 8: 1245.\n67. Deng G, Lu Y, Zlotnikov G, et al. Loss of heterozygosity in nor-\nmal tissue adjacent to breast carcinomas. Science 1996; 274:\n2057–2059.\n68. Ellsworth DL, Ellsworth RE, Love B, et al. Genomic patterns of alle-\nlic imbalance in disease free tissue adjacent to primary breast carci-\nnomas. Breast Cancer Res Treat 2004; 88: 131–139.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 150
        }
    },
    "889": {
        "text": "nomas. Breast Cancer Res Treat 2004; 88: 131–139.\n69. Braakhuis BJM, Tabor MP, Kummer JA, et al. A genetic explana-\ntion of Slaughter’s concept of ﬁeld cancerization: evidence and clin-\nical implications. Cancer Res 2003; 63: 1727–1730.\n70. Hattori N, Ushijima T. Epigenetic impact of infection on carcinogen-\nesis: mechanisms and applications. Genome Med 2016; 8: 10.\n71. Takeshima H, Ushijima T. Accumulation of genetic and epigenetic alter-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 151
        }
    },
    "890": {
        "text": "ations in normal cells and cancer risk. NPJ Precis Oncol 2019; 3: 7.\n72. Troester MA, Hoadley KA, D’Arcy M, et al. DNA defects, epige-\nnetics, and gene expression in cancer-adjacent breast: a study from\nThe Cancer Genome Atlas. NPJ Breast Cancer 2016; 2: 16007.\n73. Trujillo KA, Heaphy CM, Mai M, et al. Markers of ﬁbrosis and epi-\nthelial to mesenchymal transition demonstrate ﬁeld cancerization in\nhistologically normal tissue adjacent to breast tumors. Int J Cancer\n2011; 129: 1310–1321.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 152
        }
    },
    "891": {
        "text": "2011; 129: 1310–1321.\n74. Kurabayashi R, Takubo K, Aida J, et al. Luminal and cancer cells in\nthe breast show more rapid telomere shortening than myoepithelial\ncells and ﬁbroblasts. Hum Pathol 2008; 39: 1647–1655.\n75. Cheng ASL, Culhane AC, Chan MWY, et al. Epithelial progeny of\nestrogen-exposed breast progenitor cells display a cancer-like\nmethylome. Cancer Res 2008; 68: 1786–1796.\n76. Tripathi A, King C, de la Morenas A, et al. Gene expression abnor-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 153
        }
    },
    "892": {
        "text": "malities in histologically normal breast epithelium of breast cancer\npatients. Int J Cancer 2008; 122: 1557–1566.\n77. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized\nprobabilities of developing breast cancer for white females who are\nbeing examined annually. J Natl Cancer Inst 1989; 81: 1879–1886.\n78. Gail MH, Costantino JP, Pee D, et al. Projecting individualized\nabsolute invasive breast cancer risk in African American women.\nJ Natl Cancer Inst 2007; 99: 1782–1792.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 154
        }
    },
    "893": {
        "text": "J Natl Cancer Inst 2007; 99: 1782–1792.\n79. Matsuno RK, Costantino JP, Ziegler RG, et al. Projecting individu-\nalized absolute invasive breast cancer risk in Asian and Paciﬁc\nIslander American women. J Natl Cancer Inst 2011; 103: 951–961.\n80. Breast Cancer Now Tissue Bank (BCNTB). [Accessed 16 April\n2022]. Available from: https://breastcancernow.org/breast-cancer-\nresearch/breast-cancer-now-tissue-bank.\n81. Gadaleta E, Pirrò S, Dayem Ullah AZ, et al. BCNTB bioinformatics:",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 155
        }
    },
    "894": {
        "text": "the next evolutionary step in the bioinformatics of breast cancer tis-\nsue banking. Nucleic Acids Res 2018; 46: D1055–D1061.\n82. Breast Cancer Now Media. [Accessed 16 April 2022]. Available\nfrom:\nhttps://breastcancernow.org/about-us/media/press-releases/\nbreast-cancer-now-achieves-landmark-moment-nhs-england-\nannounces-national-metastatic-breast-cancer-audit.\n83. Independent UK Panel on Breast Cancer Screening. The beneﬁts and\nharms of breast cancer screening: an independent review. Lancet",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 156
        }
    },
    "895": {
        "text": "2012; 380: 1778–1786.\n84. Bulliard J-L, Beau A-B, Njor S, et al. Breast cancer screening and\noverdiagnosis. Int J Cancer. 2021; 149: 846–853.\n85. Molassiotis A, Tyrovolas S, Giné-V\u0002azquez I, et al. Organized breast\ncancer screening not only reduces mortality from breast cancer but\nalso signiﬁcantly decreases disability-adjusted life years: analysis\nof the Global Burden of Disease Study and screening programme\navailability in 130 countries. ESMO Open 2021; 6: 100111.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 157
        }
    },
    "896": {
        "text": "86. Herrington CS, Poulsom R, Coates PJ. Recent Advances in Pathol-\nogy: The 2019 Annual Review Issue of The Journal of Pathology.\nJ Pathol 2019; 247: 535–538.\n87. Hamada T, Nowak JA, Milner DA Jr, et al. Integration of microbiol-\nogy, molecular pathology, and epidemiology: a new paradigm to\nexplore\nthe\npathogenesis\nof\nmicrobiome-driven\nneoplasms.\nJ Pathol 2019; 247: 615–628.\n88. Ogino S, Nishihara R, VanderWeele TJ, et al. Review Article: The",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 158
        }
    },
    "897": {
        "text": "role of molecular pathological epidemiology in the study of\nField cancerization in breast cancer\n573\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com\nneoplastic and non-neoplastic diseases in the era of precision medi-\ncine. Epidemiology 2016; 27: 602–611.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 159
        }
    },
    "898": {
        "text": "cine. Epidemiology 2016; 27: 602–611.\n89. Ogino S, Lochhead P, Chan AT, et al. Molecular pathological epide-\nmiology of epigenetics: emerging integrative science to analyze\nenvironment, host, and disease. Mod Pathol 2013; 26: 465–484.\n90. Hughes LAE, Simons CCJM, van den Brandt PA, et al. Lifestyle,\ndiet, and colorectal cancer risk according to (epi)genetic instability:\ncurrent evidence and future directions of molecular pathological epi-\ndemiology. Curr Colorectal Cancer Rep 2017; 13: 455–469.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 160
        }
    },
    "899": {
        "text": "91. Mima K, Kosumi K, Baba Y, et al. The microbiome, genetics, and\ngastrointestinal neoplasms: the evolving ﬁeld of molecular patholog-\nical epidemiology to analyze the tumor–immune–microbiome inter-\naction. Hum Genet 2021; 140: 725–746.\n92. Ingman WV. The gut microbiome: a new player in breast cancer\nmetastasis. Cancer Res 2019; 79: 3539–3541.\n93. Urbaniak C, Gloor GB, Brackstone M, et al. The microbiota of\nbreast tissue and its association with breast cancer. Appl Environ",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 161
        }
    },
    "900": {
        "text": "Microbiol 2016; 82: 5039–5048.\n94. Xuan C, Shamonki JM, Chung A, et al. Microbial dysbiosis is asso-\nciated with human breast cancer. PLoS One 2014; 9: e83744.\n95. McKee AM, Kirkup BM, Madgwick M, et al. Antibiotic-induced\ndisturbances of the gut microbiota result in accelerated breast tumor\ngrowth. iScience 2021; 24: 103012.\n96. Kirkup MB, McKee A, Makin AK, et al. Perturbation of the gut\nmicrobiota by antibiotics results in accelerated breast tumour growth",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 162
        }
    },
    "901": {
        "text": "and metabolic dysregulation. bioRxiv 2019; doi.org/10.1101/553602\n[Not peer reviewed].\n97. Banerjee S, Tian T, Wei Z, et al. Distinct microbial signatures associ-\nated with different breast cancer types. Front Microbiol 2018; 9: 951.\n98. Zhang J, Xia Y, Sun J. Breast and gut microbiome in health and can-\ncer. Genes Dis 2020; 8: 581–589.\n99. Papadimitriou N, Dimou N, Tsilidis KK, et al. Physical activity and\nrisks of breast and colorectal cancer: a Mendelian randomisation",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 163
        }
    },
    "902": {
        "text": "analysis. Nat Commun 2020; 11: 597.\n100. Barone I, Giordano C, Bonoﬁglio D, et al. The weight of obesity in\nbreast cancer progression and metastasis: clinical and molecular per-\nspectives. Semin Cancer Biol 2020; 60: 274–284.\n101. Gao C, Patel CJ, Michailidou K, et al. Mendelian randomization\nstudy of adiposity-related traits and risk of breast, ovarian, prostate,\nlung and colorectal cancer. Int J Epidemiol 2016; 45: 896–908.\n102. Delgado-Cruzata L, Wu HC, Liao Y, et al. Differences in DNA",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 164
        }
    },
    "903": {
        "text": "methylation by extent of breast cancer family history in unaffected\nwomen. Epigenetics 2014; 9: 243–248.\n103. Rudolph A, Milne RL, Truong T, et al. Investigation of gene–\nenvironment interactions between 47 newly identiﬁed breast cancer\nsusceptibility loci and environmental risk factors. Int J Cancer\n2015; 136: E685–E696.\n104. Nickels S, Truong T, Hein R, et al. Evidence of gene–environment\ninteractions between common breast cancer susceptibility loci and",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 165
        }
    },
    "904": {
        "text": "established environmental risk factors. PLoS Genet 2013; 9: e1003284.\n105. Barrdahl M, Canzian F, Joshi AD, et al. Post-GWAS gene–\nenvironment interplay in breast cancer: results from the Breast and\nProstate Cancer Cohort Consortium and a meta-analysis on 79,000\nwomen. Hum Mol Genet 2014; 23: 5260–5270.\n106. Schoeps A, Rudolph A, Seibold P, et al. Identiﬁcation of new genetic\nsusceptibility loci for breast cancer through consideration of gene–",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 166
        }
    },
    "905": {
        "text": "environment interactions. Genet Epidemiol 2014; 38: 84–93.\n107. Aschard H, Zaitlen N, Lindström S, et al. Variation in predictive\nability of common genetic variants by established strata: the example\nof breast cancer and age. Epidemiology 2015; 26: 51–58.\n108. Bruno E, Oliverio A, Paradiso A, et al. Lifestyle characteristics in\nwomen carriers of BRCA mutations: results from an Italian trial\ncohort. Clin Breast Cancer 2021; 21: e168–e176.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 167
        }
    },
    "906": {
        "text": "cohort. Clin Breast Cancer 2021; 21: e168–e176.\n109. Pasanisi P, Bruno E. Breast cancer in BRCA mutations carriers: is it\ntime for a “lifestyle” primary prevention? Epidemiol Prev 2018; 42:\n369–371.\n110. Li H, Terry MB, Antoniou AC, et al. Alcohol consumption, cigarette\nsmoking, and risk of breast cancer for BRCA1 and BRCA2 mutation\ncarriers: results from The BRCA1 and BRCA2 Cohort Consortium.\nCancer Epidemiol Biomarkers Prev 2020; 29: 368–378.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 168
        }
    },
    "907": {
        "text": "111. Daniele A, Divella R, Pilato B, et al. Can harmful lifestyle, obesity\nand weight changes increase the risk of breast cancer in BRCA\n1 and BRCA 2 mutation carriers? A mini review. Hered Cancer\nClin Pract 2021; 19: 45.\n112. Li R, Di L, Li J, et al. A body map of somatic mutagenesis in mor-\nphologically normal human tissues. Nature 2021; 597: 398–403.\n113. Dotto GP. Multifocal epithelial tumors and ﬁeld cancerization: stroma\nas a primary determinant. J Clin Invest 2014; 124: 1446–1453.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 169
        }
    },
    "908": {
        "text": "114. Cohen JD, Li L, Wang Y, et al. Detection and localization of surgi-\ncally resectable cancers with a multi-analyte blood test. Science\n2018; 359: 926–930.\n115. Debernardi S, O’Brien H, Algahmdi AS, et al. A combination of uri-\nnary biomarker panel and PancRISK score for earlier detection of\npancreatic cancer: a case–control study. PLoS Med 2020; 17:\ne1003489.\n116. Liu MC, Oxnard GR, Klein EA, et al. Sensitive and speciﬁc multi-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 170
        }
    },
    "909": {
        "text": "cancer detection and localization using methylation signatures in\ncell-free DNA. Ann Oncol 2020; 31: 745–759.\n117. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating\ntumor DNA to monitor metastatic breast cancer. N Engl J Med\n2013; 368: 1199–1209.\n118. Kruger DT, Jansen MPHM, Konings IRHM, et al. High ctDNA mol-\necule numbers relate with poor outcome in advanced ER+, HER2\u0003\npostmenopausal breast cancer patients treated with everolimus and\nexemestane. Mol Oncol 2020; 14: 490–503.",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 171
        }
    },
    "910": {
        "text": "exemestane. Mol Oncol 2020; 14: 490–503.\n119. Lv J, Chen Y, Zhou G, et al. Liquid biopsy tracking during sequen-\ntial chemo-radiotherapy identiﬁes distinct prognostic phenotypes in\nnasopharyngeal carcinoma. Nat Commun 2019; 10: 3941.\n120. Moss J, Zick A, Grinshpun A, et al. Circulating breast-derived DNA\nallows universal detection and monitoring of localized breast cancer.\nAnn Oncol 2020; 31: 395–403.\n121. Phallen J, Leal A, Woodward BD, et al. Early noninvasive detection",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 172
        }
    },
    "911": {
        "text": "of response to targeted therapy in non-small cell lung cancer. Cancer\nRes 2019; 79: 1204–1213.\n122. Roesch-Ely M, Nees M, Karsai S, et al. Proteomic analysis reveals\nsuccessive aberrations in protein expression from healthy mucosa\nto invasive head and neck cancer. Oncogene 2007; 26: 54–64.\n123. Kingston B, Cutts RJ, Bye H, et al. Genomic proﬁle of advanced\nbreast cancer in circulating tumour DNA. Nat Commun 2021; 12:\n2423.\n124. Muendlein A, Geiger K, Gaenger S, et al. Signiﬁcant impact of cir-",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 173
        }
    },
    "912": {
        "text": "culating tumour DNA mutations on survival in metastatic breast can-\ncer patients. Sci Rep 2021; 11: 6761.\n125. Sharma P, Abramson VG, O’Dea A, et al. Clinical and biomarker\nresults from phase I/II study of PI3K inhibitor alpelisib plus nab-\npaclitaxel in HER2-negative metastatic breast cancer. Clin Cancer\nRes 2021; 27: 3896–3904.\n126. Tan G, Chu C, Gui X, et al. The prognostic value of circulating cell-\nfree DNA in breast cancer: a meta-analysis. Medicine (Baltimore)\n2018; 97: e0197.\n574",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 174
        }
    },
    "913": {
        "text": "2018; 97: e0197.\n574\nE Gadaleta et al\n© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd\non behalf of The Pathological Society of Great Britain and Ireland. www.pathsoc.org\nJ Pathol 2022; 257: 561–574\nwww.thejournalofpathology.com",
        "metadata": {
            "source": "PATH-257-561.pdf",
            "chunk_id": 175
        }
    },
    "914": {
        "text": "Cell, Vol. 100, 57–70, January 7, 2000, Copyright 2000 by Cell Press\nThe Hallmarks of Cancer\nReview\nevolve progressively from normalcy via a series of pre-\nDouglas Hanahan* and Robert A. Weinberg†\n*Department of Biochemistry and Biophysics and\nmalignant states into invasive cancers (Foulds, 1954).\nThese observations have been rendered more con-\nHormone Research Institute\nUniversity of California at San Francisco\ncrete by a large body of work indicating that the ge-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 0
        }
    },
    "915": {
        "text": "nomes of tumor cells are invariably altered at multiple\nSan Francisco, California 94143\n†Whitehead Institute for Biomedical Research and\nsites, having suffered disruption through lesions as sub-\ntle as point mutations and as obvious as changes in\nDepartment of Biology\nMassachusetts Institute of Technology\nchromosome complement (e.g., Kinzler and Vogelstein,\n1996). Transformation of cultured cells is itself a\nCambridge, Massachusetts 02142",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 1
        }
    },
    "916": {
        "text": "Cambridge, Massachusetts 02142\nmultistep process: rodent cells require at least two intro-\nduced genetic changes before they acquire tumorigenic\ncompetence, while their human counterparts are more\nAfter a quarter century of rapid advances, cancer re-\ndifficult to transform (Hahn et al., 1999). Transgenic\nsearch has generated a rich and complex body of knowl-\nmodels of tumorigenesis have repeatedly supported the\nedge, revealing cancer to be a disease involving dy-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 2
        }
    },
    "917": {
        "text": "conclusion that tumorigenesis in mice involves multiple\nnamic changes in the genome. The foundation has been\nrate-limiting steps (Bergers et al., 1998; see Oncogene,\nset in the discovery of mutations that produce onco-\n1999, R. DePinho and T. E. Jacks, volume 18[38], pp.\ngenes with dominant gain of function and tumor sup-\n5248–5362). Taken together, observations of human\npressor genes with recessive loss of function; both\ncancers and animal models argue that tumor develop-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 3
        }
    },
    "918": {
        "text": "classes of cancer genes have been identified through\nment proceeds via a process formally analogous to Dar-\ntheir alteration in human and animal cancer cells and\nwinian evolution, in which a succession of genetic\nby their elicitation of cancer phenotypes in experimental\nchanges, each conferring one or another type of growth\nmodels (Bishop and Weinberg, 1996).\nadvantage, leads to the progressive conversion of nor-\nSome would argue that the search for the origin and",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 4
        }
    },
    "919": {
        "text": "mal human cells into cancer cells (Foulds, 1954; Nowell,\ntreatment of this disease will continue over the next\n1976).\nquarter century in much the same manner as it has in\nthe recent past, by adding further layers of complexity\nto a scientific literature that is already complex almost\nAn Enumeration of the Traits\nbeyond measure. But we anticipate otherwise: those\nThe barriers to development of cancer are embodied\nresearching the cancer problem will be practicing a dra-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 5
        }
    },
    "920": {
        "text": "in a teleology: cancer cells have defects in regulatory\nmatically different type of science than we have experi-\ncircuits that govern normal cell proliferation and homeo-\nenced over the past 25 years. Surely much of this change\nstasis. There are more than 100 distinct types of cancer,\nwill be apparent at the technical level. But ultimately,\nand subtypes of tumors can be found within specific\nthe more fundamental change will be conceptual.\norgans. This complexity provokes a number of ques-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 6
        }
    },
    "921": {
        "text": "We foresee cancer research developing into a logical\ntions. How many distinct regulatory circuits within each\nscience, where the complexities of the disease, de-\ntype of target cell must be disrupted in order for such\nscribed in the laboratory and clinic, will become under-\na cell to become cancerous? Does the same set of\nstandable in terms of a small number of underlying prin-\ncellular regulatory circuits suffer disruption in the cells\nciples. Some of these principles are even now in the",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 7
        }
    },
    "922": {
        "text": "of the disparate neoplasms arising in the human body?\nmidst of being codified. We discuss one set of them in\nWhich of these circuits operate on a cell-autonomous\nthe present essay: rules that govern the transformation\nbasis, and which are coupled to the signals that cells\nof normal human cells into malignant cancers. We sug-\nreceive from their surrounding microenvironment within\ngest that research over the past decades has revealed\na tissue? Can the large and diverse collection of cancer-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 8
        }
    },
    "923": {
        "text": "a small number of molecular, biochemical, and cellular\nassociated genes be tied to the operations of a small\ntraits—acquired capabilities—shared by most and per-\ngroup of regulatory circuits?\nhaps all types of human cancer. Our faith in such simplifi-\nWe suggest that the vast catalog of cancer cell geno-\ncation derives directly from the teachings of cell biology\ntypes is a manifestation of six essential alterations in cell\nthat virtually all mammalian cells carry a similar molecu-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 9
        }
    },
    "924": {
        "text": "physiology that collectively dictate malignant growth\nlar machinery regulating their proliferation, differentia-\n(Figure 1): self-sufficiency in growth signals, insensitivity\ntion, and death.\nto growth-inhibitory (antigrowth) signals, evasion of pro-\nSeveral lines of evidence indicate that tumorigenesis\ngrammed cell death (apoptosis), limitless replicative\nin humans is a multistep process and that these steps\npotential, sustained angiogenesis, and tissue invasion",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 10
        }
    },
    "925": {
        "text": "reflect genetic alterations that drive the progressive\nand metastasis. Each of these physiologic changes—\ntransformation of normal human cells into highly malig-\nnovel capabilities acquired during tumor development—\nnant derivatives. Many types of cancers are diagnosed\nrepresents the successful breaching of an anticancer\nin the human population with an age-dependent inci-\ndefense mechanism hardwired into cells and tissues.\ndence implicating four to seven rate-limiting, stochastic",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 11
        }
    },
    "926": {
        "text": "We propose that these six capabilities are shared in\nevents (Renan, 1993). Pathological analyses of a number\ncommon by most and perhaps all types of human tu-\nof organ sites reveal lesions that appear to represent\nmors. This multiplicity of defenses may explain why can-\ncer is relatively rare during an average human lifetime.\nthe intermediate steps in a process through which cells\nCell\n58\nAcquired GS autonomy was the first of the six capabili-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 12
        }
    },
    "927": {
        "text": "ties to be clearly defined by cancer researchers, in large\npart because of the prevalence of dominant oncogenes\nthat have been found to modulate it. Three common\nmolecular strategies for achieving autonomy are evi-\ndent, involving alteration of extracellular growth signals,\nof transcellular transducers of those signals, or of intra-\ncellular circuits that translate those signals into action.\nWhile most soluble mitogenic growth factors (GFs) are",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 13
        }
    },
    "928": {
        "text": "made by one cell type in order to stimulate proliferation\nof another—the process of heterotypic signaling—many\ncancer cells acquire the ability to synthesize GFs to\nwhich they are responsive, creating a positive feedback\nsignaling loop often termed autocrine stimulation (Fedi\net al., 1997). Clearly, the manufacture of a GF by a cancer\ncell obviates dependence on GFs from other cells within\nthe tissue. The production of PDGF (platelet-derived\ngrowth factor) and TGFa (tumor growth factor a) by",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 14
        }
    },
    "929": {
        "text": "glioblastomas and sarcomas, respectively, are two illus-\ntrative examples (Fedi et al., 1997).\nThe cell surface receptors that transduce growth-\nstimulatory signals into the cell interior are themselves\ntargets of deregulation during tumor pathogenesis. GF\nreceptors, often carrying tyrosine kinase activities in\ntheir cytoplasmic domains, are overexpressed in many\ncancers. Receptor overexpression may enable the can-\ncer cell to become hyperresponsive to ambient levels",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 15
        }
    },
    "930": {
        "text": "Figure 1. Acquired Capabilities of Cancer\nof GF that normally would not trigger proliferation (Fedi\nWe suggest that most if not all cancers have acquired the same set\net al., 1997). For example, the epidermal GF receptor\nof functional capabilities during their development, albeit through\nvarious mechanistic strategies.\n(EGF-R/erbB) is upregulated in stomach, brain, and\nbreast tumors, while the HER2/neu receptor is overex-\npressed in stomach and mammary carcinomas (Slamon",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 16
        }
    },
    "931": {
        "text": "pressed in stomach and mammary carcinomas (Slamon\net al., 1987; Yarden and Ullrich, 1988). Additionally, gross\nWe describe each capability in turn below, illustrate with\noverexpression of GF receptors can elicit ligand-inde-\na few examples its functional importance, and indicate\npendent signaling (DiFiore et al., 1987). Ligand-indepen-\nstrategies by which it is acquired in human cancers.\ndent signaling can also be achieved through structural",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 17
        }
    },
    "932": {
        "text": "alteration of receptors; for example, truncated versions\nAcquired Capability: Self-Sufficiency\nof the EGF receptor lacking much of its cytoplasmic\nin Growth Signals\ndomain fire constitutively (Fedi et al., 1997).\nNormal cells require mitogenic growth signals (GS) be-\nCancer cells can also switch the types of extracellular\nfore they can move from a quiescent state into an active\nmatrix receptors (integrins) they express, favoring ones\nproliferative state. These signals are transmitted into the",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 18
        }
    },
    "933": {
        "text": "that transmit progrowth signals (Lukashev and Werb,\ncell by transmembrane receptors that bind distinctive\n1998; Giancotti and Ruoslahti, 1999). These bifunctional,\nclasses of signaling molecules: diffusible growth fac-\nheterodimeric cell surface receptors physically link cells\ntors, extracellular matrix components, and cell-to-cell\nto extracellular superstructures known as the extracellu-\nadhesion/interaction molecules. To our knowledge, no",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 19
        }
    },
    "934": {
        "text": "lar matrix (ECM). Successful binding to specific moieties\ntype of normal cell can proliferate in the absence of\nof the ECM enables the integrin receptors to transduce\nsuch stimulatory signals. Many of the oncogenes in the\nsignals into the cytoplasm that influence cell behavior,\ncancer catalog act by mimicking normal growth signal-\nranging from quiescence in normal tissue to motility,\ning in one way or another.\nresistance to apoptosis, and entrance into the active",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 20
        }
    },
    "935": {
        "text": "Dependence on growth signaling is apparent when\ncell cycle. Conversely, the failure of integrins to forge\npropagating normal cells in culture, which typically pro-\nthese extracellular links can impair cell motility, induce\nliferate only when supplied with appropriate diffusible\napoptosis, or cause cell cycle arrest (Giancotti and Ru-\nmitogenic factors and a proper substratum for their inte-\noslahti, 1999). Both ligand-activated GF receptors and",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 21
        }
    },
    "936": {
        "text": "grins. Such behavior contrasts strongly with that of tu-\nprogrowth integrins engaged to extracellular matrix\nmor cells, which invariably show a greatly reduced\ncomponents can activate the SOS-Ras-Raf-MAP kinase\ndependence on exogenous growth stimulation. The con-\npathway (Aplin et al., 1998; Giancotti and Ruoslahti,\nclusion is that tumor cells generate many of their own\n1999).\ngrowth signals, thereby reducing their dependence on\nThe most complex mechanisms of acquired GS auton-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 22
        }
    },
    "937": {
        "text": "The most complex mechanisms of acquired GS auton-\nstimulation from their normal tissue microenvironment.\nomy derive from alterations in components of the down-\nThis liberation from dependence on exogenously de-\nstream cytoplasmic circuitry that receives and pro-\nrived signals disrupts a critically important homeostatic\ncesses the signals emitted by ligand-activated GF\nmechanism that normally operates to ensure a proper\nreceptors and integrins. The SOS-Ras-Raf-MAPK cas-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 23
        }
    },
    "938": {
        "text": "cade plays a central role here. In about 25% of human\nbehavior of the various cell types within a tissue.\nReview\n59\nFigure 2. The Emergent Integrated Circuit of the Cell\nProgress in dissecting signaling pathways has begun to lay out a circuitry that will likely mimic electronic integrated circuits in complexity\nand finesse, where transistors are replaced by proteins (e.g., kinases and phosphatases) and the electrons by phosphates and lipids, among",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 24
        }
    },
    "939": {
        "text": "others. In addition to the prototypical growth signaling circuit centered around Ras and coupled to a spectrum of extracellular cues, other\ncomponent circuits transmit antigrowth and differentiation signals or mediate commands to live or die by apoptosis. As for the genetic\nreprogramming of this integrated circuit in cancer cells, some of the genes known to be functionally altered are highlighted in red.\ntumors, Ras proteins are present in structurally altered",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 25
        }
    },
    "940": {
        "text": "multiple cell biological effects. For example, the direct\ninteraction of the Ras protein with the survival-promot-\nforms that enable them to release a flux of mitogenic\nsignals into cells, without ongoing stimulation by their\ning PI3 kinase enables growth signals to concurrently\nevoke survival signals within the cell (Downward, 1998).\nnormal upstream regulators (Medema and Bos, 1993).\nWe suspect that growth signaling pathways suffer\nWhile acquisition of growth signaling autonomy by",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 26
        }
    },
    "941": {
        "text": "While acquisition of growth signaling autonomy by\ncancer cells is conceptually satisfying, it is also too\nderegulation in all human tumors. Although this point\nis hard to prove rigorously at present, the clues are\nsimplistic. We have traditionally explored tumor growth\nby focusing our experimental attentions on the geneti-\nabundant (Hunter, 1997). For example, in the best stud-\nied of tumors—human colon carcinomas—about half\ncally deranged cancer cells (Figure 3, left panel). It is,",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 27
        }
    },
    "942": {
        "text": "however, increasingly apparent that the growth deregu-\nof the tumors bear mutant ras oncogenes (Kinzler and\nVogelstein, 1996). We suggest that the remaining colonic\nlation within a tumor can only be explained once we\nunderstand the contributions of the ancillary cells pres-\ntumors carry defects in other components of the growth\nsignaling pathways that phenocopy ras oncogene acti-\nent in a tumor—the apparently normal bystanders such\nas fibroblasts and endothelial cells—which must play",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 28
        }
    },
    "943": {
        "text": "vation. The nature of these alternative, growth-stimulat-\ning mechanisms remains elusive.\nkey roles in driving tumor cell proliferation (Figure 3,\nright panel). Within normal tissue, cells are largely in-\nUnder intensive study for two decades, the wiring\ndiagram of the growth signaling circuitry of the mamma-\nstructed to grow by their neighbors (paracrine signals)\nor via systemic (endocrine) signals. Cell-to-cell growth\nlian cell is coming into focus (Figure 2). New downstream",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 29
        }
    },
    "944": {
        "text": "effector pathways that radiate from the central SOS-\nsignaling is likely to operate in the vast majority of human\ntumors as well; virtually all are composed of several\nRas-Raf-MAP kinase mitogenic cascade are being dis-\ncovered with some regularity (Hunter, 1997; Rommel\ndistinct cell types that appear to communicate via het-\nerotypic signaling.\nand Hafen, 1998). This cascade is also linked via a variety\nof cross-talking connections with other pathways; these",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 30
        }
    },
    "945": {
        "text": "Heterotypic signaling between the diverse cell types\nwithin a tumor may ultimately prove to be as important\ncross connections enable extracellular signals to elicit\nCell\n60\nFigure 3. Tumors as Complex Tissues\nThe field of cancer research has largely been\nguided by a reductionist focus on cancer cells\nand the genes within them (left panel)—a fo-\ncus that has produced an extraordinary body\nof knowledge. Looking forward in time, we\nbelieve that important new inroads will come",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 31
        }
    },
    "946": {
        "text": "believe that important new inroads will come\nfrom regarding tumors as complex tissues in\nwhich mutant cancer cells have conscripted\nand subverted normal cell types to serve as\nactive collaborators in their neoplastic agenda\n(right panel). The interactions between the\ngenetically altered malignant cells and these\nsupporting coconspirators will prove critical\nto understanding cancer pathogenesis and to\nthe development of novel, effective therapies.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 32
        }
    },
    "947": {
        "text": "the development of novel, effective therapies.\nin explaining tumor cell proliferation as the cancer cell-\nthe components governing the transit of the cell through\nthe G1 phase of its growth cycle. Cells monitor their\nautonomous mechanisms enumerated above. For ex-\nample, we suspect that many of the growth signals driv-\nexternal environment during this period and, on the ba-\nsis of sensed signals, decide whether to proliferate, to\ning the proliferation of carcinoma cells originate from",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 33
        }
    },
    "948": {
        "text": "the stromal cell components of the tumor mass. While\nbe quiescent, or to enter into a postmitotic state. At the\nmolecular level, many and perhaps all antiproliferative\ndifficult to validate at present, such thinking recasts the\nlogic of acquired GS autonomy: successful tumor cells\nsignals are funneled through the retinoblastoma protein\n(pRb) and its two relatives, p107 and p130. When in a\nare those that have acquired the ability to co-opt their",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 34
        }
    },
    "949": {
        "text": "normal neighbors by inducing them to release abundant\nhypophosphorylated state, pRb blocks proliferation by\nsequestering and altering the function of E2F transcrip-\nfluxes of growth-stimulating signals (Skobe and Fu-\nsenig, 1998). Indeed, in some tumors, these cooperating\ntion factors that control the expression of banks of genes\nessential for progression from G1 into S phase (Wein-\ncells may eventually depart from normalcy, coevolving\nwith their malignant neighbors in order to sustain the",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 35
        }
    },
    "950": {
        "text": "berg, 1995).\nDisruption of the pRb pathway liberates E2Fs and\ngrowth of the latter (Kinzler and Vogelstein, 1998; Olumi\net al., 1999). Further, inflammatory cells attracted to sites\nthus allows cell proliferation, rendering cells insensitive\nto antigrowth factors that normally operate along this\nof neoplasia may promote (rather than eliminate) cancer\ncells (Cordon-Cardo and Prives, 1999; Coussens et al.,\npathway to block advance through the G1 phase of the",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 36
        }
    },
    "951": {
        "text": "cell cycle. The effects of the soluble signaling molecule\n1999; Hudson et al., 1999), another example of normal\ncells conscripted to enhance tumor growth potential,\nTGFb are the best documented, but we envision other\nantigrowth factors will be found to signal through this\nanother means to acquire necessary capabilities.\npathway as well. TGFb acts in a number of ways, most\nstill elusive, to prevent the phosphorylation that inacti-\nAcquired Capability: Insensitivity\nto Antigrowth Signals",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 37
        }
    },
    "952": {
        "text": "to Antigrowth Signals\nvates pRb; in this fashion, TGFb blocks advance through\nG1. In some cell types, TGFb suppresses expression\nWithin a normal tissue, multiple antiproliferative signals\noperate to maintain cellular quiescence and tissue ho-\nof the c-myc gene, which regulates the G1 cell cycle\nmachinery in still unknown ways (Moses et al., 1990).\nmeostasis; these signals include both soluble growth\ninhibitors and immobilized inhibitors embedded in the",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 38
        }
    },
    "953": {
        "text": "More directly, TGFb causes synthesis of the p15INK4B and\np21 proteins, which block the cyclin:CDK complexes\nextracellular matrix and on the surfaces of nearby cells.\nThese growth-inhibitory signals, like their positively act-\nresponsible for pRb phosphorylation (Hannon and\nBeach, 1994; Datto et al., 1997).\ning counterparts, are received by transmembrane cell\nsurface receptors coupled to intracellular signaling cir-\nThe pRb signaling circuit, as governed by TGFb and",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 39
        }
    },
    "954": {
        "text": "other extrinsic factors, can be disrupted in a variety of\ncuits.\nAntigrowth signals can block proliferation by two dis-\nways in different types of human tumors (Fynan and\nReiss, 1993). Some lose TGFb responsiveness through\ntinct mechanisms. Cells may be forced out of the active\nproliferative cycle into the quiescent (G0) state from\ndownregulation of their TGFb receptors, while others\ndisplay mutant, dysfunctional receptors (Fynan and\nwhich they may reemerge on some future occasion",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 40
        }
    },
    "955": {
        "text": "which they may reemerge on some future occasion\nwhen extracellular signals permit. Alternatively, cells\nReiss, 1993; Markowitz et al., 1995). The cytoplasmic\nSmad4 protein, which transduces signals from ligand-\nmay be induced to permanently relinquish their prolifera-\ntive potential by being induced to enter into postmitotic\nactivated TGFb receptors to downstream targets, may\nbe eliminated through mutation of its encoding gene\nstates, usually associated with acquisition of specific",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 41
        }
    },
    "956": {
        "text": "differentiation-associated traits.\n(Schutte et al., 1996). The locus encoding p15INK4B may be\ndeleted (Chin et al., 1998). Alternatively, the immediate\nIncipient cancer cells must evade these antiprolifera-\ntive signals if they are to prosper. Much of the circuitry\ndownstream target of its actions, CDK4, may become\nunresponsive to the inhibitory actions of p15INK4B be-\nthat enables normal cells to respond to antigrowth sig-\nnals is associated with the cell cycle clock, specifically",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 42
        }
    },
    "957": {
        "text": "cause of mutations that create amino acid substitutions\nReview\n61\nin its INK4A/B-interacting domain; the resulting cyclin\nin virtually all cell types throughout the body. Once trig-\ngered by a variety of physiologic signals, this program\nD:CDK4 complexes are then given a free hand to inacti-\nvate pRb by hyperphosphorylation (Zuo et al., 1996).\nunfolds in a precisely choreographed series of steps.\nCellular membranes are disrupted, the cytoplasmic and",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 43
        }
    },
    "958": {
        "text": "Finally, functional pRb, the end target of this pathway,\nmay be lost through mutation of its gene. Alternatively,\nnuclear skeletons are broken down, the cytosol is ex-\ntruded, the chromosomes are degraded, and the nu-\nin certain DNA virus-induced tumors, notably cervical\ncarcinomas, pRb function is eliminated through seques-\ncleus is fragmented, all in a span of 30–120 min. In the\nend, the shriveled cell corpse is engulfed by nearby cells",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 44
        }
    },
    "959": {
        "text": "tration by viral oncoproteins, such as the E7 oncoprotein\nof human papillomavirus (Dyson et al., 1989). In addition,\nin a tissue and disappears, typically within 24 hr (Wyllie\net al., 1980).\ncancer cells can also turn off expression of integrins and\nother cell adhesion molecules that send antigrowth sig-\nThe apoptotic machinery can be broadly divided into\ntwo classes of components—sensors and effectors. The\nnals, favoring instead those that convey progrowth sig-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 45
        }
    },
    "960": {
        "text": "nals; these adherence-based antigrowth signals likely\nsensors are responsible for monitoring the extracellular\nand intracellular environment for conditions of normality\nimpinge on the pRb circuit as well. The bottom line is\nthat the antigrowth circuit converging onto Rb and the\nor abnormality that influence whether a cell should live\nor die. These signals regulate the second class of com-\ncell division cycle is, one way or another, disrupted in",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 46
        }
    },
    "961": {
        "text": "a majority of human cancers, defining the concept and\nponents, which function as effectors of apoptotic death.\nThe sentinels include cell surface receptors that bind\na purpose of tumor suppressor loss in cancer.\nCell proliferation depends on more than an avoidance\nsurvival or death factors. Examples of these ligand/\nreceptor pairs include survival signals conveyed by IGF-\nof cytostatic antigrowth signals. Our tissues also con-\nstrain cell multiplication by instructing cells to enter irre-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 47
        }
    },
    "962": {
        "text": "1/IGF-2 through their receptor, IGF-1R, and by IL-3 and\nits cognate receptor, IL-3R (Lotem and Sachs, 1996;\nversibly into postmitotic, differentiated states, using di-\nverse mechanisms that are incompletely understood; it\nButt et al., 1999). Death signals are conveyed by the\nFAS ligand binding the FAS receptor and by TNFa bind-\nis apparent that tumor cells use various strategies to\navoid this terminal differentiation. One strategy for\ning TNF-R1 (Ashkenazi and Dixit, 1999). Intracellular",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 48
        }
    },
    "963": {
        "text": "sensors monitor the cell’s well-being and activate the\navoiding differentiation directly involves the c-myc on-\ncogene, which encodes a transcription factor. During\ndeath pathway in response to detecting abnormalities,\nincluding DNA damage, signaling imbalance provoked\nnormal development, the growth-stimulating action of\nMyc, in association with another factor, Max, can be\nby oncogene action, survival factor insufficiency, or hyp-\noxia (Evan and Littlewood, 1998). Further, the life of most",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 49
        }
    },
    "964": {
        "text": "supplanted by alternative complexes of Max with a\ngroup of Mad transcription factors; the Mad–Max com-\ncells is in part maintained by cell–matrix and cell–cell\nadherence-based survival signals whose abrogation\nplexes elicit differentiation-inducing signals (Foley and\nEisenman, 1999). However, overexpression of the c-Myc\nelicits apoptosis (Ishizaki et al., 1995; Giancotti and Ru-\noslahti, 1999). Both soluble and immobilized apoptotic\noncoprotein, as is seen in many tumors, can reverse this",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 50
        }
    },
    "965": {
        "text": "process, shifting the balance back to favor Myc–Max\nregulatory signals likely reflect the needs of tissues to\nmaintain their constituent cells in appropriate architec-\ncomplexes, thereby impairing differentiation and pro-\nmoting growth. During human colon carcinogenesis, in-\ntural configurations.\nMany of the signals that elicit apoptosis converge\nactivation of the APC/b-catenin pathway serves to block\nthe egress of enterocytes in the colonic crypts into a",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 51
        }
    },
    "966": {
        "text": "on the mitochondria, which respond to proapoptotic\nsignals by releasing cytochrome C, a potent catalyst of\ndifferentiated, postmitotic state (Kinzler and Vogelstein,\n1996). Analogously, during the generation of avian eryth-\napoptosis (Green and Reed, 1998). Members of the Bcl-2\nfamily of proteins, whose members have either pro-\nroblastosis, the erbA oncogene acts to prevent irrevers-\nible erythrocyte differentiation (Kahn et al., 1986).\napoptotic (Bax, Bak, Bid, Bim) or antiapoptotic (Bcl-2,",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 52
        }
    },
    "967": {
        "text": "Bcl-XL, Bcl-W) function, act in part by governing mito-\nWhile the components and interconnections between\nthe various antigrowth and differentiation-inducing sig-\nchondrial death signaling through cytochrome C re-\nlease. The p53 tumor suppressor protein can elicit apo-\nnals and the core cell cycle machinery are still being\ndelineated, the existence of an antigrowth signaling cir-\nptosis by upregulating expression of proapoptotic Bax\nin response to sensing DNA damage; Bax in turn stimu-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 53
        }
    },
    "968": {
        "text": "cuitry is clear (Figure 2), as is the necessity for its circum-\nvention by developing cancers.\nlates mitochondria to release cytochrome C.\nThe ultimate effectors of apoptosis include an array\nof intracellular proteases termed caspases (Thornberry\nAcquired Capability: Evading Apoptosis\nand Lazebnik, 1998). Two “gatekeeper” caspases, 28\nThe ability of tumor cell populations to expand in number\nand 29, are activated by death receptors such as FAS",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 54
        }
    },
    "969": {
        "text": "is determined not only by the rate of cell proliferation\nor by the cytochrome C released from mitochondria,\nbut also by the rate of cell attrition. Programmed cell\nrespectively. These proximal caspases trigger the acti-\ndeath—apoptosis—represents a major source of this\nvation of a dozen or more effector caspases that execute\nattrition. The evidence is mounting, principally from\nthe death program, through selective destruction of sub-\nstudies in mouse models and cultured cells, as well as",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 55
        }
    },
    "970": {
        "text": "cellular structures and organelles, and of the genome.\nfrom descriptive analyses of biopsied stages in human\nThe possibility that apoptosis serves as a barrier to\ncarcinogenesis, that acquired resistance toward apo-\ncancer was first raised in 1972, when Kerr, Wyllie, and\nptosis is a hallmark of most and perhaps all types of\nCurrie described massive apoptosis in the cells populat-\ncancer.\ning rapidly growing, hormone-dependent tumors follow-\nObservations accumulated over the past decade indi-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 56
        }
    },
    "971": {
        "text": "cate that the apoptotic program is present in latent form\ning hormone withdrawal (Kerr et al., 1972). The discovery\nCell\n62\nof the bcl-2 oncogene by its upregulation via chromo-\nabnormalities, including hypoxia and oncogene hyper-\nexpression, are also funneled in part via p53 to the apo-\nsomal translocation in follicular lymphoma (reviewed in\nptotic machinery; these too are impaired at eliciting\nKorsmeyer, 1992) and its recognition as having anti-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 57
        }
    },
    "972": {
        "text": "apoptosis when p53 function is lost (Levine, 1997). Addi-\napoptotic activity (Vaux et al., 1988) opened up the in-\ntionally, the PI3 kinase–AKT/PKB pathway, which trans-\nvestigation of apoptosis in cancer at the molecular level.\nmits antiapoptotic survival signals, is likely involved in\nWhen coexpressed with a myc oncogene in transgenic\nmitigating apoptosis in a substantial fraction of human\nmice, the bcl-2 gene was able to promote formation of",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 58
        }
    },
    "973": {
        "text": "tumors. This survival signaling circuit can be activated\nB cell lymphomas by enhancing lymphocyte survival, not\nby extracellular factors such as IGF-1/2 or IL-3 (Evan\nby further stimulating their myc-induced proliferation\nand Littlewood, 1998), by intracellular signals emanating\n(Strasser et al., 1990); further, 50% of the infrequent\nfrom Ras (Downward, 1998), or by loss of the pTEN\nlymphomas arising in bcl-2 single transgenic transgenic\ntumor suppressor, a phospholipid phosphatase that",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 59
        }
    },
    "974": {
        "text": "tumor suppressor, a phospholipid phosphatase that\nmice had somatic translocations activating c-myc, con-\nnormally attenuates the AKT survival signal (Cantley and\nfirming a selective pressure during lymphomagenesis\nNeel, 1999). Recently, a mechanism for abrogating the\nto upregulate both Bcl-2 and c-Myc (McDonnell and\nFAS death signal has been revealed in a high fraction\nKorsmeyer, 1991).\nof lung and colon carcinoma cell lines: a nonsignaling\nFurther insight into the myc-bcl-2 interaction emerged",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 60
        }
    },
    "975": {
        "text": "decoy receptor for FAS ligand is upregulated, titrating\nlater from studying the effects of a myc oncogene on\nthe death-inducing signal away from the FAS death re-\nfibroblasts cultured in low serum. Widespread apoptosis\nceptor (Pitti et al., 1998). We expect that virtually all\nwas induced in myc-expressing cells lacking serum; the\ncancer cells harbor alterations that enable evasion of\nconsequent apoptosis could be abrogated by exoge-\napoptosis.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 61
        }
    },
    "976": {
        "text": "apoptosis.\nnous survival factors (e.g., IGF-1), by forced overexpres-\nIt is now possible to lay out a provisional apoptotic\nsion of Bcl-2 or the related Bcl-XL protein, or by disrup-\nsignaling circuitry (Figure 2); while incomplete, it is evi-\ntion of the FAS death signaling circuit (Hueber et al.,\ndent that most regulatory and effector components are\n1997). Collectively, the data indicate that a cell’s apo-\npresent in redundant form. This redundancy holds im-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 62
        }
    },
    "977": {
        "text": "ptotic program can be triggered by an overexpressed\nportant implications for the development of novel types\noncogene. Indeed, elimination of cells bearing activated\nof antitumor therapy, since tumor cells that have lost\noncogenes by apoptosis may represent the primary\nproapoptotic components are likely to retain other simi-\nmeans by which such mutant cells are continually culled\nlar ones. We anticipate that new technologies will be\nfrom the body’s tissues.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 63
        }
    },
    "978": {
        "text": "from the body’s tissues.\nable to display the apoptotic pathways still operative in\nOther examples strengthen the consensus that apo-\nspecific types of cancer cells and that new drugs will\nptosis is a major barrier to cancer that must be circum-\nenable cross-talk between the still intact components\nvented. Thus, in transgenic mice where the pRb tumor\nof parallel apoptotic signaling pathways in tumor cells,\nsuppressor was functionally inactivated in the choroid",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 64
        }
    },
    "979": {
        "text": "resulting in restoration of the apoptotic defense mecha-\nplexus, slowly growing microscopic tumors arose, ex-\nnism, with substantial therapeutic benefit.\nhibiting high apoptotic rates; the additional inactivation\nof the p53 tumor suppressor protein, a component of\nAcquired Capability: Limitless Replicative Potential\nthe apoptotic signaling circuitry, led to rapidly growing\nThree acquired capabilities—growth signal autonomy,\ntumors containing low numbers of apoptotic cells (Sy-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 65
        }
    },
    "980": {
        "text": "insensitivity to antigrowth signals, and resistance to\nmonds et al., 1994). The role of extracellular survival\napoptosis—all lead to an uncoupling of a cell’s growth\nfactors is illustrated by disease progression in trans-\nprogram from signals in its environment. In principle,\ngenic mice prone to pancreatic islet tumors. If IGF-2\nthe resulting deregulated proliferation program should\ngene expression, which is activated in this tumorigene-\nsuffice to enable the generation of the vast cell popula-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 66
        }
    },
    "981": {
        "text": "sis pathway, was abrogated using gene knockout mice,\ntions that constitute macroscopic tumors. However, re-\ntumor growth and progression were impaired, as evi-\nsearch performed over the past 30 years indicates that\ndenced by the appearance of comparatively small, be-\nthis acquired disruption of cell-to-cell signaling, on its\nnign tumors showing high rates of apoptosis (Christofori\nown, does not ensure expansive tumor growth. Many\net al., 1994). In these cells, the absence of IGF-2 did not",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 67
        }
    },
    "982": {
        "text": "and perhaps all types of mammalian cells carry an intrin-\naffect cell proliferation rates, clearly identifying it as an\nsic, cell-autonomous program that limits their multiplica-\nantiapoptotic survival factor. Collectively, these obser-\ntion. This program appears to operate independently of\nvations argue that altering components of the apoptotic\nthe cell-to-cell signaling pathways described above. It\nmachinery can dramatically affect the dynamics of tu-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 68
        }
    },
    "983": {
        "text": "too must be disrupted in order for a clone of cells to\nmor progression, providing a rationale for the inactiva-\nexpand to a size that constitutes a macroscopic, life-\ntion of this machinery during tumor development.\nthreatening tumor.\nResistance to apoptosis can be acquired by cancer\nThe early work of Hayflick demonstrated that cells in\ncells through a variety of strategies. Surely, the most\nculture have a finite replicative potential (reviewed in",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 69
        }
    },
    "984": {
        "text": "commonly occurring loss of a proapoptotic regulator\nHayflick, 1997). Once such cell populations have pro-\nthrough mutation involves the p53 tumor suppressor\ngressed through a certain number of doublings, they\ngene. The resulting functional inactivation of its product,\nstop growing—a process termed senescence. The se-\nthe p53 protein, is seen in greater than 50% of human\nnescence of cultured human fibroblasts can be circum-\ncancers and results in the removal of a key component",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 70
        }
    },
    "985": {
        "text": "vented by disabling their pRb and p53 tumor suppressor\nof the DNA damage sensor that can induce the apoptotic\nproteins, enabling these cells to continue multiplying for\nadditional generations until they enter into a second\neffector cascade (Harris, 1996). Signals evoked by other\nReview\n63\nstate termed crisis. The crisis state is characterized by\nthreshold, and this in turn permits unlimited multiplica-\nmassive cell death, karyotypic disarray associated with",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 71
        }
    },
    "986": {
        "text": "tion of descendant cells. Both mechanisms seem to be\nend-to-end fusion of chromosomes, and the occasional\nstrongly suppressed in most normal human cells in order\nemergence of a variant (1 in 107) cell that has acquired\nto deny them unlimited replicative potential.\nthe ability to multiply without limit, the trait termed im-\nThe role of telomerase in immortalizing cells can be\nmortalization (Wright et al., 1989).\ndemonstrated directly by ectopically expressing the en-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 72
        }
    },
    "987": {
        "text": "Provocatively, most types of tumor cells that are prop-\nzyme in cells, where it can convey unlimited replicative\nagated in culture appear to be immortalized, suggesting\npotential onto a variety of normal early passage, prese-\nthat limitless replicative potential is a phenotype that\nnescent cells in vitro (Bodnar et al., 1998; Vaziri and\nwas acquired in vivo during tumor progression and was\nBenchimol, 1998). Further, late passage cells poised to",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 73
        }
    },
    "988": {
        "text": "essential for the development of their malignant growth\nenter crisis continue to proliferate without giving any\nstate (Hayflick, 1997). This result suggests that at some\nevidence of crisis when supplied with this enzyme\npoint during the course of multistep tumor progression,\n(Counter et al., 1998; Halvorsen et al., 1999; Zhu et al.,\nevolving premalignant cell populations exhaust their en-\n1999). Additional clues into the importance of telomere\ndowment of allowed doublings and can only complete",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 74
        }
    },
    "989": {
        "text": "maintenance for cancer comes from analysis of mice\ntheir tumorigenic agenda by breaching the mortality bar-\nlacking telomerase function. For example, mice carrying\nrier and acquiring unlimited replicative potential.\na homozygous knockout of the cell cycle inhibitor\nObservations of cultured cells indicate that various\np16INK4A are tumor prone, particularly when exposed to\nnormal human cell types have the capacity for 60–70\ncarcinogens; the tumors that arise show comparatively",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 75
        }
    },
    "990": {
        "text": "doublings. Taken at face value, these numbers make\nelevated telomerase activity. When carcinogens were\nlittle sense when attempting to invoke cell mortality as\napplied to p16INK4A-null mice that also lacked telomerase,\nan impediment to cancer formation: 60–70 doublings\ntumor incidence was reduced, concomitant with sub-\nshould enable clones of tumor cells to expand to num-\nstantial telomere shortening and karyotypic disarray in\nbers that vastly exceed the number of cells in the human",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 76
        }
    },
    "991": {
        "text": "those tumors that did appear (Greenberg et al., 1999).\nbody. If clues from evaluation of proliferation and apo-\nWhile telomere maintenance is clearly a key compo-\nptotic rates in certain human tumors (Wyllie et al., 1980)\nnent of the capability for unlimited replication, we remain\nand transgenic mouse models (Symonds et al., 1994;\nuncertain about another one, the circumvention of cellu-\nShibata et al., 1996; Bergers et al., 1998) prove generaliz-\nlar senescence. The phenomenon of senescence was",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 77
        }
    },
    "992": {
        "text": "lar senescence. The phenomenon of senescence was\nable, the paradox can be resolved: evolving premalig-\noriginally observed as a delayed response of primary\nnant and malignant cell populations evidence chronic,\ncells to extended propagation in vitro and has thus been\nwidespread apoptosis and consequently suffer consid-\nassociated with mechanisms of divisional counting\nerable cell attrition concomitant with cell accumulation.\n(Hayflick, 1997). More recently, the senescent state has",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 78
        }
    },
    "993": {
        "text": "Thus, the number of cells in a tumor greatly underrepre-\nbeen observed to be inducible in certain cultured cells\nsents the cell generations required to produce it, raising\nin response to high level expression of genes such as\nthe generational limit of normal somatic cells as a barrier\nthe activated ras oncogene (Serrano et al., 1997).\nto cancer.\nThe above-cited observations might argue that senes-\nThe counting device for cell generations has been",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 79
        }
    },
    "994": {
        "text": "The counting device for cell generations has been\ncence, much like apoptosis, reflects a protective mecha-\ndiscovered over the past decade: the ends of chromo-\nnism that can be activated by shortened telomeres or\nsomes, telomeres, which are composed of several thou-\nconflicting growth signals that forces aberrant cells irre-\nsand repeats of a short 6 bp sequence element. Replica-\nversibly into a G0-like state, thereby rendering them inca-\ntive generations are counted by the 50–100 bp loss of",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 80
        }
    },
    "995": {
        "text": "pable of further proliferation. If so, circumvention of se-\ntelomeric DNA from the ends of every chromosome dur-\nnescence in vivo may indeed represent an essential step\ning each cell cycle. This progressive shortening has\nin tumor progression that is required for the subsequent\nbeen attributed to the inability of DNA polymerases to\napproach to and breaching of the crisis barrier. But we\ncompletely replicate the 39 ends of chromosomal DNA\nconsider an alternative model equally plausible: senes-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 81
        }
    },
    "996": {
        "text": "during each S phase. The progressive erosion of telo-\ncence could be an artifact of cell culture that does not\nmeres through successive cycles of replication eventu-\nreflect a phenotype of cells within living tissues and\nally causes them to lose their ability to protect the ends\ndoes not represent an impediment to tumor progression\nof chromosomal DNA. The unprotected chromosomal\nin vivo. Resolution of this quandary will be critical to\nends participate in end-to-end chromosomal fusions,",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 82
        }
    },
    "997": {
        "text": "completely understand the acquisition of limitless repli-\nyielding the karyotypic disarray associated with crisis\ncative potential.\nand resulting, almost inevitably, in the death of the af-\nfected cell (Counter et al., 1992).\nAcquired Capability: Sustained Angiogenesis\nTelomere maintenance is evident in virtually all types of\nThe oxygen and nutrients supplied by the vasculature\nmalignant cells (Shay and Bacchetti, 1997); 85%–90%\nare crucial for cell function and survival, obligating virtu-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 83
        }
    },
    "998": {
        "text": "of them succeed in doing so by upregulating expression\nally all cells in a tissue to reside within 100 mm of a\nof the telomerase enzyme, which adds hexanucleotide\ncapillary blood vessel. During organogenesis, this close-\nrepeats onto the ends of telomeric DNA (Bryan and\nness is ensured by coordinated growth of vessels and\nCech, 1999), while the remainder have invented a way\nparenchyma. Once a tissue is formed, the growth of\nof activating a mechanism, termed ALT, which appears",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 84
        }
    },
    "999": {
        "text": "new blood vessels—the process of angiogenesis—is\nto maintain telomeres through recombination-based in-\ntransitory and carefully regulated. Because of this de-\nterchromosomal exchanges of sequence information\npendence on nearby capillaries, it would seem plausible\n(Bryan et al., 1995). By one or the other mechanism,\ntelomeres are maintained at a length above a critical\nthat proliferating cells within a tissue would have an\nCell\n64\nintrinsic ability to encourage blood vessel growth. But",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 85
        }
    },
    "1000": {
        "text": "case angiogenesis was found to be activated in mid-\nstage lesions, prior to the appearance of full-blown tu-\nthe evidence is otherwise. The cells within aberrant pro-\nliferative lesions initially lack angiogenic ability, curtail-\nmors. Similarly, angiogenesis can be discerned in pre-\nmalignant lesions of the human cervix, breast, and skin\ning their capability for expansion. In order to progress\nto a larger size, incipient neoplasias must develop angio-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 86
        }
    },
    "1001": {
        "text": "(melanocytes) (Hanahan and Folkman, 1996); we expect\nthat induction of angiogenesis will prove to be an early\ngenic ability (Bouck et al., 1996; Hanahan and Folkman,\n1996; Folkman, 1997).\nto midstage event in many human cancers. These obser-\nvations, taken together with the effects of angiogenesis\nCounterbalancing positive and negative signals en-\ncourage or block angiogenesis. One class of these sig-\ninhibitors, indicate that neovascularization is a prerequi-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 87
        }
    },
    "1002": {
        "text": "site to the rapid clonal expansion associated with the\nnals is conveyed by soluble factors and their receptors,\nthe latter displayed on the surface of endothelial cells;\nformation of macroscopic tumors.\nTumors appear to activate the angiogenic switch by\nintegrins and adhesion molecules mediating cell–matrix\nand cell–cell association also play critical roles. The\nchanging the balance of angiogenesis inducers and\ncountervailing inhibitors (Hanahan and Folkman, 1996).",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 88
        }
    },
    "1003": {
        "text": "angiogenesis-initiating signals are exemplified by vas-\ncular endothelial growth factor (VEGF) and acidic and\nOne common strategy for shifting the balance involves\naltered gene transcription. Many tumors evidence in-\nbasic fibroblast growth factors (FGF1/2). Each binds to\ntransmembrane tyrosine kinase receptors displayed by\ncreased expression of VEGF and/or FGFs compared to\ntheir normal tissue counterparts. In others, expression\nendothelial cells (Fedi et al., 1997; Veikkola and Alitalo,",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 89
        }
    },
    "1004": {
        "text": "1999). A prototypical angiogenesis inhibitor is throm-\nof endogenous inhibitors such as thrombospondin-1 or\nb-interferon is downregulated. Moreover, both transi-\nbospondin-1, which binds to CD36, a transmembrane\nreceptor on endothelial cells coupled to intracellular Src-\ntions may occur, and indeed be linked, in some tumors\n(Singh et al., 1995; Volpert et al., 1997).\nlike tyrosine kinases (Bull et al., 1994). There are cur-\nrently more than two dozen angiogenic inducer factors",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 90
        }
    },
    "1005": {
        "text": "The mechanisms underlying shifts in the balances be-\ntween angiogenic regulators remain incompletely un-\nknown and a similar number of endogenous inhibitor\nproteins.\nderstood. In one well-documented example, the inhibi-\ntor thrombospondin-1 has been found to positively\nIntegrin signaling also contributes to this regulatory\nbalance. Quiescent vessels express one class of inte-\nregulated by the p53 tumor suppressor protein in some\ncell types. Consequently, loss of p53 function, which",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 91
        }
    },
    "1006": {
        "text": "grins, whereas sprouting capillaries express another.\nInterference with signaling from the latter class of inte-\noccurs in most human tumors, can cause thrombospon-\ndin-1 levels to fall, liberating endothelial cells from its\ngrins can inhibit angiogenesis (Varner and Cheresh,\n1996; Giancotti and Ruoslahti, 1999), underscoring the\ninhibitory effects (Dameron et al., 1994). The VEGF gene\nis also under complex transcriptional control. For exam-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 92
        }
    },
    "1007": {
        "text": "important contribution of cell adhesion to the angiogenic\nprogram (Hynes and Wagner, 1996). Extracellular prote-\nple, activation of the ras oncogene or loss of the VHL\ntumor suppressor gene in certain cell types causes\nases are physically and functionally connected with pro-\nangiogenic integrins, and both help dictate the invasive\nupregulation of VEGF expression (Rak et al., 1995; Max-\nwell et al., 1999).\ncapability of angiogenic endothelial cells (Stetler-Ste-\nvenson, 1999).",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 93
        }
    },
    "1008": {
        "text": "venson, 1999).\nAnother dimension of regulation is emerging in the\nform of proteases, which can control the bioavailability\nExperimental evidence for the importance of inducing\nand sustaining angiogenesis in tumors is both extensive\nof angiogenic activators and inhibitors. Thus, a variety\nof proteases can release bFGF stored in the ECM\nand compelling (Bouck et al., 1996; Hanahan and Folk-\nman, 1996; Folkman, 1997). The story begins almost 30\n(Whitelock et al., 1996), whereas plasmin, a proangio-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 94
        }
    },
    "1009": {
        "text": "genic component of the clotting system, can cleave itself\nyears ago with Folkman and colleagues, who used in\nvivo bioassays to demonstrate the necessity of angio-\ninto an angiogenesis inhibitor form called angiostatin\n(Gately et al., 1997). The coordinated expression of pro-\ngenesis for explosive growth of tumor explants (re-\nviewed in Folkman, 1997). Molecular proof of principle\nand antiangiogenic signaling molecules, and their mod-\nulation by proteolysis, appear to reflect the complex",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 95
        }
    },
    "1010": {
        "text": "came, for example, when anti-VEGF antibodies proved\nable to impair neovascularization and growth of subcu-\nhomeostatic regulation of normal tissue angiogenesis\nand of vascular integrity.\ntaneous tumors in mice (Kim et al., 1993), as did a domi-\nnant-interfering version of the VEGF receptor 2 (flk-1)\nAs is already apparent, tumor angiogenesis offers a\nuniquely attractive therapeutic target, indeed one that\n(Millauer et al., 1994); both results have motivated the",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 96
        }
    },
    "1011": {
        "text": "development of specific VEGF/VEGF-R inhibitors now\nis shared in common by most and perhaps all types of\nhuman tumors. The next decade will produce a catalog\nin late stage clinical trials.\nThe essential role of angiogenesis is further supported\nof the angiogenic regulatory molecules expressed by\ndifferent types of tumors, and in many cases, by their\nby the ability of an increasing catalog of antiangiogenic\nsubstances to impair the growth of tumor cells inocu-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 97
        }
    },
    "1012": {
        "text": "progenitor stages. Use of increasingly sophisticated\nmouse models will make it possible to assign specific\nlated subcutaneously in mice (Folkman, 1997). Tumors\narising in cancer-prone transgenic mice are similarly\nroles to each of these regulators and to discern the\nmolecular mechanisms that govern their production and\nsusceptible to angiogenic inhibitors (Bergers et al.,\n1999).\nactivity. Already available evidence indicates that differ-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 98
        }
    },
    "1013": {
        "text": "ent types of tumor cells use distinct molecular strategies\nThe ability to induce and sustain angiogenesis seems\nto be acquired in a discrete step (or steps) during tumor\nto activate the angiogenic switch. This raises the ques-\ntion of whether a single antiangiogenic therapeutic will\ndevelopment, via an “angiogenic switch” from vascular\nquiescence. When three transgenic mouse models were\nsuffice to treat all tumor types, or whether an ensemble\nof such therapeutics will need to be developed, each",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 99
        }
    },
    "1014": {
        "text": "analyzed throughout multistep tumorigenesis, in each\nReview\n65\nresponding to a distinct program of angiogenesis that\nChanges in expression of CAMs in the immunoglobu-\nlin superfamily also appear to play critical roles in the\nhas been developed by a specific class of human\nprocesses of invasion and metastasis (Johnson, 1991).\ntumors.\nThe clearest case involves N-CAM, which undergoes a\nswitch in expression from a highly adhesive isoform to\nAcquired Capability: Tissue Invasion and Metastasis",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 100
        }
    },
    "1015": {
        "text": "poorly adhesive (or even repulsive) forms in Wilms’ tu-\nSooner or later during the development of most types\nmor, neuroblastoma, and small cell lung cancer (John-\nof human cancer, primary tumor masses spawn pioneer\nson, 1991; Kaiser et al., 1996) and reduction in overall\ncells that move out, invade adjacent tissues, and thence\nexpression level in invasive pancreatic and colorectal\ntravel to distant sites where they may succeed in found-\ncancers (Fogar et al., 1997). Experiments in transgenic",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 101
        }
    },
    "1016": {
        "text": "ing new colonies. These distant settlements of tumor\nmice support a functional role for the normal adhesive\ncells—metastases—are the cause of 90% of human can-\nform of N-CAM in suppressing metastasis (Perl et al.,\ncer deaths (Sporn, 1996). The capability for invasion and\n1999).\nmetastasis enables cancer cells to escape the primary\nChanges in integrin expression are also evident in\ntumor mass and colonize new terrain in the body where,\ninvasive and metastatic cells. Invading and metastasiz-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 102
        }
    },
    "1017": {
        "text": "at least initially, nutrients and space are not limiting. The\ning cancer cells experience changing tissue microenvi-\nnewly formed metastases arise as amalgams of cancer\nronments during their journeys, which can present novel\ncells and normal supporting cells conscripted from the\nmatrix components. Accordingly, successful coloniza-\nhost tissue. Like the formation of the primary tumor\ntion of these new sites (both local and distant) demands\nmass, successful invasion and metastasis depend upon",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 103
        }
    },
    "1018": {
        "text": "adaptation, which is achieved through shifts in the spec-\nall of the other five acquired hallmark capabilities. But\ntrum of integrin a or b subunits displayed by the migrat-\nwhat additional cellular changes enable the acquisition\ning cells. These novel permutations result in different\nof these final capabilities during tumorigenesis?\nintegrin subtypes (of which there are greater than 22)\nInvasion and metastasis are exceedingly complex\nhaving distinct substrate preferences. Thus, carcinoma",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 104
        }
    },
    "1019": {
        "text": "processes, and their genetic and biochemical determi-\ncells facilitate invasion by shifting their expression of\nnants remain incompletely understood. At the mecha-\nintegrins from those that favor the ECM present in nor-\nnistic level, they are closely allied processes, which justi-\nmal epithelium to other integrins (e.g., a3b1 and aVb3)\nfies their association with one another as one general\nthat preferentially bind the degraded stromal compo-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 105
        }
    },
    "1020": {
        "text": "capability of cancer cells. Both utilize similar operational\nnents produced by extracellular proteases (Varner and\nstrategies, involving changes in the physical coupling\nCheresh, 1996; Lukashev and Werb, 1998). Forced ex-\nof cells to their microenvironment and activation of ex-\npression of integrin subunits in cultured cells can induce\ntracellular proteases.\nor inhibit invasive and metastatic behavior, consistent\nSeveral classes of proteins involved in the tethering",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 106
        }
    },
    "1021": {
        "text": "with a role of these receptors in acting as central deter-\nof cells to their surroundings in a tissue are altered in\nminants of these processes (Varner and Cheresh, 1996).\ncells possessing invasive or metastatic capabilities. The\nAttempts at explaining the cell biological effects of\naffected proteins include cell–cell adhesion molecules\nintegrins in terms of a small number of mechanistic rules\n(CAMs)—notably members of the immunoglobulin and\nhave been confounded by the large number of distinct",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 107
        }
    },
    "1022": {
        "text": "calcium-dependent cadherin families, both of which me-\nintegrin genes, by the even larger number of heterodi-\ndiate cell-to-cell interactions—and integrins, which link\nmeric receptors resulting from combinatorial expression\ncells to extracellular matrix substrates. Notably, all of\nof various a and b receptor subunits, and by the increas-\nthese “adherence” interactions convey regulatory sig-\ning evidence of complex signals emitted by the cyto-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 108
        }
    },
    "1023": {
        "text": "nals to the cell (Aplin et al., 1998). The most widely\nplasmic domains of these receptors (Aplin et al., 1998;\nobserved alteration in cell-to-environment interactions\nGiancotti and Ruoslahti, 1999). Still, there is little doubt\nin cancer involves E-cadherin, a homotypic cell-to-cell\nthat these receptors play central roles in the capability\ninteraction molecule ubiquitously expressed on epithe-\nfor tissue invasion and metastasis.\nlial cells. Coupling between adjacent cells by E-cadherin",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 109
        }
    },
    "1024": {
        "text": "The second general parameter of the invasive and\nbridges results in the transmission of antigrowth and\nmetastatic capability involves extracellular proteases\nother signals via cytoplasmic contacts with b-catenin\n(Coussens and Werb, 1996; Chambers and Matrisian,\nto intracellular signaling circuits that include the Lef/\n1997). Protease genes are upregulated, protease inhibi-\nTcf transcription factor (Christofori and Semb, 1999).\ntor genes are downregulated, and inactive zymogen",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 110
        }
    },
    "1025": {
        "text": "tor genes are downregulated, and inactive zymogen\nE-cadherin function is apparently lost in a majority of\nforms of proteases are converted into active enzymes.\nepithelial cancers, by mechanisms that include muta-\nMatrix-degrading proteases are characteristically asso-\ntional inactivation of the E-cadherin or b-catenin genes,\nciated with the cell surface, by synthesis with a trans-\ntranscriptional repression, or proteolysis of the extracel-\nmembrane domain, binding to specific protease re-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 111
        }
    },
    "1026": {
        "text": "membrane domain, binding to specific protease re-\nlular cadherin domain (Christofori and Semb, 1999).\nceptors, or association with integrins (Werb, 1997;\nForced expression of E-cadherin in cultured cancer cells\nStetler-Stevenson, 1999). One imagines that docking of\nand in a transgenic mouse model of carcinogenesis im-\nactive proteases on the cell surface can facilitate inva-\npairs invasive and metastatic phenotypes, whereas in-\nsion by cancer cells into nearby stroma, across blood",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 112
        }
    },
    "1027": {
        "text": "terference with E-cadherin function enhances both\nvessel walls, and through normal epithelial cell layers.\ncapabilities (Christofori and Semb, 1999). Thus, E-cad-\nThat notion notwithstanding, it is difficult to unambigu-\nherin serves as a widely acting suppressor of invasion\nously ascribe the functions of particular proteases solely\nand metastasis by epithelial cancers, and its functional\nto this capability, given their evident roles in other",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 113
        }
    },
    "1028": {
        "text": "elimination represents a key step in the acquisition of\nhallmark capabilities, including angiogenesis (Stetler-\nStevenson, 1999) and growth signaling (Werb, 1997;\nthis capability.\nCell\n66\nFigure 4. Parallel Pathways of Tumorigen-\nesis\nWhile we believe that virtually all cancers\nmust acquire the same six hallmark capabili-\nties (A), their means of doing so will vary sig-\nnificantly, both mechanistically (see text) and\nchronologically (B). Thus, the order in which",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 114
        }
    },
    "1029": {
        "text": "chronologically (B). Thus, the order in which\nthese capabilities are acquired seems likely\nbe quite variable across the spectrum of can-\ncer types and subtypes. Moreover, in some\ntumors, a particular genetic lesion may confer\nseveral capabilities simultaneously, decreas-\ning the number of distinct mutational steps\nrequired to complete tumorigenesis. Thus,\nloss of function of the p53 tumor suppressor\ncan facilitate both angiogenesis and resis-\ntance to apoptosis (e.g., in the five-step path-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 115
        }
    },
    "1030": {
        "text": "tance to apoptosis (e.g., in the five-step path-\nway shown), as well as enabling the charac-\nteristic of genomic instability. In other tumors,\na capability may only be acquired through the\ncollaboration of two or more distinct genetic\nchanges, thereby increasing the total number\nnecessary for completion of tumor progres-\nsion. Thus, in the eight-step pathway shown,\ninvasion/metastasis and resistance to apo-\nptosis are each acquired in two steps.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 116
        }
    },
    "1031": {
        "text": "ptosis are each acquired in two steps.\nBergers and Coussens, 2000), which in turn contribute\nThe available evidence suggests that most are acquired,\ndirectly or indirectly, through changes in the genomes\ndirectly or indirectly to the invasive/metastatic capa-\nbility.\nof cancer cells. But mutation of specific genes is an\ninefficient process, reflecting the unceasing, fastidious\nA further dimension of complexity derives from the\nmultiple cell types involved in protease expression and",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 117
        }
    },
    "1032": {
        "text": "maintenance of genomic integrity by a complex array\nof DNA monitoring and repair enzymes. These genome\ndisplay. In many types of carcinomas, matrix-degrading\nproteases are produced not by the epithelial cancer cells\nmaintenance teams strive to ensure that DNA sequence\ninformation remains pristine. Karyotypic order is guaran-\nbut rather by conscripted stromal and inflammatory cells\n(Werb, 1997); once released by these cells, they may be\nteed by yet other watchmen, manning so-called check-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 118
        }
    },
    "1033": {
        "text": "points, that operate at critical times in the cell’s life,\nwielded by the carcinoma cells. For example, certain\ncancer cells induce urokinase (uPA) expression in cocul-\nnotably mitosis. Together, these systems ensure that\ntured stromal cells, which then binds to the urokinase\nmutations are rare events, indeed so rare that the multi-\nreceptor (uPAR) expressed on the cancer cells (Johnsen\nple mutations known to be present in tumor cell ge-\net al., 1998).",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 119
        }
    },
    "1034": {
        "text": "et al., 1998).\nnomes are highly unlikely to occur within a human life\nThe activation of extracellular proteases and the al-\nspan.\ntered binding specificities of cadherins, CAMs, and inte-\nYet cancers do appear at substantial frequency in\ngrins are clearly central to the acquisition of invasive-\nthe human population, causing some to argue that the\nness and metastatic ability. But the regulatory circuits\ngenomes of tumor cells must acquire increased mutabil-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 120
        }
    },
    "1035": {
        "text": "and molecular mechanisms that govern these shifts re-\nity in order for the process of tumor progression to reach\nmain elusive and, at present, seem to differ from one\ncompletion in several decades time (Loeb, 1991). Mal-\ntissue environment to another. The acquired capability\nfunction of specific components of these genomic\nfor invasion and metastasis represents the last great\n“caretaker” systems has been invoked to explain this\nfrontier for exploratory cancer research. We envision",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 121
        }
    },
    "1036": {
        "text": "increased mutability (Lengauer et al., 1998). The most\nthat evolving analytic techniques will soon make it possi-\nprominent member of these systems is the p53 tumor\nble to construct comprehensive profiles of the expres-\nsuppressor protein, which, in response to DNA damage,\nsion and functional activities of proteases, integrins, and\nelicits either cell cycle arrest to allow DNA repair to take\nCAMs in a wide variety of cancer types, both before and",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 122
        }
    },
    "1037": {
        "text": "place or apoptosis if the damage is excessive. Indeed, it\nafter they acquire invasive and metastatic abilities. The\nis now clear that the functioning of the p53 DNA damage\nchallenge will then be to apply the new molecular in-\nsignaling pathway is lost in most, if not all, human can-\nsights about tissue invasiveness and metastasis to the\ncers (Levine, 1997). Moreover, a growing number of\ndevelopment of effective therapeutic strategies.\nother genes involved in sensing and repairing DNA dam-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 123
        }
    },
    "1038": {
        "text": "age, or in assuring correct chromosomal segregation\nduring mitosis, is found to be lost in different cancers,\nAn Enabling Characteristic: Genome Instability\nThe acquisition of the enumerated six capabilities during\nlabeling these caretakers as tumor suppressors (Len-\ngauer et al., 1998). Their loss of function is envisioned\nthe course of tumor progression creates a dilemma.\nReview\n67\nto allow genome instability and variability and the gener-\nthe signals exchanged between the various cell types",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 124
        }
    },
    "1039": {
        "text": "existing symbiotically within a tumor mass and knowing\nation of consequently mutant cells with selective advan-\ntages. Interestingly, recent evidence suggests that apo-\ntheir effects on the integrated circuits of each of those\ncell types.\nptosis may also be a vehicle of genomic instability, in\nthat DNA within apoptotic cell bodies can be incorpo-\nOur ability to analyze individual human cancers at\nthe genetic and biochemical levels will also undergo a",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 125
        }
    },
    "1040": {
        "text": "rated into neighboring cells following phagoctytosis\n(Holmgren et al., 1999), in principle genetically diversify-\ndramatic change. At present, description of a recently\ndiagnosed tumor in terms of its underlying genetic le-\ning any of the constituent cell types of a tumor. We place\nthis acquired characteristic of genomic instability apart\nsions remains a distant prospect. Nonetheless, we look\nahead 10 or 20 years to the time when the diagnosis of",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 126
        }
    },
    "1041": {
        "text": "from the six acquired capabilities associated with tumor\ncell phenotype and tumor physiology: it represents the\nall the somatically acquired lesions present in a tumor\ncell genome will become a routine procedure. By then,\nmeans that enables evolving populations of premalig-\nnant cells to reach these six biological endpoints.\ngenome-wide gene expression profiles of tumor cells\nwill also be routine. With all this information in hand, it\nwill become possible to test definitively our proposition",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 127
        }
    },
    "1042": {
        "text": "Alternative Pathways to Cancer\nthat the development of all types of human tumor cells\nThe paths that cells take on their way to becoming malig-\nis governed by a common set of rules such as those\nnant are highly variable. Within a given cancer type,\nimplied by the six acquired capabilities enumerated\nmutation of particular target genes such as ras or p53\nhere.\nmay be found in only a subset of otherwise histologically\nWe anticipate far deeper insight into the roles played",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 128
        }
    },
    "1043": {
        "text": "identical tumors. Further, mutations in certain onco-\nby inherited alleles in cancer susceptibility and patho-\ngenes and tumor suppressor genes can occur early in\ngenesis. At present, our understanding of the interplay\nsome tumor progression pathways and late in others. As\nat the cellular level between inherited cancer modifier\na consequence, the acquisition of biological capabilities\ngenes with oncogenes and tumor suppressor genes that\nsuch as resistance to apoptosis, sustained angiogen-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 129
        }
    },
    "1044": {
        "text": "are altered somatically is rudimentary; modifiers can in\nesis, and unlimited replicative potential can appear at\nprinciple act in any of the constituent cell types of a\ndifferent times during these various progressions. Ac-\ntumor, or elsewhere in the body, whereas the classical\ncordingly, the particular sequence in which capabilities\ncancer genes largely act in the cancer cells themselves.\nare acquired can vary widely, both among tumors of the",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 130
        }
    },
    "1045": {
        "text": "These gaps will be bridged in part by new informatics\nsame type and certainly between tumors of different\ntechnologies, enabling us to process and interpret the\ntypes (Figure 4). Furthermore, in certain tumors, a spe-\ninundation of genetic information that will soon flow from\ncific genetic event may, on its own, contribute only par-\nautomated sequencing instruments. New technologies\ntially to the acquisition of a single capability, while in",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 131
        }
    },
    "1046": {
        "text": "will also aid us in rationalizing the complex constella-\nothers, this event may aid in the simultaneous acquisi-\ntions of interacting alleles in terms of a systematics of\ntion of several distinct capabilities. Nonetheless, we be-\ncancer formation of the type that we propose here.\nlieve that independent of how the steps in these genetic\nThe metaphors used to conceptualize cancer cell\npathways are arranged, the biological endpoints that\nfunction will also shift dramatically. For decades now,",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 132
        }
    },
    "1047": {
        "text": "are ultimately reached—the hallmark capabilities of can-\nwe have been able to predict with precision the behavior\ncer—will prove to be shared in common by all types of\nof an electronic integrated circuit in terms of its constit-\ntumors.\nuent parts—its interconnecting components, each re-\nsponsible for acquiring, processing, and emitting signals\nSynthesis\naccording to a precisely defined set of rules. Two de-\nCancer cells propagated in culture and dissected into",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 133
        }
    },
    "1048": {
        "text": "cades from now, having fully charted the wiring dia-\ntheir molecular components have yielded much of the\ngrams of every cellular signaling pathway, it will be pos-\nwealth of information that we currently possess about\nsible to lay out the complete “integrated circuit of the\nthe molecular processes underlying cancer develop-\ncell” upon its current outline (Figure 2). We will then be\nment. Yet by simplifying the nature of cancer—por-\nable to apply the tools of mathematical modeling to",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 134
        }
    },
    "1049": {
        "text": "traying it as a cell-autonomous process intrinsic to the\nexplain how specific genetic lesions serve to reprogram\ncancer cell—these experimental models have turned\nthis integrated circuit in each of the constituent cell\ntheir back on a central biological reality of tumor forma-\ntypes so as to manifest cancer.\ntion in vivo: cancer development depends upon changes\nWith holistic clarity of mechanism, cancer prognosis\nin the heterotypic interactions between incipient tumor",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 135
        }
    },
    "1050": {
        "text": "and treatment will become a rational science, unrecog-\ncells and their normal neighbors. Moreover, once formed,\nnizable by current practitioners. It will be possible to\nvirtually all types of human tumors, including their meta-\nunderstand with precision how and why treatment regi-\nstatic outgrowths, continue to harbor complex mixtures\nmens and specific antitumor drugs succeed or fail. We\nof several cell types that collaborate to create malignant",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 136
        }
    },
    "1051": {
        "text": "envision anticancer drugs targeted to each of the hall-\ngrowth (Figure 3). This reconceptualization of cancer\nmark capabilities of cancer; some, used in appropriate\ncell biology has begun to drive profound changes in\ncombinations and in concert with sophisticated technol-\nhow we study this disease experimentally. Continuing\nogies to detect and identify all stages of disease pro-\nelucidation of cancer pathogenesis will depend increas-\ngression, will be able to prevent incipient cancers from",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 137
        }
    },
    "1052": {
        "text": "ingly upon heterotypic organ culture systems in vitro\ndeveloping, while others will cure preexisting cancers,\nand evermore refined mouse models in vivo. Looking\nelusive goals at present. One day, we imagine that can-\nahead into the future, these systems will help us chart\ncer biology and treatment—at present, a patchwork quilt\ncomprehensive maps of growth signaling networks in\ncancer, an endeavor that will depend on defining all of\nof cell biology, genetics, histopathology, biochemistry,\nCell",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 138
        }
    },
    "1053": {
        "text": "Cell\n68\nmolecule E-cadherin as a tumour-suppressor gene. Trends Bio-\nimmunology, and pharmacology—will become a sci-\nchem. Sci. 24, 73–76.\nence with a conceptual structure and logical coherence\nChristofori, G., Naik, P., and Hanahan, D. (1994). A second signal\nthat rivals that of chemistry or physics.\nsupplied by insulin-like growth factor II in oncogene-induced tumori-\ngenesis. Nature 369, 414–418.\nAcknowledgments\nCordon-Cardo, C., and Prives, C. (1999). At the crossroads of inflam-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 139
        }
    },
    "1054": {
        "text": "mation and tumorigenesis. J. Exp. Med. 190, 1367–1370.\nWe wish to thank Terry Schoop of Biomed Arts Associates, San\nCounter, C.M., Avilion, A.A., LeFeuvre, C.E., Stewart, N.G., Greider,\nFrancisco, for preparation of the figures, Cori Bargmann and Zena\nC.W., Harley, C.B., and Bacchetti, S. (1992). Telomere shortening\nWerb for insightful comments on the manuscript, and Normita San-\nassociated with chromosome instability is arrested in immortal cells",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 140
        }
    },
    "1055": {
        "text": "tore for editorial assistance. In addition, we are indebted to Joe\nwhich express telomerase activity. EMBO J. 11, 1921–1929.\nHarford and Richard Klausner, who allowed us to adapt and expand\nCounter, C.M., Hahn, W.C., Wei, W., Dickinson Caddle, S., Beijers-\ntheir depiction of the cell signaling network, and we appreciate\nbergen, R.L., Lansdorp, P.M., Sedivy, J.M., and Weinberg, R.A.\nsuggestions on signaling pathways from Randy Watnick, Brian Elen-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 141
        }
    },
    "1056": {
        "text": "(1998). Dissociation between telomerase activity, telomere mainte-\nbas, Bill Lundberg, Dave Morgan, and Henry Bourne. R. A. W. is\nnance and cellular immortalization. Proc. Natl. Acad. Sci. USA 95,\na Ludwig Foundation and American Cancer Society Professor of\n14723–14728.\nBiology. His work has been supported by the Department of the\nCoussens, L.M., and Werb, Z. (1996). Matrix metalloproteinases and\nArmy and the National Institutes of Health. D. H. acknowledges",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 142
        }
    },
    "1057": {
        "text": "the development of cancer. Chem. Biol. 3, 895–904.\nthe support and encouragement of the National Cancer Institute.\nCoussens, L.M., Raymond, W.W., Bergers, G., Laig-Webster, M.,\nEditorial policy has rendered the citations illustrative but not com-\nBehrendtsen, O., Werb, Z., Caughey, G.H., and Hanahan, D. (1999).\nprehensive.\nInflammatory mast cells up-regulate angiogenesis during squamous\nepithelial carcinogenesis. Genes Dev. 13, 1382–1397.\nReferences",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 143
        }
    },
    "1058": {
        "text": "References\nDameron, K.M., Volpert, O.V., Tainsky, M.A., and Bouck, N. (1994).\nControl of angiogenesis in fibroblasts by p53 regulation of throm-\nAplin, A.E., Howe, A., Alahari, S.K., and Juliano, R.L. (1998). Signal\nbospondin-1. Science 265, 1582–1584.\ntransduction and signal modulation by cell adhesion receptors: the\nDatto, M.B., Hu, P.P., Kowalik, T.F., Yingling, J., and Wang, X.F.\nrole of integrins, cadherins, immunoglobulin-cell adhesion mole-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 144
        }
    },
    "1059": {
        "text": "(1997). The viral oncoprotein E1A blocks transforming growth factor\ncules, and selectins. Pharmacol. Rev. 50, 197–263.\nb-mediated induction of p21/WAF1/Cip1 and p15/INK4B Mol. Cell.\nAshkenazi, A., and Dixit, V.M. (1999). Apoptosis control by death\nBiol. 17, 2030–2037.\nand decoy receptors. Curr. Opin. Cell Biol. 11, 255–260.\nDiFiore, P.P., Pierce, J.H., Kraus, M.H., Segatto, O., King, C.R., and\nBergers, G., and Coussens, L.M. (2000). Extrinsic regulators of epi-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 145
        }
    },
    "1060": {
        "text": "Aaronson, S.A. (1987). erbB-2 is a potent oncogene when overex-\nthelial tumor progression: metalloproteinases. Curr. Opin. Genet.\npressed in NIH/3T3 cells. Science 237, 178–182.\nDev., in press.\nDownward, J. (1998). Mechanisms and consequences of activation\nBergers, G., Hanahan, D., and Coussens, L.M. (1998). Angiogenesis\nof protein kinase B/Akt. Curr. Opin. Cell Biol. 10, 262–267.\nand apoptosis are cellular parameters of neoplastic progression in",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 146
        }
    },
    "1061": {
        "text": "Dyson, N., Howley, P.M., Munger, K., and Harlow, E. (1989). The\ntransgenic mouse models of tumorigenesis. Int. J. Dev. Biol. 42,\nhuman papillomavirus-16 E7 oncoprotein is able to bind to the reti-\n995–1002.\nnoblastoma gene product. Science 243, 934–937.\nBergers, G., Javaherian, K., Lo, K.-M., Folkman, J., and Hanahan,\nEvan, G., and Littlewood, T. (1998). A matter of life and cell death.\nD. (1999). Effects of angiogenesis inhibitors on multistage carcino-\nScience 281, 1317–1322.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 147
        }
    },
    "1062": {
        "text": "Science 281, 1317–1322.\ngenesis in mice. Science 284, 808–812.\nFedi, P., Tronick, S.R., and Aaronson, S.A. (1997). Growth factors.\nBishop, J.M., and Weinberg, R.A., eds. (1996). Molecular Oncology\nIn Cancer Medicine, J.F. Holland, R.C. Bast, D.L. Morton, E. Frei,\n(New York: Scientific American, Inc.).\nD.W. Kufe, and R.R. Weichselbaum, eds. (Baltimore, MD: Williams\nand Wilkins), pp. 41–64.\nBodnar, A.G., Ouellete, M., Frolkis, M., Holt, S.E., Chiu, C., Morin,",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 148
        }
    },
    "1063": {
        "text": "G.B., Harley, C.B., Shay, J.W., Lichtsteiner, S., and Wright, W.E.\nFogar, P., Basso, D., Pasquali, C., De Paoli, C., Sperti, C., Roveroni,\n(1998). Extension of life-span by introduction of telomerase into\nG., Pedrazzoli, G., and Plebani, M. (1997). Neural cell adhesion mole-\nnormal human cells. Science 279, 349–352.\ncule (N-CAM) in gastrointestinal neoplasias. Anticancer Res. 17,\n1227–1230.\nBouck, N., Stellmach, V., and Hsu, S.C. (1996). How tumors become",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 149
        }
    },
    "1064": {
        "text": "Foley, K.P., and Eisenman, R.N. (1999). Two MAD tails: what the\nangiogenic. Adv. Cancer Res. 69, 135–174.\nrecent knockouts of Mad1 and Mx1 tell us about the MYC/MAX/\nBryan, T.M., and Cech, T.R. (1999). Telomerase and the maintenance\nMAD network. Biochim. Biophys. Acta 1423, M37–47.\nof chromosome ends. Curr. Opin. Cell Biol. 11, 318–324.\nFolkman, J. (1997). Tumor angiogenesis. In Cancer Medicine, J.F.\nBryan, T.M., Englezou, A., Gupta, J., Bacchetti, S., and Reddel,",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 150
        }
    },
    "1065": {
        "text": "Holland, R.C. Bast, D.L. Morton, E. Frei, D.W. Kufe, and R.R. Weich-\nR.R. (1995). Telomere elongation in immortal human cells without\nselbaum, eds. (Baltimore, MD: Williams and Wilkins), pp. 181–204.\ndetectable telomerase activity. EMBO J. 14, 4240–4248.\nFoulds, L. (1954). The Experimental Study of Tumor Progression.\nBull, H.A., Brickell, P.M., and Dowd, P.M. (1994). Src-related protein\nVolumes I–III (London: Academic Press).\ntyrosine kinases are physically associated with the surface antigen",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 151
        }
    },
    "1066": {
        "text": "Fynan, T.M., and Reiss, M. (1993). Resistance to inhibition of cell\nCD36 in human dermal microvascular endothelial cells. FEBS Lett.\ngrowth by transforming growth factor-b and its role in oncogenesis.\n351, 41–44.\nCrit. Rev. Oncog. 4, 493–540.\nButt, A.J., Firth, S.M., and Baxter, R.C. (1999). The IGF axis and\nGately, S., Twardowski, P., Stack, M.S., Cundiff, D.L., Grella, D.,\nprogrammed cell death. Immunol. Cell Biol. 77, 256–262.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 152
        }
    },
    "1067": {
        "text": "Castellino, F.J., Enghild, J., Kwaan, H.C., Lee, F., Kramer, R.A., et\nCantley, L.C., and Neel, B.G. (1999). New insights into tumor sup-\nal. (1997). The mechanism of cancer-mediated conversion of plas-\npression: PTEN suppresses tumor formation by restraining the\nminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad.\nphosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA\nSci. USA 94, 10868–10872.\n96, 4240–4245.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 153
        }
    },
    "1068": {
        "text": "Sci. USA 94, 10868–10872.\n96, 4240–4245.\nGiancotti, F.G., and Ruoslahti, E. (1999). Integrin signaling. Science\nChambers, A.F., and Matrisian, L.M. (1997). Changing views of the\n285, 1028–1032.\nrole of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst.\nGreen, D.R., and Reed, J.C. (1998). Mitochondria and apoptosis.\n89, 1260–1270.\nScience 281, 1309–1312.\nChin, L., Pomerantz, J., and DePinho, R.A. (1998). The INK4a/ARF\nGreenberg, R.A., Chin, L., Femino, A., Lee, K.H., Gottlieb, G.J.,",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 154
        }
    },
    "1069": {
        "text": "tumor suppressor: one gene—two products—two pathways. Trends\nSinger, R.H., Greider, C.W., and DePinho, R.A. (1999). Short dysfunc-\nBiochem. Sci. 23, 291–296.\ntional telomeres impair tumorigenesis in the INK4aD2/3 cancer-prone\nmouse. Cell 97, 515–525.\nChristofori, G., and Semb, H. (1999). The role of the cell-adhesion\nReview\n69\nHahn, W.C., Counter, C.M., Lundberg, A.S., Beijersbgern, R.L.,\nMarkowitz, S., Wang, J., Meyeroff, L., Parsons, R., Sun, L., Lutter-",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 155
        }
    },
    "1070": {
        "text": "baugh, J., Fan, R., Zborowska, E., Kinzler, K., Vogelstein, B., et al.\nBrooks, M.W., and Weinberg, R.A. (1999). Creation of human tumor\ncells with defined genetic elements. Nature 400, 464–468.\n(1995). Inactivation of the type II TGF-b receptor in colon cancer\ncells with microsatellite instability. Science 268, 1336–1338.\nHalvorsen, T.L., Leibowitz, G., and Levine, F. (1999). Telomerase\nactivity is sufficient to allow transformed cells to escape from crisis.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 156
        }
    },
    "1071": {
        "text": "Maxwell, P.H., Wiesener, M.S., Chang, G.-W., Clifford, S.C., Vaux,\nE.C., Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and\nMol. Cell. Biol. 19, 1864–1870.\nRatcliffe, P.J. (1999). The tumour suppressor protein VHL targets\nHanahan, D., and Folkman, J. (1996). Patterns and emerging mecha-\nhypoxia-inducible factors for oxygen-dependent proteolysis. Nature\nnisms of the angiogenic switch during tumorigenesis. Cell 86,\n399, 271–275.\n353–364.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 157
        }
    },
    "1072": {
        "text": "399, 271–275.\n353–364.\nMcDonnell, T.J., and Korsmeyer, S.J. (1991). Progression from\nHannon, G.J., and Beach, D. (1994). P15INK4B is a potential effector\nlymphoid hyperplasia to high-grade malignant lymphoma in mice\nof TGF-beta-induced cell cycle arrest. Nature 371, 257–261.\ntransgenic for the t(14;18). Nature 349, 254–256.\nHarris, C.C. (1996). p53 tumor suppressor gene: from the basic\nMedema, R.H., and Bos, J.L. (1993). The role of p21-ras in receptor",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 158
        }
    },
    "1073": {
        "text": "research laboratory to the clinic—an abridged historical perspec-\ntyrosine kinase signaling. Crit. Rev. Oncog. 4, 615–661.\ntive. Carcinogenesis 17, 1187–1198.\nMillauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A.\nHayflick, L. (1997). Mortality and immortality at the cellular level. A\n(1994). Glioblastoma growth inhibited in vivo by a dominant-negative\nreview. Biochemistry 62, 1180–1190.\nFlk-1 mutant. Nature 367, 576–579.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 159
        }
    },
    "1074": {
        "text": "Flk-1 mutant. Nature 367, 576–579.\nHolmgren, L., Szeles, A., Rajnavolgyi, E., Folkman, J., Klein, G.,\nMoses, H.L., Yang, E.Y., and Pietenpol, J.A. (1990). TGF-b stimula-\nErnberg, I., and Falk, K.I. (1999). Horizontal transfer of DNA by the\ntion and inhibition of cell proliferation: new mechanistic insights.\nuptake of apoptotic bodies. Blood 93, 3956–3963.\nCell 63, 245–247.\nHudson, J.D., Shoaibi, M.A., Maestro, R., Carnero, A., Hannon, G.J.,",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 160
        }
    },
    "1075": {
        "text": "Nowell, P.C. (1976). The clonal evolution of tumor cell populations.\nand Beach, D.H. (1999). A proinflammatory cytokine inhibits p53\nScience 194, 23–28.\ntumor suppressor activity. J. Exp. Med. 190, 1375–1382.\nOlumi, A.F., Grossfeld, G.D., Hayward, S.W., Carroll, P.R., Tlsty, T.D.,\nHueber, A.O., Zornig, M., Lyon, D., Suda, T., Nagata, S., and Evan,\nand Cunha, G.R. (1999). Carcinoma-associated fibroblasts direct\nG.I. (1997). Requirement for the CD95 receptor-ligand pathway in",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 161
        }
    },
    "1076": {
        "text": "tumor progression of initiated human prostatic epithelium. Cancer\nc-Myc-induced apoptosis. Science 278, 1305–1309.\nRes. 59, 5002–5011.\nHunter, T. (1997). Oncoprotein networks. Cell 88, 333–346.\nPerl, A.-K., Dahl, U., Wilgenbus, P., Cremer, H., Semb, H., and\nHynes, R.O., and Wagner, D.D. (1996). Genetic manipulation of vas-\nChristofori, G. (1999). Reduced expresion of neural cell adhesion\ncular adhesion molecules in mice. J. Clin. Invest. 98, 2193–2195.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 162
        }
    },
    "1077": {
        "text": "molecule induces metastatic dissemination of pancreatic b tumor\nIshizaki, Y., Cheng, L., Mudge, A.W., and Raff, M.C. (1995). Pro-\ncells. Nat. Med. 5, 286–291.\ngrammed cell death by default in embryonic cells, fibroblasts, and\nPitti, R.M., Marsters, S.A., Lawrence, D.A., Roy, M., Kischkel, F.C.,\ncancer cells. Mol. Biol. Cell 6, 1443–1458.\nDowd, P., Huang, A., Donahue, C.J., Sherwood, S.W., Baldwin, D.T.,\nJohnsen, M., Lund, L.R., Romer, J., Almholt, K., and Dano K. (1998).",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 163
        }
    },
    "1078": {
        "text": "et al. (1998). Genomic amplification of a decoy receptor for Fas\nCancer invasion and tissue remodeling: common themes in proteo-\nligand in lung and colon cancer. Nature 396, 699–703.\nlytic matrix degradation. Curr. Opin. Cell Biol. 10, 667–671.\nRak, J., Filmus, J., Finkenzeller, G., Grugel, S., Marme, D., and Ker-\nJohnson, J.P. (1991). Cell adhesion molecules of the immunoglobu-\nbel, R.S. (1995). Oncogenes as inducers of tumor angiogenesis.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 164
        }
    },
    "1079": {
        "text": "lin supergene family and their role in malignant transformation and\nCancer Metastasis Rev. 14, 263–277.\nprogression to metastatic disease. Cancer Metastasis Rev. 10,\nRenan, M.J. (1993). How many mutations are required for tumorigen-\n11–22.\nesis? Implications from human cancer data. Mol. Carcinogenesis 7,\nKahn, P., Frykberg, L., Brady, C., Stanley, I., Beug, H., Vennstro¨ m,\n139–146.\nB., and Graf, T. (1986). v-erbA cooperates with sarcoma oncogenes",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 165
        }
    },
    "1080": {
        "text": "Rommel, C., and Hafen, E. (1998). Ras—a versatile cellular switch.\nin leukemic cell transformation. Cell 45, 349–356.\nCurr. Opin. Genet. Dev. 8, 412–418.\nKaiser, U., Auerbach, B., and Oldenburg, M. (1996). The neural cell\nSchutte, M., Hruban, R., Hedrick, L., Cho, K., Nadasdy, G., Weinstein,\nadhesion molecule NCAM in multiple myeloma. Leuk. Lymphoma\nC., Bova, G., Isaacs, W., Cairns, P., Nawroz, H., et al. (1996). DPC4\n20, 389–395.\ngene in various tumor types. Cancer Res. 56, 2527–2530.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 166
        }
    },
    "1081": {
        "text": "Kerr, J.F., Wyllie, A.H., and Currie, A.R. (1972). Apoptosis: a basic\nSerrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W.\nbiological phenomenon with wide-ranging implications in tissue ki-\n(1997). Oncogeneic ras provokes premature cell senescence associ-\nnetics. Br. J. Cancer 26, 239–257.\nated with accumulation of p53 and p16INK4A. Cell 88, 593–602.\nKim, K.J., Li, B., Winer, J., Armanini, M., Gillett, N., Philipps, H.S., and",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 167
        }
    },
    "1082": {
        "text": "Shibata, M.A., Maroulakou, I.G., Jorcyk, C.L., Gold, L.G., Ward, J.M.,\nFerrara, N. (1993). Inhibition of vascular endothelial growth factor-\nand Green, J.E. (1996). p53-independent apoptosis during mammary\ninduced angiogenesis suppresses tumour growth in vivo. Nature\ntumor progression in C3(1)/SV40 large T antigen transgenic mice:\n362, 841–844.\nsuppression of apoptosis during the transition from preneoplasia\nKinzler, K.W., and Vogelstein, B. (1996). Lessons from hereditary",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 168
        }
    },
    "1083": {
        "text": "to carcinoma. Cancer Res. 56, 2998–3003.\ncolorectal cancer. Cell 87, 159–170.\nShay, J.W., and Bacchetti, S. (1997). A survey of telomerase activity\nKinzler, K.W., and Vogelstein, B. (1998). Landscaping the cancer\nin human cancer. Eur. J. Cancer 33, 787–791.\nterrain. Science 280, 1036–1037.\nSingh, R.K., Gutman, M., Bucana, C.D., Sanchez, R., Llansa, N.,\nKorsmeyer, S.J. (1992). Chromosomal translocations in lymphoid\nand Fidler, I.J. (1995). Interferons alpha and beta down-regulate the",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 169
        }
    },
    "1084": {
        "text": "malignancies reveal novel proto-oncogenes. Annu. Rev. Immunol.\nexpression of basic fibroblast growth factor in human carcinomas.\n10, 785–807.\nProc. Natl. Acad. Sci. USA 92, 4562–4566.\nLengauer, C., Kinzler, K.W., and Vogelstein, B. (1998). Genetic insta-\nSkobe, M., and Fusenig, N.E. (1998). Tumorigenic conversion of\nbilities in human cancers. Nature 396, 643–649.\nimmortal human keratinocytes through stromal cell activation. Proc.\nNatl. Acad. Sci. USA 95, 1050–1055.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 170
        }
    },
    "1085": {
        "text": "Natl. Acad. Sci. USA 95, 1050–1055.\nLevine, A.J. (1997). p53, the cellular gatekeeper for growth and divi-\nsion. Cell 88, 323–331.\nSlamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., and\nMcGuire, W.L. (1987). Human breast cancer: correlation of relapse\nLoeb, L.A. (1991). Mutator phenotype may be required for multistep\ncarcinogenesis. Cancer Res. 51, 3073–3079.\nand survival with amplification of the HER-2/neu oncogene. Science\n235, 177–182.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 171
        }
    },
    "1086": {
        "text": "235, 177–182.\nLotem, J., and Sachs, L. (1996). Control of apoptosis in hematopoie-\nsis and leukemia by cytokines, tumor suppressor and oncogenes.\nSporn, M.B. (1996). The war on cancer. Lancet 347, 1377–1381.\nLeukemia 10, 925–931.\nStetler-Stevenson, W.G. (1999). Matrix metalloproteinases in angio-\ngenesis: a moving target for therapeutic intervention. J. Clin. Invest.\nLukashev, M.E., and Werb, Z. (1998). ECM signaling: orchestrating\ncell behaviour and misbehaviour. Trends Cell Biol. 8, 437–441.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 172
        }
    },
    "1087": {
        "text": "103, 1237–1241.\nCell\n70\nStrasser, A., Harris, A.W., Bath, M.L., and Cory, S. (1990). Novel\nprimitive lymphoid tumours induced in transgenic mice by coopera-\ntion between myc and bcl-2. Nature 348, 331–333.\nSymonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S.,\nJacks, T., and Van Dyke, T. (1994). p53-dependent apoptosis sup-\npresses tumor growth and progression in vivo. Cell 78, 703–711.\nThornberry, N.A., and Lazebnik, Y. (1998). Caspases: enemies within.\nScience 281, 1312–1316.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 173
        }
    },
    "1088": {
        "text": "Science 281, 1312–1316.\nVarner, J.A., and Cheresh, D.A. (1996). Integrins and cancer. Curr.\nOpin. Cell Biol. 8, 724–730.\nVaux, D.L., Cory, S., and Adams, T.M. (1988). Bcl-2 promotes the\nsurvival of hematopoietic cells and cooperates with c-myc to immor-\ntalize pre-B cells. Nature 335, 440–442.\nVaziri, H., and Benchimol, S. (1998). Reconstitution of telomerase\nactivity in normal human cells leads to elongation of telomeres and\nextended replicative life span. Curr. Biol. 8, 279–282.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 174
        }
    },
    "1089": {
        "text": "Veikkola, T., and Alitalo, K. (1999). VEGFs, receptors and angiogen-\nesis. Semin. Cancer Biol. 9, 211–220.\nVolpert, O.V., Dameron, K.M., and Bouck, N. (1997). Sequential de-\nvelopment of an angiogenic phenotype by human fibroblasts pro-\ngressing to tumorigenicity. Oncogene 14, 1495–1502.\nWeinberg, R.A. (1995). The retinoblastoma protein and cell cycle\ncontrol. Cell 81, 323–330.\nWerb, Z. (1997). ECM and cell surface proteolysis: regulating cellular\necology. Cell 91, 439–442.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 175
        }
    },
    "1090": {
        "text": "ecology. Cell 91, 439–442.\nWhitelock, J.M., Murdoch, A.D., Iozzo, R.V., and Underwood, P.A.\n(1996). The degradation of human endothelial cell-derived perlecan\nand release of bound basic fibroblast growth factor by stromelysin,\ncollagenase, plasmin, and heparanases. J. Biol. Chem. 271, 10079–\n10086.\nWright, W.E., Pereira-Smith, O.M., and Shay, J.W. (1989). Reversible\ncellular senescence: implications for immortalization of normal hu-\nman diploid fibroblasts. Mol. Cell. Biol. 9, 3088–3092.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 176
        }
    },
    "1091": {
        "text": "Wyllie, A.H., Kerr, J.F., and Currie, A.R. (1980). Cell death: the signifi-\ncance of apoptosis. Int. Rev. Cytol. 68, 251–306.\nYarden, Y., and Ullrich, A. (1988). EGF and erbB2 receptor overex-\npression in human tumors. Growth factor recepor tyrosine kinases.\nAnnu. Rev. Biochem. 57, 443–478.\nZhu, J., Wang, H., Bishop, J.M., and Blackburn, E.H. (1999). Telo-\nmerase extends the lifespan of virus-transformed human cells with-\nout net telomere lengthening. Proc. Natl. Acad. Sci. USA 96, 3723–\n3728.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 177
        }
    },
    "1092": {
        "text": "3728.\nZuo, L., Weger, J., Yang, Q., Goldstein, A.M., Tucker, M.A., Walker,\nG.J., Hayward, N., and Dracopoli, N.C. (1996). Germline mutations\nin the p16INK4A binding domain of CDK4 in familial melanoma. Nat.\nGenet. 12, 97–99.",
        "metadata": {
            "source": "PIIS0092867400816839.pdf",
            "chunk_id": 178
        }
    },
    "1093": {
        "text": "Leading Edge\nReview\nHallmarks of Cancer: The Next Generation\nDouglas Hanahan1,2,* and Robert A. Weinberg3,*\n1The Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, EPFL, Lausanne CH-1015, Switzerland\n2The Department of Biochemistry & Biophysics, UCSF, San Francisco, CA 94158, USA\n3Whitehead Institute for Biomedical Research, Ludwig/MIT Center for Molecular Oncology, and MIT Department of Biology, Cambridge,\nMA 02142, USA",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 0
        }
    },
    "1094": {
        "text": "MA 02142, USA\n*Correspondence: dh@epﬂ.ch (D.H.), weinberg@wi.mit.edu (R.A.W.)\nDOI 10.1016/j.cell.2011.02.013\nThe hallmarks of cancer comprise six biological capabilities acquired during the multistep develop-\nment of human tumors. The hallmarks constitute an organizing principle for rationalizing the\ncomplexities of neoplastic disease. They include sustaining proliferative signaling, evading growth",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 1
        }
    },
    "1095": {
        "text": "suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, and acti-\nvating invasion and metastasis. Underlying these hallmarks are genome instability, which generates\nthe genetic diversity that expedites their acquisition, and inﬂammation, which fosters multiple hall-\nmark functions. Conceptual progress in the last decade has added two emerging hallmarks of\npotential generality to this list—reprogramming of energy metabolism and evading immune",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 2
        }
    },
    "1096": {
        "text": "destruction. In addition to cancer cells, tumors exhibit another dimension of complexity: they\ncontain a repertoire of recruited, ostensibly normal cells that contribute to the acquisition of hall-\nmark traits by creating the ‘‘tumor microenvironment.’’ Recognition of the widespread applicability\nof these concepts will increasingly affect the development of new means to treat human cancer.\nINTRODUCTION\nWe have proposed that six hallmarks of cancer together consti-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 3
        }
    },
    "1097": {
        "text": "tute an organizing principle that provides a logical framework for\nunderstanding the remarkable diversity of neoplastic diseases\n(Hanahan and Weinberg, 2000). Implicit in our discussion was\nthe\nnotion\nthat\nas\nnormal\ncells\nevolve\nprogressively\nto\na neoplastic state, they acquire a succession of these hallmark\ncapabilities, and that the multistep process of human tumor\npathogenesis could be rationalized by the need of incipient\ncancer cells to acquire the traits that enable them to become",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 4
        }
    },
    "1098": {
        "text": "tumorigenic and ultimately malignant.\nWe noted as an ancillary proposition that tumors are more than\ninsular masses of proliferating cancer cells. Instead, they are\ncomplex tissues composed of multiple distinct cell types that\nparticipate in heterotypic interactions with one another. We de-\npicted the recruited normal cells, which form tumor-associated\nstroma, as active participants in tumorigenesis rather than\npassive bystanders; as such, these stromal cells contribute to",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 5
        }
    },
    "1099": {
        "text": "the development and expression of certain hallmark capabilities.\nDuring the ensuing decade this notion has been solidiﬁed and\nextended, revealing that the biology of tumors can no longer\nbe understood simply by enumerating the traits of the cancer\ncells but instead must encompass the contributions of the\n‘‘tumor microenvironment’’ to tumorigenesis.\nIn the course of remarkable progress in cancer research\nsubsequent to this publication, new observations have served",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 6
        }
    },
    "1100": {
        "text": "both to clarify and to modify the original formulation of the hall-\nmark capabilities. In addition, yet other observations have raised\nquestions and highlighted mechanistic concepts that were not\nintegral to our original elaboration of the hallmark traits. Moti-\nvated by these developments, we now revisit the original hall-\nmarks, consider new ones that might be included in this roster,\nand expand upon the functional roles and contributions made\nby recruited stromal cells to tumor biology.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 7
        }
    },
    "1101": {
        "text": "by recruited stromal cells to tumor biology.\nHALLMARK CAPABILITIES—CONCEPTUAL PROGRESS\nThe six hallmarks of cancer—distinctive and complementary\ncapabilities that enable tumor growth and metastatic dissemina-\ntion—continue to provide a solid foundation for understanding\nthe biology of cancer (Figure 1; see the Supplemental Informa-\ntion for downloadable versions of the ﬁgures for presentations).\nIn the ﬁrst section of this Review, we summarize the essence",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 8
        }
    },
    "1102": {
        "text": "of each hallmark as described in the original presentation in\n2000, followed by selected illustrations (demarcated by sub-\nheadings in italics) of the conceptual progress made over the\npast decade in understanding their mechanistic underpinnings.\nIn subsequent sections we address new developments that\nbroaden the scope of the conceptualization, describing in turn\ntwo enabling characteristics crucial to the acquisition of the six\nhallmark capabilities, two new emerging hallmark capabilities,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 9
        }
    },
    "1103": {
        "text": "the constitution and signaling interactions of the tumor microen-\nvironment crucial to cancer phenotypes, and we ﬁnally discuss\nthe new frontier of therapeutic application of these concepts.\nSustaining Proliferative Signaling\nArguably the most fundamental trait of cancer cells involves their\nability to sustain chronic proliferation. Normal tissues carefully\ncontrol the production and release of growth-promoting signals\nthat instruct entry into and progression through the cell growth-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 10
        }
    },
    "1104": {
        "text": "and-division cycle, thereby ensuring a homeostasis of cell\n646\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nnumber and thus maintenance of normal tissue architecture and\nfunction. Cancer cells, by deregulating these signals, become\nmasters of their own destinies. The enabling signals are\nconveyed in large part by growth factors that bind cell-surface\nreceptors, typically containing intracellular tyrosine kinase\ndomains. The latter proceed to emit signals via branched intra-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 11
        }
    },
    "1105": {
        "text": "cellular signaling pathways that regulate progression through\nthe cell cycle as well as cell growth (that is, increases in cell\nsize); often these signals inﬂuence yet other cell-biological prop-\nerties, such as cell survival and energy metabolism.\nRemarkably, the precise identities and sources of the prolifer-\native signals operating within normal tissues were poorly under-\nstood a decade ago and in general remain so. Moreover, we still",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 12
        }
    },
    "1106": {
        "text": "know relatively little about the mechanisms controlling the\nrelease of these mitogenic signals. In part, the understanding\nof these mechanisms is complicated by the fact that the growth\nfactor signals controlling cell number and position within tissues\nare thought to be transmitted in a temporally and spatially regu-\nlated fashion from one cell to its neighbors; such paracrine\nsignaling is difﬁcult to access experimentally. In addition, the",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 13
        }
    },
    "1107": {
        "text": "bioavailability of growth factors is regulated by sequestration in\nthe pericellular space and extracellular matrix, and by the actions\nof a complex network of proteases, sulfatases, and possibly\nother enzymes that liberate and activate them, apparently in\na highly speciﬁc and localized fashion.\nThe mitogenic signaling in cancer cells is, in contrast, better\nunderstood (Lemmon and Schlessinger, 2010; Witsch et al.,\n2010; Hynes and MacDonald, 2009; Perona, 2006). Cancer cells",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 14
        }
    },
    "1108": {
        "text": "can acquire the capability to sustain proliferative signaling in\na number of alternative ways: They may produce growth factor\nligands themselves, to which they can respond via the expres-\nsion of cognate receptors, resulting in autocrine proliferative\nstimulation. Alternatively, cancer cells may send signals to stim-\nulate normal cells within the supporting tumor-associated\nstroma, which reciprocate by supplying the cancer cells with\nvarious growth factors (Cheng et al., 2008; Bhowmick et al.,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 15
        }
    },
    "1109": {
        "text": "2004). Receptor signaling can also be deregulated by elevating\nthe levels of receptor proteins displayed at the cancer cell\nFigure 1. The Hallmarks of Cancer\nThis illustration encompasses the six hallmark\ncapabilities originally proposed in our 2000 per-\nspective.\nThe\npast\ndecade\nhas\nwitnessed\nremarkable progress toward understanding the\nmechanistic underpinnings of each hallmark.\nsurface, rendering such cells hyperre-\nsponsive to otherwise-limiting amounts\nof\ngrowth\nfactor\nligand;\nthe\nsame",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 16
        }
    },
    "1110": {
        "text": "of\ngrowth\nfactor\nligand;\nthe\nsame\noutcome can result from structural alter-\nations in the receptor molecules that\nfacilitate ligand-independent ﬁring.\nGrowth factor independence may also\nderive from the constitutive activation of\ncomponents of signaling pathways oper-\nating downstream of these receptors,\nobviating the need to stimulate these\npathways by ligand-mediated receptor\nactivation. Given that a number of distinct downstream signaling",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 17
        }
    },
    "1111": {
        "text": "pathways radiate from a ligand-stimulated receptor, the activa-\ntion of one or another of these downstream pathways, for\nexample, the one\nresponding to the Ras signal transducer,\nmay only recapitulate a subset of the regulatory instructions\ntransmitted by an activated receptor.\nSomatic Mutations Activate Additional Downstream\nPathways\nHigh-throughput DNA sequencing analyses of cancer cell\ngenomes have revealed somatic mutations in certain human",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 18
        }
    },
    "1112": {
        "text": "tumors that predict constitutive activation of signaling circuits\nusually triggered by activated growth factor receptors. Thus,\nwe now know that \u000140% of human melanomas contain\nactivating mutations affecting the structure of the B-Raf protein,\nresulting in constitutive signaling through the Raf to mitogen-\nactivated protein (MAP)-kinase pathway (Davies and Samuels\n2010). Similarly, mutations in the catalytic subunit of phosphoi-\nnositide 3-kinase (PI3-kinase) isoforms are being detected in",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 19
        }
    },
    "1113": {
        "text": "an array of tumor types, which serve to hyperactivate the PI3-\nkinase signaling circuitry, including its key Akt/PKB signal\ntransducer (Jiang and Liu, 2009; Yuan and Cantley, 2008). The\nadvantages to tumor cells of activating upstream (receptor)\nversus downstream (transducer) signaling remain obscure, as\ndoes the functional impact of crosstalk between the multiple\npathways radiating from growth factor receptors.\nDisruptions of Negative-Feedback Mechanisms that\nAttenuate Proliferative Signaling",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 20
        }
    },
    "1114": {
        "text": "Attenuate Proliferative Signaling\nRecent results have highlighted the importance of negative-\nfeedback loops that normally operate to dampen various types\nof signaling and thereby ensure homeostatic regulation of the\nﬂux of signals coursing through the intracellular circuitry (Wertz\nand Dixit, 2010; Cabrita and Christofori, 2008; Amit et al.,\n2007; Mosesson et al., 2008). Defects in these feedback mech-\nanisms are capable of enhancing proliferative signaling. The",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 21
        }
    },
    "1115": {
        "text": "prototype of this type of regulation involves the Ras oncoprotein:\nthe oncogenic effects of Ras do not result from a hyperactivation\nof its signaling powers; instead, the oncogenic mutations\naffecting ras genes compromise Ras GTPase activity, which\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n647\noperates as an intrinsic negative-feedback mechanism that nor-\nmally ensures that active signal transmission is transitory.\nAnalogous\nnegative-feedback\nmechanisms\noperate\nat",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 22
        }
    },
    "1116": {
        "text": "Analogous\nnegative-feedback\nmechanisms\noperate\nat\nmultiple nodes within the proliferative signaling circuitry. A prom-\ninent example involves the PTEN phosphatase, which counter-\nacts PI3-kinase by degrading its product, phosphatidylinositol\n(3,4,5) trisphosphate (PIP3). Loss-of-function mutations in PTEN\namplify PI3K signaling and promote tumorigenesis in a variety\nof experimental models of cancer; in human tumors, PTEN\nexpression is often lost by promoter methylation (Jiang and",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 23
        }
    },
    "1117": {
        "text": "Liu, 2009; Yuan and Cantley, 2008).\nYet another example involves the mTOR kinase, a coordinator\nof cell growth and metabolism that lies both upstream and down-\nstream of the PI3K pathway. In the circuitry of some cancer cells,\nmTOR activation results, via negative feedback, in the inhibition\nof PI3K signaling. Thus, when mTOR is pharmacologically\ninhibited in such cancer cells (such as by the drug rapamycin),\nthe associated loss of negative feedback results in increased",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 24
        }
    },
    "1118": {
        "text": "activity of PI3K and its effector Akt/PKB, thereby blunting the\nantiproliferative effects of mTOR inhibition (Sudarsanam and\nJohnson, 2010; O’Reilly et al., 2006). It is likely that compromised\nnegative-feedback loops in this and other signaling pathways\nwill prove to be widespread among human cancer cells and\nserve as an important means by which these cells can achieve\nproliferative independence. Moreover, disruption of such self-\nattenuating signaling may contribute to the development of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 25
        }
    },
    "1119": {
        "text": "adaptive resistance toward drugs targeting mitogenic signaling.\nExcessive Proliferative Signaling Can Trigger Cell\nSenescence\nEarly studies of oncogene action encouraged the notion that\never-increasing expression of such genes and the signals mani-\nfested in their protein products would result in correspondingly\nincreased cancer cell proliferation and thus tumor growth. More\nrecent research has undermined this notion, in that excessively\nelevated signaling by oncoproteins such as RAS, MYC, and",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 26
        }
    },
    "1120": {
        "text": "RAF can provoke counteracting responses from cells, speciﬁ-\ncally induction of cell senescence and/or apoptosis (Collado\nand Serrano, 2010; Evan and d’Adda di Fagagna, 2009; Lowe\net al., 2004). For example, cultured cells expressing high levels\nof the Ras oncoprotein may enter into the nonproliferative but\nviable state called senescence; in contrast, cells expressing\nlower levels of this protein may avoid senescence and proliferate.\nCells with morphological features of senescence, including",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 27
        }
    },
    "1121": {
        "text": "enlarged cytoplasm, the absence of proliferation markers, and\nexpression\nof\nthe\nsenescence-induced\nb-galactosidase\nenzyme, are abundant in the tissues of mice engineered to over-\nexpress certain oncogenes (Collado and Serrano, 2010; Evan\nand d’Adda di Fagagna, 2009) and are prevalent in some cases\nof human melanoma (Mooi and Peeper, 2006). These ostensibly\nparadoxical responses seem to reﬂect intrinsic cellular defense\nmechanisms designed to eliminate cells experiencing excessive",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 28
        }
    },
    "1122": {
        "text": "levels of certain types of signaling. Accordingly, the relative\nintensity of oncogenic signaling in cancer cells may represent\ncompromises between maximal mitogenic stimulation and\navoidance of these antiproliferative defenses. Alternatively,\nsome cancer cells may adapt to high levels of oncogenic\nsignaling by disabling their senescence- or apoptosis-inducing\ncircuitry.\nEvading Growth Suppressors\nIn addition to the hallmark capability of inducing and sustaining",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 29
        }
    },
    "1123": {
        "text": "positively acting growth-stimulatory signals, cancer cells must\nalso circumvent powerful programs that negatively regulate\ncell proliferation; many of these programs depend on the actions\nof tumor suppressor genes. Dozens of tumor suppressors that\noperate in various ways to limit cell growth and proliferation\nhave been discovered through their characteristic inactivation\nin one or another form of animal or human cancer; many of these\ngenes have been validated as bona ﬁde tumor suppressors",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 30
        }
    },
    "1124": {
        "text": "through gain- or loss-of-function experiments in mice. The two\nprototypical tumor suppressors encode the RB (retinoblas-\ntoma-associated) and TP53 proteins; they operate as central\ncontrol nodes within two key complementary cellular regulatory\ncircuits that govern the decisions of cells to proliferate or, alter-\nnatively, activate senescence and apoptotic programs.\nThe RB protein integrates signals from diverse extracellular\nand intracellular sources and, in response, decides whether or",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 31
        }
    },
    "1125": {
        "text": "not a cell should proceed through its growth-and-division cycle\n(Burkhart and Sage, 2008; Deshpande et al., 2005; Sherr and\nMcCormick, 2002). Cancer cells with defects in RB pathway\nfunction are thus missing the services of a critical gatekeeper\nof cell-cycle progression whose absence permits persistent\ncell proliferation. Whereas RB transduces growth-inhibitory\nsignals that originate largely outside of the cell, TP53 receives\ninputs from stress and abnormality sensors that function within",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 32
        }
    },
    "1126": {
        "text": "the cell’s intracellular operating systems: if the degree of\ndamage to the genome is excessive, or if the levels of nucleotide\npools, growth-promoting signals, glucose, or oxygenation are\nsuboptimal, TP53 can call a halt to further cell-cycle progression\nuntil these conditions have been normalized. Alternatively, in the\nface of alarm signals indicating overwhelming or irreparable\ndamage\nto\nsuch\ncellular\nsubsystems,\nTP53\ncan\ntrigger\napoptosis. Notably, the various effects of activated TP53 are",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 33
        }
    },
    "1127": {
        "text": "complex and highly context dependent, varying by cell type as\nwell as by the severity and persistence of conditions of cell stress\nand genomic damage.\nAlthough the two canonical suppressors of proliferation—\nTP53 and RB—have preeminent importance in regulating cell\nproliferation, various lines of evidence indicate that each oper-\nates as part of a larger network that is wired for functional redun-\ndancy. For example, chimeric mice populated throughout their",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 34
        }
    },
    "1128": {
        "text": "bodies with individual cells lacking a functional Rb gene are\nsurprisingly free of proliferative abnormalities, despite the expec-\ntation that loss of RB function would allow continuous ﬁring of the\ncell division cycle in these cells and their lineal descendants;\nsome of the resulting clusters of Rb null cells should, by all rights,\nprogress to neoplasia. Instead, the Rb null cells in such chimeric\nmice have been found to participate in relatively normal tissue\nmorphogenesis\nthroughout\nthe",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 35
        }
    },
    "1129": {
        "text": "morphogenesis\nthroughout\nthe\nbody;\nthe\nonly\nneoplasia\nobserved was in the development of pituitary tumors late in life\n(Lipinski and Jacks, 1999). Similarly, TP53 null mice develop nor-\nmally, show largely proper cell and tissue homeostasis, and\nagain develop abnormalities later in life, in the form of leukemias\nand sarcomas (Ghebranious and Donehower, 1998). Both exam-\nples must reﬂect the operations of redundantly acting mecha-\nnisms that serve to constrain inappropriate replication of cells",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 36
        }
    },
    "1130": {
        "text": "lacking these key proliferation suppressors.\n648\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nMechanisms of Contact Inhibition and Its Evasion\nFour decades of research have demonstrated that the cell-to-\ncell contacts formed by dense populations of normal cells prop-\nagated in two-dimensional culture operate to suppress further\ncell proliferation, yielding conﬂuent cell monolayers. Importantly,\nsuch ‘‘contact inhibition’’ is abolished in various types of cancer",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 37
        }
    },
    "1131": {
        "text": "cells in culture, suggesting that contact inhibition is an in vitro\nsurrogate of a mechanism that operates in vivo to ensure normal\ntissue homeostasis, one that is abrogated during the course of\ntumorigenesis. Until recently, the mechanistic basis for this\nmode of growth control remained obscure. Now, however,\nmechanisms of contact inhibition are beginning to emerge.\nOne mechanism involves the product of the NF2 gene, long\nimplicated as a tumor suppressor because its loss triggers",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 38
        }
    },
    "1132": {
        "text": "a form of human neuroﬁbromatosis. Merlin, the cytoplasmic\nNF2 gene product, orchestrates contact inhibition via coupling\ncell-surface adhesion molecules (e.g., E-cadherin) to transmem-\nbrane receptor tyrosine kinases (e.g., the EGF receptor). In so\ndoing, Merlin strengthens the adhesivity of cadherin-mediated\ncell-to-cell attachments. Additionally, by sequestering growth\nfactor receptors, Merlin limits their ability to efﬁciently emit mito-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 39
        }
    },
    "1133": {
        "text": "genic signals (Curto et al., 2007; Okada et al., 2005).\nA second mechanism of contact inhibition involves the LKB1\nepithelial polarity protein, which organizes epithelial structure\nand helps maintain tissue integrity. LKB1 can, for example,\noverrule the mitogenic effects of the powerful Myc oncogene\nwhen the latter is upregulated in organized, quiescent epithelial\nstructures; in contrast, when LKB1 expression is suppressed,\nepithelial integrity is destabilized, and epithelial cells become",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 40
        }
    },
    "1134": {
        "text": "susceptible to Myc-induced transformation (Partanen et al.,\n2009; Hezel and Bardeesy, 2008). LKB1 has also been identiﬁed\nas a tumor suppressor gene that is lost in certain human malig-\nnancies (Shaw, 2009), possibly reﬂecting its normal function as\na suppressor of inappropriate proliferation. It remains to be\nseen how frequently these two mechanisms of contact-medi-\nated growth suppression are compromised in human cancers;\nno doubt yet other contact-induced proliferative barriers are",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 41
        }
    },
    "1135": {
        "text": "yet to be discovered. Clearly mechanisms like these that enable\ncells to construct and maintain architecturally complex tissues\nrepresent important means of suppressing and counterbalanc-\ning inappropriate proliferative signals.\nCorruption of the TGF-b Pathway Promotes Malignancy\nTGF-b is best known for its antiproliferative effects, and evasion\nby cancer cells of these effects is now appreciated to be far more\nelaborate than simple shutdown of its signaling circuitry (Ikush-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 42
        }
    },
    "1136": {
        "text": "ima and Miyazono, 2010; Massague´ , 2008; Bierie and Moses,\n2006). In many late-stage tumors, TGF-b signaling is redirected\naway from suppressing cell proliferation and is found instead\nto activate a cellular program, termed the epithelial-to-mesen-\nchymal transition (EMT), that confers on cancer cells traits asso-\nciated with high-grade malignancy, as discussed in further detail\nbelow.\nResisting Cell Death\nThe concept that programmed cell death by apoptosis serves as",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 43
        }
    },
    "1137": {
        "text": "a natural barrier to cancer development has been established by\ncompelling functional studies conducted over the last two\ndecades (Adams and Cory, 2007; Lowe et al., 2004: Evan and\nLittlewood, 1998). Elucidation of the signaling circuitry governing\nthe apoptotic program has revealed how apoptosis is triggered\nin response to various physiologic stresses that cancer cells\nexperience during the course of tumorigenesis or as a result of\nanticancer therapy. Notable among the apoptosis-inducing",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 44
        }
    },
    "1138": {
        "text": "stresses are signaling imbalances resulting from elevated levels\nof oncogene signaling, as mentioned earlier, and DNA damage\nassociated with hyperproliferation. Yet other research has re-\nvealed how apoptosis is attenuated in those tumors that\nsucceed in progressing to states of high-grade malignancy and\nresistance to therapy (Adams and Cory, 2007; Lowe et al., 2004).\nThe apoptotic machinery is composed of both upstream regu-\nlators and downstream effector components (Adams and Cory,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 45
        }
    },
    "1139": {
        "text": "2007). The regulators, in turn, are divided into two major circuits,\none receiving and processing extracellular death-inducing\nsignals (the extrinsic apoptotic program, involving for example\nthe Fas ligand/Fas receptor), and the other sensing and inte-\ngrating a variety of signals of intracellular origin (the intrinsic\nprogram). Each culminates in activation of a normally latent\nprotease (caspases 8 and 9, respectively), which proceeds to",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 46
        }
    },
    "1140": {
        "text": "initiate a cascade of proteolysis involving effector caspases\nresponsible for the execution phase of apoptosis, in which the\ncell is progressively disassembled and then consumed, both\nby its neighbors and by professional phagocytic cells. Currently,\nthe intrinsic apoptotic program is more widely implicated as\na barrier to cancer pathogenesis.\nThe ‘‘apoptotic trigger’’ that conveys signals between the regu-\nlators and effectors is controlled by counterbalancing pro- and",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 47
        }
    },
    "1141": {
        "text": "antiapoptotic members of the Bcl-2 family of regulatory proteins\n(Adams and Cory, 2007). The archetype, Bcl-2, along with its\nclosest relatives (Bcl-xL, Bcl-w, Mcl-1, A1) are inhibitors of\napoptosis,acting inlargepartbybinding toand therebysuppress-\ning two proapoptotic triggering proteins (Bax and Bak); the latter\nare embedded in the mitochondrial outer membrane. When\nrelieved of inhibition by their antiapoptotic relatives, Bax and\nBak disrupt the integrity of the outer mitochondrial membrane,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 48
        }
    },
    "1142": {
        "text": "causing the release of proapoptotic signaling proteins, the most\nimportant of which is cytochrome c. The released cytochrome c\nactivates, in turn, a cascade of caspases that act via their proteo-\nlytic activities to induce the multiple cellular changes associated\nwith the apoptotic program. Bax and Bak share protein-protein\ninteraction domains, termed BH3 motifs, with the antiapoptotic\nBcl-2-like proteins that mediate their various physical interac-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 49
        }
    },
    "1143": {
        "text": "tions. The activities of a subfamily of related proteins, each of\nwhich contains a single such BH3 motif, are coupled to a variety\nof sensors of cellular abnormality; these ‘‘BH3-only’’ proteins\nact either by interfering with antiapoptotic Bcl-2 proteins or by\ndirectly stimulating the proapoptotic members of this family\n(Adams and Cory, 2007; Willis and Adams, 2005).\nAlthough the cellular conditions that trigger apoptosis remain\nto be fully enumerated, several abnormality sensors that play",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 50
        }
    },
    "1144": {
        "text": "key roles in tumor development have been identiﬁed (Adams\nand Cory, 2007; Lowe et al., 2004). Most notable is a DNA-\ndamage sensor that functions via the TP53 tumor suppressor\n(Junttila and Evan, 2009); TP53 induces apoptosis by upregulat-\ning expression of the Noxa and Puma BH3-only proteins, doing\nso in response to substantial levels of DNA breaks and other\nchromosomal abnormalities. Alternatively, insufﬁcient survival\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n649",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 51
        }
    },
    "1145": {
        "text": "Cell 144, March 4, 2011 ª2011 Elsevier Inc.\n649\nfactor signaling (for instance inadequate levels of interleukin-3 in\nlymphocytes or of insulin-like growth factor 1/2 [Igf1/2] in epithe-\nlial cells) can elicit apoptosis through a BH3-only protein called\nBim. Yet another condition leading to cell death involves hyper-\nactive signaling by certain oncoproteins, such as Myc, which\ntriggers apoptosis (in part via Bim and other BH3-only proteins)",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 52
        }
    },
    "1146": {
        "text": "unless counterbalanced by antiapoptotic factors (Junttila and\nEvan, 2009; Lowe et al., 2004).\nTumor cells evolve a variety of strategies to limit or circumvent\napoptosis. Most common is the loss of TP53 tumor suppressor\nfunction, which eliminates this critical damage sensor from the\napoptosis-inducing circuitry. Alternatively, tumors may achieve\nsimilar ends by increasing expression of antiapoptotic regulators\n(Bcl-2, Bcl-xL) or of survival signals (Igf1/2), by downregulating",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 53
        }
    },
    "1147": {
        "text": "proapoptotic factors (Bax, Bim, Puma), or by short-circuiting\nthe extrinsic ligand-induced death pathway. The multiplicity of\napoptosis-avoiding mechanisms presumably reﬂects the diver-\nsity of apoptosis-inducing signals that cancer cell populations\nencounter during their evolution to the malignant state.\nThe structure of the apoptotic machinery and program, and\nthe strategies used by cancer cells to evade its actions, were\nwidely appreciated by the beginning of the last decade. The",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 54
        }
    },
    "1148": {
        "text": "most notable conceptual advances since then have involved\nother forms of cell death that broaden the scope of ‘‘pro-\ngrammed cell death’’ as a barrier to cancer.\nAutophagy Mediates Both Tumor Cell Survival and Death\nAutophagy represents an important cell-physiologic response\nthat, like apoptosis, normally operates at low, basal levels in cells\nbut can be strongly induced in certain states of cellular stress,\nthe most obvious of which is nutrient deﬁciency (Levine and",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 55
        }
    },
    "1149": {
        "text": "Kroemer, 2008; Mizushima, 2007). The autophagic program\nenables cells to break down cellular organelles, such as ribo-\nsomes and mitochondria, allowing the resulting catabolites to\nbe recycled and thus used for biosynthesis and energy metabo-\nlism. As part of this program, intracellular vesicles termed auto-\nphagosomes envelope intracellular organelles and then fuse with\nlysosomes wherein degradation occurs. In this fashion, low-\nmolecular-weight\nmetabolites\nare\ngenerated\nthat\nsupport",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 56
        }
    },
    "1150": {
        "text": "metabolites\nare\ngenerated\nthat\nsupport\nsurvival in the stressed, nutrient-limited environments experi-\nenced by many cancer cells.\nLike apoptosis, the autophagy machinery has both regulatory\nand effector components (Levine and Kroemer, 2008; Mizush-\nima, 2007). Among the latter are proteins that mediate autopha-\ngosome formation and delivery to lysosomes. Of note, recent\nresearch has revealed intersections between the regulatory\ncircuits governing autophagy, apoptosis, and cellular homeo-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 57
        }
    },
    "1151": {
        "text": "stasis. For example, the signaling pathway involving the PI3-\nkinase, AKT, and mTOR kinases, which is stimulated by survival\nsignals to block apoptosis, similarly inhibits autophagy; when\nsurvival signals are insufﬁcient, the PI3K signaling pathway is\ndownregulated, with the result that autophagy and/or apoptosis\nmay be induced (Levine and Kroemer, 2008; Sinha and Levine,\n2008; Mathew et al., 2007).\nAnother interconnection between these two programs resides",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 58
        }
    },
    "1152": {
        "text": "in the Beclin-1 protein, which has been shown by genetic studies\nto be necessary for induction of autophagy (Levine and Kroemer,\n2008; Sinha and Levine, 2008; Mizushima, 2007). Beclin-1 is\na member of the BH3-only subfamily of apoptotic regulatory\nproteins, and its BH3 domain allows it to bind the Bcl-2/Bcl-xL\nproteins. Stress-sensor-coupled BH3 proteins can displace Be-\nclin-1 from its association with Bcl-2/Bcl-xL, enabling the liber-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 59
        }
    },
    "1153": {
        "text": "ated Beclin-1 to trigger autophagy, much as they can release\nproapoptotic Bax and Bak to trigger apoptosis. Hence, stress-\ntransducing BH3 proteins (e.g., Bid, Bad, Puma, et al.) can\ninduce apoptosis and/or autophagy depending on the physio-\nlogic state of the cell.\nMice bearing inactivated alleles of the Beclin-1 gene or of\ncertain other components of the autophagy machinery exhibit\nincreased susceptibility to cancer (White and DiPaola, 2009:",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 60
        }
    },
    "1154": {
        "text": "Levine and Kroemer, 2008). These results suggest that induction\nof autophagy can serve as a barrier to tumorigenesis that may\noperate independently of or in concert with apoptosis. Accord-\ningly, autophagy appears to represent yet another barrier that\nneeds to be circumvented during tumor development (White\nand DiPaola, 2009).\nPerhaps paradoxically, nutrient starvation, radiotherapy, and\ncertain cytotoxic drugs can induce elevated levels of autophagy",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 61
        }
    },
    "1155": {
        "text": "that are apparently cytoprotective for cancer cells, impairing\nrather than accentuating the killing actions of these stress-\ninducing situations (White and DiPaola, 2009; Apel et al., 2009;\nAmaravadi and Thompson, 2007; Mathew et al., 2007). More-\nover, severely stressed cancer cells have been shown to shrink\nvia autophagy to a state of reversible dormancy (White and\nDiPaola, 2009; Lu et al., 2008). This survival response may\nenable the persistence and eventual regrowth of some late-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 62
        }
    },
    "1156": {
        "text": "stage tumors following treatment with potent anticancer agents.\nThus, in analogy to TGF-b signaling, which can be tumor sup-\npressing at early stages of tumorigenesis and tumor promoting\nlater on, autophagy seems to have conﬂicting effects on tumor\ncells and thus tumor progression (Apel et al., 2009; White and\nDiPaola, 2009). An important agenda for future research will\ninvolve clarifying the genetic and cell-physiologic conditions\nthat dictate when and how autophagy enables cancer cells to",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 63
        }
    },
    "1157": {
        "text": "survive or causes them to die.\nNecrosis Has Proinﬂammatory and Tumor-Promoting\nPotential\nIn contrast to apoptosis, in which a dying cell contracts into an\nalmost-invisible corpse that is soon consumed by neighbors,\nnecrotic cells become bloated and explode, releasing their\ncontents into the local tissue microenvironment. Although\nnecrosis has historically been viewed much like organismic\ndeath, as a form of system-wide exhaustion and breakdown,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 64
        }
    },
    "1158": {
        "text": "the conceptual landscape is changing: cell death by necrosis\nis clearly under genetic control in some circumstances, rather\nthan being a random and undirected process (Galluzzi and\nKroemer, 2008; Zong and Thompson, 2006).\nPerhaps more important, necrotic cell death releases proin-\nﬂammatory signals into the surrounding tissue microenviron-\nment, in contrast to apoptosis and autophagy, which do not.\nAs a consequence, necrotic cells can recruit inﬂammatory cells",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 65
        }
    },
    "1159": {
        "text": "of the immune system (Grivennikov et al., 2010; White et al.,\n2010; Galluzzi and Kroemer, 2008), whose dedicated function\nis to survey the extent of tissue damage and remove associated\nnecrotic debris. In the context of neoplasia, however, multiple\nlines of evidence indicate that immune inﬂammatory cells can\nbe actively tumor promoting, given that such cells are capable\n650\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nof fostering angiogenesis, cancer cell proliferation, and invasive-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 66
        }
    },
    "1160": {
        "text": "ness (see below). Additionally, necrotic cells can release bio-\nactive regulatory factors, such as IL-1a, which can directly stim-\nulate neighboring viable cells to proliferate, with the potential,\nonce again, to facilitate neoplastic progression (Grivennikov\net al., 2010). Consequently, necrotic cell death, while seemingly\nbeneﬁcial in counterbalancing cancer-associated hyperprolifer-\nation, may ultimately do more damage than good. Accordingly,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 67
        }
    },
    "1161": {
        "text": "incipient neoplasias and potentially invasive and metastatic\ntumors may gain an advantage by tolerating some degree of\nnecrotic cell death, doing so in order to recruit tumor-promoting\ninﬂammatory cells that bring growth-stimulating factors to the\nsurviving cells within these growths.\nEnabling Replicative Immortality\nBy 2000, it was widely accepted that cancer cells require unlim-\nited replicative potential in order to generate macroscopic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 68
        }
    },
    "1162": {
        "text": "tumors. This capability stands in marked contrast to the behavior\nof the cells in most normal cell lineages in the body, which are\nable to pass through only a limited number of successive cell\ngrowth-and-division cycles. This limitation has been associated\nwith two distinct barriers to proliferation: senescence, a typically\nirreversible entrance into a nonproliferative but viable state, and\ncrisis, which involves cell death. Accordingly, when cells are",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 69
        }
    },
    "1163": {
        "text": "propagated in culture, repeated cycles of cell division lead ﬁrst\nto induction of senescence and then, for those cells that succeed\nin circumventing this barrier, to a crisis phase, in which the great\nmajority of cells in the population die. On rare occasion, cells\nemerge from a population in crisis and exhibit unlimited replica-\ntive potential. This transition has been termed immortalization,\na trait that most established cell lines possess by virtue of their",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 70
        }
    },
    "1164": {
        "text": "ability to proliferate in culture without evidence of either senes-\ncence or crisis.\nMultiple lines of evidence indicate that telomeres protecting\nthe ends of chromosomes are centrally involved in the capability\nfor unlimited proliferation (Blasco, 2005; Shay and Wright, 2000).\nThe telomeres, composed of multiple tandem hexanucleotide\nrepeats, shorten progressively in nonimmortalized cells propa-\ngated in culture, eventually losing the ability to protect the",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 71
        }
    },
    "1165": {
        "text": "ends of chromosomal DNAs from end-to-end fusions; such\nfusions generate unstable dicentric chromosomes whose reso-\nlution results in a scrambling of karyotype that threatens cell\nviability. Accordingly, the length of telomeric DNA in a cell\ndictates how many successive cell generations its progeny can\npass through before telomeres are largely eroded and have\nconsequently lost their protective functions, triggering entrance\ninto crisis.\nTelomerase, the specialized DNA polymerase that adds telo-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 72
        }
    },
    "1166": {
        "text": "mere repeat segments to the ends of telomeric DNA, is almost\nabsent in nonimmortalized cells but expressed at functionally\nsigniﬁcant levels in the vast majority (\u000190%) of spontaneously\nimmortalized cells, including human cancer cells. By extending\ntelomeric DNA, telomerase is able to counter the progressive\ntelomere erosion that would otherwise occur in its absence.\nThe presence of telomerase activity, either in spontaneously\nimmortalized cells or in the context of cells engineered to",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 73
        }
    },
    "1167": {
        "text": "express the enzyme, is correlated with a resistance to induction\nof both senescence and crisis/apoptosis; conversely, suppres-\nsion of telomerase activity leads to telomere shortening and to\nactivation of one or the other of these proliferative barriers.\nThe two barriers to proliferation—senescence and crisis/\napoptosis—have\nbeen\nrationalized\nas\ncrucial\nanticancer\ndefenses that are hard-wired into our cells, being deployed to\nimpede the outgrowth of clones of preneoplastic and frankly",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 74
        }
    },
    "1168": {
        "text": "neoplastic cells. According to this thinking, most incipient\nneoplasias exhaust their endowment of replicative doublings\nand are stopped in their tracks by one or the other of these\nbarriers. The eventual immortalization of rare variant cells that\nproceed to form tumors has been attributed to their ability to\nmaintain telomeric DNA at lengths sufﬁcient to avoid triggering\nsenescence or apoptosis, achieved most commonly by upre-\ngulating expression of telomerase or, less frequently, via an",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 75
        }
    },
    "1169": {
        "text": "alternative recombination-based telomere maintenance mech-\nanism. Hence, telomere shortening has come to be viewed as\na clocking device that determines the limited replicative poten-\ntial of normal cells and thus one that must be overcome by\ncancer cells.\nReassessing Replicative Senescence\nWhereas telomere maintenance has been increasingly substan-\ntiated as a condition critical to the neoplastic state, the concept\nof replication-induced senescence as a general barrier requires",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 76
        }
    },
    "1170": {
        "text": "reﬁnement and reformulation. (Differences in telomere structure\nand function in mouse versus human cells have also complicated\ninvestigation of the roles of telomeres and telomerase in replica-\ntive senescence.) Recent experiments have revealed that the\ninduction of senescence in certain cultured cells can be delayed\nand possibly eliminated by the use of improved cell culture\nconditions, suggesting that recently explanted primary cells",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 77
        }
    },
    "1171": {
        "text": "may be able to proliferate unimpeded in culture up the point of\ncrisis and the associated induction of apoptosis triggered by crit-\nically shortened telomeres (Ince et al., 2007; Passos et al., 2007;\nZhang et al., 2004; Sherr and DePinho, 2000). In contrast, exper-\niments in mice engineered to lack telomerase indicate that the\nconsequently shortened telomeres can shunt premalignant cells\ninto a senescent state that contributes (along with apoptosis) to",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 78
        }
    },
    "1172": {
        "text": "attenuated tumorigenesis in mice genetically destined to\ndevelop particular forms of cancer (Artandi and DePinho,\n2010). Such telomerase null mice with highly eroded telomeres\nexhibit multiorgan dysfunction and abnormalities that include\nevidence for both senescence and apoptosis, perhaps analo-\ngous to the senescence and apoptosis observed in cell culture\n(Artandi and DePinho, 2010; Feldser and Greider, 2007).\nOf note, and as discussed earlier, a morphologically similar",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 79
        }
    },
    "1173": {
        "text": "form of cell senescence induced by excessive or unbalanced\noncogene signaling is now well documented as a protective\nmechanism against neoplasia; the possible interconnections of\nthis form of senescence with telomerase and telomeres remain\nto be ascertained. Thus, cell senescence is emerging conceptu-\nally as a protective barrier to neoplastic expansion that can be\ntriggered by various proliferation-associated abnormalities,\nincluding high levels of oncogenic signaling and, apparently,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 80
        }
    },
    "1174": {
        "text": "subcritical shortening of telomeres.\nDelayed Activation of Telomerase May Both Limit\nand Foster Neoplastic Progression\nThere is now evidence that clones of incipient cancer cells often\nexperience telomere loss-induced crisis relatively early during\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n651\nthe course of multistep tumor progression due to their inability to\nexpress signiﬁcant levels of telomerase. Thus, extensively\neroded telomeres have been documented in premalignant",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 81
        }
    },
    "1175": {
        "text": "growths through the use of ﬂuorescence in situ hybridization\n(FISH), which has also revealed the end-to-end chromosomal\nfusions that signal telomere failure and crisis (Kawai et al.,\n2007; Hansel et al., 2006). These results also suggest that such\ncells have passed through a substantial number of successive\ntelomere-shortening cell divisions during their evolution from\nfully normal cells-of-origin. Accordingly, the development of\nsome human neoplasias may be aborted by telomere-induced",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 82
        }
    },
    "1176": {
        "text": "crisis long before they succeed in becoming macroscopic,\nfrankly neoplastic growths.\nIn contrast, the absence of TP53-mediated surveillance of\ngenomic integrity may permit other incipient neoplasias to\nsurvive initial telomere erosion and attendant chromosomal\nbreakage-fusion-bridge (BFB) cycles. The genomic alterations\nresulting from these BFB cycles, including deletions and ampli-\nﬁcations of chromosomal segments, evidently serve to increase",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 83
        }
    },
    "1177": {
        "text": "the mutability of the genome, thereby accelerating the acquisi-\ntion of mutant oncogenes and tumor suppressor genes. The real-\nization that impaired telomere function can actually foster tumor\nprogression has come from the study of mutant mice that lack\nboth p53 and telomerase function (Artandi and DePinho, 2010,\n2000). The proposition that these two defects can cooperatively\nenhance human tumorigenesis has not yet been directly docu-\nmented.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 84
        }
    },
    "1178": {
        "text": "mented.\nCircumstantial support for the importance of transient telo-\nmere deﬁciency in facilitating malignant progression has come,\nin addition, from comparative analyses of premalignant and\nmalignant lesions in the human breast (Raynaud et al., 2010;\nChin et al., 2004). The premalignant lesions did not express\nsigniﬁcant levels of telomerase and were marked by telomere\nshortening and nonclonal chromosomal aberrations. In contrast,\novert carcinomas exhibited telomerase expression concordantly",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 85
        }
    },
    "1179": {
        "text": "with the reconstruction of longer telomeres and the ﬁxation (via\nclonal outgrowth) of the aberrant karyotypes that would seem\nto have been acquired after telomere failure but before the acqui-\nsition of telomerase activity. When portrayed in this way, the\ndelayed acquisition of telomerase function serves to generate\ntumor-promoting mutations, whereas its subsequent activation\nstabilizes the mutant genome and confers the unlimited replica-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 86
        }
    },
    "1180": {
        "text": "tive capacity that cancer cells require in order to generate clini-\ncally apparent tumors.\nNew Functions of Telomerase\nTelomerase was discovered because of its ability to elongate\nand maintain telomeric DNA, and almost all telomerase research\nhas been posited on the notion that its functions are conﬁned to\nthis crucial function. However, in recent years it has become\napparent that telomerase exerts functions that are relevant to\ncell proliferation but unrelated to telomere maintenance. The",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 87
        }
    },
    "1181": {
        "text": "noncanonical roles of telomerase, and in particular its protein\nsubunit TERT, have been revealed by functional studies in\nmice and cultured cells; in some cases novel functions have\nbeen demonstrated in conditions where the telomerase enzy-\nmatic activity has been eliminated (Cong and Shay, 2008).\nAmong the growing list of telomere-independent functions of\nTERT/telomerase is the ability of TERT to amplify signaling by\nthe Wnt pathway, by serving as a cofactor of the b-catenin/LEF",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 88
        }
    },
    "1182": {
        "text": "transcription factor complex (Park et al., 2009). Other ascribed\ntelomere-independent effects include demonstrable enhance-\nment of cell proliferation and/or resistance to apoptosis (Kang\net al., 2004), involvement in DNA-damage repair (Masutomi\net al., 2005), and RNA-dependent RNA polymerase function\n(Maida et al., 2009). Consistent with these broader roles, TERT\ncan be found associated with chromatin at multiple sites along\nthe chromosomes, not just at the telomeres (Park et al., 2009;",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 89
        }
    },
    "1183": {
        "text": "Masutomi et al., 2005). Hence, telomere maintenance is proving\nto be the most prominent of a diverse series of functions to which\nTERT contributes. The contributions of these additional func-\ntions of telomerase to tumorigenesis remain to be fully eluci-\ndated.\nInducing Angiogenesis\nLike normal tissues, tumors require sustenance in the form of\nnutrients and oxygen as well as an ability to evacuate metabolic\nwastes and carbon dioxide. The tumor-associated neovascula-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 90
        }
    },
    "1184": {
        "text": "ture, generated by the process of angiogenesis, addresses these\nneeds. During embryogenesis, the development of the vascula-\nture involves the birth of new endothelial cells and their assembly\ninto tubes (vasculogenesis) in addition to the sprouting (angio-\ngenesis) of new vessels from existing ones. Following this\nmorphogenesis, the normal vasculature becomes largely quies-\ncent. In the adult, as part of physiologic processes such as\nwound healing and female reproductive cycling, angiogenesis",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 91
        }
    },
    "1185": {
        "text": "is turned on, but only transiently. In contrast, during tumor\nprogression, an ‘‘angiogenic switch’’ is almost always activated\nand remains on, causing normally quiescent vasculature to\ncontinually sprout new vessels that help sustain expanding\nneoplastic growths (Hanahan and Folkman, 1996).\nA compelling body of evidence indicates that the angiogenic\nswitch is governed by countervailing factors that either induce\nor oppose angiogenesis (Baeriswyl and Christofori, 2009; Berg-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 92
        }
    },
    "1186": {
        "text": "ers and Benjamin, 2003). Some of these angiogenic regulators\nare signaling proteins that bind to stimulatory or inhibitory cell-\nsurface receptors displayed by vascular endothelial cells. The\nwell-known prototypes of angiogenesis inducers and inhibitors\nare vascular endothelial growth factor-A (VEGF-A) and thrombo-\nspondin-1 (TSP-1), respectively.\nThe VEGF-A gene encodes ligands that are involved in orches-\ntrating new blood vessel growth during embryonic and postnatal",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 93
        }
    },
    "1187": {
        "text": "development, and then in homeostatic survival of endothelial\ncells, as well as in physiological and pathological situations in\nthe adult. VEGF signaling via three receptor tyrosine kinases\n(VEGFR-1–3) is regulated at multiple levels, reﬂecting this\ncomplexity of purpose. Thus, VEGF gene expression can by\nupregulated both by hypoxia and by oncogene signaling (Fer-\nrara, 2009; Mac Gabhann and Popel, 2008; Carmeliet, 2005).\nAdditionally, VEGF ligands can be sequestered in the extracel-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 94
        }
    },
    "1188": {
        "text": "lular matrix in latent forms that are subject to release and activa-\ntion by extracellular matrix-degrading proteases (e.g., MMP-9;\nKessenbrock et al., 2010). In addition, other proangiogenic\nsignals, such as members of the ﬁbroblast growth factor (FGF)\nfamily, have been implicated in sustaining tumor angiogenesis\nwhen their expression is chronically upregulated (Baeriswyl\nand Christofori, 2009). TSP-1, a key counterbalance in the\n652\nCell 144, March 4, 2011 ª2011 Elsevier Inc.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 95
        }
    },
    "1189": {
        "text": "652\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nangiogenic switch, also binds transmembrane receptors dis-\nplayed by endothelial cells and thereby evokes suppressive\nsignals that can counteract proangiogenic stimuli (Kazerounian\net al., 2008).\nThe blood vessels produced within tumors by chronically acti-\nvated angiogenesis and an unbalanced mix of proangiogenic\nsignals are typically aberrant: tumor neovasculature is marked\nby precocious capillary sprouting, convoluted and excessive",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 96
        }
    },
    "1190": {
        "text": "vessel branching, distorted and enlarged vessels, erratic blood\nﬂow, microhemorrhaging, leakiness, and abnormal levels of\nendothelial cell proliferation and apoptosis (Nagy et al., 2010;\nBaluk et al., 2005).\nAngiogenesis is induced surprisingly early during the multi-\nstage development of invasive cancers both in animal models\nand in humans. Histological analyses of premalignant, noninva-\nsive lesions, including dysplasias and in situ carcinomas arising",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 97
        }
    },
    "1191": {
        "text": "in a variety of organs, have revealed the early tripping of the\nangiogenic switch (Raica et al., 2009; Hanahan and Folkman,\n1996). Historically, angiogenesis was envisioned to be important\nonly when rapidly growing macroscopic tumors had formed, but\nmore recent data indicate that angiogenesis also contributes to\nthe microscopic premalignant phase of neoplastic progression,\nfurther cementing its status as an integral hallmark of cancer.\nThe past decade has witnessed an astonishing outpouring of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 98
        }
    },
    "1192": {
        "text": "research on angiogenesis. Amid this wealth of new knowledge,\nwe highlight several advances of particular relevance to tumor\nphysiology.\nGradations of the Angiogenic Switch\nOnce angiogenesis has been activated, tumors exhibit diverse\npatterns of neovascularization. Some tumors, including such\nhighly aggressive types as pancreatic ductal adenocarcinomas,\nare hypovascularized and replete with stromal ‘‘deserts’’ that are\nlargely avascular and indeed may even be actively antiangio-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 99
        }
    },
    "1193": {
        "text": "genic (Olive et al., 2009). Many other tumors, including human\nrenal and pancreatic neuroendocrine carcinomas, are highly\nangiogenic and consequently densely vascularized (Zee et al.,\n2010; Turner et al., 2003).\nCollectively, such observations suggest an initial tripping of\nthe angiogenic switch during tumor development that is followed\nby a variable intensity of ongoing neovascularization, the latter\nbeing controlled by a complex biological rheostat that involves",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 100
        }
    },
    "1194": {
        "text": "both the cancer cells and the associated stromal microenviron-\nment (Baeriswyl and Christofori, 2009; Bergers and Benjamin,\n2003). Of note, the switching mechanism can vary in its form,\neven though the net result is a common inductive signal (e.g.,\nVEGF). In some tumors, dominant oncogenes operating within\ntumor cells, such as Ras and Myc, can upregulate expression\nof angiogenic factors, whereas in others, such inductive signals\nare produced indirectly by immune inﬂammatory cells, as dis-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 101
        }
    },
    "1195": {
        "text": "cussed below. The direct induction of angiogenesis by onco-\ngenes that also drive proliferative signaling illustrates the impor-\ntant\nprinciple\nthat\ndistinct\nhallmark\ncapabilities\ncan\nbe\ncoregulated by the same transforming agents.\nEndogenous Angiogenesis Inhibitors Present Natural\nBarriers to Tumor Angiogenesis\nResearch in the 1990s revealed that TSP-1 as well as fragments\nof plasmin (angiostatin) and type 18 collagen (endostatin) can",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 102
        }
    },
    "1196": {
        "text": "act as endogenous inhibitors of angiogenesis (Ribatti, 2009;\nKazerounian, et al., 2008; Folkman, 2006, 2002; Nyberg et al.,\n2005). The last decade has seen reports of another dozen\nsuch agents (Ribatti, 2009; Folkman, 2006; Nyberg et al.,\n2005). Most are proteins, and many are derived by proteolytic\ncleavage of structural proteins that are not themselves angio-\ngenic regulators. A number of these endogenous inhibitors of\nangiogenesis can be detected in the circulation of normal",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 103
        }
    },
    "1197": {
        "text": "mice and humans. The genes encoding several endogenous\nangiogenesis inhibitors have been deleted from the mouse\ngermline without untoward physiological effects; the growth of\nautochthonous and implanted tumors, however, is enhanced\nas a consequence (Ribatti, 2009; Nyberg et al., 2005). By\ncontrast, if the circulating levels of an endogenous inhibitor\nare genetically increased (e.g., via overexpression in transgenic\nmice or in xenotransplanted tumors), tumor growth is impaired",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 104
        }
    },
    "1198": {
        "text": "(Ribatti, 2009; Nyberg et al., 2005); interestingly, wound healing\nand fat deposition are impaired or accelerated by elevated or\nablated expression of such genes (Cao, 2010; Seppinen et al.,\n2008). The data suggest that such endogenous angiogenesis\ninhibitors serve under normal circumstances as physiologic\nregulators that modulate transitory angiogenesis during tissue\nremodeling and wound healing; they may also act as intrinsic\nbarriers to induction and/or persistence of angiogenesis by",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 105
        }
    },
    "1199": {
        "text": "incipient neoplasias.\nPericytes Are Important Components\nof the Tumor Neovasculature\nPericytes have long been known as supporting cells that are\nclosely apposed to the outer surfaces of the endothelial tubes\nin normal tissue vasculature, where they provide important\nmechanical and physiologic support to the endothelial cells.\nTumor-associated vasculature, in contrast, was portrayed as\nlacking appreciable coverage by these auxiliary cells. However,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 106
        }
    },
    "1200": {
        "text": "careful microscopic studies conducted in recent years have re-\nvealed that pericytes are associated, albeit loosely, with the neo-\nvasculature of most if not all tumors (Raza et al., 2010; Bergers\nand Song, 2005). More importantly, mechanistic studies dis-\ncussed below have revealed that pericyte coverage is important\nfor the maintenance of a functional tumor neovasculature.\nA Variety of Bone Marrow-Derived Cells Contribute\nto Tumor Angiogenesis",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 107
        }
    },
    "1201": {
        "text": "to Tumor Angiogenesis\nIt is now clear that a repertoire of cell types originating in the bone\nmarrow play crucial roles in pathological angiogenesis (Qian and\nPollard, 2010; Zumsteg and Christofori, 2009; Murdoch et al.,\n2008; De Palma et al., 2007). These include cells of the innate\nimmune system—notably macrophages, neutrophils, mast cells,\nand myeloid progenitors—that inﬁltrate premalignant lesions\nand progressed tumors and assemble at the margins of such",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 108
        }
    },
    "1202": {
        "text": "lesions; the peri-tumoral inﬂammatory cells help to trip the angio-\ngenic switch in previously quiescent tissue and to sustain\nongoing angiogenesis associated with tumor growth, in addition\nto facilitating local invasion, as noted below. In addition, they can\nhelp protect the vasculature from the effects of drugs targeting\nendothelial cell signaling (Ferrara, 2010). Additionally, several\ntypes of bone marrow-derived ‘‘vascular progenitor cells’’ have",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 109
        }
    },
    "1203": {
        "text": "been observed in certain cases to have migrated into neoplastic\nlesions and become intercalated into the neovasculature as peri-\ncytes or endothelial cells (Patenaude et al., 2010; Kovacic and\nBoehm, 2009; Lamagna and Bergers, 2006).\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n653\nActivating Invasion and Metastasis\nIn 2000, the mechanisms underlying invasion and metastasis\nwere largely an enigma. It was clear that as carcinomas arising",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 110
        }
    },
    "1204": {
        "text": "from epithelial tissues progressed to higher pathological grades\nof malignancy, reﬂected in local invasion and distant metastasis,\nthe associated cancer cells typically developed alterations in\ntheir shape as well as in their attachment to other cells and to\nthe extracellular matrix (ECM). The best characterized alteration\ninvolved the loss by carcinoma cells of E-cadherin, a key cell-to-\ncell adhesion molecule. By forming adherens junctions with",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 111
        }
    },
    "1205": {
        "text": "adjacent epithelial cells, E-cadherin helps to assemble epithelial\ncell sheets and maintain the quiescence of the cells within these\nsheets. Increased expression of E-cadherin was well established\nas an antagonist of invasion and metastasis, whereas reduction\nof its expression was known to potentiate these phenotypes. The\nfrequently observed downregulation and occasional mutational\ninactivation of E-cadherin in human carcinomas provided strong",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 112
        }
    },
    "1206": {
        "text": "support for its role as a key suppressor of this hallmark capability\n(Berx and van Roy, 2009; Cavallaro and Christofori, 2004).\nAdditionally, expression of genes encoding other cell-to-cell\nand cell-to-ECM adhesion molecules is demonstrably altered\nin some highly aggressive carcinomas, with those favoring cyto-\nstasis typically being downregulated. Conversely, adhesion\nmolecules normally associated with the cell migrations that\noccur during embryogenesis and inﬂammation are often upregu-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 113
        }
    },
    "1207": {
        "text": "lated. For example, N-cadherin, which is normally expressed in\nmigrating neurons and mesenchymal cells during organogen-\nesis, is upregulated in many invasive carcinoma cells. Beyond\nthe gain and loss of such cell-cell/matrix attachment proteins,\nthe master regulators of invasion and metastasis were largely\nunknown or, when suspected, lacking in functional validation\n(Cavallaro and Christofori, 2004).\nThe multistep process of invasion and metastasis has been",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 114
        }
    },
    "1208": {
        "text": "schematized as a sequence of discrete steps, often termed the\ninvasion-metastasis cascade (Talmadge and Fidler, 2010; Fidler,\n2003). This depiction envisions a succession of cell-biologic\nchanges, beginning with local invasion, then intravasation by\ncancer cells into nearby blood and lymphatic vessels, transit of\ncancer cells through the lymphatic and hematogenous systems,\nfollowed by escape of cancer cells from the lumina of such\nvessels into the parenchyma of distant tissues (extravasation),",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 115
        }
    },
    "1209": {
        "text": "the formation of small nodules of cancer cells (micrometasta-\nses), and ﬁnally the growth of micrometastatic lesions into\nmacroscopic tumors, this last step being termed ‘‘colonization.’’\nResearch into the capability for invasion and metastasis has\naccelerated dramatically over the past decade as powerful\nnew research tools and reﬁned experimental models have\nbecome available, and as critical regulatory genes were identi-\nﬁed. While still an emerging ﬁeld replete with major unanswered",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 116
        }
    },
    "1210": {
        "text": "questions, signiﬁcant progress has been made in delineating\nimportant features of this complex hallmark capability. An admit-\ntedly incomplete representation of these advances is highlighted\nbelow.\nThe EMT Program Broadly Regulates Invasion\nand Metastasis\nA developmental regulatory program, referred to as the ‘‘epithe-\nlial-mesenchymal transition’’ (EMT), has become prominently\nimplicated as a means by which transformed epithelial cells",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 117
        }
    },
    "1211": {
        "text": "can acquire the abilities to invade, to resist apoptosis, and to\ndisseminate (Klymkowsky and Savagner, 2009; Polyak and\nWeinberg, 2009; Thiery et al., 2009; Yilmaz and Christofori,\n2009; Barrallo-Gimeno and Nieto, 2005). By co-opting a process\ninvolved in various steps of embryonic morphogenesis and\nwound healing, carcinoma cells can concomitantly acquire\nmultiple attributes that enable invasion and metastasis. This\nmultifaceted EMT program can be activated transiently or stably,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 118
        }
    },
    "1212": {
        "text": "and to differing degrees, by carcinoma cells during the course of\ninvasion and metastasis.\nA set of pleiotropically acting transcriptional factors, including\nSnail, Slug, Twist, and Zeb1/2, orchestrate the EMT and related\nmigratory processes during embryogenesis; most were initially\nidentiﬁed by developmental genetics. These transcriptional\nregulators are expressed in various combinations in a number\nof malignant tumor types and have been shown in experimental",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 119
        }
    },
    "1213": {
        "text": "models of carcinoma formation to be causally important for\nprogramming invasion; some have been found to elicit metas-\ntasis when ectopically overexpressed (Micalizzi et al., 2010;\nTaube et al., 2010; Schmalhofer et al., 2009; Yang and Weinberg,\n2008). Included among the cell-biological traits evoked by such\ntranscription factors are loss of adherens junctions and associ-\nated conversion from a polygonal/epithelial to a spindly/ﬁbro-\nblastic morphology, expression of matrix-degrading enzymes,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 120
        }
    },
    "1214": {
        "text": "increased motility, and heightened resistance to apoptosis—all\ntraits implicated in the processes of invasion and metastasis.\nSeveral of these transcription factors can directly repress E-cad-\nherin gene expression, thereby depriving neoplastic epithelial\ncells of this key suppressor of motility and invasiveness (Peinado\net al., 2004).\nThe available evidence suggests that these transcription\nfactors regulate one another as well as overlapping sets of target",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 121
        }
    },
    "1215": {
        "text": "genes. No rules have yet been established to describe their inter-\nactions and the conditions that govern their expression.\nEvidence from developmental genetics indicates that contextual\nsignals received from neighboring cells in the embryo are\ninvolved in triggering expression of these transcription factors\nin those cells destined to pass through an EMT (Micalizzi et al.,\n2010); in an analogous fashion, increasing evidence suggests\nthat heterotypic interactions of cancer cells with adjacent",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 122
        }
    },
    "1216": {
        "text": "tumor-associated stromal cells can induce expression of the\nmalignant cell phenotypes that are known to be choreographed\nby one or more of these transcriptional regulators (Karnoub and\nWeinberg, 2006–2007; Brabletz et al., 2001). Moreover, cancer\ncells at the invasive margins of certain carcinomas can be\nseen to have undergone an EMT, suggesting that these cancer\ncells are subject to microenvironmental stimuli distinct from\nthose received by cancer cells located in the cores of these",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 123
        }
    },
    "1217": {
        "text": "lesions (Hlubek et al., 2007).\nAlthough the evidence is still incomplete, it would appear that\nEMT-inducing transcription factors are able to orchestrate most\nsteps of the invasion-metastasis cascade save the ﬁnal step of\ncolonization. We still know rather little about the various manifes-\ntations and temporal stability of the mesenchymal state\nproduced by an EMT. Although expression of EMT-inducing\ntranscription factors has been observed in certain nonepithelial",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 124
        }
    },
    "1218": {
        "text": "tumor types, such as sarcomas and neuroectodermal tumors,\ntheir roles in programming malignant traits in these tumors are\n654\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\npresently poorly documented. Additionally, it remains to be\ndetermined\nwhether\ninvasive\ncarcinoma\ncells\nnecessarily\nacquire their capability through activation of parts of the EMT\nprogram, or whether alternative regulatory programs can also\nenable this capability.\nHeterotypic Contributions of Stromal Cells to Invasion",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 125
        }
    },
    "1219": {
        "text": "and Metastasis\nIt is increasingly apparent that crosstalk between cancer cells\nand cells of the neoplastic stroma is involved in the acquired\ncapability for invasive growth and metastasis (Egeblad et al.,\n2010; Qian and Pollard, 2010; Joyce and Pollard, 2009; Kalluri\nand Zeisberg, 2006). Such signaling may impinge on carcinoma\ncells and act to alter their hallmark capabilities as suggested\nabove. For example, mesenchymal stem cells (MSCs) present",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 126
        }
    },
    "1220": {
        "text": "in the tumor stroma have been found to secrete CCL5/RANTES\nin response to signals released by cancer cells; CCL5 then acts\nreciprocally on the cancer cells to stimulate invasive behavior\n(Karnoub et al., 2007).\nMacrophages at the tumor periphery can foster local invasion\nby supplying matrix-degrading enzymes such as metalloprotei-\nnases and cysteine cathepsin proteases (Kessenbrock et al.,\n2010; Joyce and Pollard, 2009; Palermo and Joyce, 2008; Mo-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 127
        }
    },
    "1221": {
        "text": "hamed and Sloane, 2006); in one model system, the invasion-\npromoting macrophages are activated by IL-4 produced by the\ncancer cells (Gocheva et al., 2010). And in an experimental\nmodel of metastatic breast cancer, tumor-associated macro-\nphages (TAMs) supply epidermal growth factor (EGF) to breast\ncancer cells, while the cancer cells reciprocally stimulate the\nmacrophages with CSF-1; their concerted interactions facilitate\nintravasation into the circulatory system and metastatic dissem-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 128
        }
    },
    "1222": {
        "text": "ination of the cancer cells (Qian and Pollard, 2010; Wyckoff et al.,\n2007).\nObservations like these indicate that the phenotypes of high-\ngrade malignancy do not arise in a strictly cell-autonomous\nmanner, and that their manifestation cannot be understood\nsolely through analyses of tumor cell genomes. One important\nimplication, still untested, is that the ability to negotiate most of\nthe steps of the invasion-metastasis cascade may be acquired",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 129
        }
    },
    "1223": {
        "text": "in certain tumors without the requirement that the associated\ncancer cells undergo additional mutations beyond those that\nwere needed for primary tumor formation.\nPlasticity in the Invasive Growth Program\nThe role of contextual signals in inducing an invasive growth\ncapability (often via an EMT) implies the possibility of revers-\nibility, in that cancer cells that have disseminated from a primary\ntumor to a more distant tissue site may no longer beneﬁt from the",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 130
        }
    },
    "1224": {
        "text": "activated stroma and invasion/EMT-inducing signals that they\nexperienced while residing in the primary tumor; in the absence\nof ongoing exposure to these signals, carcinoma cells may revert\nin their new homes to a noninvasive state. Thus, carcinoma cells\nthat have undergone an EMT during initial invasion and meta-\nstatic dissemination may pass through the reverse process,\ntermed the mesenchymal-epithelial transition (MET). This plas-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 131
        }
    },
    "1225": {
        "text": "ticity may result in the formation of new tumor colonies of carci-\nnoma cells exhibiting a histopathology similar to those of carci-\nnoma cells in the primary tumor that never underwent an EMT\n(Hugo et al., 2007). Moreover, the notion that cancer cells\nroutinely pass through a complete EMT program is likely to be\nsimplistic; instead, in many cases, cancer cells may enter into\nan EMT program only partially, thereby acquiring new mesen-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 132
        }
    },
    "1226": {
        "text": "chymal traits while continuing to express residual epithelial traits.\nDistinct Forms of Invasion May Underlie Different\nCancer Types\nThe EMT program regulates a particular type of invasiveness\nthat has been termed ‘‘mesenchymal.’’ In addition, two other\ndistinct modes of invasion have been identiﬁed and implicated\nin cancer cell invasion (Friedl and Wolf, 2008, 2010). ‘‘Collective\ninvasion’’ involves nodules of cancer cells advancing en masse",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 133
        }
    },
    "1227": {
        "text": "into adjacent tissues and is characteristic of, for example,\nsquamous cell carcinomas; interestingly, such cancers are\nrarely metastatic, suggesting that this form of invasion lacks\ncertain functional attributes that facilitate metastasis. Less clear\nis the prevalence of an ‘‘amoeboid’’ form of invasion (Madsen\nand Sahai, 2010; Sabeh et al., 2009), in which individual cancer\ncells show morphological plasticity, enabling them to slither",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 134
        }
    },
    "1228": {
        "text": "through existing interstices in the extracellular matrix rather\nthan clearing a path for themselves, as occurs in both the mesen-\nchymal and collective forms of invasion. It is presently unre-\nsolved whether cancer cells participating in the collective and\namoeboid forms of invasion employ components of the EMT\nprogram, or whether entirely different cell-biological programs\nare responsible for choreographing these alternative invasion\nprograms.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 135
        }
    },
    "1229": {
        "text": "programs.\nAnother emerging concept, noted above, involves the facilita-\ntion of cancer cell invasion by inﬂammatory cells that assemble\nat the boundaries of tumors, producing the extracellular\nmatrix-degrading enzymes and other factors that enable inva-\nsive growth (Kessenbrock et al., 2010; Qian and Pollard, 2010;\nJoyce and Pollard, 2009); these functions may obviate the\nneed of cancer cells to produce these proteins through activa-\ntion of EMT programs. Thus, cancer cells may secrete the",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 136
        }
    },
    "1230": {
        "text": "chemoattractants that recruit the proinvasive inﬂammatory cells\nrather than producing the matrix-degrading enzymes them-\nselves.\nThe Daunting Complexity of Metastatic Colonization\nMetastasis can be broken down into two major phases: the\nphysical dissemination of cancer cells from the primary tumor\nto distant tissues, and the adaptation of these cells to foreign\ntissue microenvironments that results in successful colonization,\ni.e., the growth of micrometastases into macroscopic tumors.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 137
        }
    },
    "1231": {
        "text": "The multiple steps of dissemination would seem to be in the\npurview of the EMT and similarly acting migratory programs.\nColonization, however, is not strictly coupled with physical\ndissemination, as evidenced by the presence in many patients\nof myriad micrometastases that have successfully disseminated\nbut never progress to macroscopic metastatic tumors (Tal-\nmadge and Fidler, 2010; McGowan et al., 2009; Aguirre-Ghiso,\n2007; Townson and Chambers, 2006; Fidler, 2003).",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 138
        }
    },
    "1232": {
        "text": "2007; Townson and Chambers, 2006; Fidler, 2003).\nIn some types of cancer, the primary tumor may release\nsystemic suppressor factors that render such micrometastases\ndormant, as revealed clinically by explosive metastatic growth\nsoon after resection of the primary growth (Demicheli et al.,\n2008; Folkman, 2002). In others, however, such as breast cancer\nand melanoma, macroscopic metastases may erupt decades\nafter a primary tumor has been surgically removed or pharmaco-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 139
        }
    },
    "1233": {
        "text": "logically destroyed; these metastatic tumor growths evidently\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n655\nreﬂect dormantmicrometastasesthathavesolved,aftermuchtrial\nand error, the complex problem of tissue colonization (Barkan,\net al., 2010; Aguirre-Ghiso, 2007; Townson and Chambers, 2006).\nOne can infer from such natural histories that micrometasta-\nses may lack other hallmark capabilities necessary for vigorous\ngrowth, such as the ability to activate angiogenesis; indeed the",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 140
        }
    },
    "1234": {
        "text": "inability of certain experimentally generated dormant microme-\ntastases to form macroscopic tumors has been ascribed to their\nfailure to activate tumor angiogenesis (Naumov et al., 2008;\nAguirre-Ghiso, 2007). Additionally, recent experiments have\nshown that nutrient starvation can induce intense autophagy\nthat causes cancer cells to shrink and adopt a state of reversible\ndormancy; such cells may exit this state and resume active\ngrowth and proliferation when changes in tissue microenviron-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 141
        }
    },
    "1235": {
        "text": "ment, such as access to more nutrients, permit (Keniﬁc et al.,\n2010; Lu et al., 2008). Other mechanisms of micrometastatic\ndormancy may involve anti-growth signals embedded in normal\ntissue extracellular matrix (Barkan et al., 2010) and tumor-sup-\npressing actions of the immune system (Teng et al., 2008;\nAguirre-Ghiso, 2007).\nMost disseminated cancer cells are likely to be poorly adap-\nted, at least initially, to the microenvironment of the tissue in",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 142
        }
    },
    "1236": {
        "text": "which they have landed. Accordingly, each type of disseminated\ncancer cell may need to develop its own set of ad hoc solutions\nto the problem of thriving in the microenvironment of one or\nanother foreign tissue (Gupta et al., 2005). These adaptations\nmight require hundreds of distinct colonization programs, each\ndictated by the type of disseminating cancer cell and the nature\nof\nthe\ntissue\nmicroenvironment\nin\nwhich\ncolonization\nis\nproceeding. As further discussed below, however, certain tissue",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 143
        }
    },
    "1237": {
        "text": "microenviroments may be preordained to be intrinsically hospi-\ntable to disseminated cancer cells (Peinado et al., 2011;\nTalmadge and Fidler, 2010).\nMetastatic dissemination has long been depicted as the last\nstep in multistep primary tumor progression, and indeed for\nmany tumors that is likely the case, as illustrated by recent\ngenome sequencing studies that present genetic evidence for\nclonal evolution of pancreatic ductal adenocarcinoma to metas-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 144
        }
    },
    "1238": {
        "text": "tasis (Campbell et al., 2010; Luebeck, 2010; Yachida et al.,\n2010). On the other hand, evidence has recently emerged\nindicating\nthat\ncells\ncan\ndisseminate\nremarkably\nearly,\ndispersing from ostensibly noninvasive premalignant lesions in\nboth mice and humans (Coghlin and Murray, 2010; Klein,\n2009). Additionally, micrometastases can be spawned from\nprimary tumors that are not obviously invasive but possess\na neovasculature lacking in lumenal integrity (Gerhardt and",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 145
        }
    },
    "1239": {
        "text": "Semb, 2008). Although cancer cells can clearly disseminate\nfrom such pre-neoplastic lesions and seed the bone marrow\nand other tissues, their capability to colonize these sites and\ndevelop\ninto\npathologically\nsigniﬁcant\nmacrometastases\nremains unproven. At present, we view this early metastatic\ndissemination as a demonstrable phenomenon in mice and hu-\nmans whose clinical signiﬁcance is yet to be established.\nBeyond the timing of their dissemination, it also remains",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 146
        }
    },
    "1240": {
        "text": "unclear when and where cancer cells develop the ability to colo-\nnize foreign tissues as macroscopic tumors. This capability may\narise during primary tumor formation as a result of a tumor’s\nparticular developmental path prior to any dissemination, such\nthat primary tumor cells entering the circulation are fortuitously\nendowed with the ability to colonize certain distant tissue sites\n(Talmadge and Fidler, 2010). Alternatively, the ability to colonize",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 147
        }
    },
    "1241": {
        "text": "speciﬁc tissues may only develop in response to the selective\npressure on already disseminated cancer cells to adapt to\ngrowth in foreign tissue microenvironments.\nHaving developed such tissue-speciﬁc colonizing ability, the\ncells in metastatic colonies may proceed to disseminate further,\nnot only to new sites in the body but also back to the primary\ntumors in which their ancestors arose. Accordingly, tissue-\nspeciﬁc colonization programs that are evident among cells",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 148
        }
    },
    "1242": {
        "text": "within a primary tumor may originate not from classical tumor\nprogression occurring within the primary lesion but instead\nfrom emigrants that have returned home (Kim et al., 2009).\nSuch reseeding is consistent with the aforementioned studies\nof human pancreatic cancer metastasis (Campbell et al.,\n2010; Luebeck, 2010; Yachida et al., 2010). Stated differently,\nthe phenotypes and underlying gene expression programs of\nthe populations of cancer cells (and of the cancer stem cells",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 149
        }
    },
    "1243": {
        "text": "discussed below) within primary tumors may be signiﬁcantly\nmodiﬁed by reverse migration of their distant metastatic\nprogeny.\nImplicit in this self-seeding process is another notion: the\nsupportive stroma that arises in a primary tumor and contributes\nto its acquisition of malignant traits may intrinsically provide\na hospitable site for reseeding and colonization by circulating\ncancer cells emanating from metastatic lesions.\nClarifying the regulatory programs that enable metastatic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 150
        }
    },
    "1244": {
        "text": "colonization represents an important agenda for future research.\nSubstantial progress is being made, for example, in deﬁning sets\nof genes (‘‘metastatic signatures’’) that correlate with and appear\nto facilitate the establishment of macroscopic metastases in\nspeciﬁc tissues (Coghlin and Murray, 2010; Bos et al., 2009;\nOlson et al., 2009; Nguyen et al., 2009; Gupta et al., 2005). The\nchallenge is considerable, given the apparent multitude of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 151
        }
    },
    "1245": {
        "text": "distinct colonization programs cited above. Moreover, coloniza-\ntion is unlikely to depend exclusively on cell-autonomous\nprocesses. Instead, it almost certainly requires the establish-\nment of a permissive tumor microenvironment composed of\ncritical stromal support cells. For these reasons, the process\nof colonization is likely to encompass a large number of cell-\nbiological programs that are, in aggregate, considerably more\ncomplex and diverse than the preceding steps of metastatic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 152
        }
    },
    "1246": {
        "text": "dissemination.\nProgramming of Hallmark Capabilities\nby Intracellular Circuitry\nIn 2000, we presented a metaphor, in which the numerous\nsignaling molecules affecting cancer cells operate as nodes\nand branches of elaborate integrated circuits that are reprog-\nrammed derivatives of the circuits operating in normal cells.\nThe ensuing decade has both solidiﬁed the original depiction\nof these circuits and expanded the catalog of signals and the",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 153
        }
    },
    "1247": {
        "text": "interconnections of their signaling pathways. It is difﬁcult if not\nimpossible to graphically portray this circuit comprehensively\nand coherently, as was already the case in 2000.\nWe now suggest a portrayal of this circuitry that is aligned with\nindividual hallmarks of cancer. Thus, the intracellular integrated\n656\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\ncircuit can be segmented into distinct subcircuits, each of which\nis specialized to support a discrete cell-biological property in",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 154
        }
    },
    "1248": {
        "text": "normal cells and is reprogrammed in order to implement\na hallmark capability in cancer cells (Figure 2). Only a subset of\nhallmark capabilities are addressed in this ﬁgure, either because\ntheir underlying control circuits remain poorly understood or\nbecause they overlap extensively with those portrayed here.\nAn additional dimension of complexity involves considerable\ninterconnections and thus crosstalk between the individual sub-\ncircuits. For example, certain oncogenic events can affect",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 155
        }
    },
    "1249": {
        "text": "multiple capabilities, as illustrated by the diverse effects that\nprominent oncogenes, such as mutant RAS and upregulated\nMYC, have on multiple hallmark capabilities (e.g., proliferative\nsignaling, energy metabolism, angiogenesis, invasion, and\nsurvival). We anticipate that future renditions of this integrated\ncircuit will encompass subcircuits and associated hallmark\ncapabilities that are still not addressed here.\nENABLING CHARACTERISTICS AND EMERGING\nHALLMARKS",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 156
        }
    },
    "1250": {
        "text": "ENABLING CHARACTERISTICS AND EMERGING\nHALLMARKS\nWe have deﬁned the hallmarks of cancer as acquired functional\ncapabilities that allow cancer cells to survive, proliferate, and\ndisseminate; these functions are acquired in different tumor\ntypes via distinct mechanisms and at various times during the\ncourse of multistep tumorigenesis. Their acquisition is made\npossible by two enabling characteristics. Most prominent is the\ndevelopment of genomic instability in cancer cells, which",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 157
        }
    },
    "1251": {
        "text": "generates random mutations including chromosomal rearrange-\nments; among these are the rare genetic changes that can\norchestrate hallmark capabilities. A second enabling character-\nistic involves the inﬂammatory state of premalignant and frankly\nmalignant lesions that is driven by cells of the immune system,\nsome of which serve to promote tumor progression through\nvarious means.\nFigure 2. Intracellular Signaling Networks Regulate the Operations of the Cancer Cell",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 158
        }
    },
    "1252": {
        "text": "An elaborate integrated circuit operates within normal cells and is reprogrammed to regulate hallmark capabilities within cancer cells. Separate subcircuits,\ndepicted here in differently colored ﬁelds, are specialized to orchestrate the various capabilities. At one level, this depiction is simplistic, as there is considerable\ncrosstalk between such subcircuits. In addition, because each cancer cell is exposed to a complex mixture of signals from its microenvironment, each of these",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 159
        }
    },
    "1253": {
        "text": "subcircuits is connected with signals originating from other cells in the tumor microenvironment, as outlined in Figure 5.\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n657\nYet other distinct attributes of cancer cells have been\nproposed to be functionally important for the development of\ncancer and might therefore be added to the list of core hallmarks\n(Negrini et al., 2010; Luo et al., 2009; Colotta et al., 2009). Two\nsuch attributes are particularly compelling. The ﬁrst involves",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 160
        }
    },
    "1254": {
        "text": "major reprogramming of cellular energy metabolism in order to\nsupport continuous cell growth and proliferation, replacing the\nmetabolic program that operates in most normal tissues and\nfuels the physiological operations of the associated cells. The\nsecond involves active evasion by cancer cells from attack and\nelimination by immune cells; this capability highlights the dichot-\nomous roles of an immune system that both antagonizes and\nenhances tumor development and progression. Both of these",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 161
        }
    },
    "1255": {
        "text": "capabilities may well prove to facilitate the development and\nprogression of many forms of human cancer and therefore can\nbe considered to be emerging hallmarks of cancer. These\nenabling characteristics and emerging hallmarks, depicted in\nFigure 3, are discussed individually below.\nAn Enabling Characteristic: Genome Instability\nand Mutation\nAcquisition of the multiple hallmarks enumerated above depends\nin large part on a succession of alterations in the genomes of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 162
        }
    },
    "1256": {
        "text": "neoplastic cells. Simply depicted, certain mutant genotypes\nconfer selective advantage on subclones of cells, enabling their\noutgrowth and eventual dominance in a local tissue environment.\nAccordingly, multistep tumor progression can be portrayed as\na succession of clonal expansions, each of which is triggered\nby the chance acquisition of an enabling mutant genotype.\nBecause heritable phenotypes, e.g., inactivation of tumor\nsuppressor genes, can also be acquired through epigenetic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 163
        }
    },
    "1257": {
        "text": "mechanisms such as DNA methylation and histone modiﬁcations\n(Berdasco and Esteller, 2010; Esteller, 2007; Jones and Baylin,\n2007), some clonal expansions may well be triggered by nonmu-\ntational changes affecting the regulation of gene expression.\nThe extraordinary ability of genome maintenance systems to\ndetect and resolve defects in the DNA ensures that rates of\nspontaneous mutation are usually very low during each cell\ngeneration. In the course of acquiring the roster of mutant genes\nneeded",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 164
        }
    },
    "1258": {
        "text": "needed\nto\norchestrate\ntumorigenesis,\ncancer\ncells\noften\nincrease the rates of mutation (Negrini et al., 2010; Salk et al.,\n2010). This mutability is achieved through increased sensitivity\nto mutagenic agents, through a breakdown in one or several\ncomponents of the genomic maintenance machinery, or both.\nIn addition, the accumulation of mutations can be accelerated\nby compromising the surveillance systems that normally monitor\ngenomic integrity and force genetically damaged cells into either",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 165
        }
    },
    "1259": {
        "text": "senescence or apoptosis (Jackson and Bartek, 2009; Kastan,\n2008; Sigal and Rotter, 2000). The role of TP53 is central here,\nleading to its being called the ‘‘guardian of the genome’’ (Lane,\n1992).\nA diverse array of defects affecting various components of the\nDNA-maintenance machinery—often referred to as the ‘‘care-\ntakers’’ of the genome (Kinzler and Vogelstein, 1997)—have\nbeen documented. The catalog of defects in these caretaker",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 166
        }
    },
    "1260": {
        "text": "genes includes those whose products are involved in (1) detect-\ning DNA damage and activating the repair machinery, (2) directly\nrepairing damaged DNA, and (3) inactivating or intercepting\nmutagenic molecules before they have damaged the DNA\n(Negrini et al., 2010; Ciccia and Elledge, 2010; Jackson and\nBartek, 2009; Kastan, 2008; Harper and Elledge, 2007; Friedberg\net al., 2006). From a genetic perspective, these caretaker genes\nbehave much like tumor suppressor genes, in that their functions",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 167
        }
    },
    "1261": {
        "text": "can be lost during the course of tumor progression, with such\nlosses being achieved either through inactivating mutations or\nvia epigenetic repression. Mutant copies of many of these care-\ntaker genes have been introduced into the mouse germline and\nresult, predictably, in increased cancer incidence, supporting\ntheir potential involvement in human cancer development\n(Barnes and Lindahl, 2004).\nFigure 3. Emerging Hallmarks and Enabling\nCharacteristics",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 168
        }
    },
    "1262": {
        "text": "Characteristics\nAn increasing body of research suggests that two\nadditional hallmarks of cancer are involved in the\npathogenesis of some and perhaps all cancers.\nOne involves the capability to modify, or repro-\ngram, cellular metabolism in order to most effec-\ntively support neoplastic proliferation. The second\nallows\ncancer\ncells\nto\nevade\nimmunological\ndestruction, in particular by T and B lymphocytes,\nmacrophages, and natural killer cells. Because",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 169
        }
    },
    "1263": {
        "text": "macrophages, and natural killer cells. Because\nneither capability is yet generalized and fully vali-\ndated, they are labeled as emerging hallmarks.\nAdditionally, two consequential characteristics of\nneoplasia facilitate acquisition of both core and\nemerging hallmarks. Genomic instability and thus\nmutability endow cancer cells with genetic alter-\nations that drive tumor progression. Inﬂammation\nby innate immune cells designed to ﬁght infections\nand heal wounds can instead result in their inad-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 170
        }
    },
    "1264": {
        "text": "and heal wounds can instead result in their inad-\nvertent support of multiple hallmark capabilities,\nthereby manifesting the now widely appreciated\ntumor-promoting consequences of inﬂammatory\nresponses.\n658\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nIn the decade since we ﬁrst enumerated the cancer hallmarks,\nanother major source of tumor-associated genomic instability\nhas been uncovered: as described earlier, the loss of telomeric",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 171
        }
    },
    "1265": {
        "text": "DNA in many tumors generates karyotypic instability and associ-\nated ampliﬁcation and deletion of chromosomal segments\n(Artandi and DePinho, 2010). When viewed in this light, telome-\nrase is more than an enabler of the hallmark capability for\nunlimited replicative potential and must also be added to the\nlist of critical caretakers responsible for maintaining genome\nintegrity.\nAdvances in the molecular-genetic analysis of cancer cell\ngenomes have provided the most compelling demonstrations",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 172
        }
    },
    "1266": {
        "text": "of function-altering mutations and of ongoing genomic instability\nduring tumor progression. One type of analysis—comparative\ngenomic hybridization (CGH)—documents the gains and losses\nof gene copy number across the cell genome; in many tumors,\nthe pervasive genomic aberrations revealed by CGH provide\nclear evidence for loss of control of genome integrity. Impor-\ntantly, the recurrence of speciﬁc aberrations (both ampliﬁcations\nand deletions) at particular sites in the genome indicates that",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 173
        }
    },
    "1267": {
        "text": "such sites are likely to harbor genes whose alteration favors\nneoplastic progression (Korkola and Gray, 2010).\nMore recently, with the advent of efﬁcient and economical\nDNA-sequencing\ntechnologies,\nhigher-resolution\nanalyses\nhave become possible. Early studies are revealing distinctive\npatterns of DNA mutations in different tumor types (see http://\ncancergenome.nih.gov/). In the not-too-distant\nfuture, the\nsequencing of entire cancer cell genomes promises to clarify",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 174
        }
    },
    "1268": {
        "text": "the prevalence of ostensibly random mutations scattered across\ncancer cell genomes. Thus, recurring genetic alterations may\npoint to a causal role of particular mutations in tumor pathogen-\nesis.\nAlthough the speciﬁcs of genome alteration vary dramatically\nbetween different tumor types, the large number of genome\nmaintenance and repair defects that have already been docu-\nmented in human tumors, together with abundant evidence of\nwidespread destabilization of gene copy number and nucleotide",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 175
        }
    },
    "1269": {
        "text": "sequence, persuade us that instability of the genome is inherent\nto the great majority of human cancer cells. This leads, in turn, to\nthe conclusion that the defects in genome maintenance and\nrepair are selectively advantageous and therefore instrumental\nfor tumor progression, if only because they accelerate the rate\nat which evolving premalignant cells can accumulate favorable\ngenotypes. As such, genome instability is clearly an enabling",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 176
        }
    },
    "1270": {
        "text": "characteristic that is causally associated with the acquisition of\nhallmark capabilities.\nAn Enabling Characteristic: Tumor-Promoting\nInﬂammation\nPathologists have long recognized that some tumors are densely\ninﬁltrated by cells of both the innate and adaptive arms of the\nimmune system and thereby mirror inﬂammatory conditions\narising in non-neoplastic tissues (Dvorak, 1986). With the advent\nof better markers for accurately identifying the distinct cell types",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 177
        }
    },
    "1271": {
        "text": "of the immune system, it is now clear that virtually every\nneoplastic lesion contains immune cells present at densities\nranging from subtle inﬁltrations detectable only with cell type-\nspeciﬁc antibodies to gross inﬂammations that are apparent\neven by standard histochemical staining techniques (Page` s\net al., 2010). Historically, such immune responses were largely\nthought to reﬂect an attempt by the immune system to eradicate\ntumors, and indeed, there is increasing evidence for antitumoral",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 178
        }
    },
    "1272": {
        "text": "responses to many tumor types with an attendant pressure on\nthe tumor to evade immune destruction, as discussed below.\nBy 2000, there were already clues that the tumor-associated\ninﬂammatory response had the unanticipated, paradoxical effect\nof enhancing tumorigenesis and progression, in effect helping\nincipient neoplasias to acquire hallmark capabilities. In the\nensuing decade, research on the intersections between inﬂam-\nmation and cancer pathogenesis has blossomed, producing",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 179
        }
    },
    "1273": {
        "text": "abundant and compelling demonstrations of the functionally\nimportant tumor-promoting effects that immune cells—largely\nof the innate immune system—have on neoplastic progression\n(DeNardo et al., 2010; Grivennikov et al., 2010; Qian and Pollard,\n2010; Colotta et al., 2009). Inﬂammation can contribute to\nmultiple hallmark capabilities by supplying bioactive molecules\nto the tumor microenvironment, including growth factors that\nsustain proliferative signaling, survival factors that limit cell",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 180
        }
    },
    "1274": {
        "text": "death, proangiogenic factors, extracellular matrix-modifying\nenzymes that facilitate angiogenesis, invasion, and metastasis,\nand inductive signals that lead to activation of EMT and other\nhallmark-facilitating\nprograms\n(DeNardo\net\nal.,\n2010;\nGrivennikov et al., 2010; Qian and Pollard, 2010; Karnoub and\nWeinberg, 2006–2007).\nImportantly, inﬂammation is in some cases evident at the\nearliest stages of neoplastic progression and is demonstrably",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 181
        }
    },
    "1275": {
        "text": "capable of fostering the development of incipient neoplasias\ninto full-blown cancers (Qian and Pollard, 2010; de Visser et al.,\n2006). Additionally, inﬂammatory cells can release chemicals,\nnotably reactive oxygen species, that are actively mutagenic for\nnearby cancer cells, accelerating their genetic evolution toward\nstates of heightened malignancy (Grivennikov et al., 2010). As\nsuch, inﬂammation can be considered an enabling characteristic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 182
        }
    },
    "1276": {
        "text": "for its contributions to the acquisition of core hallmark capabil-\nities. The cells responsible for this enabling characteristic are\ndescribed in the section below on the tumor microenvironment.\nAn Emerging Hallmark: Reprogramming Energy\nMetabolism\nThe chronic and often uncontrolled cell proliferation that repre-\nsents the essence of neoplastic disease involves not only\nderegulated control of cell proliferation but also corresponding\nadjustments of energy metabolism in order to fuel cell growth",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 183
        }
    },
    "1277": {
        "text": "and division. Under aerobic conditions, normal cells process\nglucose, ﬁrst to pyruvate via glycolysis in the cytosol and there-\nafter to carbon dioxide in the mitochondria; under anaerobic\nconditions, glycolysis is favored and relatively little pyruvate is\ndispatched\nto\nthe\noxygen-consuming\nmitochondria.\nOtto\nWarburg ﬁrst observed an anomalous characteristic of cancer\ncell energy metabolism (Warburg, 1930, 1956a, 1956b): even in\nthe presence of oxygen, cancer cells can reprogram their",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 184
        }
    },
    "1278": {
        "text": "glucose metabolism, and thus their energy production, by\nlimiting their energy metabolism largely to glycolysis, leading to\na state that has been termed ‘‘aerobic glycolysis.’’\nThe existence of this metabolic switch in cancer cells has been\nsubstantiated in the ensuing decades. Such reprogramming of\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n659\nenergy metabolism is seemingly counterintuitive, in that cancer\ncells must compensate for the \u000118-fold lower efﬁciency of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 185
        }
    },
    "1279": {
        "text": "ATP production afforded by glycolysis relative to mitochondrial\noxidative phosphorylation. They do so in part by upregulating\nglucose\ntransporters,\nnotably\nGLUT1,\nwhich\nsubstantially\nincreases glucose import into the cytoplasm (Jones and Thomp-\nson, 2009; DeBerardinis et al., 2008; Hsu and Sabatini, 2008).\nIndeed, markedly increased uptake and utilization of glucose\nhave been documented in many human tumor types, most\nreadily by noninvasively visualizing glucose uptake using posi-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 186
        }
    },
    "1280": {
        "text": "tron emission tomography (PET) with a radiolabeled analog of\nglucose (18F-ﬂuorodeoxyglucose, FDG) as a reporter.\nGlycolytic fueling has been shown to be associated with\nactivated oncogenes (e.g., RAS, MYC) and mutant tumor\nsuppressors (e.g., TP53) (DeBerardinis et al., 2008; Jones and\nThompson, 2009), whose alterations in tumor cells have been\nselected primarily for their beneﬁts in conferring the hallmark\ncapabilities of cell proliferation, avoidance of cytostatic controls,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 187
        }
    },
    "1281": {
        "text": "and attenuation of apoptosis. This reliance on glycolysis can be\nfurther accentuated under the hypoxic conditions that operate\nwithin many tumors: the hypoxia response system acts pleio-\ntropically to upregulate glucose transporters and multiple\nenzymes of the glycolytic pathway (Semenza, 2010a; Jones\nand Thompson, 2009; DeBerardinis et al., 2008). Thus, both\nthe Ras oncoprotein and hypoxia can independently increase\nthe levels of the HIF1a and HIF2a transcription factors, which",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 188
        }
    },
    "1282": {
        "text": "in turn upregulate glycolysis (Semenza, 2010a, 2010b; Kroemer\nand Pouyssegur, 2008).\nA functional rationale for the glycolytic switch in cancer cells\nhas been elusive, given the relatively poor efﬁciency of gener-\nating ATP by glycolysis relative to mitochondrial oxidative phos-\nphorylation. According to one long-forgotten (Potter, 1958) and\nrecently revived and reﬁned hypothesis (Vander Heiden et al.,\n2009), increased glycolysis allows the diversion of glycolytic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 189
        }
    },
    "1283": {
        "text": "intermediates into various biosynthetic pathways, including\nthose generating nucleosides and amino acids; this facilitates,\nin turn, the biosynthesis of the macromolecules and organelles\nrequired for assembling new cells. Moreover, Warburg-like\nmetabolism seems to be present in many rapidly dividing em-\nbryonic tissues, once again suggesting a role in supporting the\nlarge-scale biosynthetic programs that are required for active\ncell proliferation.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 190
        }
    },
    "1284": {
        "text": "cell proliferation.\nInterestingly, some tumors have been found to contain two\nsubpopulations of cancer cells that differ in their energy-gener-\nating pathways. One subpopulation consists of glucose-depen-\ndent (‘‘Warburg-effect’’) cells that secrete lactate, whereas cells\nof the second subpopulation preferentially import and utilize the\nlactate produced by their neighbors as their main energy source,\nemployingpartofthecitricacidcycletodo so(KennedyandDew-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 191
        }
    },
    "1285": {
        "text": "hirst, 2010; Feron, 2009; Semenza, 2008). These two populations\nevidently function symbiotically: the hypoxic cancer cells depend\non glucose for fuel and secrete lactate as waste, which is im-\nported and preferentially used as fuel by their better-oxygenated\nbrethren. Although this provocative mode of intratumoral symbi-\nosis has yet to be generalized, the cooperation between lactate-\nsecreting and lactate-utilizing cells to fuel tumor growth is in fact",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 192
        }
    },
    "1286": {
        "text": "not an invention of tumors but rather again reﬂects cooption of\na normal physiological mechanism, in this case one operating in\nmuscle (Kennedy and Dewhirst, 2010; Feron, 2009; Semenza,\n2008). Additionally, it is becoming apparent that oxygenation,\nranging from normoxia to hypoxia, is not necessarily static in\ntumors but instead ﬂuctuates temporally and regionally (Hardee\net al., 2009), likely as a result of the instability and chaotic organi-\nzation of the tumor-associated neovasculature.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 193
        }
    },
    "1287": {
        "text": "zation of the tumor-associated neovasculature.\nAltered energy metabolism is proving to be as widespread in\ncancer cells as many of the other cancer-associated traits that\nhave been accepted as hallmarks of cancer. This realization\nraises the question of whether deregulating cellular energy\nmetabolism is therefore a core hallmark capability of cancer cells\nthat is as fundamental as the six well-established core hallmarks.\nIn fact, the redirection of energy metabolism is largely orches-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 194
        }
    },
    "1288": {
        "text": "trated by proteins that are involved in one way or another in\nprogramming the core hallmarks of cancer. When viewed in\nthis way, aerobic glycolysis is simply another phenotype that is\nprogrammed by proliferation-inducing oncogenes.\nInterestingly, activating (gain-of-function) mutations in the iso-\ncitrate dehydrogenase 1/2 (IDH) enzymes have been reported in\nglioma and other human tumors (Yen et al., 2010). Although\nthese mutations may prove to have been clonally selected for",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 195
        }
    },
    "1289": {
        "text": "their ability to alter energy metabolism, there is confounding\ndata associating their activity with elevated oxidation and\nstability of the HIF-1 transcription factors (Reitman and Yan,\n2010), which could in turn affect genome stability and angiogen-\nesis/invasion, respectively, thus blurring the lines of phenotypic\ndemarcation. Currently, therefore, the designation of reprog-\nrammed energy metabolism as an emerging hallmark seems\nmost appropriate, to highlight both its evident importance as",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 196
        }
    },
    "1290": {
        "text": "well as the unresolved issues surrounding its functional indepen-\ndence from the core hallmarks.\nAn Emerging Hallmark: Evading Immune Destruction\nA second, still-unresolved issue surrounding tumor formation\ninvolves the role that the immune system plays in resisting or\neradicating formation and progression of incipient neoplasias,\nlate-stage tumors, and micrometastases. The long-standing\ntheory of immune surveillance proposes that cells and tissues",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 197
        }
    },
    "1291": {
        "text": "are constantly monitored by an ever-alert immune system, and\nthat such immune surveillance is responsible for recognizing\nand eliminating the vast majority of incipient cancer cells\nand thus nascent tumors. According to this logic, solid tumors\nthat do appear have somehow managed to avoid detection\nby the various arms of the immune system or have been able\nto limit the extent of immunological killing, thereby evading\neradication.\nThe role of defective immunological monitoring of tumors",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 198
        }
    },
    "1292": {
        "text": "would seem to be validated by the striking increases of certain\ncancers in immunocompromised individuals (Vajdic and van\nLeeuwen, 2009). However, the great majority of these are\nvirus-induced cancers, suggesting that much of the control of\nthis class of cancers normally depends on reducing viral burden\nin infected individuals, in part through eliminating virus-infected\ncells. These observations, therefore, seem to shed little light\non the possible role of the immune system in limiting formation",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 199
        }
    },
    "1293": {
        "text": "of the >80% of tumors of nonviral etiology. In recent years,\nhowever, an increasing body of evidence, both from genetically\nengineered mice and from clinical epidemiology, suggests that\n660\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nthe immune system operates as a signiﬁcant barrier to tumor\nformation and progression, at least in some forms of non-virus-\ninduced cancer.\nWhen mice genetically engineered to be deﬁcient for various\ncomponents of the immune system were assessed for the devel-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 200
        }
    },
    "1294": {
        "text": "opment of carcinogen-induced tumors, it was observed that\ntumors arose more frequently and/or grew more rapidly in the\nimmunodeﬁcient mice relative to immunocompetent controls.\nIn particular, deﬁciencies in the development or function of\nCD8+ cytotoxic T lymphocytes (CTLs), CD4+ Th1 helper T cells,\nor natural killer (NK) cells each led to demonstrable increases\nin tumor incidence; moreover, mice with combined immunodeﬁ-\nciencies in both T cells and NK cells were even more susceptible",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 201
        }
    },
    "1295": {
        "text": "to cancer development. The results indicated that, at least in\ncertain experimental models, both the innate and adaptive\ncellular arms of the immune system are able to contribute signif-\nicantly to immune surveillance and thus tumor eradication (Teng\net al., 2008; Kim et al., 2007).\nIn addition, transplantation experiments have shown that\ncancer cells that originally arose in immunodeﬁcient mice are\noften inefﬁcient at initiating secondary tumors in syngeneic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 202
        }
    },
    "1296": {
        "text": "immunocompetent hosts, whereas cancer cells from tumors\narising in immunocompetent mice are equally efﬁcient at initi-\nating transplanted tumors in both types of hosts (Teng et al.,\n2008; Kim et al., 2007). Such behavior has been interpreted as\nfollows: Highly immunogenic cancer cell clones are routinely\neliminated in immunocompetent hosts—a process that has\nbeen referred to as ‘‘immunoediting’’—leaving behind only\nweakly immunogenic variants to grow and generate solid",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 203
        }
    },
    "1297": {
        "text": "tumors; such weakly immunogenic cells can thereafter colonize\nboth immunodeﬁcient and immunocompetent hosts. Con-\nversely, when arising in immunodeﬁcient hosts, the immuno-\ngenic cancer cells are not selectively depleted and can, instead,\nprosper along with their weakly immunogenic counterparts.\nWhen cells from such nonedited tumors are serially transplanted\ninto syngeneic recipients, the immunogenic cancer cells are\nrejected when they confront, for the ﬁrst time, the competent",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 204
        }
    },
    "1298": {
        "text": "immune systems of their secondary hosts (Smyth et al., 2006).\n(Unanswered in these particular experiments is the question of\nwhether the chemical carcinogens used to induce such tumors\nare prone to generate cancer cells that are especially immuno-\ngenic.)\nClinical epidemiology also increasingly supports the existence\nof antitumoral immune responses in some forms of human\ncancer (Bindea et al., 2010; Ferrone and Dranoff, 2010; Nelson,\n2008). For example, patients with colon and ovarian tumors",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 205
        }
    },
    "1299": {
        "text": "that are heavily inﬁltrated with CTLs and NK cells have a better\nprognosis than those that lack such abundant killer lymphocytes\n(Page` s et al., 2010; Nelson, 2008); the case for other cancers is\nsuggestive but less compelling and is the subject of ongoing\ninvestigation. Additionally, some immunosuppressed organ\ntransplant recipients have been observed to develop donor-\nderived cancers, suggesting that in the ostensibly tumor-free",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 206
        }
    },
    "1300": {
        "text": "donors, the cancer cells were held in check, in a dormant state,\nby a fully functional immune system (Strauss and Thomas, 2010).\nStill, the epidemiology of chronically immunosuppressed\npatients does not indicate signiﬁcantly increased incidences of\nthe major forms of nonviral human cancer, as noted above.\nThis might be taken as an argument against the importance of\nimmune surveillance as an effective barrier to tumorigenesis\nand tumor progression. We note, however, that HIV and pharma-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 207
        }
    },
    "1301": {
        "text": "cologically\nimmunosuppressed\npatients\nare\npredominantly\nimmunodeﬁcient in the T and B cell compartments and thus do\nnot present with the multicomponent immunological deﬁciencies\nthat have been produced in the genetically engineered mutant\nmice lacking both NK cells and CTLs; this leaves open the possi-\nbility that such patients still have residual capability for an immu-\nnological defense against cancer that is mounted by NK and\nother innate immune cells.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 208
        }
    },
    "1302": {
        "text": "other innate immune cells.\nIn truth, the above discussions of cancer immunology simplify\ntumor-host immunological interactions, as highly immunogenic\ncancer cells may well evade immune destruction by disabling\ncomponents of the immune system that have been dispatched\nto eliminate them. For example, cancer cells may paralyze inﬁl-\ntrating CTLs and NK cells, by secreting TGF-b or other immuno-\nsuppressive factors (Yang et al., 2010; Shields et al., 2010). More",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 209
        }
    },
    "1303": {
        "text": "subtle mechanisms operate through the recruitment of inﬂam-\nmatory cells that are actively immunosuppressive, including\nregulatory T cells (Tregs) and myeloid-derived suppressor cells\n(MDSCs). Both can suppress the actions of cytotoxic lympho-\ncytes (Mougiakakos et al., 2010; Ostrand-Rosenberg and Sinha,\n2009).\nIn light of these considerations and the still-rudimentary\ndemonstrations of antitumor immunity as a signiﬁcant barrier\nto tumor formation and progression in humans, we present",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 210
        }
    },
    "1304": {
        "text": "immunoevasion as another emerging hallmark, whose gener-\nality as a core hallmark capability remains to be ﬁrmly estab-\nlished.\nTHE TUMOR MICROENVIRONMENT\nOver the past decade, tumors have increasingly been recog-\nnized as organs whose complexity approaches and may even\nexceed that of normal healthy tissues. When viewed from this\nperspective, the biology of a tumor can only be understood\nby studying the individual specialized cell types within it",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 211
        }
    },
    "1305": {
        "text": "(Figure 4, upper) as well as the ‘‘tumor microenvironment’’\nthat they construct during the course of multistep tumorigenesis\n(Figure 4, lower). This depiction contrasts starkly with the\nearlier, reductionist view of a tumor as nothing more than\na collection of relatively homogeneous cancer cells, whose\nentire biology could be understood by elucidating the cell-\nautonomous properties of these cells. We enumerate here\na set of cell types known to contribute in important ways to",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 212
        }
    },
    "1306": {
        "text": "the biology of many tumors and discuss the regulatory signaling\nthat controls their individual and collective functions. Most of\nthese observations stem from the study of carcinomas, in which\nthe neoplastic epithelial cells constitute a compartment (the\nparenchyma) that is clearly distinct from the mesenchymal cells\nforming the tumor-associated stroma.\nCancer Cells and Cancer Stem Cells\nCancer cells are the foundation of the disease; they initiate",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 213
        }
    },
    "1307": {
        "text": "tumors and drive tumor progression forward, carrying the\noncogenic and tumor suppressor mutations that deﬁne cancer\nas a genetic disease. Traditionally, the cancer cells within tumors\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n661\nhave been portrayed as reasonably homogeneous cell popula-\ntions until relatively late in the course of tumor progression,\nwhen\nhyperproliferation\ncombined\nwith\nincreased\ngenetic\ninstability spawn distinct clonal subpopulations. Reﬂecting",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 214
        }
    },
    "1308": {
        "text": "such clonal heterogeneity, many human tumors are histopatho-\nlogically diverse, containing regions demarcated by various\ndegrees of differentiation, proliferation, vascularity, inﬂamma-\ntion, and/or invasiveness. In recent years, however, evidence\nhas accumulated pointing to the existence of a new dimension\nof\nintratumor\nheterogeneity\nand\na\nhitherto-unappreciated\nsubclass of neoplastic cells within tumors, termed cancer stem\ncells (CSCs).",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 215
        }
    },
    "1309": {
        "text": "cells (CSCs).\nAlthough the evidence is still fragmentary, CSCs may prove to\nbe a common constituent of many if not most tumors, albeit\nbeing present with widely varying abundance. CSCs are deﬁned\noperationally through their ability to efﬁciently seed new tumors\nupon inoculation into recipient host mice (Cho and Clarke, 2008;\nLobo et al., 2007). This functional deﬁnition is often comple-\nmented by including the expression in CSCs of markers that",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 216
        }
    },
    "1310": {
        "text": "are also expressed by the normal stem cells in the tissue-of-\norigin (Al-Hajj et al., 2003).\nCSCs were initially implicated in the pathogenesis of hemato-\npoietic malignancies (Reya et al., 2001; Bonnet and Dick, 1997)\nand then years later were identiﬁed in solid tumors, in particular\nbreast carcinomas and neuroectodermal tumors (Gilbertson and\nRich, 2007; Al-Hajj et al., 2003). Fractionation of cancer cells on\nthe basis of displayed cell-surface markers has yielded subpop-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 217
        }
    },
    "1311": {
        "text": "ulations of neoplastic cells with a greatly enhanced ability, rela-\ntive to the corresponding majority populations, to seed new\ntumors upon implantation in immunodeﬁcient mice. These\nFigure 4. The Cells of the Tumor Microenviron-\nment\n(Upper) An assemblage of distinct cell types constitutes\nmost solid tumors. Both the parenchyma and stroma of\ntumors contain distinct cell types and subtypes that\ncollectively\nenable\ntumor\ngrowth\nand\nprogression.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 218
        }
    },
    "1312": {
        "text": "collectively\nenable\ntumor\ngrowth\nand\nprogression.\nNotably, the immune inﬂammatory cells present in tumors\ncan include both tumor-promoting as well as tumor-killing\nsubclasses.\n(Lower) The distinctive microenvironments of tumors. The\nmultiple stromal cell types create a succession of tumor\nmicroenvironments that change as tumors invade normal\ntissue and thereafter seed and colonize distant tissues.\nThe abundance, histologic organization, and phenotypic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 219
        }
    },
    "1313": {
        "text": "characteristics of the stromal cell types, as well as of the\nextracellular matrix (hatched background), evolve during\nprogression, thereby enabling primary, invasive, and then\nmetastatic growth. The surrounding normal cells of the\nprimary and metastatic sites, shown only schematically,\nlikely also affect the character of the various neoplastic\nmicroenvironments. (Not shown are the premalignant\nstages in tumorigenesis, which also have distinctive",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 220
        }
    },
    "1314": {
        "text": "microenvironments that are created by the abundance\nand characteristics of the assembled cells.)\noften-rare tumor-initiating cells proved to share\ntranscriptional\nproﬁles\nwith\ncertain\nnormal\ntissue stem cell populations, motivating their\ndesignation as stem-like.\nThe origins of CSCs within a solid tumor have\nnot been clariﬁed and indeed may well vary from\none tumor type to another. In some tumors, normal tissue stem\ncells may serve as the cells-of-origin that undergo oncogenic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 221
        }
    },
    "1315": {
        "text": "transformation to yield CSCs; in others, partially differentiated\ntransit-amplifying cells, also termed progenitor cells, may suffer\nthe initial oncogenic transformation thereafter assuming more\nstem-like character. Once primary tumors have formed, the\nCSCs, like their normal counterparts, may self-renew as well\nas spawn more differentiated derivatives; in the case of\nneoplastic CSCs, these descendant cells form the great bulk of\nmany tumors. It remains to be established whether multiple",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 222
        }
    },
    "1316": {
        "text": "distinct classes of increasingly neoplastic stem cells form during\ninception and subsequent multistep progression of tumors, ulti-\nmately yielding the CSCs that have been described in fully devel-\noped cancers.\nRecent research has interrelated the acquisition of CSC traits\nwith the EMT transdifferentiation program discussed above\n(Singh and Settleman, 2010; Mani et al., 2008; Morel et al.,\n2008). Induction of this program in certain model systems can",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 223
        }
    },
    "1317": {
        "text": "induce many of the deﬁning features of stem cells, including\nself-renewal ability and the antigenic phenotypes associated\nwith both normal and cancer stem cells. This concordance\nsuggests that the EMT program not only may enable cancer cells\nto physically disseminate from primary tumors but also can\nconfer on such cells the self-renewal capability that is crucial\nto their subsequent clonal expansion at sites of dissemination\n(Brabletz et al., 2005). If generalized, this connection raises an",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 224
        }
    },
    "1318": {
        "text": "important corollary hypothesis: the heterotypic signals that\ntrigger an EMT, such as those released by an activated, inﬂam-\nmatory stroma, may also be important in creating and maintain-\ning CSCs.\n662\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nAn increasing number of human tumors are reported to\ncontain subpopulations with the properties of CSCs, as deﬁned\noperationally through their efﬁcient tumor-initiating capabilities\nupon xenotransplantation into mice. Nevertheless, the im-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 225
        }
    },
    "1319": {
        "text": "portance of CSCs as a distinct phenotypic subclass of\nneoplastic cells remains a matter of debate, as does their oft-\ncited rarity within tumors (Boiko et al., 2010; Gupta et al., 2009;\nQuintana et al., 2008). Indeed, it is plausible that the phenotypic\nplasticity operating within tumors may produce bidirectional\ninterconversion between CSCs and non-CSCs, resulting in\ndynamic variation in the relative abundance of CSCs. Such\nplasticity could complicate deﬁnitive measurement of their prev-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 226
        }
    },
    "1320": {
        "text": "alence. Analogous plasticity is already implicated in the EMT\nprogram, which can be engaged reversibly (Thiery and Sleeman,\n2006).\nThese complexities notwithstanding, it is evident that this\nnew dimension of tumor heterogeneity holds important implica-\ntions for successful cancer therapies. Increasing evidence in\na variety of tumor types suggests that cells with properties of\nCSCs are more resistant to various commonly used chemother-\napeutic treatments (Singh and Settleman, 2010; Creighton",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 227
        }
    },
    "1321": {
        "text": "et al., 2009; Buck et al., 2007). Their persistence may help to\nexplain the almost-inevitable disease recurrence following\napparently successful debulking of human solid tumors by radi-\nation and various forms of chemotherapy. Indeed, CSCs may\nwell prove to underlie certain forms of tumor dormancy,\nwhereby latent cancer cells persist for years or even decades\nafter\nsurgical\nresection\nor\nradio/chemotherapy,\nonly\nto\nsuddenly erupt and generate life-threatening disease. Hence,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 228
        }
    },
    "1322": {
        "text": "CSCs may represent a double-threat, in that they are more\nresistant to therapeutic killing and, at the same time, endowed\nwith the ability to regenerate a tumor once therapy has been\nhalted.\nThis phenotypic plasticity implicit in CSC state may also\nenable the formation of functionally distinct subpopulations\nwithin a tumor that support overall tumor growth in various\nways. For example, an EMT can convert epithelial carcinoma\ncells into mesenchymal, ﬁbroblast-like cancer cells that may",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 229
        }
    },
    "1323": {
        "text": "well assume the duties of cancer-associated ﬁbroblasts (CAFs)\nin some tumors. Remarkably, several recent reports have\ndocumented the ability of glioblastoma cells (or possibly their\nassociated CSC subpopulations) to transdifferentiate into endo-\nthelial-like cells that can substitute for bona ﬁde host-derived\nendothelial cells in forming a tumor-associated neovasculature\n(Soda et al., 2011; El Hallani et al., 2010; Ricci-Vitiani et al.,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 230
        }
    },
    "1324": {
        "text": "2010; Wang et al., 2010). Observations like these indicate that\ncertain tumors may acquire stromal support by inducing some\nof their own cancer cells to undergo various types of metamor-\nphosis to produce stromal cell types rather than relying on\nrecruited host cells to provide their functions.\nThe discovery of CSCs and biological plasticity in tumors\nindicates that a single, genetically homogeneous population of\ncells within a tumor may nevertheless be phenotypically hetero-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 231
        }
    },
    "1325": {
        "text": "geneous due to the presence of cells in distinct states of differ-\nentiation. However, an equally important source of phenotypic\nvariability may derive from the genetic heterogeneity within\na tumor that accumulates as cancer progression proceeds.\nThus, elevated genetic instability operating in later stages of\ntumor progression may drive rampant genetic diversiﬁcation\nthat outpaces the process of Darwinian selection, generating\ngenetically distinct subpopulations far more rapidly than they",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 232
        }
    },
    "1326": {
        "text": "can be eliminated.\nSuch thinking is increasingly supported by in-depth sequence\nanalysis of tumor cell genomes, which has become practical due\nto recent major advances in DNA (and RNA) sequencing tech-\nnology. Thus the sequencing of the genomes of cancer cells\nmicrodissected from different sectors of the same tumor\n(Yachida et al., 2010) has revealed striking intratumoral genetic\nheterogeneity. Some of this genetic diversity may be reﬂected",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 233
        }
    },
    "1327": {
        "text": "in the long-recognized histological heterogeneity within indi-\nvidual human tumors. Alternatively, this genetic diversiﬁcation\nmay enable functional specialization, producing subpopulations\nof cancer cells that contribute distinct, complementary capabil-\nities, which then accrue to the common beneﬁt of overall tumor\ngrowth as described above.\nEndothelial Cells\nMuch of the cellular heterogeneity within tumors is found in\ntheir stromal compartments. Prominent among the stromal",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 234
        }
    },
    "1328": {
        "text": "constituents are the cells forming the tumor-associated vascu-\nlature.\nMechanisms\nof\ndevelopment,\ndifferentiation,\nand\nhomeostasis of endothelial cells composing the arteries, veins,\nand capillaries were already well understood in 2000. So too\nwas the concept of the ‘‘angiogenic switch,’’ which activates\nquiescent endothelial cells, causing them to enter into a cell-\nbiological program that allows them to construct new blood\nvessels (see above). Over the last decade, a network of inter-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 235
        }
    },
    "1329": {
        "text": "connected signaling pathways involving ligands of signal-trans-\nducing receptors displayed by endothelial cells (e.g., Notch,\nNeuropilin, Robo, and Eph-A/B) has been added to the\nalready-prominent VEGF, angiopoietin, and FGF signals. These\nnewly characterized pathways have been functionally impli-\ncated in developmental and tumor-associated angiogenesis\nand illustrate the complex regulation of endothelial cell pheno-\ntypes (Pasquale, 2010; Ahmed and Bicknell, 2009; Dejana",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 236
        }
    },
    "1330": {
        "text": "et al., 2009; Carmeliet and Jain, 2000).\nOther avenues of research are revealing distinctive gene\nexpression proﬁles of tumor-associated endothelial cells and\nidentifying cell-surface markers displayed on the lumenal\nsurfaces of normal versus tumor endothelial cells (Nagy et al.,\n2010; Ruoslahti et al., 2010; Ruoslahti, 2002). Differences in\nsignaling, in transcriptome proﬁles, and in vascular ‘‘ZIP codes’’\nwill likely prove to be important for understanding the conversion",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 237
        }
    },
    "1331": {
        "text": "of normal endothelial cells into tumor-associated endothelial\ncells. Such knowledge may lead, in turn, to opportunities to\ndevelop novel therapies that exploit these differences in order\nto selectively target tumor-associated endothelial cells.\nClosely related to the endothelial cells of the general circula-\ntion are those forming lymphatic vessels (Tammela and Alitalo,\n2010). Their role in the tumor-associated stroma, speciﬁcally in",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 238
        }
    },
    "1332": {
        "text": "supporting tumor growth, is poorly understood. Indeed, because\nof high interstitial pressure within solid tumors, intratumoral\nlymphatic vessels are typically collapsed and nonfunctional; in\ncontrast, however, there are often functional, actively growing\n(‘‘lymphangiogenic’’) lymphatic vessels at the peripheries of\ntumors and in the adjacent normal tissues that cancer cells\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n663\ninvade. These associated lymphatics likely serve as channels for",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 239
        }
    },
    "1333": {
        "text": "the seeding of metastases in the draining lymph nodes that are\ncommonly observed in a number of cancer types.\nPericytes\nAs noted earlier, pericytes represent a specialized mesenchymal\ncell type (related to smooth muscle cells) with ﬁnger-like projec-\ntions that wrap around the endothelial tubing of blood vessels. In\nnormal tissues, pericytes are known to provide paracrine\nsupport signals to the normally quiescent endothelium. For\nexample, Ang-1 secreted by pericytes conveys antiproliferative",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 240
        }
    },
    "1334": {
        "text": "stabilizing signals that are received by the Tie2 receptors\nexpressed on the surface of endothelial cells; some pericytes\nalso produce low levels of VEGF that serve a trophic function\nin endothelial homeostasis (Gaengel et al., 2009; Bergers and\nSong, 2005). Pericytes also collaborate with the endothelial cells\nto synthesize the vascular basement membrane that anchors\nboth pericytes and endothelial cells and helps vessel walls to\nwithstand the hydrostatic pressure of blood ﬂow.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 241
        }
    },
    "1335": {
        "text": "withstand the hydrostatic pressure of blood ﬂow.\nGenetic and pharmacological perturbation of the recruitment\nand association of pericytes has demonstrated the functional\nimportance of these cells in supporting the tumor endothelium\n(Pietras and Ostman, 2010; Gaengel et al., 2009; Bergers and\nSong,\n2005).\nFor\nexample,\npharmacological\ninhibition\nof\nsignaling through the PDGF receptor expressed by tumor peri-\ncytes and bone marrow-derived pericyte progenitors results in",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 242
        }
    },
    "1336": {
        "text": "reduced pericyte coverage of tumor vessels, which in turn desta-\nbilizes vascular integrity and function (Pietras and Ostman, 2010;\nRaza et al., 2010; Gaengel et al., 2009); interestingly, and in\ncontrast, the pericytes of normal vessels are not prone to such\npharmacological disruption, providing another example of the\ndifferences in regulation of normal quiescent and tumor vascula-\nture. An intriguing hypothesis, still to be fully substantiated, is",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 243
        }
    },
    "1337": {
        "text": "that tumors with poor pericyte coverage of their vasculature\nmay be more prone to permit cancer cell intravasation into the\ncirculatory\nsystem,\nenabling\nsubsequent\nhematogenous\ndissemination (Raza et al., 2010; Gerhardt and Semb, 2008).\nImmune Inﬂammatory Cells\nAs also discussed above, inﬁltrating cells of the immune system\nare increasingly accepted to be generic constituents of tumors.\nThese inﬂammatory cells operate in conﬂicting ways: both",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 244
        }
    },
    "1338": {
        "text": "tumor-antagonizing and tumor-promoting leukocytes can be\nfound, in various proportions, in most if not all neoplastic lesions.\nAlthough the presence of tumor-antagonizing CTLs and NK cells\nis not surprising, the prevalence of immune cells that functionally\nenhance\nhallmark\ncapabilities\nwas\nlargely\nunanticipated.\nEvidence began to accumulate in the late 1990s that the inﬁltra-\ntion of neoplastic tissues by cells of the immune system serves,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 245
        }
    },
    "1339": {
        "text": "perhaps counterintuitively, to promote tumor progression. Such\nwork traced its conceptual roots back to the association of sites\nof chronic inﬂammation with tumor formation, and to the obser-\nvation that tumors could be portrayed as wounds that never heal\n(Scha¨ fer and Werner, 2008: Dvorak, 1986). In the course of\nnormal wound healing and ﬁghting infections, immune inﬂamma-\ntory cells appear transiently and then disappear, in contrast to",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 246
        }
    },
    "1340": {
        "text": "their persistence in sites of chronic inﬂammation, where their\npresence has been associated with various tissue pathologies,\nincluding ﬁbrosis, aberrant angiogenesis, and neoplasia (Griven-\nnikov et al., 2010; Karin et al., 2006).\nOver the past decade, the manipulation of genes involved in\nthe determination or effector functions of various immune cell\ntypes, together with pharmacological inhibitors of such cells or\ntheir functions, has shown them to play diverse and critical roles",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 247
        }
    },
    "1341": {
        "text": "in fostering tumorigenesis. The roster of tumor-promoting\ninﬂammatory cells now includes macrophage subtypes, mast\ncells, and neutrophils, as well as T and B lymphocytes (Coffelt\net al., 2010; DeNardo et al., 2010; Egeblad et al., 2010; Johans-\nson et al., 2008; Murdoch et al., 2008; DePalma et al., 2007).\nSuch studies are yielding a growing list of signaling molecules\nreleased by inﬂammatory cells that serve as effectors of their\ntumor-promoting actions. These include the tumor growth factor",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 248
        }
    },
    "1342": {
        "text": "EGF, the angiogenic growth factor VEGF, other proangiogenic\nfactors such as FGF2, chemokines, and cytokines that amplify\nthe inﬂammatory state; in addition, these cells may produce\nproangiogenic and/or proinvasive matrix-degrading enzymes,\nincluding MMP-9 and other matrix metalloproteinases, cysteine\ncathepsin proteases, and heparanase (Qian and Pollard, 2010;\nMurdoch et al., 2008). Consistent with their expression of these\ndiverse effectors, tumor-inﬁltrating inﬂammatory cells have been",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 249
        }
    },
    "1343": {
        "text": "shown to induce and help sustain tumor angiogenesis, to stimu-\nlate cancer cell proliferation, to facilitate, via their presence at the\nmargins of tumors, tissue invasion, and to support the metastatic\ndissemination and seeding of cancer cells (Coffelt et al., 2010;\nEgeblad et al., 2010; Qian and Pollard, 2010; Mantovani, 2010;\nJoyce and Pollard, 2009; Mantovani et al., 2008; Murdoch\net al., 2008; DePalma et al., 2007).\nIn addition to fully differentiated immune cells present in tumor",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 250
        }
    },
    "1344": {
        "text": "stroma, a variety of partially differentiated myeloid progenitors\nhave been identiﬁed in tumors (Murdoch et al., 2008). Such cells\nrepresent intermediaries between circulating cells of bone\nmarrow origin and the differentiated immune cells typically found\nin normal and inﬂamed tissues. Importantly, these progenitors,\nlike their more differentiated derivatives, have demonstrable\ntumor-promoting activity. Of particular interest, a class of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 251
        }
    },
    "1345": {
        "text": "tumor-inﬁltrating myeloid cells (deﬁned as coexpressing the\nmacrophage marker CD11b and the neutrophil marker Gr1)\nhas been shown to suppress CTL and NK cell activity, having\nbeen independently identiﬁed as MDSCs (Qian and Pollard,\n2010; Ostrand-Rosenberg and Sinha, 2009). This attribute raises\nthe possibility that recruitment of certain myeloid cells may be\ndoubly beneﬁcial for the developing tumor, by directly promoting\nangiogenesis and tumor progression while at the same time",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 252
        }
    },
    "1346": {
        "text": "affording a means to evade immune destruction.\nThe counterintuitive existence of both tumor-promoting and\ntumor-antagonizing\nimmune\ncells\ncan\nbe\nrationalized\nby\ninvoking the diverse roles of the immune system: On the one\nhand, the immune system speciﬁcally detects and targets infec-\ntious agents with the adaptive immune response, which is sup-\nported by cells of the innate immune system. On the other, the\ninnate immune system is involved in wound healing and clearing",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 253
        }
    },
    "1347": {
        "text": "dead cells and cellular debris. These specialized tasks are\naccomplished by distinct subclasses of inﬂammatory cells,\nnamely a class of conventional macrophages and neutrophils\n(engaged in supporting adaptive immunity), and subclasses of\n‘‘alternatively\nactivated’’\nmacrophages,\nneutrophils,\nand\n664\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nmyeloid progenitors that are engaged in wound healing and\ntissue housecleaning (Egeblad et al., 2010; Mantovani, 2010;",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 254
        }
    },
    "1348": {
        "text": "Qian and Pollard, 2010; Johansson et al., 2008). The latter\nsubtypes of immune cells are one of the major sources of the\nangiogenic, epithelial, and stromal growth factors and matrix-re-\nmodeling enzymes that are needed for wound healing, and it is\nthese cells that are recruited and subverted to support\nneoplastic progression. Similarly, subclasses of B and T\nlymphocytes may facilitate the recruitment, activation, and\npersistence\nof\nsuch\nwound-healing\nand\ntumor-promoting",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 255
        }
    },
    "1349": {
        "text": "of\nsuch\nwound-healing\nand\ntumor-promoting\nmacrophages and neutrophils (DeNardo et al., 2010; Egeblad\net al., 2010; Biswas and Mantovani, 2010). Of course, other\nsubclasses of B and T lymphocytes and innate immune cell\ntypes can mount demonstrable tumor-killing responses. The\nbalance between the conﬂicting inﬂammatory responses in\ntumors is likely to prove instrumental in prognosis and, quite\npossibly, in therapies designed to redirect these cells toward\ntumor destruction.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 256
        }
    },
    "1350": {
        "text": "tumor destruction.\nCancer-Associated Fibroblasts\nFibroblasts are found in various proportions across the spectrum\nof carcinomas, constituting in many cases the preponderant cell\npopulation of the tumor stroma. The term ‘‘cancer-associated\nﬁbroblast’’ subsumes at least two distinct cell types: (1) cells\nwith similarities to the ﬁbroblasts that create the structural foun-\ndation supporting most normal epithelial tissues and (2) myoﬁ-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 257
        }
    },
    "1351": {
        "text": "broblasts, whose biological roles and properties differ markedly\nfrom those of tissue-derived ﬁbroblasts. Myoﬁbroblasts are\nidentiﬁable by their expression of a-smooth muscle actin\n(SMA). They are rare in most healthy epithelial tissues, although\ncertain tissues, such as the liver and pancreas, contain appre-\nciable numbers of a-SMA-expressing cells. Myoﬁbroblasts tran-\nsiently increase in abundance in wounds and are also found in\nsites of chronic inﬂammation. Although beneﬁcial to tissue",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 258
        }
    },
    "1352": {
        "text": "repair, myoﬁbroblasts are problematic in chronic inﬂammation,\ncontributing to the pathological ﬁbrosis observed in tissues\nsuch as lung, kidney, and liver.\nRecruited myoﬁbroblasts and reprogrammed variants of\nnormal tissue-derived ﬁbroblastic cells have been demonstrated\nto enhance tumor phenotypes, notably cancer cell proliferation,\nangiogenesis,\nand\ninvasion\nand\nmetastasis;\ntheir\ntumor-\npromoting activities have largely been deﬁned by transplantation",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 259
        }
    },
    "1353": {
        "text": "of cancer-associated ﬁbroblasts admixed with cancer cells into\nmice, and more recently by genetic and pharmacologic pertur-\nbation of their functions in tumor-prone mice (Dirat et al., 2010;\nPietras and Ostman, 2010; Ra¨ sa¨ nen and Vaheri, 2010; Shimoda\net al., 2010; Kalluri and Zeisberg, 2006; Bhowmick et al., 2004).\nBecause they secrete a variety of extracellular matrix compo-\nnents, cancer-associated ﬁbroblasts are implicated in the forma-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 260
        }
    },
    "1354": {
        "text": "tion of the desmoplastic stroma that characterizes many\nadvanced carcinomas. The full spectrum of functions contrib-\nuted by both subtypes of cancer-associated ﬁbroblasts to tumor\npathogenesis remains to be elucidated.\nStem and Progenitor Cells of the Tumor Stroma\nThe various stromal cell types that constitute the tumor microen-\nvironment may be recruited from adjacent normal tissue—the\nmost obvious reservoir of such cell types. However, in recent",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 261
        }
    },
    "1355": {
        "text": "years, the bone marrow has increasingly been implicated as\na key source of tumor-associated stromal cells (Bergfeld and\nDeClerck, 2010; Fang and Salven, 2011; Giaccia and Schipani,\n2010; Patenaude et al., 2010; Lamagna and Bergers, 2006).\nMesenchymal stem and progenitor cells have been found to\ntransit into tumors from the marrow, where they may differentiate\ninto the various well-characterized stromal cell types. Some of\nthese recent arrivals may also persist in an undifferentiated or",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 262
        }
    },
    "1356": {
        "text": "partially differentiated state, exhibiting functions that their more\ndifferentiated progeny lack.\nThe\nbone\nmarrow\norigins\nof\nstromal\ncell\ntypes\nhave\nbeen demonstrated using tumor-bearing mice in which the\nbone marrow cells and thus their disseminated progeny have\nbeen selectively labeled with reporters such as green ﬂuorescent\nprotein (GFP). While immune inﬂammatory cells have been long\nknown to derive from the bone marrow, more recently the",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 263
        }
    },
    "1357": {
        "text": "progenitors of pericytes and of various subtypes of cancer-asso-\nciated ﬁbroblasts originating from the bone marrow have been\ndescribed in various mouse models of cancer (Bergfeld and\nDeClerck, 2010; Fang and Salven, 2011; Giaccia and Schipani,\n2010; Lamagna and Bergers, 2006); the prevalence and func-\ntional importance of endothelial progenitors for tumor angiogen-\nesis is currently unresolved (Fang and Salven, 2011; Patenaude",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 264
        }
    },
    "1358": {
        "text": "et al., 2010). Taken together, these various lines of evidence indi-\ncate that tumor-associated stromal cells may be supplied to\ngrowing tumors by proliferation of preexisting stromal cells, by\ndifferentiation in situ of local stem/progenitor cells originating\nin the neighboring normal tissue, or via recruitment of bone\nmarrow-derived stem/progenitor cells.\nHeterotypic Signaling Orchestrates\nthe Cells of the Tumor Microenvironment\nDepictions of the intracellular circuitry governing cancer cell",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 265
        }
    },
    "1359": {
        "text": "biology (e.g., Figure 2) will need to be complemented by similar\ndiagrams charting the complex\ninteractions\nbetween the\nneoplastic and stromal cells within a tumor and the dynamic\nextracellular matrix that they collectively erect and remodel (Ege-\nblad et al., 2010; Kessenbrock et al., 2010; Pietras and Ostman,\n2010; Polyak et al., 2009). A reasonably complete, graphic\ndepiction of the network of microenvironmental signaling inter-\nactions is still far beyond our reach, as the great majority of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 266
        }
    },
    "1360": {
        "text": "signaling molecules and pathways remain to be identiﬁed. We\nprovide instead a hint of such interactions in Figure 5, upper.\nThese few well-established examples are intended to exemplify\na signaling network of remarkable complexity that is of critical\nimportance to tumor pathogenesis.\nAnother dimension of complexity is not represented in this\nsimple schematic: both neoplastic cells and the stromal cells\naround them change progressively during the multistep transfor-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 267
        }
    },
    "1361": {
        "text": "mation of normal tissues into high-grade malignancies. This\nhistopathological progression must reﬂect underlying changes\nin heterotypic signaling between tumor parenchyma and stroma.\nSuch stepwise progression is likely to depend on back-and-\nforth reciprocal interactions between the neoplastic cells and\nthe supporting stromal cells, as depicted in Figure 5, lower.\nThus, incipient neoplasias begin the interplay by recruiting and\nactivating stromal cell types that assemble into an initial preneo-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 268
        }
    },
    "1362": {
        "text": "plastic stroma, which in turn responds reciprocally by enhancing\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n665\nFigure 5. Signaling Interactions in the Tumor Microenvironment during Malignant Progression\n(Upper) The assembly and collective contributions of the assorted cell types constituting the tumor microenvironment are orchestrated and maintained by\nreciprocal heterotypic signaling interactions, of which only a few are illustrated.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 269
        }
    },
    "1363": {
        "text": "(Lower) The intracellular signaling depicted in the upper panel within the tumor microenvironment is not static but instead changes during tumor progression as\na result of reciprocal signaling interactions between cancer cells of the parenchyma and stromal cells that convey the increasingly aggressive phenotypes that\nunderlie growth, invasion, and metastatic dissemination. Importantly, the predisposition to spawn metastatic lesions can begin early, being inﬂuenced by the",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 270
        }
    },
    "1364": {
        "text": "differentiation program of the normal cell-of-origin or by initiating oncogenic lesions. Certain organ sites (sometimes referred to as ‘‘fertile soil’’ or ‘‘metastatic\nniches’’) can be especially permissive for metastatic seeding and colonization by certain types of cancer cells, as a consequence of local properties that are either\nintrinsic to the normal tissue or induced at a distance by systemic actions of primary tumors. Cancer stem cells may be variably involved in some or all of the",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 271
        }
    },
    "1365": {
        "text": "different stages of primary tumorigenesis and metastasis.\n666\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nthe neoplastic phenotypes of the nearby cancer cells. The\ncancer cells, which may further evolve genetically, again feed\nsignals back to the stroma, continuing the reprogramming of\nnormal stromal cells to serve the budding neoplasm; ultimately\nsignals originating in the tumor stroma enable cancer cells to\ninvade normal adjacent tissues and disseminate.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 272
        }
    },
    "1366": {
        "text": "invade normal adjacent tissues and disseminate.\nThis model of reciprocal heterotypic signaling must be\nextended to encompass the ﬁnal stage of multistep tumor\nprogression—metastasis (Figure 5, lower right). The circulating\ncancer cells that are released from primary tumors leave a micro-\nenvironment created by the supportive stroma of such tumors.\nHowever, upon landing in a distant organ, these cancer cells\nencounter a naive, fully normal, tissue microenvironment.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 273
        }
    },
    "1367": {
        "text": "Consequently, many of the heterotypic signals that shaped their\nphenotype while they resided within primary tumors may be\nabsent in sites of dissemination, constituting a barrier to growth\nof the seeded cancer cells. Thus, the succession of reciprocal\ncancer cell to stromal cell interactions that deﬁned multistep\nprogression in the primary tumor now must be repeated anew\nin distant tissues as disseminated cancer cells proceed to colo-\nnize their newfound organ sites.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 274
        }
    },
    "1368": {
        "text": "nize their newfound organ sites.\nAlthough this logic applies in some cases of metastasis, in\nothers, as mentioned earlier, certain tissue microenvironments\nmay, for various reasons, already be supportive of freshly\nseeded cancer cells; such permissive sites have been referred\nto as ‘‘metastatic niches’’ (Peinado et al., 2011; Coghlin and\nMurray, 2010). Implicit in this term is the notion that cancer cells\nseeded in such sites may not need to begin by inducing",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 275
        }
    },
    "1369": {
        "text": "a supportive stroma because it already preexists, at least in\npart. Such permissivity may be intrinsic to the tissue site\n(Talmadge and Fidler, 2010) or preinduced by circulating factors\nreleased by the primary tumor (Peinado et al., 2011). The most\nwell-documented components of induced premetastatic niches\nare tumor-promoting inﬂammatory cells, although other cell\ntypes and the ECM may well prove to play important roles in\ndifferent metastatic contexts.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 276
        }
    },
    "1370": {
        "text": "different metastatic contexts.\nThe likelihood that signaling interactions between cancer cells\nand their supporting stroma evolve during the course of multi-\nstage tumor development clearly complicates the goal of fully\nelucidating the mechanisms of cancer pathogenesis. For\nexample, this reality poses challenges to systems biologists\nseeking to chart the crucial regulatory networks than orchestrate\nmalignant progression. Moreover, it seems likely that under-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 277
        }
    },
    "1371": {
        "text": "standing these dynamic variations will become crucial to the\ndevelopment of novel therapies designed to successfully target\nboth primary and metastatic tumors.\nTHERAPEUTIC TARGETING\nThe introduction of mechanism-based targeted therapies to\ntreat human cancers has been heralded as one of the fruits of\nthree decades of remarkable progress of research into the\nmechanisms of cancer pathogenesis. We do not attempt here\nto enumerate the myriad therapies that are under development",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 278
        }
    },
    "1372": {
        "text": "or have been introduced of late into the clinic. Instead, we\nconsider how the description of hallmark principles is beginning\nto inform therapeutic development at present and may increas-\ningly do so in the future.\nThe rapidly growing armamentarium of targeted therapeutics\ncan be categorized according to their respective effects on\none or more hallmark capabilities, as illustrated in the examples\npresented in Figure 6. Indeed, the observed efﬁcacy of these",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 279
        }
    },
    "1373": {
        "text": "drugs represents, in each case, a validation of a particular capa-\nbility: if a capability is truly important for the biology of tumors,\nthen its inhibition should impair tumor growth and progression.\nWe note that most of the hallmark-targeting cancer drugs\ndeveloped to date have been deliberately directed toward\nspeciﬁc molecular targets that are involved in one way or another\nin enabling particular capabilities. Such speciﬁcity of action has",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 280
        }
    },
    "1374": {
        "text": "been considered a virtue, as it presents inhibitory activity against\na target while having, in principle, relatively fewer off-target\neffects and thus less nonspeciﬁc toxicity. In fact, resulting clin-\nical responses have generally been transitory, being followed\nby almost-inevitable relapses.\nOne interpretation of this history, supported by growing exper-\nimental evidence, is that each of the core hallmark capabilities is\nregulated by partially redundant signaling pathways. Conse-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 281
        }
    },
    "1375": {
        "text": "quently, a targeted therapeutic agent inhibiting one key pathway\nin a tumor may not completely shut off a hallmark capability, al-\nlowing some cancer cells to survive with residual function until\nthey or their progeny eventually adapt to the selective pressure\nimposed by the therapy being applied. Such adaptation, which\ncan be accomplished by mutation, epigenetic reprogramming,\nor remodeling of the stromal microenvironment, can reestablish",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 282
        }
    },
    "1376": {
        "text": "the functional capability, permitting renewed tumor growth and\nclinical relapse. Given that the number of parallel signaling path-\nways supporting a given hallmark must be limited, it may\nbecome possible to target all of these supporting pathways ther-\napeutically, thereby preventing the development of adaptive\nresistance.\nIn response to therapy, cancer cells may also reduce their\ndependence on a particular hallmark capability, becoming",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 283
        }
    },
    "1377": {
        "text": "more dependent on another; this represents a quite different\nform of acquired drug resistance. This concept is exempliﬁed\nby recent discoveries of unexpected responses to antiangio-\ngenic therapies. Some have anticipated that effective inhibition\nof angiogenesis would render tumors dormant and might even\nlead to their dissolution (Folkman and Kalluri, 2004). Instead,\nthe clinical responses to antiangiogenic therapies have been\nfound to be transitory (Azam et al., 2010; Ebos et al., 2009; Berg-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 284
        }
    },
    "1378": {
        "text": "ers and Hanahan, 2008).\nIn certain preclinical models, where potent angiogenesis inhib-\nitors succeed in suppressing this hallmark capability, tumors\nadapt and shift from a dependence upon continuing angiogen-\nesis to heightening the activity of another instead—invasiveness\nand metastasis (Azam et al., 2010: Ebos et al., 2009; Bergers and\nHanahan, 2008). By invading nearby tissues, initially hypoxic\ncancer cells evidently gain access to normal, preexisting tissue",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 285
        }
    },
    "1379": {
        "text": "vasculature. Initial clinical validation of this adaptive/evasive\nresistance is apparent in the increased invasion and local metas-\ntasis seen when human glioblastomas are treated with antian-\ngiogenic therapies (Ellis and Reardon, 2009; Norden et al.,\n2009; Verhoeff et al., 2009). The applicability of this lesson to\nother human cancers has yet to be established.\nAnalogous adaptive shifts in dependence on other hallmark\ntraits may also limit efﬁcacy of analogous hallmark-targeting",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 286
        }
    },
    "1380": {
        "text": "Cell 144, March 4, 2011 ª2011 Elsevier Inc.\n667\ntherapies. For example, the deployment of apoptosis-inducing\ndrugs may induce cancer cells to hyperactivate mitogenic\nsignaling, enabling them to compensate for the initial attrition\ntriggered by such treatments. Such considerations suggest\nthat drug development and the design of treatment protocols\nwill beneﬁt from incorporating the concepts of functionally\ndiscrete hallmark capabilities and of the multiple biochemical",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 287
        }
    },
    "1381": {
        "text": "pathways involved in supporting each of them. Thus, in partic-\nular, we can envisage that selective cotargeting of multiple\ncore and emerging hallmark capabilities and enabling character-\nistics (Figure 6) in mechanism-guided combinations will result in\nmore effective and durable therapies for human cancer.\nCONCLUSION AND FUTURE VISION\nWe have sought here to revisit, reﬁne, and extend the concept of\ncancer hallmarks, which has provided a useful conceptual",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 288
        }
    },
    "1382": {
        "text": "framework for understanding the complex biology of cancer.\nThe six acquired capabilities—the hallmarks of cancer—have\nstood the test of time as being integral components of most\nforms of cancer. Further reﬁnement of these organizing princi-\nples will surely come in the foreseeable future, continuing the\nremarkable conceptual progress of the last decade.\nLooking ahead, we envision signiﬁcant advances during the\ncoming decade in our understanding of invasion and metastasis.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 289
        }
    },
    "1383": {
        "text": "Similarly, the role of aerobic glycolysis in malignant growth will\nbe elucidated, including a resolution of whether this metabolic\nreprogramming is a discrete capability separable from the core\nhallmark of chronically sustained proliferation. We remain\nperplexed as to whether immune surveillance is a barrier that\nvirtually all tumors must circumvent, or only an idiosyncrasy of\nan especially immunogenic subset of them; this issue too will\nbe resolved in one way or another.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 290
        }
    },
    "1384": {
        "text": "be resolved in one way or another.\nYet other areas are currently in rapid ﬂux. In recent years, elab-\norate molecular mechanisms controlling transcription through\nchromatin modiﬁcations have been uncovered, and there are\nFigure 6. Therapeutic Targeting of the Hallmarks of Cancer\nDrugs that interfere with each of the acquired capabilities necessary for tumor growth and progression have been developed and are in clinical trials or in some",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 291
        }
    },
    "1385": {
        "text": "cases approved for clinical use in treating certain forms of human cancer. Additionally, the investigational drugs are being developed to target each of the\nenabling characteristics and emerging hallmarks depicted in Figure 3, which also hold promise as cancer therapeutics. The drugs listed are but illustrative\nexamples; there is a deep pipeline of candidate drugs with different molecular targets and modes of action in development for most of these hallmarks.\n668",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 292
        }
    },
    "1386": {
        "text": "668\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nclues that speciﬁc shifts in chromatin conﬁguration occur during\nthe acquisition of certain hallmark capabilities (Berdasco and Es-\nteller, 2010). Functionally signiﬁcant epigenetic alterations seem\nlikely to be factors not only in the cancer cells but also in the\naltered cells of the tumor-associated stroma. It is unclear at\npresent whether an elucidation of these epigenetic mechanisms",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 293
        }
    },
    "1387": {
        "text": "will materially change our overall understanding of the means by\nwhich hallmark capabilities are acquired or simply add additional\ndetail to the regulatory circuitry that is already known to govern\nthem.\nSimilarly, the discovery of hundreds of distinct regulatory mi-\ncroRNAs has already led to profound changes in our under-\nstanding of the genetic control mechanisms that operate in\nhealth and disease. By now dozens of microRNAs have been",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 294
        }
    },
    "1388": {
        "text": "implicated in various tumor phenotypes (Garzon et al., 2010),\nand yet these only scratch the surface of the real complexity,\nas the functions of hundreds of microRNAs known to be present\nin our cells and altered in expression in different forms of cancer\nremain total mysteries. Here again, we are unclear as to whether\nfuture progress will cause fundamental shifts in our under-\nstanding of the pathogenetic mechanisms of cancer or only",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 295
        }
    },
    "1389": {
        "text": "add detail to the elaborate regulatory circuits that have already\nbeen mapped out.\nFinally, the circuit\ndiagrams of heterotypic interactions\nbetween the multiple distinct cell types that assemble and\ncollaborate to produce different forms and progressively malig-\nnant stages of cancer are currently rudimentary. In another\ndecade, we anticipate that the signaling circuitry describing\nthe intercommunication between these various cells within",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 296
        }
    },
    "1390": {
        "text": "tumors will be charted in far greater detail and clarity, eclipsing\nour current knowledge. And, as before (Hanahan and Weinberg,\n2000), we continue to foresee cancer research as an increasingly\nlogical science, in which myriad phenotypic complexities are\nmanifestations of a small set of underlying organizing principles.\nSUPPLEMENTAL INFORMATION\nSupplemental Information includes six ﬁgures that are downloadable for\npresentations and can be found with this article online at doi:10.1016/j.cell.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 297
        }
    },
    "1391": {
        "text": "2011.02.013.\nACKNOWLEDGMENTS\nWe thank Terry Schoop (OFC Graphics, Kensington, CA, USA) for exceptional\nefforts in preparing the ﬁgures. And we thank Gerard Evan (Cambridge, UK),\nErwin Wagner (Madrid, ESP), and Zena Werb (San Francisco, USA) for valu-\nable comments and suggestions on the manuscript. D.H. and R.A.W. are\nAmerican Cancer Society Research Professors. Research in the authors’ labo-\nratories has been largely supported by the U.S. National Cancer Institute. Due",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 298
        }
    },
    "1392": {
        "text": "to space limitations, many primary and historical publications have not been\ncited, particularly in cases where topical reviews are available.\nREFERENCES\nAdams, J.M., and Cory, S. (2007). The Bcl-2 apoptotic switch in cancer devel-\nopment and therapy. Oncogene 26, 1324–1337.\nAguirre-Ghiso, J.A. (2007). Models, mechanisms and clinical evidence for\ncancer dormancy. Nat. Rev. Cancer 7, 834–846.\nAhmed, Z., and Bicknell, R. (2009). Angiogenic signalling pathways. Methods\nMol. Biol. 467, 3–24.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 299
        }
    },
    "1393": {
        "text": "Mol. Biol. 467, 3–24.\nAl-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J., and Clarke,\nM.F. (2003). Prospective identiﬁcation of tumorigenic breast cancer cells.\nProc. Natl. Acad. Sci. USA 100, 3983–3988.\nAmaravadi, R.K., and Thompson, C.B. (2007). The roles of therapy-induced\nautophagy and necrosis in cancer treatment. Clin. Cancer Res. 13, 7271–7279.\nAmit, I., Citri, A., Shay, T., Lu, Y., Katz, M., Zhang, F., Tarcic, G., Siwak, D., La-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 300
        }
    },
    "1394": {
        "text": "had, J., Jacob-Hirsch, J., et al. (2007). A module of negative feedback regula-\ntors deﬁnes growth factor signaling. Nat. Genet. 39, 503–512.\nApel, A., Zentgraf, H., Bu¨ chler, M.W., and Herr, I. (2009). Autophagy-A double-\nedged sword in oncology. Int. J. Cancer 125, 991–995.\nArtandi, S.E., and DePinho, R.A. (2000). Mice without telomerase: what can\nthey teach us about human cancer? Nat. Med. 6, 852–855.\nArtandi, S.E., and DePinho, R.A. (2010). Telomeres and telomerase in cancer.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 301
        }
    },
    "1395": {
        "text": "Carcinogenesis 31, 9–18.\nAzam, F., Mehta, S., and Harris, A.L. (2010). Mechanisms of resistance to anti-\nangiogenesis therapy. Eur. J. Cancer 46, 1323–1332.\nBaeriswyl, V., and Christofori, G. (2009). The angiogenic switch in carcinogen-\nesis. Semin. Cancer Biol. 19, 329–337.\nBaluk, P., Hashizume, H., and McDonald, D.M. (2005). Cellular abnormalities\nof blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102–111.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 302
        }
    },
    "1396": {
        "text": "Barkan, D., Green, J.E., and Chambers, A.F. (2010). Extracellular matrix:\na gatekeeper in the transition from dormancy to metastatic growth. Eur. J.\nCancer 46, 1181–1188.\nBarnes,D.E.,andLindahl, T.(2004). Repair andgenetic consequences ofendog-\nenous DNA base damage in mammalian cells. Annu. Rev. Genet. 38, 445–476.\nBarrallo-Gimeno, A., and Nieto, M.A. (2005). The Snail genes as inducers of cell\nmovement and survival: implications in development and cancer. Develop-\nment 132, 3151–3161.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 303
        }
    },
    "1397": {
        "text": "ment 132, 3151–3161.\nBerdasco, M., and Esteller, M. (2010). Aberrant epigenetic landscape in\ncancer: How cellular identity goes awry. Dev. Cell 19, 698–711.\nBergers, G., and Benjamin, L.E. (2003). Tumorigenesis and the angiogenic\nswitch. Nat. Rev. Cancer 3, 401–410.\nBergers, G., and Hanahan, D. (2008). Modes of resistance to anti-angiogenic\ntherapy. Nat. Rev. Cancer 8, 592–603.\nBergers, G., and Song, S. (2005). The role of pericytes in blood-vessel forma-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 304
        }
    },
    "1398": {
        "text": "tion and maintenance. Neuro-oncol. 7, 452–464.\nBergfeld, S.A., and DeClerck, Y.A. (2010). Bone marrow-derived mesen-\nchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev.\n29, 249–261.\nBerx, G., and van Roy, F. (2009). Involvement of members of the cadherin\nsuperfamily in cancer. Cold Spring Harb. Perspect. Biol. 1, a003129.\nBhowmick, N.A., Neilson, E.G., and Moses, H.L. (2004). Stromal ﬁbroblasts in\ncancer initiation and progression. Nature 432, 332–337.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 305
        }
    },
    "1399": {
        "text": "Bierie, B., and Moses, H.L. (2006). Tumour microenvironment: TGFbeta: the\nmolecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506–520.\nBindea, G., Mlecnik, B., Fridman, W.H., Page` s, F., and Galon, J. (2010). Natural\nimmunity to cancer in humans. Curr. Opin. Immunol. 22, 215–222.\nBiswas, S.K., and Mantovani, A. (2010). Macrophage plasticity and interaction\nwith lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 306
        }
    },
    "1400": {
        "text": "Blasco, M.A. (2005). Telomeres and human disease: ageing, cancer and\nbeyond. Nat. Rev. Genet. 6, 611–622.\nBoiko, A.D., Razorenova, O.V., van de Rijn, M., Swetter, S.M., Johnson, D.L.,\nLy, D.P., Butler, P.D., Yang, G.P., Joshua, B., Kaplan, M.J., et al. (2010).\nHuman melanoma-initiating cells express neural crest nerve growth factor\nreceptor CD271. Nature 466, 133–137.\nBonnet, D., and Dick, J.E. (1997). Human acute myeloid leukemia is organized",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 307
        }
    },
    "1401": {
        "text": "as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3,\n730–737.\nBos,P.D., Zhang,X.H.,Nadal,C.,Shu,W., Gomis,R.R.,Nguyen,D.X.,Minn, A.J.,\nvan de Vijver, M.J., Gerald, W.L., Foekens, J.A., and Massague´, J. (2009). Genes\nthat mediate breast cancer metastasis to the brain. Nature 459, 1005–1009.\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n669\nBrabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A.,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 308
        }
    },
    "1402": {
        "text": "Knuechel, R., and Kirchner, T. (2001). Variable beta-catenin expression in\ncolorectal cancers indicates tumor progression driven by the tumor environ-\nment. Proc. Natl. Acad. Sci. USA 98, 10356–10361.\nBrabletz, T., Jung, A., Spaderna, S., Hlubek, F., and Kirchner, T. (2005).\nOpinion: migrating cancer stem cells - an integrated concept of malignant\ntumour progression. Nat. Rev. Cancer 5, 744–749.\nBuck, E., Eyzaguirre, A., Barr, S., Thompson, S., Sennello, R., Young, D.,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 309
        }
    },
    "1403": {
        "text": "Iwata, K.K., Gibson, N.W., Cagnoni, P., and Haley, J.D. (2007). Loss of homo-\ntypic cell adhesion by epithelial-mesenchymal transition or mutation limits\nsensitivity to epidermal growth factor receptor inhibition. Mol. Cancer Ther.\n6, 532–541.\nBurkhart, D.L., and Sage, J. (2008). Cellular mechanisms of tumour suppres-\nsion by the retinoblastoma gene. Nat. Rev. Cancer 8, 671–682.\nCabrita, M.A., and Christofori, G. (2008). Sprouty proteins, masterminds of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 310
        }
    },
    "1404": {
        "text": "receptor tyrosine kinase signaling. Angiogenesis 11, 53–62.\nCampbell, P.J., Yachida, S., Mudie, L.J., Stephens, P.J., Pleasance, E.D.,\nStebbings, L.A., Morsberger, L.A., Latimer, C., McLaren, S., Lin, M.L., et al.\n(2010). The patterns and dynamics of genomic instability in metastatic pancre-\natic cancer. Nature 467, 1109–1113.\nCao, Y. (2010). Adipose tissue angiogenesis as a therapeutic target for obesity\nand metabolic diseases. Nat. Rev. Drug Discov. 9, 107–115.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 311
        }
    },
    "1405": {
        "text": "Carmeliet, P. (2005). VEGF as a key mediator of angiogenesis in cancer.\nOncology 69 (Suppl 3), 4–10.\nCarmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other\ndiseases. Nature 407, 249–257.\nCavallaro, U., and Christofori, G. (2004). Cell adhesion and signalling by cad-\nherins and Ig-CAMs in cancer. Nat. Rev. Cancer 4, 118–132.\nCheng, N., Chytil, A., Shyr, Y., Joly, A., and Moses, H.L. (2008). Transforming\ngrowth factor-beta signaling-deﬁcient ﬁbroblasts enhance hepatocyte growth",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 312
        }
    },
    "1406": {
        "text": "factor signaling in mammary carcinoma cells to promote scattering and inva-\nsion. Mol. Cancer Res. 6, 1521–1533.\nChin, K., de Solorzano, C.O., Knowles, D., Jones, A., Chou, W., Rodriguez,\nE.G., Kuo, W.L., Ljung, B.M., Chew, K., Myambo, K., et al. (2004). In situ anal-\nyses of genome instability in breast cancer. Nat. Genet. 36, 984–988.\nCho, R.W., and Clarke, M.F. (2008). Recent advances in cancer stem cells.\nCurr. Opin. Genet. Dev. 18, 1–6.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 313
        }
    },
    "1407": {
        "text": "Curr. Opin. Genet. Dev. 18, 1–6.\nCiccia, A., and Elledge, S.J. (2010). The DNA damage response: making it safe\nto play with knives. Mol. Cell 40, 179–204.\nCoffelt, S.B., Lewis, C.E., Naldini, L., Brown, J.M., Ferrara, N., and De Palma,\nM. (2010). Elusive identities and overlapping phenotypes of proangiogenic\nmyeloid cells in tumors. Am. J. Pathol. 176, 1564–1576.\nCoghlin, C., and Murray, G.I. (2010). Current and emerging concepts in tumour\nmetastasis. J. Pathol. 222, 1–15.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 314
        }
    },
    "1408": {
        "text": "metastasis. J. Pathol. 222, 1–15.\nCollado, M., and Serrano, M. (2010). Senescence in tumours: evidence from\nmice and humans. Nat. Rev. Cancer 10, 51–57.\nColotta, F., Allavena, P., Sica, A., Garlanda, C., and Mantovani, A. (2009).\nCancer-related inﬂammation, the seventh hallmark of cancer: links to genetic\ninstability. Carcinogenesis 30, 1073–1081.\nCong, Y., and Shay, J.W. (2008). Actions of human telomerase beyond telo-\nmeres. Cell Res. 18, 725–732.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 315
        }
    },
    "1409": {
        "text": "meres. Cell Res. 18, 725–732.\nCreighton, C.J., Li, X., Landis, M., Dixon, J.M., Neumeister, V.M., Sjolund, A.,\nRimm, D.L., Wong, H., Rodriguez, A., Herschkowitz, J.I., et al. (2009). Residual\nbreast cancers after conventional therapy display mesenchymal as well as\ntumor-initiating features. Proc. Natl. Acad. Sci. USA 106, 13820–13825.\nCurto, M., Cole, B.K., Lallemand, D., Liu, C.H., and McClatchey, A.I. (2007).\nContact-dependent inhibition of EGFR signaling by Nf2/Merlin. J. Cell Biol.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 316
        }
    },
    "1410": {
        "text": "177, 893–903.\nDavies, M.A., and Samuels, Y. (2010). Analysis of the genome to personalize\ntherapy for melanoma. Oncogene 29, 5545–5555.\nDeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G., and Thompson, C.B. (2008).\nThe biology of cancer: Metabolic reprogramming fuels cell growth and prolif-\neration. Cell Metab. 7, 11–20.\nDejana, E., Orsenigo, F., Molendini, C., Baluk, P., and McDonald, D.M. (2009).\nOrganization and signaling of endothelial cell-to-cell junctions in various",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 317
        }
    },
    "1411": {
        "text": "regions of the blood and lymphatic vascular trees. Cell Tissue Res. 335, 17–25.\nDemicheli, R., Retsky, M.W., Hrushesky, W.J., Baum, M., and Gukas, I.D.\n(2008). The effects of surgery on tumor growth: a century of investigations.\nAnn. Oncol. 19, 1821–1828.\nDeNardo, D.G., Andreu, P., and Coussens, L.M. (2010). Interactions between\nlymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.\nCancer Metastasis Rev. 29, 309–316.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 318
        }
    },
    "1412": {
        "text": "Cancer Metastasis Rev. 29, 309–316.\nDe Palma, M., Murdoch, C., Venneri, M.A., Naldini, L., and Lewis, C.E. (2007).\nTie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic\nimplications. Trends Immunol. 28, 519–524.\nDeshpande, A., Sicinski, P., and Hinds, P.W. (2005). Cyclins and cdks in devel-\nopment and cancer: a perspective. Oncogene 24, 2909–2915.\nde Visser, K.E., Eichten, A., and Coussens, L.M. (2006). Paradoxical roles of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 319
        }
    },
    "1413": {
        "text": "the immune system during cancer development. Nat. Rev. Cancer 6, 24–37.\nDirat, B., Bochet, L., Escourrou, G., Valet, P., and Muller, C. (2010). Unraveling\nthe obesity and breast cancer links: a role for cancer-associated adipocytes?\nEndocr. Dev. 19, 45–52.\nDvorak, H.F. (1986). Tumors: wounds that do not heal. Similarities between\ntumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650–1659.\nEbos, J.M., Lee, C.R., and Kerbel, R.S. (2009). Tumor and host-mediated path-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 320
        }
    },
    "1414": {
        "text": "ways of resistance and disease progression in response to antiangiogenic\ntherapy. Clin. Cancer Res. 15, 5020–5025.\nEgeblad, M., Nakasone, E.S., and Werb, Z. (2010). Tumors as organs: complex\ntissues that interface with the entire organism. Dev. Cell 18, 884–901.\nEl Hallani, S., Boisselier, B., Peglion, F., Rousseau, A., Colin, C., Idbaih, A.,\nMarie, Y., Mokhtari, K., Thomas, J.L., Eichmann, A., et al. (2010). A new alter-\nnative mechanism in glioblastoma vascularization: tubular vasculogenic",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 321
        }
    },
    "1415": {
        "text": "mimicry. Brain 133, 973–982.\nEllis, L.M., and Reardon, D.A. (2009). Cancer: The nuances of therapy. Nature\n458, 290–292.\nEsteller, M. (2007). Cancer epigenomics: DNA methylomes and histone-modi-\nﬁcation maps. Nat. Rev. Genet. 8, 286–298.\nEvan, G.I., and d’Adda di Fagagna, F. (2009). Cellular senescence: hot or\nwhat? Curr. Opin. Genet. Dev. 19, 25–31.\nEvan, G., and Littlewood, T. (1998). A matter of life and cell death. Science 281,\n1317–1322.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 322
        }
    },
    "1416": {
        "text": "1317–1322.\nFang, S., and Salven, P. (2011). Stem cells in tumor angiogenesis. J. Mol. Cell.\nCardiol. 50, 290–295.\nFeron, O. (2009). Pyruvate into lactate and back: from the Warburg effect to\nsymbiotic energy fuel exchange in cancer cells. Radiother. Oncol. 92, 329–\n333.\nFeldser, D.M., and Greider, C.W. (2007). Short telomeres limit tumor progres-\nsion in vivo by inducing senescence. Cancer Cell 11, 461–469.\nFerrara, N. (2009). Vascular endothelial growth factor. Arterioscler. Thromb.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 323
        }
    },
    "1417": {
        "text": "Vasc. Biol. 29, 789–791.\nFerrara, N. (2010). Pathways mediating VEGF-independent tumor angiogen-\nesis. Cytokine Growth Factor Rev. 21, 21–26.\nFerrone, C., and Dranoff, G. (2010). Dual roles for immunity in gastrointestinal\ncancers. J. Clin. Oncol. 28, 4045–4051.\nFidler, I.J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’\nhypothesis revisited. Nat. Rev. Cancer 3, 453–458.\nFolkman, J. (2002). Role of angiogenesis in tumor growth and metastasis.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 324
        }
    },
    "1418": {
        "text": "Semin. Oncol. 29(6, Suppl 16), 15–18.\nFolkman, J. (2006). Angiogenesis. Annu. Rev. Med. 57, 1–18.\nFolkman, J., and Kalluri, R. (2004). Cancer without disease. Nature 427, 787.\n670\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nFriedberg, E.C., Aguilera, A., Gellert, M., Hanawalt, P.C., Hays, J.B., Lehmann,\nA.R., Lindahl, T., Lowndes, N., Sarasin, A., and Wood, R.D. (2006). DNA repair:\nfrom molecular mechanism to human disease. DNA Repair (Amst.) 5, 986–996.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 325
        }
    },
    "1419": {
        "text": "Friedl, P., and Wolf, K. (2008). Tube travel: the role of proteases in individual\nand collective cancer cell invasion. Cancer Res. 68, 7247–7249.\nFriedl, P., and Wolf, K. (2010). Plasticity of cell migration: a multiscale tuning\nmodel. J. Cell Biol. 188, 11–19.\nGaengel, K., Genove´ , G., Armulik, A., and Betsholtz, C. (2009). Endothelial-\nmural cell signaling in vascular development and angiogenesis. Arterioscler.\nThromb. Vasc. Biol. 29, 630–638.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 326
        }
    },
    "1420": {
        "text": "Thromb. Vasc. Biol. 29, 630–638.\nGalluzzi, L., and Kroemer, G. (2008). Necroptosis: a specialized pathway of\nprogrammed necrosis. Cell 135, 1161–1163.\nGarzon, R., Marcucci, G., and Croce, C.M. (2010). Targeting microRNAs in\ncancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775–\n789.\nGerhardt, H., and Semb, H. (2008). Pericytes: gatekeepers in tumour cell\nmetastasis? J. Mol. Med. 86, 135–144.\nGhebranious, N., and Donehower, L.A. (1998). Mouse models in tumor",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 327
        }
    },
    "1421": {
        "text": "suppression. Oncogene 17, 3385–3400.\nGiaccia, A.J., and Schipani, E. (2010). Role of carcinoma-associated ﬁbro-\nblasts and hypoxia in tumor progression. Curr. Top. Microbiol. Immunol.\n345, 31–45.\nGilbertson, R.J., and Rich, J.N. (2007). Making a tumour’s bed: glioblastoma\nstem cells and the vascular niche. Nat. Rev. Cancer 7, 733–736.\nGocheva, V., Wang, H.W., Gadea, B.B., Shree, T., Hunter, K.E., Garfall, A.L.,\nBerman, T., and Joyce, J.A. (2010). IL-4 induces cathepsin protease activity",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 328
        }
    },
    "1422": {
        "text": "in tumor-associated macrophages to promote cancer growth and invasion.\nGenes Dev. 24, 241–255.\nGrivennikov, S.I., Greten, F.R., and Karin, M. (2010). Immunity, inﬂammation,\nand cancer. Cell 140, 883–899.\nGupta, G.P., Minn, A.J., Kang, Y., Siegel, P.M., Serganova, I., Cordo´ n-Cardo,\nC., Olshen, A.B., Gerald, W.L., and Massague´ , J. (2005). Identifying site-\nspeciﬁc metastasis genes and functions. Cold Spring Harb. Symp. Quant.\nBiol. 70, 149–158.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 329
        }
    },
    "1423": {
        "text": "Biol. 70, 149–158.\nGupta, P.B., Chaffer, C.L., and Weinberg, R.A. (2009). Cancer stem cells:\nmirage or reality? Nat. Med. 15, 1010–1012.\nHanahan, D., and Folkman, J. (1996). Patterns and emerging mechanisms of\nthe angiogenic switch during tumorigenesis. Cell 86, 353–364.\nHanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100,\n57–70.\nHansel, D.E., Meeker, A.K., Hicks, J., De Marzo, A.M., Lillemoe, K.D., Schulick,",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 330
        }
    },
    "1424": {
        "text": "R., Hruban, R.H., Maitra, A., and Argani, P. (2006). Telomere length variation in\nbiliary tract metaplasia, dysplasia, and carcinoma. Mod. Pathol. 19, 772–779.\nHardee, M.E., Dewhirst, M.W., Agarwal, N., and Sorg, B.S. (2009). Novel\nimaging provides new insights into mechanisms of oxygen transport in tumors.\nCurr. Mol. Med. 9, 435–441.\nHarper, J.W., and Elledge, S.J. (2007). The DNA damage response: Ten years\nafter. Mol. Cell 28, 739–745.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 331
        }
    },
    "1425": {
        "text": "after. Mol. Cell 28, 739–745.\nHezel, A.F., and Bardeesy, N. (2008). LKB1; linking cell structure and tumor\nsuppression. Oncogene 27, 6908–6919.\nHlubek, F., Brabletz, T., Budczies, J., Pfeiffer, S., Jung, A., and Kirchner, T.\n(2007). Heterogeneous expression of Wnt/beta-catenin target genes within\ncolorectal cancer. Int. J. Cancer 121, 1941–1948.\nHugo, H., Ackland, M.L., Blick, T., Lawrence, M.G., Clements, J.A., Williams,\nE.D., and Thompson, E.W. (2007). Epithelial—mesenchymal and mesen-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 332
        }
    },
    "1426": {
        "text": "chymal—epithelial transitions in carcinoma progression. J. Cell. Physiol.\n213, 374–383.\nHsu, P.P., and Sabatini, D.M. (2008). Cancer cell metabolism: Warburg and\nbeyond. Cell 134, 703–707.\nHynes, N.E., and MacDonald, G. (2009). ErbB receptors and signaling path-\nways in cancer. Curr. Opin. Cell Biol. 21, 177–184.\nIkushima, H., and Miyazono, K. (2010). TGFbeta signalling: a complex web in\ncancer progression. Nat. Rev. Cancer 10, 415–424.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 333
        }
    },
    "1427": {
        "text": "cancer progression. Nat. Rev. Cancer 10, 415–424.\nInce, T.A., Richardson, A.L., Bell, G.W., Saitoh, M., Godar, S., Karnoub, A.E.,\nIglehart, J.D., and Weinberg, R.A. (2007). Transformation of different human\nbreast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell\n12, 160–170.\nJackson, S.P., and Bartek, J. (2009). The DNA-damage response in human\nbiology and disease. Nature 461, 1071–1078.\nJiang, B.H., and Liu, L.Z. (2009). PI3K/PTEN signaling in angiogenesis and",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 334
        }
    },
    "1428": {
        "text": "tumorigenesis. Adv. Cancer Res. 102, 19–65.\nJohansson, M., Denardo, D.G., and Coussens, L.M. (2008). Polarized immune\nresponses differentially regulate cancer development. Immunol. Rev. 222,\n145–154.\nJones, P.A., and Baylin, S.B. (2007). The epigenomics of cancer. Cell 128, 683–\n692.\nJones, R.G., and Thompson, C.B. (2009). Tumor suppressors and cell metab-\nolism: a recipe for cancer growth. Genes Dev. 23, 537–548.\nJoyce, J.A., and Pollard, J.W. (2009). Microenvironmental regulation of metas-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 335
        }
    },
    "1429": {
        "text": "tasis. Nat. Rev. Cancer 9, 239–252.\nJunttila, M.R., and Evan, G.I. (2009). p53—a Jack of all trades but master of\nnone. Nat. Rev. Cancer 9, 821–829.\nKalluri, R., and Zeisberg, M. (2006). Fibroblasts in cancer. Nat. Rev. Cancer 6,\n392–401.\nKang, H.J., Choi, Y.S., Hong, S.B., Kim, K.W., Woo, R.S., Won, S.J., Kim, E.J.,\nJeon, H.K., Jo, S.Y., Kim, T.K., et al. (2004). Ectopic expression of the catalytic\nsubunit of telomerase protects against brain injury resulting from ischemia and",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 336
        }
    },
    "1430": {
        "text": "NMDA-induced neurotoxicity. J. Neurosci. 24, 1280–1287.\nKarin, M., Lawrence, T., and Nizet, V. (2006). Innate immunity gone awry: link-\ning microbial infections to chronic inﬂammation and cancer. Cell 124, 823–835.\nKarnoub, A.E., and Weinberg, R.A. (2006–2007). Chemokine networks and\nbreast cancer metastasis. Breast Dis. 26, 75–85.\nKarnoub, A.E., Dash, A.B., Vo, A.P., Sullivan, A., Brooks, M.W., Bell, G.W.,\nRichardson, A.L., Polyak, K., Tubo, R., and Weinberg, R.A. (2007). Mesen-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 337
        }
    },
    "1431": {
        "text": "chymal stem cells within tumour stroma promote breast cancer metastasis.\nNature 449, 557–563.\nKastan, M.B. (2008). DNA damage responses: mechanisms and roles in\nhuman disease: 2007 G.H.A. Clowes Memorial Award Lecture. Mol. Cancer\nRes. 6, 517–524.\nKawai, T., Hiroi, S., Nakanishi, K., and Meeker, A.K. (2007). Telomere length\nand telomerase expression in atypical adenomatous hyperplasia and small\nbronchioloalveolar carcinoma of the lung. Am. J. Clin. Pathol. 127, 254–262.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 338
        }
    },
    "1432": {
        "text": "Kazerounian, S., Yee, K.O., and Lawler, J. (2008). Thrombospondins in cancer.\nCell. Mol. Life Sci. 65, 700–712.\nKeniﬁc, C.M., Thorburn, A., and Debnath, J. (2010). Autophagy and metas-\ntasis: another double-edged sword. Curr. Opin. Cell Biol. 22, 241–245.\nKennedy, K.M., and Dewhirst, M.W. (2010). Tumor metabolism of lactate: the\ninﬂuence and therapeutic potential for MCT and CD147 regulation. Future\nOncol. 6, 127–148.\nKessenbrock, K., Plaks, V., and Werb, Z. (2010). Matrix metalloproteinases:",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 339
        }
    },
    "1433": {
        "text": "Regulators of the tumor microenvironment. Cell 141, 52–67.\nKim, M.Y., Oskarsson, T., Acharyya, S., Nguyen, D.X., Zhang, X.H., Norton, L.,\nand Massague´ , J. (2009). Tumor self-seeding by circulating cancer cells. Cell\n139, 1315–1326.\nKim, R., Emi, M., and Tanabe, K. (2007). Cancer immunoediting from immune\nsurveillance to immune escape. Immunology 121, 1–14.\nKinzler, K.W., and Vogelstein, B. (1997). Cancer-susceptibility genes. Gate-\nkeepers and caretakers. Nature 386, 761–763.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 340
        }
    },
    "1434": {
        "text": "keepers and caretakers. Nature 386, 761–763.\nKlein, C.A. (2009). Parallel progression of primary tumours and metastases.\nNat. Rev. Cancer 9, 302–312.\nKlymkowsky, M.W., and Savagner, P. (2009). Epithelial-mesenchymal transi-\ntion: a cancer researcher’s conceptual friend and foe. Am. J. Pathol. 174,\n1588–1593.\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n671\nKorkola, J., and Gray, J.W. (2010). Breast cancer genomes—form and func-\ntion. Curr. Opin. Genet. Dev. 20, 4–14.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 341
        }
    },
    "1435": {
        "text": "tion. Curr. Opin. Genet. Dev. 20, 4–14.\nKovacic, J.C., and Boehm, M. (2009). Resident vascular progenitor cells: an\nemerging role for non-terminally differentiated vessel-resident cells in vascular\nbiology. Stem Cell Res. (Amst.) 2, 2–15.\nKroemer, G., and Pouyssegur, J. (2008). Tumor cell metabolism: Cancer’s\nAchilles’ heel. Cancer Cell 13, 472–482.\nLamagna, C., and Bergers, G. (2006). The bone marrow constitutes a reservoir\nof pericyte progenitors. J. Leukoc. Biol. 80, 677–681.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 342
        }
    },
    "1436": {
        "text": "Lane, D.P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15–16.\nLemmon, M.A., and Schlessinger, J. (2010). Cell signaling by receptor tyrosine\nkinases. Cell 141, 1117–1134.\nLevine, B., and Kroemer, G. (2008). Autophagy in the pathogenesis of disease.\nCell 132, 27–42.\nLipinski, M.M., and Jacks, T. (1999). The retinoblastoma gene family in differ-\nentiation and development. Oncogene 18, 7873–7882.\nLobo, N.A., Shimono, Y., Qian, D., and Clarke, M.F. (2007). The biology of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 343
        }
    },
    "1437": {
        "text": "cancer stem cells. Annu. Rev. Cell Dev. Biol. 23, 675–699.\nLowe, S.W., Cepero, E., and Evan, G. (2004). Intrinsic tumour suppression.\nNature 432, 307–315.\nLuebeck, E.G. (2010). Cancer: Genomic evolution of metastasis. Nature 467,\n1053–1055.\nLu, Z., Luo, R.Z., Lu, Y., Zhang, X., Yu, Q., Khare, S., Kondo, S., Kondo, Y., Yu,\nY., Mills, G.B., et al. (2008). The tumor suppressor gene ARHI regulates au-\ntophagy and tumor dormancy in human ovarian cancer cells. J. Clin. Invest.\n118, 3917–3929.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 344
        }
    },
    "1438": {
        "text": "118, 3917–3929.\nLuo, J., Solimini, N.L., and Elledge, S.J. (2009). Principles of cancer therapy:\nOncogene and non-oncogene addiction. Cell 136, 823–837.\nMac Gabhann, F., and Popel, A.S. (2008). Systems biology of vascular endo-\nthelial growth factors. Microcirculation 15, 715–738.\nMadsen, C.D., and Sahai, E. (2010). Cancer dissemination—Lessons from\nleukocytes. Dev. Cell 19, 13–26.\nMaida, Y., Yasukawa, M., Furuuchi, M., Lassmann, T., Possemato, R., Oka-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 345
        }
    },
    "1439": {
        "text": "moto, N., Kasim, V., Hayashizaki, Y., Hahn, W.C., and Masutomi, K. (2009).\nAn RNA-dependent RNA polymerase formed by TERT and the RMRP RNA.\nNature 461, 230–235.\nMani, S.A., Guo, W., Liao, M.J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M.,\nReinhard, F., Zhang, C.C., Shipitsin, M., et al. (2008). The epithelial-mesen-\nchymaltransitiongeneratescellswithpropertiesofstemcells.Cell133,704–715.\nMantovani, A. (2010). Molecular pathways linking inﬂammation and cancer.\nCurr. Mol. Med. 10, 369–373.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 346
        }
    },
    "1440": {
        "text": "Curr. Mol. Med. 10, 369–373.\nMantovani, A., Allavena, P., Sica, A., and Balkwill, F. (2008). Cancer-related\ninﬂammation. Nature 454, 436–444.\nMassague´ , J. (2008). TGFb in cancer. Cell 134, 215–230.\nMasutomi, K., Possemato, R., Wong, J.M., Currier, J.L., Tothova, Z., Manola,\nJ.B., Ganesan, S., Lansdorp, P.M., Collins, K., and Hahn, W.C. (2005). The\ntelomerase reverse transcriptase regulates chromatin state and DNA damage\nresponses. Proc. Natl. Acad. Sci. USA 102, 8222–8227.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 347
        }
    },
    "1441": {
        "text": "Mathew, R., Karantza-Wadsworth, V., and White, E. (2007). Role of autophagy\nin cancer. Nat. Rev. Cancer 7, 961–967.\nMcGowan, P.M., Kirstein, J.M., and Chambers, A.F. (2009). Micrometastatic\ndisease\nand\nmetastatic\noutgrowth:\nclinical\nissues\nand\nexperimental\napproaches. Future Oncol. 5, 1083–1098.\nMicalizzi, D.S., Farabaugh, S.M., and Ford, H.L. (2010). Epithelial-mesen-\nchymal transition in cancer: parallels between normal development and tumor",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 348
        }
    },
    "1442": {
        "text": "progression. J. Mammary Gland Biol. Neoplasia 15, 117–134.\nMizushima, N. (2007). Autophagy: process and function. Genes Dev. 21, 2861–\n2873.\nMohamed, M.M., and Sloane, B.F. (2006). Cysteine cathepsins: multifunc-\ntional enzymes in cancer. Nat. Rev. Cancer 6, 764–775.\nMooi, W.J., and Peeper, D.S. (2006). Oncogene-induced cell senescence—\nhalting on the road to cancer. N. Engl. J. Med. 355, 1037–1046.\nMorel, A.-P., Lie` vre, M., Thomas, C., Hinkal, G., Ansieau, S., and Puisieux, A.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 349
        }
    },
    "1443": {
        "text": "(2008). Generation of breast cancer stem cells through epithelial-mesen-\nchymal transition. PLoS ONE 3, e2888.\nMosesson, Y., Mills, G.B., and Yarden, Y. (2008). Derailed endocytosis: an\nemerging feature of cancer. Nat. Rev. Cancer 8, 835–850.\nMougiakakos, D., Choudhury, A., Lladser, A., Kiessling, R., and Johansson,\nC.C. (2010). Regulatory T cells in cancer. Adv. Cancer Res. 107, 57–117.\nMurdoch,C.,Muthana,M.,Coffelt,S.B.,andLewis,C.E.(2008).Theroleofmyeloid",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 350
        }
    },
    "1444": {
        "text": "cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 8, 618–631.\nNagy, J.A., Chang, S.H., Shih, S.C., Dvorak, A.M., and Dvorak, H.F. (2010).\nHeterogeneity of the tumor vasculature. Semin. Thromb. Hemost. 36,\n321–331.\nNaumov, G.N., Folkman, J., Straume, O., and Akslen, L.A. (2008). Tumor-\nvascular interactions and tumor dormancy. APMIS 116, 569–585.\nNegrini, S., Gorgoulis, V.G., and Halazonetis, T.D. (2010). Genomic insta-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 351
        }
    },
    "1445": {
        "text": "bility—an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol. 11, 220–228.\nNelson, B.H. (2008). The impact of T-cell immunity on ovarian cancer\noutcomes. Immunol. Rev. 222, 101–116.\nNguyen, D.X., Bos, P.D., and Massague´ , J. (2009). Metastasis: from dissemi-\nnation to organ-speciﬁc colonization. Nat. Rev. Cancer 9, 274–284.\nNorden, A.D., Drappatz, J., and Wen, P.Y. (2009). Antiangiogenic therapies for\nhigh-grade glioma. Nat. Rev. Neurol. 5, 610–620.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 352
        }
    },
    "1446": {
        "text": "high-grade glioma. Nat. Rev. Neurol. 5, 610–620.\nNyberg, P., Xie, L., and Kalluri, R. (2005). Endogenous inhibitors of angiogen-\nesis. Cancer Res. 65, 3967–3979.\nOkada, T., Lopez-Lago, M., and Giancotti, F.G. (2005). Merlin/NF-2 mediates\ncontact inhibition of growth by suppressing recruitment of Rac to the plasma\nmembrane. J. Cell Biol. 171, 361–371.\nOlive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Hon-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 353
        }
    },
    "1447": {
        "text": "ess, D., Madhu, B., Goldgraben, M.A., Caldwell, M.E., Allard, D., et al. (2009).\nInhibition of Hedgehog signaling enhances delivery of chemotherapy in\na mouse model of pancreatic cancer. Science 324, 1457–1461.\nOlson, P., Lu, J., Zhang, H., Shai, A., Chun, M.G., Wang, Y., Libutti, S.K., Na-\nkakura, E.K., Golub, T.R., and Hanahan, D. (2009). MicroRNA dynamics in the\nstages of tumorigenesis correlate with hallmark capabilities of cancer. Genes\nDev. 23, 2152–2165.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 354
        }
    },
    "1448": {
        "text": "Dev. 23, 2152–2165.\nO’Reilly, K.E., Rojo, F., She, Q.B., Solit, D., Mills, G.B., Smith, D., Lane, H., Hof-\nmann, F., Hicklin, D.J., Ludwig, D.L., et al. (2006). mTOR inhibition induces\nupstream receptor tyrosine kinase signaling and activates Akt. Cancer Res.\n66, 1500–1508.\nOstrand-Rosenberg, S., and Sinha, P. (2009). Myeloid-derived suppressor\ncells: linking inﬂammation and cancer. J. Immunol. 182, 4499–4506.\nPage` s, F., Galon, J., Dieu-Nosjean, M.C., Tartour, E., Saute` s-Fridman, C., and",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 355
        }
    },
    "1449": {
        "text": "Fridman, W.H. (2010). Immune inﬁltration in human tumors: a prognostic factor\nthat should not be ignored. Oncogene 29, 1093–1102.\nPalermo, C., and Joyce, J.A. (2008). Cysteine cathepsin proteases as pharma-\ncological targets in cancer. Trends Pharmacol. Sci. 29, 22–28.\nPark, J.I., Venteicher, A.S., Hong, J.Y., Choi, J., Jun, S., Shkreli, M., Chang, W.,\nMeng, Z., Cheung, P., Ji, H., et al. (2009). Telomerase modulates Wnt signalling\nby association with target gene chromatin. Nature 460, 66–72.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 356
        }
    },
    "1450": {
        "text": "Partanen, J.I., Nieminen, A.I., and Klefstrom, J. (2009). 3D view to tumor\nsuppression: Lkb1, polarity and the arrest of oncogenic c-Myc. Cell Cycle 8,\n716–724.\nPasquale, E.B. (2010). Eph receptors and ephrins in cancer: bidirectional sig-\nnalling and beyond. Nat. Rev. Cancer 10, 165–180.\nPassos, J.F., Saretzki, G., and von Zglinicki, T. (2007). DNA damage in telo-\nmeres and mitochondria during cellular senescence: is there a connection?\nNucleic Acids Res. 35, 7505–7513.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 357
        }
    },
    "1451": {
        "text": "Nucleic Acids Res. 35, 7505–7513.\nPatenaude, A., Parker, J., and Karsan, A. (2010). Involvement of endothelial\nprogenitor cells in tumor vascularization. Microvasc. Res. 79, 217–223.\n672\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\nPeinado, H., Lavothskin, S., and Lyden, D. (2011). The secreted factors\nresponsible for pre-metastatic niche formation: Old sayings and new thoughts.\nSemin. Cancer Biol. Published online January 18, 2011. 10.1016/j.semcancer.\n2011.01.002.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 358
        }
    },
    "1452": {
        "text": "2011.01.002.\nPeinado, H., Marin, F., Cubillo, E., Stark, H.J., Fusenig, N., Nieto, M.A., and\nCano, A. (2004). Snail and E47 repressors of E-cadherin induce distinct inva-\nsive and angiogenic properties in vivo. J. Cell Sci. 117, 2827–2839.\nPerona, R. (2006). Cell signalling: growth factors and tyrosine kinase recep-\ntors. Clin. Transl. Oncol. 8, 77–82.\nPietras, K., and Ostman, A. (2010). Hallmarks of cancer: interactions with the\ntumor stroma. Exp. Cell Res. 316, 1324–1331.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 359
        }
    },
    "1453": {
        "text": "tumor stroma. Exp. Cell Res. 316, 1324–1331.\nPolyak, K., and Weinberg, R.A. (2009). Transitions between epithelial and\nmesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev.\nCancer 9, 265–273.\nPolyak, K., Haviv, I., and Campbell, I.G. (2009). Co-evolution of tumor cells and\ntheir microenvironment. Trends Genet. 25, 30–38.\nPotter, V.R. (1958). The biochemical approach to the cancer problem. Fed.\nProc. 17, 691–697.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 360
        }
    },
    "1454": {
        "text": "Proc. 17, 691–697.\nQian, B.Z., and Pollard, J.W. (2010). Macrophage diversity enhances tumor\nprogression and metastasis. Cell 141, 39–51.\nQuintana, E., Shackleton, M., Sabel, M.S., Fullen, D.R., Johnson, T.M., and\nMorrison, S.J. (2008). Efﬁcient tumour formation by single human melanoma\ncells. Nature 456, 593–598.\nRaica, M., Cimpean, A.M., and Ribatti, D. (2009). Angiogenesis in pre-malig-\nnant conditions. Eur. J. Cancer 45, 1924–1934.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 361
        }
    },
    "1455": {
        "text": "nant conditions. Eur. J. Cancer 45, 1924–1934.\nRa¨ sa¨ nen, K., and Vaheri, A. (2010). Activation of ﬁbroblasts in cancer stroma.\nExp. Cell Res. 316, 2713–2722.\nRaynaud, C.M., Hernandez, J., Llorca, F.P., Nuciforo, P., Mathieu, M.C.,\nCommo, F., Delaloge, S., Sabatier, L., Andre´ , F., and Soria, J.C. (2010). DNA\ndamage repair and telomere length in normal breast, preneoplastic lesions,\nand invasive cancer. Am. J. Clin. Oncol. 33, 341–345.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 362
        }
    },
    "1456": {
        "text": "Raza, A., Franklin, M.J., and Dudek, A.Z. (2010). Pericytes and vessel matura-\ntion during tumor angiogenesis and metastasis. Am. J. Hematol. 85, 593–598.\nReitman, Z.J., and Yan, H. (2010). Isocitrate dehydrogenase 1 and 2 mutations\nin cancer: alterations at a crossroads of cellular metabolism. J. Natl. Cancer\nInst. 102, 932–941.\nReya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells,\ncancer, and cancer stem cells. Nature 414, 105–111.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 363
        }
    },
    "1457": {
        "text": "Ribatti, D. (2009). Endogenous inhibitors of angiogenesis: a historical review.\nLeuk. Res. 33, 638–644.\nRicci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., Cenci, T.,\nMaira, G., Parati, E.A., Stassi, G., Larocca, L.M., and De Maria, R. (2010).\nTumour vascularization via endothelial differentiation of glioblastoma stem-\nlike cells. Nature 468, 824–828.\nRuoslahti, E. (2002). Specialization of tumour vasculature. Nat. Rev. Cancer 2,\n83–90.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 364
        }
    },
    "1458": {
        "text": "83–90.\nRuoslahti, E., Bhatia, S.N., and Sailor, M.J. (2010). Targeting of drugs and\nnanoparticles to tumors. J. Cell Biol. 188, 759–768.\nSabeh, F., Shimizu-Hirota, R., and Weiss, S.J. (2009). Protease-dependent\nversus -independent cancer cell invasion programs: three-dimensional amoe-\nboid movement revisited. J. Cell Biol. 185, 11–19.\nSalk, J.J., Fox, E.J., and Loeb, L.A. (2010). Mutational heterogeneity in human\ncancers: origin and consequences. Ann. Rev. Pathol. 5, 51–75.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 365
        }
    },
    "1459": {
        "text": "Scha¨ fer, M., and Werner, S. (2008). Cancer as an overhealing wound: an old\nhypothesis revisited. Nat. Rev. Mol. Cell Biol. 9, 628–638.\nSchmalhofer, O., Brabletz, S., and Brabletz, T. (2009). E-cadherin, beta-cate-\nnin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 28,\n151–166.\nSemenza, G.L. (2008). Tumor metabolism: cancer cells give and take lactate.\nJ. Clin. Invest. 118, 3835–3837.\nSemenza, G.L. (2010a). HIF-1: upstream and downstream of cancer metabo-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 366
        }
    },
    "1460": {
        "text": "lism. Curr. Opin. Genet. Dev. 20, 51–56.\nSemenza, G.L. (2010b). Deﬁning the role of hypoxia-inducible factor 1 in\ncancer biology and therapeutics. Oncogene 29, 625–634.\nSeppinen, L., Sormunen, R., Soini, Y., Elamaa, H., Heljasvaara, R., and Pihla-\njaniemi, T. (2008). Lack of collagen XVIII accelerates cutaneous wound healing,\nwhile overexpression of its endostatin domain leads to delayed healing. Matrix\nBiol. 27, 535–546.\nShaw, R.J. (2009). Tumor suppression by LKB1: SIK-ness prevents metas-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 367
        }
    },
    "1461": {
        "text": "tasis. Sci. Signal. 2, pe55.\nShay, J.W., and Wright, W.E. (2000). Hayﬂick, his limit, and cellular ageing. Nat.\nRev. Mol. Cell Biol. 1, 72–76.\nSherr, C.J., and DePinho, R.A. (2000). Cellular senescence: Mitotic clock or\nculture shock? Cell 102, 407–410.\nSherr, C.J., and McCormick, F. (2002). The RB and p53 pathways in cancer.\nCancer Cell 2, 103–112.\nShields, J.D., Kourtis, I.C., Tomei, A.A., Roberts, J.M., and Swartz, M.A.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 368
        }
    },
    "1462": {
        "text": "(2010). Induction of lymphoidlike stroma and immune escape by tumors that\nexpress the chemokine CCL21. Science 328, 749–752.\nShimoda, M., Mellody, K.T., and Orimo, A. (2010). Carcinoma-associated\nﬁbroblasts are a rate-limiting determinant for tumour progression. Semin.\nCell Dev. Biol. 21, 19–25.\nSigal, A., and Rotter, V. (2000). Oncogenic mutations of the p53 tumor\nsuppressor: the demons of the guardian of the genome. Cancer Res. 60,\n6788–6793.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 369
        }
    },
    "1463": {
        "text": "6788–6793.\nSingh, A., and Settleman, J. (2010). EMT, cancer stem cells and drug resis-\ntance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751.\nSinha, S., and Levine, B. (2008). The autophagy effector Beclin 1: a novel BH3-\nonly protein. Oncogene 27 (Suppl 1), S137–S148.\nSmyth, M.J., Dunn, G.P., and Schreiber, R.D. (2006). Cancer immunosurveil-\nlance and immunoediting: the roles of immunity in suppressing tumor develop-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 370
        }
    },
    "1464": {
        "text": "ment and shaping tumor immunogenicity. Adv. Immunol. 90, 1–50.\nSoda, Y., Marumoto, T., Friedmann-Morvinski, D., Soda, M., Liu, F., Michiue,\nH., Pastorino, S., Yang, M., Hoffman, R.M., Kesari, S., and Verma, I.M. (2011).\nFeature Article: Transdifferentiation of glioblastoma cells into vascular endo-\nthelial cells. Proc. Natl. Acad. Sci. USA. Published online January 24, 2011.\nSudarsanam, S., and Johnson, D.E. (2010). Functional consequences of",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 371
        }
    },
    "1465": {
        "text": "mTOR inhibition. Curr. Opin. Drug Discov. Devel. 13, 31–40.\nStrauss, D.C., and Thomas, J.M. (2010). Transmission of donor melanoma by\norgan transplantation. Lancet Oncol. 11, 790–796.\nTalmadge, J.E., and Fidler, I.J. (2010). AACR centennial series: the biology of\ncancer metastasis: historical perspective. Cancer Res. 70, 5649–5669.\nTammela, T., and Alitalo, K. (2010). Lymphangiogenesis: Molecular mecha-\nnisms and future promise. Cell 140, 460–476.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 372
        }
    },
    "1466": {
        "text": "nisms and future promise. Cell 140, 460–476.\nTaube, J.H., Herschkowitz, J.I., Komurov, K., Zhou, A.Y., Gupta, S., Yang, J.,\nHartwell, K., Onder, T.T., Gupta, P.B., Evans, K.W., et al. (2010). Core epithe-\nlial-to-mesenchymal transition interactome gene-expression signature is\nassociated with claudin-low and metaplastic breast cancer subtypes. Proc.\nNatl. Acad. Sci. USA 107, 15449–15454.\nTeng, M.W.L., Swann, J.B., Koebel, C.M., Schreiber, R.D., and Smyth, M.J.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 373
        }
    },
    "1467": {
        "text": "(2008). Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc.\nBiol. 84, 988–993.\nThiery, J.P., and Sleeman, J.P. (2006). Complex networks orchestrate epithe-\nlial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131–142.\nThiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-\nmesenchymal transitions in development and disease. Cell 139, 871–890.\nTownson, J.L., and Chambers, A.F. (2006). Dormancy of solitary metastatic\ncells. Cell Cycle 5, 1744–1750.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 374
        }
    },
    "1468": {
        "text": "cells. Cell Cycle 5, 1744–1750.\nTurner, H.E., Harris, A.L., Melmed, S., and Wass, J.A. (2003). Angiogenesis in\nendocrine tumors. Endocr. Rev. 24, 600–632.\nVajdic, C.M., and van Leeuwen, M.T. (2009). Cancer incidence and risk factors\nafter solid organ transplantation. Int. J. Cancer 125, 1747–1754.\nCell 144, March 4, 2011 ª2011 Elsevier Inc.\n673\nVander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Under-\nstanding the Warburg effect: the metabolic requirements of cell proliferation.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 375
        }
    },
    "1469": {
        "text": "Science 324, 1029–1033.\nVerhoeff, J.J., van Tellingen, O.,Claes, A., Stalpers, L.J., vanLinde, M.E., Richel,\nD.J., Leenders, W.P., and van Furth, W.R. (2009). Concerns about anti-angio-\ngenic treatment in patients with glioblastoma multiforme. BMC Cancer 9, 444.\nWang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K.E., Geber, A.,\nFligelman, B., Leversha, M., Brennan, C., and Tabar, V. (2010). Glioblastoma\nstem-like cells give rise to tumour endothelium. Nature 468, 829–833.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 376
        }
    },
    "1470": {
        "text": "Warburg, O. (1956a). On the origin of cancer cells. Science 123, 309–314.\nWarburg, O. (1956b). On respiratory impairment in cancer cells. Science 124,\n269–270.\nWarburg, O.H. (1930). The Metabolism of Tumours: Investigations from the\nKaiser Wilhelm Institute for Biology, Berlin-Dahlem (London, UK: Arnold\nConstable).\nWertz, I.E., and Dixit, V.M. (2010). Regulation of death receptor signaling by the\nubiquitin system. Cell Death Differ. 17, 14–24.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 377
        }
    },
    "1471": {
        "text": "ubiquitin system. Cell Death Differ. 17, 14–24.\nWhite, E., Karp, C., Strohecker, A.M., Guo, Y., and Mathew, R. (2010). Role of\nautophagy in suppression of inﬂammation and cancer. Curr. Opin. Cell Biol.\n22, 212–217.\nWhite, E., and DiPaola, R.S. (2009). The double-edged sword of autophagy\nmodulation in cancer. Clin. Cancer Res. 15, 5308–5316.\nWillis, S.N., and Adams, J.M. (2005). Life in the balance: how BH3-only\nproteins induce apoptosis. Curr. Opin. Cell Biol. 17, 617–625.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 378
        }
    },
    "1472": {
        "text": "Witsch, E., Sela, M., and Yarden, Y. (2010). Roles for growth factors in cancer\nprogression. Physiology (Bethesda) 25, 85–101.\nWyckoff, J.B., Wang, Y., Lin, E.Y., Li, J.F., Goswami, S., Stanley, E.R., Segall,\nJ.E., Pollard, J.W., and Condeelis, J. (2007). Direct visualization of macro-\nphage-assisted tumor cell intravasation in mammary tumors. Cancer Res.\n67, 2649–2656.\nYachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hru-",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 379
        }
    },
    "1473": {
        "text": "ban, R.H., Eshleman, J.R., Nowak, M.A., et al. (2010). Distant metastasis\noccurs late during the genetic evolution of pancreatic cancer. Nature 467,\n1114–1117.\nYang, J., and Weinberg, R.A. (2008). Epithelial-mesenchymal transition: At the\ncrossroads of development and tumor metastasis. Dev. Cell 14, 818–829.\nYang, L., Pang, Y., and Moses, H.L. (2010). TGF-beta and immune cells: an\nimportant regulatory axis in the tumor microenvironment and progression.\nTrends Immunol. 31, 220–227.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 380
        }
    },
    "1474": {
        "text": "Trends Immunol. 31, 220–227.\nYen, K.E., Bittinger, M.A., Su, S.M., and Fantin, V.R. (2010). Cancer-associ-\nated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29,\n6409–6417.\nYilmaz, M., and Christofori, G. (2009). EMT, the cytoskeleton, and cancer cell\ninvasion. Cancer Metastasis Rev. 28, 15–33.\nYuan, T.L., and Cantley, L.C. (2008). PI3K pathway alterations in cancer: vari-\nations on a theme. Oncogene 27, 5497–5510.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 381
        }
    },
    "1475": {
        "text": "ations on a theme. Oncogene 27, 5497–5510.\nZee, Y.K., O’Connor, J.P., Parker, G.J., Jackson, A., Clamp, A.R., Taylor, M.B.,\nClarke, N.W., and Jayson, G.C. (2010). Imaging angiogenesis of genitourinary\ntumors. Nat. Rev. Urol. 7, 69–82.\nZhang, H., Herbert, B.S., Pan, K.H., Shay, J.W., and Cohen, S.N. (2004).\nDisparate effects of telomere attrition on gene expression during replicative\nsenescence of human mammary epithelial cells cultured under different condi-\ntions. Oncogene 23, 6193–6198.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 382
        }
    },
    "1476": {
        "text": "tions. Oncogene 23, 6193–6198.\nZong, W.X., and Thompson, C.B. (2006). Necrotic death as a cell fate. Genes\nDev. 20, 1–15.\nZumsteg, A., and Christofori, G. (2009). Corrupt policemen: inﬂammatory cells\npromote tumor angiogenesis. Curr. Opin. Oncol. 21, 60–70.\n674\nCell 144, March 4, 2011 ª2011 Elsevier Inc.",
        "metadata": {
            "source": "PIIS0092867411001279.pdf",
            "chunk_id": 383
        }
    },
    "1477": {
        "text": "Molecular Cell\nReview\nCancer Epigenetics: Tumor Heterogeneity,\nPlasticity of Stem-like States, and Drug Resistance\nHariharan Easwaran,1 Hsing-Chen Tsai,1 and Stephen B. Baylin1,*\n1The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore,\nMD 21287, USA\n*Correspondence: sbaylin@jhmi.edu\nhttp://dx.doi.org/10.1016/j.molcel.2014.05.015",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 0
        }
    },
    "1478": {
        "text": "http://dx.doi.org/10.1016/j.molcel.2014.05.015\nThe existence of subpopulations of cells in cancers with increased tumor-initiating capacities and self-\nrenewal potential, often termed ‘‘cancer stem cells,’’ is a much discussed and key area of cancer biology.\nSuch cellular heterogeneity is very important because of its impact on therapy and especially states of\ntreatment resistance. A major question is whether there is plasticity for evolution of these cell states during",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 1
        }
    },
    "1479": {
        "text": "tumorigenesis that can involve movement between cell populations in a reversible fashion. In this review, we\ndiscuss the possible role of epigenetic abnormalities as well as genetic alterations in such dynamics and in\nthe creation of cellular heterogeneity in cancers of all types.\nIntroduction\nCellular heterogeneity is a well-recognized attribute of both\nnormal and neoplastic tissues. The difference is that, in the\nformer, there is an ordered developmental program underlying",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 2
        }
    },
    "1480": {
        "text": "the heterogeneity. This order dictates that from a single genome,\nor the ‘‘hard drive’’ of DNA, without base sequence changes,\nmultiple cell types can be generated through the ‘‘software pack-\nages’’ of proper coordination of dynamic signal transduction\nand, subsequently, long-term maintenance of gene expression\npatterns through epigenetic mechanisms (Allis et al., 2008).\nThese control processes ensure proper balance between cells\ncapable of continued self-renewal or being maintained in stem-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 3
        }
    },
    "1481": {
        "text": "cell-like states and their generation of progeny cells committed\nto tissue lineages and differentiation. By contrast, disorder char-\nacterizes cancer cell populations. One driving factor for this is\nobviously genetic instability through which mutations alter\ngene function such that cells either do not exit self-renewal\nstates and/or commit properly to tissue lineage and differentia-\ntion (Stratton et al., 2009; Vogelstein et al., 2013). In this review,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 4
        }
    },
    "1482": {
        "text": "we visit the possibility that aberrations of epigenetic control may\nalso signiﬁcantly contribute to the disorder of cancer. If so, the\nconsequences are profound given that reversal of abnormalities\nfor therapy strategies is difﬁcult in terms of correcting mutations\nbut much more promising in terms of reversing epigenetic abnor-\nmalities. Also, and related to therapy strategies, the points we\nwill make are key because the dynamic variability or heterogene-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 5
        }
    },
    "1483": {
        "text": "ity of cell populations provides the driving force for tumors in\norder to utilize selection pressures to evolve. Although progres-\nsive mutations certainly do play a role in such evolution, we will\nemphasize that epigenetic changes are also key factors and\nmay be especially important to the emergence of and plasticity\nfor formation of the most tumor initiating cell subpopulations in\ncancer. Such cells may also be key for treatment resistance;",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 6
        }
    },
    "1484": {
        "text": "indeed, they may be the major factor in therapy failures that\nplague the management of the most common cancers and those\nwith the highest mortality statistics.\nInherent to the above concept of cancer cell heterogeneity\n(given that it contributes to tumor initiation and progression) is\nthe cancer stem cell (CSC) hypothesis. However one frames\nthis concept, most cancer biologists accept that, at any given\ntime in a cancer, there are populations of cells with cancer-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 7
        }
    },
    "1485": {
        "text": "cell-renewal and tumor-initiating properties (Beck and Blanpain,\n2013; Nguyen et al., 2012; Wang and Dick, 2008). Their fre-\nquency may differ from tumor to tumor, ranging from virtually\nall the cells to small populations. Also, arguments continue as\nto whether there is a hierarchical arrangement for such popula-\ntions versus their less tumorigenic counterparts or whether there\nis plasticity in which such stem-cell-like populations can always",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 8
        }
    },
    "1486": {
        "text": "be generated, especially under stress situations, from other cells\nin the population (Meacham and Morrison, 2013). Whatever the\nexact situation, in addressing the biology of the heterogeneity\nand evolution of CSC subpopulations, both genetic and epige-\nnetic dynamics must be considered. In this review, we discuss\nthe possibility that during cancer evolution and tumor initiation\nfrom cancer-risk states that predispose cells to undergo\ntransformation, such as inﬂammation a cellular plasticity may",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 9
        }
    },
    "1487": {
        "text": "exist allowing dynamic shifts of more and less virulent cells\ndiffering in their tumor initiation and therapeutic resistance capa-\nbilities. We will speciﬁcally address the potential importance of\nepigenetic abnormalities, which may underlie such plasticity in\ncell phenotypes and their link to processes by which, from can-\ncer-risk states through tumor progression, cells survive stress in\norder to create cancer cell populations. We will also consider",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 10
        }
    },
    "1488": {
        "text": "how the epigenetic molecular proﬁles of cancers may reﬂect\nthe cell subcompartments in normal cell renewal systems from\nwhich cancers arise and, in turn, how these issues frame the\nmolecular and cell phenotype subpopulations of self-renewing\ncells in tumors.\nClonal Evolution of Tumors and Evolution of Cell\nHeterogeneity\nFrom a histologic and cell population standpoint phenotypic het-\nerogeneity in tumor tissues has long been observed (Beck and",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 11
        }
    },
    "1489": {
        "text": "Blanpain, 2013; Nguyen et al., 2012; Wang and Dick, 2008).\nWhether this heterogeneity contributes to functional subpopula-\ntions, such as those with metastatic capabilities or stem-cell-like\n716\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\nproperties as discussed above, has been the subject of intense\nstudy. Despite the heterogeneity, most likely the diverse cancer\ncell subpopulations arise within the clone originally giving rise to",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 12
        }
    },
    "1490": {
        "text": "the cancer. However, it is increasingly being recognized at a\nmolecular level that clonal subpopulations evolve in tumors\nalong courses that may vary considerably by tumor type (Garr-\naway and Lander, 2013; Vogelstein et al., 2013; Yachida et al.,\n2010). Here, we describe the concepts of tumor cell heterogene-\nity in the context of genetic alterations and aim to distinguish\nthese from those because of epigenetic alterations.\nContribution to Tumor Heterogeneity From Mutations",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 13
        }
    },
    "1491": {
        "text": "Recent deep-sequencing exercises are providing invaluable in-\nsights into the evolutionary dynamics of cancer cell populations\nand contributions to drug resistance and tumor relapse. Impor-\ntantly, these studies have reinforced some early hypotheses\nabout the stem-cell origins in the natural history of cancers\n(Cairns, 1975) and the clonal evolution of cancers through\nDarwinian selection (Nowell, 1976). Thus, analysis of genome\ncopy number at the level of single-cell and genetic mutations",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 14
        }
    },
    "1492": {
        "text": "from different sites in a tumor and metastasis from the same pa-\ntient have revealed genetic heterogeneity within the same tumor\ntissue (Anderson et al., 2011; Navin et al., 2011; Gerlinger et al.,\n2012). Most recently, this phenomenon has been observed in\nsubpopulation differences between the primary tumor and\ndistant metastases (Gerlinger et al., 2012). These studies have\nrevealed that there may be transitions, arising either from subclo-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 15
        }
    },
    "1493": {
        "text": "nal evolution of heterogeneous cell populations present at the\nearliest points in tumor evolution or through the new appearance\nof such cells that manifest as a linear evolutionary process with\nbranching points (Gerlinger et al., 2012) (Figure 1). In this\nconcept, independent subclones arise in bursts of subclonal\nexpansion (Navin et al., 2011) that may well arise in response\nto pressures from Darwinian selection—including those imposed",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 16
        }
    },
    "1494": {
        "text": "on cancers from therapeutic intervention (Mullighan et al., 2008).\nA prime example from deep-sequencing studies is renal cancer\nin which the key early mutations in the VHL gene are constant\nfrom early time points on, whereas other mutations arise along\na branching pattern consistent with emerging subclones (Gerlin-\nger et al., 2012). From a therapy point of view, such spatial\ngenetic heterogeneity within the same tumor and metastases",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 17
        }
    },
    "1495": {
        "text": "translates into variegated diagnostic signatures that will have\nimportant implications for targeted therapeutic approaches\n(Anderson et al., 2011; Yang et al., 2012). However, to date,\nEpigenetic\nsubclone\nGenetic\nsubclone\nParental\nsubclone\nA Heterogenous Tumor\nAcquired mutation\nFounder mutation(s)\nEpigenetic states that regulate functional properties of tumor subclones,\nincluding self-renewing capacity, drug tolerance, metastatic potential, etc.\nAging\nROS\nInflammation\nEpigenetic \nsubclone",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 18
        }
    },
    "1496": {
        "text": "Aging\nROS\nInflammation\nEpigenetic \nsubclone\nGenetic/epigenetic \nsubclone\nFounder \ntumor cell\nNormal\ncell\nGenetic and epigenetic\ninstability\nAcquired mutation in epigenetc modifying proteins\nChromatin\nchanges\nMethylation\nchanges\nFigure 1. Genetic and Epigenetic Contributions to Tumor Heterogeneity\nDuring oncogenesis, environmental stress such as chronic inﬂammation, accumulating reactive oxygen species (ROS), or aging may promote clonal expansion of",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 19
        }
    },
    "1497": {
        "text": "cells with genetic or epigenetic abnormalities. These cells then acquire further mutations or epigenetic alterations and become founder tumor cells that initiate\nprecancer or cancer. The evolution of tumor clones continues as tumors develop. In an established tumor, the parental subclone may acquire new driver or\npassenger mutations (genetic subclone), or undergo epigenetic alterations on the levels of chromatin or DNA methylation, or both (epigenetic subclones). Some",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 20
        }
    },
    "1498": {
        "text": "subclones may acquire mutations in epigenetic modifying proteins resulting in emergence of epigenetic changes (genetic/epigenetic subclones). Either genetic or\nepigenetic subclones can exhibit different functional attributes from the parental clone in terms of self-renewing capacity, drug tolerance, or metastatic potential.\nThus, both genetic and epigenetic mechanisms contribute to the intratumoral heterogeneity.\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\n717\nMolecular Cell\nReview",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 21
        }
    },
    "1499": {
        "text": "717\nMolecular Cell\nReview\nmost therapeutically targeted mutations are those that are domi-\nnant in the tumor, most likely to have occurred in the founder\nclone. Certainly, new mutations in the targeted gene do evolve\nwith therapy resistance (Sierra et al., 2010), and recent studies\nindicate that these may have been present in tumor subclones\nwhen therapy was initiated (Turke et al., 2010).\nIn the context of tumor ‘‘stem cell’’ populations, a widely held",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 22
        }
    },
    "1500": {
        "text": "model for the evolution of cancer is that initial oncogenic muta-\ntions result in transformation of a tissue stem or progenitor cell\n(Greaves and Maley, 2012). This cell then acquires the aberrant\nproperty of unrestricted growth, giving rise to patches of genet-\nically altered cells in the normal tissue or organ that becomes the\nsubstrate for tumor progression via selection due to genetic vari-\nation (Braakhuis et al., 2003). Certainly, the driver mutations such",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 23
        }
    },
    "1501": {
        "text": "as those for K-RAS in multiple tumor types, APC in colorectal\ncancer, and VHL in renal cancers likely are central forces that\ninduce appearance of cells with tumor initiating and self-renewal\nproperties. We will discuss later the concepts of shifts in self-\nrenewing cell subpopulations in cancers that may appear with\ntime in response to various survival pressures and the plasticity\nof the cell populations involved.\nContribution to Tumor Heterogeneity from Epigenetic\nAlterations",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 24
        }
    },
    "1502": {
        "text": "Alterations\nBrief Overview of the Concept of Epigenetics\nBefore considering evidence for the role of epigenetics, it is\nimportant to strictly deﬁne this term versus other nongenetic pro-\ncesses, such as signal transduction, which serve to change and\nmaintain cell phenotypes (Ptashne, 2007). The original deﬁnition\nof the term, coined by Waddington (2012), referred to stable\nchanges in cell phenotype on the basis of other than genetic\nchanges. Today’s deﬁnition encompasses the concept that",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 25
        }
    },
    "1503": {
        "text": "epigenetic control means a stable, or heritable, change in gene\nexpression without any changes in DNA sequence (Bird, 2007).\nCertainly the consequences of the gene expression changes\nare what contribute to the phenotype. Strictly speaking, an\nepigenetic event implies that the constituent molecular determi-\nnants should be heritable through every round of cell replication,\nthereby acting to maintain a stable pattern of gene expression\nsubserving a given cell state. This pattern can be preserved",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 26
        }
    },
    "1504": {
        "text": "even if the original transcription stimuli for the initiation of\ninvolved gene states are no longer present. The most agreed\nupon parameter which strictly ﬁts this deﬁnition is DNA methyl-\nation, which is the covalent modiﬁcation of DNA by a methyl\ngroup, occurring in humans at predominantly cytosines in a\nCpG context (Bestor, 1990). During cell division, DNA methyl-\nation is maintained on the parent DNA strand and copied on\nthe daughter strand. The patterns of DNA methylation at any",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 27
        }
    },
    "1505": {
        "text": "point in time can help maintain transcriptional activities of the\ngenome, both for canonical genes and noncoding RNAs, and\npotentially in enhancer regions, generally serving as a compo-\nnent of transcription repression (Baylin and Jones, 2011; Bern-\nstein et al., 2012). However, when present in the body of genes,\nthe relationship can be the inverse wherein gene expression may\nbe enhanced in the presence of DNA methylation, which may\nfacilitate transcriptional elongation (Shenker and Flanagan,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 28
        }
    },
    "1506": {
        "text": "2012) or alternate promoter usage (Maunakea et al., 2010).\nDNA methylation cannot modulate transcription alone but must\nwork in association with repressive chromatin modiﬁcations\n(Allis et al., 2008; Baylin and Jones, 2011). It is less well proven\nwhether these histone marks remain associated with DNA during\nreplication. However, in a holistic sense if they are re-established\nheritably after DNA replication, they serve to maintain the stable",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 29
        }
    },
    "1507": {
        "text": "patterns of transcription for maintenance of cell phenotypes and\nthus are essential to epigenetic control of the genome. Thus,\nhistone modiﬁcations, in addition to DNA methylation, are vital\nto control of normal cellular states, and vis a vis the focus of\nthis review, cancer cell populations.\nKey to each of the above processes is their interaction\nwith how nucleosomes are positioned linearly, and three-\ndimensionally, in the context of DNA, thus providing the ‘‘pack-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 30
        }
    },
    "1508": {
        "text": "aging’’ component of epigenetics (Korber and Becker, 2010).\nThe critical end result of this positioning, in association with\nDNA methylation and chromatin modiﬁcations, is the establish-\nment in normal cells of proper boundaries, which separate\nthe tightly packaged and repressive nucleosome domains from\nthe more spaced and loosely conﬁgured nucleosome arrange-\nments. The latter facilitate active or permissive transcriptional\nstates (Fan et al., 2005; Thurman et al., 2007). Early in tumor pro-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 31
        }
    },
    "1509": {
        "text": "gression, there is increasing evidence that these boundaries\nbreak down (Baylin and Jones, 2011; Hansen et al., 2011; Ber-\nman et al., 2012). The result is alteration of structural control of\nDNA replication and a cancer ‘‘epigenome’’ in which hundreds\nof coding and non-coding regions have altered transcription\nstates. For the most studied abnormalities, those of DNA methyl-\nation, both widespread losses and more focal gains often occur",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 32
        }
    },
    "1510": {
        "text": "simultaneously within deﬁned megabase regions (Berman et al.,\n2012; Hon et al., 2012). The gains are often cancer-speciﬁc and\ninvolve normally non-DNA-methylated CpG islands located in\nproximal promoter regions of hundreds of genes (Baylin and\nJones, 2011; Berman et al., 2012). This change can be associ-\nated with loss of gene expression, which can serve as an alterna-\ntive to mutations for abolition of tumor suppressor gene function\nthrough associated gene silencing. In addition to DNA methyl-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 33
        }
    },
    "1511": {
        "text": "ation abnormalities, chromatin changes, such as those driven\nby overactivity of the long term gene silencing protein complex,\npolycomb group proteins (PcG), are frequently observed in\nmultiple tumor types (You and Jones, 2012).\nEpigenetic Alterations in Tumor Progression\nPrimal to understanding the contribution of epigenetic changes\nin tumor progression is the key issue of how epigenetic changes\ntrack with the different progression stages of cancers. Although",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 34
        }
    },
    "1512": {
        "text": "such studies are far fewer than those for mutations, it is very clear\nthat abnormalities of DNA methylation occur quite early during\ntumorigenesis frequently manifesting in premalignant cells\n(Suzuki et al., 2004; Esteller et al., 2000; Greenspan et al.,\n2006; Licchesi et al., 2008) and in the context of ﬁeld canceriza-\ntion (Shen et al., 2005; Mehrotra et al., 2008; Nonn et al., 2009;\nBaylin and Jones, 2011; Ushijima, 2007) (Figure 1). These alter-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 35
        }
    },
    "1513": {
        "text": "ations include the above discussed widespread losses and pro-\nmoter-focal gains of DNA methylation. These focal gains can\ninvolve\nwell-identiﬁed\ntumor\nsuppressor\ngenes\nsuch\nas\nCDKN2A, which displays increasing frequency of methylation\nduring progression from lung airway basal cell hyperplasia\n(17%) to squamous metaplasia (24%) to carcinoma in situ\n(50%) (Belinsky et al., 1998). Anti-Wnt activity genes become\n718\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\nMolecular Cell\nReview",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 36
        }
    },
    "1514": {
        "text": "Molecular Cell\nReview\nsilenced and hypermethylated in early colon neoplasia and evi-\ndence indicates they may fundamentally complement key WNT\npathway mutations, such as for the APC gene, for colon tumor\ninitiation and/or early progression (Suzuki et al., 2004). With\nrespect to these above early changes, it is important to note\nthat many of the same parameters linked to occurrence of ge-\nnetic changes are now being linked to causation of epigenetic",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 37
        }
    },
    "1515": {
        "text": "aberrancies. Thus, aging (Ahuja et al., 1998; Maegawa et al.,\n2014), chronic inﬂammation (Niwa and Ushijima, 2010), and envi-\nronmental exposures (Liu et al., 2010) are now well-juxtaposed\nfactors that alter the epigenome. Examples include a rat model\nof lung carcinogenesis in which a tobacco-speciﬁc carcinogen\n(4-methylnitrosamino-1-(3-pyridyl)-1-butanone) causes frequent\nhypermethylation of CDKN2A promoter in the early lesions\n(hyperplastic lesions and adenomas), and this change is then",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 38
        }
    },
    "1516": {
        "text": "observed at a very high frequency (>90%) in the adenocarci-\nnomas that later emerge (Belinsky et al., 1998). Furthermore,\nCDKN2A promoter methylation is observed in rat lung tumors\ninduced by exposure to various mutagenic agents (X-rays, pluto-\nnium-239 oxide, beryllium metal, and cigarette smoke), indi-\ncating that the methylation induction can occur in response to\ndifferent types of environmental insults. Epigenetic changes\nhave been observed in various models of inﬂammation in mice",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 39
        }
    },
    "1517": {
        "text": "(Ushijima, 2007; Hahn et al., 2008), cigarette smoke exposure\n(Liu et al., 2010), and other environmental carcinogens (such\nas cobalt) (Li et al., 2009). Aging is a leading scenario linked to\nincreasing frequency of promoter CpG island DNA hypermethy-\nlation of many genes, best outlined to date for normal colon over\na time span that well tracks with risk for colon carcinoma (Ahuja\net al., 1998; Toyota et al., 1999). For chronic inﬂammatory",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 40
        }
    },
    "1518": {
        "text": "changes, not only have the occurrences of DNA methylation\nabnormalities been chronicled but also the molecular parame-\nters linked to boundary shifts which could trigger simultaneous\nlosses and gains of DNA methylation are beginning to be deci-\nphered, as will be revisited below (O’Hagan et al., 2011). As for\ngenetic changes, epigenetic alterations are now being mecha-\nnistically associated with various types of DNA damage ongoing\nin chronic inﬂammatory environments (Tili et al., 2011).",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 41
        }
    },
    "1519": {
        "text": "One of the most exciting developments in recent years has\nbeen the tying of epigenetic changes to genetic alterations in\nvirtually all tumor types. Thus, very frequent mutations in the\ngenes that encode for chromatin, nucleosome remodeling, and\nDNA methylation modifying proteins have been observed\n(Shen and Laird, 2013; You and Jones, 2012). Because the\nprecise ramiﬁcations of most of these mutations have yet to be\ndelineated, we will outline below their potential implications for",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 42
        }
    },
    "1520": {
        "text": "understanding initiation and maintenance of stem-cell-like\nsubpopulations in speciﬁc cancer types.\nEpigenetic Regulation of Cancer Stem-like Cell\nSubpopulations\nBeyond the fact that epigenetic abnormalities are prevalent in\nearly tumorigenesis, much less is known about epigenetic\nchanges in terms of how the cancer epigenome evolves with\nand contributes functionally to the heterogeneity of tumor-cell\npopulations within the original tumor clone. As mentioned in",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 43
        }
    },
    "1521": {
        "text": "the case of renal cancer, genetic changes can be mapped along\na branching evolutionary tree during tumor progression (Gerlin-\nger et al., 2012). Such patterns are not well-delineated for epige-\nnetic alterations. However, a concept that is now emerging is\nthat, from very early tumorigenesis steps on, at least as moni-\ntored by DNA methylation, the epigenome is in a state of chaotic\nshifting (Hansen et al., 2011). In this scenario, the widespread",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 44
        }
    },
    "1522": {
        "text": "losses seem quite random and nonclonal, whereas the focal\ngains in promoter regions are far more clonal (Aryee et al.,\n2013). This is consistent with earlier studies of individual genes\nin tumors wherein the focal promoter gains were constant be-\ntween more putative stem-cell populations and their progeny\n(Yi et al., 2008). This conservation of epigenetic changes indi-\ncates that the aberrant hypermethylation that occurs early on\nis maintained and that at least some of the changes potentially",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 45
        }
    },
    "1523": {
        "text": "arise as a result of selection during subsequent steps of evolu-\ntion. Deﬁning which genes function as driver versus passenger\nevents for such selection is currently a major question in cancer\nepigenetics research. In this regard, a recent study indicated\nthat, in a colon cancer cell line with engineered deletion of two\nmajor DNA methyltransferases (DNMTs) and 95% or more loss\nof DNA methylation, a group of genes still retain promoter hyper-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 46
        }
    },
    "1524": {
        "text": "methylation and that their loss of function may be essential for\nsurvival of the cells (De Carvalho et al., 2012).\nHow, in the above dynamics, do epigenetic abnormalities\ncontribute to key cell subpopulations in cancers and particularly\nthose with stem-like function? A key to their potential importance\ncomes from the nature of genes with focal gains in promoter CpG\nislands and associated transcriptional silencing. Several groups,\nincluding ours, have documented that a large proportion of",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 47
        }
    },
    "1525": {
        "text": "genes with this cancer speciﬁc change are those with a history\nof a speciﬁc pattern of chromatin regulation in embryonic stem\ncells (Schlesinger et al., 2007; Widschwendter et al., 2007;\nOhm et al., 2007) and that we have also traced back to adult\nstem cells (Easwaran et al., 2012). This chromatin, termed ‘‘biva-\nlent chromatin’’ (Azuara et al., 2006; Bernstein et al., 2006),\nis\ndeﬁned\nby\nsimultaneous\npresence\nof\nthe\nrepressive\n(H3K27me3) and active (H3K4me3) histone marks and normally",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 48
        }
    },
    "1526": {
        "text": "involves genes with non-DNA-methylated promoter CpG islands\nin embryonic and adult stem cells. These genes, when in a biva-\nlent state, often have a low, poised level of transcription and\ngenerally switch to either an active state with predominantly\npromoter H3K4me3 or a repressed stat with predominantly\nH3K27me3 during differentiation (Bernstein et al., 2006). The\nmajority of promoter DNA hypermethylated genes in cancer\ncome from this pool, and many of these control the balance",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 49
        }
    },
    "1527": {
        "text": "between maintaining self-renewal and commitment to differenti-\nation in embryogenesis (Easwaran et al., 2012).\nAlthough the existence of the bivalent state is now well estab-\nlished in terms of a promoter zone in which both the H3K27me3\nand H3K4me3 marks exist surrounding transcription start site,\nsome changes concerning the concept are emerging. First, the\nterm bivalency refers to a zonal distribution of the marks, and\nonly recently has it established that there are individual nucleo-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 50
        }
    },
    "1528": {
        "text": "somes that can carry both marks (Voigt et al., 2012). Second,\nthere are suggestions that bivalency emerges to follow states\nof transcription rather than setting them. In this view, the degree\nof the H3K27me3 occupancy builds by default when transcrip-\ntion is low (Di Croce and Helin, 2013). Thus, the initially proposed\nrole for bivalent chromatin in maintaining developmental genes\nin a poised state for later activation or suppression might be an",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 51
        }
    },
    "1529": {
        "text": "Molecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\n719\nMolecular Cell\nReview\noversimpliﬁed scenario. However, there is still no doubt that\nmany genes marked by bivalent promoters do reside in relatively\nlow expression states, and these genes undergo activation or\nsilencing during differentiation in association with conversion\nto H3K4me3 or H3K27me3 marks. Then, it follows that the tran-\nscriptionally ‘‘off’’ state mediated by H3K27me3 can be modiﬁed",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 52
        }
    },
    "1530": {
        "text": "by signal transduction for a range of generally low level transcrip-\ntion, which is reﬂected by varying simultaneous levels of the\nactive H3K4me3 mark (De Gobbi et al., 2011). Such a model is\nconsistent with studies showing that bivalent promoters mostly\nhave paused RNA Pol II (Brookes et al., 2012; Min et al., 2011).\nIn such a state, these genes may be primed to be activated or\nsilenced in response to the right environmental cue and",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 53
        }
    },
    "1531": {
        "text": "presence of transcription factors. Importantly, when DNA hyper-\nmethylated in cancer, these genes with potential roles in\ndifferentiation are less responsive to such cues and are fully sup-\npressed because of a lack of, or markedly reduced level of,\nH3K4me3 and H3K27me3 (Easwaran et al., 2012) (Figure 2).\nWe suggest that, in cancer, for gene promoters where DNA\nmethylation replaces zones of bivalent marking, abnormal\nsilencing for individuals or groups of such genes may help select",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 54
        }
    },
    "1532": {
        "text": "events in initiation and/or progression of the cancer. We have\nhypothesized that their silencing, perhaps for different groups\nin different tumor types, can contribute mechanisms for how\ncancer cell subpopulations are held in an abnormal state of\nself-renewal potential at the expense of proper capacity to\nrespond to lineage commitment and differentiation cues (Eas-\nwaran et al., 2012). This state is a fundamental defect of cancer\ncells and particularly those termed cancer ‘‘stem cells.’’ Recent",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 55
        }
    },
    "1533": {
        "text": "studies illustrate how epigenetic abnormalities may drive these\ncell properties and serves as another illustration of how they\ncan collaborate with genetic changes. Mutations in the isocitric\ndehydrogenase genes (IDH) have been linked to the genes that\nare bivalent in embryonic stem cells and DNA hypermethylated\nin subsets of glioblastomas (GBMs) (Noushmehr et al., 2010;\nParsons et al., 2008), chondrosarcomas (Amary et al., 2011),\nand acute myelogenous leukemias (AMLs) (Figueroa et al.,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 56
        }
    },
    "1534": {
        "text": "2010). The molecular underpinning appears to be a combi-\nnation of abnormal depletion of the Krebs cycle constituent\na-keto-glutarate at the expense of marked increases in D-2-\nhydroxyglutarate (D-2-HG), which has been termed an ‘‘onco-\nmetabolite’’ (Dang et al., 2009). This oncometabolite inhibits\nvarious\nFe(II)/2-oxoglutarate-dependent\ndioxygenases\n(Xu\net al., 2011), including various histone demethylases that protect\nNormal\nTumor\nBivalent domain\nH3K27me3\nH3K4me3\nGene 2\nGene 1\nGene 1\nGene 2",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 57
        }
    },
    "1535": {
        "text": "H3K27me3\nH3K4me3\nGene 2\nGene 1\nGene 1\nGene 2\nTranscriptional\nregulators\npoised\npoised\nActive\nRepressed\nTranscriptional\nregulators\nBivalent domain\nH3K27me3\nH3K4me3\nGene 2\nGene 1\nGene 1\nGene 2\nTranscriptional\nregulators\npoised\npoised\nActive\nRepressed\nTranscriptional\nregulators\nGene 2\nMethylated\nGene 3\npoised\nGene 3\nMethylated\nFigure 2. Epigenetic Plasticity in Normal and Cancer Cells",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 58
        }
    },
    "1536": {
        "text": "In normal embryonic and adult stem cell states, many developmental genes maintain both active (H3K4me3) and repressed (H3K27me3) marks, or bivalent\nchromatin, at their promoter regions. This state helps maintain genes in poised states for transcription. During normal differentiation, bivalent domains will resolve\ninto either active marks (H3K4me3), attendant to active transcription of certain differentiation-related genes, or repressive marks (H3K27me3), which accompany",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 59
        }
    },
    "1537": {
        "text": "silencing of stem cell-related genes. Under certain circumstances, the resolution of bivalent domains can be reversed and cells may undergo dedifferentiation.\nAlso, bivalency of genes may arise in cell populations distal to stem cell states. In a cancer cell, these chromatin shifts may be vital to cellular plasticity. Some of\nthe bivalent genes may assume cancer-speciﬁc promoter DNA hypermethylation and thus be locked in a more permanent silenced state.\n720",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 60
        }
    },
    "1538": {
        "text": "720\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\nMolecular Cell\nReview\nagainst DNA methylation by diminishing chromatin marks that\nattract DNA methylation, and the TET family of enzymes that\ncatalyze DNA demethylation by converting 5-methylcytosine\n(5mC) into 5-hydroxymethylcytosine (5hmC). Mice with genetic\nknockin of IDH mutations have abnormally increased numbers\nof early hematopoietic progenitors and blockage of lineage",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 61
        }
    },
    "1539": {
        "text": "commitment (Cairns and Mak, 2013; Sasaki et al., 2012). A similar\nphenotype has been seen for engineered mouse cells (Lu et al.,\n2013) and patient-derived glioma xenografts with an IDH1 muta-\ntion (Borodovsky et al., 2013; Turcan et al., 2013). Critically, the\nbuildup of abnormal DNA methylation in the genes under discus-\nsion has been seen in each of the above scenarios, and treatment\nof cells with DNA demethylating agents can restore cell ability for",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 62
        }
    },
    "1540": {
        "text": "induction of differentiation (Borodovsky et al., 2013; Turcan et al.,\n2013). A challenge in all of this work is to directly identify whether,\nand which, genes that are bivalently marked in embryonic and\nadult stem cells may be responsible for abnormal retention of\nthe cancer stem-cell-like properties.\nThere is also growing evidence that CSCs can harbor key\nepigenetic states deﬁned not just by DNA methylation alterations\nbut also solely the histone modiﬁcations discussed above. For",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 63
        }
    },
    "1541": {
        "text": "example, in AML, the AML-CSCs and non-CSCs differ in their\nhistone modiﬁcation patterns (H3K4me3 and H3K27me3) but\nnot DNA methylation patterns (Yamazaki et al., 2013). In\nGBMs, the GBM-CSCs have aberrant activation of multiple\ntranscription factors because of a loss of the polycomb mark\nH3K27me3 from their promoters (Rheinbay et al., 2013).\nAberrant expression of one of these transcription factors\n(ASCL1) causes Wnt activation, which is required for mainte-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 64
        }
    },
    "1542": {
        "text": "nance of the CSC state and its tumorigenecity. A dramatic\ninstance of such loss of H3K27me3, and an example of inter-\nactions between genetics and epigenetics, occurs in a type of\npediatric brain tumor. Although these tumors harbor a mutation\nin the K27 residue of histone H3 in only one of multiple alleles\nencoding this histone (Shen and Laird, 2013), this change\nappears to act as a dominant-negative effect inhibiting all\nEZH2 activity resulting in loss of H3K27me3 (Lewis et al.,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 65
        }
    },
    "1543": {
        "text": "2013). In turn, this probably results in abnormal target gene acti-\nvation, which might initiate and drive these tumors.\nEpigenetic Regulation of Cancer Cell Plasticity\nOur understanding of the clonal evolution of epigenetic alter-\nations regulating gene expression is very limited. The median fre-\nquency of methylated gene promoters per tumor is in the range\nof 250–800, depending on the tumor type, which is far higher in\ncomparison to the frequency of nonsynonymous gene mutations",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 66
        }
    },
    "1544": {
        "text": "per tumor, which is maximally in the range of 150–170 (Vogel-\nstein et al., 2013). Furthermore, in comparison to the sponta-\nneous mutation rate in normal and cancer cells, which is about\n10\u000110 mutations per nucleotide base pair per division (Jones\net al., 2008), the error rate for gaining or losing methylation is\nfar higher, estimated at 2 3 10\u00015 per CpG site per division\n(Yatabe et al., 2001). Therefore, despite the fact that focal pro-\nmoter DNA hypermethylation is consistent between primary",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 67
        }
    },
    "1545": {
        "text": "tumors and their metastatic counterparts (Aryee et al., 2013),\nthe high error rate for replicating DNA methylation may indicate\nfar more epigenetic than genetic variability occurs as tumors\nevolve. The precise ramiﬁcations of this epigenetic variability\nremain to be fully resolved. However, epigenetic changes and\nespecially DNA methylation are heritable and can directly inﬂu-\nence gene function when strategically located. Therefore, they",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 68
        }
    },
    "1546": {
        "text": "may contribute to clonal selection and thus be a factor in creating\ntumor cell heterogeneity.\nThus, epigenetic alterations arising stochastically or as part of\nan aberrant transcriptional program can potentially impart selec-\ntive advantage just like genetic aberrations, such as inducing\nsilencing of key tumor-suppressor genes or inducing dysfunc-\ntion in DNA repair genes. Such epigenetic variation might be\none of the changes contributing to a cellular plasticity for forma-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 69
        }
    },
    "1547": {
        "text": "tion of tumor initiating subpopulations during tumor evolution.\nThis would be a factor in countering the strictly hierarchical\ntheory for existence of CSCs as a stable population, with unre-\nstricted tumor initiating potential that always give rise to progeny\ncells lacking or reduced for the tumor-initiating property\n(Greaves and Maley, 2012; Gupta et al., 2011). By either theory\nor combinations thereof, tumors will be inherently heteroge-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 70
        }
    },
    "1548": {
        "text": "neous in their cell populations on the basis of their epigenetic\nmakeup.\nAs mentioned, the question regarding a strict hierarchical\nmodel of tumors versus the plasticity model is still debated.\nHowever, evidence for tumor-cell populations that can reversibly\nshift between functional states, including between stem-like and\nmore committed cells, and a role in epigenetic shifts, is\nemerging. A key example is the concept that epithelial to mesen-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 71
        }
    },
    "1549": {
        "text": "chymal transition (EMT) in cancer occurs along a spectrum found\nfor normal cell transitions that are active from model organisms\nto man and which allow the proper control of organogenesis\n(Tam and Weinberg, 2013; Thiery et al., 2009). In the concept\nof EMT, the mesenchymal cells are more stem like and have\nproperties allowing for continued self-renewal, which preserves\nstem-like populations in renewing systems, including for migra-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 72
        }
    },
    "1550": {
        "text": "tory capabilities. These activities are fundamental for tissue for-\nmation during development and also in adult cell renewal.\nInherent to this process, both in normal settings and cancer, is\nthat with various cues cells can bidirectionally slide along this\nspectrum going from mesenchymal to epithelial characteristics\nand reverse this course as situations warrant (Figure 3). This\nhas been experimentally seen for both normal and cancer-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 73
        }
    },
    "1551": {
        "text": "related mammary epithelial renewal. Although transitions occur\neven in normal cells, such switching occurs more efﬁciently in\ntransformed cells (Chaffer et al., 2011). Thus, for breast cancer,\nthe data indicate that more stem-like or mesenchymal pheno-\ntype cells can appear, and shift, at any time during tumor evolu-\ntion leading to mixed cell populations in tumors with respect to\nmore epithelial cell properties. (Chaffer et al., 2011; Marjanovic\net al., 2013)",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 74
        }
    },
    "1552": {
        "text": "et al., 2013)\nHow do epigenetic properties speciﬁcally enter the picture for\ncontrolling EMT plasticity? It is postulated that for EMT states at\nany given point in time, chromatin regulation of key transcription\nfactors and their downstream targets is critical (Chaffer et al.,\n2011; Marjanovic et al., 2013). In this regulation, WNT activation,\nTGF-b activation, and regulation of E-cadherin are all key\npathway controls. For the chromatin regulation, gene silencing",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 75
        }
    },
    "1553": {
        "text": "may be particularly important as controlled by the PcG proteins\nand the attendant H3K27me3 mark and particularly in the setting\nof promoter bivalency (Chaffer et al., 2011; Marjanovic et al.,\n2013). Thus, especially for the mesenchymal or stem-like cells,\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\n721\nMolecular Cell\nReview\nsuch bivalency may hold genes like E-cadherin in a poised state\nthat would otherwise allow epithelial characteristics to accrue if",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 76
        }
    },
    "1554": {
        "text": "activated and suppress factors that allow WNT or TGF-b activa-\ntion. In contrast, and key for the concept of plasticity, some\ngenes may similarly be held in bivalent states in more epithelial\ncells, which, if more active, might otherwise trigger EMT.\nOverall, we hypothesize that a molecular progression along the\ntypes of chromatin regulation discussed above and inherent to\nthe earlier outlined relationships between bivalent chromatin",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 77
        }
    },
    "1555": {
        "text": "and abnormal promoter DNA methylation is key for cellular plas-\nticity existing in cancers (Figures 2 and 3). Furthermore, our own\nstudies indicate that cellular stresses affecting early events in tu-\nmor progression, probably during premalignant stages, are key to\ninitiating progressive chromatin alterations in cancer. These\nepigenetic changes may allow survival of cell clones associated\nwith increased cancer risk states, such as those induced by",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 78
        }
    },
    "1556": {
        "text": "chronic inﬂammation (O’Hagan et al., 2011). In these dynamics,\nprotein complexes with interaction between PcG proteins and\nDNMTs can rapidly move into promoter, CpG islands and asso-\nciate withtranscriptional silencing of theinvolvedgenes(O’Hagan\net al., 2011). These shifts normally are probably transient events\nthat serve to protect these promoter regions from errors of DNA\ndamage repair that might accrue if transcription were not halted.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 79
        }
    },
    "1557": {
        "text": "However, during continued environmental insults, such as in\nchronic inﬂammation, low gene transcription associated with\nchromatin states such as bivalency and/or typical of PcG marked\ngenes might render associated promoters vulnerable to retention\nof the above protein complexes and induce onset of time-depen-\ndent accrual of abnormal DNA methylation (O’Hagan et al., 2011).\nIndeed, initiation of such methylation in a time frame as short as\n30 min can be observed after exposure of cells to H2O2",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 80
        }
    },
    "1558": {
        "text": "(O’Hagan et al., 2011). The deeper silencing of stem-cell-related\ngenes with this abnormal DNA methylation and/or transcription-\nFigure 3. Cancer May Derive from Different\nCompartments during Normal Cell\nDifferentiation and Have Plasticity for\nMovement of Cell Subtypes\nDuring normal cell differentiation, self-renewing\ntissue stem cells undergo a series of chromatin\nstate transitions and give rise to progenitor and\ndifferentiated cells. Cellular transformation may",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 81
        }
    },
    "1559": {
        "text": "differentiated cells. Cellular transformation may\ntake place at different stages during normal dif-\nferentiation and give rise to malignant cells that\ncarry similar but abnormal chromatin states rela-\ntive to their normal counterparts. Notably, tumor\ncells may exhibit a cellular plasticity through which\nthey\ncan\nswitch\nbetween\nmore\nstem\ncell-\nlike states and more differentiated cell states\nthrough mesenchymal-epithelial transition (MET)\nor epithelial-mesenchymal transition (EMT).",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 82
        }
    },
    "1560": {
        "text": "or epithelial-mesenchymal transition (EMT).\nally repressive chromatin could reduce\nthe plasticity of cell population changes\nand help lock in cell clones with abnormal\nretention of self-renewal capacity at the\nexpense of capacity for differentiation\n(Easwaran et al., 2012). These types of\nchromatin\nalterations\ncould\nalso\ncontribute to emergence of subclones in\ntumors for phenotypic heterogeneity with\nrespect to plasticity for evolution and/or reversibility of tumor",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 83
        }
    },
    "1561": {
        "text": "initiating and self-renewal properties (Figure 2). Subclones with\nthe least plasticity for reversion of stem-like properties could\ncome to dominate the cell populations of a cancer at any given\npoint in time of tumor progression.\nIn the above hypotheses, altered chromatin patterns during\ncancer development would be a factor for evolution of cellular\nheterogeneity by helping to lock in tumor phenotypes, which\nmay reﬂect the cell compartments from which the tumors arise",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 84
        }
    },
    "1562": {
        "text": "(Figure 3). The type of chromatin abnormalities would, in turn,\nalso reﬂect such timing and be dependent upon the degree of\nmolecular progression from the more plastic expression states\nof bivalency or PcG control to the tightest form of abnormal\ngene silencing associated with promoter CpG island DNA hyper-\nmethylation. Perhaps these proposed dynamics may have roots\nin relationships between given cancers and the normal stem cell\ncompartments in which they arise. Such relationships could be",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 85
        }
    },
    "1563": {
        "text": "determinants of which genes, relative to their initial chromatin\npatterns during cell stresses in cancer risk states, undergo\nepigenetic abnormalities such as abnormal promoter DNA\nmethylation (Easwaran et al., 2012). Breast cancers may be a\nkey example of these possibilities. Multiple groups (Fang et al.,\n2011), including ours (Easwaran et al., 2012), have reported\nthat the more differentiated luminal phenotype breast cancers\nwith epithelial features have far more genes with promoter",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 86
        }
    },
    "1564": {
        "text": "CpG island DNA hypermethylation than the basal or triple-nega-\ntive tumors, which are more stem-like with mesenchymal pheno-\ntype. These latter, proposed to derive from a more primitive, and/\nor less committed normal breast epithelial compartment (Lo and\nSukumar, 2008), might arise faster with cell phenotypes more\ndependent on retention of PcG driven chromatin control than\nits conversion to DNA methylation. In contrast, development of",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 87
        }
    },
    "1565": {
        "text": "luminal phenotype tumors may evolve over a longer time course\n722\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\nMolecular Cell\nReview\nwith more chromatin evolution from bivalency/PcG control to\npromoter DNA methylation. The latter change may reﬂect and/\nor help lock in subpopulations of self-renewing cells reﬂective\nof the origin of luminal tumors in more committed stem/progen-\nitor cell compartments in normal breast epithelium. Plasticity of",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 88
        }
    },
    "1566": {
        "text": "the resultant populations for self-renewing properties may still\nbe present, but the EMT phenotypes involved might be of the\nmore mixed EMT-epithelial types proposed recently in the range\nof breast cancer cell phenotypes (Tam and Weinberg, 2013).\nThe high frequency of DNA methylation patterns in luminal\nbreast cancer, termed CpG island hypermethylation phenotype\n(CIMP), and differences from basal and triple-negative tumors,\nhas great relevance for other cancer types as well. Classic",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 89
        }
    },
    "1567": {
        "text": "CIMP has been deﬁned in colorectal cancer and again is a pattern\nseparating one group of tumors arising in the right side of the\ncolon from the more common ones arising on the left side (Toyota\net al., 1999; Weisenberger et al., 2006). We have mentioned\nearlier that tumors with IDH mutations, ﬁrst recognized in brain\ntumors, are accompanied by a CIMP pattern again involving\ngenes with a history of bivalency (Turcan et al., 2012) and having",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 90
        }
    },
    "1568": {
        "text": "a phenotype of being locked in a self-renewal state resistant to\ndifferentiation induction (Lu et al., 2012, 2013). The cells of origin\nin this scenario may be particularly relevant. These mutations are\nconﬁned almost totally to a form of low-grade gliomas occurring\nin a far younger group of patients than the more typical gliomas\n(Parsons et al., 2008; Yan et al., 2009). Also, they arise in a pro-\nneural, or more committed neural stem cell than the glial cell",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 91
        }
    },
    "1569": {
        "text": "origins of typical gliomas and grow much more slowly with a far\nbetter prognosis (Noushmehr et al., 2010; Parsons et al., 2008).\nMutation-mediated drug resistance\nEpigenetic-mediated drug resistance\nFounder mutation\nAcquired mutation\nDrug-sensitive epigenetic state\nPre-existing drug-tolerant epigenetic state\nDrug withdrawal\nor epigenetic therapy\nDrug-tolerant cells\nDrug-sensitive cells\nCancer cells\nTargeted therapy / Chemotherapy\nCancer cells\nDrug-tolerant cells\nDrug withdrawal",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 92
        }
    },
    "1570": {
        "text": "Cancer cells\nDrug-tolerant cells\nDrug withdrawal\nor epigenetic therapy\nDrug-tolerant cells\nDrug-sensitive cells\nCancer cells\nTherapy-induced drug-tolerant epigenetic state\nEpigenetic-mediated sensitization of cancer cell to therapy\nEpigenetic therapy\nDrug-sensitive\ncancer cells\nDrug-tolerant\ncancer cells\nTargeted therapy / Chemotherapy\nTargeted therapy / Chemotherapy\nTargeted therapy / Chemotherapy\nA\nB\nC\nFigure 4. Genetic and Epigenetic\nMechanisms for Drug Resistance and",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 93
        }
    },
    "1571": {
        "text": "Mechanisms for Drug Resistance and\nImplications of Epigenetic Therapy\nTop panel: Cancers may consist of different\nsubclones that carry a founder mutation(s) alone\nor additional acquired mutations that confer\ndrug-resistant states. When treated with targeted\ntherapies, a pre-existing drug-tolerant clone may\nremain unaffected and through outgrowth can\ncome to dominate the entire cancer population.\nMiddle panel: Cancer subclones with epigenetic-\nmediated drug tolerance may exist in the original",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 94
        }
    },
    "1572": {
        "text": "mediated drug tolerance may exist in the original\ncaner population or develop as a result of targeted\nchemotherapy.\nThe\ndrug\ntolerance\nmay\nbe\nreversed and cells may return to the sensitive\nepigenetic state after a prolonged drug withdrawal\nor after the tumor is treated with epigenetic ther-\napy,\nsuch\nas\nlow-dose\nhistone\ndeacetylase\n(HDAC)\ninhibitors\nand/or\nDNA\ndemethylating\nagents.\nLower panel: Epigenetic therapy may convert\ncancer cells in a drug-resistance state to either",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 95
        }
    },
    "1573": {
        "text": "cancer cells in a drug-resistance state to either\ntargeted therapy or chemotherapy sensitivity\nthat was not effective for the original cancer\npopulation.\nThe Implications of Epigenetic\nAbnormalities for Cancer\nTreatment and a Role in Treatment\nResistance\nIn addition to their importance for under-\nstanding basic facets of tumor biology,\nepigenetic alterations have increasingly been recognized as inte-\ngral for new approaches to cancer therapies and for their",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 96
        }
    },
    "1574": {
        "text": "possible role in treatment resistance, the major barrier to suc-\ncessful therapies for advanced malignancies (Figure 4). Potential\nfor preventing, delaying, or reversing such resistance with epige-\nnetic therapies, such as use of small molecules that can reverse\nDNA methylation and histone deacetylation, have been the sub-\njects of recent reviews, as have implications for targeting other\nchromatin regulatory proteins (Azad et al., 2013; Baylin and",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 97
        }
    },
    "1575": {
        "text": "Jones, 2011). A background context for this is the excitement\nsurrounding recent data indicating a role for chromatin changes\nin linking simultaneous emergence of stem cell populations and\ntheir role in the evolution of treatment resistance to multiple ther-\napy types (Sharma et al., 2010). Certainly, and especially for tar-\ngeted therapies, such resistance can be due to new mutations\narising directly in the targeted molecule or in genes in the direct",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 98
        }
    },
    "1576": {
        "text": "downstream pathways or complementing pathways (Redmond\net al., 2008) (Figure 4). However, it may be that epigenetic alter-\nations could play just as important a role in such resistance. As\nwe have pointed out, every cancer has multiple genes with\nepigenetic alterations in every key pathway fundamental to\ntumor development. In fact, a reversible type of resistance has\nbeen experimentally induced in cancer cells (Figure 4). This\nresistance, reversible with drug withdrawal or treatment by",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 99
        }
    },
    "1577": {
        "text": "low doses of histone deacetylase inhibitors, correlates with\nselection and/or induction of stem-like cancer cells from hetero-\ngeneous tumor cell populations. In turn, a key association in\nthese cell subpopulations is very high levels in these cells of\nthe H3K4me3 demethylase JARID1A and decreased overall\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\n723\nMolecular Cell\nReview\nH3K4me3 (Roesch et al., 2010; Sharma et al., 2010). A close rela-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 100
        }
    },
    "1578": {
        "text": "tive of this protein, JARID1B, has been associated with mainte-\nnance of tumor initiating cells (Roesch et al., 2010). All of these\ndata juxtapose cancer cell subpopulation plasticity with respect\nto stem-like phenotypes and chromatin alterations. Notably, the\nreversibility of epigenetic abnormalities in cancer subpopula-\ntions with inherent drug tolerance also provides a potentially\nexciting therapeutic strategy. Epigenetic therapy could be uti-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 101
        }
    },
    "1579": {
        "text": "lized as a priming therapy, which may sensitize cancer cells,\nwhich are otherwise drug resistant, to conventional/targeted\nchemotherapy (Figure 4).\nConclusion and Future Directions\nWe have reviewed data to suggest that, beginning in cancer risk\nstates and moving forward through tumor progression, epige-\nnetic abnormalities may play key roles in determining patterns\nof cellular heterogeneity in cancers. These may vary at any\nsteady-state point in time during tumor evolution. We have",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 102
        }
    },
    "1580": {
        "text": "deﬁned the concept of molecular progression for epigenetic\nchanges occurring even before frank tumor appearance, which\nmay be induced by agents predisposing to cancer. These events\ncould modulate evolution of nonhierarchical subpopulations of\ncancer stem-like and tumor-initiating cells. We have also raised\nthe hypothesis that a key underlying mechanism for how such\nchromatin patterns arise may be inherent to responses of cells\nto chronic stress, which may select for or induce stem-like cell",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 103
        }
    },
    "1581": {
        "text": "populations that otherwise would not survive and have the capac-\nity to maintaincellrenewal. In turn, we suggest that the initial chro-\nmatin makeup of such cells may set the stage for patterns of\nepigenetic abnormalities that might help maintain self-renewal\nproperties at theexpense of normal responsesto lineage commit-\nment and differentiation cues. Thus, the cell compartments from\nwhich a tumor arises, and the duration of time to tumor appear-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 104
        }
    },
    "1582": {
        "text": "ance, may dictate the extent of molecular progression of\nepigenetic abnormalities and the degree of cell plasticity. Various\ntechnical challenges have to be overcome in studies aimed at\nfurther understanding the role of epigenetic alterations in tumor\nheterogeneity. First, measuring the variations in epigenetic alter-\nations within a tumor is very challenging. Although with the advent\nof deep sequencing this could be tackled in the case of DNA",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 105
        }
    },
    "1583": {
        "text": "methylation, this remains a challenge for histone modiﬁcations\nby the sheer nature of these modiﬁcations. Second, important\nto this endeavor will be efforts to sort out the direct and indirect\ngene and molecular pathway targets of the genes subject to\ntumor-speciﬁc\nepigenetic\nalterations\nand\nto\ndeﬁne\ntheir\ndriver-versus-passenger roles in tumorigenesis. Finally, we\nhave stressed that any tumor cell constitution represents inter-\nplay between the above dynamics and the genetic abnormalities",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 106
        }
    },
    "1584": {
        "text": "arising at each stage of tumor progression from initiation onward.\nParticularly intriguing are the frequent mutations that are being\nincreasingly recognized for genes encoding major determinants\nof epigenomes and how these dictate the phenotypic makeup\nof cancers. For the future, investigation strategies will be key for\nnot only determining the role of these mutations in determining\npatterns of epigenetic abnormalities in cancer, but for exploring",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 107
        }
    },
    "1585": {
        "text": "facets of all the dynamics we have been discussing in this review.\nIn addition to advancing our understanding of cancer biology,\nthe data reviewed and the concepts derived are extremely impor-\ntant for their translational potential. There is a rapidly evolving en-\nterprise for targeting epigenetic abnormalities as a therapeutic\nstrategy for cancer. Attempts are ongoing to use older drugs in\nnewer, more targeted ways, and efforts are building to develop",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 108
        }
    },
    "1586": {
        "text": "new drugs that target a myriad of proteins that regulate the epige-\nnome (Cole, 2008; Dawson and Kouzarides, 2012; Vedadi et al.,\n2011). All of these endeavors will beneﬁt immensely from consid-\nering the implications of the cellular and molecular biology we\nhave reviewed and some of the hypotheses put forth. Particularly\nimportant may be the patterns of epigenetic abnormalities we\nhave discussed for different tumor types and for subtypes within",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 109
        }
    },
    "1587": {
        "text": "tumor categories. Targeting of therapies to ﬁt the precise epige-\nnetic abnormalities contributing to the phenotype of a given\ncancer may, in the end, determine the success or failure of\nsuch strategies. Epigenetic therapies may eventually work best\nnot only in combination with other treatment modalities, but\nespecially may beneﬁt from following biochemically driven hy-\npotheses for combining drugs targeting different regulators of",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 110
        }
    },
    "1588": {
        "text": "the cancer epigenome. Already, in this regard, use of older drugs\ntargeting the epigenetic machinery, like DNA demethylating\nagents and histone deactylase inhibitors, are showing very prom-\nising signs of efﬁcacy by potentially sensitizing to other therapies\n(Juergens et al., 2011). The future of the epigenetic therapy lies in\nfollowing up on the potential leads for using epigenetic drugs to\nreverse and/or delay resistance to current cancer therapies. As",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 111
        }
    },
    "1589": {
        "text": "we learn more about relationships between epigenetics and their\ncontribution to cellular composition of cancers, the future\nappears very bright for leveraging its translational potential.\nACKNOWLEDGMENTS\nPortions of this review are supported by National Cancer Institute (NCI)\nCA043318, National Institutes of Environmental Health Sciences (NIEHS)\nES011858, National Institutes of Health (NIH) HL099775, and the Hodson\nEndowment Fund. We want to thank Kathy Bender for manuscript preparation",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 112
        }
    },
    "1590": {
        "text": "and submission.\nREFERENCES\nAhuja, N., Li, Q., Mohan, A.L., Baylin, S.B., and Issa, J.P. (1998). Aging and DNA\nmethylation in colorectal mucosa and cancer. Cancer Res. 58, 5489–5494.\nAllis, C.D., Jenuwein, T., and Reinberg, D. (2008). Epigenetics, First Edition.\n(Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press).\nAmary, M.F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F.,\nPollock, R., O’Donnell, P., Grigoriadis, A., Diss, T., et al. (2011). IDH1 and",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 113
        }
    },
    "1591": {
        "text": "IDH2 mutations are frequent events in central chondrosarcoma and central\nand\nperiosteal\nchondromas\nbut\nnot\nin\nother\nmesenchymal\ntumours.\nJ. Pathol. 224, 334–343.\nAnderson, K., Lutz, C., van Delft, F.W., Bateman, C.M., Guo, Y., Colman, S.M.,\nKempski, H., Moorman, A.V., Titley, I., Swansbury, J., et al. (2011). Genetic\nvariegation of clonal architecture and propagating cells in leukaemia. Nature\n469, 356–361.\nAryee, M.J., Liu, W., Engelmann, J.C., Nuhn, P., Gurel, M., Haffner, M.C.,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 114
        }
    },
    "1592": {
        "text": "Esopi, D., Irizarry, R.A., Getzenberg, R.H., Nelson, W.G., et al. (2013). DNA\nmethylation alterations exhibit intraindividual stability and interindividual\nheterogeneity in prostate cancer metastases. Sci. Transl. Med. 5, 69ra10.\nAzad, N., Zahnow, C.A., Rudin, C.M., and Baylin, S.B. (2013). The future of\nepigenetic therapy in solid tumours—lessons from the past. Nat Rev Clin\nOncol 10, 256–266.\nAzuara, V., Perry, P., Sauer, S., Spivakov, M., Jørgensen, H.F., John, R.M.,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 115
        }
    },
    "1593": {
        "text": "Gouti, M., Casanova, M., Warnes, G., Merkenschlager, M., and Fisher,\n724\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\nMolecular Cell\nReview\nA.G. (2006). Chromatin signatures of pluripotent cell lines. Nat. Cell Biol. 8,\n532–538.\nBaylin, S.B., and Jones, P.A. (2011). A decade of exploring the cancer epige-\nnome - biological and translational implications. Nat. Rev. Cancer 11,\n726–734.\nBeck, B., and Blanpain, C. (2013). Unravelling cancer stem cell potential. Nat.\nRev. Cancer 13, 727–738.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 116
        }
    },
    "1594": {
        "text": "Rev. Cancer 13, 727–738.\nBelinsky, S.A., Nikula, K.J., Palmisano, W.A., Michels, R., Saccomanno, G.,\nGabrielson, E., Baylin, S.B., and Herman, J.G. (1998). Aberrant methylation\nof p16(INK4a) is an early event in lung cancer and a potential biomarker for\nearly diagnosis. Proc. Natl. Acad. Sci. USA 95, 11891–11896.\nBerman, B.P., Weisenberger, D.J., Aman, J.F., Hinoue, T., Ramjan, Z., Liu, Y.,\nNoushmehr, H., Lange, C.P., van Dijk, C.M., Tollenaar, R.A., et al. (2012).",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 117
        }
    },
    "1595": {
        "text": "Regions of focal DNA hypermethylation and long-range hypomethylation in\ncolorectal cancer coincide with nuclear lamina-associated domains. Nat.\nGenet. 44, 40–46.\nBernstein, B.E., Mikkelsen, T.S., Xie, X., Kamal, M., Huebert, D.J., Cuff, J., Fry,\nB., Meissner, A., Wernig, M., Plath, K., et al. (2006). A bivalent chromatin\nstructure marks key developmental genes in embryonic stem cells. Cell 125,\n315–326.\nBernstein, B.E., Birney, E., Dunham, I., Green, E.D., Gunter, C., and Snyder,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 118
        }
    },
    "1596": {
        "text": "M.; ENCODE Project Consortium (2012). An integrated encyclopedia of DNA\nelements in the human genome. Nature 489, 57–74.\nBestor, T.H. (1990). DNA methylation: evolution of a bacterial immune function\ninto a regulator of gene expression and genome structure in higher eukaryotes.\nPhilos. Trans. R. Soc. Lond. B Biol. Sci. 326, 179–187.\nBird, A. (2007). Perceptions of epigenetics. Nature 447, 396–398.\nBorodovsky, A., Salmasi, V., Turcan, S., Fabius, A.W., Baia, G.S., Eberhart,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 119
        }
    },
    "1597": {
        "text": "C.G., Weingart, J.D., Gallia, G.L., Baylin, S.B., Chan, T.A., and Riggins, G.J.\n(2013). 5-azacytidine reduces methylation, promotes differentiation and\ninduces tumor regression in a patient-derived IDH1 mutant glioma xenograft.\nOncotarget 4, 1737–1747.\nBraakhuis, B.J., Tabor, M.P., Kummer, J.A., Leemans, C.R., and Brakenhoff,\nR.H. (2003). A genetic explanation of Slaughter’s concept of ﬁeld canceriza-\ntion: evidence and clinical implications. Cancer Res. 63, 1727–1730.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 120
        }
    },
    "1598": {
        "text": "Brookes, E., de Santiago, I., Hebenstreit, D., Morris, K.J., Carroll, T., Xie, S.Q.,\nStock, J.K., Heidemann, M., Eick, D., Nozaki, N., et al. (2012). Polycomb asso-\nciates genome-wide with a speciﬁc RNA polymerase II variant, and regulates\nmetabolic genes in ESCs. Cell Stem Cell 10, 157–170.\nCairns, J. (1975). Mutation selection and the natural history of cancer. Nature\n255, 197–200.\nCairns, R.A., and Mak, T.W. (2013). Oncogenic isocitrate dehydrogenase mu-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 121
        }
    },
    "1599": {
        "text": "tations: mechanisms, models, and clinical opportunities. Cancer Discov 3,\n730–741.\nChaffer, C.L., Brueckmann, I., Scheel, C., Kaestli, A.J., Wiggins, P.A., Ro-\ndrigues, L.O., Brooks, M., Reinhardt, F., Su, Y., Polyak, K., et al. (2011). Normal\nand neoplastic nonstem cells can spontaneously convert to a stem-like state.\nProc. Natl. Acad. Sci. USA 108, 7950–7955.\nCole, P.A. (2008). Chemical probes for histone-modifying enzymes. Nat.\nChem. Biol. 4, 590–597.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 122
        }
    },
    "1600": {
        "text": "Chem. Biol. 4, 590–597.\nDang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M.,\nFantin, V.R., Jang, H.G., Jin, S., Keenan, M.C., et al. (2009). Cancer-associated\nIDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744.\nDawson, M.A., and Kouzarides, T. (2012). Cancer epigenetics: from mecha-\nnism to therapy. Cell 150, 12–27.\nDe Carvalho, D.D., Sharma, S., You, J.S., Su, S.F., Taberlay, P.C., Kelly, T.K.,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 123
        }
    },
    "1601": {
        "text": "Yang, X., Liang, G., and Jones, P.A. (2012). DNA methylation screening iden-\ntiﬁes driver epigenetic events of cancer cell survival. Cancer Cell 21, 655–667.\nDe Gobbi, M., Garrick, D., Lynch, M., Vernimmen, D., Hughes, J.R., Goardon,\nN., Luc, S., Lower, K.M., Sloane-Stanley, J.A., Pina, C., et al. (2011). Genera-\ntion of bivalent chromatin domains during cell fate decisions. Epigenetics\nChromatin 4, 9.\nDi Croce, L., and Helin, K. (2013). Transcriptional regulation by Polycomb",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 124
        }
    },
    "1602": {
        "text": "group proteins. Nat. Struct. Mol. Biol. 20, 1147–1155.\nEaswaran, H., Johnstone, S.E., Van Neste, L., Ohm, J., Mosbruger, T., Wang,\nQ., Aryee, M.J., Joyce, P., Ahuja, N., Weisenberger, D., et al. (2012). A DNA\nhypermethylation module for the stem/progenitor cell signature of cancer.\nGenome Res. 22, 837–849.\nEsteller, M., Sparks, A., Toyota, M., Sanchez-Cespedes, M., Capella, G.,\nPeinado, M.A., Gonzalez, S., Tarafa, G., Sidransky, D., Meltzer, S.J., et al.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 125
        }
    },
    "1603": {
        "text": "(2000). Analysis of adenomatous polyposis coli promoter hypermethylation\nin human cancer. Cancer Res. 60, 4366–4371.\nFan, H.Y., Trotter, K.W., Archer, T.K., and Kingston, R.E. (2005). Swapping\nfunction of two chromatin remodeling complexes. Mol. Cell 17, 805–815.\nFang, F., Turcan, S., Rimner, A., Kaufman, A., Giri, D., Morris, L.G., Shen, R.,\nSeshan, V., Mo, Q., Heguy, A., et al. (2011). Breast cancer methylomes estab-\nlish an epigenomic foundation for metastasis. Sci. Transl. Med. 3, 75ra25.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 126
        }
    },
    "1604": {
        "text": "Figueroa, M.E., Abdel-Wahab, O., Lu, C., Ward, P.S., Patel, J., Shih, A., Li, Y.,\nBhagwat, N., Vasanthakumar, A., Fernandez, H.F., et al. (2010). Leukemic\nIDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt\nTET2 function, and impair hematopoietic differentiation. Cancer Cell 18,\n553–567.\nGarraway, L.A., and Lander, E.S. (2013). Lessons from the cancer genome.\nCell 153, 17–37.\nGerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 127
        }
    },
    "1605": {
        "text": "E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012). Intratumor\nheterogeneity and branched evolution revealed by multiregion sequencing.\nN. Engl. J. Med. 366, 883–892.\nGreaves, M., and Maley, C.C. (2012). Clonal evolution in cancer. Nature 481,\n306–313.\nGreenspan, E.J., Jablonski, M.A., Rajan, T.V., Levine, J., Belinsky, G.S., and\nRosenberg, D.W. (2006). Epigenetic alterations in RASSF1A in human aberrant\ncrypt foci. Carcinogenesis 27, 1316–1322.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 128
        }
    },
    "1606": {
        "text": "crypt foci. Carcinogenesis 27, 1316–1322.\nGupta, P.B., Fillmore, C.M., Jiang, G., Shapira, S.D., Tao, K., Kuperwasser, C.,\nand Lander, E.S. (2011). Stochastic state transitions give rise to phenotypic\nequilibrium in populations of cancer cells. Cell 146, 633–644.\nHahn, M.A., Hahn, T., Lee, D.H., Esworthy, R.S., Kim, B.W., Riggs, A.D., Chu,\nF.F., and Pfeifer, G.P. (2008). Methylation of polycomb target genes in intesti-\nnal cancer is mediated by inﬂammation. Cancer Res. 68, 10280–10289.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 129
        }
    },
    "1607": {
        "text": "Hansen, K.D., Timp, W., Bravo, H.C., Sabunciyan, S., Langmead, B., McDo-\nnald, O.G., Wen, B., Wu, H., Liu, Y., Diep, D., et al. (2011). Increased methyl-\nation variation in epigenetic domains across cancer types. Nat. Genet. 43,\n768–775.\nHon, G.C., Hawkins, R.D., Caballero, O.L., Lo, C., Lister, R., Pelizzola, M.,\nValsesia, A., Ye, Z., Kuan, S., Edsall, L.E., et al. (2012). Global DNA hypome-\nthylation coupled to repressive chromatin domain formation and gene",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 130
        }
    },
    "1608": {
        "text": "silencing in breast cancer. Genome Res. 22, 246–258.\nJones, S., Chen, W.D., Parmigiani, G., Diehl, F., Beerenwinkel, N., Antal, T.,\nTraulsen, A., Nowak, M.A., Siegel, C., Velculescu, V.E., et al. (2008). Compar-\native lesion sequencing provides insights into tumor evolution. Proc. Natl.\nAcad. Sci. USA 105, 4283–4288.\nJuergens, R.A., Wrangle, J., Vendetti, F.P., Murphy, S.C., Zhao, M., Coleman,\nB., Sebree, R., Rodgers, K., Hooker, C.M., Franco, N., et al. (2011). Combina-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 131
        }
    },
    "1609": {
        "text": "tion epigenetic therapy has efﬁcacy in patients with refractory advanced non-\nsmall cell lung cancer. Cancer Discov 1, 598–607.\nKorber, P., and Becker, P.B. (2010). Nucleosome dynamics and epigenetic\nstability. Essays Biochem. 48, 63–74.\nLewis, P.W., Mu¨ ller, M.M., Koletsky, M.S., Cordero, F., Lin, S., Banaszynski,\nL.A., Garcia, B.A., Muir, T.W., Becher, O.J., and Allis, C.D. (2013). Inhibition\nof PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblas-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 132
        }
    },
    "1610": {
        "text": "toma. Science 340, 857–861.\nLi, Q., Ke, Q., and Costa, M. (2009). Alterations of histone modiﬁcations by\ncobalt compounds. Carcinogenesis 30, 1243–1251.\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\n725\nMolecular Cell\nReview\nLicchesi, J.D., Westra, W.H., Hooker, C.M., and Herman, J.G. (2008).\nPromoter hypermethylation of hallmark cancer genes in atypical adenomatous\nhyperplasia of the lung. Clin. Cancer Res. 14, 2570–2578.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 133
        }
    },
    "1611": {
        "text": "Liu, F., Killian, J.K., Yang, M., Walker, R.L., Hong, J.A., Zhang, M., Davis, S.,\nZhang, Y., Hussain, M., Xi, S., et al. (2010). Epigenomic alterations and gene\nexpression proﬁles in respiratory epithelia exposed to cigarette smoke\ncondensate. Oncogene 29, 3650–3664.\nLo, P.K., and Sukumar, S. (2008). Epigenomics and breast cancer. Pharmaco-\ngenomics 9, 1879–1902.\nLu, C., Ward, P.S., Kapoor, G.S., Rohle, D., Turcan, S., Abdel-Wahab, O., Ed-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 134
        }
    },
    "1612": {
        "text": "wards, C.R., Khanin, R., Figueroa, M.E., Melnick, A., et al. (2012). IDH mutation\nimpairs histone demethylation and results in a block to cell differentiation.\nNature 483, 474–478.\nLu, C., Venneti, S., Akalin, A., Fang, F., Ward, P.S., Dematteo, R.G., Intlekofer,\nA.M., Chen, C., Ye, J., Hameed, M., et al. (2013). Induction of sarcomas by\nmutant IDH2. Genes Dev. 27, 1986–1998.\nMaegawa, S., Gough, S.M., Watanabe-Okochi, N., Lu, Y., Zhang, N., Castoro,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 135
        }
    },
    "1613": {
        "text": "R.J., Estecio, M.R., Jelinek, J., Liang, S., Kitamura, T., et al. (2014). Age-related\nepigenetic drift in the pathogenesis of MDS and AML. Genome Res. 24,\n580–591.\nMarjanovic, N.D., Weinberg, R.A., and Chaffer, C.L. (2013). Cell plasticity and\nheterogeneity in cancer. Clin. Chem. 59, 168–179.\nMaunakea, A.K., Nagarajan, R.P., Bilenky, M., Ballinger, T.J., D’Souza, C.,\nFouse, S.D., Johnson, B.E., Hong, C., Nielsen, C., Zhao, Y., et al. (2010).",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 136
        }
    },
    "1614": {
        "text": "Conserved role of intragenic DNA methylation in regulating alternative pro-\nmoters. Nature 466, 253–257.\nMeacham, C.E., and Morrison, S.J. (2013). Tumour heterogeneity and cancer\ncell plasticity. Nature 501, 328–337.\nMehrotra, J., Varde, S., Wang, H., Chiu, H., Vargo, J., Gray, K., Nagle, R.B.,\nNeri, J.R., and Mazumder, A. (2008). Quantitative, spatial resolution of the\nepigenetic ﬁeld effect in prostate cancer. Prostate 68, 152–160.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 137
        }
    },
    "1615": {
        "text": "Min, I.M., Waterfall, J.J., Core, L.J., Munroe, R.J., Schimenti, J., and Lis, J.T.\n(2011). Regulating RNA polymerase pausing and transcription elongation in\nembryonic stem cells. Genes Dev. 25, 742–754.\nMullighan, C.G., Phillips, L.A., Su, X., Ma, J., Miller, C.B., Shurtleff, S.A., and\nDowning, J.R. (2008). Genomic analysis of the clonal origins of relapsed acute\nlymphoblastic leukemia. Science 322, 1377–1380.\nNavin, N., Kendall, J., Troge, J., Andrews, P., Rodgers, L., McIndoo, J., Cook,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 138
        }
    },
    "1616": {
        "text": "K., Stepansky, A., Levy, D., Esposito, D., et al. (2011). Tumour evolution\ninferred by single-cell sequencing. Nature 472, 90–94.\nNguyen, L.V., Vanner, R., Dirks, P., and Eaves, C.J. (2012). Cancer stem cells:\nan evolving concept. Nat. Rev. Cancer 12, 133–143.\nNiwa, T., and Ushijima, T. (2010). Induction of epigenetic alterations by chronic\ninﬂammation and its signiﬁcance on carcinogenesis. Adv. Genet. 71, 41–56.\nNonn, L., Ananthanarayanan, V., and Gann, P.H. (2009). Evidence for ﬁeld",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 139
        }
    },
    "1617": {
        "text": "cancerization of the prostate. Prostate 69, 1470–1479.\nNoushmehr, H., Weisenberger, D.J., Diefes, K., Phillips, H.S., Pujara, K.,\nBerman, B.P., Pan, F., Pelloski, C.E., Sulman, E.P., Bhat, K.P., et al.; Cancer\nGenome Atlas Research Network (2010). Identiﬁcation of a CpG island\nmethylator phenotype that deﬁnes a distinct subgroup of glioma. Cancer\nCell 17, 510–522.\nNowell, P.C. (1976). The clonal evolution of tumor cell populations. Science\n194, 23–28.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 140
        }
    },
    "1618": {
        "text": "194, 23–28.\nO’Hagan, H.M., Wang, W., Sen, S., Destefano Shields, C., Lee, S.S., Zhang,\nY.W., Clements, E.G., Cai, Y., Van Neste, L., Easwaran, H., et al. (2011).\nOxidative damage targets complexes containing DNA methyltransferases,\nSIRT1, and polycomb members to promoter CpG Islands. Cancer Cell 20,\n606–619.\nOhm, J.E., McGarvey, K.M., Yu, X., Cheng, L., Schuebel, K.E., Cope, L.,\nMohammad, H.P., Chen, W., Daniel, V.C., Yu, W., et al. (2007). A stem cell-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 141
        }
    },
    "1619": {
        "text": "like chromatin pattern may predispose tumor suppressor genes to DNA hyper-\nmethylation and heritable silencing. Nat. Genet. 39, 237–242.\nParsons, D.W., Jones, S., Zhang, X., Lin, J.C., Leary, R.J., Angenendt, P., Man-\nkoo, P., Carter, H., Siu, I.M., Gallia, G.L., et al. (2008). An integrated genomic\nanalysis of human glioblastoma multiforme. Science 321, 1807–1812.\nPtashne, M. (2007). On the use of the word ‘epigenetic’. Curr. Biol. 17, R233–\nR236.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 142
        }
    },
    "1620": {
        "text": "R236.\nRedmond, K.M., Wilson, T.R., Johnston, P.G., and Longley, D.B. (2008).\nResistance mechanisms to cancer chemotherapy. Front. Biosci. 13, 5138–\n5154.\nRheinbay, E., Suva` , M.L., Gillespie, S.M., Wakimoto, H., Patel, A.P., Shahid,\nM., Oksuz, O., Rabkin, S.D., Martuza, R.L., Rivera, M.N., et al. (2013). An aber-\nrant transcription factor network essential for Wnt signaling and stem cell\nmaintenance in glioblastoma. Cell Rep 3, 1567–1579.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 143
        }
    },
    "1621": {
        "text": "Roesch, A., Fukunaga-Kalabis, M., Schmidt, E.C., Zabierowski, S.E., Brafford,\nP.A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., and Herlyn, M. (2010). A tempo-\nrarily distinct subpopulation of slow-cycling melanoma cells is required for\ncontinuous tumor growth. Cell 141, 583–594.\nSasaki, M., Knobbe, C.B., Munger, J.C., Lind, E.F., Brenner, D., Bru¨ stle, A.,\nHarris, I.S., Holmes, R., Wakeham, A., Haight, J., et al. (2012). IDH1(R132H)",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 144
        }
    },
    "1622": {
        "text": "mutation increases murine haematopoietic progenitors and alters epigenetics.\nNature 488, 656–659.\nSchlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmer-\nman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B.E., et al.\n(2007). Polycomb-mediated methylation on Lys27 of histone H3 pre-marks\ngenes for de novo methylation in cancer. Nat. Genet. 39, 232–236.\nSharma, S.V., Lee, D.Y., Li, B., Quinlan, M.P., Takahashi, F., Maheswaran, S.,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 145
        }
    },
    "1623": {
        "text": "McDermott, U., Azizian, N., Zou, L., Fischbach, M.A., et al. (2010). A chro-\nmatin-mediated reversible drug-tolerant state in cancer cell subpopulations.\nCell 141, 69–80.\nShen, H., and Laird, P.W. (2013). Interplay between the cancer genome and\nepigenome. Cell 153, 38–55.\nShen, L., Kondo, Y., Rosner, G.L., Xiao, L., Hernandez, N.S., Vilaythong, J.,\nHoulihan, P.S., Krouse, R.S., Prasad, A.R., Einspahr, J.G., et al. (2005).\nMGMT promoter methylation and ﬁeld defect in sporadic colorectal cancer.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 146
        }
    },
    "1624": {
        "text": "J. Natl. Cancer Inst. 97, 1330–1338.\nShenker, N., and Flanagan, J.M. (2012). Intragenic DNA methylation: implica-\ntions of this epigenetic mechanism for cancer research. Br. J. Cancer 106,\n248–253.\nSierra, J.R., Cepero, V., and Giordano, S. (2010). Molecular mechanisms of ac-\nquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75.\nStratton, M.R., Campbell, P.J., and Futreal, P.A. (2009). The cancer genome.\nNature 458, 719–724.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 147
        }
    },
    "1625": {
        "text": "Nature 458, 719–724.\nSuzuki, H., Watkins, D.N., Jair, K.W., Schuebel, K.E., Markowitz, S.D., Chen,\nW.D., Pretlow, T.P., Yang, B., Akiyama, Y., Van Engeland, M., et al. (2004).\nEpigenetic inactivation of SFRP genes allows constitutive WNT signaling in\ncolorectal cancer. Nat. Genet. 36, 417–422.\nTam, W.L., and Weinberg, R.A. (2013). The epigenetics of epithelial-mesen-\nchymal plasticity in cancer. Nat. Med. 19, 1438–1449.\nThiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 148
        }
    },
    "1626": {
        "text": "mesenchymal transitions in development and disease. Cell 139, 871–890.\nThurman, R.E., Day, N., Noble, W.S., and Stamatoyannopoulos, J.A. (2007).\nIdentiﬁcation of higher-order functional domains in the human ENCODE\nregions. Genome Res. 17, 917–927.\nTili, E., Michaille, J.J., Wernicke, D., Alder, H., Costinean, S., Volinia, S., and\nCroce, C.M. (2011). Mutator activity induced by microRNA-155 (miR-155) links\ninﬂammation and cancer. Proc. Natl. Acad. Sci. USA 108, 4908–4913.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 149
        }
    },
    "1627": {
        "text": "Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J.G., Baylin, S.B., and Issa,\nJ.P. (1999). CpG island methylator phenotype in colorectal cancer. Proc.\nNatl. Acad. Sci. USA 96, 8681–8686.\nTurcan, S., Rohle, D., Goenka, A., Walsh, L.A., Fang, F., Yilmaz, E., Campos,\nC., Fabius, A.W., Lu, C., Ward, P.S., et al. (2012). IDH1 mutation is sufﬁcient to\nestablish the glioma hypermethylator phenotype. Nature 483, 479–483.\n726\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\nMolecular Cell\nReview",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 150
        }
    },
    "1628": {
        "text": "Molecular Cell\nReview\nTurcan, S., Fabius, A.W., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J.,\nViale, A., Riggins, G.J., and Chan, T.A. (2013). Efﬁcient induction of differenti-\nation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor\nDecitabine. Oncotarget 4, 1729–1736.\nTurke, A.B., Zejnullahu, K., Wu, Y.L., Song, Y., Dias-Santagata, D., Lifshits, E.,\nToschi, L., Rogers, A., Mok, T., Sequist, L., et al. (2010). Preexistence and",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 151
        }
    },
    "1629": {
        "text": "clonal selection of MET ampliﬁcation in EGFR mutant NSCLC. Cancer Cell\n17, 77–88.\nUshijima, T. (2007). Epigenetic ﬁeld for cancerization. J. Biochem. Mol. Biol.\n40, 142–150.\nVedadi, M., Barsyte-Lovejoy, D., Liu, F., Rival-Gervier, S., Allali-Hassani, A.,\nLabrie, V., Wigle, T.J., Dimaggio, P.A., Wasney, G.A., Siarheyeva, A., et al.\n(2011). A chemical probe selectively inhibits G9a and GLP methyltransferase\nactivity in cells. Nat. Chem. Biol. 7, 566–574.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 152
        }
    },
    "1630": {
        "text": "activity in cells. Nat. Chem. Biol. 7, 566–574.\nVogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Jr.,\nand Kinzler, K.W. (2013). Cancer genome landscapes. Science 339, 1546–\n1558.\nVoigt, P., LeRoy, G., Drury, W.J., 3rd, Zee, B.M., Son, J., Beck, D.B., Young,\nN.L., Garcia, B.A., and Reinberg, D. (2012). Asymmetrically modiﬁed nucleo-\nsomes. Cell 151, 181–193.\nWaddington, C.H. (2012). The epigenotype. 1942. Int. J. Epidemiol. 41, 10–13.",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 153
        }
    },
    "1631": {
        "text": "Wang, J.C.Y., and Dick, J.E. (2008). Cancer Stem Cells. In DeVita, Hellman,\nand Rosenberg’s Cancer: Principles & Practice of Oncology, Eighth Edition,\nV.T. DeVita, Jr., T.S. Lawrence, and S.A. Rosenberg, eds. (Philadelphia: Lip-\npincott Williams & Wilkins).\nWeisenberger, D.J., Siegmund, K.D., Campan, M., Young, J., Long, T.I.,\nFaasse, M.A., Kang, G.H., Widschwendter, M., Weener, D., Buchanan, D.,\net al. (2006). CpG island methylator phenotype underlies sporadic microsatel-",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 154
        }
    },
    "1632": {
        "text": "lite instability and is tightly associated with BRAF mutation in colorectal\ncancer. Nat. Genet. 38, 787–793.\nWidschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth,\nC., Weisenberger, D.J., Campan, M., Young, J., Jacobs, I., and Laird, P.W.\n(2007). Epigenetic stem cell signature in cancer. Nat. Genet. 39, 157–158.\nXu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.H., Ito, S., Yang, C., Wang,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 155
        }
    },
    "1633": {
        "text": "P., Xiao, M.T., et al. (2011). Oncometabolite 2-hydroxyglutarate is a competi-\ntive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell 19,\n17–30.\nYachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M.,\nHruban, R.H., Eshleman, J.R., Nowak, M.A., et al. (2010). Distant metastasis\noccurs late during the genetic evolution of pancreatic cancer. Nature 467,\n1114–1117.\nYamazaki, J., Estecio, M.R., Lu, Y., Long, H., Malouf, G.G., Graber, D., Huo, Y.,",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 156
        }
    },
    "1634": {
        "text": "Ramagli, L., Liang, S., Kornblau, S.M., et al. (2013). The epigenome of AML\nstem and progenitor cells. Epigenetics 8, 92–104.\nYan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., Kos,\nI., Batinic-Haberle, I., Jones, S., Riggins, G.J., et al. (2009). IDH1 and IDH2 mu-\ntations in gliomas. N. Engl. J. Med. 360, 765–773.\nYang, J., Luo, H., Li, Y., Li, J., Cai, Z., Su, X., Dai, D., Du, W., Chen, T., and\nChen, M. (2012). Intratumoral heterogeneity determines discordant results of",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 157
        }
    },
    "1635": {
        "text": "diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric\ncancer specimens. Cell Biochem. Biophys. 62, 221–228.\nYatabe, Y., Tavare´ , S., and Shibata, D. (2001). Investigating stem cells in\nhuman colon by using methylation patterns. Proc. Natl. Acad. Sci. USA 98,\n10839–10844.\nYi, J.M., Tsai, H.C., Glo¨ ckner, S.C., Lin, S., Ohm, J.E., Easwaran, H., James,\nC.D., Costello, J.F., Riggins, G., Eberhart, C.G., et al. (2008). Abnormal DNA",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 158
        }
    },
    "1636": {
        "text": "methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res.\n68, 8094–8103.\nYou, J.S., and Jones, P.A. (2012). Cancer genetics and epigenetics: two sides\nof the same coin? Cancer Cell 22, 9–20.\nMolecular Cell 54, June 5, 2014 ª2014 Elsevier Inc.\n727\nMolecular Cell\nReview",
        "metadata": {
            "source": "PIIS1097276514004092.pdf",
            "chunk_id": 159
        }
    },
    "1637": {
        "text": "Cancer Cell\nReview\nTumor Cell Metabolism: Cancer’s Achilles’ Heel\nGuido Kroemer1,2,3,* and Jacques Pouyssegur4\n1INSERM, U848, F-94805 Villejuif, France\n2Institut Gustave Roussy, F-94805 Villejuif, France\n3Universite´ Paris Sud, Paris 11, F-94805 Villejuif, France\n4Institute for Signaling, Developmental Biology and Cancer Research, CNRS UMR 6543, University of Nice,\nCentre Antoine Lacassagne, 33 Avenue Valombrose, F-06189 Nice, France\n*Correspondence: kroemer@igr.fr\nDOI 10.1016/j.ccr.2008.05.005",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 0
        }
    },
    "1638": {
        "text": "DOI 10.1016/j.ccr.2008.05.005\nThe essential hallmarks of cancer are intertwined with an altered cancer cell-intrinsic metabolism, either as\na consequence or as a cause. As an example, the resistance of cancer mitochondria against apoptosis-\nassociated permeabilization and the altered contribution of these organelles to metabolism are closely re-\nlated. Similarly, the constitutive activation of signaling cascades that stimulate cell growth has a profound",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 1
        }
    },
    "1639": {
        "text": "impact on anabolic metabolism. Here, we review the peculiarities of tumor cell metabolism that might be\ntaken advantage of for cancer treatment. Speciﬁcally, we discuss the alterations in signal transduction path-\nways and/or enzymatic machineries that account for metabolic reprogramming of transformed cells.\nMetabolic Reprogramming to the Advantage\nof Cancer Cells\nThe ﬁrst tumor-speciﬁc alteration, altered metabolism, was dis-\ncovered by the Nobel Prize winner Otto Warburg in the 1920s.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 2
        }
    },
    "1640": {
        "text": "The ‘‘Warburg phenomenon’’ consists of an increase in glycoly-\nsis that is maintained in conditions of high oxygen tension (‘‘aer-\nobic glycolysis’’) and gives rise to enhanced lactate production\n(Brahimi-Horn et al., 2007; Warburg et al., 1924). In addition, or\nalternatively, cancer cells use elevated amounts of glucose as\na carbon source for anabolic reactions. Although the Warburg\nphenomenon is not universally applicable to all cancers (Funes",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 3
        }
    },
    "1641": {
        "text": "et al., 2007), enhanced glucose uptake is sufﬁciently prevalent\nthat it is taken advantage of to image cancer in clinics using\nthe glucose analog 2-(18F)-ﬂuoro-2-deoxy-D-glucose (FDG) by\npositron emission tomography (PET). FDG-PET combined with\ncomputer tomography (PET/CT) has a >90% sensitivity and\nspeciﬁcity for the detection of metastases of most epithelial\ncancers (Mankoff et al., 2007).\nThere are several reasons why enhanced glucose uptake for",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 4
        }
    },
    "1642": {
        "text": "glycolytic ATP generation or anabolic reactions constitutes an\nadvantage for tumor growth (Figure 1):\nFirst, in conditions of aerobic glycolysis, cells can live in con-\nditions of ﬂuctuating oxygen tension (due to inconstant he-\nmodynamics of distant blood vessels) that would be lethal\nfor cells that rely on oxidative phosphorylation (OXPHOS) to\ngenerate ATP (Pouyssegur et al., 2006).\nSecond, cancer cells generate bicarbonic and lactic acids,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 5
        }
    },
    "1643": {
        "text": "lactate being the principal end product of aerobic glycolysis.\nSuch acids condition their environment (Koukourakis et al.,\n2006), favor tumor invasion (Swietach et al., 2007), and\nsuppress anticancer immune effectors (Fischer et al., 2007).\nLactate that is produced by tumor cells can be taken up by\nstromal cells (via the monocarboxylate transporters MCT1\nand MCT2) to regenerate pyruvate that either can be ex-\ntruded to refuel the cancer cell or can be used for OXPHOS",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 6
        }
    },
    "1644": {
        "text": "(Koukourakis et al., 2006). This arrangement generates a\nmicroecosystem in which anaerobic components (cancer\ncells) and aerobic components (nontransformed stromal\ncells) engage in complementary metabolic pathways, thus\nbuffering and recycling products of anaerobic metabolism\nto sustain cancer cell survival and growth.\nThird, tumors can metabolize glucose through the pentose\nphosphate pathway (PPP) to generate nicotinamide adenine\ndinucleotide phosphate (NADPH) that ensures the cell’s anti-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 7
        }
    },
    "1645": {
        "text": "oxidant defenses against a hostile microenvironment and\nchemotherapeutic agents (Gatenby and Gillies, 2004). More-\nover, NADPH can contribute to fatty acid synthesis. The non-\noxidative part of the PPP (in which ribose 5-phosphate, an in-\ntermediate of the PPP, is fueled into glycolysis) is controlled\nby transketolase reactions, and the transketolase-1 isoform\n(TKL1) is overexpressed in multiple cancers (Foldi et al.,\n2007; Langbein et al., 2006).",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 8
        }
    },
    "1646": {
        "text": "2007; Langbein et al., 2006).\nFourth, and most importantly, cancer cells use intermediates\nof the glycolytic pathway for anabolic reactions (for instance,\nglucose 6-phosphate for glycogen and ribose 5-phosphate\nsynthesis, dihydroxyacetone phosphate for triacylglyceride\nand phospholipid synthesis, and pyruvate for alanine and ma-\nlate synthesis) (Gatenby and Gillies, 2004). The embryonic\nisoform of pyruvate kinase (PK), which dephosphorylates",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 9
        }
    },
    "1647": {
        "text": "phosphoenolpyruvate (PEP) to pyruvate, is highly expressed\nin tumors yet is absent from adult tissues except adipocytes\n(Christofk et al., 2008a). Interestingly, this isoform, PKM2, os-\ncillates from high (tetrameric) to low (dimeric) activity (Chris-\ntofk et al., 2008a; Mazurek et al., 2005). The low-active\ndimeric form of PKM2 provides the metabolic advantage\nthat the phosphometabolites upstream of pyruvate accumu-\nlate and are then available as precursors for the synthesis of",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 10
        }
    },
    "1648": {
        "text": "amino acids, nucleic acids, and lipids (Mazurek et al., 2005)\nwhile lactate production is avoided. This principle of ‘‘deviat-\ning’’ (at least part of the) intermediates from the glycolytic\npathways toward anabolic reactions also applies to the me-\ntabolism of glycolytically derived pyruvate. In proliferating\ncancer cells, pyruvate may enter a truncated tricarboxylic\nacid (TCA) cycle. The net result of this truncated TCA cycle\nis that acetyl-CoA is exported from the mitochondrial matrix\n472",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 11
        }
    },
    "1649": {
        "text": "472\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\n(Figure 1) and becomes available for the synthesis of fatty\nacids, cholesterol, and isoprenoids. Indeed, fatty acid syn-\nthase (FASN), which synthesizes long-chain fatty acids from\nacetyl-CoA, malonyl-CoA, and NADPH, is upregulated or ac-\ntivated in many cancers (Wang et al., 2005). Similarly, choline\nkinase (ChoK), which forms phosphorylcholine, is often over-\nexpressed in cancer (Glunde and Bhujwalla, 2007).",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 12
        }
    },
    "1650": {
        "text": "expressed in cancer (Glunde and Bhujwalla, 2007).\nThus, the entire metabolism (in particular glycolysis and the\nTCA cycle) is reorganized to augment anabolic reactions linked\nto cell growth and proliferation. However, it would be difﬁcult\nto reconcile enhanced lactate production (which would result\nin a net loss of carbon that could have been used for anabolic re-\nactions) with reduced PK activity (which rather would reduce py-\nruvate and hence lactate production) and a truncated TCA cycle",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 13
        }
    },
    "1651": {
        "text": "(which would consume pyruvate) unless the net consumption of\nglucose was much higher in cancer cells than in their normal\ncounterparts.\nMechanisms of Metabolic Reprogramming\nThe molecular mechanisms that underlie metabolic reprogram-\nming of cancer cells are complex (Figure 2). Primary defects in\nOXPHOS have been invoked to explain the Warburg phenome-\nnon because tumor mitochondria are often relatively small,\nlack cristae, and are deﬁcient in the b-F1 subunit of the ATP(syn-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 14
        }
    },
    "1652": {
        "text": "th)ase (Lopez-Rios et al., 2007). Mitochondrial DNA (mtDNA) mu-\ntations may arise as a result of tumor progression (Brandon et al.,\n2006), but some mtDNA mutations might actively contribute\nto tumor progression. Thus, expression of a mutant mtDNA-\nencoded NADH dehydrogenase subunit 2 (associated with\nhead and neck squamous carcinoma) as a nuclear, mitochon-\ndrion-targeted gene product concomitantly stimulates aerobic\nglycolysis, reactive oxygen species (ROS) production, and tumor",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 15
        }
    },
    "1653": {
        "text": "growth (Zhou et al., 2007).\nOne of the principal mechanisms of aerobic glycolysis resides\nin the activation of hypoxia-inducible factor (HIF), a transcription\nfactor that is activated by hypoxic stress but also by oncogenic,\nFigure 1. Metabolic Reprogramming in Cancer Cells\nIn normal cells, aerobic glycolysis implies the conversion of glucose via pyruvate into acetyl-CoA and its complete oxidation (through the mitochondrion-localized",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 16
        }
    },
    "1654": {
        "text": "tricarboxylic acid [TCA] cycle and oxidative phosphorylation) to CO2 and H2O (which generates 38 ATP molecules per molecule of glucose). In contrast, in tumor\ncells, glycolysis tends to be aborted at either of two steps. First, aerobic glycolysis in tumor cells implies conversion of glucose into pyruvate (which generates only\ntwo ATP molecules per molecule of glucose) and subsequently into the waste product lactic acid. Second, in tumor cells, acetyl-CoA tends to be introduced into",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 17
        }
    },
    "1655": {
        "text": "a truncated TCA cycle, with the net result that acetyl-CoA is exported into the cytosol and serves as a building block for cell growth and proliferation. In this trun-\ncated TCA cycle, citrate is preferentially exported to the cytosol via the tricarboxylate transporter. Once in the cytosol, citrate is cleaved by ATP citrate lyase (ACL)\nto generate oxaloacetate and acetyl-CoA. Oxaloacetate is reduced to malate, then reimported into mitochondria and reconverted to oxaloacetate in the matrix",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 18
        }
    },
    "1656": {
        "text": "(while generating NADH that represses the TCA cycle), and it reacts with acetyl-CoA to complete the substrate cycle. Small arrows pointing up or down indicate\ncancer-associated upregulation/activation or downregulation/inhibition of enzymes, respectively. Alterations indicated in red can be caused by the activation of\nHIF-1. CA9 and CA12, carbonic anhydrases 9 and 12; CPT, carnitine palmitoyltransferase; GLUT, glucose transporter; GSH, glutathione; HIF, hypoxia-inducible",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 19
        }
    },
    "1657": {
        "text": "factor; IDO, indoleamine 2,3-dioxygenase; HK, hexokinase; OXPHOS, oxidative phosphorylation; LAT1, L-type amino acid transporter 1; LDHA, lactate dehy-\ndrogenase isoform A; MCT, monocarboxylate transporter; PDH, pyruvate dehydrogenase; PDK, pyruvate dehydrogenase kinase; PFK, phosphofructokinase;\nPI3K, phosphatidylinositol 3-kinase; PGM, phosphoglycerate mutase; PKM2, pyruvate kinase isoform M2; PPP, pentose phosphate pathway; SCO2, synthesis",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 20
        }
    },
    "1658": {
        "text": "of cytochrome c oxidase 2; TLK, transketolase; VDAC, voltage-dependent anion channel.\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\n473\nCancer Cell\nReview\ninﬂammatory, metabolic, and oxidative stress (Harris, 2002;\nSemenza, 2007; Taylor and Pouyssegur, 2007). HIF-1 is a heter-\nodimer composed of constitutive, stable b subunits and unstable\na subunits, which are synthesized yet degraded under normoxic\nconditions due to the sequential action of oxygen-dependent",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 21
        }
    },
    "1659": {
        "text": "prolyl hydroxylases (PHDs) and the VHL ubiquitin ligase. HIF-1\nstimulates the conversion of glucose to pyruvate and lactate\nby upregulating glucose transporter (GLUT) isoform 1 (GLUT1),\nhexokinase (HK1 and HK2, which catalyze the initial step of\nglycolysis), and lactate dehydrogenase A (LDHA), as well as the\nlactate-extruding\nenzyme\nmonocarboxylate\ntransporter\n4\n(MCT4) (Pouyssegur et al., 2006; Semenza, 2007).\nIn addition, HIF-1 decreases the conversion of pyruvate to",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 22
        }
    },
    "1660": {
        "text": "acetyl-CoA by pyruvate dehydrogenase (PDH). For this, HIF-1\ntransactivates the gene encoding PDH kinase 1 (PDK1), which\ninhibits PDH (Kim et al., 2006; Papandreou et al., 2006). Ace-\ntyl-CoA is normally fed to the TCA cycle, producing the electron\ndonors NADH and FADH2, which donate electrons to the respi-\nratory chain complexes I and II, respectively. Hence, by inhibiting\nPDH, HIF-1 compromises OXPHOS. In addition, HIF-1 facilitates",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 23
        }
    },
    "1661": {
        "text": "the adaptation of mitochondria to hypoxia by transactivating the\ncytochrome c oxidase (COX) subunit COX4-2 and LON, a prote-\nase that degrades COX4-1 (Fukuda et al., 2007). HIF-1 counter-\nacts the stimulatory action of Myc on mitochondrial biogenesis,\nthereby reducing mitochondrial mass (Zhang et al., 2007). In\ncontrast, HIF-1 cooperates with c-Myc to promote aerobic\nglycolysis by induction of HK2 and PDK1 (Dang et al., 2008).\nBesides by a decrease in O2 tension, HIF-1 can be induced as",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 24
        }
    },
    "1662": {
        "text": "a result of tumorigenic germline mutations of two enzymes of the\nTCA cycle: the mitochondrial matrix protein fumarate hydratase\n(FH) and the inner mitochondrial membrane protein succinate\ndehydrogenase (SDH). SDH is also a functional member of\ncomplex II of the respiratory chain. Loss-of-function mutations\nof FH or of SDH subunits (SDHB, SDHC, and SDHD) induce\nthe accumulation of the TCA cycle intermediates fumarate or\nsuccinate, which competitively inhibit the a-ketoglutarate-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 25
        }
    },
    "1663": {
        "text": "dependent HIF-1a prolyl hydroxylase, the enzyme that usually\ntargets HIF-1a for destruction in an oxygen-dependent fashion\n(Gottlieb and Tomlinson, 2005). These examples illustrate that in-\nduction of HIF-1 may contribute to the metabolic and oncogenic\nchanges induced by primary mitochondrial dysfunctions.\nBeyond the central role of HIF-1 activation, oncogenes and tu-\nmor suppressor genes determine metabolic reprogramming of\ncancer cells at several levels (Table 1), establishing multiple links",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 26
        }
    },
    "1664": {
        "text": "between tumor cell biology and tumor biochemistry. Perhaps the\nmost signiﬁcant example of a switch from respiration to aerobic\nglycolysis is provided by the inactivation of the tumor suppressor\np53, as discussed in the next section.\nHallmarks of Cancer Linked to Metabolic Change\nCancer cells differ from healthy cells due to a plethora of molec-\nular changes (Hanahan and Weinberg, 2000; Zitvogel et al.,\n2006), many of which may be mechanistically linked to metabolic\nreprogramming (Figure 3).",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 27
        }
    },
    "1665": {
        "text": "reprogramming (Figure 3).\nSelf-Sufﬁciency in Growth Signals\nGrowth factors usually activate receptor tyrosine kinases\n(RTKs), which then stimulate two key signal-transducing kinase\npathways: the Ras/Raf/MAP kinase (ERK) pathway and the\nphosphatidylinositol 3-kinase (PI3K) pathway. ERK and PI3K\nconverge to activate mTOR for stimulating cell growth. Most\ncancers harbor activating mutations of the master regulators\n(K-Ras, H-Ras, N-Ras, B-Raf, the p110a PI3K subunit, and",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 28
        }
    },
    "1666": {
        "text": "RTKs) or their downstream effectors (such as the kinases Akt\nand PDK1), or inactivating mutations in negative regulators of\nthese proteins (Shaw and Cantley, 2006) (Table 1). There are\nmultiple mechanisms through which the constitutive activation\nof growth factor signals can cause cancer-associated metabolic\nreprogramming.\nThe activation of tyrosine kinases including RTK and Scr family\nkinases results in the phosphorylation of enzymes on tyrosine\nFigure 2. Molecular Mechanisms of",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 29
        }
    },
    "1667": {
        "text": "Figure 2. Molecular Mechanisms of\nCancer-Speciﬁc Metabolic Reprogramming\nAs a result of oncogenic gain-of-function events\n(pink) or the lossof tumor suppressors (green)affect-\ning the PI3K/Akt/mTOR/HIF axis and/or inactivation\nof the p53 system, a stereotyped pattern of meta-\nbolic changes is induced, leading to cancer-associ-\natedalterationsinmetabolism.Notethatarrowscon-\nnecting different proteins do not necessarily indicate\ndirect interactions. ACL, ATP citrate lyase; AMPK,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 30
        }
    },
    "1668": {
        "text": "AMP-activated kinase; CA9 and CA12, carbonic an-\nhydrases 9 and 12; ChoK, choline kinase; CPT, car-\nnitine palmitoyltransferase; FH, fumarate hydratase;\nGLUT, glucose transporter; HIF, hypoxia-inducible\nfactor; HK, hexokinase; OXPHOS, oxidative phos-\nphorylation; LAT1, L-type amino acid transporter 1;\nLDHA, lactate dehydrogenase isoform A; MCT,\nmonocarboxylate transporter; mTOR, mammalian\ntarget of rapamycin; NF, neuroﬁbromin; PDK, pyru-\nvate dehydrogenase kinase; PFK, phosphofructoki-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 31
        }
    },
    "1669": {
        "text": "vate dehydrogenase kinase; PFK, phosphofructoki-\nnase; PI3K, phosphatidylinositol 3-kinase; PIP3,\nphosphatidylinositol triphosphate; PGM, phospho-\nglycerate mutase; PHD, prolyl hydroxylase; PKM2,\npyruvate kinase isoform M2; SCO2, synthesis of\ncytochrome c oxidase 2; SDH, succinate dehydro-\ngenase; TSC, tuberous sclerosis complex; VDAC,\nvoltage-dependent anion channel; VHL, von Hippel-\nLindau ubiquitin ligase.\n474\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\nCancer Cell\nReview",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 32
        }
    },
    "1670": {
        "text": "Cancer Cell\nReview\nresidues. This indirectly modulates the activity of the cancer-\nspeciﬁc isoform of pyruvate kinase, PKM2, which can bind to\nphosphotyrosine-containing peptides (Christofk et al., 2008b).\nUpon interaction between PKM2 and such phosphotyrosine-\ncontaining peptides, PKM2 releases its allosteric activator,\nFBP. This results in the inhibition of PKM2 activity as PKM2 tran-\nsits from its active tetrameric state to its inactive dimeric state",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 33
        }
    },
    "1671": {
        "text": "(Christofk et al., 2008b). This mechanism may contribute to the\nstimulation of anabolic reaction by oncogenic tyrosine kinases.\nThe partial inhibition of PKM2 (which catalyzes the last step of\nglycolysis, upstream of pyruvate) allows the intermediates of\nglycolysis to ‘‘deviate’’ toward anabolic reactions and simulta-\nneously\navoids\nexcessive\npyruvate\nproduction.\nHowever,\nPKM2 inhibition alone is not sufﬁcient to account for the can-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 34
        }
    },
    "1672": {
        "text": "cer-speciﬁc reprogramming, which relies on additional features\nincluding a general increase in glycolytic ﬂux.\nCell-autonomous overactivation of the PI3K/Akt system,\ndownstream of RTKs, mediates an increase in glucose and\namino acid ﬂux through the plasma membrane that may be at-\ntributable in part to the activation of HIF-1a (Pouyssegur et al.,\n2006). Akt stimulates the expression of one glucose transporter\n(GLUT1) and induces the translocation of another (GLUT4) to the",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 35
        }
    },
    "1673": {
        "text": "Table 1. Metabolic Effects of Selected Oncogenes and Tumor Suppressor Genes\nGene\nEffects\nDisease\nReference\nOncogenes\nPI3K\nActivates Akt via PIP3; reduces\n(via Akt) expression of the\nb-oxidation enzyme carnitine\npalmitoyltransferase 1A (CPT1A)\nOvarian and gastrointestinal\ncancer\nDeberardinis et al. (2006)\nAkt\nUpregulates fatty acid synthase\n(FASN); activates mTOR\ncomplex 1\nBreast and ovarian cancer\nWang et al. (2005)\nHer2\nIncreases, through activation\nof PI3K, Akt, and mTOR,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 36
        }
    },
    "1674": {
        "text": "of PI3K, Akt, and mTOR,\nexpression of FASN and acetyl-\nCoA carboxylase a (ACCa) at the\ntranslational level\nMammary carcinoma\nYoon et al. (2007)\nTyrosine kinases\nGenerate phosphotyrosines that\ncan bind to pyruvate kinase\nisoform PKM2, converting it from\na tetramer to a less active dimer\nMultiple cancers\nChristofk et al. (2008b)\nE7 from HPV16\nBinds PKM2, converting it from\na tetramer to a less active dimer\nCervical carcinoma\nMazurek et al. (2005)\nTumor Suppressors\np53\nRequired for expression of",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 37
        }
    },
    "1675": {
        "text": "Tumor Suppressors\np53\nRequired for expression of\nSCO2 and hence optimal\nOXPHOS; enhances the\nexpression of TIGAR,\na glycolysis inhibitor; reduces\nthe expression of the glycolytic\nenzyme phosphoglyceromutase\nMultiple cancers\nMatoba et al. (2006);\nBensaad et al. (2006);\nKondoh et al. (2005)\nVHL\nUbiquitin ligase required for\ndegradation of HIF-1a\nClear cell renal carcinoma\nShaw and Cantley (2006)\nTSC1 (hamartin) and\nTSC2 (tuberin)\nNegative regulators of Rheb\n(which inhibits mTOR)",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 38
        }
    },
    "1676": {
        "text": "Negative regulators of Rheb\n(which inhibits mTOR)\nTuberous sclerosis complex and\nlymphangioleiomyomatosis\nShaw and Cantley (2006)\nPTEN\nNegative regulator of class I PI3K\nCowden syndrome and prostate\ncancer\nShaw and Cantley (2006)\nLKB1\nRequired for activation of AMPK\nPeutz-Jeghers syndrome and\nsporadic lung adenocarcinoma\nShaw and Cantley (2006)\nNF1\nNegative regulator of RAS and\nPI3K-Akt pathway\nNeuroﬁbromatosis\nShaw and Cantley (2006)\nPML\nNegative regulator of mTOR\ncomplex 1",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 39
        }
    },
    "1677": {
        "text": "PML\nNegative regulator of mTOR\ncomplex 1\nPromyelocytic leukemia and\nlung cancer\nShaw and Cantley (2006)\nSuccinate dehydrogenase\nsubunits SDHB, C, and D\nAccumulated succinate\ncompetitively inhibits HIF-1a\nprolyl hydroxylases (PHDs)\nParaganglioma (SDHB, C, and\nD) and pheochromocytoma\n(SDHB and D)\nGottlieb and Tomlinson (2005)\nFumarate hydratase (fumarase)\nAccumulated fumarate inhibits\nPHDs\nLeiomyomatosis and papillary\nrenal carcinoma\nGottlieb and Tomlinson (2005)",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 40
        }
    },
    "1678": {
        "text": "renal carcinoma\nGottlieb and Tomlinson (2005)\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\n475\nCancer Cell\nReview\nplasma membrane. Akt stimulates glycolysis through the activat-\ning phosphorylation of 6-phosphofructo-2-kinase (PFK2) and\nfatty acid synthesis through the phosphorylation of ATP citrate\nlyase (Manning and Cantley, 2007). Through mechanisms that\nare not fully elucidated, Akt stimulates the association of HK1\nand HK2 with mitochondria (Pastorino et al., 2005), thus linking",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 41
        }
    },
    "1679": {
        "text": "residual ATP synthesis by mitochondria to the catalysis of the\nﬁrst, rate-limiting step of glycolysis. In addition, PI3K causes\nthe transcriptional downregulation of carnitine palmitoyltransfer-\nase 1A (CPT1A) (Deberardinis et al., 2006), an enzyme located in\nthe outer mitochondrial membrane that esteriﬁes long-chain\nfatty acids to carnitine, thereby initiating the mitochondrial im-\nport of fatty acids and channeling them to b-oxidation. One of",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 42
        }
    },
    "1680": {
        "text": "the net effects of PI3K activation is hence an inhibition of b-oxi-\ndation, which may contribute to the ‘‘glucose addiction’’ of can-\ncer cells (Deberardinis et al., 2006). PI3K activation also induces\nFASN, and the activating phosphorylation of Akt and FASN\ncorrelates in tissue microarrays (e.g., in ovarian cancer) (Wang\net al., 2005).\nmTOR, a serine/threonine kinase, is activated downstream of\nthe constitutively activated PI3K/Akt system. mTOR enhances",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 43
        }
    },
    "1681": {
        "text": "cap-dependent protein translation and cell growth while inhibit-\ning catabolic reactions mediated by autophagy. Several clinical\ntrials are currently examining the therapeutic efﬁcacy of mTOR\ninhibitors (Faivre et al., 2006). Increased activation of the PI3K/\nAkt/mTOR pathway leads to phosphorylation of 4E-BP1, an\ninhibitor of the eukaryotic translation initiation factor eIF4E,\nresulting in increased eIF4E activity and cap-dependent transla-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 44
        }
    },
    "1682": {
        "text": "tion in cancers. eIF4E overexpression can be tumorigenic, and\nits inhibition can suppress the growth of xenografted human\ncancers (Graff et al., 2007). Conversely, mTOR is inhibited by\nhypoxia, and breast cancers often overexpress 4E-BP1 and\neIF4G to increase the cap-independent translation of proangio-\ngenic, hypoxia, and survival mRNAs (Braunstein et al., 2007).\nHence, the contribution of cap-dependent versus cap-indepen-\ndent translation to cancer growth remains to be investigated in",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 45
        }
    },
    "1683": {
        "text": "further detail.\nEvading Apoptosis\nDefective apoptosis not only is crucial for initial oncogenesis\nbut contributes to chemotherapy resistance. Cancer cells often\nmanifest resistance against mitochondrial membrane permeabi-\nlization (MMP), which is one of the decisive steps of apoptosis\n(Kroemer et al., 2007). One link between apoptosis inhibition\nand metabolic reprogramming may be provided by the associa-\ntion of HK with the voltage-dependent anion channel (VDAC). HK",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 46
        }
    },
    "1684": {
        "text": "has been shown to associate more tightly with the outer mito-\nchondrial protein VDAC in tumor cells than in normal control cells\n(Pedersen, 2007). This increased HK-VDAC interaction may be\ndue to the constitutive activation of Akt. Akt induces the translo-\ncation of HK to the outer mitochondrial membrane where it binds\nto VDAC, presumably because Akt interferes with the glycogen\nsynthase kinase 3 (GSK3)-mediated phosphorylation of VDAC\n(Pastorino et al., 2005) or because Akt phosphorylates HK",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 47
        }
    },
    "1685": {
        "text": "(Miyamoto et al., 2008). When associated with VDAC, HK may\nFigure 3. The Seven Hallmarks of Cancer and Their Links to Tumor Metabolism\nThe hypothetical links between different metabolic alterations and the seven nonmetabolic characteristics of neoplasia (circle) are depicted. Centripetal arrows\n(pointing from the inside outwards) indicate how the seven hallmarks of cancer can impinge on metabolism. Centrifugal arrows (pointing from the outside inwards)",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 48
        }
    },
    "1686": {
        "text": "illustrate how neoplasia-associated metabolic reprogramming can contribute to the acquisition of the seven hallmarks. Ang-2, angiopoietin-2; GLUT, glucose\ntransporter; HIF, hypoxia-inducible factor; HK, hexokinase; OXPHOS, oxidative phosphorylation; PGM, phosphoglycerate mutase; PI3K, phosphatidylinositol\n3-kinase; SCO2, synthesis of cytochrome c oxidase 2; VDAC, voltage-dependent anion channel; VEGF, vascular endothelial growth factor.\n476\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 49
        }
    },
    "1687": {
        "text": "476\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\nCancer Cell\nReview\nefﬁciently couple residual OXPHOS to the initial, rate-limiting\nstep of glycolysis. In addition, HK can inhibit MMP, presumably\nthrough an effect on the permeability transition pore complex\n(PTPC) (which also involves VDAC). Accordingly, peptides that\ncompetitively disrupt the VDAC-HK interaction can induce\nMMP and subsequent apoptosis (Robey and Hay, 2006). On the-\noretical grounds, such VDAC-HK-dissociating agents would",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 50
        }
    },
    "1688": {
        "text": "have a dual effect and hence revert the hyperglycolytic state\nwhile facilitating apoptosis induction.\nComplete or partial OXPHOS defects may also induce apo-\nptosis resistance. Total inhibition of the respiratory chain can\nsuppress the activation of the proapoptotic Bcl-2 proteins Bax\nand Bak, either of which serves as a near obligate mediator of\nMMP (Tomiyama et al., 2006). Thus, severe OXPHOS defects,\nas are found in some cancers, might be automatically coupled",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 51
        }
    },
    "1689": {
        "text": "to a blockade of MMP and hence an inhibition of apoptosis.\nOXPHOS defects also reduce the capacity of certain xenobiotics\nto elicit ROS generation in mitochondria, thereby abrogating\ntheir proapoptotic activity. This latter mechanism may explain\nthe fact that r\u0002 cells (cells that lack mitochondrial DNA and hence\nOXPHOS) are resistant against a series of compounds that in-\nduce apoptosis by provoking futile redox cycles in mitochondria",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 52
        }
    },
    "1690": {
        "text": "(Galluzzi et al., 2006; Kroemer et al., 2007). Thus, a state of de-\nﬁcient OXPHOS might automatically compromise the intrinsic\npathway of apoptosis through a variety of distinct mechanisms.\nOther links between mitochondrial alterations in cancer and\ndisabled apoptosis are more indirect. A hyperpolarization of\nthe inner mitochondrial transmembrane potential, as is fre-\nquently seen in cancer cells (perhaps secondary to defects in\nthe F1F0 ATPase) (Galluzzi et al., 2006), can reduce the propen-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 53
        }
    },
    "1691": {
        "text": "sity of PTPC opening (Zoratti and Szabo, 1995). There is also\na correlation between mitochondrial hyperpolarization and a rel-\native deﬁciency in voltage-gated plasma membrane K+ channels\n(Kv), enhancing cytosolic K+ to a level that exerts a tonic inhibi-\ntory effect on caspases and apoptosis-inducing factor (AIF)\n(Bonnet et al., 2007). Pharmacological inhibition of PDK1, which\nis often overactivated in cancer, leads to reactivation of PDH and",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 54
        }
    },
    "1692": {
        "text": "reportedly corrects both the activity of Kv channels and mito-\nchondrial hyperpolarization, thereby inducing cancer cell apo-\nptosis (Bonnet et al., 2007). Thus, PDK1 inhibitors may constitute\nyet another example of dual-hit agents that simultaneously\nreverse apoptosis resistance and metabolic reprogramming.\nLimitless Replicative Potential\nTo ensure replicative potential, tumor cells often mutate or lose\nsenescence-inducing proteins such as p53. Loss of p53 is also",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 55
        }
    },
    "1693": {
        "text": "driven by Darwinian selection in a hypoxic environment, because\nhypoxia-mediated activation of p53 can trigger cell death (Culm-\nsee and Mattson, 2005). As brieﬂy stated above, inactivation of\np53 can directly cause the Warburg phenomenon through sev-\neral mechanisms. Thus, p53 positively regulates the expression\nof the protein synthesis of cytochrome c oxidase 2 (SCO2),\nwhich is required for assembling COX (Matoba et al., 2006).\np53 negatively regulates phosphoglycerate mutase (PGM), the",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 56
        }
    },
    "1694": {
        "text": "enzyme that converts 3-phosphoglycerate (3PG) to 2-phospho-\nglycerate (2PG) in glycolysis (Kondoh et al., 2005). Moreover,\np53 transcriptionally activates TIGAR (TP53-induced glycolysis\nand apoptosis regulator), an isoform of PFK2 that inhibits overall\nphosphofructokinase activity, lowers the levels of FBP, and\nhence inhibits glycolysis (because FBP is an allosteric activator\nof the glycolytic enzyme 6-phosphofructo-1-kinase) while chan-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 57
        }
    },
    "1695": {
        "text": "neling glucose to the PPP (Bensaad et al., 2006). At present,\nthere have been no systematic studies to determine through\nwhich dominant (SCO2-, PGM-, or TIGAR-dependent?) pathway\ninactivation of p53 impacts on cancer cell metabolism. Given the\nmajor contribution of p53 to cancer cell biology, this issue\nurgently awaits clariﬁcation.\nSustained Angiogenesis\nMany tumors show increased expression of vascular endothelial\ngrowth factor (VEGF) as a result of activated signaling pathways",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 58
        }
    },
    "1696": {
        "text": "(ERK, PI3K), an action that is ampliﬁed by hypoxia. Indeed, re-\ncent work indicates that the expression of VEGF is cooperatively\ninduced by HIF-1 and c-Myc (Kim et al., 2007a). Another intrigu-\ning link between abnormal metabolism and cancer-mediated an-\ngiogenesis is provided by F1F0 ATPase. Both endothelial cells\nand tumor cells express the F1F0 ATPase (normally an inner mi-\ntochondrial membrane protein complex) at the cell surface,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 59
        }
    },
    "1697": {
        "text": "where it may extrude protons from the cytosol to the extracellular\nmilieu and hence contribute to the net export of protons that is\nrequired to maintain aerobic glycolysis. An endogenous angio-\ngenesis inhibitor, angiostatin, binds and inhibits surface F1F0\nATPase, causing intracellular acidiﬁcation. Similarly, an antibody\ntargeting the b catalytic subunit of F1F0 ATPase has an angiosta-\ntin-like antiangiogenic effect (Chi et al., 2007). These results hint",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 60
        }
    },
    "1698": {
        "text": "at the possibility of using a single agent that targets the cell-\nsurface F1F0 ATPase for subverting cancer-associated angio-\ngenesis and metabolic reprogramming.\nTissue Invasion and Metastasis\nOne mechanistic link between tumor metabolism and invasion/\nmetastasis is provided by HIF. HIF-1a activation causes the\nloss of E-cadherin (Esteban et al., 2006; Pouyssegur et al.,\n2006), the cadherin isoform that is required for the maintenance",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 61
        }
    },
    "1699": {
        "text": "of intercellular contacts within epithelia and that is lost during the\nepithelium-mesenchyme transition (EMT). HIF-1a activation also\ncauses the expression of the met proto-oncogene and of TWIST,\nboth of which favor EMT (Pennacchietti et al., 2003; Yang et al.,\n2008), and induces two proteins that play a cardinal role in me-\ntastasis, the chemokine receptor CXCR4 (Igney and Krammer,\n2002) and lysyl oxidase (LOX) (Erler et al., 2006). Thus, one single",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 62
        }
    },
    "1700": {
        "text": "cause, HIF-1a activation, may entail both metabolic reprogram-\nming and enhanced tissue invasion/metastasis. Accordingly,\nmtDNA mutations can stimulate the metastatic potential of\ncancer cells, presumably because enhanced ROS generation\nby mitochondria leads to the activation of HIF-1a (Ishikawa\net al., 2008).\nAerobic glycolysis (and hence enhanced production of pro-\ntons) causes acidiﬁcation of the extracellular milieu due to the\naction of multiple proton-extruding enzymes. The monocarbox-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 63
        }
    },
    "1701": {
        "text": "ylate transporters MCT1 and MCT4 (which cotransport H+ with\nmonocarboxylate anions such as lactate) and the ubiquitous\nNa+-H+ exchanger are activated by growth factors, oncogenic\ntransformation, hypoxia, and low intracellular pH (Counillon\nand Pouyssegur, 2000). In addition, cancer cells may use the\nsurface V-type H+ ATPase and/or the surface F1F0 ATPase as\nproton pumps. Tumor cells often express the exquisitely HIF-\ninducible carbonic anhydrase isoforms 9 and 12 (CA9 and",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 64
        }
    },
    "1702": {
        "text": "CA12). CA9 and CA12 are transmembrane enzymes that hydrate\nextracellular CO2, thereby generating membrane-impermeable\nH+ and HCO3\n\u0003. Rapid recapture of HCO3\n\u0003 by anion transporters\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\n477\nCancer Cell\nReview\nassociated with CA9 as a ‘‘metabolome’’ (Morgan et al., 2007)\nensures maintenance of a normal intracellular pH, which in turn\nis essential for cell survival (Pouyssegur et al., 2006; Swietach",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 65
        }
    },
    "1703": {
        "text": "et al., 2007). Extracellular acidity supports invasion and metasta-\nsis, perhaps due to the pH-dependent activation of cathepsins\nand metalloproteinases that degrade extracellular matrix and\nbasement membranes (Swietach et al., 2007). Irrespective of\nthese mechanistic details, it may be expected that pharmacolog-\nical inhibitors of the enzymes responsible for lactate production\nand/or proton extrusion would have an antimetastatic effect, in\naddition to reducing tumor growth.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 66
        }
    },
    "1704": {
        "text": "addition to reducing tumor growth.\nAvoidance of Immunosurveillance\nThe metabolic microenvironment of tumor cells may inhibit the\nfunction of antitumor immune effectors such as cytotoxic T lym-\nphocytes (CTLs) and natural killer (NK) cells while attracting\ninﬂammatory\ncells\nthat\nparticipate\nin\ntumor\nprogression.\nTumor-associated macrophages (TAMs) are often enriched in\nhypoxic and tumor perinecrotic areas and constitute a negative\nprognostic marker. Within TAMs, HIF-1 is essential to upregulate",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 67
        }
    },
    "1705": {
        "text": "glycolysis so that the cells can migrate into tumor beds (Cramer\net al., 2003). TAMs facilitate angiogenesis, promote tumor cell\nmigration, and exert local immunosuppressive effects (Condee-\nlis and Pollard, 2006). As a result, pharmacological HIF-1 inhibi-\ntion should—theoretically—reduce TAM inﬁltration into tumors.\nAcidiﬁcation of tumor beds can inhibit the activity of NK cells\n(Lardner, 2001). Patients with high tumor burden have increased",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 68
        }
    },
    "1706": {
        "text": "serum lactate levels (Fischer et al., 2007), and lactate may exert\npotent immunosuppressive effects, as seen in advanced cancer.\nThus, lactate suppresses the proliferation, cytokine production,\nand cytolytic activity of CTLs. As a possible mechanism of this\nimmunosuppressive effect, extracellular lactate blocks the ca-\npacity of CTLs to export intracellular lactate by the monocarbox-\nylate transporter MCT1. The resulting lactate overload is incom-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 69
        }
    },
    "1707": {
        "text": "patible with normal CTL functions (Fischer et al., 2007). Cancer\ncells often overexpress indoleamine 2,3-dioxygenase (IDO), an\nenzyme that catabolizes tryptophan (which is taken up by upre-\ngulated L-type amino acid transporter 1 [LAT1]) to the kynurenine\npathway and oxidative stress. IDO overexpression has been\nimplicated in cancer-associated anorexia/cachexia (Munn and\nMellor, 2007), and kynurenine produced by tumor cells can kill\nCTLs by apoptosis (Puccetti and Grohmann, 2007). These exam-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 70
        }
    },
    "1708": {
        "text": "ples illustrate that therapeutic interventions designed to correct\nabnormal tumor metabolism and, in particular, the inhibition of\nproton extrusion, lactate production, or IDO might reestablish\na defective antitumor immune response.\nConclusions and Therapeutic Perspectives\nAs discussed above, alterations in cancer cell metabolism are in-\ntricately linked to the principal hallmarks of cancer. These links\nare established in several distinct scenarios. First, metabolic",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 71
        }
    },
    "1709": {
        "text": "reprogramming may be the consequence of nonmetabolic\noncogenic events. Thus, major oncogenic events (such as\nconstitutive activation of growth factor pathways, constitutive\nactivation of HIF-1, and inactivation of p53) may constitute the\ncommon cause of metabolic programming and well-studied hall-\nmarks of cancer such as autonomous growth, resistance against\napoptosis, limitless replication, and angiogenesis (Figure 2 and\ncentrifugal arrows in Figure 3). Second, classical features of",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 72
        }
    },
    "1710": {
        "text": "cancer may be conditioned by metabolic reprogramming.\nThus, primary metabolic defects in OXPHOS may contribute to\napoptosis resistance, while local extracellular emanations of\nthe deregulated cancer cell metabolism may contribute to inva-\nsion, metastasis, and immunosuppression (centripetal arrows in\nFigure 3). Third, at an additional level of complexity, we must\nconsider coevolution of the distinct traits of malignancy. The\ndual cause-effect relationship between tumor-speciﬁc meta-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 73
        }
    },
    "1711": {
        "text": "bolic and nonmetabolic hallmarks is likewise conditioned by\nthe need of proliferating cancer cells to simultaneously subvert\nmultiple cell-intrinsic and cell-extrinsic tumor suppressor mech-\nanisms and hence to emerge from a selection process that\nforces the coevolution of all hallmarks of cancer, whether meta-\nbolic or nonmetabolic.\nIrrespective of these theoretical and speculative consider-\nations, the intimate relationship between cancer-associated",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 74
        }
    },
    "1712": {
        "text": "metabolic reprogramming and all other cardinal features has\ntherapeutic implications at several levels. First, therapeutic sub-\nversion of the nonmetabolic properties of cancer (interruption of\ncell-autonomous growth signals, restoration of apoptosis, inhibi-\ntion of angiogenesis, etc.) may suppress cancer-speciﬁc meta-\nbolic programs and hence restore the normal state. This may ex-\nplain the extraordinary performance of FDG-PET as a predictor",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 75
        }
    },
    "1713": {
        "text": "of therapeutic outcome (Bonnet et al., 2007). Second, inhibition\nof the processes and enzymes that participate in metabolic\nprogramming may have a dramatic effect on tumors, not only\nby limiting cancer cell-speciﬁc bioenergetic ﬂow and anabolic\nreactions but also by reversing the neoplastic phenotype\nand hence stopping growth, inducing apoptosis, and/or blocking\nangiogenesis and invasion.\nSuch ‘‘dual hits’’ are exempliﬁed by the inhibition of HIF (which",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 76
        }
    },
    "1714": {
        "text": "inhibits angiogenesis), reestablishment of p53 function (which\nrestores apoptosis and senescence), or suppression of the\nPI3K/Akt/mTOR pathway (which inhibits growth), three interven-\ntions that should also normalize metabolic functions (Figure 3).\nMoreover, small inhibitors of enzymes that occupy a central\nrole both in cancer-speciﬁc metabolism and in other hallmarks\nof cancer might be targeted for therapy (Table 2). For instance,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 77
        }
    },
    "1715": {
        "text": "low-glucose conditions and inhibitors of glycolysis preferentially\ninduce apoptosis in ‘‘glucose-addicted’’ cells that carry active\noncogenes (e.g., Ras, Her2, and Akt) or lack tumor suppressors\n(e.g., TSC1/2, LKB1, and p53) (Shaw, 2006). The HK2 inhibitor\n3-bromopyruvate induces apoptosis in hepatocellular carcino-\nmas in vitro and in vivo (Ko et al., 2004). This effect may involve\nthe inhibition of glycolysis as well as the dissociation of the anti-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 78
        }
    },
    "1716": {
        "text": "apoptotic interaction between HK2 and VDAC (Kim et al.,\n2007b), providing yet another example of a dual hit that has\nbeen validated at the experimental level, in tumor-bearing\nmice. Similarly, inhibition of PDK1 can restore PDH activity\n(and OXPHOS) while triggering apoptosis in tumor cells in vitro\nand in vivo (Bonnet et al., 2007).\nThe preclinical and clinical evaluation of metabolic inhibitors\nfor cancer therapy is in its infancy, perhaps with the notable",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 79
        }
    },
    "1717": {
        "text": "exception of mTOR antagonists (Faivre et al., 2006) and (unfortu-\nnately rather nonspeciﬁc) activators of AMPK that are given as\noral antidiabetics and reduce the incidence of cancer (Evans\net al., 2006). The lack of enzymatic inhibitors acting at an accept-\nable degree of speciﬁcity is one of the principal obstacles to\nevaluating whether inhibition of bioenergetic and anabolic path-\nways, alone or in combination therapies, might ﬁnally target the\n478",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 80
        }
    },
    "1718": {
        "text": "478\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\nCancer Cell\nReview\nTable 2. Potential Metabolic Targets for the Treatment of Cancer\nTarget\nDesired Effects\nExamples of Compounds\nReference\nGlycolysis\nGlucose uptake\nInhibition of glucose transport or\nof the initial steps of glycolysis\n2-deoxyglucose has\nradiosensitizing and\nchemosensitizing effects\nSimons et al. (2007)\nHexokinase (HK1 and HK2)\nInhibition of enzymatic activity and\ndissociation from mitochondria\n3-bromopyruvate has potent",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 81
        }
    },
    "1719": {
        "text": "3-bromopyruvate has potent\nantitumor effects in vitro and in vivo\nKim et al. (2007b);\nPedersen (2007)\nPyruvate dehydrogenase\nkinase 1 (PDK1)\nInhibition of PDK1 for deinhibition\nof pyruvate dehydrogenase\nDichloroacetate (DCA)\nBonnet et al. (2007)\nLactate dehydrogenase A (LDHA)\nInhibition\nsiRNA\nFantin et al. (2006)\nPyruvate kinase (PK) isoenzyme\nPKM2\nTranslocation of PKM2 to the\nnucleus for induction of apoptosis\nSomatostatin and its derivative\nTT-232 (in vitro)\nStetak et al. (2007)",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 82
        }
    },
    "1720": {
        "text": "TT-232 (in vitro)\nStetak et al. (2007)\nFatty Acid Synthesis\nATP citrate lyase (ACL)\nInhibition\nSB-2049990 inhibits pancreatic\ncancer growth in nude mice\nHatzivassiliou et al. (2005)\nAcetyl-CoA carboxylase (ACC)\nInhibition\nSoraphen A induces apoptosis\nor autophagy in vitro\nBeckers et al. (2007)\nFatty acid synthase (FASN)\nInhibition\nCerulenin and its derivative C57\ninhibit human ovarian cancer\ncell growth in SCID mice\nWang et al. (2005)\nCholine kinase (ChoK)\nInhibition\nMN58b reduces",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 83
        }
    },
    "1721": {
        "text": "Choline kinase (ChoK)\nInhibition\nMN58b reduces\nphosphomonoesters in human\ncancer xenografts\nAl-Saffar et al. (2006)\nHIF\nHIF-1a prolyl hydroxylases (PHDs)\nActivation of PHDs for inhibition\nof HIF, achieved by reversal of\nfumarate- or succinate-mediated\ninhibition of PHDs\nCell-permeating a-ketoglutarate\nderivatives reverse HIV activation\nin SDH- or FH-deﬁcient cells\nin vitro\nMacKenzie et al. (2007)\nHypoxia-inducible factor 1 (HIF-1)\nInhibition of DNA binding\nEchinomycin\n(Kong et al. (2005)",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 84
        }
    },
    "1722": {
        "text": "Echinomycin\n(Kong et al. (2005)\nReactive oxygen species (ROS)\nAntioxidants neutralize ROS\nand reduce HIF-1 function\nvia PHDs and VHL\nN-acetylcysteine (NAC);\nvitamin C\nGao et al. (2007)\nHypoxia\nCytotoxic effects of components\nthat are enriched in hypoxic cells\nTirapazamine (TPZ), a hypoxia-\nactivated prodrug, is in clinical\nevaluation for combination\nchemotherapy\nBrizel and Esclamado (2006)\nProton Extrusion\nNa+/H+ exchanger\nInhibition\nCariporide\nPouyssegur et al. (2006)\nBicarbonate/Cl\u0003 exchanger",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 85
        }
    },
    "1723": {
        "text": "Bicarbonate/Cl\u0003 exchanger\nInhibition\nS3705\nPouyssegur et al. (2006)\nMCT1 lactate/H+ symporter\nInhibition\na-cyano-4-OH-cinnamate\nPouyssegur et al. (2006)\nCarbonic anhydrases 9 and\n12 (CA9 and CA12)\nInhibition\nSulfonamide indisulam\nThiry et al. (2006)\nF1F0 ATP synthase\nInhibition\nAngiostatin; antibodies\nChi et al. (2007)\nOther\nAMPK\nActivation\nBiguanides (e.g., metformin)\nand thiazolidinediones (e.g.,\ntroglitazone) activate AMPK\nindirectly, probably through\ninhibition of OXPHOS, and reduce",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 86
        }
    },
    "1724": {
        "text": "inhibition of OXPHOS, and reduce\nthe risk of cancer in diabetic patients\nEvans et al. (2006)\neIF4E\nInhibition of translation initiation\nmediated by eIF4E\nAntisense oligonucleotide\ninhibits growth of human\nbreast cancer xenografts\nGraff et al. (2007)\nL-type amino acid transporter 1\n(LAT1)\nInhibition to reduce amino acid\ntransport\n2-aminobicyclo (2.2.1)-heptane\n2-carboxylic acid inhibits tumor\ngrowth in a xenograft model\nNawashiro et al. (2006)\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\n479",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 87
        }
    },
    "1725": {
        "text": "Cancer Cell 13, June 2008 ª2008 Elsevier Inc.\n479\nCancer Cell\nReview\nAchilles’ heel of cancer. It can be anticipated that the develop-\nment of highly speciﬁc, preferentially isoenzyme-selective meta-\nbolic inhibitors will generate an entirely novel armamentarium for\nour battle against cancer.\nACKNOWLEDGMENTS\nWe thank N. Joza and L. Zitvogel for critical reading. G.K. and J.P. are both\nsupported by the Ligue Nationale Contre le Cancer (Equipe Labellise´ e),",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 88
        }
    },
    "1726": {
        "text": "Agence Nationale de Recherche, Cance´ ropoˆ le Iˆle-de-France and PACA,\nInstitut National du Cancer, CNRS, and INSERM. G.K. is supported by the\nEuropean\nCommunity\n(Active\np53,\nApoSys,\nChemoRes,\nDeathTrain,\nTransDeath, and RIGHT).\nREFERENCES\nAl-Saffar, N.M., Troy, H., Ramirez de Molina, A., Jackson, L.E., Madhu, B.,\nGrifﬁths, J.R., Leach, M.O., Workman, P., Lacal, J.C., Judson, I.R., and Chung,\nY.L. (2006). Noninvasive magnetic resonance spectroscopic pharmacody-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 89
        }
    },
    "1727": {
        "text": "namic markers of the choline kinase inhibitor MN58b in human carcinoma\nmodels. Cancer Res. 66, 427–434.\nBeckers, A., Organe, S., Timmermans, L., Scheys, K., Peeters, A., Bru-\nsselmans, K., Verhoeven, G., and Swinnen, J.V. (2007). Chemical inhibition\nof acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively\nin cancer cells. Cancer Res. 67, 8180–8187.\nBensaad, K., Tsuruta, A., Selak, M.A., Vidal, M.N., Nakano, K., Bartrons, R.,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 90
        }
    },
    "1728": {
        "text": "Gottlieb, E., and Vousden, K.H. (2006). TIGAR, a p53-inducible regulator of\nglycolysis and apoptosis. Cell 126, 107–120.\nBonnet, S., Archer, S.L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thomp-\nson, R., Lee, C.T., Lopaschuk, G.D., Puttagunta, L., Bonnet, S., et al. (2007). A\nmitochondria-K+ channel axis is suppressed in cancer and its normalization\npromotes apoptosis and inhibits cancer growth. Cancer Cell 11, 37–51.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 91
        }
    },
    "1729": {
        "text": "Brahimi-Horn, M.C., Chiche, J., and Pouyssegur, J. (2007). Hypoxia signalling\ncontrols metabolic demand. Curr. Opin. Cell Biol. 19, 223–229.\nBrandon, M., Baldi, P., and Wallace, D.C. (2006). Mitochondrial mutations in\ncancer. Oncogene 25, 4647–4662.\nBraunstein, S., Karpisheva, K., Pola, C., Goldberg, J., Hochman, T., Yee, H.,\nCangiarella, J., Arju, R., Formenti, S.C., and Schneider, R.J. (2007). A hyp-\noxia-controlled cap-dependent to cap-independent translation switch in",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 92
        }
    },
    "1730": {
        "text": "breast cancer. Mol. Cell 28, 501–512.\nBrizel, D.M., and Esclamado, R. (2006). Concurrent chemoradiotherapy for lo-\ncally advanced, nonmetastatic, squamous carcinoma of the head and neck:\nconsensus, controversy, and conundrum. J. Clin. Oncol. 24, 2612–2617.\nChi, S.L., Wahl, M.L., Mowery, Y.M., Shan, S., Mukhopadhyay, S., Hilder-\nbrand, S.C., Kenan, D.J., Lipes, B.D., Johnson, C.E., Marusich, M.F., et al.\n(2007). Angiostatin-like activity of a monoclonal antibody to the catalytic sub-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 93
        }
    },
    "1731": {
        "text": "unit of F1F0 ATP synthase. Cancer Res. 67, 4716–4724.\nChristofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten,\nR.E., Wei, R., Fleming, M.D., Schreiber, S.L., and Cantley, L.C. (2008a). The M2\nsplice isoform of pyruvate kinase is important for cancer metabolism and\ntumour growth. Nature 452, 230–233.\nChristofk, H.R., Vander Heiden, M.G., Wu, N., Asara, J.W., and Cantley, L.C.\n(2008b). Pyruvate kinase M2 is a phosphotyrosine binding protein. Nature\n452, 181–186.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 94
        }
    },
    "1732": {
        "text": "452, 181–186.\nCondeelis, J., and Pollard, J.W. (2006). Macrophages: obligate partners for\ntumor cell migration, invasion, and metastasis. Cell 124, 263–266.\nCounillon, L., and Pouyssegur, J. (2000). The expanding family of eucaryotic\nNa(+)/H(+) exchangers. J. Biol. Chem. 275, 1–4.\nCramer, T., Yamanishi, Y., Clausen, B.E., Forster, I., Pawlinski, R., Mackman,\nN., Haase, V.H., Jaenisch, R., Corr, M., Nizet, V., et al. (2003). HIF-1alpha is",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 95
        }
    },
    "1733": {
        "text": "essential for myeloid cell-mediated inﬂammation. Cell 112, 645–657.\nCulmsee, C., and Mattson, M.P. (2005). p53 in neuronal apoptosis. Biochem.\nBiophys. Res. Commun. 331, 761–777.\nDang, C.V., Kim, J.-W., Gao, P., and Yustein, J. (2008). The interplay between\nMYC and HIF in cancer. Nat. Rev. Cancer 8, 51–56.\nDeberardinis, R.J., Lum, J.J., and Thompson, C.B. (2006). Phosphatidylinosi-\ntol 3-kinase-dependent modulation of carnitine palmitoyltransferase 1A ex-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 96
        }
    },
    "1734": {
        "text": "pression regulates lipid metabolism during hematopoietic cell growth. J.\nBiol. Chem. 281, 37372–37380.\nErler, J.T., Bennewith, K.L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q.T., Chi,\nJ.T., Jeffrey, S.S., and Giaccia, A.J. (2006). Lysyl oxidase is essential for hyp-\noxia-induced metastasis. Nature 440, 1222–1226.\nEsteban, M.A., Tran, M.G., Harten, S.K., Hill, P., Castellanos, M.C., Chandra,\nA., Raval, R., O’Brien, T.S., and Maxwell, P.H. (2006). Regulation of E-cadherin",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 97
        }
    },
    "1735": {
        "text": "expression by VHL and hypoxia-inducible factor. Cancer Res. 66, 3567–3575.\nEvans, J.M., Ogston, S.A., Emslie-Smith, A., and Morris, A.D. (2006). Risk of\nmortality and adverse cardiovascular outcomes in type 2 diabetes: a compar-\nison of patients treated with sulfonylureas and metformin. Diabetologia 49,\n930–936.\nFaivre, S., Kroemer, G., and Raymond, E. (2006). Current development of\nmTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5, 671–688.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 98
        }
    },
    "1736": {
        "text": "Fantin, V.R., St-Pierre, J., and Leder, P. (2006). Attenuation of LDH-A expres-\nsion uncovers a link between glycolysis, mitochondrial physiology, and tumor\nmaintenance. Cancer Cell 9, 425–434.\nFischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M.,\nGottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007). Inhibitory effect of\ntumor cell-derived lactic acid on human T cells. Blood 109, 3812–3819.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 99
        }
    },
    "1737": {
        "text": "Foldi, M., Stickeler, E., Bau, L., Kretz, O., Watermann, D., Gitsch, G., Kayser,\nG., Zur Hausen, A., and Coy, J.F. (2007). Transketolase protein TKTL1 overex-\npression: A potential biomarker and therapeutic target in breast cancer. Oncol.\nRep. 17, 841–845.\nFukuda, R., Zhang, H., Kim, J.W., Shimoda, L., Dang, C.V., and Semenza, G.L.\n(2007). HIF-1 regulates cytochrome oxidase subunits to optimize efﬁciency of\nrespiration in hypoxic cells. Cell 129, 111–122.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 100
        }
    },
    "1738": {
        "text": "respiration in hypoxic cells. Cell 129, 111–122.\nFunes, J.M., Quintero, M., Henderson, S., Martinez, D., Qureshi, U., West-\nwood, C., Clements, M.O., Bourboulia, D., Pedley, R.B., Moncada, S., and\nBoshoff, C. (2007). Transformation of human mesenchymal stem cells in-\ncreases their dependency on oxidative phosphorylation for energy production.\nProc. Natl. Acad. Sci. USA 104, 6223–6228.\nGalluzzi, L., Larochette, N., Zamzami, N., and Kroemer, G. (2006). Mitochondria",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 101
        }
    },
    "1739": {
        "text": "as therapeutic targets for cancer chemotherapy. Oncogene 25, 4812–4830.\nGao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z.M.,\nFelsher, D.W., Cheng, L., Pevsner, J., et al. (2007). HIF-dependent antitumori-\ngenic effect of antioxidants in vivo. Cancer Cell 12, 230–238.\nGatenby, R.A., and Gillies, R.J. (2004). Why do cancers have high aerobic\nglycolysis? Nat. Rev. Cancer 4, 891–899.\nGlunde, K., and Bhujwalla, Z.M. (2007). Choline kinase alpha in cancer progno-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 102
        }
    },
    "1740": {
        "text": "sis and treatment. Lancet Oncol. 8, 855–857.\nGottlieb, E., and Tomlinson, I.P. (2005). Mitochondrial tumour suppressors:\na genetic and biochemical update. Nat. Rev. Cancer 5, 857–866.\nGraff, J.R., Konicek, B.W., Vincent, T.M., Lynch, R.L., Monteith, D., Weir, S.N.,\nSchwier, P., Capen, A., Goode, R.L., Dowless, M.S., et al. (2007). Therapeutic\nsuppression of translation initiation factor eIF4E expression reduces tumor\ngrowth without toxicity. J. Clin. Invest. 117, 2638–2648.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 103
        }
    },
    "1741": {
        "text": "Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100,\n57–70.\nHarris, A.L. (2002). Hypoxia–a key regulatory factor in tumour growth. Nat. Rev.\nCancer 2, 38–47.\nHatzivassiliou, G., Zhao, F., Bauer, D.E., Andreadis, C., Shaw, A.N., Dhanak,\nD., Hingorani, S.R., Tuveson, D.A., and Thompson, C.B. (2005). ATP citrate\nlyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311–321.\nIgney, F.H., and Krammer, P.H. (2002). Death and anti-death: tumour resis-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 104
        }
    },
    "1742": {
        "text": "tance to apoptosis. Nat. Rev. Cancer 2, 277–288.\nIshikawa, K., Takenaga, K., Akimoto, M., Koshikawa, N., Yamaguchi, A., Ima-\nnishi, H., Nakada, K., Honma, Y., and Hayashi, J.-I. (2008). ROS-generating\n480\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\nCancer Cell\nReview\nmitochondrial DNA mutations can regulate tumor cell metastasis. Science 320,\n661–664.\nKim, J.W., Tchernyshyov, I., Semenza, G.L., and Dang, C.V. (2006). HIF-1-me-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 105
        }
    },
    "1743": {
        "text": "diated expression of pyruvate dehydrogenase kinase: a metabolic switch\nrequired for cellular adaptation to hypoxia. Cell Metab. 3, 177–185.\nKim, J.W., Gao, P., Liu, Y.C., Semenza, G.L., and Dang, C.V. (2007a). Hypoxia-\ninducible factor 1 and dysregulated c-Myc cooperatively induce vascular\nendothelial growth factor and metabolic switches hexokinase 2 and pyruvate\ndehydrogenase kinase 1. Mol. Cell. Biol. 27, 7381–7393.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 106
        }
    },
    "1744": {
        "text": "Kim, W., Yoon, J.H., Jeong, J.M., Cheon, G.J., Lee, T.S., Yang, J.I., Park, S.C.,\nand Lee, H.S. (2007b). Apoptosis-inducing antitumor efﬁcacy of hexokinase II\ninhibitor in hepatocellular carcinoma. Mol. Cancer Ther. 6, 2554–2562.\nKo, Y.H., Smith, B.L., Wang, Y., Pomper, M.G., Rini, D.A., Torbenson, M.S.,\nHullihen, J., and Pedersen, P.L. (2004). Advanced cancers: eradication in all\ncases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys.\nRes. Commun. 324, 269–275.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 107
        }
    },
    "1745": {
        "text": "Res. Commun. 324, 269–275.\nKondoh, H., Lleonart, M.E., Gil, J., Wang, J., Degan, P., Peters, G., Martinez,\nD., Carnero, A., and Beach, D. (2005). Glycolytic enzymes can modulate cellu-\nlar life span. Cancer Res. 65, 177–185.\nKong, D., Park, E.J., Stephen, A.G., Calvani, M., Cardellina, J.H., Monks, A.,\nFisher, R.J., Shoemaker, R.H., and Melillo, G. (2005). Echinomycin, a small-\nmolecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer\nRes. 65, 9047–9055.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 108
        }
    },
    "1746": {
        "text": "Res. 65, 9047–9055.\nKoukourakis, M.I., Giatromanolaki, A., Harris, A.L., and Sivridis, E. (2006).\nComparison of metabolic pathways between cancer cells and stromal cells\nin colorectal carcinomas: a metabolic survival role for tumor-associated\nstroma. Cancer Res. 66, 632–637.\nKroemer, G., Galluzzi, L., and Brenner, C. (2007). Mitochondrial membrane\npermeabilization in cell death. Physiol. Rev. 87, 99–163.\nLangbein, S., Zerilli, M., Zur Hausen, A., Staiger, W., Rensch-Boschert, K.,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 109
        }
    },
    "1747": {
        "text": "Lukan, N., Popa, J., Ternullo, M.P., Steidler, A., Weiss, C., et al. (2006). Expres-\nsion of transketolase TKTL1 predicts colon and urothelial cancer patient\nsurvival: Warburg effect reinterpreted. Br. J. Cancer 94, 578–585.\nLardner, A. (2001). The effects of extracellular pH on immune function. J.\nLeukoc. Biol. 69, 522–530.\nLopez-Rios, F., Sanchez-Arago, M., Garcia-Garcia, E., Ortega, A.D., Berren-\ndero, J.R., Pozo-Rodriguez, F., Lopez-Encuentra, A., Ballestin, C., and",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 110
        }
    },
    "1748": {
        "text": "Cuezva, J.M. (2007). Loss of the mitochondrial bioenergetic capacity underlies\nthe glucose avidity of carcinomas. Cancer Res. 67, 9013–9017.\nMacKenzie, E.D., Selak, M.A., Tennant, D.A., Payne, L.J., Crosby, S., Freder-\niksen, C.M., Watson, D.G., and Gottlieb, E. (2007). Cell-permeating alpha-ke-\ntoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-\ndeﬁcient cells. Mol. Cell. Biol. 27, 3282–3289.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 111
        }
    },
    "1749": {
        "text": "deﬁcient cells. Mol. Cell. Biol. 27, 3282–3289.\nMankoff, D.A., Eary, J.F., Link, J.M., Muzi, M., Rajendran, J.G., Spence, A.M.,\nand Krohn, K.A. (2007). Tumor-speciﬁc positron emission tomography imag-\ning in patients: [18F] ﬂuorodeoxyglucose and beyond. Clin. Cancer Res. 13,\n3460–3469.\nManning, B.D., and Cantley, L.C. (2007). AKT/PKB signaling: navigating down-\nstream. Cell 129, 1261–1274.\nMatoba, S., Kang, J.G., Patino, W.D., Wragg, A., Boehm, M., Gavrilova, O.,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 112
        }
    },
    "1750": {
        "text": "Hurley, P.J., Bunz, F., and Hwang, P.M. (2006). p53 regulates mitochondrial\nrespiration. Science 312, 1650–1653.\nMazurek, S., Boschek, C.B., Hugo, F., and Eigenbrodt, E. (2005). Pyruvate\nkinase type M2 and its role in tumor growth and spreading. Semin. Cancer\nBiol. 15, 300–308.\nMiyamoto, S., Murphy, A.N., and Brown, J.H. (2008). Akt mediates mitochon-\ndrial protection in cardiomyocytes through phosphorylation of mitochondrial",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 113
        }
    },
    "1751": {
        "text": "hexokinase-II. Cell Death Differ. 15, 521–529. Published online December 7,\n2007. 10.1038/sj.cdd.4402285.\nMorgan, P.E., Pastorekova, S., Stuart-Tilley, A.K., Alper, S.L., and Casey, J.R.\n(2007). Interactions of transmembrane carbonic anhydrase, CAIX, with bicar-\nbonate transporters. Am. J. Physiol. Cell Physiol. 293, C738–C748.\nMunn, D.H., and Mellor, A.L. (2007). Indoleamine 2,3-dioxygenase and tumor-\ninduced tolerance. J. Clin. Invest. 117, 1147–1154.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 114
        }
    },
    "1752": {
        "text": "Nawashiro, H., Otani, N., Shinomiya, N., Fukui, S., Ooigawa, H., Shima, K.,\nMatsuo, H., Kanai, Y., and Endou, H. (2006). L-type amino acid transporter 1\nas a potential molecular target in human astrocytic tumors. Int. J. Cancer\n119, 484–492.\nPapandreou, I., Cairns, R.A., Fontana, L., Lim, A.L., and Denko, N.C. (2006).\nHIF-1 mediates adaptation to hypoxia by actively downregulating mitochon-\ndrial oxygen consumption. Cell Metab. 3, 187–197.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 115
        }
    },
    "1753": {
        "text": "drial oxygen consumption. Cell Metab. 3, 187–197.\nPastorino, J.G., Hoek, J.B., and Shulga, N. (2005). Activation of glycogen syn-\nthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by\nphosphorylating voltage-dependent anion channel and potentiates chemo-\ntherapy-induced cytotoxicity. Cancer Res. 65, 10545–10554.\nPedersen, P.L. (2007). Warburg, me and Hexokinase 2: Multiple discoveries of\nkey molecular events underlying one of cancers’ most common phenotypes,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 116
        }
    },
    "1754": {
        "text": "the ‘‘Warburg Effect’’, i.e., elevated glycolysis in the presence of oxygen. J.\nBioenerg. Biomembr. 39, 211–222.\nPennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., and\nComoglio, P.M. (2003). Hypoxia promotes invasive growth by transcriptional\nactivation of the met protooncogene. Cancer Cell 3, 347–361.\nPouyssegur, J., Dayan, F., and Mazure, N.M. (2006). Hypoxia signalling in\ncancer and approaches to enforce tumour regression. Nature 441, 437–443.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 117
        }
    },
    "1755": {
        "text": "Puccetti, P., and Grohmann, U. (2007). IDO and regulatory T cells: a role for re-\nverse signalling and non-canonical NF-kappaB activation. Nat. Rev. Immunol.\n7, 817–823.\nRobey, R.B., and Hay, N. (2006). Mitochondrial hexokinases, novel media-\ntors of the antiapoptotic effects of growth factors and Akt. Oncogene 25,\n4683–4696.\nSemenza, G.L. (2007). Hypoxia-inducible factor 1 (HIF-1) pathway. Sci. STKE\n2007, cm8.\nShaw, R.J. (2006). Glucose metabolism and cancer. Curr. Opin. Cell Biol. 18,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 118
        }
    },
    "1756": {
        "text": "598–608.\nShaw, R.J., and Cantley, L.C. (2006). Ras, PI(3)K and mTOR signalling controls\ntumour cell growth. Nature 441, 424–430.\nSimons, A.L., Ahmad, I.M., Mattson, D.M., Dornfeld, K.J., and Spitz, D.R.\n(2007). 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity\nvia metabolic oxidative stress in human head and neck cancer cells. Cancer\nRes. 67, 3364–3370.\nStetak, A., Veress, R., Ovadi, J., Csermely, P., Keri, G., and Ullrich, A. (2007).",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 119
        }
    },
    "1757": {
        "text": "Nuclear translocation of the tumor marker pyruvate kinase M2 induces\nprogrammed cell death. Cancer Res. 67, 1602–1608.\nSwietach, P., Vaughan-Jones, R.D., and Harris, A.L. (2007). Regulation of\ntumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26,\n299–310.\nTaylor, C.T., and Pouyssegur, J. (2007). Oxygen, hypoxia, and stress. Ann. N Y\nAcad. Sci. 1113, 87–94.\nThiry, A., Dogne, J.M., Masereel, B., and Supuran, C.T. (2006). Targeting tu-",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 120
        }
    },
    "1758": {
        "text": "mor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol.\nSci. 27, 566–573.\nTomiyama, A., Serizawa, S., Tachibana, K., Sakurada, K., Samejima, H.,\nKuchino, Y., and Kitanaka, C. (2006). Critical role for mitochondrial oxidative\nphosphorylation in the activation of tumor suppressors Bax and Bak. J. Natl.\nCancer Inst. 98, 1462–1473.\nWang, H.Q., Altomare, D.A., Skele, K.L., Poulikakos, P.I., Kuhajda, F.P., Di",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 121
        }
    },
    "1759": {
        "text": "Cristofano, A., and Testa, J.R. (2005). Positive feedback regulation between\nAKT activation and fatty acid synthase expression in ovarian carcinoma cells.\nOncogene 24, 3574–3582.\nWarburg, O., Posener, K., and Negelein, E. (1924). U¨ ber den Stoffwechsel der\nTumoren. Biochem. Z. 152, 319–344.\nYang, M.H., Wu, M.Z., Chiou, S.H., Chen, P.M., Chang, S.Y., Liu, C.J., Teng,\nS.C., and Wu, K.J. (2008). Direct regulation of TWIST by HIF-1alpha promotes\nmetastasis. Nat. Cell Biol. 10, 295–305.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 122
        }
    },
    "1760": {
        "text": "metastasis. Nat. Cell Biol. 10, 295–305.\nYoon, S., Lee, M.Y., Park, S.W., Moon, J.S., Koh, Y.K., Ahn, Y.H., Park, B.W.,\nand Kim, K.S. (2007). Up-regulation of acetyl-CoA carboxylase alpha and fatty\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\n481\nCancer Cell\nReview\nacid synthase by human epidermal growth factor receptor 2 at the translational\nlevel in breast cancer cells. J. Biol. Chem. 282, 26122–26131.\nZhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K.I.,",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 123
        }
    },
    "1761": {
        "text": "Dang, C.V., and Semenza, G.L. (2007). HIF-1 inhibits mitochondrial biogenesis\nand cellular respiration in VHL-deﬁcient renal cell carcinoma by repression of\nC-MYC activity. Cancer Cell 11, 407–420.\nZhou, S., Kachhap, S., Sun, W., Wu, G., Chuang, A., Poeta, L., Grumbine,\nL., Mithani, S.K., Chatterjee, A., Koch, W., et al. (2007). Frequency and phe-\nnotypic implications of mitochondrial DNA mutations in human squamous\ncell cancers of the head and neck. Proc. Natl. Acad. Sci. USA 104, 7540–\n7545.",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 124
        }
    },
    "1762": {
        "text": "7545.\nZitvogel, L., Tesniere, A., and Kroemer, G. (2006). Cancer despite immunosur-\nveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6,\n715–727.\nZoratti, M., and Szabo, I. (1995). The mitochondrial permeability transition.\nBiochim. Biophys. Acta 1241, 139–176.\n482\nCancer Cell 13, June 2008 ª2008 Elsevier Inc.\nCancer Cell\nReview",
        "metadata": {
            "source": "PIIS1535610808001608.pdf",
            "chunk_id": 125
        }
    },
    "1763": {
        "text": "Journal of Pathology\nJ Pathol 2017; 241: 183–191\nPublished online 18 November 2016 in Wiley Online Library\n(wileyonlinelibrary.com) DOI: 10.1002/path.4821\nINVITED REVIEW\nMeasuring cancer evolution from the genome\nTrevor A Graham\n1,* and Andrea Sottoriva\n2,*\n1 Evolution and Cancer Laboratory, Barts Cancer Institute, Queen Mary University of London, London, UK\n2 Cancer Evolutionary Genomics and Modelling Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, Sutton, UK",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 0
        }
    },
    "1764": {
        "text": "*Correspondence to: TA Graham, Evolution and Cancer Laboratory, Barts Cancer Institute, Charterhouse Square, Queen Mary University of London,\nEC1M 6BQ, UK. E-mail: t.graham@qmul.ac.uk\nOr A Sottoriva, Cancer Evolutionary Genomics and Modelling Laboratory, Centre for Evolution and Cancer, The Institute of Cancer Research, Sutton,\nSM2 5NG, UK. E-mail: Andrea.Sottoriva@icr.ac.uk\nAbstract\nThe temporal dynamics of cancer evolution remain elusive, because it is impractical to longitudinally observe",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 1
        }
    },
    "1765": {
        "text": "cancers unperturbed by treatment. Consequently, our knowledge of how cancers grow largely derives from\ninferences made from a single point in time – the endpoint in the cancer’s evolution, when it is removed from the\nbody and studied in the laboratory. Fortuitously however, the cancer genome, by virtue of ongoing mutations that\nuniquely mark clonal lineages within the tumour, provides a rich, yet surreptitious, record of cancer development.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 2
        }
    },
    "1766": {
        "text": "In this review, we describe how a cancer’s genome can be analysed to reveal the temporal history of mutation and\nselection, and discuss why both selective and neutral evolution feature prominently in carcinogenesis. We argue\nthat selection in cancer can only be properly studied once we have some understanding of what the absence of\nselection looks like. We review the data describing punctuated evolution in cancer, and reason that punctuated",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 3
        }
    },
    "1767": {
        "text": "phenotype evolution is consistent with both gradual and punctuated genome evolution. We conclude that, to\nmap and predict evolutionary trajectories during carcinogenesis, it is critical to better understand the relationship\nbetween genotype change and phenotype change.\nCopyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 4
        }
    },
    "1768": {
        "text": "Keywords: clonal evolution of cancer; neutral evolution; selection; punctuated equilibrium; gradualism; saltation; hopeful monsters;\nsubclones; intratumour heterogeneity; next-generation sequencing\nReceived 26 September 2016; Revised 5 October 2016; Accepted 7 October 2016\nNo conflicts of interest were declared.\nIntroduction\nHow do cancers grow? This basic question continues to\nbe difficult to answer, for the obvious reason that longi-\ntudinal observation of tumour growth is nearly always",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 5
        }
    },
    "1769": {
        "text": "impractical, both in humans and in model systems.\nConsequently, our understanding of tumour formation\nrelies on historical inference based on the composition\nof excised tumours. In other words, our understanding\nof the temporal process of tumour evolution is largely\nderived from data collected at a single time point: the\ntime point at the end of the process when the tumour\nends up on the specimen table. However, this state of\naffairs is not as sorry as it may sound, as, fortunately, the",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 6
        }
    },
    "1770": {
        "text": "tumour genome (or, more accurately, the genomes of all\nthe cells in the tumour) provides a surreptitious but rich\nrecord of a tumour’s growth.\nEach time that a cell divides, errors during DNA\nreplication mean that new mutations are introduced\ninto the genomes of the daughter cells [1–3]. Epige-\nnetic marks (e.g. DNA methylation) are also copied\nwith limited fidelity [4]. Larger-scale chromosomal\nor part-chromosome losses or amplifications [somatic",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 7
        }
    },
    "1771": {
        "text": "copy number alterations (SCNAs)] and other structural\nrearrangements also occur at an appreciable frequency\nin many cancers [5,6]. It is these naturally occurring\n(epi)genetic alterations that record the ancestry of the\ncells in the tumour, and, because tumours are clonally\nderived, all of the cells in the tumour will carry the\nmutations in the first cancer cell, whereas later-arising\nsubclones are identifiable by their sharing of a particu-",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 8
        }
    },
    "1772": {
        "text": "lar unique set of variants; therefore, the order of clone\ndevelopment can be inferred by comparing the sets of\nmutations present in different cells of the tumour. The\nlogic of this kind of analysis is at the heart of phylo-\ngenetics methods as applied to cancer [7]. Moreover, if\na particular type of mutation accrues at a constant rate\n(for example, the same number of new mutations are\nintroduced in each cell division; this appears to be the",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 9
        }
    },
    "1773": {
        "text": "case for C > T transitions within specific three-base pair\nmotifs, for instance - see ref. [1]), then counting the num-\nber of mutations of the type that are unique to a particular\nlineage gives an estimate of the relative time that the lin-\neage arose. A constant mutation rate is referred to as a\n‘molecular clock’, and, if the rate at which the molec-\nular clock ‘ticks’ is known, then the absolute time of\nevents (where time is measured in cell divisions elapsed)",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 10
        }
    },
    "1774": {
        "text": "Copyright © 2016 Pathological Society of Great Britain and Ireland.\nJ Pathol 2017; 241: 183–191\nPublished by John Wiley & Sons, Ltd. www.pathsoc.org\nwww.thejournalofpathology.com\n184\nTA Graham and A Sottoriva\ncan also be determined [8]. These methods have been\napplied to a wide variety of cancers and have provided\nnew insights into the order and timing of mutation accu-\nmulation (for some examples, see [9–25]).\nHowever, mutation is not the only force shaping",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 11
        }
    },
    "1775": {
        "text": "However, mutation is not the only force shaping\nthe cancer genome: evolutionary selection also plays\na critical role. Selection refers to the situation where\none group of cells within the tumour is evolutionar-\nily ‘favoured’ over another, such that the favoured cells\nhave more offspring than the not-favoured cells. The\nfavouring is a result of the cell evolving a new phe-\nnotypic trait that gives it an advantage in the current\nmicroenvironment (context) of the tumour; the trait is",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 12
        }
    },
    "1776": {
        "text": "referred to as adaptive. For example, a cell with a low\nmetabolic demand might grow faster than a cell with a\nhigh metabolic demand when both cells are together in\na nutrient-poor microenvironment. The result of selec-\ntion is that any mutation in the selected (favoured) pop-\nulation becomes more common in the tumour popu-\nlation as a whole, whereas negatively selected clones\n(not favoured) become relatively less common. Conse-\nquently, selection plays a central role in shaping the fre-",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 13
        }
    },
    "1777": {
        "text": "quency distribution of mutations within a tumour.\nTo understand how a tumour has grown from its\ngenome, we therefore need to understand both mutation\nand selection, and, critically, how these two processes\ntogether shape the pattern and frequency of mutations\nin the genome. Mutation and selection are deeply inter-\ntwined, as a new mutation may produce a new adaptive\ntrait and therefore drive selection, and, conversely, a\nnew microenvironmental selective pressure (such as",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 14
        }
    },
    "1778": {
        "text": "targeted therapy) may mean that a pre-existing mutation\nbecomes adaptive and so increases in frequency [26]. In\ngeneral, mutation is considered to be a random process;\nany mutation may occur at any time with some (low\nand/or fluctuating) probability, whereas selection is\nnon-random; only particular mutations are adaptive in\na given context [27,28]. For example, loss of normal\nfunction of the APC gene provides a clear selective\nadvantage to cells in the intestine [29–31], but not, say,",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 15
        }
    },
    "1779": {
        "text": "to those in the lung, even though, presumably, APC\nmutation occurs at comparable rates in both tissues.\nThus, the frequency at which particular mutations are\nobserved across a tumour is a function both of the rate\nat which the mutations occur, and of the likelihood\nthe mutation has of being adaptive and driving clonal\nexpansion to a detectable level.\nTissue architecture –which we can broadly think of\nas the ‘mechanical microenvironment’ – provides addi-",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 16
        }
    },
    "1780": {
        "text": "tional selective constraints on tumour evolution. Many\nepithelia have glandular architecture (e.g. the crypts in\nthe colon, and ducts in the prostate and breast), and\nit is the abnormal growth of these glands (rather than\nthe cells within them as such) that underlies neoplastic\ngrowth. Thus, cancer development requires evolution at\nmultiple levels in epithelial tissues [32]: in the example\nof the colon, first a mutated cell must repopulate the",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 17
        }
    },
    "1781": {
        "text": "crypt, and then the mutant crypt itself must divide to\nform a glandular adenoma [33]. Computational mod-\nelling suggests that these tissue architectures have (at\nTable 1. Definition of terms\nNeutral evolution\nEvolution in which all individuals in\nthe population have equal fitness.\nIn a growing population (such as a\nnewly formed tumour), this means\nthat all cells grow at the same rate\nDrift\nStochastic effects (e.g. random cell\ndeath in a tumour) can cause some\n‘lucky’ individuals in a population",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 18
        }
    },
    "1782": {
        "text": "‘lucky’ individuals in a population\nto have more offspring than others,\nso the ‘lucky lineage’ increases in\nsize. Consequently, drift can cause\nfluctuations in subclone size in the\nabsence of selection\nSelection\nThe process that results in one\nindividual in a population, because\nof its particular well-adapted traits,\nhaving more offspring than another\nless well-adapted individual\nFitness\nThe relative ability of an individual to\nproduce surviving offspring in a\npopulation\nPunctuated equilibrium",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 19
        }
    },
    "1783": {
        "text": "population\nPunctuated equilibrium\nThe process whereby apparently\nabrupt changes in the phenotype of\nthe population at large occur\nbecause of gradual evolution in\nsmall, spatially isolated niches\nHopeful monster/saltation\nThe process whereby abrupt changes\nin phenotype are cause by\nunderlying (large-scale) punctuated\nchanges in the genome. In cancer,\nmassive genome alterations\noccurring in a single cell division\nare examples of saltatory genome\nevolution",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 20
        }
    },
    "1784": {
        "text": "are examples of saltatory genome\nevolution\nleast in part) evolved to suppress clonal evolution [34].\nTissue architecture means that, in solid tumours, clonal\nexpansions are spatially delineated, so the indicators of\nmutation and selection within the genome are likely to\nshow intratumour heterogeneity.\nIt is clear that cancer formation requires the acqui-\nsition of a number of key driver alterations (mutations\nand epigenetic changes in cancer cells) [35,36]. The",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 21
        }
    },
    "1785": {
        "text": "precise number of drivers per cancer is uncertain – and\nindeed, given the inherently contextual nature of selec-\ntion, a comprehensive list of cancer-specific drivers is\nunlikely to exist in reality. It serves our purposes here to\nthink of driver mutations as mutations that are positively\nselected in their (changing) microenvironmental context\nwithin the tumour. A central question in tumour evolu-\ntion is: what is the temporal pattern of driver alteration",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 22
        }
    },
    "1786": {
        "text": "acquisition? The competing theories are gradualism and\npunctuation (see Table 1 for a definition of terms). The\ngradualist theory proposes that cancer evolution happens\nvia a steady accumulation of driver mutations and a con-\ncomitant steady series of selective clonal outgrowths,\nwhereas the punctuated theory proposes that the evolu-\ntion of cancer occurs in fits and starts.\nIn this review, we address how mutation and selec-\ntion together shape the cancer genome, with particular",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 23
        }
    },
    "1787": {
        "text": "reference to the manifestations of graduated and punc-\ntuated evolution.\nCopyright © 2016 Pathological Society of Great Britain and Ireland.\nJ Pathol 2017; 241: 183–191\nPublished by John Wiley & Sons, Ltd. www.pathsoc.org\nwww.thejournalofpathology.com",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 24
        }
    },
    "1788": {
        "text": "www.thejournalofpathology.com\n 10969896, 2017, 2, Downloaded from https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4821 by Turkey Cochrane Evidence Aid, Wiley Online Library on [22/08/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\nMeasuring cancer evolution\n185",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 25
        }
    },
    "1789": {
        "text": "Measuring cancer evolution\n185\nFigure 1. The influence of selection in the cancer genome. (A) A simulated distribution of VAFs in a cancer that is evolving neutrally. VAF\ndistributions are naturally produced by next-generation genome sequencing. The distribution has a peak around 0.5 – these are the clonal\nvariants present in all cancer cells. The distribution of subclonal variants (those at lower frequencies) follows a 1/f distribution, whereby",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 26
        }
    },
    "1790": {
        "text": "there are ever more mutations at ever lower frequency. Neutral cancer evolution can be detected by comparing the observed distribution of\nmutation frequencies in a cancer with this expected theoretical distribution. (B) VAF distribution for an in silico model of a cancer in which\na fitter subclone has clonally expanded within the tumour. The cluster of mutations within the subclone are ‘passenger’ mutations dragged",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 27
        }
    },
    "1791": {
        "text": "along to higher frequency within the tumour during the clonal expansion. Even though there is selection, there is still a ‘background’ of\nneutral evolution – this is the neutral evolution within the selected subclone and in the residual tumour cells.\nDetecting selection and neutrality from\nthe cancer genome\nClonal selection, whatever the biological mechanism\ndriving it, ultimately results in the relative outgrowth\nof the selected clone within the tumour. The clonal",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 28
        }
    },
    "1792": {
        "text": "outgrowth appears in the cancer’s genome via an\n‘over-representation’ of the mutations in the selected\nclone, as compared with the ‘null’ case, where the\ngenome evolved in the absence of selection (Figure 1).\nIn principle, then, detecting selection just requires spot-\nting the characteristic ‘clonal outgrowths’, and many\ndifferent bioinformatics tools have been developed to\nspot the ‘clusters’ of mutations at similar frequency\nin tumour next-generation sequencing data that are",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 29
        }
    },
    "1793": {
        "text": "characteristic of these outgrowths [22,37–39]. It is\nimportant to note here that the evolutionary dynamics of\nthe selected clone are largely revealed by the passenger\nmutations in that clone, not the drivers themselves: as\nthe selected clone grows out, all of the many passenger\nmutations in the clone are carried along to higher fre-\nquency, making the selected clone visible against the\nmilieu of unselected mutations in the tumour. There-\nfore, both driver and passenger mutations in the clone",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 30
        }
    },
    "1794": {
        "text": "are affected by selection, but passenger mutations are\ngenerally more informative, as they are more numerous\n[40]. This is just because, as evolution is a blind force,\nfor every ‘successful’ driver mutation, many ‘unsuc-\ncessful’ mutations have occurred in a genome as large\nas the human one.\nMoreover, this means that clonal selection is always\nvisible in the frequency distribution of mutations in\ncancer, irrespective of the biological mechanism that",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 31
        }
    },
    "1795": {
        "text": "provides the selective advantage. For example, sup-\npose that, rather than acquiring a new driver muta-\ntion, a clone gains a selective advantage because of\na sudden change in microenvironmental context (such\nas a new non-cell-autonomous interaction within the\ntumour [41]); even though the clone’s advantage is\ncell-extrinsically driven, its passenger mutations will\nstill become over-represented.\nHowever, we argue that, to be able to reliably spot",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 32
        }
    },
    "1796": {
        "text": "clonal outgrowths in a cancer’s genome, we first require\nan understanding of what the ‘null case’ – evolution\nin the absence of clonal selection – looks like. The\nabsence of clonal selection is referred to as ‘neutral\nevolution’, and, by definition, neutral evolution (in a\ngrowing population such as a tumour) is the case when\nall cells grow at the same rate. The definition of neutral\nevolution also encompasses stochastic drift. In a drifting",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 33
        }
    },
    "1797": {
        "text": "population, all cells grow at the same average rate, but,\nat any single point in time, any one lineage might,\nbecause of random effects, grow or shrink slightly faster\nthan another. We note that, if a ‘lucky’ clone happens\nto drift to proportionally high frequency in a neutrally\nevolving asexual population such as cancer, it could\nappear indistinguishable from a selected clone.\nMathematical modelling (or perhaps more accurately\nput: population genetics theory) provides a formal",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 34
        }
    },
    "1798": {
        "text": "description of the frequency of subclonal mutations\nwithin a neutrally growing tumour [42–44]. Under neu-\ntrality, the cumulative number of mutations at frequency\nf follows a ‘1/f’ distribution: this means that the number\nof mutations at a particular frequency in the tumour\nwill double each time that the frequency halves, or,\nmore loosely, when a tumour is growing neutrally there\nwill be ever more mutations at ever lower frequencies.\nThis mathematical result can be understood intuitively:",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 35
        }
    },
    "1799": {
        "text": "because a small number of new mutations are expected\nto accrue each time that a cell divides, then, as the\ntumour population increases in size, more and more\nnew mutations are accrued by the population as a whole,\nand the 1/f distribution is reached because precisely\ntwice as many new mutations are expected each time\nCopyright © 2016 Pathological Society of Great Britain and Ireland.\nJ Pathol 2017; 241: 183–191\nPublished by John Wiley & Sons, Ltd. www.pathsoc.org\nwww.thejournalofpathology.com",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 36
        }
    },
    "1800": {
        "text": "www.thejournalofpathology.com\n 10969896, 2017, 2, Downloaded from https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4821 by Turkey Cochrane Evidence Aid, Wiley Online Library on [22/08/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n186\nTA Graham and A Sottoriva\nthat the population doubles in size. To test for selection",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 37
        }
    },
    "1801": {
        "text": "in a growing cancer, it therefore suffices to ask whether\nor not the distribution of mutation frequencies observed\nin the cancer (as measured by next-generation sequenc-\ning) follows a 1/f distribution: in the case where it does\nnot, we can reject the null hypothesis of neutrality in\nfavour of recent selection.\nThis 1/f test must be applied with caution. Limited\ndepth sequencing can blur the signal from the evolu-\ntionary dynamics (the signals of both selection and",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 38
        }
    },
    "1802": {
        "text": "neutrality alike) [42]. It is conceivable that a particular\n‘just-right’ combination of subclones could produce a\nvariable allele frequency (VAF) distribution that mas-\nquerades as a 1/f distribution (if the selected subclones\nhappened to reach a particular set of sizes and the ‘noise’\nin the sequencing data blurred their passenger mutation\nVAFs appropriately). Although the allele frequencies\nalone cannot discount this possibility, neutral evolution",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 39
        }
    },
    "1803": {
        "text": "nevertheless provides a much more parsimonious expla-\nnation of a 1/f-like VAF distribution. Moreover, we note\nthat the 1/f test provides an objective indication of the\npresence or absence of subclonal selection, which does\nnot require prior knowledge of the identity of subclonal\ndrivers.\nThe ratio of non-synonymous (NS) mutations (which\nare likely to alter fitness by changing protein structure\nand function) to synonymous (S) mutations (which are",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 40
        }
    },
    "1804": {
        "text": "likely to be neutral) at a particular locus is another pop-\nular test for selection [45,46]. Typically, the NS/S ratio\nis normalized by the number of possible NS and S muta-\ntions that can occur at the locus of interest (the normal-\nized ratio is referred to as dN/dS), and then deviations in\nthe normalized ratio above 1 indicate positive selection\n(more NS mutations than expected by chance), whereas\ndeviations below 1 indicate negative selection (fewer NS",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 41
        }
    },
    "1805": {
        "text": "mutations than expected by chance). Applying dN/dS\nto cancer is complicated by the differential and evolv-\ning mutation rates of three-base pair motifs [47], which\ncan potentially skew the dN/dS values, but, nevertheless,\ncorrected dN/dS values within large cohorts of tumours\nhas revealed evidence of positive selection in cancer\nfor particular gene sets, such as the kinases [48]. We\nnote that applying dN/dS to detect subclonal selection\nwithin a tumour is extremely challenging, because, if",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 42
        }
    },
    "1806": {
        "text": "the selection is caused by a single base pair change (e.g.\nthe common KRAS c.35G > T mutation), then the signal\nfrom this locus will be ‘drowned out’ by all the other pas-\nsenger mutations within the clone, and applying dN/dS\non a gene-by-gene basis in individual tumours is not pos-\nsible, because of the relatively low numbers of detected\nsomatic mutations in any individual cancer.\nHow often does selection occur?\nWe recently looked for evidence of clonal selection",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 43
        }
    },
    "1807": {
        "text": "across cancer types by using the 1/f test described above.\nRemarkably, our analysis showed that, in ∼30% of can-\ncers of 14 different solid cancer types, we were unable\nto reject the null hypothesis of neutral evolution [42].\nIn cancer model systems, neutral drift of tumour cells is\nalso observed [49]. Therefore, the signature of selection\nappears to be somewhat rarer than we might naively have\nexpected from a gradualistic evolutionary perspective.\nHow often should we expect to see selection",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 44
        }
    },
    "1808": {
        "text": "How often should we expect to see selection\nmanifested in the cancer genome?\nFirst, we only expect to see clonal outgrowth if the clone\nis ‘caught in the act’ of growing out – e.g. if the clone\nhad already expanded to at least a minimal detectable\nsize at the time when the tumour was sampled, but it has\nnot yet expanded to repopulate the entire tumour [50].\nThe latter point is important because once a selected\nclone has taken over the whole tumour then all the cells",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 45
        }
    },
    "1809": {
        "text": "within the clone are the same as one another – and so the\npopulation then again evolves neutrally. The duration of\ntime during which a clone can be ‘caught in the act’\nof expanding is determined by the selective advantage\nof the clone (relative to the residual ‘host’ cells in the\ntumour): fitter clones will grow out more quickly. Unfor-\ntunately, empirical measurements of selective advan-\ntages of clones in growing tumours are lacking, so our",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 46
        }
    },
    "1810": {
        "text": "expectations of the likelihood of detecting a selected\nclone mid-expansion are largely based on guesswork.\nWithin the intestinal crypt (which has a constant pop-\nulation size), empirical measurement of the selective\nadvantages of the tumour suppressor gene APC and\nthe proto-oncogene KRAS reveal almost 50% increases\nin the probability of stem cell replacement [29]. If\ntumour subclones experienced similarly large selective\nadvantages, we might expect to only rarely see partially",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 47
        }
    },
    "1811": {
        "text": "expanded clones. Intriguingly, however, abstract math-\nematical modelling of mutation accumulation in grow-\ning tumours suggests that very low selective advantages\nfor new driver mutations (of the order of <1%) lead to\nreasonably long times before cancer occurs (in the mod-\nels, cancer is defined by a subclone having accumulated\na critical driver mutation burden) [51,52]. In addition,\nour own computational modelling shows that even size-\nable selective advantages produce only slight changes in",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 48
        }
    },
    "1812": {
        "text": "clone frequency in a growing population, and this result\nis even more pronounced when a new clone is formed\nin an already large tumour [14]. Together, these results\nwould predict that partially expanded subclones would\nbe commonplace if they were initiated at a sufficiently\nhigh rate. Clearly, empirical measurement of the differ-\nential fitness of tumour subclones is required.\nSecond, the likelihood of seeing selection is also\ndetermined by the rate at which new selected clones",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 49
        }
    },
    "1813": {
        "text": "are generated, either by clone-intrinsic mutation or by\nthe creation of a favourable microenvironment. This\nrate is directly related to the number of potential driver\nalterations that a clone can acquire: if there are many\npotential drivers, then new driver mutations are likely\nto occur frequently. Interestingly, genome sequencing\nstudies on large cohorts (such as the Cancer Genome\nCopyright © 2016 Pathological Society of Great Britain and Ireland.\nJ Pathol 2017; 241: 183–191",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 50
        }
    },
    "1814": {
        "text": "J Pathol 2017; 241: 183–191\nPublished by John Wiley & Sons, Ltd. www.pathsoc.org\nwww.thejournalofpathology.com\n 10969896, 2017, 2, Downloaded from https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4821 by Turkey Cochrane Evidence Aid, Wiley Online Library on [22/08/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 51
        }
    },
    "1815": {
        "text": "Measuring cancer evolution\n187\nAtlas; http://cancergenome.nih.gov/) consistently reveal\nfairly short lists of recurrently mutated genes in each\ncancer type: for example, in a cohort of 276 colorectal\ncancers, only 24 genes were mutated at a significantly\ngreater than background frequency [53]. These studies\nsuggest that the number of drivers may actually be quite\nlimited, and hence neutral dynamics may be relatively\ncommon in cancers because of the low rate of driver\nmutation accrual.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 52
        }
    },
    "1816": {
        "text": "mutation accrual.\nThird, our ability to detect selection is, of course, lim-\nited by the resolution of our tools for finding it. The\ncurrent standard of moderate-depth exome sequencing\nis 100× coverage, facilitating reasonably reliable detec-\ntion of mutations at ∼5% frequency. This means that low\nselective advantages that cause only slight changes in\nclone frequency are largely indistinguishable from the\nbackground neutral evolution. The ‘mini-driver’ hypoth-",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 53
        }
    },
    "1817": {
        "text": "esis, which postulates that there are many mutations\nthat each cause small fitness effects in cancers [54],\nwould clearly be challenging to confirm or refute from\nmoderate-depth sequencing data. Moreover, as a tumour\ngrows, newly generated clones form ever lower propor-\ntions of the tumour cell population, so detecting them\nbecomes ever more challenging as the tumour becomes\nlarger: thus the ∼5% sensitivity of sequencing provides a\nwindow to detect only those clones that form very early",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 54
        }
    },
    "1818": {
        "text": "in a cancer’s growth, or those that rapidly (e.g. within a\nsmall proportion of the lifetime of the cancer) grow to a\ndetectable size.\nEvolutionary dynamics and tumour progression\nManifest ongoing selection in cancers appears to be\nassociated with a worse prognosis, because, across can-\ncer types, tumours with three or more large clones have a\nworse prognosis than tumours with fewer clones [55,56],\nand putative subclonal driver mutations are also associ-\nated with a worse prognosis [55].",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 55
        }
    },
    "1819": {
        "text": "ated with a worse prognosis [55].\nHowever, neutral evolution has a potential ‘dark side’\nfor prognosis, by virtue of it allowing huge variation\nto be generated and persist in a tumour. Whereas, by\ndefinition, the diversity in a neutrally evolving tumour\nis non-adaptive to the current microenvironment, if the\nmicroenvironment were to change – through the appli-\ncation of therapy, for instance – then variants within\nthis reservoir of pre-existing variation could suddenly",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 56
        }
    },
    "1820": {
        "text": "become adaptive. Thus, neutrally evolving tumours may\nbe particularly prone to developing therapy resistance.\nThe relationship between neutral and selective evolu-\ntionary dynamics and tumour progression should be the\nfocus of future work.\nOur recent analysis of the evolution of colorectal\ncancer led us to put forward the ‘Big Bang’ model\nof cancer growth, whereby the tumour mass grows as\na single clonal expansion wherein differential clonal",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 57
        }
    },
    "1821": {
        "text": "selection within the tumour has little influence on the\nsubclonal composition of the tumour, and instead clonal\nmosaicism is determined largely by the time of clone\ngeneration [14]. As the clonal composition of a Big Bang\ntumour is determined simply by which clones were gen-\nerated at the beginning of cancer growth, we speculated\nthat a tumour’s prognosis is similarly predetermined. In\nother words, in the absence of clonal selection, the phe-",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 58
        }
    },
    "1822": {
        "text": "notype of the ‘first’ cancer cells should determine the\ncancer’s behaviour thereafter. Consequently, we specu-\nlate that reading these ‘initial phenotypes’ in the grown\ncancer may be prognostic, e.g. by looking for the degree\nof clonal mixing as a readout of cell migration ability,\nor the degree to which a clone coexists in multiple\ndifferent microenvironments as a readout of plasticity.\nPunctuated evolution\nIn the evolutionary biology literature, punctuated evolu-",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 59
        }
    },
    "1823": {
        "text": "tion is (loosely) defined as an apparently abrupt change\nin phenotype, and was originally suggested by Eldredge\nand Gould to explain the large morphological differ-\nences between species that appeared to occur without\nthe presence of intermediate morphotypes in the fossil\nrecord [57]. The original descriptions of punctuated\nevolution put forward the idea that an ancestral species\nbecame subdivided into (spatially) isolated distinct\nniches, in which each subpopulation independently",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 60
        }
    },
    "1824": {
        "text": "niches, in which each subpopulation independently\n(and gradually) evolved until the point when one of\nthose subspecies – by now grossly altered as compared\nwith the ancestor – was able to escape the niche and\nexpand its population significantly (Figure 2A). Because\nthe isolating niche was small, the intermediate forms\nwere lost to the fossil record, and only the widespread\nancestral and then the new grossly altered populations\nwere captured. The result was an apparently punctuated",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 61
        }
    },
    "1825": {
        "text": "evolution of species – interspersed by long periods of\ntime during which apparently no ‘important evolution’\nhappened. This pattern of events was described as\npunctuated equilibrium.\nPunctuated equilibrium has frequently been conflated\nwith saltation theory, although the two theories are dis-\ntinct. The difference is that the two theories describe\npunctuated phenotype change and punctuated genotype\nchange, respectively. Saltation theory suggests that new",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 62
        }
    },
    "1826": {
        "text": "species can be generated rapidly because of sudden\nlarge-scale mutation(s) – in other words, the underlying\ngenetic evolution causing the speciation event is itself\npunctuated (Figure 2B). Punctuated equilibrium, on the\nother hand, proposes that gross phenotypic change is\nthe consequence of gradual (although perhaps rapid)\ngenetic evolution in an isolated population. Richard\nGoldschmidt described the gross mutations as hope-\nful monsters – striving for ‘perfection’ in one big jump",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 63
        }
    },
    "1827": {
        "text": "[58]; however, it is more likely that most gross genetic\nrearrangements will be maladaptive.\nIt is increasingly clear that the punctuated evolution\nof both phenotypes and genotypes occurs during cancer\ndevelopment.\nPunctuated phenotype change is clearly seen in the\ndevelopment of neoplasia: typically, a neoplastic lesion\nCopyright © 2016 Pathological Society of Great Britain and Ireland.\nJ Pathol 2017; 241: 183–191\nPublished by John Wiley & Sons, Ltd. www.pathsoc.org",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 64
        }
    },
    "1828": {
        "text": "www.thejournalofpathology.com\n 10969896, 2017, 2, Downloaded from https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4821 by Turkey Cochrane Evidence Aid, Wiley Online Library on [22/08/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n188\nTA Graham and A Sottoriva",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 65
        }
    },
    "1829": {
        "text": "188\nTA Graham and A Sottoriva\nFigure 2. Punctuated equilibrium and hopeful monsters. (A) Mutations accumulate within small spatially isolated niches (here, an intestinal\ncrypt is depicted), and only after a sufficient number of adaptive mutations are acquired is clonal expansion initiated. From a macroscopic\nperspective, the evolution of the neoplasia appears to be punctuated, even though the driver mutations were acquired gradually within the",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 66
        }
    },
    "1830": {
        "text": "crypt. (B) The generation of a hopeful monster – a clone with a grossly altered genotype – in a single cell division produces a neoplasm in\na single ‘catastrophic’ step.\n(such as a colorectal adenoma) – with a grossly different\nphenotype to that of the normal cells – arises ‘abruptly’\nwithout intermediate partial neoplastic forms (although\nwe acknowledge that one could argue that crypt hyper-\nplasia may sometimes be an intermediate form in the",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 67
        }
    },
    "1831": {
        "text": "intestine). It is important to recognize that such punc-\ntuated phenotype change (normal to malignant cells)\nmay be underpinned by gradual genotype evolution. In\nthe example of intestinal neoplasia, it is clear that loss of\nthe normal function of the APC gene is sufficient to gen-\nerate adenomas [30,31]. Loss of normal APC function\ncan be caused by the ‘gradual’ accumulation of the two\nmutational hits on each of the APC alleles [59], and it is",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 68
        }
    },
    "1832": {
        "text": "clear that the gross changes in phenotype (normal to neo-\nplastic) need not be accompanied by large-scale genetic\nalteration [60]. In leukaemia, ‘intermediate’ clone geno-\ntypes are present at only very low frequency, potentially\nindicating punctuated equilibrium-like evolutionary\ndynamics [61]. In follicular lymphoma, disease transfor-\nmation is associated with an increased mutation burden,\nand often also the acquisition of mutations in key",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 69
        }
    },
    "1833": {
        "text": "‘driver’ genes, although the underlying temporal pattern\nof mutation accumulation remains undetermined [21].\nThe genotype–phenotype map describes the relation-\nship between genetic change and phenotypic traits. APC\nloss in the intestine demonstrates how slight changes in\ngenotype (e.g. single base pair changes) can cause large\nchanges in phenotype: this is an example where mapping\nbetween the space of possible genotypes and phenotypes\nis not smooth. Moreover, phenotypic change may not",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 70
        }
    },
    "1834": {
        "text": "occur until multiple independent mutations in a num-\nber of key genes have accumulated and act in tandem\nto cause phenotypic alteration (this is called epistasis).\nEpistasis can underlie punctuated equilibrium in can-\ncer – an individual lineage may steadily acquire indi-\nvidual driver mutations but not clonally expand until it\nhas the full complement of drivers necessary to enhance\nits fitness. Intriguingly, in colorectal [62,63] and lung",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 71
        }
    },
    "1835": {
        "text": "[20] cancers, the majority of the driver mutations often\nappear to be clonal throughout the cancer, perhaps\nimplying that the growth of these cancers can be initiated\nonly when a complete epistatically-interacting comple-\nment of drivers is obtained. Epistasis clearly adds much\ncomplexity to the relationship between genotypes and\nphenotypes. Resolving the genotype–phenotype map is\nkey to understanding evolutionary trajectories in cancer,\nalthough, given the inherently contextual definition of",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 72
        }
    },
    "1836": {
        "text": "phenotypes and the near-infinite space of possible geno-\ntypes, the resolution will be extremely challenging to\nachieve.\nIt is increasingly clear that Goldschmidt’s hope-\nful monsters – punctuated changes in genotype – are\nfrequently found in cancer (Figure 3). Chromothrip-\nsis – chromosome shattering and reassembly in an\naberrant manner – has now been reported in many dif-\nferent cancer types [64–66], and this saltatory mutation\noccurs following a single ‘catastrophic’ mitosis [67].",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 73
        }
    },
    "1837": {
        "text": "Chromoplexy – the interleaving of different chromoso-\nmal regions into one aberrant block – has been reported\nin prostate cancer, and is likely to occur in a single cell\ndivision [68]. More generally, genome doubling is a rel-\natively common saltatory mutation type observed across\ncancer types [69], and, furthermore, the tolerance of\ngenome doubling facilitates subsequent chromosomal\ninstability [70]. In breast cancer, sequencing of individ-\nual nuclei detects clones with dramatic copy number",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 74
        }
    },
    "1838": {
        "text": "deviation from the diploid genome, and no evidence\nof cells with intermediate patterns of copy number\nalteration [71,72] (Figure 3). Similarly relatively homo-\ngeneous intratumour patterns of grossly deviant copy\nnumber alterations are observed in many cancer types,\nincluding colorectal [62] and ovarian [17] cancer and\nthe premalignant disease Barrett’s oesophagus [25,73],\nsuggesting underlying saltatory mutational mechanisms.\nHow often are these hopeful monsters formed?",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 75
        }
    },
    "1839": {
        "text": "How often are these hopeful monsters formed?\nThe monsters that we sample in cancer are the\nCopyright © 2016 Pathological Society of Great Britain and Ireland.\nJ Pathol 2017; 241: 183–191\nPublished by John Wiley & Sons, Ltd. www.pathsoc.org\nwww.thejournalofpathology.com",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 76
        }
    },
    "1840": {
        "text": "www.thejournalofpathology.com\n 10969896, 2017, 2, Downloaded from https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4821 by Turkey Cochrane Evidence Aid, Wiley Online Library on [22/08/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\nMeasuring cancer evolution\n189",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 77
        }
    },
    "1841": {
        "text": "Measuring cancer evolution\n189\nFigure 3. Primary data indicating punctuated copy number evolution. Copy number profiles of individual breast cancer cells from a single\nbreast cancer case showing the same grossly altered genomes are observed in all cells sampled, and no intermediate forms are detected.\nImage scaled, cropped and reprinted with permission from [72].\nones that have fortuitously stumbled upon an adap-\ntive\ngenotype–phenotype\ncombination.\nHowever,",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 78
        }
    },
    "1842": {
        "text": "tive\ngenotype–phenotype\ncombination.\nHowever,\nmany saltatory mutations presumably lead to altered\nmaladapted\nphenotypes,\nor\nphenotypes\nthat\nare\nlethal – indeed, this is often the case for chromo-\nsomal instability [74]. Logically, therefore, this means\nthat, for every saltatory mutation that produces an adap-\ntive phenotype, there are probably many more saltatory\nmutations that produce maladapted phenotypes. This\nlikely abundance of ‘maladapted monsters’ in cancer",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 79
        }
    },
    "1843": {
        "text": "types (or their premalignant precursors) that frequently\nshow saltatory mutation is a testable prediction, and,\nfurthermore, the detection of maladapted monsters\ncould prove to be a useful prognostic biomarker in\npremalignant diseases such as Barrett’s oesophagus, in\nwhich large-scale genome alteration appears to be a key\npunctuated event in cancer formation [25,73].\nAn important aside is the potential for punctuated\nevolution of the rate of single-nucleotide alterations",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 80
        }
    },
    "1844": {
        "text": "(SNAs). SNAs accumulate according to a relatively\nsmall number of underlying mutational processes asso-\nciated with natural replication errors, defective DNA\nreplication and repair machinery, and mutagen expo-\nsures [47]. Although the accumulation of SNAs is a\nclearly a gradual process (although, as noted above,\nindividual SNAs can cause punctuated change in phe-\nnotype), we note that the abrupt ‘switching on’ of a\nnew mutational process can cause punctuated changes",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 81
        }
    },
    "1845": {
        "text": "in the SNA mutation rate. For example, mutation of the\nmismatch repair machinery causes a sudden increase in\na cell’s point mutation rate [75].\nConclusion: neutrality and selection,\nand punctuation and gradualism, are each two\nsides of the same coin\nCancer genomes show frequent evidence of both neutral\nevolution and clonal selection. As neutral evolution\nis just the evolution that happens between selection\nevents – e.g. the evolution that happens within a",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 82
        }
    },
    "1846": {
        "text": "events – e.g. the evolution that happens within a\nclone – the frequent detection of neutral evolution in\ncancer should come as no surprise. It is our opinion\nthat, in fact, it would be more surprising if a signature\nof neutral evolution was never seen in cancer, because\nthis would mean that new ‘driver’ mutations accrue all\nthe time in our cells – an implication that appears to be\nat odds with the relatively low age-dependent incidence\nof cancer [76] and the small number of drivers with",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 83
        }
    },
    "1847": {
        "text": "respect to passengers [40].\nAt\na\nmolecular\nlevel,\ncancers\nunquestionably\nshow\nboth\ngradual\n(the\nsteady\naccumulation\nof\nsingle-nucleotide variants) and punctuated (large-scale\ncopy number alterations) genotype change. However,\nwhether or not phenotype change is similarly punctuated\ndepends on the relationship between the genotype and\nphenotype, and also on the microenvironment context.\nThus, to be able to predict and manipulate the evolution-",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 84
        }
    },
    "1848": {
        "text": "ary trajectories of cancer for respective prognostic and\ntherapeutic benefits, it is critical that we understand the\ngenotype–phenotype map and the associated transitions\naround genotype–phenotype space. To achieve this, we\ncritically need to understand exactly which phenotypes\nCopyright © 2016 Pathological Society of Great Britain and Ireland.\nJ Pathol 2017; 241: 183–191\nPublished by John Wiley & Sons, Ltd. www.pathsoc.org\nwww.thejournalofpathology.com",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 85
        }
    },
    "1849": {
        "text": "www.thejournalofpathology.com\n 10969896, 2017, 2, Downloaded from https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4821 by Turkey Cochrane Evidence Aid, Wiley Online Library on [22/08/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License\n190\nTA Graham and A Sottoriva\nin cancer are selected and why – genetics help us to",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 86
        }
    },
    "1850": {
        "text": "understand the accessibility of the space of different\nphenotypes, but genetics alone cannot give us the full\npicture of cancer evolution.\nFinally, a word of caution is necessary. Studies have\nshown that treatment frequently selects for rare sub-\nclones in a tumour – and sometimes subclones that were\nso rare that they went undetected in the pretreatment\nsamples [26,77–80]. Thus, although the evolutionary\ndynamics of large tumour subclones – the focus of this",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 87
        }
    },
    "1851": {
        "text": "review – are clearly of much interest for understanding\nthe basic biology of cancer evolution, we must ask our-\nselves if these dynamics directly relate to a patient’s\nprognosis. It is our conviction that these evolutionary\ndynamics are clinically relevant, because only by learn-\ning the ‘rules of cancer evolution’ can we hope to effec-\ntively intervene and change the evolutionary course.\nAuthor contributions statement\nTG and AS co-wrote the manuscript.\nAcknowledgements",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 88
        }
    },
    "1852": {
        "text": "Acknowledgements\nTG and AS are grateful for support from the Wellcome\nTrust. TG is also a Cancer Research UK Career Devel-\nopment Fellow. AS is also supported by the Chris Rokos\nFellowship in Evolution and Cancer. The funders had\nno influence on the content of this review. The authors\nare grateful to Marc Williams for providing images for\nFigure 1, and to Nicholas Navin for providing Figure 3.\nReferences\n1. Alexandrov LB, Jones PH, Wedge DC, et al. Clock-like mutational",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 89
        }
    },
    "1853": {
        "text": "processes in human somatic cells. Nat Genet 2015; 47: 1402–1407.\n2. Xue Y, Wang Q, Long Q, et al. Human Y chromosome base-\nsubstitution mutation rate measured by direct sequencing in a\ndeep-rooting pedigree. Curr Biol 2009; 19: 1453–1457.\n3. 1000Genomes Project Consortium, Abecasis GR, Altshuler D, et al.\nA map of human genome variation from population-scale sequenc-\ning. Nature 2010; 467: 1061–1073.\n4. Laird CD, Pleasant ND, Clark AD, et al. Hairpin-bisulfite PCR:",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 90
        }
    },
    "1854": {
        "text": "assessing epigenetic methylation patterns on complementary strands\nof individual DNA molecules. Proc Natl Acad Sci USA 2004; 101:\n204–209.\n5. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in\nhuman cancers. Nature 1998; 396: 643–649.\n6. Rajagopalan H, Lengauer C. Aneuploidy and cancer. Nature 2004;\n432: 338–341.\n7. Schwarz RF, Trinh A, Sipos B, et al. Phylogenetic quantification of\nintra-tumour heterogeneity. PLoS Comput Biol 2014; 10: e1003535.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 91
        }
    },
    "1855": {
        "text": "8. Shibata D, Tavare S. Counting divisions in a human somatic cell tree:\nhow, what and why? Cell Cycle 2006; 5: 610–614.\n9. de Bruin EC, McGranahan N, Mitter R, et al. Spatial and temporal\ndiversity in genomic instability processes defines lung cancer evolu-\ntion. Science 2014; 346: 251–256.\n10. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and\nevolution of clear cell renal cell carcinomas defined by multiregion\nsequencing. Nat Genet 2014; 46: 225–233.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 92
        }
    },
    "1856": {
        "text": "sequencing. Nat Genet 2014; 46: 225–233.\n11. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity\nand branched evolution revealed by multiregion sequencing. N Engl\nJ Med 2012; 366: 883–892.\n12. Thirlwell C, Will OCC, Domingo E, et al. Clonality assessment and\nclonal ordering of individual neoplastic crypts shows polyclonality\nof colorectal adenomas. Gastroenterology 2010; 138: 1441–1454.\n13. Siegmund K, Marjoram P, Woo Y, et al. Inferring clonal expansion",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 93
        }
    },
    "1857": {
        "text": "and cancer stem cell dynamics from DNA methylation patterns in\ncolorectal cancers. Proc Natl Acad Sci USA 2009; 106: 4828–4833.\n14. Sottoriva A, Kang H, Ma Z, et al. A Big Bang model of human\ncolorectal tumor growth. Nat Genet 2015; 47: 209–216.\n15. Jones S, Chen W-D, Parmigiani G, et al. Comparative lesion\nsequencing provides insights into tumor evolution. Proc Natl Acad\nSci USA 2008; 105: 4283–4288.\n16. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 94
        }
    },
    "1858": {
        "text": "during the genetic evolution of pancreatic cancer. Nature 2010; 467:\n1114–1117.\n17. Schwarz RF, Ng CK, Cooke SL, et al. Spatial and temporal hetero-\ngeneity in high-grade serous ovarian cancer: a phylogenetic analysis.\nPLoS Med 2015; 12: e1001789.\n18. Sottoriva A, Spiteri I, Piccirillo SG, et al. Intratumor heterogeneity\nin human glioblastoma reflects cancer evolutionary dynamics. Proc\nNatl Acad Sci USA 2013; 110: 4009–4014.\n19. Sottoriva A, Spiteri I, Shibata D, et al. Single-molecule genomic",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 95
        }
    },
    "1859": {
        "text": "data delineate patient-specific tumor profiles and cancer stem cell\norganization. Cancer Res 2013; 73: 41–49.\n20. Zhang J, Fujimoto J, Zhang J, et al. Intratumor heterogeneity in local-\nized lung adenocarcinomas delineated by multiregion sequencing.\nScience 2014; 346: 256–259.\n21. Okosun J, Bodor C, Wang J, et al. Integrated genomic analysis\nidentifies recurrent mutations and evolution patterns driving the\ninitiation and progression of follicular lymphoma. Nat Genet 2014;\n46: 176–181.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 96
        }
    },
    "1860": {
        "text": "46: 176–181.\n22. Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21\nbreast cancers. Cell 2012; 149: 994–1007.\n23. Yates LR, Gerstung M, Knappskog S, et al. Subclonal diversification\nof primary breast cancer revealed by multiregion sequencing. Nat\nMed 2015; 21: 751–759.\n24. Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history\nof lethal metastatic prostate cancer. Nature 2015; 520: 353–357.\n25. Li X, Galipeau PC, Paulson TG, et al. Temporal and spatial evolution",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 97
        }
    },
    "1861": {
        "text": "of somatic chromosomal alterations: a case-cohort study of Barrett’s\nesophagus. Cancer Prev Res (Phila) 2014; 7: 114–127.\n26. Diaz LA, Jr, Williams RT, Wu J, et al. The molecular evolution of\nacquired resistance to targeted EGFR blockade in colorectal cancers.\nNature 2012; 486: 537–540.\n27. Sieber OM, Tomlinson SR, Tomlinson IPM. Tissue, cell and stage\nspecificity of (epi)mutations in cancers. Nat Rev Cancer 2005; 5:\n649–655.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 98
        }
    },
    "1862": {
        "text": "649–655.\n28. Lipinski KA, Barber LJ, Davies MN, et al. Cancer evolution and the\nlimits of predictability in precision cancer medicine. Trends Cancer\n2016; 2: 49–63.\n29. Vermeulen L, Morrissey E, van der Heijden M, et al. Defining stem\ncell dynamics in models of intestinal tumor initiation. Science 2013;\n342: 995–998.\n30. Lamlum H, Papadopoulou A, Ilyas M, et al. APC mutations are\nsufficient for the growth of early colorectal adenomas. Proc Natl Acad\nSci USA 2000; 97: 2225–2228.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 99
        }
    },
    "1863": {
        "text": "Sci USA 2000; 97: 2225–2228.\n31. Sansom OJ, Reed KR, Hayes AJ, et al. Loss of Apc in vivo imme-\ndiately perturbs Wnt signaling, differentiation, and migration. Genes\nDev 2004; 18: 1385–1390.\n32. Aktipis CA, Boddy AM, Gatenby RA, et al. Life history trade-offs\nin cancer evolution. Nat Rev Cancer 2013; 13: 883–892.\n33. Humphries A, Wright NA. Colonic crypt organization and tumorige-\nnesis. Nat Rev Cancer 2008; 8: 415–424.\nCopyright © 2016 Pathological Society of Great Britain and Ireland.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 100
        }
    },
    "1864": {
        "text": "J Pathol 2017; 241: 183–191\nPublished by John Wiley & Sons, Ltd. www.pathsoc.org\nwww.thejournalofpathology.com\n 10969896, 2017, 2, Downloaded from https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4821 by Turkey Cochrane Evidence Aid, Wiley Online Library on [22/08/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 101
        }
    },
    "1865": {
        "text": "Measuring cancer evolution\n191\n34. Pepper JW, Sprouffske K, Maley CC. Animal cell differentiation\npatterns suppress somatic evolution. PLoS Comput Biol 2007; 3:\ne250.\n35. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature\n2009; 458: 719–724.\n36. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome\nlandscapes. Science 2013; 339: 1546–1558.\n37. Roth A, Khattra J, Yap D, et al. PyClone: statistical inference\nof clonal population structure in cancer. Nat Methods 2014; 11:",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 102
        }
    },
    "1866": {
        "text": "396–398.\n38. Andor N, Harness JV, Muller S, et al. EXPANDS: expanding ploidy\nand allele frequency on nested subpopulations. Bioinformatics 2014;\n30: 50–60.\n39. Fischer A, Vazquez-Garcia I, Illingworth CJ, et al. High-definition\nreconstruction of clonal composition in cancer. Cell Rep 2014; 7:\n1740–1752.\n40. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature\n2009; 458: 719–724.\n41. Marusyk A, Tabassum DP, Altrock PM, et al. Non-cell-autonomous",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 103
        }
    },
    "1867": {
        "text": "driving of tumour growth supports sub-clonal heterogeneity. Nature\n2014; 514: 54–58.\n42. Williams MJ, Werner B, Barnes CP, et al. Identification of neu-\ntral tumor evolution across cancer types. Nat Genet 2016; 48:\n238–244.\n43. Bozic I, Gerold JM, Nowak MA. Quantifying clonal and subclonal\npassenger mutations in cancer evolution. PLoS Comput Biol 2016;\n12: e1004731.\n44. Durrett R. Population genetics of neutral mutations in exponen-",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 104
        }
    },
    "1868": {
        "text": "tially growing cancer cell populations. Ann Appl Probab 2013; 23:\n230–250.\n45. Ostrow SL, Barshir R, DeGregori J, et al. Cancer evolution is asso-\nciated with pervasive positive selection on globally expressed genes.\nPLoS Genet 2014; 10: e1004239.\n46. Martincorena I, Roshan A, Gerstung M, et al. Tumor evolution.\nHigh burden and pervasive positive selection of somatic mutations\nin normal human skin. Science 2015; 348: 880–886.\n47. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of muta-",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 105
        }
    },
    "1869": {
        "text": "tional processes in human cancer. Nature 2013; 500: 415–421.\n48. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation\nin human cancer genomes. Nature 2007; 446: 153–158.\n49. Driessens G, Beck B, Caauwe A, et al. Defining the mode of tumour\ngrowth by clonal analysis. Nature 2012; 488: 527–530.\n50. Merlo LMF, Pepper JW, Reid BJ, et al. Cancer as an evolutionary\nand ecological process. Nat Rev Cancer 2006; 6: 924–935.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 106
        }
    },
    "1870": {
        "text": "51. Beerenwinkel N, Antal T, Dingli D, et al. Genetic progression and\nthe waiting time to cancer. PLoS Comput Biol 2007; 3: e225.\n52. Bozic I, Antal T, Ohtsuki H, et al. Accumulation of driver and\npassenger mutations during tumor progression. Proc Natl Acad Sci\nUSA 2010; 107: 18545–18550.\n53. Cancer Genome Atlas Network. Comprehensive molecular charac-\nterization of human colon and rectal cancer. Nature 2012; 487:\n330–337.\n54. Castro-Giner F, Ratcliffe P, Tomlinson I. The mini-driver model of",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 107
        }
    },
    "1871": {
        "text": "polygenic cancer evolution. Nat Rev Cancer 2015; 15: 680–685.\n55. Andor N, Graham TA, Jansen M, et al. Pan-cancer analysis of the\nextent and consequences of intratumor heterogeneity. Nat Med 2016;\n22: 105–113.\n56. Morris LG, Riaz N, Desrichard A, et al. Pan-cancer analysis of\nintratumor heterogeneity as a prognostic determinant of survival.\nOncotarget 2016; 7: 10051–10063.\n57. Eldredge N, Gould SJ. Punctuated equilibria: an alternative to",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 108
        }
    },
    "1872": {
        "text": "phyletic gradualism. In Models in Paleobiology, Schopf T (ed.), Free-\nman, Cooper & Co., San Francisco, 1972; 82–115.\n58. Goldschmidt R. The Material Basis of Evolution. Yale University\nPress: New Haven, 1940.\n59. Rowan AJ, Lamlum H, Ilyas M, et al. APC mutations in\nsporadic colorectal tumors: a mutational ‘hotspot’ and interde-\npendence of the ‘two hits’. Proc Natl Acad Sci USA 2000; 97:\n3352–3357.\n60. Jones A, Thirlwell C, Howarth K, et al. Analysis of copy number",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 109
        }
    },
    "1873": {
        "text": "changes suggests chromosomal instability in a minority of large\ncolorectal adenomas. J Pathol 2007; 213: 249–256.\n61. Campbell PJ, Pleasance ED, Stephens PJ, et al. Subclonal phyloge-\nnetic structures in cancer revealed by ultra-deep sequencing. Proc\nNatl Acad Sci USA 2008; 105: 13081–13086.\n62. Kim TM, Jung SH, An CH, et al. Subclonal genomic archi-\ntectures of primary and metastatic colorectal cancer based on\nintratumoral genetic heterogeneity. Clin Cancer Res 2015; 21:\n4461–4472.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 110
        }
    },
    "1874": {
        "text": "4461–4472.\n63. Jesinghaus M, Wolf T, Pfarr N, et al. Distinctive spatiotemporal\nstability of somatic mutations in metastasized microsatellite-stable\ncolorectal cancer. Am J Surg Pathol 2015; 39: 1140–1147.\n64. Stephens PJ, Greenman CD, Fu B, et al. Massive genomic rearrange-\nment acquired in a single catastrophic event during cancer develop-\nment. Cell 2011; 144: 27–40.\n65. Kloosterman WP, Hoogstraat M, Paling O, et al. Chromothripsis is a",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 111
        }
    },
    "1875": {
        "text": "common mechanism driving genomic rearrangements in primary and\nmetastatic colorectal cancer. Genome Biol 2011; 12: R103.\n66. Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neu-\nroblastoma identifies chromothripsis and defects in neuritogenesis\ngenes. Nature 2012; 483: 589–593.\n67. Zhang CZ, Spektor A, Cornils H, et al. Chromothripsis from DNA\ndamage in micronuclei. Nature 2015; 522: 179–184.\n68. Baca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 112
        }
    },
    "1876": {
        "text": "prostate cancer genomes. Cell 2013; 153: 666–677.\n69. Carter SL, Cibulskis K, Helman E, et al. Absolute quantification of\nsomatic DNA alterations in human cancer. Nat Biotechnol 2012; 30:\n413–421.\n70. Dewhurst SM, McGranahan N, Burrell RA, et al. Tolerance of\nwhole-genome doubling propagates chromosomal instability and\naccelerates cancer genome evolution. Cancer Discov 2014; 4:\n175–185.\n71. Wang Y, Waters J, Leung ML, et al. Clonal evolution in breast cancer",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 113
        }
    },
    "1877": {
        "text": "revealed by single nucleus genome sequencing. Nature 2014; 512:\n155–160.\n72. Gao R, Davis A, McDonald TO, et al. Punctuated copy number\nevolution and clonal stasis in triple-negative breast cancer. Nat Genet\n2016; 48: 1119–1130.\n73. Stachler MD, Taylor-Weiner A, Peng S, et al. Paired exome analysis\nof Barrett’s esophagus and adenocarcinoma. Nat Genet 2015; 47:\n1047–1055.\n74. Gordon DJ, Resio B, Pellman D. Causes and consequences of aneu-\nploidy in cancer. Nat Rev Genet 2012; 13: 189–203.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 114
        }
    },
    "1878": {
        "text": "75. Tsao JL, Yatabe Y, Salovaara R, et al. Genetic reconstruction of\nindividual colorectal tumor histories. Proc Natl Acad Sci USA 2000;\n97: 1236–1241.\n76. Armitage P, Doll R. The age distribution of cancer and a multi-stage\ntheory of carcinogenesis. Br J Cancer 1954; 8: 1–12.\n77. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute\nmyeloid leukaemia revealed by whole-genome sequencing. Nature\n2012; 481: 506–510.",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 115
        }
    },
    "1879": {
        "text": "2012; 481: 506–510.\n78. Anderson K, Lutz C, van Delft FW, et al. Genetic variegation of\nclonal architecture and propagating cells in leukaemia. Nature 2011;\n469: 356–361.\n79. Findlay JM, Castro-Giner F, Makino S, et al. Differential clonal evo-\nlution in oesophageal cancers in response to neo-adjuvant chemother-\napy. Nat Commun 2016; 7: 11111.\n80. Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution\nand resistance to EGFR blockade in the blood of colorectal cancer",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 116
        }
    },
    "1880": {
        "text": "patients. Nat Med 2015; 21: 795–801.\nCopyright © 2016 Pathological Society of Great Britain and Ireland.\nJ Pathol 2017; 241: 183–191\nPublished by John Wiley & Sons, Ltd. www.pathsoc.org\nwww.thejournalofpathology.com",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 117
        }
    },
    "1881": {
        "text": "www.thejournalofpathology.com\n 10969896, 2017, 2, Downloaded from https://pathsocjournals.onlinelibrary.wiley.com/doi/10.1002/path.4821 by Turkey Cochrane Evidence Aid, Wiley Online Library on [22/08/2025]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License",
        "metadata": {
            "source": "The Journal of Pathology - 2016 - Graham - Measuring cancer evolution from the genome.pdf",
            "chunk_id": 118
        }
    }
}